

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 15, 2004, 03:38:00 ; Search time 4864 Seconds  
(without alignments)  
10461.497 Million cell updates/sec

Title: US-09-978-299A-329

Perfect score: 1174

Sequence: 1 cggacgcgtggggaaaccc.....taagttactcaaatctgtg 1174

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 22

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database :

GenEmbl.\*

1: gb.ba.\*

2: gb.htg.\*

3: gb.in.\*

4: gb.om.\*

5: gb.ov.\*

6: gb.pat.\*

7: gb.ph.\*

8: gb.pl.\*

9: gb.pr.\*

10: gb.ro.\*

11: gb.scs.\*

12: gb.sy.\*

13: gb.un.\*

14: gb.vi.\*

15: em.ba.\*

16: em.fun.\*

17: em.hum.\*

18: em.in.\*

19: em.mu.\*

20: em.om.\*

21: em.or.\*

22: em.ov.\*

23: em.pat.\*

24: em.ph.\*

25: em.pl.\*

26: em.ro.\*

27: em.sts.\*

28: em.un.\*

29: em.vi.\*

30: em.htg.hum.\*

31: em.htg.inv.\*

32: em.htg.other.\*

33: em.htg.mus.\*

34: em.htg.pln.\*

35: em.htg.rod.\*

36: em.htg.mam.\*

37: em.htg.vrt.\*

38: em.sy.\*

39: em.htgo.hum.\*

40: em.htgo.mus.\*

41: em.htgo.other.\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	1174	100.0	1174	6	AX454422	Sequence AX454422
2	1174	100.0	1174	6	AX464138	Sequence AX464138
3	1174	100.0	1174	6	AX490900	Sequence AX490900
4	1174	100.0	1174	9	AY359029	Homo sapi BD127562 Primer fo
5	1163.8	99.1	1634	6	BD127562	Sequence AK075187 Homo sapi
6	1163.8	99.1	1634	9	AK075187	Sequence AX775907
7	1163.8	99.1	1636	6	AX775907	Human tra BD210070
8	1163.8	99.1	1704	6	BD210070	Homo sapi AF290615
9	1163.8	99.1	1709	9	AF290615	Human pro BD191327
10	1151.8	98.1	1695	6	BD191327	Sequence AX136301
11	1121	95.5	1457	6	AX136301	Secretory BD123603
12	1118	95.2	1457	9	AK075505	Homo sapi AK075505
13	1118	95.2	1457	9	AK075505	Sequence AX683249
14	1118	95.2	1457	9	AK075505	Sequence AX775909
15	1106	94.2	1138	6	AX775912	Sequence BC016374
16	1106	94.2	1138	6	AX775912	Homo sapi BC003106
17	1105	94.1	1465	6	AX775909	Human BD191202
18	1105	94.1	1515	9	BC016374	Sequence AR379540
19	1104	94.0	1130	6	BD031106	Human pro BD233458
20	1049	89.4	1816	6	BD191202	Sequence
21	974	83.0	1742	6	AR379540	Human pro
22	969	82.5	969	6	BD233458	Human pro

## ALIGNMENTS

RESULT 1  
LOCUS AX454422 1174 bp DNA linear PAT 06-JUL-2002  
DEFINITION Sequence 7 from Patent WO0208284.  
ACCESSION AX454422  
VERSION AX454422.1 GI:21713835  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Baker, K.P., Ferrara, N., Gerber, H., Gerritsen, M.E., Goddard, A.,  
Godowski, P.J., Gurney, A.L., Hillan, K.J., Marsters, S.A., Pan, J.,  
Paoni, N.F., Stephan, J.P., Watanabe, C.K., Williams, P.M., Wood, W.I.  
and Ye, W.  
TITLE Compositions and methods for the diagnosis and treatment of  
disorders involving angiogenesis  
JOURNAL Patent: WO 0208284-A 7 31-JAN-2002;  
Genentech, Inc. (US) ; Baker, Kevin P. (US) ; Ferrara, Napoleone  
(US) ; Gerber, Hanspeter (US) ; Gerritsen, Mary E. (US) ; Goddard,  
Audrey (US) ; Godowski, Paul J. (US) ; Gurney, Austin L. (US) ;  
Hillan, Kenneth J. (US) ; Marsters, Scot A. (US) ; Pan, James (US)  
; Paoni, Nicholas F. (US) ; Stephan, Jean-Philippe F. (US) ;  
Watanabe, Colin K. (US) ; Williams, P. Mickey (US) ; Wood, William  
I. (US)  
FEATURES  
source  
1..1174  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 100.0%; Score 1174; DB 6; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 2.1e-274;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACCGGTGGGGGAACCCCTTCGAGAAACAGCACACAGCTGAGTGTGTCAGAG 60



541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA 600  
541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA 600  
601 GTTATATTCAGTCTTAGCCAGGAATCCAGTACGACCATATTTGGAGCAGGAGCTTACA 660  
601 GTTATATTCAGTCTTAGCCAGGAATCCAGTACGACCATATTTGGAGCAGGAGCTTACA 660  
661 AATTGGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
661 AATTGGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
781 TCTGGGTGGATTTTAACTPACAACTCTTGTCTCTCGGTGATGTTATGCTTTGGATTTGT 840  
781 TCTGGGTGGATTTTAACTPACAACTCTTGTCTCTCGGTGATGTTATGCTTTGGATTTGT 840  
841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGCTTCCCTCTGAGAAGCTGAGTATCTAT 900  
841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGCTTCCCTCTGAGAAGCTGAGTATCTAT 900  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGCTTCTCTCTGTG 960  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGCTTCTCTCTGTG 960  
961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
1021 CTGCTCATCTGAAATTAAGCTTTTCTTTTAAAGAGCAGTGTATAGACATCTAA 1080  
1021 CTGCTCATCTGAAATTAAGCTTTTCTTTTAAAGAGCAGTGTATAGACATCTAA 1080  
1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTTAAGAAATCA 1140  
1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTTAAGAAATCA 1140  
1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174  
1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174

RESULT 3  
AX490900  
LOCUS AX490900 1174 bp DNA linear PAT 16-AUG-2002  
DEFINITION Sequence 7 from Patent WO0200690.  
ACCESSION AX490900  
VERSION AX490900.1 GI:22323787  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1  
Baker, K.P., Ferrara, N., Gerber, H., Gerritsen, M.E., Goddard, A.,  
Godowski, P.J., Gurney, A.L., Hillan, K.J., Marsters, S.A., Pan, J.,  
Pavoni, N.P., Stephan, J.P., Watanabe, C.K., Williams, P.M., Wood, W.I.  
and Ye, W.  
Compositions and methods for the diagnosis and treatment of  
disorders involving angiogenesis  
JOURNAL Patent: WO 0200690-A 7 03-JAN-2002;  
Genentech, Inc. (US)  
FEATURES  
Location/Qualifiers  
1..1174  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

ORIGIN

Query Match 100.0%; Score 1174; DB 6; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 2,1e-274;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCTGGGGGAACCTTCGGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAACCTTCGGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCCGAAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCCGAAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
QY 121 CCGTGTCTGTCTGACCATGGCTTGGCCGAGAGTTGGGGACCCCTTCGGCTGAGCA 180  
DB 121 CCGTGTCTGTCTGACCATGGCTTGGCCGAGAGTTGGGGACCCCTTCGGCTGAGCA 180  
QY 181 TTTGACTCGGCTTTGGGTGATAGGGCTCTTGGCCACCGGGCTGTGAGTTGACTACCTACCCC 240  
DB 181 TTTGACTCGGCTTTGGGTGATAGGGCTCTTGGCCACCGGGCTGTGAGTTGACTACCTACCCC 240  
QY 241 TTGCACACCTTACCTTAAGGAAGAGGAGTTGTACGATGTGAGAGGTTGCGAGCTGTTT 300  
DB 241 TTGCACACCTTACCTTAAGGAAGAGGAGTTGTACGATGTGAGAGGTTGCGAGCTGTTT 300  
QY 301 TCAATTTGTCACTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATCTGAA 360  
DB 301 TCAATTTGTCACTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATCTGAA 360  
QY 361 TCTGCATGTA CAGAAGCATATTCCTAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
DB 361 TCTGCATGTA CAGAAGCATATTCCTAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
QY 421 CAGAACTCAGCTGCTGCTGAACTGAGACAGAACTATTTATGCTTCCCTGATGCCAATA 480  
DB 421 CAGAACTCAGCTGCTGCTGAACTGAGACAGAACTATTTATGCTTCCCTGATGCCAATA 480  
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTTGGAGTGACATGATGGACTCC 540  
DB 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTTGGAGTGACATGATGGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA 600  
QY 601 GTTATATTCAGTCTTAGCCAGGAATCCAGTACGACCATATTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTTAGCCAGGAATCCAGTACGACCATATTTGGAGCAGGAGCTTACA 660  
QY 661 AATTGGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB 661 AATTGGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGGTGGATTTTAACTPACAACTCTTGTCTCTCGGTGATGTTATGCTTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTPACAACTCTTGTCTCTCGGTGATGTTATGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGCTTCTCTCTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGCTTCTCTCTGTG 960  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTAAGCTTTTCTTTTAAAGAGCAGTGTATAGACATCTAA 1080

```

Db      1021  CTTGCTCATCTTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Qy      1081  AATTCACACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140
Db      1081  AATTCACACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140
Qy      1141  CTATAAATGCAATAAAGTACTCAATCTGTG 1174
Db      1141  CTATAAATGCAATAAAGTACTCAATCTGTG 1174

RESULT 4
AY359029      1174 bp      mRNA      linear      PRI 03-OCT-2003
LOCUS      Homo sapiens clone DNA26847 C10RFB8 (UNQ169) mRNA, complete cds.
DEFINITION
ACCESSION      AY359029
VERSION      AY359029.1 GI:37183175
KEYWORDS      FLI CDNA
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1174)
AUTHORS      Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
Dowd,P., Eaton,D., Foster,J., Crowley,C., Currell,B., Deuel,B.,
Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
Lee,J., Lewis,B., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,
Stinson,J., Vagts,A., Vanden,R., Watanabe,C., Wieand,D., Woods,K.,
Xie,M.H., Yanaura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
Goddard,A., Wood,W.I. and Godowski,P.
The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
Effort to Identify Novel Human Secreted and Transmembrane Proteins:
A Bioinformatics Assessment
Genome Res. 13 (10), 2265-2270 (2003)
JOURNAL
PUBMED      12975309
REFERENCE
2 (bases 1 to 1174)
AUTHORS      Clark,H.F.
Direct Submission
JOURNAL
Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
Inc., 1 DNA Way, South San Francisco, CA 94080, USA
FEATURES
source
1..1174
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="DNA26847"
1..1174
/locus_tag="UNQ169"
70..1041
/locus_tag="UNQ169"
/note="PRO195"
/codon_start=1
/product="C10RFB"
/protein_id="AAQ89388.1"
/db_xref="GI:37183176"
/translation="MAAPKGLWVRITQLGPELLLLTALAGSGTASAEAFDSVLGD
TASCHACALTYPLHYPKBEELIYACORGLFSICQFVDDGIDILNRKLECSAAGT
AYSQSDEQVACHLGNOLPPAELRQELMSLPRWHLLFFPLTLVRSFWSMDPSAOS
FITSWTFVLQDDGKIVIFQSKPEIQVAPHEQPTNLRSSLSKSYLQMRNSQAH
RNFEDESGDFGRCLNSGMILITLVLSVWLLNCCATVATAVEQYVPSEKLSI
YGLDFEWNQKLNRYFASLSLVVRSKTDEHBEAGPLTKVNLHSEI"

Query Match      100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred No. 2,1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAG 60
Db      1  CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAG 60

```

```

Qy      61  GGGAAACAAGATGGCGGCGCCGAGGAGGCTCTGGGTGAGGA CCCAACTGGGGCTCCCG 120
Db      61  GGGAAACAAGATGGCGGCGCCGAGGAGGCTCTGGGTGAGGA CCCAACTGGGGCTCCCG 120
Qy      121  CGGCTGCTGCTGCAACATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180
Db      121  CGGCTGCTGCTGCAACATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180
Qy      181  TTGACCTCGGTCTTGGGTGATACGGCGTCTTGGCACCGGGCCTGTCTCAGTTGACCTACCCC 240
Db      181  TTGACCTCGGTCTTGGGTGATACGGCGTCTTGGCACCGGGCCTGTCTCAGTTGACCTACCCC 240
Qy      241  TTGCAACACTACCTTAAGGAAGAGAGTGTACGCATGTACAGAGAGTTTCAGAGCTGTTT 300
Db      241  TTGCAACACTACCTTAAGGAAGAGAGTGTGTACGCATGTACAGAGAGTTTCAGAGCTGTTT 300
Qy      301  TCAATTTCTCAGTTTGTGGATGATGAATTAATCGAACTAAATGGAATGTGAA 360
Db      301  TCAATTTCTCAGTTTGTGGATGATGAATTAATCGAACTAAATGGAATGTGAA 360
Qy      361  TCTGATGTACAGAGCAATTTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTC 420
Db      361  TCTGATGTACAGAGCAATTTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTC 420
Qy      421  CAGAACTCAGCTGCCATTCGCTGAATCGACAACAACCTTATGTCCTCGATGCCAAAA 480
Db      421  CAGAACTCAGCTGCCATTCGCTGAATCGACAACAACCTTATGTCCTCGATGCCAAAA 480
Qy      481  ATGCACCTACTCTTCTCTAACTCTGGTGAAGTCAATCTGGAGTGCATGTGAGTGCCTCC 540
Db      481  ATGCACCTACTCTTCTCTAACTCTGGTGAAGTCAATCTGGAGTGCATGTGAGTGCCTCC 540
Qy      541  GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600
Db      541  GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600
Qy      601  GTTATATTCAGTCTTAAGCCAGAAATCCAGTACCCACACATTTGGAGCAGGAGCTTACA 660
Db      601  GTTATATTCAGTCTTAAGCCAGAAATCCAGTACCCACACATTTGGAGCAGGAGCTTACA 660
Qy      661  AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGAG 720
Db      661  AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGAG 720
Qy      721  CACAGAAATTTCTTGAAGATGGAAGATGATGGCTTTTAAAGTGCCTCTCTCTTAAC 780
Db      721  CACAGAAATTTCTTGAAGATGGAAGATGATGGCTTTTAAAGTGCCTCTCTCTTAAC 780
Qy      781  TCTGGGTGATTTTAACTACAACTCTCTCTCGGTGATGGTATTTGCTTGGATTGT 840
Db      781  TCTGGGTGATTTTAACTACAACTCTCTCTCGGTGATGGTATTTGCTTGGATTGT 840
Qy      841  TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db      841  TGTGCAACTGTTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Qy      901  GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTCTTCTCTTGTG 960
Db      901  GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTCTTCTCTTGTG 960
Qy      961  GTTGTGTAGATCTAAACATGAAGTCAATCAAGAGCAGGCGCTCTACCTACAAAAAGTGAAT 1020
Db      961  GTTGTGTAGATCTAAACATGAAGTCAATCAAGAGCAGGCGCTCTACCTACAAAAAGTGAAT 1020
Qy      1021  CTTGCTCATTTGAAATTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db      1021  CTTGCTCATTTGAAATTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Qy      1081  AATTCACACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140
Db      1081  AATTCACACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140

```



Qy		1141	CTATAAATGCAATAAAAGTTACTCAAATCTGTG	1174
D6		1141	CTATAAATGCAATAAAAGTTACTCAAATCTGTG	1174

## RESULT 5

Accession #	LOCUS	Size	Library	Accession #
BD127562	BD127562	1634 bp	DNA	linear PAT 18-SEP-2002
	DEFINITION	Primer for synthesizing full-length cDNA and use thereof.		

ACCESSION BD127562  
 VERSION BD127562.1 GI:23222507  
 KEYWORDS JF 2002017375-A/2993.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

ORIGIN

Query Match 99.1%; Score 1163.8; DB 6; Length 1634;  
Best Local Similarity 99.8%; Pred. No. 6.5e-272;  
Matches 1155; Conservative 0; Mismatches 2; Indels 0; Gaps 0

Kojima, S., Nagahari, K., Masuho, Y., Ono, T., Okano, K., Yoshikawa, Y., Aotsuka, S., Sasaki, N., Hattori, A., Okumura, K., Iwayanagi, T. and Niimiya, K.

## TITLE

Unpublished

2 (bases 1 to 1634)

Direct Submission

Submitted (25-MAR-2002)

Takao Isogai, Helix Research Institute, Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail: genomics@hri.co.jp, Tel: 81-438-52-3975, Fax: 81-438-52-3986)

NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology; cDNA library construction: Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure, Human Genome Center; cDNA 5'- & 3'-end one pass sequencing and clone selection: Helix Research Institute (supported by Japan Key Technology Center etc.).

## FEATURES

source

1..1634  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="PLACE1007626"  
/tissue\_type="placenta"  
/clone\_lib="PLACE1"  
/note="cloning vector: pME18SFL3"

## ORIGIN

Query Match 99.1%; Score 1163.8; DB 9; Length 1634;

Best Local Similarity 99.8%; Pred. No. 6.5e-272;

Matches 1165; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

8 GTGGGGAAACCTTCGAGAGAAACAGCAACAGCTGAGCTGTGACAGAGGGGAC 67  
129 GAGGAGAAACCTTCGAGAGAAACAGCAACAGCTGAGCTGTGACAGAGGGGAA 188  
68 AGATGGCGCGCGGAGGAGGAGCTCTGGGTGAGAGCCAACTGGGGCTCCCGCGCTGC 127  
189 AGATGGCGCGCGGAGGAGGAGCTCTGGGTGAGAGCCAACTGGGGCTCCCGCGCTGC 248  
128 TGTGCTGACATGGCGCTTGGCGGAGGTTGGGAGCCGCTTCGGCTGAGCAATTTGACT 187  
249 TGTGCTGACATGGCGCTTGGCGGAGGTTGGGAGCCGCTTCGGCTGAGCAATTTGACT 308  
188 CGCTCTTGGTGATACGGGCTCTTGCACCGGGGCTGTGAGTGGACCTACCCCTTGACA 247  
309 CGCTCTTGGTGATACGGGCTCTTGCACCGGGGCTGTGAGTGGACCTACCCCTTGACA 368  
248 CCTACCTAAGAGAGGAGTTGTACGCAATGTCAGAGGTTGCAAGGCTGTTTCAATTT 307  
369 CCTACCTAAGAGAGGAGTTGTACGCAATGTCAGAGGTTGCAAGGCTGTTTCAATTT 428  
308 GTGAGTTTGGTGATGGAATTTGACTTAAATCGAATAATGGAATGGAATCTGCAT 367  
429 GTGAGTTTGGTGATGGAATTTGACTTAAATCGAATAATGGAATGGAATCTGCAT 488  
368 GTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTGGCAGATC 427  
489 GTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTGGCAGATC 548  
428 AGCTGCATCTCGTGAATCGAGAGAGCAATTTATGTCCTGATGCCAAATGCAACC 487  
549 AGCTGCATCTCGTGAATCGAGAGAGCAATTTATGTCCTGATGCCAAATGCAACC 608  
488 TACTCTTTCTCTAATCTGGTGAATCTATCTGGAGTGACATGAGCACTCCGACAGA 547  
609 TACTCTTTCTCTAATCTGGTGAATCTATCTGGAGTGACATGAGCACTCCGACAGA 668  
548 GCTTCATCACTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATATGTTATAT 607  
669 GCTTCATCACTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATATGTTATAT 728

608 TCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGAGAGGAGGCTTACAAATTTGA 667  
729 TCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGAGAGGAGGCTTACAAATTTGA 788  
668 GAGATCATCTTAAAGCAAAATGCTCTGCAATGAGAAATTCACAAAGGCGCAGAGA 727  
789 GAGATCATCTTAAAGCAAAATGCTCTGCAATGAGAAATTCACAAAGGCGCAGAGA 848  
728 ATTCTTCTTGAAGATGAGAAAGTGAATGGCTTTTAAAGATGCCCTCTCTTAACTCTGGGT 787  
849 ATTCTTCTTGAAGATGAGAAAGTGAATGGCTTTTAAAGATGCCCTCTCTTAACTCTGGGT 908  
788 GGATTTAACTACAACTTTGCTCTCTCGGTGATGATGATTTGCTTTGGATTTGGTGCAA 847  
909 GGATTTAACTACAACTTTGCTCTCTCGGTGATGATGATTTGCTTTGGATTTGGTGCAA 968  
848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTCGAAGCTGAGTATCTATGTTGATC 907  
969 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTCGAAGCTGAGTATCTATGTTGATC 1028  
908 TGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTTGGTTGTTA 967  
1029 TGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTTGGTTGTTA 1088  
968 GATCTAAACCTGAAGATCATGAAGAGCAGGGGCTCTACCTACAAAAGTGAATCTTGGCTC 1027  
1089 GATCTAAACCTGAAGATCATGAAGAGCAGGGGCTCTACCTACAAAAGTGAATCTTGGCTC 1148  
1028 ATTCTGAAATTAAGATGATTTTCTTTTAAAGACAGATGTAATAGACATCTAAATTTCA 1087  
1149 ATTCTGAAATTAAGATGATTTTCTTTTAAAGACAGATGTAATAGACATCTAAATTTCA 1208  
1088 CTCCTCATAGAGCTTTTAAATGATGTTTCAATGATATAGGCTTTAAGAAATCACTATAA 1147  
1209 CTCCTCATAGAGCTTTTAAATGATGTTTCAATGATATAGGCTTTAAGAAATCACTATAA 1268  
1148 ATGCAATTAAGATGATCTCAATCTGTG 1174  
1269 ATGCAATTAAGATGATCTCAATCTGTG 1295  
RESULT 7  
AX775907  
LOCUS  
DEFINITION  
Sequence 177 from Patent WO03048202.  
AX775907  
ACCESSION  
AX775907.1 GI:32693625  
VERSION  
KEYWORDS  
Homo sapiens (human)  
SOURCE  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1  
AUTHORS  
Matsuda, A. and Muramatsu, S.  
TITLE  
NF-kB activating gene  
JOURNAL  
Patent: WO 03048202-A 177 12-JUN-2003;  
Asahi Kasei Kabushiki Kaisha (JP)  
FEATURES  
Location/Qualifiers  
source  
1..1696  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
251..1222  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAE11653.1"  
/db\_xref="GI:32693626"  
TASCHRAQLTVPKHEEYACQGRFLSICQFVDDGIDLRKLECSACTE  
AYSDBOYACHGCONLPALRQQLMSLPMKHLPLPLTLVRSFWDMDSAQ  
FITTSWTYLOADDGKVIPOSKPEIOYAPHEOEPNLRESLSKMSYIQVMSQAH  
RNFLDGSDFGLRCLSLNSWLTTLTLVLSVLLWCATVATATVAVQVPSKLSI  
YGLLEFMNEQKLNRYPASSLVVRSKEDHEAGPLTKYNLAHSEI"

## ORIGIN

Query Match 99.1%; Score 1163.8; DB 6; Length 1696;  
Best Local Similarity 99.8%; Pred. No. 6.5e-272;  
Matches 1165; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 8 GTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGGAACA 67  
DB 189 GAGGAGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGGAACA 248

QY 68 AGATGGCGGCGCGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGC 127  
DB 249 AGATGGCGGCGCGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGC 308

QY 128 TGTCTGACATGGCCCTTCGCGGAGGTTTCGGGACCGCTTCGGCTGGAAGCAATTGACT 187  
DB 309 TGTCTGACATGGCCCTTCGCGGAGGTTTCGGGACCGCTTCGGCTGGAAGCAATTGACT 368

QY 188 CGGTCTGGGTGATACGGCTCTTCGCCACCGGCTCTGAGTTCAGTTCAGCTACCCCTTCGACA 247  
DB 369 CGGTCTGGGTGATACGGCTCTTCGCCACCGGCTCTGAGTTCAGTTCAGCTACCCCTTCGACA 428

QY 248 CCTACCCCTAAGGAGAGGAGTTGTACGATGTTCAGAGAGGTTTCAGGCTGTTTTCAATTT 307  
DB 429 CCTACCCCTAAGGAGAGGAGTTGTACGATGTTCAGAGAGGTTTCAGGCTGTTTTCAATTT 488

QY 308 GTCAATTTGGATGATGGAATTCAGTTCAGTTCAGTTCAGTTCAGTTCAGTTCAGTTCAGT 367  
DB 489 GTCAATTTGGATGATGGAATTCAGTTCAGTTCAGTTCAGTTCAGTTCAGTTCAGTTCAGT 548

QY 368 GTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGCTGCCAGATC 427  
DB 549 GTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGCTGCCAGATC 608

QY 428 AGCTGCCATTCGCTGAATGATGAGCAAGAACCACTTATGCTCCCTGATGCCAAATTCGACC 487  
DB 609 AGCTGCCATTCGCTGAATGATGAGCAAGAACCACTTATGCTCCCTGATGCCAAATTCGACC 668

QY 488 TACTCTTTCTCTAATCTGCTGAGGTCATCTCGGAGTGCATGATGAGTGCATGAGTGCATGAG 547  
DB 669 TACTCTTTCTCTAATCTGCTGAGGTCATCTCGGAGTGCATGATGAGTGCATGAGTGCATGAG 728

QY 548 GCTTCATCAATCTCTGATGAGCTTTTATCTCAAGCGGATGAGGAAATAGTTATAT 607  
DB 729 GCTTCATCAATCTCTGATGAGCTTTTATCTCAAGCGGATGAGGAAATAGTTATAT 788

QY 608 TCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGGAGGAGCTCAAAATTTGA 667  
DB 789 TCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGGAGGAGCTCAAAATTTGA 848

QY 668 GAGAAATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCAGAGGCGACAGGA 727  
DB 849 GAGAAATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCAGAGGCGACAGGA 908

QY 728 ATTTCTTGAAGTGAAGAGTATGAGTGGCTTTTAAAGATGCTCTCTTAATCTGCTGGT 787  
DB 909 ATTTCTTGAAGTGAAGAGTATGAGTGGCTTTTAAAGATGCTCTCTTAATCTGCTGGT 968

QY 788 GGATTTTAACTACAACTCTTCTCTCTCGGTGATGATTTGCTTTGGATTTGTTGCAAA 847  
DB 969 GGATTTTAACTACAACTCTTCTCTCTCGGTGATGATTTGCTTTGGATTTGTTGCAAA 1028

QY 848 CTGTTGCTACAGCTGTGGAGAGTATGCTTCCCTCTGAGAGCTGAGTATCTATGAGTCT 907  
DB 1029 CTGTTGCTACAGCTGTGGAGAGTATGCTTCCCTCTGAGAGCTGAGTATCTATGAGTCT 1088

QY 908 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTTGGTTGTTA 967  
DB 1089 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTTGGTTGTTA 1148

QY 968 GATCTAAAATGAGATCATGAGAGCAGGCTCTTACCTACAAAGTGAATCTTGCTC 1027  
DB 1149 GATCTAAAATGAGATCATGAGAGCAGGCTCTTACCTACAAAGTGAATCTTGCTC 1208

QY 1028 ATTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAAATTTCCA 1087  
DB 1209 ATTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAAATTTCCA 1268

QY 1088 CTCCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCTTAAAGAAATCACTATATA 1147  
DB 1269 CTCCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCTTAAAGAAATCACTATATA 1328

QY 1148 ATGCAATAAAGTTACTCAAAATCTGTG 1174  
DB 1329 ATGCAATAAAGTTACTCAAAATCTGTG 1355

RESULT 8  
BD210070 1704 bp DNA linear PAT 17-JUL-2003  
LOCUS Human transmembrane protein.  
DEFINITION BD210070  
ACCESSION BD210070  
VERSION BD210070.1 GI:33019840  
KEYWORDS JP 2002516082-A/63.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 1704)  
Tang,T.Y., Lal,P., Hillman,J.L., Yue,H., Guegler,K.J., Corley,N.C.,  
Bhandan,O., Patterson,C., Gorgone,G.A., Kaser,M.R., Baughn,M.R. and  
Young,J.A.  
TITLE Human transmembrane protein  
JOURNAL Patent: JP 2002516082-A 63 04-JUN-2002;  
INCYTE PHARMACEUTICALS INC  
COMMENT OS Homo sapiens (human)  
PN JP 2002516082-A/63  
PD 04-JUN-2002 JP 2000550875  
PF 28-MAY-1999 JP 2000550875  
PR 29-MAY-1998 US 60/087260,02-JUL-1998 US 60/091674 PR  
02-OCT-1998 US 60/102954,24-NOV-1998 US 60/109869 PI TOM Y  
TANG,PREETI LAL,JENNIFER L HILLMAN,HENRY YUE,KARL J PI GUEGLER,  
PI NEIL C CORLEY,OLGA BANDMAN,CHANDRA PATTERSON,GINA A GORGONE,  
PI MATTHEW R KASER,MARIAH R BAUGHN,JANICE AU YOUNG PC  
C12N15/09,A61K38/00,A61K45/00,A61P1/04,A61P1/08,A61P1/10 PC  
PC A61P3/10,A61P5/24,A61P7/02,A61P9/10,A61P11/06 PC  
A61P17/06,A61P19/02,A61P25/06,A61P25/14,A61P25/16,  
PC A61P25/28,  
PC A61P31/04,A61P31/10,A61P31/12,A61P33/00,A61P35/00,A61P37/02,  
PC C07K14/705,  
PC C07K16/18,C12P21/02,C12Q1/68,G01N33/50,C12N15/00,A61K37/02 CC  
Incyte Clone No: 2454013  
FH Key Location/Qualifiers  
FT source 1..1704  
/organism='Homo sapiens (human)'.  
FEATURES  
source  
1..1704  
/organism='Homo sapiens'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:9606'  
ORIGIN  
Query Match 99.1%; Score 1163.8; DB 6; Length 1704;  
Best Local Similarity 99.8%; Pred. No. 6.5e-272;  
Matches 1165; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 8 GTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGGAACA 67  
DB 183 GAGGAGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGGAACA 242

QY 68 AGATGGCGGCGCGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGC 127  
DB 243 AGATGGCGGCGCGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGC 302

```
QY 128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTGGCTGAAGCATTTGACT 187
Db 303 TGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTGGCTGAAGCATTTGACT 362
QY 188 CGGTCTTGCGGTGATACGGCGTCTTGCCACACGGGCGCTGTCAGTTGACCTACCCCTTCGACA 247
Db 363 CGGTCTTGCGGTGATACGGCGTCTTGCCACACGGGCGCTGTCAGTTGACCTACCCCTTCGACA 422
QY 248 CCTACCTTAAGAGAGAGAGTGTACGATGTCAGAGAGTGTGACGCTGTTTCAATTT 307
Db 423 CCTACCTTAAGAGAGAGAGTGTACGATGTCAGAGAGTGTGACGCTGTTTCAATTT 482
QY 308 GTCACTTTGTGATGATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAAT 367
Db 483 GTCACTTTGTGATGATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAAT 542
QY 368 GTACAGAAAGCATATCCAACTGATGAGAGCAATATGTTGCCATCTTGGTTCGCAAAATC 427
Db 543 GTACAGAAAGCATATCCAACTGATGAGCAATATGTTGCCATCTTGGTTCGCAAAATC 602
QY 428 AGCTGCCATTCGCTGAAGTGAAGCAAGCAAACTTATGTCCTGATGCGCAAAATGCAAC 487
Db 603 AGCTGCCATTCGCTGAAGTGAAGCAAGCAAACTTATGTCCTGATGCGCAAAATGCAAC 662
QY 488 TACTCTTTCTCTAATCTGCTGAGGTCATCTCGAGTGATGATGAGTCTCCGACAG 547
Db 663 TACTCTTTCTCTAATCTGCTGAGGTCATCTCGAGTGATGATGAGTCTCCGACAG 722
QY 548 GCTTCATACCTCTCATGAGCTTTTATCTTCAAGCGGATGCGGAATATGATAT 607
Db 723 GCTTCATACCTCTCATGAGCTTTTATCTTCAAGCGGATGCGGAATATGATAT 782
QY 608 TCAGCTTAAGCAGAAATCCAGTACGACCAATTTGGAGCGAGGCTTCAAAATTTGA 667
Db 783 TCAGCTTAAGCAGAAATCCAGTACGACCAATTTGGAGCGAGGCTTCAAAATTTGA 842
QY 668 GAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCAGAGCGACAGGA 727
Db 843 GAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCAGAGCGACAGGA 902
QY 728 ATTTCTTTGAAGATGAGAAAGTATGCTTTTAAAGATGCTCTCTTAACTCTGGGT 787
Db 903 ATTTCTTTGAAGATGAGAAAGTATGCTTTTAAAGATGCTCTCTTAACTCTGGGT 962
QY 788 GGATTTTAACTTAACTCTTCTCTCGGTGATGATGCTTTGGATTTGTTGCA 847
Db 963 GGATTTTAACTTAACTCTTCTCTCGGTGATGATGCTTTGGATTTGTTGCA 1022
QY 848 CTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGCTGACT 907
Db 1023 CTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGCTGACT 1082
QY 908 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTGTTA 967
Db 1083 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTGTTA 1142
QY 968 GATCTAAACTGAAGATCATGAAGAGCAGGCGCTTACCTTACAAAGTCAATCTTGCTC 1027
Db 1143 GATCTAAACTGAAGATCATGAAGAGCAGGCGCTTACCTTACAAAGTCAATCTTGCTC 1202
QY 1028 ATCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAAATTTCA 1087
Db 1203 ATCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAAATTTCA 1262
QY 1088 CTCTCTCATAGAGCTTTTAAATGTTTTCATTTGGATATAGGCTTTAAGAAATCATATA 1147
Db 1263 CTCTCTCATAGAGCTTTTAAATGTTTTCATTTGGATATAGGCTTTAAGAAATCATATA 1322
QY 1148 ATGCAAAATAAGTTACTCAATCTGTG 1174
Db 1323 ATGCAAAATAAGTTACTCAATCTGTG 1349
```

```
RESULT 9
AF290615 1709 bp mRNA linear PRI 01-APR-2001
LOCUS Homo sapiens clone E9271 liver membrane-bound protein mRNA,
DEFINITION complete cds.
ACCESSION AF290615
VERSION AF290615.1 GI:13491977
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Qu, X., Zhang, C., Zhai, Y., Wu, S., Yu, Y., Wei, H., Xing, G., Lu, C.,
Zhou, G., Dong, C. and He, F.
TITLE Homo sapiens liver membrane-bound protein mRNA
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1709)
AUTHORS Qu, X., Zhang, C., Yu, Y., Wu, S., Wei, H., Xing, G., Zhai, Y., Lu, C.,
Wang, M. and He, F.
TITLE Direct Submission
JOURNAL Submitted (28-JUL-2000) Department of Genomics and Proteomics,
Institute of Radiation Medicine, Beijing Taiping Road 27, Beijing
100850, P. R. China
FEATURES
source
1..1709
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosome="1"
/map="lp33-p32.1"
/clone="E9271"
/tissue_type="liver"
/dev_stage="fetus"
251..1222
note="LMBP: similar to mouse thymic dendritic
cell-derived factor 1"
/codon_start=1
/product="liver membrane-bound protein"
/protein_id="AAK28026.1"
/db_xref="GI:13491978"
/translational="MAAPKSLWVRQLGLPPLLTLTALAGSGTASAEAFDSVLGD
TASCHACOLTYPLHTYKKEELVACQRCRLFSICQFVDDGIDINRKLCEACTE
AYQSDEQYACHLGCQQLPFAELRQQLSLMPKMLLPPLTLVRSFSDMWSAOS
FITSSTFYQADDKLVIFQSKPFIQYAPHLQEPFTNLRSSLSKMSYLRNSQAH
RNFLPDGSDGFLRCLSLNSGWLFTTLVLVSVLLWICCATVAVBQYVPSKLSI
YGDLEFMNQKLNRYPASSLVVVRVRSKTDHBEAGPLPTKVNLAHSEI"
CDS
Query Match 99.18; Score 1163.8; DB 9; Length 1709;
Best Local Similarity 99.88; Pred. No. 6.5e-272;
Matches 1165; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 8 GTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGAAACA 67
Db 189 GAGGAGAAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGAAACA 248
QY 68 AGATGGCGCGCCGAGGGGAGCTCTGGGTGAGGACCAACTGGGGCTCCCGCGCTGC 127
Db 249 AGATGGCGCGCCGAGGGGAGCTCTGGGTGAGGACCAACTGGGGCTCCCGCGCTGC 308
QY 128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTGGCTGAAGCATTTGACT 187
Db 309 TGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTGGCTGAAGCATTTGACT 368
QY 188 CGGTCTTGCGGTGATACGGCGTCTTGCCACACGGGCGCTGTCAGTTGACCTACCCCTTCGACA 247
Db 369 CGGTCTTGCGGTGATACGGCGTCTTGCCACACGGGCGCTGTCAGTTGACCTACCCCTTCGACA 428
QY 248 CCTACCTTAAGAGAGAGTGTGATGCAATGTCAGAGAGTGTGACGCTGTTTCAATTT 307
Db 429 CCTACCTTAAGAGAGAGTGTGATGCAATGTCAGAGAGTGTGACGCTGTTTCAATTT 488
```



586 AGCTGCCATTCCGCTGAACCTGAGACAGAACAACTTATGTCCCTGATGCCAAAATGCAAC 645  
488 TACTCTTCTCTTAACTCTGCTGAGGTCATCTCTGGAGTGACATGATGAGTCCGGCAGAGA 547  
646 TACTCTTCTCTTAACTCTGCTGAGGTCATCTCTGGAGTGACATGATGAGTCCGGCAGAGA 705  
548 GCTTCATTAACCTCTTCACTGAGGCTTTTATCTTCAAGCGGATGACGGAATAATAGTTATAT 607  
706 GCTTCATTAACCTCTTCACTGAGGCTTTTATCTTCAAGCGGATGACGGAATAATAGTTATAT 765  
608 TCCAGTCTAAGCAGAAATCCAGTACGACACCAATTTGGAGCAGAGCCTTCAAAATTTGA 667  
766 TCCAGTCTAAGCAGAAATCCAGTACGACACCAATTTGGAGCAGAGCCTTCAAAATTTGA 825  
668 GAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCGCAGAGA 727  
826 GAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCGCAGAGA 885  
728 ATTTCTTTGAGATGAGAAATGATGCTTTTAAAGATGCTCTCTTAACTCTTGGGT 787  
886 ATTTCTTTGAGATGAGAAATGATGCTTTTAAAGATGCTCTCTTAACTCTTGGGT 945  
788 GGATTTTAACTCAAACTCTTCTCTCGGTGATGCTTATGCTTTGGATTTGTTGCAAA 847  
946 GGATTTTAACTCAAACTCTTCTCTCGGTGATGCTTATGCTTTGGATTTGTTGCAAA 1005  
848 CTGTTGCTACAGCTGAGCAGATGATGCTCTGAGAGCTGAGATCTCTATGCTGACT 907  
1006 CTGTTGCTACAGCTGAGCAGATGATGCTCTGAGAGCTGAGATCTCTATGCTGACT 1065  
908 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGTCTCTCTTGGTGTGTTA 967  
1066 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGTCTCTCTTGGTGTGTTA 1125  
968 GATCTTAACTGAGATCATGAGAGCAGAGGCTCTACCTACCAAAATGAGTCTGCTC 1027  
1126 GATCTTAACTGAGATCATGAGAGCAGAGGCTCTACCTACCAAAATGAGTCTGCTC 1185  
1028 ATTCTGAAATTTAAGCATTTTCTTTTAAAGACAGAGTGTAAATAGACATCTTAAATTTCCA 1087  
1186 ATTCTGAAATTTAAGCATTTTCTTTTAAAGACAGAGTGTAAATAGACATCTTAAATTTCCA 1245  
1088 CTCTCATAGAGCTTTTAAATGCTTCAATGATAGAGCTTAAAGAAATCACTATAA 1147  
1246 CTCTCATAGAGCTTTTAAATGCTTCAATGATAGAGCTTAAAGAAATCACTATAA 1305  
1148 ATGCAATTAAGTTACTCAAACTCTGT 1174  
1306 ATGCAATTAAGTTACTCAAACTCTGT 1332  
RESULT 11  
LOCUS BD233468  
DEFINITION Human protein having hydrophobic domain and DNA encoding the same.  
ACCESSION BD233468  
VERSION BD233468.1 GI:33043238  
KEYWORDS JP 2002519016-A/14.  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 1121)  
AUTHORS Kato, S. and Kimura, T.  
TITLE Human protein having hydrophobic domain and DNA encoding the same  
JOURNAL Patent: JP 2002519016-A 14 02-JUL-2002;  
SAGAMI CHEMICAL RESEARCH CENTER, PROTEGENE INC  
COMMENT OS Homo sapiens (human)  
PN JP 2002519016-A/14  
PD 02-JUL-2002  
PF 18-JUN-1999 JP 2000557267  
PI SEISHI KATO, TOMOKO KIMURA  
PC

C12N15/09, C07K14/47, C12N1/15, C12N1/19, C12N5/10, C12N5/00, C12N5/ PC  
00  
CC Human protein having hydrophobic domain and DNA encoding the  
CC same  
FH Key Location/Qualifiers  
FT source 1..1121  
FT /organism='Homo sapiens (human)'.  
FEATURES  
source  
1..1121  
/organism='Homo sapiens'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:9606'  
ORIGIN  
Query Match 95.58; Score 1121; DB 6; Length 1121;  
Best Local Similarity 100.0%; Pred. No. 1.6e-261;  
Matches 1121; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
54 GACAGAGGGGAAACAAGATGGCGCGCGGAGGAGGAGGCTCTGGGTGAGGACCAACTGGG 113  
Db 1 GACAGAGGGGAAACAAGATGGCGCGCGGAGGAGGAGGCTCTGGGTGAGGAGGAGGAGG 60  
114 GCTCCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 173  
Db 61 GCTCCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 120  
174 TGAAGCATTTGACTCGGTCTTGGGTGATACGGGTCTTGGCCACCGGGGCTGTGAGTTGAC 233  
Db 121 TGAAGCATTTGACTCGGTCTTGGGTGATACGGGTCTTGGCCACCGGGGCTGTGAGTTGAC 180  
234 CTACCCCTTGACACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCT 293  
Db 181 CTACCCCTTGACACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCT 240  
294 GCTGTTTTCAATTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 353  
Db 241 GCTGTTTTCAATTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 300  
354 ATGTGAATCTGCATGTACAGAGCATATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 413  
Db 301 ATGTGAATCTGCATGTACAGAGCATATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360  
414 TGGTTGCCAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 473  
Db 361 TGGTTGCCAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420  
474 GCCAAAATGCACTTACTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 533  
Db 421 GCCAAAATGCACTTACTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 480  
534 GGACTCCGCGCAGAGCTTCAATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 593  
Db 481 GGACTCCGCGCAGAGCTTCAATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 540  
594 AAAAAATAGTTATTTCCAGTCTAAGCAGAAATCCAGTACGACCAATTTGGAGGAGGAGGA 653  
Db 541 AAAAAATAGTTATTTCCAGTCTAAGCAGAAATCCAGTACGACCAATTTGGAGGAGGAGGA 600  
654 GCTTACAAATTTGAGAGATCATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 713  
Db 601 GCTTACAAATTTGAGAGATCATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 660  
714 ACAAGCGCAGAGAAATTTTCTTGAAGATGGAAGAGTGAAGGCTTTTAAAGATGCTCTC 773  
Db 661 ACAAGCGCAGAGAAATTTTCTTGAAGATGGAAGAGTGAAGGCTTTTAAAGATGCTCTC 720  
774 TCTTAATCTGGTGGATTTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACT 833  
Db 721 TCTTAATCTGGTGGATTTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACT 780  
834 GATTGTTGTCGCAACTGTTGCTTACAGCTGTGAGCAGATATGTTCCCTCTGAGAACTGAG 893  
Db 781 GATTGTTGTCGCAACTGTTGCTTACAGCTGTGAGCAGATATGTTCCCTCTGAGAACTGAG 840

QY 894 TATCTATGGTGGACCTTGAGTGTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTC 953  
DB 841 TATCTATGGTGGACCTTGAGTGTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTC 900  
QY 954 TCTTGTGGTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTTACCTACAAA 1013  
DB 901 TCTTGTGGTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTTACCTACAAA 960  
QY 1014 AGTGAATCTTCTCATCTGAAATTTAAGCAATTTTCTTTAAAGACCAAGTGTATAGA 1073  
DB 961 AGTGAATCTTCTCATCTGAAATTTAAGCAATTTTCTTTAAAGACCAAGTGTATAGA 1020  
QY 1074 CATCTAAATTTCCACTCTCATAGAGCTTTTAAAGTGTATGATATAGGCCCTTAA 1133  
DB 1021 CATCTAAATTTCCACTCTCATAGAGCTTTTAAAGTGTATGATATAGGCCCTTAA 1080  
QY 1134 GAAATCACTATAAATGCAATAAAGTTACTCAAACTCTGTG 1174  
DB 1081 GAAATCACTATAAATGCAATAAAGTTACTCAAACTCTGTG 1121

RESULT 12  
AX136301  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

AX136301  
Sequence 223 from Patent EP1067182.  
AX136301  
AX136301.1 GI:14272707  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Ota, T., Isogai, T., Nishikawa, T., Kawai, Y., Sugiyama, T. and  
Hayashi, K.  
Secretory protein or membrane protein  
Patent: EP 1067182-A 223 10-JAN-2001;  
Helix Research Institute (JP)  
Location/Qualifiers  
1..1457  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
14..985  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAC39792.1"  
/db\_xref="GI:14272708"  
/translation="MAAPKGLSLWRTQGLPPLLLTALAGSGTSASAEAFDSVLGD  
TASCHRAQOLYPLHTYKBEELYACQGRCLFSIQFVDDIDLNRKLECSACTE  
AYSDQEQYACHLGCQNLPAELRQQLMSLMPKHLPLTLVRSFWSMDMSAQS  
FITSWTFLQADQKIVIFOSKEIOYAPHLQEPNTLRESLSKMSVLYOMNSOAH  
RNFLDQESDGLCLSLNSGWLITTLVLVSVLLWICCATVATAVEQVVPSEKLSI  
YGDLEFMNEQKLNRYPASSLVVRSKTEDHEEAGPLPTKYNLAHSEI"

CDS  
1457  
Query Match 95.2%; Score 1118; DB 6; Length 1457;  
Best Local Similarity 100.0%; Pred. No. 8.8e-261;  
Matches 1118; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 57 AGAGGGGACACAGATGGGGCCGACGAGGAGCTCTGGGTGAGGACCCAACTGGGGCT 116  
DB 1 AGAGGGGACACAGATGGGGCCGACGAGGAGCTCTGGGTGAGGACCCAACTGGGGCT 60  
QY 117 CCGCGCGTGTCTGTGCTGACCATGGCTTGGCGGAGGTTTCGGGGACCGCTTCGGGTGA 176  
DB 61 CCGCGCGTGTCTGTGCTGACCATGGCTTGGCGGAGGTTTCGGGGACCGCTTCGGGTGA 120  
QY 177 AGCATTTGACTCGGTCTTGGGTGTATACGGCGTCTTGGCCACGGGCCCTGTGAGTTGACCTA 236  
DB 121 AGCATTTGACTCGGTCTTGGGTGTATACGGCGTCTTGGCCACGGGCCCTGTGAGTTGACCTA 180

QY 237 CCCTTSCACACCTACCTAAGGAAGAGGAGTGTGTACGATCTCAGAGAGTGTGAGGCT 296  
DB 181 CCCTTSCACACCTAAGGAAGAGGAGTGTGTACGATCTCAGAGAGTGTGAGGCT 240  
QY 297 GTTTTCAATTTGTGAGTGTGATGATGGAATTTAAATCGAATCGAATCGAATCGAATG 356  
DB 241 GTTTTCAATTTGTGAGTGTGATGATGGAATTTAAATCGAATCGAATCGAATG 300  
QY 357 TGAATCTGCAATGACAGAGCATATTTCCAACTGTGATGAGCAATATGCTTGCATCTTGG 416  
DB 301 TGAATCTGCAATGACAGAGCATATTTCCAACTGTGATGAGCAATATGCTTGCATCTTGG 360  
QY 417 TTGCCAGAAATCAGCTGCCATTTCCCTGAACTGTGAGCAAGCAACTATGCTCCCTGATGCC 476  
DB 361 TTGCCAGAAATCAGCTGCCATTTCCCTGAACTGTGAGCAAGCAACTATGCTCCCTGATGCC 420  
QY 477 AAAAATGCACCTACTCTTTTCTCTAACTCTGTGTGAGGTCAATTTCTGGAGTGACATGGA 536  
DB 421 AAAAATGCACCTACTCTTTTCTCTAACTCTGTGTGAGGTCAATTTCTGGAGTGACATGGA 480  
QY 537 CTCGGCAAGAGCTTCATAACCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGAAA 596  
DB 481 CTCGGCAAGAGCTTCATAACCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGAAA 540  
QY 597 AATAGTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTTTGGAGCAGAGCC 656  
DB 541 AATAGTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTTTGGAGCAGAGCC 600  
QY 657 TACAAATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACA 716  
DB 601 TACAAATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACA 660  
QY 717 AGCCACAGAGAAATTTTCTTCAAGATGAGAGAAATGATGCTTTTAAAGATGCTCTCTCT 776  
DB 661 AGCCACAGAGAAATTTTCTTCAAGATGAGAGAAATGATGCTTTTAAAGATGCTCTCTCT 720  
QY 777 TAATCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTGGAT 836  
DB 721 TAATCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTGGAT 780  
QY 837 TTGTTGTGCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTAT 896  
DB 781 TTGTTGTGCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTAT 840  
QY 897 CTATGGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCT 956  
DB 841 CTATGGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCT 900  
QY 957 TGTGGTGTAGATCTTAAACTGAAGTCAATGAAGCAGGAGGCTTCTACCTACAAAAGT 1016  
DB 901 TGTGGTGTAGATCTTAAACTGAAGTCAATGAAGCAGGAGGCTTCTACCTACAAAAGT 960  
QY 1017 GAAATCTTGTCTCATCTGAAATTTTAAAGCATTTTCTTTTAAAGACCAAGTGTATAGACAT 1076  
DB 961 GAAATCTTGTCTCATCTGAAATTTTAAAGCATTTTCTTTTAAAGACCAAGTGTATAGACAT 1020  
QY 1077 CTAAAAATTCACCTCTCATAGAGCTTTTAAATGGTTCATTTGGATATAGGCTTAAAGA 1136  
DB 1021 CTAAAAATTCACCTCTCATAGAGCTTTTAAATGGTTCATTTGGATATAGGCTTAAAGA 1080  
QY 1137 ATCACTATAAATGCAATAAAGTTACTCAAACTCTGTG 1174  
DB 1081 ATCACTATAAATGCAATAAAGTTACTCAAACTCTGTG 1118

RESULT 13  
BD123603  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS

BD123603  
Secretory protein or membrane protein.  
BD123603  
BD123603.1 GI:23218548  
JP 2002017376-A/112.



```
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Ota, T., Isogai, T., Nishikawa, T., Kawai, Y., Sugiyama, T. and
Hayashi, K.
TITLE Secretory protein or membrane protein
JOURNAL Patent: JP 2002017376-A 112 22-JAN-2002;
COMMENT HELIX RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002017376-A/112
PF 07-JUL-2000 JP 2002053173
PI TOSHIO Ota, TAKAO ISOGAI, TETSUO NISHIKAWA, YURI KAWAI, TOMOYASU
PI SUGIYAMA,
PI KOJI HAYASHI
PC
C12N15/09, C07K14/47, C07K16/18, C12N1/19, C12N1/21, C12N5/ PC
10, C12P21/02, C12Q1/68//C12P21/08, C12N15/00, C12N5/00 CC
Secretory protein or membrane protein
PH Key Location/Qualifiers
FT CDS (14)..(982).
FEATURES
source
1..1457
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 95.2%; Score 1118; DB 6; Length 1457;
Best Local Similarity 100.0%; Pred. No. 8.8e-261;
Matches 1118; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 57 AGAGGGGAACAAGATGGCGGCCGCAAGAGGAGGCTCTGGGTGAGGACCCCACTGGGGCT 116
DB 1 AGAGGGGAACAAGATGGCGGCCGCAAGAGGAGGCTCTGGGTGAGGACCCCACTGGGGCT 60
QY 117 CCGCGCGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTCGGCTGA 176
DB 61 CCGCGCGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTCGGCTGA 120
QY 177 AGCAATTTGACTGGCTTGGGTGATACGGCGCTTTGGCCACCGGCGCTGTCAAGTTGACCTA 236
DB 121 AGCAATTTGACTGGCTTGGGTGATACGGCGCTTTGGCCACCGGCGCTGTCAAGTTGACCTA 180
QY 237 CCGCTTGCACACTCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCT 296
DB 181 CCGCTTGCACACTCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCT 240
QY 297 GTTTTCAATTTGCTAGTTTGTGGATGGAATTCGACTTAATCGAATCAATTAATTTGGAATG 356
DB 241 GTTTTCAATTTGCTAGTTTGTGGATGGAATTCGACTTAATCGAATCAATTAATTTGGAATG 300
QY 357 TGAATCTGATGTACAGAGCATATTCCTCAATCTGATGCAATATGCTTCCCATCTTGG 416
DB 301 TGAATCTGATGTACAGAGCATATTCCTCAATCTGATGCAATATGCTTCCCATCTTGG 360
QY 417 TTCCAGAAATCAGCTGCCATTCGCTGAATCGACGACAGCAACCTATATGTCCTCGATGCC 476
DB 361 TTCCAGAAATCAGCTGCCATTCGCTGAATCGACGACAGCAACCTATATGTCCTCGATGCC 420
QY 477 AAAAATGCACCTACTCTTCTTCACTCTGCTAGGTCATCTGGAGTCATGATGGA 536
DB 421 AAAAATGCACCTACTCTTCTTCACTCTGCTAGGTCATCTGGAGTCATGATGGA 480
QY 537 CTCGGACACAGCTTCATTAACCTCTTCAATGACTTTTATCTTCAAGCCGATGACGAAA 596
DB 481 CTCGGACACAGCTTCATTAACCTCTTCAATGACTTTTATCTTCAAGCCGATGACGAAA 540
QY 597 AATAGTTATATTCAGCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCGAGGCC 656
```

```
DB 541 AATAGTTATATTCAGCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCGAGGCC 600
QY 657 TACAAATTTGAGAGATCATCTCTTAAGCAAAATGTCTCTATCTCAAAATGAGAATTCACA 716
DB 601 TACAAATTTGAGAGATCATCTCTTAAGCAAAATGTCTCTATCTCAAAATGAGAATTCACA 660
QY 717 AGCCACAGGAAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCCCTCTCTCT 776
DB 661 AGCCACAGGAAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCCCTCTCTCT 720
QY 777 TAACTCTGGGTGGATTTTAACTCAACTCTTGTCTCTCGGTGATGATTTGCTTTGGAT 836
DB 721 TAACTCTGGGTGGATTTTAACTCAACTCTTGTCTCTCGGTGATGATTTGCTTTGGAT 780
QY 837 TTGTGTCAACTGTTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCGTGGAT 896
DB 781 TTGTGTCAACTGTTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCGTGGAT 840
QY 897 CTATGGTGACCTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCT 956
DB 841 CTATGGTGACCTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCT 900
QY 957 TGTGTTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGT 1016
DB 901 TGTGTTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGT 960
QY 1017 GAATCTTCTCATTTCTGAAATTTTAAAGCATTTTCTTTTAAAGACAAAGTATAACAT 1076
DB 961 GAATCTTCTCATTTCTGAAATTTTAAAGCATTTTCTTTTAAAGACAAAGTATAACAT 1020
QY 1077 CTAAATTTCCACTCTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAGAA 1136
DB 1021 CTAAATTTCCACTCTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAGAA 1080
QY 1137 ATCACTATAAATGCAATAAAGTTACTCAATCTGTG 1174
DB 1081 ATCACTATAAATGCAATAAAGTTACTCAATCTGTG 1118
RESULT 14
AK075505 1457 bp mRNA linear PRI 03-SEP-2002
LOCUS Homo sapiens cDNA PSEC0203 fis, clone HEMBA1002441.
DEFINITION AK075505
ACCESSION AK075505.1 GI:22761691
VERSION oligo capping; fis (full insert sequence).
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Ota, T., Nishikawa, T., Suzuki, Y., Kawai-Hio, Y., Hayashi, K.,
Ishii, S., Saito, K., Yamamoto, J., Wakamatsu, A., Nagai, T.,
Nakamura, Y., Nagahashi, K., Sugano, S. and Isogai, T.
HRI human cDNA sequencing project
TITLE HRI human cDNA sequencing project
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1457)
AUTHORS Isogai, T. and Yamamoto, J.
TITLE Direct Submission
JOURNAL
COMMENT
FEATURES
source
1..1457
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEMBA1002441"
```



/tissue\_type="whole embryo, mainly head"  
/clone\_lib="HEMBA1"  
/dev\_stage="embryo, 10 weeks"  
/notes="cloning vector: pME18SFL3"  
14..985  
/notes="unnamed protein product"  
/codon\_start=1  
/protein\_id="BAC11658.1"  
/db\_xref="GI:22761692"  
/translations="MAAPKGLWVRLTQLGLPPLLLITMALAGSGTASAEAFDSVLGD  
TASCHACOLYPLHYVPEKEELYACORGRFLPSICOFVDDGIDINRNLKLECSACTE  
AYSQSEYOYACHLGCQNLPPPAELRQELKSLMPKXHLPLPLTLVRSFWSMDMSAOS  
FITSWTYIQADDGKLVIFQSKPEIQIAPHLEQEPFTNRESLSKSNLYLQWRSQAH  
RNFLDEGSEDFRLCSLNSGWTLLTLLVLSVLLWCCATTAATVAVQVPESEKLIS  
YGLDFPMNEOKLARYPASSLVVRSKTEDEEAGPLPTKYNLAHSEI"

## CDS

## ORIGIN

Query Match 95.2%; Score 1118; DB 9; Length 1457;  
Best Local Similarity 100.0%; Pred. No. 8.8e-261; Indels 0; Gaps 0;  
Matches 1118; Conservative 0; Mismatches 0;  
QY 57 AGAGGGGAACAAGATGCGGCGCGCGAAGGGAGCCTCTGGGTGAGACCACTGGGGCT 116  
DB 1 AGAGGGGAACAAGATGCGGCGCGCGAAGGGAGCCTCTGGGTGAGACCACTGGGGCT 60  
QY 117 CCCGCCGCTGCTGCTGACCAATGGCCTTGGCGGAGGTTGCGGACCGCTTCGGCTGA 176  
DB 61 CCCGCCGCTGCTGCTGACCAATGGCCTTGGCGGAGGTTGCGGACCGCTTCGGCTGA 120  
QY 177 AGCAATTTGACTCGGTCTTGGGTGATACGGCTCTTCCACCGCGGCTGTCAAGTTGACCTA 236  
DB 121 AGCAATTTGACTCGGTCTTGGGTGATACGGCTCTTCCACCGCGGCTGTCAAGTTGACCTA 180  
QY 237 CCCCTTGACACCTACCTTAAGGAAGAGGAGTGTACGATGTCAGAGGTTGCAAGCT 296  
DB 181 CCCCTTGACACCTACCTTAAGGAAGAGGAGTGTACGATGTCAGAGGTTGCAAGCT 240  
QY 297 GTTTTCAATTTGTGAGTGTGATGGAATTTGACTTAATTCGAACCTAAATTTGGAATG 356  
DB 241 GTTTTCAATTTGTGAGTGTGATGGAATTTGACTTAATTCGAACCTAAATTTGGAATG 300  
QY 357 TGAATCTGCATGTACAGAGCATATTCCTCATCTGATGAGCATATGCTTGCATCTTGG 416  
DB 301 TGAATCTGCATGTACAGAGCATATTCCTCATCTGATGAGCATATGCTTGCATCTTGG 360  
QY 417 TTGCCAGAAATCAGTGCCTGCTGAACTCAGACCAAGAACTTATGTCCTGATGCC 476  
DB 361 TTGCCAGAAATCAGTGCCTGCTGAACTCAGACCAAGAACTTATGTCCTGATGCC 420  
QY 477 AAAAAATGACCTACTCTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGTGGA 536  
DB 421 AAAAAATGACCTACTCTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGTGGA 480  
QY 537 CTCCGCACAGAGCTTCATAAAGCTTTCATGAGCTTTTATCTTCAAGCCGATACCGAA 596  
DB 481 CTCCGCACAGAGCTTCATAAAGCTTTCATGAGCTTTTATCTTCAAGCCGATACCGAA 540  
QY 597 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGAGCC 656  
DB 541 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGAGCC 600  
QY 657 TACAAATTTGAGAGTATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACA 716  
DB 601 TACAAATTTGAGAGTATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACA 660  
QY 717 AGCGCACAGAAATTTCTTGAAGTGGAGAAAGTATGGCTTTTTAAGATCCCTCTCTCT 776  
DB 661 AGCGCACAGAAATTTCTTGAAGTGGAGAAAGTATGGCTTTTTAAGATCCCTCTCTCT 720  
QY 777 TAATCTGGGTGGATTTTAACTACAACTTTGCTCTCGGTGATGATGCTTTTGGAT 836  
DB 721 TAATCTGGGTGGATTTTAACTACAACTTTGCTCTCGGTGATGATGCTTTTGGAT 780

QY 837 TTCTTGTCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTAT 896  
DB 781 TTCTTGTCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTAT 840  
QY 897 CTATGTGTACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCT 956  
DB 841 CTATGTGTACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCT 900  
QY 957 TGTGGTGTGTAGATCTAATAACTGAAGATCATGAAGCAGGCGCTCTACCTACAAAAGT 1016  
DB 901 TGTGGTGTGTAGATCTAATAACTGAAGATCATGAAGCAGGCGCTCTACCTACAAAAGT 960  
QY 1017 GAATCTGTCTCATCTTGAATTTTAAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACAT 1076  
DB 961 GAATCTGTCTCATCTTGAATTTTAAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACAT 1020  
QY 1077 CTAAATTCACCTCTCTCATAGAGCTTTTAAATGTTTCATTTGGATATAGGCTTAAGAA 1136  
DB 1021 CTAAATTCACCTCTCTCATAGAGCTTTTAAATGTTTCATTTGGATATAGGCTTAAGAA 1080  
QY 1137 ATCACTATAAATGCAATTAAGTTTACTCAAAATCTGTG 1174  
DB 1081 ATCACTATAAATGCAATTAAGTTTACTCAAAATCTGTG 1118  
RESULT 15  
AX683269 1138 bp DNA linear PAT 29-MAR-2003  
LOCUS Sequence 13 from Patent WO03006687.  
DEFINITION AX683269  
ACCESSION AX683269  
VERSION AX683269.1 GI:29370420  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Reuner, B., Bunk, D. and Henkel, T.  
TITLE Novel target genes for diseases of the heart  
PATENT: WO 03006687-A 13 23-JAN-2003;  
JOURNAL Medigene AG (DE)  
FEATURES  
Location/Qualifiers  
source 1..1138  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 94.2%; Score 1106; DB 6; Length 1138;  
Best Local Similarity 99.9%; Pred. No. 7.1e-258; Indels 1; Gaps 1;  
Matches 1117; Conservative 0; Mismatches 0;  
QY 57 AGAGGGGAACAAGATGCGGCGCGCGAAGGGAGCCTCTGGGTGAGACCACTGGGGCT 116  
DB 3 AGAGGGGAACAAGATGCGGCGCGCGAAGGGAGCCTCTGGGTGAGACCACTGGGGCT 61  
QY 117 CCCGCCGCTGCTGCTGACCAATGGCCTTGGCGGAGGTTTGGGACCGCTTCGGCTGA 176  
DB 62 CCCGCCGCTGCTGCTGACCAATGGCCTTGGCGGAGGTTTGGGACCGCTTCGGCTGA 121  
QY 177 AGCAATTTGACTCGGTCTTGGGTGATACGGCTCTTGCACCGGCGCTGTCAAGTTGACCTA 236  
DB 122 AGCAATTTGACTCGGTCTTGGGTGATACGGCTCTTGCACCGGCGCTGTCAAGTTGACCTA 181  
QY 237 CCCCTTGACACCTACCTTAAGGAAGAGGAGTGTACGATGTCAGAGGTTGCAAGCT 296  
DB 182 CCCCTTGACACCTACCTTAAGGAAGAGGAGTGTACGATGTCAGAGGTTGCAAGCT 241  
QY 297 GTTTTCAATTTGTGAGTGTGATGGAATTTGACTTAATTCGAACCTAAATTTGGAATG 356  
DB 242 GTTTTCAATTTGTGAGTGTGATGGAATTTGACTTAATTCGAACCTAAATTTGGAATG 301  
QY 357 TGAATCTGCATGTACAGAGCATATTCCTCATCTGATGAGCATATGCTTGCATCTTGG 416

Db 302 TGAATCTGATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGTTGCCATCTGG 361  
Qy 417 TTGCCAGATCAGCTGCCATTCGCTGAATCGAGACAGAACTATATGTCCTCGATGCC 476  
Db 362 TTGCCAGATCAGCTGCCATTCGCTGAATCGAGACAGAACTATATGTCCTCGATGCC 421  
Qy 477 AAAAAATGCACTACTCTTTCTCTTAATCTGATGAGTCAATCTGGAGTCAATGATGGA 536  
Db 422 AAAAAATGCACTACTCTTTCTCTTAATCTGATGAGTCAATCTGGAGTCAATGATGGA 481  
Qy 537 CTCGCGACAGAGCTTCATCAATCTCTTCATGAGTCTTTTATCTCAAGCCGATGACGAAA 596  
Db 482 CTCGCGACAGAGCTTCATCAATCTCTTCATGAGTCTTTTATCTCAAGCCGATGACGAAA 541  
Qy 597 AATAGTTATATTCAGTCTTAAGCCGAAATCCAGTACGACACATTTGGAGCAGAGCC 656  
Db 542 AATAGTTATATTCAGTCTTAAGCCGAAATCCAGTACGACACATTTGGAGCAGAGCC 601  
Qy 657 TACAAATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACA 716  
Db 602 TACAAATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACA 661  
Qy 717 AGCGCACAGAAATTTCTTGAAGATGAGAAATGATGCTTTTGAAGTCCCTCTCTCT 776  
Db 662 AGCGCACAGAAATTTCTTGAAGATGAGAAATGATGCTTTTGAAGTCCCTCTCTCT 721  
Qy 777 TAACTCTGGGTGATTTTAACTACCAACTCTTCTCTCTCGGTGATGATGCTTTTGGAT 836  
Db 722 TAACTCTGGGTGATTTTAACTACCAACTCTTCTCTCTCGGTGATGATGCTTTTGGAT 781  
Qy 837 TTGTTGTGCACTGTGCTACAGCTGTGAGAGCAATGATGCTTTTGAAGTCCCTCTCTCT 896  
Db 782 TTGTTGTGCACTGTGCTACAGCTGTGAGAGCAATGATGCTTTTGAAGTCCCTCTCTCT 841  
Qy 897 CTATGTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTCACTACCAAAAGT 956  
Db 842 CTATGTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTCACTACCAAAAGT 901  
Qy 957 TGTGTTGTTAGATCTAAATCTGAAGATCATGAAGACAGGGCTCTTACCTACAAAGT 1016  
Db 902 TGTGTTGTTAGATCTAAATCTGAAGATCATGAAGACAGGGCTCTTACCTACAAAGT 961  
Qy 1017 GAATCTGTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTCACTACCAAAAGT 1076  
Db 962 GAATCTGTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTCACTACCAAAAGT 1021  
Qy 1077 CTAAATTTCCACTCTCTCATAGAGCTTTTAAATGCTTTTAAATGCTTTTAAAGTAAAG 1136  
Db 1022 CTAAATTTCCACTCTCTCATAGAGCTTTTAAATGCTTTTAAATGCTTTTAAAGTAAAG 1081  
Qy 1137 ATCACTATAAATGCAATTAAGATTAATCTCAATCTGTG 1174  
Db 1082 ATCACTATAAATGCAATTAAGATTAATCTCAATCTGTG 1119

RESULT 16  
AX779812 1138 bp DNA linear PAT 14-JUL-2003  
LOCUS  
DEFINITION Sequence 1969 from Patent WO03039443.  
ACCESSION AX779812  
VERSION AX779812.1 GI:32696806  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Haferlach, T., Schoch, C., Kern, W., Kohlmann, A., Schnittger, S.,  
Dugas, M., Eils, R., Bors, B. and Mergenthaler, S.  
TITLE Novel genetic markers for leukemias  
JOURNAL Patent: WO 03039443-A 1969 15-MAY-2003;  
Deutsches Krebsforschungszentrum (DE) ;

Ludwig-Maximilian-Universitaet Muenchen (DE) ; Haferlach, Torsten,  
PD Dr. Dr. (DE) ; Schoch, Claudia (DE) ; Kern, Wolfgang (DE)  
FEATURES  
source Location/Qualifiers  
1..1138  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 94.2%; Score 1106; DB 6; Length 1138;  
Best Local Similarity 99.9%; Pred. No. 7.1e-258;  
Matches 1117; Conservative 0; Mismatches 0; Indels 1; Gaps 1;  
Qy 57 AGAGGGGACACAGATGGCGGCGGAGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCT 116  
Db 3 AGAGGGGACACAGATGGCGGCGGCGGAGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCT 61  
Qy 117 CCGCCGCTGCTGCTGTGATGACCATGGCTTTGGCCGAGGTTTCGGGGACCCGCTTCGGCTGA 176  
Db 62 CCGCCGCTGCTGCTGTGATGACCATGGCTTTGGCCGAGGTTTCGGGGACCCGCTTCGGCTGA 121  
Qy 177 AGCATTTGACCTGCTGCTGGGTGATACGGGCTCTTGCACCGGGCTGTGAGTTGACCTA 236  
Db 122 AGCATTTGACCTGCTGCTGGGTGATACGGGCTCTTGCACCGGGCTGTGAGTTGACCTA 181  
Qy 237 CCCCTTGCACACCTACCTTAAGGAGGAGGTTGTACGATGTACAGAGGTTTCAGGCT 296  
Db 182 CCCCTTGCACACCTACCTTAAGGAGGAGGTTGTACGATGTACAGAGGTTTCAGGCT 241  
Qy 297 GTTTTCAATTTGCTGCTGCTGGGTGATGAGTGAATGACTTAATCGAACTAAATTTGATG 356  
Db 242 GTTTTCAATTTGCTGCTGCTGGGTGATGAGTGAATGACTTAATCGAACTAAATTTGATG 301  
Qy 357 TGAATCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCTACTTTGG 416  
Db 302 TGAATCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCTACTTTGG 361  
Qy 417 TTGCCAGAAATCAGCTGCCATTCGCTGAATGAGACAGAACTATATGTCCTCGATGCC 476  
Db 362 TTGCCAGAAATCAGCTGCCATTCGCTGAATGAGACAGAACTATATGTCCTCGATGCC 421  
Qy 477 AAAAAATGCACTACTCTTTCTCTTAATCTGATGAGTCAATCTGGAGTCAATGATGGA 536  
Db 422 AAAAAATGCACTACTCTTTCTCTTAATCTGATGAGTCAATCTGGAGTCAATGATGGA 481  
Qy 537 TTCCGCAAGAGCTTCATCACTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGAAA 596  
Db 482 TTCCGCAAGAGCTTCATCACTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGAAA 541  
Qy 597 AATAGTTATATTCAGTCTTAAGCCGAAATCCAGTACGACACATTTGGAGCAGAGCC 656  
Db 542 AATAGTTATATTCAGTCTTAAGCCGAAATCCAGTACGACACATTTGGAGCAGAGCC 601  
Qy 657 TACAAATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACA 716  
Db 602 TACAAATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACA 661  
Qy 717 AGCGCACAGGAAATTTCTTGAAGATGAGAAATGATGCTTTTGAAGTCCCTCTCTCTCT 776  
Db 662 AGCGCACAGGAAATTTCTTGAAGATGAGAAATGATGCTTTTGAAGTCCCTCTCTCTCT 721  
Qy 777 TAACTCTGGGTGATTTTAACTACCAACTCTTCTCTCTCGGTGATGATGCTTTTGGAT 836  
Db 722 TAACTCTGGGTGATTTTAACTACCAACTCTTCTCTCTCGGTGATGATGCTTTTGGAT 781  
Qy 837 TTGTTGTGCACTGTGCTACAGCTGTGAGAGCAATGATGCTTTTGAAGTCCCTCTCTCTCT 896  
Db 782 TTGTTGTGCACTGTGCTACAGCTGTGAGAGCAATGATGCTTTTGAAGTCCCTCTCTCTCT 841  
Qy 897 CTATGTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTCACTACCAAAAGT 956  
Db 842 CTATGTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTCACTACCAAAAGT 901

```

QY 957 TGTGTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGGCTCTACCTCAAAAAGT 1016
|
|
|
Db 902 TGTGTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGGCTCTACCTCAAAAAGT 961
|
|
|
QY 1017 GAATCTTGCTCATCTCGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTAATAGACAT 1076
|
|
|
Db 962 GAATCTTGCTCATCTCGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTAATAGACAT 1021
|
|
|
QY 1077 CTAAATTCCTCTCTCATAGAGCTTTTAAATAGTGTTCATTTGATATAGGCTTAAAGAA 1136
|
|
|
Db 1022 CTAAATTCCTCTCTCATAGAGCTTTTAAATAGTGTTCATTTGATATAGGCTTAAAGAA 1081
|
|
|
QY 1137 ATCACTATAAATGCATAAAGTACTCAATCTGTG 1174
|
|
|
Db 1082 ATCACTATAAATGCATAAAGTACTCAATCTGTG 1119
|
|
|
RESULT 17
AX775909
LOCUS AX775909 1466 bp mRNA linear PAT 14-JUL-2003
DEFINITION Sequence 179 from Patent WO03048202.
ACCESSION AX775909
VERSION AX775909.1 GI:32693627
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Matsuda, A. and Muramatsu, S.
TITLE NF-kB activating gene
JOURNAL Patent: WO 03048202-A 179 12-JUN-2003;
Asahi Kasei Kabushiki Kaisha (JP)
FEATURES
source
1..1466
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
18..992
/feature="unnamed protein product"
/codon_start=1
/protein_id="CAE11654.1"
/db_xref="GI:32693628"
/translation="MAAPKSLWVTRTQLGLPPLLLTNALAGSGTASAEAFSVLGD
TASCHRAQCLTYPLTPYKBEELACQRCGLFSICQFVDGIDLNTRKLECSACTE
AYSQDEQVACQGNQQLPAELRQEQMLPKMLLPPLTLVRSFKLEMDMSAQ
FTTSWTFYLOADDKQIVIPKPEIQVAPHELEQPTNRESLSKMSDLOMRNSQA
HNFLEDEGSDGLRCLSLNSGWIITLVLVSVLLWICCATVATAVEQYVPSEKLS
IYGDLEFNEQKLNRYPASSLVVRSKTEDHEEAGPLTKVNLHSEI"
ORIGIN
Query Match 94.1%; Score 1105; DB 6; Length 1466;
Best Local Similarity 99.7%; Pred. No. 1.3e-257;
Matches 1118; Conservative 0; Mismatches 0; Indels 3; Gaps 1;
QY 57 AGAGGGGACACAGATGGCGGCGCCGAGGAGGCTCTGGGTGAGGACCCCACTGGGGCT 116
|
|
|
Db 5 AGAGGGGACACAGATGGCGGCGCCGAGGAGGCTCTGGGTGAGGACCCCACTGGGGCT 64
|
|
|
QY 117 CCGCGCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGCGGGACCGCTTCGGCTGA 176
|
|
|
Db 65 CCGCGCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGCGGGACCGCTTCGGCTGA 124
|
|
|
QY 177 AGCATTTGACTGGCTTGGGTGATACGGCGCTTTGCCACCGGGGCTGTGAGTTGACCTA 236
|
|
|
Db 125 AGCATTTGACTGGCTTGGGTGATACGGCGCTTTGCCACCGGGGCTGTGAGTTGACCTA 184
|
|
|
QY 237 CCGCTTGACACACTACCTTAAGAGAGAGGAGTGTACGCATGTACAGAGGTTGCGAGCT 296
|
|
|
Db 185 CCGCTTGACACACTACCTTAAGAGAGAGGAGTGTACGCATGTACAGAGGTTGCGAGCT 244
|
|
|
QY 297 GTTTTCAATTTGCTAGTTGCTGATGATGAATGACATTAATGAACTAAATTTGGGAATG 356
|
|
|

```

```

Db 245 GTTTTCAATTTGTCAAGTTGTGGATGATGAATGACTTAAATCGAACTAAATTTGAATG 304
|
|
|
QY 357 TGAATCTGCATGTACAGAAGCATATTCCTCAATCTGTAGAGCAATATATCTTGCCTCTTTG 416
|
|
|
Db 305 TGAATCTGCATGTACAGAAGCATATTCCTCAATCTGTAGAGCAATATATCTTGCCTCTTTG 364
|
|
|
QY 417 TTGCCAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAAACAATTTATGTCCTGATGCC 476
|
|
|
Db 365 TTGCCAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAAACAATTTATGTCCTGATGCC 424
|
|
|
QY 477 AAAAATGCACCTACTCTTTCTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGA 536
|
|
|
Db 425 AAAAATGCACCTACTCTTTCTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGA 484
|
|
|
QY 537 CTCGCGACAGAGCTTCTAATCTCTTCAATGAGACTTTTATCTTCAAGCCGATGACGAAA 596
|
|
|
Db 485 CTCGCGACAGAGCTTCTAATCTCTTCAATGAGACTTTTATCTTCAAGCCGATGACGAAA 544
|
|
|
QY 597 AATAGTTATATTCAGTCTAAGCCAGAAAATCCAGTAGCCACCAATTTGGAGCAGGAGCC 656
|
|
|
Db 545 AATAGTTATATTCAGTCTAAGCCAGAAAATCCAGTAGCCACCAATTTGGAGCAGGAGCC 604
|
|
|
QY 657 TACAAATTTGAGAGAATCATCTCTAAGCAAAAATGTCT--ATCTGCAAAATGAGAAATTC 713
|
|
|
Db 605 TACAAATTTGAGAGAATCATCTCTAAGCAAAAATGTCTCTCAGATCTGCAAAATGAGAAATTC 664
|
|
|
QY 714 ACAAGCGCACAGGAATTTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCGCTCTC 773
|
|
|
Db 665 ACAAGCGCACAGGAATTTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCGCTCTC 724
|
|
|
QY 774 TCTTAACTCTGGGTGGATTTTAACTACAACCTCTTCTCTCGGTGATGATGTTGCTTTG 833
|
|
|
Db 725 TCTTAACTCTGGGTGGATTTTAACTACAACCTCTTCTCTCGGTGATGATGTTGCTTTG 784
|
|
|
QY 834 GATTTGTTGCTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTCAGAGCTGAG 893
|
|
|
Db 785 GATTTGTTGCTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTCAGAGCTGAG 844
|
|
|
QY 894 TATCTATGCTGACTTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 953
|
|
|
Db 845 TATCTATGCTGACTTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 904
|
|
|
QY 954 TCTTGTGTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGGCTCTACCTACAAA 1013
|
|
|
Db 905 TCTTGTGTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGGCTCTACCTACAAA 964
|
|
|
QY 1014 AGTGAATCTTGCTCATCTGCAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGA 1073
|
|
|
Db 965 AGTGAATCTTGCTCATCTGCAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGA 1024
|
|
|
QY 1074 CATCTAAAATTCGACTCTCTCATAGAGCTTTTAAATGCTTTCATGATATAGCCCTTAA 1133
|
|
|
Db 1025 CATCTAAAATTCGACTCTCTCATAGAGCTTTTAAATGCTTTCATGATATAGCCCTTAA 1084
|
|
|
QY 1134 GAAATCACTATAAATGCAAAATAAGTTACTCAATCTGTG 1174
|
|
|
Db 1085 GAAATCACTATAAATGCAAAATAAGTTACTCAATCTGTG 1125
|
|
|
RESULT 18
BC016374
LOCUS BC016374 1515 bp mRNA linear PRI 12-NOV-2003
DEFINITION Homo sapiens chromosome 1 open reading frame 8, mRNA (cDNA clone
MGC:27259 IMAGE:4618034), complete cds.
ACCESSION BC016374
VERSION BC016374.1 GI:16741047
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,

```



Db 1025 CATCTAAATCCCACTCCTCATAGAGCTTTTAAATGGTTTCATGATATAGGCTTAA 1084

QY 1134 GAAATCACTATAAATCAAAATAAAGTTACTCAAACTGTG 1174

Db 1085 GAAATCACTATAAATCAAAATAAAGTTACTCAAACTGTG 1125

RESULT 19

BC003106

LOCUS

DEFINITION Homo sapiens chromosome 1 open reading frame 8, mRNA (cDNA clone

ACCSSION BC003106

VERSION BC003106.1 GI:13111876

KEYWORDS

SOURCE

ORGANISM Homo sapiens (human)

REFERENCE

AUTHORS

1 (bases 1 to 1130)

Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, P., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.P., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Udwin, T.B., Toshiyuki, S., Carninci, P., Prange, C., Raja, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullahy, S.J., Bosak, S.A., McSwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Helton, E., Kettelman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Binkley, R.W., Touchman, J.W., Green, E.D., Dickinson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smallos, D.E., Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

22388257

12477932

2 (bases 1 to 1130)

Strausberg, R.

Direct Submission

Submitted (13-FEB-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

NIH-MGC Project URL: <http://mgc.nci.nih.gov>

Contact: MGC help desk

Email: [cgapbs-remail.nih.gov](mailto:cgapbs-remail.nih.gov)

Tissue Procurement: ATCC

cDNA Library Preparation: Rubin Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Genome Sequence Centre, BC Cancer Agency, Vancouver, BC, Canada

[info@bcgsc.bc.ca](mailto:info@bcgsc.bc.ca)

Steven Jones, Jennifer Asano, Ian Bosdet, Yaron Butterfield, Susan Chan, Readman Chiu, Chris Fjell, Erin Garland, Ran Guin, Leticia Hsiao, Martin Krzywinski, Reta Kutsche, Oliver Lee, Soo Sen Lee, Victor Ling, Carrie Mathewson, Candice McLeavy, Steven Nese, Pawan Pandoh, Anna-Liisa Prabhun, Parvaneh Saeedi, Jacqueline Schein, Duane Smallos, Michael Smith, Lorraine Spence, Jeff Stott, Michael Thorne, Miranada Tsai, Nataesja van den Bosch, Jill Vardy, George Yang, Scott Zuyderduyn, Marco Marra.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

Series: IRAL Plate: 6 Row: J Column: 2

This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 20070190.

FEATURES

source

Location/Qualifiers

1..1130

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/clone="MGC:1961 IMAGE:3501639"

/issue\_type="Brain, neuroblastoma"

/clone\_lib="NIH\_MGC\_19"

/lab\_host="DH10B-R"

/notes="Vector: pOTB7"

1..1130

/gene="Clorf8"

/note="synonym: HSPC001"

/db\_xref="LocusID:9528"

69..971

/codon\_start=1

/product="Clorf8 protein"

/protein\_id="AAH03106.1"

/db\_xref="GI:13111877"

/db\_xref="LocusID:9528"

/translation="MALAGSGTGAAGAFDSVLGDTASCHRACOLTYPLHTVPEEEL YACQRCRUFSCQFVDDIDINRKLKESACTRAYSQSDEQYACHGCGQNLPPAE LRQQLMPLMKPHLLFPULVRSPWDMDSAQSFITSSWTFYLDQDKLIVIPQK PETQYAPHLQEPFTNLRSSLSKMSYLQMRNSQAHNFLEDSGDFRCLSLNSGWI LTTTLVSVMLLWVICATVATAVQYVPSEKLSIYGLDFPMNEQKLNRYFPASSLVV RSKTDEHBAGPLPTKVLNLAHSEI"

ORIGIN

Query Match 94.0%; Score 1104; DB 9; Length 1130;

Best Local Similarity 100.0%; Pred. No. 2.2e-257;

Matches 1104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 TGGGGGGCGGAAAGGGAGGCGCTCTGGGTGAGGACCCCACTCGGGCTCCGCGCGCTGCTGC 130

Db 1 TGGGGGGCGGAAAGGGAGGCGCTCTGGGTGAGGACCCCACTCGGGCTCCGCGCGCTGCTGC 60

QY 131 TGTGACCATGGCGCTTGGCGGAGGTTGGGAGACCGCTTGGCTGAAGCATTTGACTCGG 190

Db 61 TGTGACCATGGCGCTTGGCGGAGGTTGGGAGACCGCTTGGCTGAAGCATTTGACTCGG 120

QY 191 TCTTGGGTGATACGGGCTCTTGGCACGGGCGCTGTGACGTTGACCTACCCCTTGCAACCT 250

Db 121 TCTTGGGTGATACGGGCTCTTGGCACGGGCGCTGTGACGTTGACCTACCCCTTGCAACCT 180

QY 251 ACCCTAAGGAAGAGGAGTGTGACGATGTCAGAGAGGTTGCGAGGCTGTTTCAATTTGTC 310

Db 181 ACCCTAAGGAAGAGGAGTGTGACGATGTCAGAGAGGTTGCGAGGCTGTTTCAATTTGTC 240

QY 311 AGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAATCTGCAATGA 370

Db 241 AGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAATCTGCAATGA 300

QY 371 CAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCCATCTTGGTTCGCAAGATCAGC 430

Db 301 CAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCCATCTTGGTTCGCAAGATCAGC 360

QY 431 TGCATTCGCTGACTGAGCAGAGACCACTTATGTCCTGATGCCAAATGCGCACTAC 490

Db 361 TGCATTCGCTGACTGAGCAGAGACCACTTATGTCCTGATGCCAAATGCGCACTAC 420

QY 491 TCTTTCCTCTAACTCTGGTGAGGTCAATTTCTGGAGTGACATGATGAGCTCCGACAGAGT 550

Db 421 TCTTTCCTCTAACTCTGGTGAGGTCAATTTCTGGAGTGACATGATGAGCTCCGACAGAGT 480

QY 551 TCATPAACTCTTCTGAGCTTTTATCTTCAAGCCGATGACGGAATAAGTATATTC 610

Db 481 TCATPAACTCTTCTGAGCTTTTATCTTCAAGCCGATGACGGAATAAGTATATTC 540

QY 611 AGTCTAAGCAGAAATCCAGTAGCCACCATTTGGAGGAGGAGCTTACAAATTTGAGAG 670

Db 541 AGTCTAAGCAGAAATCCAGTAGCCACCATTTGGAGGAGGAGCTTACAAATTTGAGAG 600

QY 671 AATCATCTCTAAGCAAAATGTCTTATCTGCAATAGAGAAATTCACAAAGCGCAGGAAT 730

Db 601 AATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCGCACAGGAAT 660  
Qy 731 TTCTTGAAGATGAGAAAGTATGCTCTTTTAAAGATGCTCTCTCTTAACTCTGGGTGGA 790  
Db 661 TTCTTGAAGATGAGAAAGTATGCTCTTTTAAAGATGCTCTCTCTTAACTCTGGGTGGA 720  
Qy 791 TTTTAACTACAACTCTTCTCTCGGTGAGGTATGCTTTTGAATTTGTTGGCAACTG 850  
Db 721 TTTTAACTACAACTCTTCTCTCGGTGAGGTATGCTTTTGAATTTGTTGGCAACTG 780  
Qy 851 TTGCTACAGCTGTGAGCAGTATGCTCTCTGAGAGCTGAGTATCATATGTTGACTTGG 910  
Db 781 TTGCTACAGCTGTGAGCAGTATGCTCTCTGAGAGCTGAGTATCATATGTTGACTTGG 840  
Qy 911 AGTTATTAAGTAAACAAAGCTTAAACAGATATCAGCTTCTCTCTTGGTGTAGAT 970  
Db 841 AGTTATTAAGTAAACAAAGCTTAAACAGATATCAGCTTCTCTCTTGGTGTAGAT 900  
Qy 971 CTAAACTGAGATCATGAGAGCAGGCTCTTACCTACAGAAAGTCAATCTTGTCTCAAT 1030  
Db 901 CTAAACTGAGATCATGAGAGCAGGCTCTTACCTACAGAAAGTCAATCTTGTCTCAAT 960  
Qy 1031 CTGAAATTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAAATTTCCACTC 1090  
Db 961 CTGAAATTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAAATTTCCACTC 1020  
Qy 1091 CTGATAGAGCTTTTAAATGCTTCAATGATAGAGCTTAAAGATCACTATAAATG 1150  
Db 1021 CTGATAGAGCTTTTAAATGCTTCAATGATAGAGCTTAAAGATCACTATAAATG 1080  
Qy 1151 CAAATAAAGTTACTCAAAATCTGTG 1174  
Db 1081 CAAATAAAGTTACTCAAAATCTGTG 1104

RESULT 20  
BD191202  
LOCUS 186 human secreted proteins.  
DEFINITION 186 human secreted proteins.  
ACCESSION BD191202  
VERSION BD191202.1 GI:33000941  
KEYWORDS JP 2002510192-A/166.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 1816)  
AUTHORS Ruben,S.M., Rosen,C.A., Fischer,C.L., Soppet,D.R., Carter,K.C.,  
Bednarik,D.P., Endress,G.A., Yu,G.L., N.J., Feng,P., Young,P.E.,  
Greene,J.M., Ferris,A.M., Duan,R., Hu,J.S., Florence,K.A.,  
Olsen,H.S., Ebner,R., Brewer,L.A., Moore,P.A., Shi,Y.,  
Lafleur,D.W., Li,Y., Zeng,Z. and Kyaw,H.  
186 human secreted proteins  
Patent: JP 2002510192-A 166 02-APR-2002;  
HUMAN GENOME SCIENCES INC  
PN JP 2002510192-A/166  
PD 02-APR-2002  
PP 06-MAR-1998 JP 1998538883  
PR 07-MAR-1997 US 60/040162,07-MAR-1997 US 60/040333 PR  
07-MAR-1997 US 60/038621,07-MAR-1997 US 60/040161 PR  
07-MAR-1997 US 60/040626,07-MAR-1997 US 60/040334 PR  
07-MAR-1997 US 60/040336,07-MAR-1997 US 60/040163 PR  
11-APR-1997 US 60/043580,11-APR-1997 US 60/043568 PI  
M RUBEN CRAIG A ROSEN, CARRIE L FISCHER, DANIEL R Soppet, PI  
KENNETH C CARTER, DANIEL P BEDNARIK, GREGORY  
A ENDRESS, GUO LIANG  
PI YU JIAN NI,  
PI PING FENG, PAUL E YOUNG, JOHN M GREENE, ANN  
M FERRIE, ROXANNE DUAN,  
PI JING SHAN HU, KIMBERLY A FLORENCE, HENRIK  
S OLSEN, REINHARD EBNER,  
PI LAURIE A BREWER, PAUL A MOORE, YANGGU SHI, DAVID W LAFLEUR PI  
, YI LI, ZHIZHEN ZENG,

PI HLA KYAW  
PC C12N15/12, C12N5/10, C12N1/21, C07K14/47, C07K16/18, C12Q1/69, PC  
G01N33/50,  
PC G01N33/53, G01N33/68, A61K38/17  
CC Strandedness: Double;  
CC Topology: Linear;  
FH Key Location/Qualifiers.  
FEATURES  
source 1.1816  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
ORIGIN  
Query Match 89.4%; Score 1049; DB 6; Length 1816;  
Best Local Similarity 94.7%; Pred. No. 5.3e-244;  
Matches 1119; Conservative 11; Mismatches 37; Indels 15; Gaps 4;  
Qy 8 GTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAGGGGAACA 67  
Db 222 GAGGAGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAGGGGAACA 281  
Qy 68 AGATGGGGGGCCGGAAGGGGAGCTCTGGGTGAGGACCCACACTGGGGCTCCCGCCGCTGC 127  
Db 282 AGATGGGGGGCCGGAAGGGGAGCTCTGGGTGAGGACCCACACTGGGGCTCCCGCCGCTGC 341  
Qy 128 TGCTGCTGACCATGGCTTGGCCGGAGGTTCCGGGGACCGCTTCGGCTGAAGCATTTGACT 187  
Db 342 TGCTGCTGACCATGGCTTGGCCGGAGGTTCCGGGGACCGCTTCGGCTGAAGCATTTGACT 401  
Qy 188 CGGTCTTGGGTGATACCGGCTTCTTGGCACCGGGCTGTGTGAGTGAACCTACCCCTTGCA 247  
Db 402 CGGTCTTGGGTGATACCGGCTTCTTGGCACCGGGCTGTGTGAGTGAACCTACCCCTTGCA 461  
Qy 248 CCTACCCCTAAGGAAGAGAGTGTGTGACATGTGACAGAGGTTGACGGCTGTGTTCATTT 307  
Db 462 CCTACCCCTAAGGAAGAGAGTGTGTGACATGTGACAGAGGTTGACGGCTGTGTTCATTT 521  
Qy 308 GTCAAGTTTGTGATGATGGAATGACATTAATCGAACTAAATGGAATGGAATGCAAT 367  
Db 522 GTCAAGTTTGTGATGATGGAATGACATTAATCGAACTAAATGGAATGGAATGCAAT 581  
Qy 368 GTACAGAGCATATTTCCCAATCTGTGAGCAATATGCTTGCATCTTGGTTGCCAGATC 427  
Db 582 GTACAGAGCATATTTCCCAATCTGTGAGCAATATGCTTGCATCTTGGTTGCCAGATC 641  
Qy 428 AGCTGCCATTCGCTGAACTGAGACAAGAACCACTATGTCCCTGATGCCAAAAATGCAAC 487  
Db 642 AGCTGCCATTCGCTGAACTGAGACAAGAACCACTATGTCCCTGATGCCAAAAATGCAAC 701  
Qy 488 TACTCTTTCTCTAAGCTGTGTGAGGTCATTTGAGTGAACATGATGAGTCCGACAGA 547  
Db 702 TACTCTTTCTCTAAGCTGTGTGAGGTCATTTGAGTGAACATGATGAGTCCGACAGA 761  
Qy 548 GCTTCATAACCTCTTCTATGGAATTTTATCTTCAAGCCGATGACGGAATAATAGTTATAT 607  
Db 762 GCTTCATAACCTCTTCTATGGAATTTTATCTTCAAGCCGATGACGGAATAATAGTTATAT 821  
Qy 608 TCCAGTCTAAGCC--AGAAATCCAGTACGACCAACACTTTTGGAGC--AGGACCTACAA 661  
Db 822 TCCRGCTCTAAGCCCAAGRAATCCCAAGTACGACCAACACTTTTGGAGCCAGGAGCCCTACCAA 881  
Qy 662 ATTTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCT--GCAATGAGAAATTCACAAG 718  
Db 882 ATTTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCT--GCAATGAGAAATTCACAAG 941  
Qy 719 CGCACAGGAATTTTCTGAGATGAGAAAGTATGCTTTTAAAGTATGCTCTCTCTTA 778  
Db 942 CGCACAGGAATTTTCTGAGATGAGAAAGTATGCTTTTAAAGTATGCTCTCTCTTA 1001  
Qy 779 ACTCTGGGTGGAATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTCTTTGGAATTT 838  
Db 1002 ACTCTGGGTGGAATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTCTTTGGAATTT 1061

QY 839 GTTGTGCAACTGTTGTCTACAGCTGTGGAGCA-----GTATGTTCCCTCTGAGAGCTGA 892  
Db 1062 GTTGTGCAACTGTTGTCTACAGCTGTGGAGCACTATAGTTTCCCTCTGAGAGCTGA 1121  
QY 893 GTATCTATGTTGAGCTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTT 952  
Db 1122 GTATCTATGTTGAGCTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTT 1181  
QY 953 CTCTTGTGTTGTTAGATCTAAATCAAGATCATGAGAGAGAGGCGCTCTACCTACAA 1012  
Db 1182 CTCTTGTGTTGTTAGATCTAAATCAAGATCATGAGAGAGAGGCGCTCTACCTACAA 1241  
QY 1013 AAGTGAATCTTGCTCATTCTGAATTTTAAAGCAATTTTCTTTTAAAGAGCAAGTGAATAG 1072  
Db 1242 AAGTGAATCTTGCTCATTCTGAATTTTAAAGCAATTTTCTTTTAAAGAGCAAGTGAATAG 1301  
QY 1073 ACATCTAAATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAA 1132  
Db 1302 ACATCTAAATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAA 1361  
QY 1133 AGAATCACTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
Db 1362 AGAATCACTATAAATGCAATAAAGTTACTCAAAATCTGTG 1403

RESULT 21  
AR379540  
LOCUS AR379540 1742 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 85 from patent US 6607879.  
ACCESSION AR379540  
VERSION AR379540.1 GI:40087174  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1742)  
AUTHORS Cocks,B.G., Stuart,S.G. and Seilhamer,J.J.  
TITLE Compositions for the detection of blood cell and immunological response gene expression  
JOURNAL Patent: US 6607879-A 85 19-AUG-2003;  
FEATURES  
source 1..1742  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 83.0%; Score 974; DB 6; Length 1742;  
Best Local Similarity 97.1%; Pred. No. 9e-226;  
Matches 1152; Conservative 0; Mismatches 15; Indels 19; Gaps 15;  
QY 8 GTGGGGGAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGC-TGTGACAGAGGGGAAC 66  
Db 154 GAGGAGGAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGGAAC 213  
QY 67 AAGATGGCGGCGCCGGAAGGG-GAGCCTCTGGGTGAGGACCCAACTGGGGGCTCCCGCGCT 125  
Db 214 AAGATGGCGGCGCCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGGCTCCCGCGCT 273  
QY 126 GCTGCTGTGACATGCGCTTGGCGGAGG-TTGGGAGCCGCTTGGCTGAGACATTTG 184  
Db 274 GCTGCTGTGACATGCGCTTGGCGGAGGTTTGGGAGCCGCTTGGCTGAGACATTTG 333  
QY 185 ACTCGGTCTTGGGTGATACGGGCTCTTGGC-ACCGGGCTGTGAGTTGACCTACCCCTTG 243  
Db 334 ACTCGGTCTTGGGTGATACGGGCTCTTGGC-ACCGGGCTGTGAGTTGACCTACCCCTTG 393  
QY 244 CACACCTACCTTAA-GGAGAGAGATTTGATCGATGTGAGAGAGTTGC-AGGCTGTTTT 301  
Db 394 CACACCTACCTTAAAGGAAGAGGATTTGATCGATGTGAGAGAGTTTCAAGGCTGTTTT 453  
QY 302 CAA--TTTCTCAGTTTGTGATGAGGAA-TTGACTTAAATCGAACTAAATTTGAATGTG 358

Db 454 CAAATTTGTCAAGTTTCTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTG 513  
QY 359 AATCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTT--GCATCTTTGG 416  
Db 514 AATCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTTGCCAATTTGGT 573  
QY 417 TTGCCAGAAATCAGCTCCCAATTCGCTGAATGAGACAAGCAACATTTATGTCCTCATGCC 476  
Db 574 TTGCCAGAAATCAGCTCCCAATTCGCTGAATGAGACAAGCAACATTTATGTCCTCATGCC 633  
QY 477 AAAAATGCACCTACTCTTCCCTCTAACTCTGCTGAGGTCATTTCTGGAGTGACATGATGA 536  
Db 634 AAAAATGCACCTACTCTTCCCTCTAACTCTGCTGAGGTCATTTCTGGAGTGACATGATGA 593  
QY 537 CTCGCGACAGAGCTTCATAACCTC-TTCATGGAATTTTTTATCTTCAAGCCGATGACGGA 595  
Db 694 CTCGCGACAGAGCTTCATAACCTC-TTCATGGAATTTTTTATCTTCAAGCCGATGACGGA 753  
QY 596 AATAGTATTTATTTCCAGTCTTAAGCCGAAATCCAGTACGACCAATTTGGAGCAGGAGC 655  
Db 754 AATAGTATTTATTTCCAGTCTTAAGCCGAAATCCAGTACGACCAATTTGGAGCAGGAGC 813  
QY 656 CTACAAATTTTGAGA-GAATCATCTCTAAGCAAAATGTCCT---ATCTGCAAAATGA-GAAA 710  
Db 814 CTACAAATTTTGAGAGGAATCATCTCTAAGCAAAATGTCCTCAGATCTGCAATATGAGAAA 873  
QY 711 TTCAAGAGCGCAGAGAAATTTCTTGAAG-ATGCGAAGAGTGAATGCTTTTAAAGATGCC 769  
Db 874 TTCAAGAGCGCAGAGAAATTTCTTGAAGTATGAGAAAGTGAATGCTTTTAAAGATGCC 933  
QY 770 TCTCTCTTAATCTGCGTGGATTTTAACTACAATCTTGTCTCTCTCGGTGATGTTATGC 829  
Db 934 TCTCTCTTAATCTGCGTGGATTTTAACTACAATCTTGTCTCTCTCGGTGATGTTATGC 993  
QY 830 TTT-GGAATTTGTTGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAG 888  
Db 994 TTTGGGAATTTGTTGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAG 1053  
QY 889 CTGAGTATCTATGTTGAGCTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCT 948  
Db 1054 CTGAGTATCTATGTTGAGCTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCT 1113  
QY 949 TCTTCTCTTGTGTTGTTAGATCTTAAATCTGAAGATCATGAGAGCAGGCGCTTACCT 1008  
Db 1114 TCTTCTCTTGTGTTGTTAGATCTTAAATCTGAAGATCATGAGAGCAGGCGCTTACCT 1173  
QY 1009 ACAAAGTGAATCTTCTGCTCATCTGAAATTTTAAAGCAATTTTCTTTTAAAGAGCAAGTGA 1068  
Db 1174 ACAAAGTGAATCTTCTGCTCATCTGAAATTTTAAAGCAATTTTCTTTTAAAGAGCAAGTGA 1233  
QY 1069 ATAGACATCTAAAATTTCCACTCTCTCATAGAGCTTTTAAATGCTTTTCAATGGATATAGC 1128  
Db 1234 ATAGACATCTAAAATTTCCACTCTCTCATAGAGCTTTTAAATGCTTTTCAATGGATATAGC 1293  
QY 1129 CTTAAGAAATCACTATAAATGCAATTAAGTTTACTCAAAATCTGTG 1174  
Db 1294 CTTAAGAAATCACTATAAATGCAATTAAGTTTACTCAAAATCTGTG 1339

RESULT 22  
BD233458  
LOCUS BD233458  
DEFINITION Human protein having hydrophobic domain and DNA encoding the same.  
ACCESSION BD233458  
VERSION BD233458.1 GI:33043228  
KEYWORDS JP 2002519016-A/4.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 969)  
AUTHORS Kato,S. and Kimura,T.  
TITLE Human protein having hydrophobic domain and DNA encoding the same



JOURNAL Patent: JP 2002519016-A 4 02-JUL-2002;  
SAGAMI CHEMICAL RESEARCH CENTER, PROTEGENE INC  
COMMENT OS Homo sapiens (human)  
PN JP 2002519016-A/4  
PD 02-JUL-2002  
PF 18-JUN-1999 JP 2000557267  
PI SEISHI KATO, TOMOKO KIMURA  
PC C12N15/09, C07K14/47, C12N1/15, C12N1/19, C12N5/10, C12N5/00, C12N5/ PC  
00  
CC Human protein having hydrophobic domain and DNA encoding the  
CC same  
FH Key source Location/Qualifiers  
FT 1..969  
FT Location/Qualifiers  
FEATURES  
source  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

## ORIGIN

Query Match 82.5%; Score 969; DB 6; Length 969;  
Best Local Similarity 100.0%; Pred. No. 1.4e-224;  
Matches 969; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 70 ATGGCGGCGCCGAAGGGAGCCTCTGGGTGAGACCCCAACTGGGGCTCCCGCGCTGCTG 129  
DB 1 ATGGCGGCGCCGAAGGGAGCCTCTGGGTGAGACCCCAACTGGGGCTCCCGCGCTGCTG 60  
QY 130 CTGCTGACCATGCGCTTGGCCGGAGGTTGGGGAGCCGCTTGGGTGAGAGCATTTGACTCG 189  
DB 61 CTGCTGACCATGCGCTTGGCCGGAGGTTGGGGAGCCGCTTGGGTGAGAGCATTTGACTCG 120  
QY 190 GTCTTGGGTGATACGGCGCTTGGCCAGGGGCTGTGAGTGGACCTACCCCTTGCACACC 249  
DB 121 GTCTTGGGTGATACGGCGCTTGGCCAGGGGCTGTGAGTGGACCTACCCCTTGCACACC 180  
QY 250 TACCCTAAGGAAGAGAGTTGACGATGTACAGAGTTGAGAGTTGAGGCTCTTTTCAATTGT 309  
DB 181 TACCCTAAGGAAGAGAGTTGACGATGTACAGAGTTGAGAGTTGAGGCTCTTTTCAATTGT 240  
QY 310 CAGTTTGTGGATGATGGAATTTGACTTAATCGAATTAATCGAATTTGGAATTTGCAATGT 369  
DB 241 CAGTTTGTGGATGATGGAATTTGACTTAATCGAATTTGGAATTTGCAATTTGCAATGT 300  
QY 370 ACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTTGGTTGCCAGAAACAG 429  
DB 301 ACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTTGGTTGCCAGAAACAG 360  
QY 430 CTGCCATTGCTGAAGTGAAGAGCAACCTTATGCTCCCTGATGCCAATAATGCACCTA 489  
DB 361 CTGCCATTGCTGAAGTGAAGAGCAACCTTATGCTCCCTGATGCCAATAATGCACCTA 420  
QY 490 CTCTTTCTCTAACTCTGGTGAAGTCAATCTGAGTGAATGATGAGTCCGCAAGAGC 549  
DB 421 CTCTTTCTCTAACTCTGGTGAAGTCAATCTGAGTGAATGATGAGTCCGCAAGAGC 480  
QY 550 TTCTATACCTCTTCATGGACTTTTATCTTCAAGCGATGACGGAAATAGTTATATTC 609  
DB 481 TTCTATACCTCTTCATGGACTTTTATCTTCAAGCGATGACGGAAATAGTTATATTC 540  
QY 610 CAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCCTACAAATTTGAGA 669  
DB 541 CAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCCTACAAATTTGAGA 600  
QY 670 GAATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCGCAGAGGAT 729  
DB 601 GAATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCGCAGAGGAT 660  
QY 730 TTTCTTGAAGTGAAGAGTGGCTTTTAAAGATGCTCTCTTTAACTCTGGGTGG 789  
DB 661 TTTCTTGAAGTGAAGAGTGGCTTTTAAAGATGCTCTCTTTAACTCTGGGTGG 720

Search completed: June 15, 2004, 05:14:15  
Job time : 4881 secs

QY 790 ATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGCTTTGGATTTGTGCAACT 849  
DB 721 ATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGCTTTGGATTTGTGCAACT 780  
QY 850 GTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGCTGACTTG 909  
DB 781 GTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGCTGACTTG 840  
QY 910 GAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTTGTTGTAGA 969  
DB 841 GAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTTGTTGTAGA 900  
QY 970 TCTAAACTGAAGATCATGAGAGCAGGGCCCTCTACCTACAAAAGTGAATCTTGTCTCAT 1029  
DB 901 TCTAAACTGAAGATCATGAGAGCAGGGCCCTCTACCTACAAAAGTGAATCTTGTCTCAT 960  
QY 1030 TCTGAAAT 1038  
DB 961 TCTGAAAT 969



GenCore version 5.1.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 15, 2004, 03:37:20 ; Search time 538 Seconds

(without alignment)  
9270.232 Million cell updates/sec

Title: US-09-978-299a-329

Perfect score: 1174

Sequence: 1 cggagcggtgggggaaccc.....taagttactcaaatctgtg 1174

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 210

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database : N\_Geneseq\_29Jan04:\*

1: Geneseqn1980s:\*

2: Geneseqn1990s:\*

3: Geneseqn2000s:\*

4: Geneseqn2001as:\*

5: Geneseqn2001bs:\*

6: Geneseqn2002s:\*

7: Geneseqn2003as:\*

8: Geneseqn2003bs:\*

9: Geneseqn2003cs:\*

10: Geneseqn2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1174	100.0	1174	2	Aaz34171 Human PRO
2	1174	100.0	1174	3	Aac78540 Human PRO
3	1174	100.0	1174	3	Aaa77533 Human PRO
4	1174	100.0	1174	4	Aas21379 Human CDN
5	1174	100.0	1174	4	Aac97400 Human ang
6	1174	100.0	1174	6	Ab188075 Human PRO
7	1174	100.0	1174	6	Ab195564 Human ang
8	1174	100.0	1174	7	Abx9276 DNA encod
9	1174	100.0	1174	7	Ac42704 Novel hum
10	1174	100.0	1174	7	Ac42704 Novel hum
11	1174	100.0	1174	7	Ac67129 cDNA enco
12	1174	100.0	1174	7	Ac63739 Novel hum
13	1174	100.0	1174	7	ACA03738 cDNA enco
14	1174	100.0	1174	7	ACA71903 Human sec
15	1174	100.0	1174	7	Abx92543 cDNA enco
16	1174	100.0	1174	7	Abx92543 cDNA enco
17	1174	100.0	1174	7	Ac41930 Human sec
18	1174	100.0	1174	7	Ac66284 Human CDN
19	1174	100.0	1174	7	ACA04159 Human CDN
20	1174	100.0	1174	8	Ada45790 Novel hum
21	1174	100.0	1174	8	ADA76221 Human PRO
22	1174	100.0	1174	8	ADA18871 Human PRO
23	1174	100.0	1174	8	ADA61494 Homo sapi
					ADB19279 Novel hum

24	1174	100.0	1174	8	ADB27820 cDNA enco
25	1174	100.0	1174	8	Ada86299 Novel hum
26	1174	100.0	1174	8	ADB15863 Human PRO
27	1174	100.0	1174	8	Ada47649 Human PRO
28	1174	100.0	1174	8	Ada67444 Human PRO
29	1174	100.0	1174	8	ADB30451 cDNA enco
30	1174	100.0	1174	8	Ada85747 Novel hum
31	1174	100.0	1174	8	Ada96959 Human PRO
32	1174	100.0	1174	8	Ada79263 Human PRO
33	1174	100.0	1174	8	Ada87402 Novel hum
34	1174	100.0	1174	8	ADB16604 Human PRO
35	1174	100.0	1174	8	Ada91696 Novel hum
36	1174	100.0	1174	8	ADB14759 Human PRO
37	1174	100.0	1174	8	Ada24868 Novel hum
38	1174	100.0	1174	8	ADB18720 Novel hum
39	1174	100.0	1174	8	Ada93935 Human PRO
40	1174	100.0	1174	8	ADB19831 Novel hum
41	1174	100.0	1174	8	ADB13143 Human PRO
42	1174	100.0	1174	8	ACD98559 Novel hum
43	1174	100.0	1174	8	ACD29885 Novel hum
44	1174	100.0	1174	8	ADA12529 Human CDN
45	1174	100.0	1174	8	Ada74397 Human PRO
46	1174	100.0	1174	8	ADB24630 Human PRO
47	1174	100.0	1174	8	Ada82154 Human PRO
48	1174	100.0	1174	8	Ada75117 Human PRO
49	1174	100.0	1174	8	Ada85195 Novel hum
50	1174	100.0	1174	8	Ada84543 Novel hum
51	1174	100.0	1174	8	ADB29899 cDNA enco
52	1174	100.0	1174	8	Ada80427 Human PRO
53	1174	100.0	1174	8	Ada75669 Human PRO
54	1174	100.0	1174	8	Ada46894 Human PRO
55	1174	100.0	1174	8	ADB25190 Human PRO
56	1174	100.0	1174	8	Ada93366 Human PRO
57	1174	100.0	1174	8	ADB26716 cDNA enco
58	1174	100.0	1174	8	ADB31003 cDNA enco
59	1174	100.0	1174	8	Ada60931 Homo sapi
60	1174	100.0	1174	8	ADB24078 Human PRO
61	1174	100.0	1174	8	Ada96407 Human PRO
62	1174	100.0	1174	8	Ada80979 Human PRO
63	1174	100.0	1174	8	Ada95855 Human PRO
64	1174	100.0	1174	8	ADB26164 cDNA enco
65	1174	100.0	1174	8	ADB21649 Novel hum
66	1174	100.0	1174	8	ACD29300 Novel hum
67	1174	100.0	1174	8	Ada77428 Human PRO
68	1174	100.0	1174	8	ADB18168 cDNA enco
69	1174	100.0	1174	8	Ada86851 Novel hum
70	1174	100.0	1174	8	Ada87954 Novel hum
71	1174	100.0	1174	8	Ada46342 Novel hum
72	1174	100.0	1174	8	ADB28372 cDNA enco
73	1174	100.0	1174	8	ADB28924 cDNA enco
74	1174	100.0	1174	8	Ada76876 Human PRO
75	1174	100.0	1174	8	Ada88506 Human PRO
76	1174	100.0	1174	8	Ada97511 Human PRO
77	1174	100.0	1174	8	ADB27268 cDNA enco
78	1174	100.0	1174	8	ADB22201 Novel hum
79	1174	100.0	1174	8	Ada66892 Human PRO
80	1174	100.0	1174	8	ADB22753 Human PRO
81	1174	100.0	1174	8	ADB23526 Human PRO
82	1174	100.0	1174	8	Ada92248 Novel hum
83	1174	100.0	1174	8	ADB15311 Human PRO
84	1174	100.0	1174	8	ADB38563 Novel hum
85	1174	100.0	1174	8	ADB38011 Novel hum
86	1174	100.0	1174	9	ADB66483 Novel hum
87	1174	100.0	1174	9	ADB89563 Human PRO
88	1174	100.0	1174	9	ADB90295 Human PRO
89	1174	100.0	1174	9	ADB39396 Novel hum
90	1174	100.0	1174	9	ADB73835 Human PRO
91	1174	100.0	1174	9	ADB47019 Novel hum
92	1174	100.0	1174	9	ADB86626 Human PRO
93	1174	100.0	1174	9	ADB76551 Human PRO
94	1174	100.0	1174	9	ADB77231 Novel hum
95	1174	100.0	1174	9	ADB34388 Human PRO
96	1174	100.0	1174	9	ADB35492 Human PRO

97	1174	100.0	1174	9	ADB33836	Human PRO
98	1174	100.0	1174	9	ADB34940	Human PRO
99	1174	100.0	1174	9	ADB36044	Human PRO
100	1174	100.0	1174	9	ADB46339	Novel hum
101	1174	100.0	1174	9	ADC43977	Human CDN
102	1174	100.0	1174	9	ADC61737	Human CDN
103	1174	100.0	1174	9	ADC63701	Human CDN
104	1174	100.0	1174	9	ADC66801	Human CDN
105	1174	100.0	1174	9	ADC68925	Human CDN
106	1174	100.0	1174	9	ADC62985	Human CDN
107	1174	100.0	1174	9	ADC68050	Human CDN
108	1174	100.0	1174	9	ADC41370	Human CDN
109	1174	100.0	1174	9	ADC67425	Human CDN
110	1174	100.0	1174	9	ADC62361	Human CDN
111	1174	100.0	1174	9	ADC41994	Human CDN
112	1174	100.0	1174	9	ADC50312	Novel hum
113	1174	100.0	1174	9	ADC71859	Novel hum
114	1174	100.0	1174	9	ADC59838	Novel hum
115	1174	100.0	1174	9	ADC52845	Novel hum
116	1174	100.0	1174	9	ADC57199	Novel hum
117	1174	100.0	1174	9	ADC60390	Novel hum
118	1174	100.0	1174	9	ADC50865	Novel hum
119	1174	100.0	1174	9	ADC65392	Novel hum
120	1174	100.0	1174	9	ADC54490	Novel hum
121	1174	100.0	1174	9	ADC53451	Novel hum
122	1174	100.0	1174	9	ADC58974	Novel hum
123	1174	100.0	1174	9	ADC55852	Novel hum
124	1174	100.0	1174	9	ADC58422	Novel hum
125	1174	100.0	1174	9	ADC03096	Novel hum
126	1174	100.0	1174	9	ADC90088	Novel hum
127	1174	100.0	1174	9	ADC69507	Novel hum
128	1174	100.0	1174	9	ADC48396	Human PRO
129	1174	100.0	1174	9	ADC40925	Human PRO
130	1174	100.0	1174	9	ADC40450	Novel hum
131	1174	100.0	1174	9	ADC80456	Novel hum
132	1174	100.0	1174	9	ADC10963	Human PRO
133	1174	100.0	1174	9	ADC10296	Human PRO
134	1174	100.0	1174	9	ADC47844	Human PRO
135	1174	100.0	1174	9	ADC79904	Novel hum
136	1174	100.0	1174	9	ADC11256	Human sec
137	1174	100.0	1174	9	ADC09373	Human PRO
138	1174	100.0	1174	9	ADC41086	Novel hum
139	1174	100.0	1174	9	ADC52225	CDNA enco
140	1174	100.0	1174	9	ADC52965	CDNA enco
141	1174	100.0	1174	9	ADC53517	Novel hum
142	1174	100.0	1174	9	ADC37049	Human sec
143	1174	100.0	1174	9	ADC51673	CDNA enco
144	1174	100.0	1174	9	ADC02472	Human PRO
145	1174	100.0	1174	9	ADC01906	Human PRO
146	1174	100.0	1174	9	ADC54088	Novel hum
147	1174	100.0	1174	9	ADC49363	Human CDN
148	1174	100.0	1174	9	ADC92405	Human PRO
149	1174	100.0	1174	9	ADC91301	Human PRO
150	1174	100.0	1174	9	ADC03915	Human PRO
151	1174	100.0	1174	9	ADC32212	Novel hum
152	1174	100.0	1174	9	ADC22144	CDNA enco
153	1174	100.0	1174	9	ADC79368	CDNA enco
154	1174	100.0	1174	9	ADC35417	Human CDN
155	1174	100.0	1174	9	ADC16531	Human CDN
156	1174	100.0	1174	9	ADC73146	Human CDN
157	1174	100.0	1174	9	ADC41904	Human PRO
158	1174	100.0	1174	9	ADC17721	Human PRO
159	1174	100.0	1174	9	ADC91853	Human PRO
160	1174	100.0	1174	9	ADC33316	Novel hum
161	1174	100.0	1174	9	ADC33868	Novel hum
162	1174	100.0	1174	9	ADC79920	CDNA enco
163	1174	100.0	1174	9	ADC92957	Human PRO
164	1174	100.0	1174	9	ADC72504	Human CDN
165	1174	100.0	1174	9	ADC19377	Human PRO
166	1174	100.0	1174	9	ADC18825	Human PRO
167	1174	100.0	1174	9	ADC43021	Human PRO
168	1174	100.0	1174	9	ADC95810	Human PRO
169	1174	100.0	1174	9	ADC22696	CDNA enco
170	1174	100.0	1174	9	ADD78814	CDNA enco
171	1174	100.0	1174	9	ADD32764	Novel hum
172	1174	100.0	1174	9	ADD42456	Human PRO
173	1174	100.0	1174	9	ADD17155	Human CDN
174	1174	100.0	1174	9	ADD80472	CDNA enco
175	1174	100.0	1174	9	ADD89500	Human PRO
176	1174	100.0	1174	9	ADD40784	Human PRO
177	1174	100.0	1174	9	ADD04583	Human PRO
178	1174	100.0	1174	9	ADC81008	Novel hum
179	1174	100.0	1174	10	ADD76456	Human PRO
180	1174	100.0	1174	10	ADD78820	Human PRO
181	1174	100.0	1174	10	ADD86224	Human PRO
182	1174	100.0	1174	10	ADD75672	Human PRO
183	1174	100.0	1174	10	ADD48663	Human CDN
184	1174	100.0	1174	10	ADD41257	Human sec
185	1174	100.0	1174	10	ADD23248	CDNA enco
186	1174	100.0	1174	10	ADD23800	CDNA enco
187	1174	100.0	1174	10	ADD24443	CDNA enco
188	1174	100.0	1174	10	ADD87268	Human PRO
189	1174	100.0	1174	10	ADD89134	Human PRO
190	1174	100.0	1174	10	ADD18273	Human PRO
191	1174	100.0	1174	10	ADD88582	Human PRO
192	1174	100.0	1174	10	ADD89764	Human CDN
193	1163.8	99.1	1634	4	AAK94533	Human ful
194	1163.8	99.1	1656	9	ADC37344	Nuclear f
195	1163.8	99.1	1704	3	AAK56760	Human tra
196	1151.8	98.1	1695	2	AAV59792	Human sec
197	1151.8	98.1	1695	6	AB973786	Human CDN
198	1151.8	98.1	1695	8	ACD82929	CDNA sequ
199	1121.8	95.5	1121	3	AAK90051	Hydrophob
200	1118	95.2	1457	5	AAK93855	Human CDN
201	1106	94.2	1138	7	AAK82075	Human CBC
202	1106	94.2	1138	7	ABZ72012	Human unk
203	1106	94.2	1138	7	ABZ75896	Heart dis
204	1105	94.1	1466	9	ABK37346	Nuclear f
205	1103	94.0	1109	6	ABK35662	CDNA sequ
206	1097	93.4	1472	2	AAV35556	Secreted
207	1049	89.4	1756	2	AAV59667	Human sec
208	1049	89.4	1816	6	ABK73654	Human CDN
209	1049	89.4	1816	8	ACD82797	CDNA sequ
210	969	82.5	969	3	AAZ90041	Hydrophob

## ALIGNMENTS

RESULT 1  
ID AAZ34171 standard; cDNA; 1174 BP.  
XX  
AC AAZ34171;  
DT 07-DEC-1999 (first entry)  
XX  
DE Human PRO195 nucleotide sequence.  
XX  
Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation;  
KW probe; blood coagulation disorder; cancer; cellular adhesion disorder;  
KW secreted protein; transmembrane protein; ss.  
XX Homo sapiens.  
OS WO9946281-A2.  
PN 16-SEP-1999.  
PD 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1998; 98US-0077450P.  
XX 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.  
PR 17-MAR-1998; 98US-00040220.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079566P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082767P.  
PR 23-APR-1998; 98US-0082796P.  
PR 27-APR-1998; 98US-0083336P.  
PR 27-APR-1998; 98US-0083332P.  
PR 29-APR-1998; 98US-0083332P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 29-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084411P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 13-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.

PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
XX (GETH ) GENENTECH INC.  
XX Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;  
XX WPI; 1999-551358/46.  
XX P-FSDS; AAY41733.  
XX New secreted and transmembrane polypeptides and their polynucleotides,  
XX useful for treating blood coagulation disorders, cancers and cellular  
XX adhesion disorders.  
XX Claim 2; Fig 131; 530pp; English.  
XX The present invention describes secreted and transmembrane polypeptides  
XX and their polynucleotides. The nucleotide sequences are useful as sources  
XX of probes, primers, for chromosome mapping, and for generation of  
XX antisense sequences. They can also be used to create transgenic animals.  
XX The proteins can be used to treat a variety of diseases and disorders,  
XX depending on their function. Diseases that may be treated include blood  
XX coagulation disorders, cancers and cellular adhesion disorders. They may  
XX also be used to raise antibodies. AA23891 to AA23436, and AAY41655 to  
XX AA41774 represent polynucleotide and polypeptide sequence given in the  
XX exemplification of the present invention  
XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query March 100.0%; Score 1174; DB 2; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGGAAACCTTCGAGAAAACAGCAACAGCTGAGCTCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCTTCGAGAAAACAGCAACAGCTGAGCTCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGGCGGAGGAGCTTGGGTGAGGAGCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGGCGGAGGAGCTTGGGTGAGGAGCCCACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCATGGCTTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGTGACCATGGCTTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTCACCTCGGCTTTGGGTGATACGGCGTCTTGCCACCGGGCTGTGAGTTGACCTACCCC 240  
DB 181 TTTCACCTCGGCTTTGGGTGATACGGCGTCTTGCCACCGGGCTGTGAGTTGACCTACCCC 240  
QY 241 TTGCACACCTACCTCAAGGAAGAGGAGTTGTACGATGTCCAGAGGTTGCGAGGCTGTTT 300  
DB 241 TTGCACACCTACCTCAAGGAAGAGGAGTTGTACGATGTCCAGAGGTTGCGAGGCTGTTT 300  
QY 301 TCAATTTTGTGAGTTGTGAGTATGGAATGCACTTAAATCGAACTAAATGGAATGAA 360  
DB 301 TCAATTTTGTGAGTTGTGAGTATGGAATGCACTTAAATCGAACTAAATGGAATGAA 360  
QY 361 TCTGCATGTACAGAGCATATTCCTATCTGATGAGCAATATCTTGGCCATCTTGGTTCG 420  
DB 361 TCTGCATGTACAGAGCATATTCCTATCTGATGAGCAATATCTTGGCCATCTTGGTTCG 420  
QY 421 CAGAAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGAAACAATATGTCCTGATGCCAAAA 480  
DB 421 CAGAAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGAAACAATATGTCCTGATGCCAAAA 480

481 ATGCACCTACTCTTTCTCTTAACCTCTGCTGAGTCAATCTGGAGTGACATGATGGACTCC 540  
481 ATGCACCTACTCTTTCTCTTAACCTCTGCTGAGTCAATCTGGAGTGACATGATGGACTCC 540  
541 GCACAGAGCTTCATACCTCTCTTCAATGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
541 GCACAGAGCTTCATACCTCTCTTCAATGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
601 GTTATATTCAGTCTTAAGCCCAAGAAATCCAGTACGCCACCAATTTGGAGCAGGACCTACA 660  
601 GTTATATTCAGTCTTAAGCCCAAGAAATCCAGTACGCCACCAATTTGGAGCAGGACCTACA 660  
661 AATTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGCAAAATTCACAAAGCG 720  
661 AATTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGCAAAATTCACAAAGCG 720  
721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
781 TCTGGTGATTTTAACTCAACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
781 TCTGGTGATTTTAACTCAACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCTCTGAGAGCTGAGTATCTAT 900  
841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCTCTGAGAGCTGAGTATCTAT 900  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAACAGATATCCAGTCTTCTCTCTG 960  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAACAGATATCCAGTCTTCTCTCTG 960  
961 GTTGTAGATCTAAACTGAAGATCATCAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020  
961 GTTGTAGATCTAAACTGAAGATCATCAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020  
1021 CTGTCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080  
1021 CTGTCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080  
1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
1141 CTATAAATGCAAAATTAAGTCTCAATCTGTG 1174  
1141 CTATAAATGCAAAATTAAGTCTCAATCTGTG 1174

RESULT 2  
AAC78540  
ID AAC78540 standard; cDNA; 1174 BP.  
XX  
AC AAC78540;  
XX  
DT 08-FEB-2001 (first entry)  
XX  
DE Human PRO195 (UNQ169) nucleotide sequence SEQ ID NO:329.  
XX  
KW Human; secreted protein; transmembrane protein; PRO; EST; cytosolic;  
KW expressed sequence tag; detection; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200053756-A2.  
XX  
PD 14-SEP-2000.  
XX  
PF 18-FEB-2000; 2000WO-US004341.  
XX  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-01239572.  
PR 29-MAR-1999; 99US-0126773P.

21-APR-1999; 99US-0130232P.  
28-APR-1999; 99US-0131445P.  
14-MAY-1999; 99US-0134287P.  
23-JUN-1999; 99US-0141037P.  
26-JUL-1999; 99US-0145698P.  
29-OCT-1999; 99US-0162506P.  
30-NOV-1999; 99WO-US028313.  
02-DEC-1999; 99WO-US028551.  
02-DEC-1999; 99WO-US028565.  
16-DEC-1999; 99WO-US030095.  
30-DEC-1999; 99WO-US031243.  
30-DEC-1999; 99WO-US031274.  
05-JAN-2000; 2000WO-US000219.  
06-JAN-2000; 2000WO-US000277.  
06-JAN-2000; 2000WO-US000376.  
XX (GETH) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Deanoyers L, Eaton DL;  
PI Ferrara N, Filyaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;  
PI Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;  
PI Kljavin IV, Kuo SS, Napier MA, Pan J, Paoni NP, Roy MA, Shelton DL;  
PI Stewart TA, Tumas D, Williams PM, Wood WI;  
XX WPI; 2000-611443/58.  
DR P-PSDB; AAB44289.  
XX  
PT Novel PRO polypeptides and polynucleotides used in detection methods, to  
PT target bioactive molecules to specific cells, and to modulate cellular  
PT activities.  
XX  
PS Claim 2; Fig 131; 636pp; English.  
XX  
CC AAC78458 to AAC78599 represent polynucleotide and EST (expressed sequence  
CC tag) sequences which encode secreted or transmembrane PRO polypeptides.  
CC The PRO polynucleotides and polypeptides have cytosolic activity. The  
CC polynucleotides and polypeptides can be used for detecting the presence  
CC of PRO polypeptides in samples, for linking bioactive molecules to cells  
CC and for modulating biological activities of cells, using the polypeptides  
CC for specific targeting. The polypeptide targeting can be used to kill the  
CC target cells, e.g. for the treatment of cancers. The polypeptide pairs  
CC provide specific targeting of bioactive molecules to cells. AAC78600 to  
CC AAC78987 represent PCR primers and probes used in the isolation of the  
CC PRO polynucleotide sequences  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other; ;  
Query Match 100.0%; Score 1174; DB 3; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
QY 61 CGGAAACAAGATGGCGGCCCGAAGGGAGGCTCTTGGGTGAGGACCCCAACTGGGGCTCCG 120  
DB 61 CGGAAACAAGATGGCGGCCCGAAGGGAGGCTCTTGGGTGAGGACCCCAACTGGGGCTCCG 120  
QY 121 CGGCTGCTGCTGCTGACCATGCTTGGCGGAGGCTTGGGTGAGGACCCCAACTGGGGCTCCG 180  
DB 121 CGGCTGCTGCTGCTGACCATGCTTGGCGGAGGCTTGGGTGAGGACCCCAACTGGGGCTCCG 180  
QY 181 TTTGACTCGGCTTGGGTGATACCGGCTTTCGCCACCGGGGCTGTGAGTGTGACATCCCC 240  
DB 181 TTTGACTCGGCTTGGGTGATACCGGCTTTCGCCACCGGGGCTGTGAGTGTGACATCCCC 240  
QY 241 TTGCAACCTACCTTAAGAAAGAGAGTGTACCATGTGACAGAGCTTCAGGCTGTTT 300  
DB 241 TTGCAACCTACCTTAAGAAAGAGAGTGTACCATGTGACAGAGCTTCAGGCTGTTT 300  
QY 301 TCAATTTGCTGCTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 360





PT polypeptides, and detect the presence of mammalian tumors e.g. lung,  
PT breast, prostate, cervical.

XX Claim 3; Fig 271; 813pp; English.

XX AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO  
CC polypeptides. The PRO polypeptides are useful to detect other PRO  
CC polypeptides, to link bioactive molecules to cells expressing PRO  
CC polypeptides, to modulate biological activities of cells expressing PRO  
CC polypeptides, and to detect the presence of mammalian lung, colon,  
CC breast, prostate, rectal, cervical or liver tumors by comparing PRO  
CC polypeptide expression in a cell sample to that in a control sample. Some  
CC of the 275 sequences are also useful to stimulate the release of tumour  
CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or  
CC differentiation of chondrocytes, the proliferation or gene expression in  
CC pericyte cells, the release of proteoglycans from cartilage, the  
CC proliferation of inner ear utricular supporting cells or of T-  
CC lymphocytes, the release of a cytokine from peripheral blood monocytes  
CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO  
CC polypeptides may modulate glucose or free fatty acid uptake by skeletal  
CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor  
CC VIIA. The PRO polypeptides can be used in assays to identify molecules  
CC involved in binding interactions. The polynucleotides encoding PRO  
CC polypeptides can be used to generate probes, antisense RNA/DNA,  
CC transgenic or knock out animals and can be used in gene therapy

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match	100.08;	Score 1174;	DB 4;	Length 1174;
Best Local Similarity	100.08;	Pred. No. 0;		
Matches 1174;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY 1	CGGACGCTGGGGAAACCCCTCCGAGAAACACAAACAGCTGAGCTGTGACAGAG 60			
DB 1	CGGACGCTGGGGAAACCCCTCCGAGAAACACAAACAGCTGAGCTGTGACAGAG 60			
QY 61	GGGACAGATGGCGCGCGGAGGGAGCCTCTGGGTGAGGACCCACACTGGGGCTCCCG 120			
DB 61	GGGACAGATGGCGCGCGGAGGGAGCCTCTGGGTGAGGACCCACACTGGGGCTCCCG 120			
QY 121	CGCTGCTGCTGTGACCATGCGCTTCGCGGAGGCTTCGGGACCGCTTCGGGTGAGCA 180			
DB 121	CGCTGCTGCTGTGACCATGCGCTTCGCGGAGGCTTCGGGACCGCTTCGGGTGAGCA 180			
QY 181	TTTGACTCGGTCTGGGTGATACGGCTCTTGGCACCGGGCTGTGAGTGACCTACCC 240			
DB 181	TTTGACTCGGTCTGGGTGATACGGCTCTTGGCACCGGGCTGTGAGTGACCTACCC 240			
QY 241	TTGCACACTACCCCTAAGGAGAGAGTTGATCGCATGTGACAGAGCTTCAGGCTGTT 300			
DB 241	TTGCACACTACCCCTAAGGAGAGAGTTGATCGCATGTGACAGAGCTTCAGGCTGTT 300			
QY 301	TCAAATTTGTCAGTTTGTGGATGATGGAAATGACTTAATCGAATAAATGGAATGAA 360			
DB 301	TCAAATTTGTCAGTTTGTGGATGATGGAAATGACTTAATCGAATAAATGGAATGAA 360			
QY 361	CTGCAATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTC 420			
DB 361	CTGCAATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTC 420			
QY 421	CAGAAATACGCTGCCATTCGCTGAATGAGCAAGAAACAATATGCTGATGCCAA 480			
DB 421	CAGAAATACGCTGCCATTCGCTGAATGAGCAAGAAACAATATGCTGATGCCAA 480			
QY 481	ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTCTGGAGTGACATGAGGACTCC 540			
DB 481	ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTCTGGAGTGACATGAGGACTCC 540			
QY 541	GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGAAAATA 600			
DB 541	GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGAAAATA 600			
QY 601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGACCTACA 660			

DB 601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGACCTACA 660	
QY 661	AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720	
DB 661	AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720	
QY 721	CACAGGAATTTTCTGAGATGAGAGATGAGTGGCTTTTAAAGATGCCCTCTCTCTTAAC 780	
DB 721	CACAGGAATTTTCTGAGATGAGAGATGAGTGGCTTTTAAAGATGCCCTCTCTCTTAAC 780	
QY 781	TCCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGGATTTCT 840	
DB 781	TCCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGGATTTCT 840	
QY 841	TGTCGAATCTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900	
DB 841	TGTCGAATCTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900	
QY 901	GCTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960	
DB 901	GCTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960	
QY 961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGAGGGGCTCTACTACAAAGTGAAT 1020	
DB 961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGAGGGGCTCTACTACAAAGTGAAT 1020	
QY 1021	CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAGAGTGTATAGACATCTAA 1080	
DB 1021	CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAGAGTGTATAGACATCTAA 1080	
QY 1081	AATTCACCTCTCATAGAGCTTTTAAAGATGTTTCAATTTGATATAGGCTTTAAGAAATCA 1140	
DB 1081	AATTCACCTCTCATAGAGCTTTTAAAGATGTTTCAATTTGATATAGGCTTTAAGAAATCA 1140	
QY 1141	CTATAAATGCAATTAAGTACTCTCAATCTGTG 1174	
DB 1141	CTATAAATGCAATTAAGTACTCTCAATCTGTG 1174	
RESULT 5		
AAC97400		
ID AAC97400	standard; cDNA; 1174 BP.	
XX AAC97400;		
AC AAC97400;		
XX 28-FEB-2001	(first entry)	
DT Human	angiogenesis-associated protein PRO195 cDNA, SEQ ID NO:45.	
XX Human	angiogenesis-associated protein; PRO; endothelial cell growth;	
XX Human	cardiac hypertrophy; cardiovascular disorder; endothelial disorder;	
XX Human	angiogenic disorder; atherosclerosis; osteoporosis; hypertension;	
XX Human	myocardial infarction; diabetic retinopathy; rheumatoid arthritis;	
XX Human	Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;	
XX Human	Alzheimer's disease; Huntington's disease; stroke; drug screening;	
XX Human	gene therapy; transgenic animal; ss.	
XX Homo sapiens.		
XX WO200053753-A2.		
PN 14-SEP-2000.		
PD 05-JAN-2000;	2000WO-US0000219.	
PF 08-MAR-1999;	99WO-US005028.	
PR 12-MAR-1999;	99US-0123957P.	
PR 14-MAY-1999;	99US-0134287P.	
PR 02-JUN-1999;	99WO-US012252.	
PR 23-JUN-1999;	99US-0141037P.	
PR 20-JUL-1999;	99US-0144758P.	
PR 26-JUL-1999;	99US-0145698P.	





XX	ABL88075 standard; cDNA; 1174 BP.	XX	Claim 2; Fig 7; 565pp; English.
XX	ABL88075;	XX	ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
XX	16-MAY-2002 (first entry)	XX	ABB85003. The PRO proteins and polynucleotides have cardiac, cytosolic,
XX	Human PRO195 cDNA sequence SEQ ID NO:7.	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	Human; angiogenesis; cardiac; cytosolic; antidiabetic; hypotensive;	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	vulnerable; antidiabetic; cardiac; cytosolic; antidiabetic; hypotensive;	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	gene therapy; cardiovascular disorder; endothelial disorder; cancer;	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	age-related macular degeneration; arterial restenosis; angina;	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	rheumatoid arthritis; myocardial infarction; thrombophlebitis;	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	wound healing; chromosome mapping; gene mapping; gene; ss.	CC	antidiabetic, hypotensive, and antidiabetic activities. The PRO polynucleotides,
XX	Homo sapiens.	XX	mapping, ABL88259 to ABL88267 represent primers and probes used in the
XX	WO200200690-A2.	XX	exemplification of the present invention
XX	03-JAN-2002.	XX	Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
XX	20-JUN-2001; 2001WO-US019692.	XX	Query Match 100.0%; Score 1174; DB 6; Length 1174;
XX	23-JUN-2000; 2000US-0213637P.	XX	Best Local Similarity 100.0%; Pred. No. 0;
XX	20-JUL-2000; 2000US-0219556P.	XX	Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX	25-JUL-2000; 2000US-0220624P.	QY	1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
XX	25-JUL-2000; 2000US-0220664P.	DB	1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
XX	28-JUL-2000; 2000WO-US020710.	QY	61 GGGACAGATGCGCGCGCGGAGGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
XX	02-AUG-2000; 2000US-0222695P.	DB	61 GGGACAGATGCGCGCGCGGAGGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
XX	17-AUG-2000; 2000US-00643657.	QY	121 CGGTGCTGCTGTGACCATGGCTTGGCGGAGGTTGGGGGACCGCTTCGGCTGAAGCA 180
XX	23-AUG-2000; 2000WO-US023352.	DB	121 CGGTGCTGCTGTGACCATGGCTTGGCGGAGGTTGGGGGACCGCTTCGGCTGAAGCA 180
XX	24-AUG-2000; 2000WO-US023328.	QY	181 TTGACTCGCTTGGGTGATACGGCTCTTGGCAGCGGCTGTGAGTGGCTGCTGCTGCTG 240
XX	07-SEP-2000; 2000US-0230978P.	DB	181 TTGACTCGCTTGGGTGATACGGCTCTTGGCAGCGGCTGTGAGTGGCTGCTGCTGCTG 240
XX	18-SEP-2000; 2000US-00664610.	QY	241 TTGACACCTACCTAAAGAGAGGAGTGTGACGATGTGACGAGGTTGCAGGCTGCTGTTT 300
XX	18-SEP-2000; 2000US-00665350.	DB	241 TTGACACCTACCTAAAGAGAGGAGTGTGACGATGTGACGAGGTTGCAGGCTGCTGTTT 300
XX	24-OCT-2000; 2000US-0242922P.	QY	301 TCATTTGTCAGTTTGGTGTGATGGAATGACTTAATCGAACTAATTTGGAATGTGAA 360
XX	08-NOV-2000; 2000WO-US030952.	DB	301 TCATTTGTCAGTTTGGTGTGATGGAATGACTTAATCGAACTAATTTGGAATGTGAA 360
XX	10-NOV-2000; 2000WO-US030873.	QY	361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATCTGCTGCTGCTGCTGCTG 420
XX	01-DEC-2000; 2000WO-US032678.	DB	361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATCTGCTGCTGCTGCTGCTG 420
XX	20-DEC-2000; 2000US-00747259.	QY	421 CAGATCAGCTGCCATTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 480
XX	20-DEC-2000; 2000WO-US034956.	DB	421 CAGATCAGCTGCCATTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 480
XX	22-JAN-2001; 2001US-00767609.	QY	481 ATGCACCTACTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTT 540
XX	28-FEB-2001; 2001US-00796498.	DB	481 ATGCACCTACTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTT 540
XX	28-FEB-2001; 2001WO-US006520.	QY	541 GCACAGAGCTTCATAACCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTT 600
XX	01-MAR-2001; 2001WO-US006666.	DB	541 GCACAGAGCTTCATAACCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTCTTCTT 600
XX	09-MAR-2001; 2001US-00802706.	QY	601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCCTTACA 660
XX	14-MAR-2001; 2001US-00808689.	DB	601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCCTTACA 660
XX	22-MAR-2001; 2001US-00816744.	QY	661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720
XX	05-APR-2001; 2001US-00828366.	DB	661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720
XX	10-MAY-2001; 2001US-00854208.	QY	721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAAC 780
XX	10-MAY-2001; 2001US-00854280.	DB	721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAAC 780
XX	25-MAY-2001; 2001US-00866034.	QY	
XX	25-MAY-2001; 2001WO-US017092.	DB	
XX	30-MAY-2001; 2001US-00870574.	QY	
XX	30-MAY-2001; 2001WO-US017443.	DB	
XX	01-JUN-2001; 2001WO-US017800.	QY	
XX	(GETH ) GENENTECH INC.	DB	
XX	Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;	QY	
XX	Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;	DB	
XX	Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;	QY	
XX	WFI; 2002-090516/12.	DB	
XX	P-FSDB; ABB84820.	QY	
XX	One hundred and eighty seven nucleic acids encoding PRO polypeptides,	DB	
XX	useful in diagnosis and treatment of cardiovascular (e.g. myocardial	QY	
XX	infarction), endothelial or angiogenic disorders in a mammal.	DB	

721	Db		CACAGGAATTTCTTGGAAGATGGAGAAAGTGATGCTTTTAAAGATGCCTCTCTCTTAAC	780
781	Qy		TCTGGGTGGATTTTAACTCAACTCTGTGCTCTCGGTGATGGTATTGCTTTGGATTGT	840
781	Db		TCTGGGTGGATTTTAACTCAACTCTGTGCTCTCGGTGATGGTATTGCTTTGGATTGT	840
841	Qy		TGTCAACTGTGCTCAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
841	Db		TGTCAACTGTGCTCAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
901	Qy		GGTGACTGGAGTTTATGAANTGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTGTG	960
901	Db		GGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTGTG	960
961	Qy		GTTCTGTAGTCTAAACTGGAAGTCAATGAAGAGCAGGGCCTCTACCTCAAAAAGTGAAT	1020
961	Db		GTTCTGTAGTCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTCAAAAAGTGAAT	1020
1021	Qy		CTTGCTCATTCGAAATTTAAAGCATTTTCTTTTAAAGACAAGTGTAAATGACATCTAA	1080
1021	Db		CTTGCTCATTCGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATGACATCTAA	1080
1081	Qy		AATTCCACTCCTCATAGAGCTTTTAAATAGGTTTCATTGGATATAGGCCTTTAAGAAATCA	1140
1081	Db		AATTCCACTCCTCATAGAGCTTTTAAATAGGTTTCATTGGATATAGGCCTTTAAGAAATCA	1140
1141	Qy		CTATAAATGCAAAATAAGTTACTCAAAATCTGTG	1174
1141	Db		CTATAAATGCAAAATAAGTTACTCAAAATCTGTG	1174

## RESULT 7

RESOLUTION  
ABL95564

ABL953364 ID ABL95564 standard: cdNA: 1174 BP.

XX  
XX  
49CCCTGVAA  
AC  
ABT.95564.

AC  
AC  
XX  
ABLG93364;

19-III-2002 (first entry)  
XX

DI 19-JUL-2002 (FIRST ENTRY)  
YY

XX  
DE Human angiogenesis related cDNA PRO195 SEQ ID NO: 7

DE Human angio genesis related CDNA yy

**XX**

KW Human; angiotensin

KW atherogclerosis

cardiant; cytostatic; antiang

vw antiarteriosclerotic; gene; s

0  
9  
C  
-  
S  
C  
U

C  
B  
C  
T  
O

0  
8  
C  
T  
O

Homo sapiens.

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525

PN WO200208284-A2.

	C
	C
	C
	C
	T
	K
	H
	T
	C
⊗	C

PD 31-JAN-2002.

[illegible]

PF 09-JUL-2001; 2001WO-US021735.

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525

PR 20-JUL-2000; 2000US-02195556P.

PR 25-JUL-2000; 2000US-0220624P.

PR 25-JUL-2000; 2000US-0220664P.

PR 28-JUL-2000; 2000WO-US020710.

PR 02-AUG-2000; 2000US-0222695P.

PR 17-AUG-2000; 2000US-00643657.

22-JAN-2001; 2001US-00767609. PR  
28-FEB-2001; 2001US-00796498. PR  
28-FEB-2001; 2001WO-US006520. PR  
01-MAR-2001; 2001WO-US006666. PR  
09-MAR-2001; 2001US-00802706. PR  
14-MAR-2001; 2001US-00808689. PR  
22-MAR-2001; 2001US-00816744. PR  
05-APR-2001; 2001US-00828366. PR  
10-MAY-2001; 2001US-00854208. PR  
10-MAY-2001; 2001US-00854280. PR  
25-MAY-2001; 2001US-00866028. PR  
25-MAY-2001; 2001US-00866034. PR  
25-MAY-2001; 2001US-00866034. PR  
25-MAY-2001; 2001WO-US017092. PR  
30-MAY-2001; 2001US-00870574. PR  
30-MAY-2001; 2001WO-US017443. PR  
01-JUN-2001; 2001WO-US017800. PR  
20-JUN-2001; 2001WO-US019692. PR

Claim 1: Fig 7: 567pp: English.

The present invention provides the protein and coding sequences of human PRO proteins, these are useful for treating disorders such as cardiovascular, endothelial and/or angiotensin converting enzyme related cardiac hypertrophy, trauma, radiation induced arterial stenosis, rheumatoid arthritis, atherosclerosis, hypertension, arterial restenosis, thrombophlebitis, lymphoma, tumour angiogenesis, hyperlipidaemia, multiple myeloma, leukaemia, lymphoma, carcinoma and melanoma (such as breast carcinoma and liver carcinoma) and wound healing. The present sequence is a coding sequence of the invention.

Case	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	1481	1482	1483	1484	1485	1486	1487	1488	1489	1490	1491	1492	1493	1494	1495	1496	1497	1498	1499	1500
Case	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252																																																																																																																																																																																																																																																								

Query Match 100.0%; Score 1174; DB 6; Length 1174;

Query Match	100.0%	Pred. No. 0;
Best Local Similarity	100.0%	Pred. No. 0;

Best local similarity 100.00, local ratio 0.00  
Matches 1174: Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY	1	CGGACGGCTGGGGGAACCCCTTCGAGAAACACGACACAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGGCTGGGGGAACCCCTTCGAGAAACACGACACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGACACAGATGGGGGGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
Db	61	GGGACACAGATGGGGGGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CGGCTGCTGCTGCTGACCAATCGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGTGAAGCA	180



18-FEB-2000; 2000WO-US004342.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
01-MAR-2000; 2000WO-US005601.  
02-MAR-2000; 2000WO-US005745.  
02-MAR-2000; 2000WO-US005841.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
21-MAR-2000; 2000WO-US007532.  
30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.  
24-AUG-2000; 2000WO-US023328.  
08-NOV-2000; 2000WO-US030952.  
10-NOV-2000; 2000WO-US030873.  
01-DEC-2000; 2000WO-US032678.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
01-MAR-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US005666.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00808689.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Deanyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-341980/32.  
P-PSDB; ABO17751.

New secreted and transmembrane PRO nucleic acids, for treating  
inflammation, organ failure, atherosclerosis, cardiac injury,  
infertility, birth defects, premature aging, acquired immunodeficiency  
syndrome (AIDS), or cancer.

Claim 2; Fig 271; 660pp; English.

The invention describes an isolated nucleic acid (I) comprising, or which  
has 80 % sequence identity to, or the full-length coding sequence of, one  
of 275 nucleotide sequences, and which encodes a corresponding

CC polypeptide selected from 275 amino acid sequences, where all sequences  
CC are given in the specification. The polypeptide encoded by (I) is used to  
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a  
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the  
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate  
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit  
CC the proliferation or differentiation of cells or gene expression,  
CC stimulate the release of proteoglycans, stimulate the release of cytokine  
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide  
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic  
CC acid and polypeptide encoded by it, are useful for treating inflammatory  
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,  
CC birth defects, premature aging, acquired immunodeficiency syndrome  
CC (AIDS) cancer, or diabetic complications. The nucleic acid is useful as  
CC hybridisation probes, in chromosome and gene mapping, and in generating  
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,  
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.  
CC This sequence encodes a novel human secreted and transmembrane PRO  
CC polypeptide  
XX  
SQ

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
DB |||||  
QY 61 GGGAAACAGATGGGGCCCGAAGGGAGCCTCTGGGTGAGGAGCCCACTGGGGCTCCG 120  
DB |||||  
QY 121 CGGTCGCTGCTGCACCATGCGCTTGGCGGAGGTTGGCGGAGCGCTTCGGCTGAAGCA 180  
DB |||||  
QY 181 TTGACTCGGCTTGGGTGATAGCGCGCTTTGCCACCGGCGCTGTCACTGACCTACCC 240  
DB |||||  
QY 241 TTGCACACCTACCTAAGCAAGAGGAGTTGTACCATGTTCAGAGAGGTTGCAGGCTCTTT 300  
DB |||||  
QY 301 TCAATTTGTCACTTTGGATGATGGAATTGCACTTAAATCGAACTAAATTGGAATGTGAA 360  
DB |||||  
QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTCATGAGCAATATGCTTGCATCTTGGTTGC 420  
DB |||||  
QY 421 CAGATCAGCTGCCATTCGCTGAATGAGACAAGAACAACTTATGTGCTCCTGATGCCAAA 480  
DB |||||  
QY 481 ATGCACCTACTCTTCCCTCTAACTCTGGTGAAGTCATTTCTGAGTGAATGATGATGATTC 540  
DB |||||  
QY 541 GCACAGAGCTTCATACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600  
DB |||||  
QY 601 GTTATATTCAGTCTTAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660  
DB |||||  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAGCG 720  
DB |||||

QY	721	CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATCCCTCTCTCTTAAC	780
Db	721	CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATCCCTCTCTCTTAAC <td>780</td>	780
QY	781	TCTGGGTGGATTTTAACTACAACTCTTGCTCTCGGTGAAGTATTTGTTTGGATTTCGT	840
Db	781	TCTGGGTGGATTTTAACTACAACTCTTGCTCTCGGTGAAGTATTTGTTTGGATTTCGT	840
QY	841	TGTGCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTTCCCTCTCAGAAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTTCCCTCTCAGAAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGTTCCTCTCTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGTTCCTCTCTTGTG	960
QY	961	GTGTGTAGATCTAAACTGAAAGATCATGAAGAAGCAGGGCTCTACTCTACAAAGTGAAT	1020
Db	961	GTGTGTAGATCTAAACTGAAAGATCATGAAGAAGCAGGGCTCTACTCTACAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGGAATTTAAGCAATTTTCTTTTAAAGCAAGTGAATAGACATCTAA	1080
Db	1021	CTTGCTCATCTGGAATTTAAGCAATTTTCTTTTAAAGCAAGTGAATAGACATCTAA	1080
QY	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATGTGATATAGCCCTTAAGAATCA	1140
Db	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATGTGATATAGCCCTTAAGAATCA	1140
QY	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
RESULT 9	ACD42704	ID ACD42704 standard; cDNA; 1174 BP.	
XX	AC	ACD42704;	
XX	AC	ACD42704;	
DT	09-SEP-2003	(first entry)	
XX	XX	Novel human secreted and transmembrane protein PRO195 cDNA.	
DE	DE	Human; secreted and transmembrane protein; PRO; virucide; gene therapy;	
KW	KW	cell death; growth induction cascade; blood coagulation cascade;	
KW	KW	viral infection; gene; ss.	
XX	OS	Homo sapiens.	
XX	XX	US2003050239-A1.	
FN	FN	13-MAR-2003.	
PD	PD	15-OCT-2001; 2001US-00978191.	
XX	XX	17-OCT-1997; 97US-0062250P.	
XX	XX	03-NOV-1997; 97US-0064249P.	
XX	XX	13-NOV-1997; 97US-0065311P.	
XX	XX	21-NOV-1997; 97US-0066364P.	
XX	XX	10-MAR-1998; 98US-0077450P.	
XX	XX	11-MAR-1998; 98US-0077632P.	
XX	XX	11-MAR-1998; 98US-0077641P.	
XX	XX	11-MAR-1998; 98US-0077649P.	
XX	XX	12-MAR-1998; 98US-0077791P.	
XX	XX	13-MAR-1998; 98US-0078004P.	
XX	XX	17-MAR-1998; 98US-00040220.	
XX	XX	20-MAR-1998; 98US-0078896P.	
XX	XX	20-MAR-1998; 98US-0078930P.	
XX	XX	20-MAR-1998; 98US-0078936P.	
XX	XX	20-MAR-1998; 98US-0078939P.	
XX	XX	22-MAR-1998; 98US-0079294P.	
XX	XX	26-MAR-1998; 98US-0079656P.	
XX	XX	27-MAR-1998; 98US-0079663P.	
XX	XX	27-MAR-1998; 98US-0079664P.	
XX	XX	27-MAR-1998; 98US-0079689P.	
XX	XX	27-MAR-1998; 98US-0079728P.	
XX	XX	27-MAR-1998; 98US-0079786P.	
XX	XX	30-MAR-1998; 98US-0079920P.	
XX	XX	30-MAR-1998; 98US-0079923P.	
XX	XX	31-MAR-1998; 98US-0080105P.	
XX	XX	31-MAR-1998; 98US-0080107P.	
XX	XX	31-MAR-1998; 98US-0080165P.	
XX	XX	31-MAR-1998; 98US-0080194P.	
XX	XX	01-APR-1998; 98US-0080327P.	
XX	XX	01-APR-1998; 98US-0080328P.	
XX	XX	01-APR-1998; 98US-0080333P.	
XX	XX	01-APR-1998; 98US-0080334P.	
XX	XX	08-APR-1998; 98US-0081043P.	
XX	XX	08-APR-1998; 98US-0081070P.	
XX	XX	08-APR-1998; 98US-0081071P.	
XX	XX	09-APR-1998; 98US-0081203P.	
XX	XX	09-APR-1998; 98US-0081195P.	
XX	XX	09-APR-1998; 98US-0081229P.	
XX	XX	15-APR-1998; 98US-0081817P.	
XX	XX	15-APR-1998; 98US-0081819P.	
XX	XX	15-APR-1998; 98US-0081838P.	
XX	XX	15-APR-1998; 98US-0081952P.	
XX	XX	15-APR-1998; 98US-0081955P.	
XX	XX	21-APR-1998; 98US-0082568P.	
XX	XX	21-APR-1998; 98US-0082569P.	
XX	XX	22-APR-1998; 98US-0082700P.	
XX	XX	22-APR-1998; 98US-0082704P.	
XX	XX	22-APR-1998; 98US-0082797P.	
XX	XX	22-APR-1998; 98US-0082804P.	
XX	XX	23-APR-1998; 98US-0082796P.	
XX	XX	27-APR-1998; 98US-0083336P.	
XX	XX		

PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98US-0116897P.  
PR 07-OCT-1998; 98US-0121141.  
PR 02-NOV-1998; 98US-00184216.  
PR 08-NOV-1998; 98US-00187368.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99US-0000106.  
PR 08-MAR-1999; 99US-00254465.  
PR 08-MAR-1999; 99US-00050028.  
PR 10-MAR-1999; 99US-00265686.  
PR 10-MAR-1999; 99US-0005190.  
PR 12-MAR-1999; 99US-00267213.  
PR 12-MAR-1999; 99US-0123957P.  
PR 29-MAR-1999; 99US-0126773P.  
PR 12-APR-1999; 99US-00284291.  
PR 21-APR-1999; 99US-0130232P.  
PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99US-0134287P.  
PR 14-MAY-1999; 99US-0134287P.  
PR 02-JUN-1999; 99US-05010733.  
PR 16-JUN-1999; 99US-05012252.  
PR 23-JUN-1999; 99US-0139557P.  
PR 07-JUL-1999; 99US-0141037P.  
PR 26-JUL-1999; 99US-0142680P.  
PR 28-JUL-1999; 99US-0145698P.  
PR 25-AUG-1999; 99US-0146222P.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 29-OCT-1999; 99US-00380142.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99US-05028313.  
PR 02-DEC-1999; 99US-05028551.  
PR 16-DEC-1999; 99US-05028565.  
PR 30-DEC-1999; 99US-05030095.  
PR 30-DEC-1999; 99US-05031243.  
PR 30-DEC-1999; 99US-05031274.  
PR 03-JAN-2000; 2000US-05000219.  
PR 06-JAN-2000; 2000US-05000277.  
PR 11-FEB-2000; 2000US-05000376.  
PR 18-FEB-2000; 2000US-05003565.  
PR 24-FEB-2000; 2000US-05004341.  
PR 02-MAR-2000; 2000US-05005004.  
PR 10-MAR-2000; 2000US-05005841.  
PR 21-MAR-2000; 2000US-05006319.  
PR 30-MAR-2000; 2000US-05007532.  
PR 17-MAY-2000; 2000US-05013705.  
PR 22-MAY-2000; 2000US-05014042.  
PR 30-MAY-2000; 2000US-05014941.  
PR 02-JUN-2000; 2000US-05015264.  
PR 28-JUL-2000; 2000US-05020710.  
PR 24-AUG-2000; 2000US-05023328.  
PR 08-NOV-2000; 2000US-00709238.  
PR 27-NOV-2000; 2000US-00723749.  
PR 01-DEC-2000; 2000US-05032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-FEB-2001; 2000US-05034956.  
PR 22-MAR-2001; 2001US-00808520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 22-MAR-2001; 2001US-00816920.  
PR 22-MAR-2001; 2001US-00909552.

PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00854280.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001US-00886342.  
PR 29-JUN-2001; 2001US-00886342.  
PR 09-JUL-2001; 2001US-00886342.  
PR 30-JUL-2001; 2001US-00918585.  
XX (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen MB;  
Query Match 100.0%; Score 1174; DB 7; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCTGGGGGAAACCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGACCACCTGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGACCACCTGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTGGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTGGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTTGGGTGATACGCGCTCTTGGCCACCGGCGCTCTCAGTTGACCTACCCC 240  
DB 181 TTTGACTCGGCTTGGGTGATACGCGCTCTTGGCCACCGGCGCTCTCAGTTGACCTACCCC 240  
QY 241 TTGCAACCTACCTTAAGGAAGAGGAGTTGACCATGTGAGAGGTTGAGGCTGTTT 300  
DB 241 TTGCAACCTACCTTAAGGAAGAGGAGTTGACCATGTGAGAGGTTGAGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTGTGATGAGGAAATGACCTAAATGAACTAAATGGAATGTGAA 360  
DB 301 TCAATTTGTGAGTTGTGATGAGGAAATGACCTAAATGAACTAAATGGAATGTGAA 360  
QY 361 TGTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTC 420  
DB 361 TGTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTC 420  
QY 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480  
DB 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480  
QY 481 ATGCACTACTCTTTCCTTAACTCTGAGAGGTCATCTTGGAGTGACATGAGGACTCC 540  
DB 481 ATGCACTACTCTTTCCTTAACTCTGAGAGGTCATCTTGGAGTGACATGAGGACTCC 540  
QY 541 GCACAGAGCTTCATAACTCTTTCATGACTTTTATCTTCAAGCCGATGACGGAATA 600  
DB 541 GCACAGAGCTTCATAACTCTTTCATGACTTTTATCTTCAAGCCGATGACGGAATA 600  
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAACAATTTGGAGAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAACAATTTGGAGAGGAGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720  
QY 721 CACAGAAATTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATCCCTCTCTTTAAC 780  
DB 721 CACAGAAATTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATCCCTCTCTTTAAC 780

```
QY 781 TCTGGTGGATTTAACTACAACTCTTGCTCTCGGTGATGGTATGCTTTGGATTGT 840
DB 781 TCTGGTGGATTTAACTACAACTCTTGCTCTCGGTGATGGTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGCTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGCTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGACAGCGCTCTACCTACAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGACAGCGCTCTACCTACAAAGTGAAT 1020
QY 1021 CTGTGCTACTTCTGAAGATTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
DB 1021 CTGTGCTACTTCTGAAGATTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGGATATAGGCTTAAAGATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGGATATAGGCTTAAAGATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
DB 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 10
ACA67129
ID ACA67129 standard; cDNA; 1174 BP.
AC XX
XX XX
XX XX
DT 23-JUN-2003 (first entry)
XX XX
DE cDNA encoding human PRO polypeptide #136.
XX XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW hearing loss; coagulation disorder; stroke; heart attack; cardiac;
KW antidiabetic; anorectic; vulnary; antiarthritic; osteopathic;
KW antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.
XX XX
OS Homo sapiens.
XX XX
PN US2003004311-A1.
XX XX
PD 02-JAN-2003.
XX XX
PF 19-DEC-2001; 2001US-00028072.
XX XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 18-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059388P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063350P.
PR 28-OCT-1997; 97US-0063550P.
PR 29-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078510P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018624.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
```

06-JAN-2000; 2000WO-US000277.  
06-JAN-2000; 2000WO-US000376.  
11-FEB-2000; 2000WO-US000376.  
18-FEB-2000; 2000WO-US000341.  
18-FEB-2000; 2000WO-US000341.  
22-FEB-2000; 2000WO-US000414.  
24-FEB-2000; 2000WO-US000414.  
24-FEB-2000; 2000WO-US000504.  
01-MAR-2000; 2000WO-US000501.  
02-MAR-2000; 2000WO-US000574.  
(GETH ) GENENTECH INC.  
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
WPI: 2003-352836/33.  
P-PSDB; ABU81005.  
XX  
New isolated PRO polypeptide useful for treating diabetes, rheumatoid  
PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or  
PT heart attack.  
XX  
Claim 2; Fig 271; 643pp; English.  
XX  
The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides and polynucleotides are useful for preparing a medicament  
CC useful in the treatment of diabetes, bone and/or cartilage disorders  
CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,  
CC hyper- or hypo-insulinemia, hearing loss, and coagulation disorders  
CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic  
CC assays for PRO, by detecting its expression in specific cells, tissues or  
CC serum, and for affinity purification of PRO from recombinant cell culture  
CC or natural sources. ACA66994-ACA67268 represent cDNA sequences encoding  
CC the human PRO polypeptides of the invention. Note: The sequence data for  
CC this patent was obtained in electronic format directly from the USPTO web  
CC site at seqdata.uspto.gov/patseq/entry.html  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 7; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGAGCGGTGGGGAACCTTCCGAGAAACACGACACAGCTGAGCTGTGTGACAG 60  
DB 1 CGGAGCGGTGGGGAACCTTCCGAGAAACACGACACAGCTGAGCTGTGTGACAG 60  
QY 61 GGGAAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGGTGAGGCCCAACTGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGGTGAGGCCCAACTGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGCTGACCATGCGCTTCCGAGAGGTTCGGGACCGCTTGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGCTGACCATGCGCTTCCGAGAGGTTCGGGACCGCTTGGCTGAAGCA 180  
QY 181 TTGTAGCTCGGTCTGGGTGATACGCGCTTTCGCCACCGGGCTCTCAGTTGACCTACCCC 240  
DB 181 TTGTAGCTCGGTCTGGGTGATACGCGCTTTCGCCACCGGGCTCTCAGTTGACCTACCCC 240  
QY 241 TTGCACCTACCTTAAGAGAGAGAGTTGACGATGTACAGAGTTGACGAGCTGTGTT 300  
DB 241 TTGCACCTACCTTAAGAGAGAGAGTTGACGATGTACAGAGTTGACGAGCTGTGTT 300  
QY 301 TCAATTGTGCTGTTGTGGATGATGGAATTCAGTTAAATCGAATAATGGAAATGAA 360  
DB 301 TCAATTGTGCTGTTGTGGATGATGGAATTCAGTTAAATCGAATAATGGAAATGAA 360  
QY 361 TCTGATGTACAGAGCATATCCCAATCTCATGAGCAATATGCTGCCATCTTGGTGC 420

DB 361 TCTGATGTACAGAGCATATCCCAATCTCATGAGCAATATGCTGCCATCTTGGTGC 420  
QY 421 CAGAACTGAGCTGCGCTGAACTGAGACAGCAACCTTATGTCCTGATGCCAAA 480  
DB 421 CAGAACTGAGCTGCGCTGAACTGAGACAGCAACCTTATGTCCTGATGCCAAA 480  
QY 481 ATGACCTACTCTTCTTAACTCTGAGTCAATCTGAGTCAATCTGAGTCAATCTGAGTCA 540  
DB 481 ATGACCTACTCTTCTTAACTCTGAGTCAATCTGAGTCAATCTGAGTCAATCTGAGTCA 540  
QY 541 GCACAGAGCTTCATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGAGCCTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGAGCCTACA 660  
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTTAAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTTAAAC 780  
QY 781 TCTGGTGGATTTTAACTACAATCTTCTCTGCTCGGTGATGATATGCTTTGGATTTGT 840  
DB 781 TCTGGTGGATTTTAACTACAATCTTCTCTGCTCGGTGATGATATGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
QY 901 GGTGACTGAGATTTTAAATGAAGCAAAAGCTAAAAGATATCCAGCTTCTTCTTTGTG 960  
DB 901 GGTGACTGAGATTTTAAATGAAGCAAAAGCTAAAAGATATCCAGCTTCTTCTTTGTG 960  
QY 961 GTTCTGATCTTAAACTGAGATCATGAGAGAGAGGCTCTACCTACCAAGTGAAT 1020  
DB 961 GTTCTGATCTTAAACTGAGATCATGAGAGAGAGGCTCTACCTACCAAGTGAAT 1020  
QY 1021 CTTCTCATCTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATATAGACATCTAA 1080  
DB 1021 CTTCTCATCTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCTATAGAGCTTTTAAAGTGTTCATTGGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCCACTCTCTATAGAGCTTTTAAAGTGTTCATTGGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATAAAGTTACTCAAACTGTG 1174  
DB 1141 CTATAAATGCAATAAAGTTACTCAAACTGTG 1174  
RESULT 11  
ACA63739  
ID ACA63739 standard; cDNA; 1174 BP.  
XX  
AC ACA63739;  
XX  
DT 16-JUN-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX  
Human; secreted and transmembrane protein; PRO; antiinflammatory;  
KW antiarteriosclerotic; cardiant; anti-infertility; anti-Hiv; cytostatic;  
KW antidiabetic; gene therapy; inflammatory disease; organ failure;  
KW atherosclerosis; cardiac injury; infertility; birth defect;  
KW premature aging; AIDS; cancer; diabetic complication; chromosome mapping;  
KW gene mapping; pharmaceutical; diagnostic; biosensor; bioreactor;  
KW tissue typing; gene; ss  
XX



```
OS PR 06-JAN-2000; 2000WO-US000376.
XX PR 11-FEB-2000; 2000WO-US003565.
PN PR 18-FEB-2000; 2000WO-US004341.
XX PR 24-FEB-2000; 2000WO-US005004.
PD PR 02-MAR-2000; 2000WO-US005841.
XX PR 10-MAR-2000; 2000WO-US006319.
XX PR 21-MAR-2000; 2000WO-US007532.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 17-MAY-2000; 2000WO-US013705.
XX PR 22-MAY-2000; 2000WO-US014042.
XX PR 30-MAY-2000; 2000WO-US014941.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 28-JUL-2000; 2000WO-US020710.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 20-DEC-2000; 2000WO-US034956.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 22-MAR-2001; 2001WO-US009552.
XX PR 25-MAY-2001; 2001WO-US017092.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 20-JUN-2001; 2001WO-US019692.
XX PR 29-JUN-2001; 2001WO-US021065.
XX PR 09-JUL-2001; 2001WO-US021735.
XX PR (GETH ) GENENTECH INC.
XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IU, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-328860/31.
XX P-PSDE; ABU72241.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,
XX cardiac injury, infertility, birth defects, premature aging, AIDS, or
XX cancer.
XX Claim 2; Fig 131; 453pp; English.
XX
XX The invention describes an isolated nucleic acid (1) comprising, or which
XX is at least 80 % sequence identity to, or the full-length coding sequence
XX of, any of 118 300-2100 nucleotide sequences, which encodes its
XX corresponding PRO polypeptide selected from 118 100-700 amino acid
XX sequences, all given in the specification. The nucleic acids and
XX polypeptides are useful for treating inflammatory diseases, organ
XX failure, atherosclerosis, cardiac injury, infertility, birth defects,
XX premature aging, AIDS, cancer, or diabetic complications. The nucleic
XX acids are useful as hybridisation probes, in chromosome and gene mapping,
XX and in generating antisense RNA or DNA. The polypeptides are useful as
XX pharmaceuticals, diagnostics, biosensors or bioeffectors. Both are useful
XX in tissue typing. This sequence encodes a novel human secreted and
XX transmembrane PRO polypeptide
XX
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1174; DB 7; Length 1174;
XX Best Local Similarity 100.0%; Freq. No. 0;
XX Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 CGGACGCTGGGGGAAACCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAG 60
XX Db 1 CGGACGCTGGGGGAAACCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAG 60
XX
XX Qy 61 GGGAAACAGATGGCGCGCGCGAGGGGAGCTCTGGGTGAGACCCCACTGGGGTCCCG 120
XX Db 61 GGGAAACAGATGGCGCGCGCGAGGGGAGCTCTGGGTGAGACCCCACTGGGGTCCCG 120
XX
XX Qy 121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGAACA 180
XX Db 121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGAACA 180
```



PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001WO-US017800.  
PR 14-JUN-2001; 2001US-00874503.  
PR 19-JUN-2001; 2001US-00882636.  
PR 20-JUN-2001; 2001US-00886342.  
PR 21-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908927.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-332040/31.

P-PSDB; ABU66705.

XX New secreted and transmembrane PRO nucleic acids, useful for gene  
PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue  
PT typing, and in chromosome identification.

XX Claim 2; Fig 271; 660pp; English.

XX The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides are useful for detecting other PRO polypeptides, for linking  
CC bioactive molecules to cells expressing PRO polypeptides, for modulating  
CC biological activities of cells expressing PRO polypeptides, and for  
CC identifying agonists or antagonists. The PRO polypeptides are useful for  
CC for stimulating the release of tumour necrosis factor (TNF)-alpha from  
CC human blood, for stimulating the proliferation or differentiation of  
CC chondrocytes, and detecting the presence of tumours. The polynucleotide  
CC sequences encoding PRO polypeptides are useful as hybridisation probes,

CC in chromosome and gene mapping, in the generation of antisense RNA and  
CC DNA, in the preparation of PRO polypeptides, for generating transgenic  
CC animals or knockout animals, for the genetic analysis of individuals with  
CC genetic disorders, and in gene therapy. ACA03603-ACA03877 represent cDNAs  
CC encoding the human PRO polypeptides of the invention. Note: the sequence  
CC data for this patent was obtained in electronic format directly from the  
CC USPTO web site at seqdata.uspto.gov/psipidEntry.html

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGGCTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
QY 61 GGGACACAGATGGCGCGCGGAGGAGGCTCTGGGTGAGGAGCCCACTGGGGCTCCG 120  
DB 61 GGGACACAGATGGCGCGCGGAGGAGGCTCTGGGTGAGGAGCCCACTGGGGCTCCG 120  
QY 121 CCGCTGCTGCTGCTGACCATGGCTTCGGCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGCTGACCATGGCTTCGGCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180  
QY 181 TTGACTCGGTCTGGGTGATACGGCGTCTTGCCACCGGSCCTGTCAGTGCATACCTACCCC 240  
DB 181 TTGACTCGGTCTGGGTGATACGGCGTCTTGCCACCGGSCCTGTCAGTGCATACCTACCCC 240  
QY 241 TTGCACACCTACCCCTAAGGAGGAGGTTGTCGCGATGTCAGAGAGGTTGCAGCTGTTT 300  
DB 241 TTGCACACCTACCCCTAAGGAGGAGGTTGTCGCGATGTCAGAGAGGTTGCAGCTGTTT 300  
QY 361 TCTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATCTTCGCCATCTTGGTTGC 420  
DB 361 TCTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATCTTCGCCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAATTATGTCCCTGATGCAAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAATTATGTCCCTGATGCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTTAACTCTGGTGAGTCACTTCGGAGTGCATGATGGACTCC 540  
DB 481 ATGCACCTACTCTTCTCTTAACTCTGGTGAGTCACTTCGGAGTGCATGATGGACTCC 540  
QY 541 GCACAGAGTTTCAATACCTCTTCATGACCTTTTATCTTCAAGCCGATGACGAAAAATA 600  
DB 541 GCACAGAGTTTCAATACCTCTTCATGACCTTTTATCTTCAAGCCGATGACGAAAAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTCAGCAACCATTTGGAGCAGGAGCCCTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTCAGCAACCATTTGGAGCAGGAGCCCTACA 660  
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATAGAAAATTCACAAGCG 720  
DB 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATAGAAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGGAGAGGAGTGGCTTTTAAAGATGCCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGGAGAGGAGTGGCTTTTAAAGATGCCTCTCTTAAC 780  
QY 781 TCTGGGTGGAATTTAACTACAACCTTCTGCTCGGTGATGTTGTTGGATTTGT 840  
DB 781 TCTGGGTGGAATTTAACTACAACCTTCTGCTCGGTGATGTTGTTGGATTTGT 840  
QY 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
DB |||||  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
DB |||||  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGACGAGGCTCTTACCTACAAAAGTGAAT 1020  
DB |||||  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGACGAGGCTCTTACCTACAAAAGTGAAT 1020  
DB |||||  
QY 1021 CTTGTCTCATTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
DB |||||  
QY 1021 CTTGTCTCATTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
DB |||||  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTGATATAGAGCAATCA 1140  
DB |||||  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTGATATAGAGCAATCA 1140  
DB |||||  
QY 1141 CTTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
DB |||||  
QY 1141 CTTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
DB |||||

## RESULT 13

ACA71903

ID ACA71903 standard; cDNA; 1174 BP.

XX AC ACA71903;

XX DT 11-AUG-2003 (first entry)

XX DE Human secreted and transmembrane polypeptide PRO195 cDNA.

XX KW Human; ss; gene; thrombolytic agent; interferon; interleukin; cytokine;

XX KW erythropoietin; colony stimulating factor; cancer; colorectal carcinoma;

XX KW apoptosis related condition; AIDS; amyotrophic lateral sclerosis;

XX KW inflammatory disease; asthma; atherosclerosis; neurodegenerative disease;

XX KW gastrointestinal disorder; Alzheimer's disease; Parkinson's disease;

XX KW hypertension; myocardial ischaemia; kidney disease; carcinogenesis;

XX KW glomerulonephritis; lung disease; pulmonary hypertension; preclampsia;

XX KW bronchial asthma; gastric ulcer; renal failure; cardiovascular disease;

XX KW inflammatory bowel disease; reproductive disorder; premature labour.

XX OS Homo sapiens.

XX PN US2002177553-A1.

XX PD 28-NOV-2002.

XX PF 15-OCT-2001; 2001US-00978192.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 03-NOV-1997; 97US-0064249P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 21-NOV-1997; 97US-0066364P.

XX PR 10-MAR-1998; 98US-0077450P.

XX PR 11-MAR-1998; 98US-0077632P.

XX PR 11-MAR-1998; 98US-0077641P.

XX PR 11-MAR-1998; 98US-0077649P.

XX PR 12-MAR-1998; 98US-0077791P.

XX PR 13-MAR-1998; 98US-0078004P.

XX PR 17-MAR-1998; 98US-00040220.

XX PR 20-MAR-1998; 98US-0078886P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 20-MAR-1998; 98US-0078936P.

XX PR 20-MAR-1998; 98US-0078939P.

XX PR 25-MAR-1998; 98US-0079294P.

XX PR 26-MAR-1998; 98US-0079656P.

XX PR 27-MAR-1998; 98US-0079663P.

XX PR 27-MAR-1998; 98US-0079664P.

XX PR 27-MAR-1998; 98US-0079689P.

XX PR 27-MAR-1998; 98US-0079728P.

XX PR 27-MAR-1998; 98US-0079786P.

XX PR 30-MAR-1998; 98US-0079920P.

(GETH ) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

Kiljavin IJ, Kuo SS, Napiet MA, Pan J, Paoni NF, Roy MA, Shelton DL;

Stewart TA, Tumas D, Williams FM, Wood WI;

XX WPI; 2003-328499/31.  
DR P-ESDB; ABU84921.  
XX  
XX New isolated PRO polypeptides e.g. PRO213, PRO274 and PRO300, for use as  
PT pharmaceuticals, diagnostics, biosensors and bioreactors, for identifying  
PT modulators of receptor-ligand interactions.  
XX  
XX Claim 2; SEQ ID NO 329; 55pp; English.  
XX  
XX The invention relates to an isolated secreted and transmembrane  
CC polypeptide, designated as PRO polypeptide. The PRO polypeptide is useful  
CC in PRO polypeptide detection methods. The PRO polypeptide is useful for  
CC linking a bioactive molecule to a cell. The PRO polypeptide or an  
CC antibody against it is useful for modulating a biological activity of a  
CC cell. The PRO polypeptide is useful in industrial applications including  
CC pharmaceuticals, diagnostics, biosensors and bioreactors. The PRO  
CC polypeptide is also useful as a thrombolytic agent, interferon,  
CC interleukin, erythropoietin, colony stimulating factor and other  
CC cytokines. The PRO polypeptide is useful for treating disease such as  
CC cancer e.g. colorectal carcinoma; apoptosis related conditions e.g. AIDS,  
CC amyotrophic lateral sclerosis; inflammatory disease e.g. asthma,  
CC atherosclerosis; neurodegenerative disease e.g. Alzheimer's disease,  
CC Parkinson's disease; cardiovascular disease e.g. hypertension and  
CC myocardial ischaemia; kidney disease e.g. renal failure and  
CC glomerulonephritis; lung disease e.g. pulmonary hypertension, bronchial  
CC asthma; gastrointestinal disorders e.g. gastric ulcer and inflammatory  
CC bowel disease; reproductive disorders e.g. premature labour and  
CC pre-eclampsia; carcinogenesis. The present sequence represents a cDNA  
CC encoding a PRO polypeptide of the invention. Note: The sequence data for  
CC this patent did not form part of the printed specification but was  
CC obtained in electronic format directly from USPTO at  
CC seqdata.uspto.gov/sequence.html?DocID=20020177553  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGGGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60

QY 61 GGGAAACAGATGGCGGCGCGGAGGAGCCTCTGGGTGAGGACCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGCGGCGCGGAGGAGCCTCTGGGTGAGGACCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGACCATGGCTTCGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGACCATGGCTTCGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGGCTCTTGGCCACCGGCGCTGTCAGTGTACCTACCC 240  
DB 181 TTTGACTCGGTCTTGGGTGATACGGGCTCTTGGCCACCGGCGCTGTCAGTGTACCTACCC 240

QY 241 TTGCACACCTACCTAAGGAGGAGCTTGTACGCATGTCCAGAGAGTTGCGAGGCTGTTT 300  
DB 241 TTGCACACCTACCTAAGGAGGAGCTTGTACGCATGTCCAGAGAGTTGCGAGGCTGTTT 300

QY 301 TCAATTTGTCAATTTGGTGTGATGGAATTTGACTTAAATCGAACTAAATGGAATGTGAA 360  
DB 301 TCAATTTGTCAATTTGGTGTGATGGAATTTGACTTAAATCGAACTAAATGGAATGTGAA 360

QY 361 TCTCGATGTACAGAGCATATCCCATCTGATGAGCAATGCTTGGCCATCTTGGTTCG 420  
DB 361 TCTCGATGTACAGAGCATATCCCATCTGATGAGCAATGCTTGGCCATCTTGGTTCG 420

QY 421 CAGAATCAGCTGCCATTCGCTGAGCTGAGCAAGAACAACTTATGTCCTGTATGCCAAA 480  
DB 421 CAGAATCAGCTGCCATTCGCTGAGCTGAGCAAGAACAACTTATGTCCTGTATGCCAAA 480

QY 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGAGTACTCC 540

Db 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGAGTACTCC 540  
QY 541 GCACAGAGCTTCATACACCTCTTCATGGAATTTTATCTTCAAGCGGATGACGGAATAA 600  
Db 541 GCACAGAGCTTCATACACCTCTTCATGGAATTTTATCTTCAAGCGGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAACATTTGGAGGAGGCTTACA 660  
Db 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAACATTTGGAGGAGGCTTACA 660  
QY 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720  
Db 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTGAGATGAGAGAAATGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTGAGATGAGAGAAATGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGGATTTGT 840  
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGTGAGAGATGATTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTTGCTACAGCTGTGAGAGATGATTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGATGAACAAAGAGTAAACAGATATCCAGCTTCTTCTCTGTG 960  
Db 901 GGTGACTTGGAGTTTATGATGAACAAAGAGTAAACAGATATCCAGCTTCTTCTCTGTG 960  
QY 961 GTTGTAGATCTAAAATCTGAAGATCATGAAGAGGAGGCGCTCTACCTACAAAATGAAT 1020  
Db 961 GTTGTAGATCTAAAATCTGAAGATCATGAAGAGGAGGCGCTCTACCTACAAAATGAAT 1020  
QY 1021 CTTGCTCATCTCGAATTTAAGCATTTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
Db 1021 CTTGCTCATCTCGAATTTAAGCATTTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTTACTCAAAATCTGTG 1174  
Db 1141 CTATAAATGCAATTAAGTTACTCAAAATCTGTG 1174

RESULT 14  
ABX89275  
ID ABX89275 standard; cDNA; 1174 BP.  
XX  
AC ABX89276;  
XX  
DT 13-MAY-2003 (first entry)  
XX  
DE DNA encoding novel secreted and transmembrane protein PRO195.  
XX  
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
KW cardiac insufficiency disorder; cancer; tumour; immune response;  
KW adrenal cortical capillary endothelial growth; c-fos induction;  
KW vascular endothelial growth factor inhibition; VEGF inhibition;  
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;  
KW retinal neurons cell survival; rod photoreceptor cell survival;  
KW retinal disorder; retinosis pigmentosa; kidney disorder;  
KW mammalian kidney mesangial cell proliferation; Berger disease;  
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;  
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ss.  
XX Homo sapiens.  
OS  
XX  
PN US2003017563-A1.  
XX

PD 23-JAN-2003.  
XX 07-MAY-2002; 2002US-00140808.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US003376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023388.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001US-00887879.  
PR 21-JUN-2001; 2001WO-US019692.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908927.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-148238/14.  
XX P-PSDB; ABUS9786.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX Claim 2; Fig 271; 659pp; English.  
XX The invention describes an isolated human PRO polypeptide. The PRO  
CC polypeptides are useful in detecting PRO polypeptides in a sample, in  
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
CC in modulating at least one biological activity of a cell expressing a PRO  
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186  
CC stimulate adrenal cortical capillary endothelial growth, and PRO136,  
CC PRO943, PRO828, PRO1346 or PRO335, PRO826, PRO819, PRO1126,  
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus  
CC useful for treating conditions or disorders where angiogenesis would be  
CC beneficial, e.g. wound healing and antagonist of this polypeptide are  
CC useful for treating cancerous tumors. PRO812 inhibits vascular  
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial  
CC cells and is thus useful for inhibiting endothelial cell growth in  
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,  
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of  
CC stimulated T-lymphocytes and are therapeutically useful for enhancing  
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of  
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of  
CC rod photoreceptor cells) and therefore are useful for treating retinal  
CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813  
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,  
CC and therefore are useful for treating kidney disorders associated with  
CC decreased mesangial cell function such as Berger disease or other  
CC nephropathies associated with dermatitis, herpetiformis or Crohn's  
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the  
CC proliferation and/or redifferentiation of chondrocytes in culture and are





PR 20-NOV-1998; 98WO-US024855.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 05-JAN-1999; 99WO-US000106.  
PR 05-MAR-1999; 99WO-US0254465.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99US-00265686.  
PR 10-MAR-1999; 99WO-US005190.  
PR 12-APR-1999; 99US-00284291.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 22-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380142.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 30-DEC-1999; 99WO-US031243.  
PR 05-JAN-2000; 99WO-US031274.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000US-00709238.  
PR 27-NOV-2000; 2000US-00723749.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 22-MAR-2001; 2001US-00816920.  
PR 22-MAR-2001; 2001WO-US009552.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 30-JUL-2001; 2001US-00918585.

(GETH ) GENENTECH INC.

XX Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton D;  
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;  
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;  
PI Stewart TA, Tumas D, Williams PM, Wood WI;  
XX WPI; 2003-288163/28.  
DR P-FSDB; ABU61119.

XX Novel secreted and transmembrane polypeptides and polynucleotides  
PT encoding them useful for treating cancer, kidney diseases, bone,  
PT cartilage disorders and immune deficiencies.

XX Claim 2; Fig 131; 459pp; English.  
XX The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides are useful for detecting other PRO polypeptides, for linking  
CC bioactive molecules to cells expressing PRO polypeptides, for modulating  
CC biological activities of cells expressing PRO polypeptides, and for for  
CC identifying agonists or antagonists. The bioactive molecule maybe a  
CC toxin, radiolabel or antibody, and causes apoptosis or death of the cell.  
CC The PRO polypeptides are useful for treating immune disorders, diabetes  
CC or hyper- or hypo-insulinaemia, cardiac insufficiency, nervous system  
CC disorders, kidney disorders, bone and cartilage disorders or arthritis,  
CC tumours, and wound healing. The polynucleotide sequences encoding PRO  
CC polypeptides are useful as hybridisation probes, in chromosome and gene  
CC mapping, in the generation of antisense RNA and DNA, in the preparation  
CC of PRO polypeptides, for generating transgenic animals or knockout  
CC animals, for the genetic analysis of individuals with genetic disorders,  
CC and in gene therapy. The present sequence encodes a human PRO polypeptide  
CC of the invention. Note: The sequence data for this patent was obtained in  
CC electronic format directly from the USPTO web site at  
CC seqdata.uspto.gov/psipdIDentry.html  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
SQ  
Query Match 100.0%; Score 1174; DB 7; Length 1174;  
Best Local Similarity 100.0%; P-red. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
QY 61 GGGAAACAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
QY 121 CGCTGCTGCTGCTGACATGGCTTGGCCGAGGCTTGGGGACCGCTTGGCTGAGCA 180  
DB 121 CGCTGCTGCTGCTGACATGGCTTGGCCGAGGCTTGGGGACCGCTTGGCTGAGCA 180  
QY 181 TTGACTCGGTCTTGGGTGATACGGCTCTTGCCACCGGGCCTGTGAGTTCACCTACCC 240  
DB 181 TTGACTCGGTCTTGGGTGATACGGCTCTTGCCACCGGGCCTGTGAGTTCACCTACCC 240  
QY 241 TTGCACACCTACCTAAGGAGAGAGTTGATCGATGTGACAGAGTTGCAGGCTGTTT 300  
DB 241 TTGCACACCTACCTAAGGAGAGAGTTGATCGATGTGACAGAGTTGCAGGCTGTTT 300  
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360  
DB 301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360  
QY 361 TGTGATGTACAGAGCATATTCCTCAATCTGATGAGCATATGCTTGCCTTTCCTTC 420  
DB 361 TGTGATGTACAGAGCATATTCCTCAATCTGATGAGCATATGCTTGCCTTTCCTTC 420  
QY 421 CAGATCAGCTGCCATTCGCTGGAACAGACAGAACTATATGTCCTGATGCCAAA 480  
DB 421 CAGATCAGCTGCCATTCGCTGGAACAGACAGAACTATATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTTTCCTTAACTCTGCTGAGGTCAATCTGAGTGCATATGAGCTCC 540  
DB 481 ATGCACCTACTCTTTTCCTTAACTCTGCTGAGGTCAATCTGAGTGCATATGAGCTCC 540  
QY 541 GCACAGCTTCATAACTCTTCATGACCTTTTATCTTCAAGCCGATGACGAAATA 600  
DB 541 GCACAGCTTCATAACTCTTCATGACCTTTTATCTTCAAGCCGATGACGAAATA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660

QY 661 AATTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB |||||  
QY 661 AATTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB |||||  
QY 721 CACAGGAATTTCTTGAAGATGGAAGATGGCTTTTAAAGATGCGCTCTCTCTTAAC 780  
DB |||||  
QY 721 CACAGGAATTTCTTGAAGATGGAAGATGGCTTTTAAAGATGCGCTCTCTCTTAAC 780  
DB |||||  
QY 781 TCTGGTGGATTTTAACTTACAACTCTTGTCTCTCGGTGATGTTATGCTTTGATTTGT 840  
DB |||||  
QY 841 TGTGCAACTGTGTGACAGCTGTGAGCAGATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB |||||  
QY 841 TGTGCAACTGTGTGACAGCTGTGAGCAGATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB |||||  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960  
DB |||||  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960  
DB |||||  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGACAGCGGCTCTTACCTACAAAAGTGAAT 1020  
DB |||||  
QY 1021 CTTGCTCATCTGGAATTTAGCAATTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
DB |||||  
QY 1021 CTTGCTCATCTGGAATTTAGCAATTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
DB |||||  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTTAAGAAATCA 1140  
DB |||||  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTTAAGAAATCA 1140  
DB |||||  
QY 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174  
DB |||||  
QY 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174  
DB |||||

RESULT 16  
ACD41930  
ID ACD41930 standard; cDNA; 1174 BP.  
XX AC ACD41930;  
XX DT 05-SEP-2003 (first entry)  
XX DE Human secreted/transmembrane protein (PRO) cDNA #136.  
XX KW Human; ss; gene; PRO; secreted protein; transmembrane protein; tumour;  
KW cytosolic; gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;  
KW proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;  
KW PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;  
KW chondrocyte cell proliferation; chondrocyte cell differentiation;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell; A-peptide; factor VIIA.  
XX OS Homo sapiens.  
XX PN US2003036179-A1.  
XX PD 20-FEB-2003.  
XX PF 10-MAY-2002; 2002US-00142431.  
XX PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.  
PR 17-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028554.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 16-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI: 2003-466355/44.  
 P-PSDB; AB024976.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 271; 659pp; English.

The invention relates to an isolated nucleic acid comprising at least 80% sequence identity to a PRO (secreted and transmembrane protein) cDNA comprising a nucleic acid (a) encoding a PRO polypeptide, or its extracellular domain (with or without its associated signal peptide), which comprises any of the 275 120-850 residue amino acid sequences, given in the specification; (b) comprising any of the 275 300-3500 nucleotide sequences given in the specification; or (c) comprising the full-length coding sequence of the nucleotide sequences given in the specification, or of the DNA deposited under any of the American Type Culture Collection (ATCC) Accession Numbers listed in the specification. Also included are a vector comprising the novel nucleic acid, a host cell comprising the vector, producing a PRO polypeptide, the isolated PRO polypeptides detailed above, a chimeric molecule comprising the PRO polypeptide of fused to a heterologous amino acid sequence, an anti-PRO antibody, detecting a PRO polypeptide in a sample suspected of containing the PRO polypeptide, linking a bioactive molecule to a cell expressing a PRO polypeptide, modulating at least one biological activity of a cell expressing a PRO polypeptide, stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, (or proteoglycans from cartilage or cytokine from peripheral blood mononuclear cells (PBMC)), modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, stimulating the proliferation or differentiation of chondrocyte cells (or proliferation of or gene expression in pericyte cells), stimulating the proliferation of inner ear utricular supporting cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the binding of A-peptide to factor VIIa, or differentiation of adipocyte cells, detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the nucleotide sequences given in the specification. The polynucleotide is useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The polynucleotide may also be used in preparing PRO polypeptides by recombinant techniques, and in generating either transgenic animals or knock-out animals which, in turn, are useful in the development and screening of therapeutically useful reagents. The PRO polypeptide or the antibody is used in preparing a medicament for treating a condition responsive to the polypeptide or antibody, such as tumours, and in various diagnostic assays. The present sequence encodes a PRO polypeptide

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match	100.0%; Score 1174; DB 7; Length 1174;	Best Local Similarity 100.0%; Pred. No. 0;	Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1	CGGACGGTGGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60	
DB 1	CGGACGGTGGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60	
QY 61	GGGAAACAGATGGCGGCGCGGAGAGGAGCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG	120	
DB 61	GGGAAACAGATGGCGGCGCGGAGAGGAGCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG	120	
QY 121	CGCTGCTGCTGTGACATGCGCTTGGCCGAGGTTGGGGAGCCGCTTCGGCTGAGCA	180	
DB 121	CGCTGCTGCTGTGACATGCGCTTGGCCGAGGTTGGGGAGCCGCTTCGGCTGAGCA	180	
QY 181	TTTGACTCGGTCTTGGGTGATACCGGCTCTTTGGCCACCGGGCCTGTGAGTGAACCTACCCC	240	
DB 181	TTTGACTCGGTCTTGGGTGATACCGGCTCTTTGGCCACCGGGCCTGTGAGTGAACCTACCCC	240	
QY 241	TTGCACACCTACCTTAAGGAGAGAGGATTGTGACATGTGACAGAGTTGCGAGCTGTTT	300	
DB 241	TTGCACACCTACCTTAAGGAGAGAGGATTGTGACATGTGACAGAGTTGCGAGCTGTTT	300	
QY 301	TCAATTTCTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAAATGTGA	360	
DB 301	TCAATTTCTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAAATGTGA	360	
QY 361	TGTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTC	420	
DB 361	TGTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTC	420	
QY 421	CAGATCAGCTGCCATTCGCTGACTGAGACAGCAAGCAACTTATGTCCTCCCTGATGCCAAA	480	
DB 421	CAGATCAGCTGCCATTCGCTGACTGAGACAGCAAGCAACTTATGTCCTCCCTGATGCCAAA	480	
QY 481	ATGCACCTACTCTTCTCTCTAACTCTCTGGTGAAGTCACTTCTGGAGTGACATGAGTCTCC	540	
DB 481	ATGCACCTACTCTTCTCTCTAACTCTCTGGTGAAGTCACTTCTGGAGTGACATGAGTCTCC	540	
QY 541	GCACAGAGCTTCATAACCTCTCTCATGCACTTTTATCTTCAAGCCGATGACGGAATAA	600	
DB 541	GCACAGAGCTTCATAACCTCTCTCATGCACTTTTATCTTCAAGCCGATGACGGAATAA	600	
QY 601	GTATATTTCCAGTCTTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGCTTACA	660	
DB 601	GTATATTTCCAGTCTTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGCTTACA	660	
QY 661	AAATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG	720	
DB 661	AAATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG	720	
QY 721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCTCTCTCTTAAC	780	
DB 721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCTCTCTCTTAAC	780	
QY 781	TCGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGTTGCTTGGATTTGT	840	
DB 781	TCGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGTTGCTTGGATTTGT	840	
QY 841	TCGTCAACTGTGTGTACAGCTGTGGAGCAGTATGCTTCCCTCTCGAGAGCTGAGTATCTAT	900	
DB 841	TCGTCAACTGTGTGTACAGCTGTGGAGCAGTATGCTTCCCTCTCGAGAGCTGAGTATCTAT	900	
QY 901	GTGACTTGGAGTTTAACTGAATGAACAAAGCTAAACAGATATCAGCTTCTTCTTGTG	960	
DB 901	GTGACTTGGAGTTTAACTGAATGAACAAAGCTAAACAGATATCAGCTTCTTCTTGTG	960	
QY 961	GTGTGTTAGATCTAAACCTGAAGATCATCAAGAAAGCAGGGCTCTTACCTCAAAAGTGAAT	1020	
DB 961	GTGTGTTAGATCTAAACCTGAAGATCATCAAGAAAGCAGGGCTCTTACCTCAAAAGTGAAT	1020	





PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010733.  
 PR 02-JUN-1999; 98WO-US012252.  
 PR 01-SEP-1999; 98WO-US020111.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 05-OCT-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.  
 PR 30-DEC-1999; 98WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003365.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004342.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006894.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000US-US034356.  
 PR 28-FEB-2001; 2001US-00796496.  
 PR 01-MAR-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00806689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 XX  
 PA (GETH ) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerriksen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 DR WPI, 2003-331925/31.  
 DR P-PSDB; ABU66981.

XX New secreted and transmembrane nucleic acids and polypeptides, designated  
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
 PT cancer.

XX Claim 2; Fig 271; 659pp; English.

XX The invention relates to an isolated nucleic acid comprising, or which is  
 CC at least 80% identical to, or the full-length coding sequence of, any of  
 CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide  
 CC (one of 275 secreted or transmembrane proteins). The nucleic acid further  
 CC comprises the full-length coding sequence of the DNA deposited under  
 CC American Type Culture Collection (ATCC) accession number in a list given  
 CC in the specification. Also included are vectors and host cells for  
 CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO  
 CC extracellular domains and mature sequences, methods of detecting PRO  
 CC proteins, methods for stimulating the release of TNF-alpha (tumour  
 CC necrosis factor alpha) from human blood, (and the proliferation of  
 CC differentiation of chondrocyte cells, the proliferation of, or gene  
 CC expression in pericyte cells, the release or proteoglycans from  
 CC cartilage, proliferation of inner ear uricular supporting cells, the  
 CC proliferation of T-lymphocyte cells, the release of a cytokine from  
 CC peripheral blood mononuclear cells (PBMC), or the proliferation of  
 CC endothelial cells), a method for modulating the uptake of glucose or free  
 CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the  
 CC binding of A-peptide to factor VIIA, or the differentiation of adipocyte  
 CC cells, a method for detecting the presence of a tumour in a mammal and an  
 CC oligonucleotide probe derived from any of the nucleotide sequences cited  
 CC above. The nucleic acids and polypeptides are useful for treating  
 CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,  
 CC infertility, birth defects, premature aging, AIDS (acquired  
 CC immunodeficiency syndrome), cancer, or diabetic complications. The  
 CC nucleic acids are useful as hybridisation probes, in chromosome and gene  
 CC mapping, and in generating antisense RNA or DNA. The polypeptides are  
 CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both  
 CC are useful in tissue typing. The present sequence encodes a PRO protein  
 CC of the invention

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

QY	1021	CTTGCTCAATCTGAAATTTAAAGCAATTTTCTTTTAAAGACGAAGTGAATAGACATCTAA	108
Db	1021	CTTGCTCAATCTGAAATTTAAAGCAATTTTCTTTTAAAGACGAAGTGAATAGACATCTAA	108
QY	1081	AAATTCACCTCTCATAGAGCTTTTAAATGGGTTTTCATTTGGATATAGGCGCTTAAAGAAATCA	1140
Db	1081	AAATTCACCTCTCATAGAGCTTTTAAATGGGTTTTCATTTGGATATAGGCGCTTAAAGAAATCA	1140
QY	1141	CTATAAATGCAAAATTAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAATGCAAAATTAAGTTACTCAAAATCTGTG	1174
RESULT 19			
ADRA45790			
ID	ADA45790	standard; cDNA; 1174 BP.	
XX	ADA45790;		
AC			
XX			
DT	20-NOV-2003	(first entry)	
XX			
DE		Novel human secreted and transmembrane protein PRO195 cDNA.	
XX			
KW		Human; secreted and transmembrane protein; PRO; gene; ss;	
KW		Tumour necrosis factor alpha release; TNF-alpha release;	
KW		glucose uptake modulator; FFA uptake; modulator;	
KW		cell proliferation stimulator; cell differentiation stimulator;	
KW		cell differentiation inhibitor; cytokine release stimulator; tumour;	
KW		lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW		cervical tumour; liver tumour; chromosome mapping; gene mapping;	
KW		gene therapy; chromosome identification; chromosome marker.	
XX			
OS		Homo sapiens.	
XX			
US	US2003022328-A1.		
XX			
PD	30-JAN-2003.		
XX			
PF	16-APR-2002; 2002US-00123904.		
XX			
PR	31-MAR-1997; 97WO-US005230.		
PR	12-JUN-1998; 98WO-US012456.		
PR	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		
PR	17-SEP-1998; 98WO-US019437.		
PR	07-OCT-1998; 98WO-US021141.		
PR	23-OCT-1998; 98WO-US022591.		
PR	29-OCT-1998; 98WO-US022992.		
PR	20-NOV-1998; 98WO-US024855.		
PR	01-DEC-1998; 98WO-US025108.		
PR	05-JAN-1999; 99WO-US000106.		
PR	08-MAR-1999; 99WO-US005028.		
PR	10-MAR-1999; 99WO-US005190.		
PR	20-APR-1999; 99WO-US008615.		
PR	14-MAY-1999; 99WO-US010733.		
PR	02-JUN-1999; 99WO-US012252.		
PR	01-SEP-1999; 99WO-US020111.		
PR	08-SEP-1999; 99WO-US020594.		
PR	13-SEP-1999; 99WO-US020944.		
PR	15-SEP-1999; 99WO-US021090.		
PR	15-SEP-1999; 99WO-US021547.		
PR	05-OCT-1999; 99WO-US023089.		
PR	23-NOV-1999; 99WO-US028214.		
PR	30-NOV-1999; 99WO-US028313.		
PR	30-NOV-1999; 99WO-US028409.		
PR	01-DEC-1999; 99WO-US028301.		
PR	01-DEC-1999; 99WO-US028634.		
PR	02-DEC-1999; 99WO-US028551.		

PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US031070.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747359.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 20-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH) GENENTECH INC.

XX Baker KF, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-584997/55.  
DR P-PSDB; ADA45791.  
XX Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, identifying agonists or  
PT antagonists of polypeptide, and as molecular weight markers.  
XX Claim 2; Fig 271; 659pp; English.  
PS The invention describes 305 nucleic acids encoding PRO (secreted and  
XX transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in paricycle  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PBMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCCGAAAGGGGAGCCTCTGGGTGAGGACCACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCCGAAAGGGGAGCCTCTGGGTGAGGACCACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGACCATGGCTTGGCCGAGGTTGGGGACCCCTTCGGCTGAGCA 180  
DB 121 CCGCTGCTGCTGACCATGGCTTGGCCGAGGTTGGGGACCCCTTCGGCTGAGCA 180  
QY 181 TTTGACTCGGCTTGGGTGATAGCGGCTCTTGCCACCGGSCCTGTGAGTTGACTACCCC 240  
DB 181 TTTGACTCGGCTTGGGTGATAGCGGCTCTTGCCACCGGSCCTGTGAGTTGACTACCCC 240  
QY 241 TTGCACACCTTACCCCTAAGGAAGAGGAGTTGTAGCATGTGACAGAGTTGCAGGCTGTTT 300  
DB 241 TTGCACACCTTACCCCTAAGGAAGAGGAGTTGTAGCATGTGACAGAGTTGCAGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTTGGGATGATGGAATTTGATCTTAAATCGAACTAAATTTGAAATGAA 360  
DB 301 TCAATTTGTGAGTTTGGGATGATGGAATTTGATCTTAAATCGAACTAAATTTGAAATGAA 360  
QY 361 TCTCATGTACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCATCTTGTGTC 420  
DB 361 TCTCATGTACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCATCTTGTGTC 420  
QY 421 CAGAAATCAGCTGCCATTCGGCTGAACTGAGACAGAACTTATGTCCTGATGCCAAA 480



Db 421 CAGAAATCAGCTGCCATTGCGTGAATGAGCAAGAACTTATGTCCTCCGATGCCAAA 480  
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGCAATCTCTGAGTGACATGAGCTCC 540  
Db 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGCAATCTCTGAGTGACATGAGCTCC 540  
QY 541 GCACAGAGCTTCAATACCTCTTCATGGAATTTTATCTTCAAGCGATGACGGAATAA 600  
Db 541 GCACAGAGCTTCAATACCTCTTCATGGAATTTTATCTTCAAGCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCAGTACGCCACACATTTGGAGGAGGCTTACA 660  
Db 601 GTTATATTCAGTCTTAAGCCAGAAATCAGTACGCCACACATTTGGAGGAGGCTTACA 660  
QY 661 AATTTGAGGAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
Db 661 AATTTGAGGAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTTGAAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGAATTTAACTACAACTCTTCTCTCGGTGATGATGATGATGATGATGATGAT 840  
Db 781 TCTGGTGGAATTTAACTACAACTCTTCTCTCGGTGATGATGATGATGATGATGATGAT 840  
QY 841 TGTGCAACTGTTGTACAGCTGTGAGCAGTATGTTCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTTGTACAGCTGTGAGCAGTATGTTCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTG 960  
QY 961 GTTGTAGATCTAACTGAGATCATGAGCAGGCTCTACCTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAACTGAGATCATGAGCAGGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTGCTCATCTTGAATTTAAAGCAATTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
Db 1021 CTGCTCATCTTGAATTTAAAGCAATTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCAGAGCTTTTAAAGTGTTCATGAGATATAGGCTTAAAGTAAATCA 1140  
Db 1081 AATTCACCTCTCAGAGCTTTTAAAGTGTTCATGAGATATAGGCTTAAAGTAAATCA 1140  
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
Db 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 20  
ADA76221  
ID ADA76221 standard; cdna; 1174 BP.  
AC  
XX  
AC  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polynucleotide #136.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

OS XX  
PN 97WO-US005230.  
XX 98WO-US012456.  
XX 98WO-US014552.  
PD 98WO-US017888.  
XX 98WO-US018824.  
XX 98WO-US019093.  
PF 98WO-US019094.  
PF 98WO-US019177.  
PF 98WO-US019330.  
PF 98WO-US019437.  
PF 98WO-US021141.  
PF 98WO-US022991.  
PF 98WO-US022992.  
PF 98WO-US024855.  
PF 98WO-US025108.  
PF 98WO-US000106.  
PF 98WO-US005028.  
PF 98WO-US005190.  
PF 98WO-US008615.  
PF 98WO-US010733.  
PF 98WO-US012252.  
PF 98WO-US020111.  
PF 98WO-US020594.  
PF 98WO-US020944.  
PF 98WO-US021090.  
PF 98WO-US021547.  
PF 98WO-US023089.  
PF 98WO-US028214.  
PF 98WO-US028313.  
PF 98WO-US028409.  
PF 98WO-US028301.  
PF 98WO-US028634.  
PF 98WO-US028551.  
PF 98WO-US028564.  
PF 98WO-US028565.  
PF 98WO-US030095.  
PF 98WO-US030911.  
PF 98WO-US030999.  
PF 98WO-US030720.  
PF 98WO-US031243.  
PF 98WO-US031274.  
PF 98WO-US000219.  
PF 2000WO-US000277.  
PF 2000WO-US000376.  
PF 2000WO-US000376.  
PF 2000WO-US003365.  
PF 2000WO-US004341.  
PF 2000WO-US004342.  
PF 2000WO-US004342.  
PF 2000WO-US004914.  
PF 2000WO-US004914.  
PF 2000WO-US005004.  
PF 2000WO-US005801.  
PF 2000WO-US005746.  
PF 2000WO-US005841.  
PF 2000WO-US006319.  
PF 2000WO-US006884.  
PF 2000WO-US007377.  
PF 2000WO-US007377.  
PF 2000WO-US008439.  
PF 2000WO-US013705.  
PF 2000WO-US014042.  
PF 2000WO-US014941.  
PF 2000WO-US015364.  
PF 2000WO-US020710.  
PF 2000WO-US022031.  
PF 2000WO-US023522.

Homo sapiens.  
US2003073212-A1.  
17-APR-2003.  
16-APR-2002; 2002US-00123903.  
31-MAR-1997; 97WO-US005230.  
12-JUN-1998; 98WO-US012456.  
14-JUL-1998; 98WO-US014552.  
28-AUG-1998; 98WO-US017888.  
10-SEP-1998; 98WO-US018824.  
14-SEP-1998; 98WO-US019093.  
14-SEP-1998; 98WO-US019094.  
14-SEP-1998; 98WO-US019177.  
16-SEP-1998; 98WO-US019330.  
17-SEP-1998; 98WO-US019437.  
07-OCT-1998; 98WO-US021141.  
29-OCT-1998; 98WO-US022991.  
29-OCT-1998; 98WO-US022992.  
20-NOV-1998; 98WO-US024855.  
01-DEC-1998; 98WO-US025108.  
05-JAN-1999; 98WO-US000106.  
08-MAR-1999; 98WO-US005028.  
10-MAR-1999; 98WO-US005190.  
20-APR-1999; 98WO-US008615.  
14-MAY-1999; 98WO-US010733.  
02-JUN-1999; 98WO-US012252.  
01-SEP-1999; 98WO-US020111.  
08-SEP-1999; 98WO-US020594.  
13-SEP-1999; 98WO-US020944.  
15-SEP-1999; 98WO-US021090.  
15-SEP-1999; 98WO-US021547.  
05-OCT-1999; 98WO-US023089.  
29-NOV-1999; 98WO-US028214.  
30-NOV-1999; 98WO-US028313.  
30-NOV-1999; 98WO-US028409.  
01-DEC-1999; 98WO-US028301.  
01-DEC-1999; 98WO-US028634.  
02-DEC-1999; 98WO-US028551.  
02-DEC-1999; 98WO-US028564.  
02-DEC-1999; 98WO-US028565.  
16-DEC-1999; 98WO-US030095.  
20-DEC-1999; 98WO-US030911.  
20-DEC-1999; 98WO-US030999.  
22-DEC-1999; 98WO-US030720.  
30-DEC-1999; 98WO-US031243.  
30-DEC-1999; 98WO-US031274.  
05-JAN-2000; 98WO-US000219.  
06-JAN-2000; 2000WO-US000277.  
06-JAN-2000; 2000WO-US000376.  
11-FEB-2000; 2000WO-US000376.  
18-FEB-2000; 2000WO-US004341.  
18-FEB-2000; 2000WO-US004342.  
22-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
01-MAR-2000; 2000WO-US005801.  
02-MAR-2000; 2000WO-US005746.  
02-MAR-2000; 2000WO-US005841.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
21-MAR-2000; 2000WO-US007377.  
30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015364.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.



QY 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTCAGAGCTGAGTATCTAT 900  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
Db 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTCAGAGCTGAGTATCTAT 900  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
QY 901 GGTCACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
Db 901 GGTCACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
QY 961 GTTGTAGATCTAAACTGAAGTCATGAGACGAGGAGGCTCTACTACAAAGTGAAT 1020  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
Db 961 GTTGTAGATCTAAACTGAAGTCATGAGACGAGGAGGCTCTACTACAAAGTGAAT 1020  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
QY 1021 CTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
Db 1021 CTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCTTGTATGATGAGCTTAAAGTAAATCA 1140  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCTTGTATGATGAGCTTAAAGTAAATCA 1140  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
PR 06-JAN-2000; 2000WO-US000376.  
Db 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007177.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US030873.  
PR 20-DEC-2000; 2000US-0074259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00756498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.

RESULT 21

ADA18871

ID ADA18871 standard; cdNA; 1174 BP.

XX AC ADA18871;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;  
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;  
KW Glucose uptake; rFA; adipocyte cell; pericyte cell; proteoglycan;  
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;  
KW factor VIIA; endothelial cell.

XX OS Homo sapiens.

XX US2003054517-A1.

XX PN 20-MAR-2003.

XX PD 08-MAY-2002; 2002US-00141755.

XX PF 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 23-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 08-MAR-1999; 99WO-US000106.

PR 10-MAR-1999; 99WO-US005028.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,  
Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-521854/49.

P-PSDB; ADA18872.

New PRO nucleic acid, useful for preparing a composition for treating  
e.g., tumors.

Claim 2; Fig 271; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. lung, colon, breast, prostate, rectal, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for modulating the uptake of glucose or FFA by adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the release of cytokines from PBMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells and for stimulating the proliferation of endothelial cells. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
Query Match          100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60
DB 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60
QY 61 GGGAAACAGATGGCGGCGCGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
DB 61 GGGAAACAGATGGCGGCGCGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CCGTGTGCTGTGACCATGCGCTTGGCGGAGAGTTCGGGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGTGTGCTGTGACCATGCGCTTGGCGGAGAGTTCGGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTGTGACTCGTCTTGGGTGATACCGGCTTTCGCCACCGGGCTGTGACGTGACCTACCCC 240
DB 181 TTGTGACTCGTCTTGGGTGATACCGGCTTTCGCCACCGGGCTGTGACGTGACCTACCCC 240
QY 241 TTGCACCACTACCCCTAAGAAAGAGAGTTGPAACCATGTGCAGAGAGTTGCAGGCTGTTT 300
DB 241 TTGCACCACTACCCCTAAGAAAGAGAGTTGPAACCATGTGCAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGCTGATGATGGAATGACTTAAATCGAATTAATGGAATGTGAA 360
```

```
DB 301 TCAATTTGTGCTGATGATGGAATGACTTAAATCGAATTAATGGAATGTGAA 360
QY 361 TCTGATGTACAGAGCATATATCCCAATCTCATGAGCAATATGCTTGGCATCTTGGTTC 420
DB 361 TCTGATGTACAGAGCATATATCCCAATCTCATGAGCAATATGCTTGGCATCTTGGTTC 420
QY 421 CAGAAATCAGCTGCCATTCCGCTGAAGCTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480
DB 421 CAGAAATCAGCTGCCATTCCGCTGAAGCTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTTCCCTTAACCTCTGCTGAGGCTCATCTGAGAGTGCATGATGAGCTCC 540
DB 481 ATGCACCTACTCTTTTCCCTTAACCTCTGCTGAGGCTCATCTGAGAGTGCATGATGAGCTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCAATGAGCTTTTATCTTCAAGCGGATGACGGAATAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCAATGAGCTTTTATCTTCAAGCGGATGACGGAATAATA 600
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAACATTTGGAGCAGAGACCTACA 660
DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAACATTTGGAGCAGAGACCTACA 660
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGAAATTTCTTGAAGATGGAGAAAGTGAAGCTTTTAAAGATGCTCTCTCTTAAC 780
DB 721 CACAGAAATTTCTTGAAGATGGAGAAAGTGAAGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGGTGATTTTAACTAACAATCTTGTCTCTCGGTGATGATGATTTGATTTGT 840
DB 781 TCTGGGTGATTTTAACTAACAATCTTGTCTCTCGGTGATGATGATTTGATTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGATGATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGATGATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTGTAGATCTAAAACTGAAGATCATGAAAGCAGAGCGCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTGTAGATCTAAAACTGAAGATCATGAAAGCAGAGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
DB 1021 CTTGCTCATTTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATTTGATATAGGCTTAAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATTTGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATATAATGCAATTAAGTTACTCAAACTGTG 1174
DB 1141 CTATATAATGCAATTAAGTTACTCAAACTGTG 1174
```

RESULT 22

ADA61494

ID ADA61494 standard; cDNA; 1174 BP.

XX

AC ADA61494;

XX

DT 20-NOV-2003 (first entry)

XX

DE Homo sapiens.

XX

Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX Novel.  
OS human.  
OS secreted.  
OS and.  
OS transmembrane.  
OS protein.  
OS PRO195.  
OS CDNA.  
XX US2003049816-A1.  
XX 13-MAR-2003.  
PD 15-APR-2002; 2002US-00123262.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022921.  
PR 29-OCT-1998; 98WO-US022932.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 03-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-FEB-2001; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 01-MAR-2001; 2001WO-US008520.  
PR 01-MAR-2001; 2001WO-US008566.  
PR 14-MAR-2001; 2001US-00802706.  
PR 22-MAR-2001; 2001US-00808689.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882336.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;  
PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI: 2003-695892/66.  
DR P-PSDB; ADA61495.  
XX New PRO nucleic acid and encode polypeptides, are useful for  
PT manufacturing a medicament for diagnosing or treating cancer.  
XX Claim 2; Fig 271; 660pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte

cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping. In generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGGGTGGGGAACCCCTTCGAGAAAACAGCAAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACGGGTGGGGAACCCCTTCGAGAAAACAGCAAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAGATGGCGGCGCGAGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
DB	61	GGGAACAGATGGCGGCGCGAGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGACCATGCGCCCTGGCGGAGTTCGGGGACCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGACCATGCGCCCTGGCGGAGTTCGGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAGTTGACCTAC	240
DB	181	TTTGACTCGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAGTTGACCTAC	240
QY	241	TTGCACACCTACCTAAGGAAGAGAGTTGTACGATGTCAGAGAGGTTGCAGGCTGTTT	300
DB	241	TTGCACACCTACCTAAGGAAGAGAGTTGTACGATGTCAGAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTGTCAGTTTGGATGGATGGAATTGACTTAATCGAATCGAATGGAATGTGAA	360
DB	301	TCAATTGTCAGTTTGGATGGATGGAATTGACTTAATCGAATCGAATGGAATGTGAA	360
QY	361	TCTGCATGTCAGAGGATATTCCTCAATCTGATGAGCAATGCTTGGCATCTTGGTGC	420
DB	361	TCTGCATGTCAGAGGATATTCCTCAATCTGATGAGCAATGCTTGGCATCTTGGTGC	420
QY	421	CAGAACTCAGCTGCCATTGCTGAACTGAGCAAGAACAACTTATGCTCCCTGATGCCAAA	480
DB	421	CAGAACTCAGCTGCCATTGCTGAACTGAGCAAGAACAACTTATGCTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTCTCTCAACTCTGGTGGTGCATCTGGAGTGACATGAGCTCC	540
DB	481	ATGCACCTACTCTTCTCTCAACTCTGGTGGTGCATCTGGAGTGACATGAGCTCC	540
QY	541	GCACAGAGCTTCATAAACCTCTTTCATGACCTTTTATCTTCAAGCCGATGACGGAATA	600
DB	541	GCACAGAGCTTCATAAACCTCTTTCATGACCTTTTATCTTCAAGCCGATGACGGAATA	600
QY	601	GTTATATTCAGTCTAAGCAGAAATCCAGTACGCACCACTTTGGAGGAGGACCTACA	660
DB	601	GTTATATTCAGTCTAAGCAGAAATCCAGTACGCACCACTTTGGAGGAGGACCTACA	660
QY	661	AATTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG	720
DB	661	AATTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC	780

DB	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC	780
QY	781	TCGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGCTTTGGATTTGT	840
DB	781	TCGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGCTTTGGATTTGT	840
QY	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCTCTGAGAGCTGAGTATCTAT	900
DB	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCTCTGAGAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTCTCTTGTG	960
DB	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTCTCTTGTG	960
QY	961	GTGTGTAGATCTAAAACCTGAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
DB	961	GTGTGTAGATCTAAAACCTGAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA	1080
DB	1021	CTTGCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA	1080
QY	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTGATATAGGCTTAAAGAAATCA	1140
DB	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTGATATAGGCTTAAAGAAATCA	1140
QY	1141	CTATTAATGCAATTAAGTTACTCTCAATCTGTG	1174
DB	1141	CTATTAATGCAATTAAGTTACTCTCAATCTGTG	1174

RESULT 23  
ADB19279  
ID ADB19279 standard; cDNA; 1174 BP.  
XX ADB19279;  
AC ADB19279;  
DT 20-NOV-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
XX Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; INF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokin.  
XX Homo sapiens.  
XX OS  
XX US2003068796-A1.  
PD 10-APR-2003.  
XX  
PF 15-APR-2002; 2002US-00123261.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 29-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006584.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015364.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.

PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff B, Gao W;  
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;  
XX WPI; 2003-695927/66.  
DR P-PSDB; ADB19280.  
XX Novel secreted and transmembrane PRO polypeptides useful for stimulating  
PT the release of tumor necrosis factor alpha and detecting the presence of  
PT a tumor in a mammal.  
XX Claim 2; Fig 271; 660pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or PFA by skeletal muscle cells or adipocyt  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
SQ Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAACAGCAACGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAACAGCAACGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGCGCGCGCGAGAGGGAGCCTCTGGTGAGAACCCAACTGGGGTCCCG 120  
DB 61 GGGAAACAAGATGCGCGCGCGAGAGGGAGCCTCTGGTGAGAACCCAACTGGGGTCCCG 120  
QY 121 CCGCTGCTGCTGACCATGGCTTGGCGGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGACCATGGCTTGGCGGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTACCTACCCC 240  
DB 181 TTTGACTCGGCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTACCTACCCC 240  
QY 241 TTGCACACCTACCTAAGGAGGAGTTGTACGCATGTACAGAGGTTGCAGGGCTGTTT 300  
DB 241 TTGCACACCTACCTAAGGAGGAGTTGTACGCATGTACAGAGGTTGCAGGGCTGTTT 300  
QY 301 TCAATTTGTGATGATGGAATTTGACTTAATCGAACTAAATTTGAAATGTGAA 360  
DB 301 TCAATTTGTGATGATGGAATTTGACTTAATCGAACTAAATTTGAAATGTGAA 360  
QY 361 TCTGATGTACAGAGCATATTCCTAATCTGATGAGCAATATGCTTCCATTTGGTTC 420  
DB 361 TCTGATGTACAGAGCATATTCCTAATCTGATGAGCAATATGCTTCCATTTGGTTC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCTCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCTCTGATGCCAAA 480  
QY 481 ATGACCTACTCTTTTCTTAATCTGAGTGAAGTCAATCTGGAGTGACATGAGTACTCC 540  
DB 481 ATGACCTACTCTTTTCTTAATCTGAGTGAAGTCAATCTGGAGTGACATGAGTACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTATGAGACTTTTATCTTCAAGCCGATGACGGAATAATA 600

Db 541 GCACAGAGCTTCAACCTCTTATGAGCTTTTATCTTCAAGCCGATGACCGAAAAATA 600  
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGAGCAGAGCTTACA 660  
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGAGCAGAGCTTACA 660  
Qy 661 AATTTGAGAGATCATCTTAAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGGG 720  
Db 661 AATTTGAGAGATCATCTTAAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGGG 720  
Qy 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCTCTCTTTAAC 780  
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCTCTCTTTAAC 780  
Qy 781 TCTGGGTGGATTTTAACTCAACCTCTGCTCTCGGTGATGTTTGGATTTGT 840  
Db 781 TCTGGGTGGATTTTAACTCAACCTCTGCTCTCGGTGATGTTTGGATTTGT 840  
Qy 841 TGTCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
Db 841 TGTCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
Qy 901 GGTGACTTGGATTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
Db 901 GGTGACTTGGATTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
Qy 961 GTTGTAGATCTAAATCTGAAGATCATGAAGAGCAGGGCTCTACTACAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAATCTGAAGATCATGAAGAGCAGGGCTCTACTACAAAAGTGAAT 1020  
Qy 1021 CTTCGCTATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db 1021 CTTCGCTATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Qy 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGCCCTTAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGCCCTTAAGAAATCA 1140  
Qy 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
RESULT 24  
ID ADB27820 standard; cDNA; 1174 BP.  
AC ADB27820;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE cDNA encoding human PRO polypeptide #136.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003082704-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 24-APR-2002; 2002US-00131819.  
XX

PR 09-DEC-1999; 99US-0170262P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-765415/72.  
DR P-PSDB; ADB27821.  
XX  
PT New PRO nucleic acid, useful for preparing a composition for treating  
XX e.g., tumor or for tissue typing.  
PS Claim 2; Fig 271; 637pp; English.  
CC  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
Db 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
Qy 61 GGGAAACAAGATGCGCGCCGACGAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
Db 61 GGGAAACAAGATGCGCGCCGACGAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
Qy 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Qy 181 TTTGACTCGGTCCTTGGGTGATACGGCTCTTGCCACCGGGCTGTGTCAGTGTACCTACCCC 240  
Db 181 TTTGACTCGGTCCTTGGGTGATACGGCTCTTGCCACCGGGCTGTGTCAGTGTACCTACCCC 240





Query Match 100.0%; Score 1174; DB 8; Length 1174; Best Local Similarity 100.0%; Pred. No. 0; Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY	1	CGGACGCTGGGGGAAAACCTTCGGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60						
DB	1	CGGACGCTGGGGGAAAACCTTCGGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60						
QY	61	GGGAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120						
DB	61	GGGAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120						
QY	121	CGCGTCGCTGCTGACCATCGCCTTTGGCCGGAGGTTTCGGGACCGCTTCGCGCTGAAGCA	180						
DB	121	CGCGTCGCTGCTGACCATCGCCTTTGGCCGGAGGTTTCGGGACCGCTTCGCGCTGAAGCA	180						
QY	181	TTTGACTCGGTCTTTGGGTGATCGGCGTCTTGCCACCGGGCCTGTCACTTGACCTACCCC	240						
DB	181	TTTGACTCGGTCTTTGGGTGATCGGCGTCTTGCCACCGGGCCTGTCACTTGACCTACCCC	240						
QY	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTAGCGATGTACAGAGAGGTTGACAGCTGTTT	300						
DB	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTAGCGATGTACAGAGAGGTTGACAGCTGTTT	300						
QY	301	TCAATTTCTCAGTTTGGGATGATGAAATGACTTAAATCGAACTAAATTCGAAATGTGAA	360						
DB	301	TCAATTTCTCAGTTTGGGATGATGAAATGACTTAAATCGAACTAAATTCGAAATGTGAA	360						
QY	361	TCTGCATGTACAGAAGCATATTCCAAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420						
DB	361	TCTGCATGTACAGAAGCATATTCCAAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420						
QY	421	CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAAA	480						
DB	421	CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAAA	480						
QY	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGTGCATCTCGAGTGACATGATGAGCTCC	540						
DB	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGTGCATCTCGAGTGACATGATGAGCTCC	540						
QY	541	GCACAGAGCTTCAATGCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA	600						
DB	541	GCACAGAGCTTCAATGCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA	600						
QY	601	GTTATATTCAGTCTAAGCAGCAAAATCCAGTACGACCACTTTGGAGCAGAGCCTACA	660						
DB	601	GTTATATTCAGTCTAAGCAGCAAAATCCAGTACGACCACTTTGGAGCAGAGCCTACA	660						
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCG	720						
DB	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCG	720						
QY	721	CACAGGAATTTCTTGAAGATGGAAGAAAGTGATGGCTTTTAAAGTGCCTCTCTTTAAAC	780						
DB	721	CACAGGAATTTCTTGAAGATGGAAGAAAGTGATGGCTTTTAAAGTGCCTCTCTTTAAAC	780						
QY	781	TCTGGGTGGATTTTAACTACAATCTTGGTCTCTGGTGATGGTATGCTTTGGATTTGT	840						
DB	781	TCTGGGTGGATTTTAACTACAATCTTGGTCTCTGGTGATGGTATGCTTTGGATTTGT	840						
QY	841	TGTGCAACTGTTTGTCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900						
DB	841	TGTGCAACTGTTTGTCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900						
QY	901	GGTGAATTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960						
DB	901	GGTGAATTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960						
QY	961	GTTGTTAGATCTAAACTGAGATCATGAGAGAGCAGGGCCTTACCTACAAAAGTGAAT	1020						
DB	961	GTTGTTAGATCTAAACTGAGATCATGAGAGAGCAGGGCCTTACCTACAAAAGTGAAT	1020						
QY	1021	CTTGCTCATTTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA	1080						

Db	1021	CTTGCTCATTCTGAAATTTAAGCAATTTTCTTTTAAAGACAGAGTGAATAGACATCTAA	1080
Qy	1081	AATTCACACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
Db	1081	AATTCACACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
Qy	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
RESULT 26			
ADBI5863			
ID	ADBI5863 standard; cDNA; 1174 BP.		
XX	AC ADBI5863;		
XX	AC ADBI5863;		
DT	20-NOV-2003 (first entry)		
XX	Human PRO polynucleotide #136.		
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
KW	immune system cell infiltration.		
XX	Homo sapiens.		
OS	US2003087350-A1.		
FN	08-MAY-2003.		
PD	22-APR-2002; 2002US-00127821.		
XX	04-AUG-1998; 98US-0095301P.		
PR	02-JUN-1999; 99WO-US012252.		
PR	25-AUG-1999; 99US-00380137.		
PR	30-MAR-2000; 2000WO-US008439.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	19-DEC-2001; 2001US-00028072.		
XX	(GETH ) GENENTECH INC.		
FA	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;		
XX	Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX	WPI; 2003-786941/74.		
DR	P-PSDB; ADBI5864.		
XX	New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,		
PT	and for manufacturing a medicament for diagnosing or treating tumor.		
XX	Claim 2; Fig 271; 637pp; English.		
XX	The invention relates to isolated human PRO polypeptides (secreted and		
CC	transmembrane polypeptides) and the polynucleotides encoding them. The		
CC	invention also relates to an antibody which specifically binds to a PRO		
CC	polypeptide, a method for stimulating the release of tumour necrosis		
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the		
CC	proliferation or differentiation of chondrocyte cells and a method for		
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,		
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The		
CC	polynucleotides are useful in molecular biology, including uses as		
CC	hybridisation probes, in chromosome and gene mapping, in generating		
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also		

CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGAGCGTGGGGAACCCCTCCGAGAAACACACACACACACAGCTGCTGTGACAGAG 60  
DB 1 CGGAGCGTGGGGAACCCCTCCGAGAAACACACACACACAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATCGCGCGCCGAGGGAGCCTCTGGGTGAGACCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATCGCGCGCCGAGGGAGCCTCTGGGTGAGACCCAACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGCTACCACTGCGCTTGGCCGAGAGTTGCGGACCGCTTGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGCTACCACTGCGCTTGGCCGAGAGTTGCGGACCGCTTGGCTGAAGCA 180  
QY 181 TTTGACTCGGTCTGGGTGATACGGCGCTTTGGCCACCGGGCGCTCTCAGTTGACCTACCCC 240  
DB 181 TTTGACTCGGTCTGGGTGATACGGCGCTTTGGCCACCGGGCGCTCTCAGTTGACCTACCCC 240  
QY 241 TTGCACACTACCTTAAGAGAGAGAGTTGACGATGTACGATGTACAGAGGTTCAGGCTGTTT 300  
DB 241 TTGCACACTACCTTAAGAGAGAGAGTTGACGATGTACGATGTACAGAGGTTCAGGCTGTTT 300  
QY 301 TCAATTTGTGCTGTTGTGATGATGGAATTCGACTTAAATCGAATTAATTTGGAATGTAA 360  
DB 301 TCAATTTGTGCTGTTGTGATGATGGAATTCGACTTAAATCGAATTAATTTGGAATGTAA 360  
QY 361 TCTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420  
DB 361 TCTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCTCGATGCGCAAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCTCGATGCGCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTACTCTGTTGAGGTTCATCTTGGAGTGACATGAGGACTCC 540  
DB 481 ATGCACCTACTCTTCTCTACTCTGTTGAGGTTCATCTTGGAGTGACATGAGGACTCC 540  
QY 541 GCACAGAGCTTCAATACCTCTTCTGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCAATACCTCTTCTGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCAGTACGACCAATTTGGAGCAGGACCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCAGTACGACCAATTTGGAGCAGGACCTTACA 660

QY 661 AATTTGAGAGATCATCTCTTAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTCTTAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGAGGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGAGGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACATAACAATCTTGTCTCTCGGTGATGCTATTGCTTGGATTTGT 840  
DB 781 TCTGGTGGATTTTAACATAACAATCTTGTCTCTCGGTGATGCTATTGCTTGGATTTGT 840  
QY 841 TGTCCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
DB 841 TGTCCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
QY 901 CGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
DB 901 CGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAGAGAGCAGGCTCTACTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAAGATCATGAGAGAGCAGGCTCTACTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
DB 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCTACAGCTTTTAAAGTGTTCATTGGATATAGCCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCTACAGCTTTTAAAGTGTTCATTGGATATAGCCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
RESULT 27  
ADA47649  
ID ADA47649 standard; cDNA; 1174 BP.  
XX  
AC ADA47649;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polynucleotide #136.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; PFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003073215-A1.  
XX  
PD 17-APR-2003.  
XX  
PF 07-MAY-2002; 2002US-00140925.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 11-FEB-2000; 2000WO-US000376.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023322.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 28-FEB-2001; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006566.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001WO-US019692.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUN-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908627.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 16-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI: 2003-644801/61.  
 DR P-PSDB; ADA47650.  
 XX  
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 PT in gene therapy, detecting the presence of tumor in a mammal, or  
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle  
 PT cells or adipocyte cells.  
 XX  
 PS Claim 2; Fig 271; 659pp; English.  
 XX

CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.  
 XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;			
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	CGGACGCTGGGGAAACCTTCGAGAAAACAGCAACAGCTGCTGTGTGACAGAG	60
DB	1	CGGACGCTGGGGAAACCTTCGAGAAAACAGCAACAGCTGCTGTGTGACAGAG	60
QY	61	GGGAAACAGATGGCGCGCGCGAGGGAGCTCTGGGGTGGAGACCCAACTGGGGCTCCCG	120
DB	61	GGGAAACAGATGGCGCGCGCGAGGGAGCTCTGGGGTGGAGACCCAACTGGGGCTCCCG	120
QY	121	CGCGTGTGCTCTCAACATGCTTGGCCGCGAGGTTGGGGACCGCTTCGGGTGAAGCA	180
DB	121	CGCGTGTGCTCTCAACATGCTTGGCCGCGAGGTTGGGGACCGCTTCGGGTGAAGCA	180
QY	181	TTTGTACTGGTCTTGGGTGATACGGCGCTTGGCCACCGGGCTGTGACTGACCTACCC	240
DB	181	TTTGTACTGGTCTTGGGTGATACGGCGCTTGGCCACCGGGCTGTGACTGACCTACCC	240
QY	241	TTGCAACCTACCTAAGGAGAGGAGTTGACGATGTTCAGAGAGTTGCAGGCTGTTT	300
DB	241	TTGCAACCTACCTAAGGAGAGGAGTTGACGATGTTCAGAGAGTTGCAGGCTGTTT	300
QY	301	TCAATTTGTGCTGTTGGTGTGATGCTTAACTGAATCGAATTAATTTGGATGTGA	360
DB	301	TCAATTTGTGCTGTTGGTGTGATGCTTAACTGAATCGAATTAATTTGGATGTGA	360
QY	361	TCTGATGTACAGAGCAATTTCCCAATCTGATGAGCAATATGCTGCCATCTTTGGTTC	420
DB	361	TCTGATGTACAGAGCAATTTCCCAATCTGATGAGCAATATGCTGCCATCTTTGGTTC	420
QY	421	CAGATCAGCTGCCATTTGGTGAATGAGCAAGCAACTTATGTCCTGATGCCAAA	480
DB	421	CAGATCAGCTGCCATTTGGTGAATGAGCAAGCAACTTATGTCCTGATGCCAAA	480
QY	481	ATGCACTACTCTTCTCTAATCTGCTGAGGTCATTTCTGAGTGCATGATGACTCC	540
DB	481	ATGCACTACTCTTCTCTAATCTGCTGAGGTCATTTCTGAGTGCATGATGACTCC	540
QY	541	GCACAGAGCTTCAATACCTCTTCTGATGAGTATTTATCTTCAAGCGATGACGAAAATA	600
DB	541	GCACAGAGCTTCAATACCTCTTCTGATGAGTATTTATCTTCAAGCGATGACGAAAATA	600
QY	601	GTTATATTCAGTCTAAGCAGAAATCAGTACGACCAATTTGGAGCAGGAGCTTACA	660
DB	601	GTTATATTCAGTCTAAGCAGAAATCAGTACGACCAATTTGGAGCAGGAGCTTACA	660
QY	661	AATTTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCAGAGCG	720
DB	661	AATTTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCAGAGCG	720
QY	721	CACAGAAATTTCTTGAAGATGGAGAAATGATGCTTTTAAAGATGCTCTCTTAAAC	780
DB	721	CACAGAAATTTCTTGAAGATGGAGAAATGATGCTTTTAAAGATGCTCTCTTAAAC	780
QY	781	TCTGGTGGATTTAACTACAACTCTTCTCTCGGTGATGATTTGCTTGGATTTGT	840
DB	781	TCTGGTGGATTTAACTACAACTCTTCTCTCGGTGATGATTTGCTTGGATTTGT	840
QY	841	TGTGCAACTGTGCTACAGCTGTGAGCAGATGTTCCCTCTGAGAGCTGAGTATCTAT	900
DB	841	TGTGCAACTGTGCTACAGCTGTGAGCAGATGTTCCCTCTGAGAGCTGAGTATCTAT	900
QY	901	GTTGACTTGGATTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG	960
DB	901	GTTGACTTGGATTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTTGTTAGATCTAAACTGAAGATCATCAAGACGCGCTCTACCTACAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAACTGAAGATCATCAAGACGCGCTCTACCTACAAAGTGAAT	1020
QY	1021	CTTGCTCATCTTGAATTAAGCAATTTCTTTTAAAGACAGCTGTAATAGACATCTAA	1080
DB	1021	CTTGCTCATCTTGAATTAAGCAATTTCTTTTAAAGACAGCTGTAATAGACATCTAA	1080

Db	1021	CTTGCTCATCTTGAATTAAGCAATTTCTTTTAAAGACAGCTGTAATAGACATCTAA	1080
QY	1081	AATTCCTCTCTCATAGAGCTTTTAAATGCTTTTCAATGATAGGCTTTAAGAAATCA	1140
DB	1081	AATTCCTCTCTCATAGAGCTTTTAAATGCTTTTCAATGATAGGCTTTAAGAAATCA	1140
QY	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174
DB	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174
RESULT 28			
ADA67444			
ID	ADA67444	standard; cDNA; 1174 BP.	
XX	ADA67444;		
AC	ADA67444;		
XX	20-NOV-2003	(first entry)	
DT	20-NOV-2003	(first entry)	
XX	Human PRO polynucleotide #136.		
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;		
XX	immune system cell infiltration.		
XX	Homo sapiens.		
OS	US2003068795-A1.		
PN	10-APR-2003.		
XX	15-APR-2002; 2002US-00123236.		
PF	31-MAR-1997; 97WO-US005230.		
XX	12-JUN-1998; 98WO-US012456.		
PR	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		
PR	17-SEP-1998; 98WO-US019437.		
PR	07-OCT-1998; 98WO-US021141.		
PR	29-OCT-1998; 98WO-US022991.		
PR	29-OCT-1998; 98WO-US022992.		
PR	20-NOV-1998; 98WO-US024855.		
PR	01-DEC-1998; 98WO-US025108.		
PR	05-JAN-1999; 99WO-US000106.		
PR	08-MAR-1999; 99WO-US005028.		
PR	10-MAR-1999; 99WO-US005190.		
PR	20-APR-1999; 99WO-US008615.		
PR	14-MAY-1999; 99WO-US010733.		
PR	02-JUN-1999; 99WO-US012252.		
PR	01-SEP-1999; 99WO-US020111.		
PR	08-SEP-1999; 99WO-US020594.		
PR	13-SEP-1999; 99WO-US020944.		
PR	15-SEP-1999; 99WO-US021090.		
PR	05-OCT-1999; 99WO-US021547.		
PR	29-NOV-1999; 99WO-US023089.		
PR	30-NOV-1999; 99WO-US028214.		
PR	30-NOV-1999; 99WO-US028313.		
PR	30-NOV-1999; 99WO-US028409.		
PR	01-DEC-1999; 99WO-US028301.		
PR	01-DEC-1999; 99WO-US028634.		
PR	02-DEC-1999; 99WO-US028551.		

PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034356.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX

DR WPI; 2003-695926/66.  
DR P-PSDB; ADA67445.  
PT Novel isolated PRO secreted and transmembrane polypeptides useful for  
PT stimulating the release of tumor necrosis factor-alpha from human blood  
PT and detecting the presence of a tumor in a mammal.  
XX Claim 2; Fig 271; 660pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGAAACCTTCGGAGAAAACGCAACGAGCTGAGCTGCTGCACAG 60  
DB 1 CGGACGGCTGGGGAAACCTTCGGAGAAAACGCAACGAGCTGAGCTGCTGCACAG 60  
QY 61 GGGAAACAAGATGGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCATGGCCTTTGGCGGAGGTTGGGGACCGCTTCGGCTGAGCA 180  
DB 121 CCGCTGCTGCTGTGACCATGGCCTTTGGCGGAGGTTGGGGACCGCTTCGGCTGAGCA 180  
QY 181 TTTGACTCGGTTGGGTGATACGGGCTTTGGCACCGGGGCTGTGAGTTGACCTACCCC 240  
DB 181 TTTGACTCGGTTGGGTGATACGGGCTTTGGCACCGGGGCTGTGAGTTGACCTACCCC 240  
QY 241 TTGCACACCTTACCTAAGGAAGAGGTTGTACGCAATGTACAGAGGTTGCGGCTGTTT 300  
DB 241 TTGCACACCTTACCTAAGGAAGAGGTTGTACGCAATGTACAGAGGTTGCGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTGGTGATGGAATTTGACTTAAATCGAACTAAATGGAATGTGAA 360  
DB 301 TCAATTTGTGAGTTGGTGATGGAATTTGACTTAAATCGAACTAAATGGAATGTGAA 360

QY 361 TCTGATGTCAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
Db TCTGATGTCAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
QY 421 CAGATCAGCTGCGATTCGCTGATGAGCAAGCAACTATGCTCCCTGATGCCAAA 480  
Db CAGATCAGCTGCGATTCGCTGATGAGCAAGCAACTATGCTCCCTGATGCCAAA 480  
QY 481 ATGACCTACTCTTTCTCTTAATCTGCTGAGGTCATCTCGAGTGACATGATGACTCC 540  
Db ATGACCTACTCTTTCTCTTAATCTGCTGAGGTCATCTCGAGTGACATGATGACTCC 540  
QY 541 GCACAGACTTCATACTCTTCTGACTTTTATCTTCAAGCGATGACGGAATAA 600  
Db GCACAGACTTCATACTCTTCTGACTTTTATCTTCAAGCGATGACGGAATAA 600  
QY 601 GTTATATCCAGTCTTAAGCCAGAAATCCAGTACCCACACATTTGGAGCAGGCTTACA 660  
Db GTTATATCCAGTCTTAAGCCAGAAATCCAGTACCCACACATTTGGAGCAGGCTTACA 660  
QY 661 AATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATAGAAATTCACAAGCG 720  
Db AATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATAGAAATTCACAAGCG 720  
QY 721 CACAGAAATTTCTTGAAGATGGAAGTATGCTGCTTTTAAAGTCCCTCTCTTAAAC 780  
Db CACAGAAATTTCTTGAAGATGGAAGTATGCTGCTTTTAAAGTCCCTCTCTTAAAC 780  
QY 781 TCTGGTGGATTTTAACTACAACTCTGCTCTCGGATGATGCTTCTGATTTGT 840  
Db TCTGGTGGATTTTAACTACAACTCTGCTCTCGGATGATGCTTCTGATTTGT 840  
QY 841 TGTGCACTGTTGTACAGCTGTGGAGCAGTATGCTCCCTGAGAGCTGATCTAT 900  
Db TGTGCACTGTTGTACAGCTGTGGAGCAGTATGCTCCCTGAGAGCTGATCTAT 900  
QY 901 GGTGCTGAGTTTATGATCAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960  
Db GGTGCTGAGTTTATGATCAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960  
QY 961 GTTGTAGATCTAAATGAGATCATGAGCAGGCTCTACCTACAAAGTGAAT 1020  
Db GTTGTAGATCTAAATGAGATCATGAGCAGGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTGCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080  
Db CTGCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCAGAGCTTTTAAATGCTTTTCAATGATATAGCCTTAAGATCA 1140  
Db AATTCACCTCTCAGAGCTTTTAAATGCTTTTCAATGATATAGCCTTAAGATCA 1140  
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
Db CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 29

ADB30451

ID ADB30451 standard; cdna; 1174 BP.

XX

AC ADB30451;

XX

DT 20-NOV-2003 (first entry)

XX

DE cDNA encoding human PRO polypeptide #136.

XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;





QY 781 TCTGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGTATTGCTTTGGATTGT 840  
DB TCTGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGTATTGCTTTGGATTGT 840  
QY 841 TGTGCAACTGTGTGACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB TGTGCAACTGTGTGACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTGGAGTTATGAATGAACAAAGCTAAACAGATATCGAGTCTTCTTCTGTG 960  
DB GGTGACTGGAGTTATGAATGAACAAAGCTAAACAGATATCGAGTCTTCTTCTGTG 960  
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGCAGGCGCTCTACTACAAAAGTGAAT 1020  
DB GTTGTAGATCTAAACCTGAAGATCATGAAGCAGGCGCTCTACTACAAAAGTGAAT 1020  
QY 1021 CTTCGCTGATCTGAAATTAAGCAATTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
DB CTTCGCTGATCTGAAATTAAGCAATTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
DB AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174  
DB CTATAAATGCAATTAAGTTACTCAATCTGTG 1174

RESULT 30  
ADA85747  
ID ADA85747 standard; cDNA; 1174 BP.  
XX AC ADA85747;  
XX AC ADA85747;  
DT 20-NOV-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX Homo sapiens.  
XX OS  
XX US2003082693-A1.  
XX 01-MAY-2003.  
XX 22-APR-2002; 2002US-00127843.  
XX 05-JUN-2000; 2000US-0209832P.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786907/74.  
XX P-PSDB; ADA85748.  
XX New PRO nucleic acid, useful for preparing a composition for treating  
XX e.g., tumor or for tissue typing.

PS Claim 2; Fig 271; 637pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGAAACCTTCGAGAAACACAGCAACGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGGCTGGGGAAACCTTCGAGAAACACAGCAACGCTGAGCTGCTGACAGAG 60  
QY 61 GGGAAACAGATGCGGCGCGGAGAGCGCTCTGGGTGAGGACCCAACTGGGGTCCCG 120  
DB 61 GGGAAACAGATGCGGCGCGGAGAGCGCTCTGGGTGAGGACCCAACTGGGGTCCCG 120  
QY 121 CCGCTGCTGCTGACCATGGCTTTGGCGGAGGTTGGGACCGCTTCGGCTCAAGCA 180  
DB 121 CCGCTGCTGCTGACCATGGCTTTGGCGGAGGTTGGGACCGCTTCGGCTCAAGCA 180  
QY 181 TTTGACTCGGTCTTGGGTGATACGGGTCTTTGCCACCGGGCCTGTGAGTTGACCTACCC 240  
DB 181 TTTGACTCGGTCTTGGGTGATACGGGTCTTTGCCACCGGGCCTGTGAGTTGACCTACCC 240  
QY 241 TTGCACACCTACCTAAGGAGAGGTTGTACGCAATGTCAGAGAGTTGCGAGGCTGTT 300  
DB 241 TTGCACACCTACCTAAGGAGAGGTTGTACGCAATGTCAGAGAGTTGCGAGGCTGTT 300  
QY 301 TCAATTTGTGATGTTGTGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATG 360  
DB 301 TCAATTTGTGATGTTGTGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATG 360  
QY 361 TCTGCATGTACAGAGCATATTCCTATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATTCCTATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420  
QY 421 CAGAACTCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCCTGATGCCAAA 480  
DB 421 CAGAACTCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCCTGATGCCAAA 480  
QY 481 ATGACCTACTCTTTTCTTAACTCTGGTGAGTCAATCTGGAGTGACATGATGAGCTCC 540  
DB 481 ATGACCTACTCTTTTCTTAACTCTGGTGAGTCAATCTGGAGTGACATGATGAGCTCC 540

QY 541 GCACAGAGCTTCATAAAGCTCTTCATGAGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
DB 541 GCACAGAGCTTCATAAAGCTCTTCATGAGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAATTTGAGCAGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAATTTGAGCAGAGCTTACA 660  
QY 661 AATTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGATTTCTTGAAGTGGAGAAAGTGGCTTTTAAAGTGGCTCTCTCTTAAC 780  
DB 721 CACAGGATTTCTTGAAGTGGAGAAAGTGGCTTTTAAAGTGGCTCTCTCTTAAC 780  
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCGGTGATGTTGCTTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCGGTGATGTTGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
QY 901 GGTGACCTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGT 960  
DB 901 GGTGACCTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGT 960  
QY 961 GTTGTAGATCTAAAGTGAAGATCATGAAGAGCAGGGCTCTACTACAAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAAGTGAAGATCATGAAGAGCAGGGCTCTACTACAAAAGTGAAT 1020  
QY 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
DB 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCTAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCCACTCTCTAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATATAATGCATAAATAAGTTACTCAATCTGTG 1174  
DB 1141 CTATATAATGCATAAATAAGTTACTCAATCTGTG 1174

## RESULT 31

ADA96959

ID ADA96959 standard; cDNA; 1174 BP.

AC ADA96959;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human PRO polynucleotide #136.

XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;

KW immune system cell infiltration.

XX

OS Homo sapiens.

XX

XX US2003082705-A1.

XX

XX 01-MAY-2003.

XX

XX 24-APR-2002; 2002US-00131829.

XX

XX

XX 09-DEC-1999; 99US-0170262P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurley AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI: 2003-755112/71.  
DR P-PSDB; ADA96960.  
XX  
XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.  
XX  
XX Claim 2; Fig 271; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAAAGTGTCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAAAGTGTCTGTGACAGAG 60  
QY 61 GGGACAAAGATGGCGCGCGCGGAGGAGCCCTGGGTGAGGACCCCACTGGGGTCCCG 120  
DB 61 GGGACAAAGATGGCGCGCGCGGAGGAGCCCTGGGTGAGGACCCCACTGGGGTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCAATGGCTTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAGCA 180  
DB 121 CCGCTGCTGCTGTGACCAATGGCTTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAGCA 180  
QY 181 TTGACTCGGTCTGGGTGATACGGGTCTTCCACCGGGGCTGTGAGTACCTACCCC 240

Db 181 TTGACTCGTCTTGGGTGATACGGCGCTTGTGCAACGGGCGCTGTGAGTTGACCTTACCC 240  
Qy 241 TTGCACACTACCTAAGGAGAGAGTGTACGCATGTACAGAGAGTTTCCAGGCTGTTT 300  
Db 241 TTGCACACTACCTAAGGAGAGAGTGTACGCATGTACAGAGAGTTTCCAGGCTGTTT 300  
Qy 301 TCATTTTGTCAAGTTTGGATGATGAAATGCACTTAATCGAACTAAATGGAATGGA 360  
Db 301 TCATTTTGTCAAGTTTGGATGATGAAATGCACTTAATCGAACTAAATGGAATGGA 360  
Qy 361 TCTGATGTACAGAGCATATTCCTAATCTGATGAGCAATATCTTGGCATCTTGTTC 420  
Db 361 TCTGATGTACAGAGCATATTCCTAATCTGATGAGCAATATCTTGGCATCTTGTTC 420  
Qy 421 CAGATCAGCTGCCATTCGCTGAATGAGCAAGCAACTTATGTCCTGATGCCAAA 480  
Db 421 CAGATCAGCTGCCATTCGCTGAATGAGCAAGCAACTTATGTCCTGATGCCAAA 480  
Qy 481 ATGCACCTACTCTTCTCTAATCTCTGATGAGTTCATCTGAGTGCATGATGACTCC 540  
Db 481 ATGCACCTACTCTTCTCTAATCTCTGATGAGTTCATCTGAGTGCATGATGACTCC 540  
Qy 541 GCACAGAGCTCAATACCTCTTCTGATGAGTTCATCTGAGTGCATGATGACTCC 600  
Db 541 GCACAGAGCTCAATACCTCTTCTGATGAGTTCATCTGAGTGCATGATGACTCC 600  
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGAGGCTTACA 660  
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGAGGCTTACA 660  
Qy 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
Qy 721 CACAGGATTTCTTGAAGTGGAGAGTGCATGCTTTTAAAGTCCCTCTCTCTTAC 780  
Db 721 CACAGGATTTCTTGAAGTGGAGAGTGCATGCTTTTAAAGTCCCTCTCTCTTAC 780  
Qy 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGTTTGGATTTGT 840  
Db 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGTTTGGATTTGT 840  
Qy 841 TGTGCACTGTGTACAGCTGTGGAGCAGTATCTCCCTCTGAGAGCTGAGTACTAT 900  
Db 841 TGTGCACTGTGTACAGCTGTGGAGCAGTATCTCCCTCTGAGAGCTGAGTACTAT 900  
Qy 901 GGTGACTTGGAGTTTATGAATGAAACAAAGCTAAGACATATCCAGTCTTCTTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAAACAAAGCTAAGACATATCCAGTCTTCTTGTG 960  
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGCAGGCGCTTACCTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGCAGGCGCTTACCTACAAAGTGAAT 1020  
Qy 1021 CTTGCTCATCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080  
Db 1021 CTTGCTCATCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080  
Qy 1081 AATTCACCTCTCAGAGCTTTTAAATGTTTCTTATGATATAGGCTTAAAGATCA 1140  
Db 1081 AATTCACCTCTCAGAGCTTTTAAATGTTTCTTATGATATAGGCTTAAAGATCA 1140  
Qy 1141 CTAATAATGCAATTAAGTGTACTCAATCTGTG 1174  
Db 1141 CTAATAATGCAATTAAGTGTACTCAATCTGTG 1174

RESULT 32

ADA79263

ID ADA79263 standard; cdna; 1174 BP.

XX

AC ADA79263;

XX

DT 20-NOV-2003 (first entry)  
XX Human PRO polynucleotide #136.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
XX cancer; adrenal, lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; FFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.  
OS Homo sapiens.  
FN US2003082763-A1.  
XX 01-MAY-2003.  
XX 17-APR-2002; 2002US-00124818.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 13-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.

01-MAR-2000; 2000WO-US005501.  
02-MAR-2000; 2000WO-US005746.  
02-MAR-2000; 2000WO-US005941.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
21-MAR-2000; 2000WO-US007532.  
30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.  
24-AUG-2000; 2000WO-US023328.  
08-NOV-2000; 2000WO-US030952.  
10-NOV-2000; 2000WO-US030873.  
01-DEC-2000; 2000WO-US032578.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US006666.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00808689.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.  
(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755116/71.

P-PSDB; ADA79264.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
in detection and treatment of cancer and in modulating the uptake of  
glucose or free fatty acid by skeletal muscle cells or adipocyte cells.

Claim 2; Fig 271; 659pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating  
proliferation of or gene expression in pericyte cells, for stimulating  
the proliferation of inner ear utricular supporting cells or T-lymphocyte  
cells, for inducing endothelial cell tube formation and for treating  
various bone and/or cartilage disorders such as sports injuries and  
arthritis. PRO polypeptides which stimulate the release of proteoglycans  
from cartilage are useful for treating sports-related joint problems,  
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
polypeptides are also useful for treating various mammalian haemoglobin-  
associated disorders such as various thalassaemias and conditions which  
may benefit from enhanced local immune system cell infiltration. This  
sequence represents a human PRO polynucleotide of the invention. Note:  
The sequence data for this patent is also available in electronic format  
from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match	100.0%;	Score 1174;	DB 8;	Length 1174;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1174;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY 1	CGGACGGTGGGGAAACCTTCCGAGAAACAGCAACAGCTGAGCTGTGCACAG	60		
DB 1	CGGACGGTGGGGAAACCTTCCGAGAAACAGCAACAGCTGAGCTGTGCACAG	60		
QY 61	GGGAACAAGATGGCGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCCACTGGGGTCCCG	120		
DB 61	GGGAACAAGATGGCGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCCACTGGGGTCCCG	120		
QY 121	CCGCTGCTGCTGACCAATGGCTTGGCGGAGGTTGGGACCGCTTCGGCTGAAGCA	180		
DB 121	CCGCTGCTGCTGACCAATGGCTTGGCGGAGGTTGGGACCGCTTCGGCTGAAGCA	180		
QY 181	TTTGACTCGGCTTTGGGTGATACGGGCTCTTGCCACCGGGCCCTGTCACTGACCTACCC	240		
DB 181	TTTGACTCGGCTTTGGGTGATACGGGCTCTTGCCACCGGGCCCTGTCACTGACCTACCC	240		
QY 241	TTGCACACCTTACCCCTAAGGAAGAGAGTTGTACGCAATGTCAGAGGTTGAGGCTGTTT	300		
DB 241	TTGCACACCTTACCCCTAAGGAAGAGAGTTGTACGCAATGTCAGAGGTTGAGGCTGTTT	300		
QY 301	TCAATTTGTCAGTTTGTGGATGATGAAATTTGACTTAAATCGAACTAAATTTGAATGTGA	360		
DB 301	TCAATTTGTCAGTTTGTGGATGATGAAATTTGACTTAAATCGAACTAAATTTGAATGTGA	360		
QY 361	TCTGCAATGTACAGAACATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC	420		
DB 361	TCTGCAATGTACAGAACATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC	420		
QY 421	CAGATCAGTTCGCTTCGCTGAGCTGAGACAGAACACTTATGTCCTGATGCCAAA	480		
DB 421	CAGATCAGTTCGCTTCGCTGAGCTGAGACAGAACACTTATGTCCTGATGCCAAA	480		
QY 481	ATGCACCTACTCTTTTCTTAACCTCTGGTGAAGTCAATCTGGAGTGACATGATGACTCC	540		
DB 481	ATGCACCTACTCTTTTCTTAACCTCTGGTGAAGTCAATCTGGAGTGACATGATGACTCC	540		
QY 541	GCACAGAGCTTCATACCTCTTCATGAGCTTTTATCTTCAGCCGATGACCGGAATA	600		
DB 541	GCACAGAGCTTCATACCTCTTCATGAGCTTTTATCTTCAGCCGATGACCGGAATA	600		
QY 601	GTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA	660		

```
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTTGGAGCAGGACCTTACA 660
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGAAATTTCTGGAAGATGGAAGAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780
Db 721 CACAGAAATTTCTGGAAGATGGAAGAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780
QY 781 TCTGGGTGATTTTAACTACAATCTTGTCTCTCGGTGATGCTATGCTTTGATTTGT 840
Db 781 TCTGGGTGATTTTAACTACAATCTTGTCTCTCGGTGATGCTATGCTTTGATTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTTCCCTCTGAGAACTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTTCCCTCTGAGAACTGAGTATCTAT 900
QY 901 GGTGACTTGGATTTATGAATCAACAAAGCTTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db 901 GGTGACTTGGATTTATGAATCAACAAAGCTTAAACAGATATCCAGCTTCTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGTGTATATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGTGTATATAGACATCTAA 1080
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140
QY 1141 CTATATAATGCAATTAAGTTACTCAATCTGTG 1174
Db 1141 CTATATAATGCAATTAAGTTACTCAATCTGTG 1174

RESULT 33
ADA87402
ID ADA87402 standard; cDNA; 1174 BP.
AC
XX ADA87402;
XX
XX 20-NOV-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO195 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; gene; ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX Glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
XX
XX US2003087345-A1.
XX
XX 08-MAY-2003.
XX
XX 16-APR-2002; 2002US-00123907.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022591.
PR 29-OCT-1998; 98WO-US022592.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US020111.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 05-JAN-2000; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004514.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-0074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 23-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
```



QY 1141 CTATATAATGCAATAAAGTTACTCAATCTGTG 1174  
 DB 1141 CTATATAATGCAATAAAGTTACTCAATCTGTG 1174

## RESULT 34

ADBL6604  
 ID ADBL6604 standard; cDNA; 1174 BP.

XX ADBL6604;

XX 20-NOV-2003 (first entry)

DE Human PRO polynucleotide #136.

KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; gliocyte; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003087349-A1.

XX 08-MAY-2003.

XX 19-APR-2002; 2002US-00125928.

XX 19-JUN-1998; 98US-0089947P.

PR 02-JUN-1999; 99NO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 02-MAR-2000; 2000WO-US005841.

PR 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786940/74.

XX P-PSDB; ADBL6605.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
 PT and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC polypeptides are also useful for treating various rheumatoid arthritis, PRO  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. NO. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60

DB 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60

QY 61 GGGACACAGATGGCGGCGCGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

DB 61 GGGACACAGATGGCGGCGCGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

QY 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTGGGGAGCCGCTTCGGGTGAAGCA 180

DB 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTGGGGAGCCGCTTCGGGTGAAGCA 180

QY 181 TTGACTCGCTTGGGTGATACCGGCTCTTGCCACGGGCGCTGTGAGTTGACCTACCCC 240

DB 181 TTGACTCGCTTGGGTGATACCGGCTCTTGCCACGGGCGCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACTACCCCTAAGGAAGAGGAGTTGTGACGATGTGACAGAGGTTGACGGCTGTTT 300

DB 241 TTGCACACTACCCCTAAGGAAGAGGAGTTGTGACGATGTGACAGAGGTTGACGGCTGTTT 300

QY 301 TCAATTTGCTAGTTTGGATGATGGAATTTGACTTAATCGAACTAAATTTGGAATGTGA 360

DB 301 TCAATTTGCTAGTTTGGATGATGGAATTTGACTTAATCGAACTAAATTTGGAATGTGA 360

QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTGTGATGAGCAATATCTTGGCATCTTGTTC 420

DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTGTGATGAGCAATATCTTGGCATCTTGTTC 420

QY 421 CAGATCAGTGGCATTGCTGAACTGAGACAAAGAACAACTTAATGTCCTGTATGCCAAA 480

DB 421 CAGATCAGTGGCATTGCTGAACTGAGACAAAGAACAACTTAATGTCCTGTATGCCAAA 480

QY 481 ATGCACCTTACTCTTCTTCTTAACTCTGCTGAGTCTTCTGGAGTGACATGATGGACTCC 540

DB 481 ATGCACCTTACTCTTCTTCTTAACTCTGCTGAGTCTTCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600

DB 541 GCACAGAGCTTCATAACCTCTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCGAGGCGCTACA 660

DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCGAGGCGCTACA 660

QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGGG 720

DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGGG 720

QY 721 CACAGGATTTTCTTGAAGTGGAGAAAGTATGGCTTTTAAAGTGCCTCTCTCTTAAC 780

DB 721 CACAGGATTTTCTTGAAGTGGAGAAAGTATGGCTTTTAAAGTGCCTCTCTCTTAAC 780







```
QY 541 GCACAGCTTCATACCTCTTCATGAGCTTTTATCTTCAAGCGATGACGGAATAAATA 600
Db 541 GCACAGCTTCATACCTCTTCATGAGCTTTTATCTTCAAGCGATGACGGAATAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGACCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGACCTTACA 660
QY 661 AATTTGAGGATCATCTCTAAGCAAAATGCTCTATCTGAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGGATCATCTCTAAGCAAAATGCTCTATCTGAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC 780
QY 781 TCTGGGTGATTTTAACTACAACTCTTCTCTCTCGGTGATGATGCTTTGATTTGT 840
Db 781 TCTGGGTGATTTTAACTACAACTCTTCTCTCTCGGTGATGATGCTTTGATTTGT 840
QY 841 TGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGTCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGTCTTCTCTTGTG 960
QY 961 GTTGTAGATCTTAAACTGGAATCATCAAGCAGCGGCTCTACCTACAAAGTGAT 1020
Db 961 GTTGTAGATCTTAAACTGGAATCATCAAGCAGCGGCTCTACCTACAAAGTGAT 1020
QY 1021 CTTGCTCATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCACCTCTCTACAGCTTTTAAATGCTTTTCAATGATAGCTTACCTTAAAGATCA 1140
Db 1081 AATTCACCTCTCTACAGCTTTTAAATGCTTTTCAATGATAGCTTACCTTAAAGATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174
Db 1141 CTATAAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174

RESULT 36
ADBI4759
ID ADBI4759 standard; cDNA; 1174 BP.
XX
AC ADBI4759;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087351-A1.
XX
XX 08-MAY-2003.
PD 22-APR-2002; 2002US-00127822.
PF
```

```
XX
PR 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TR, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786942/74.
DR P-PSDB; ADBI4760.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
```

```
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. NO. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGACAGCTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Db 1 CGACAGCTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGCGGCGCGGAGGAGCTCTGGGTGAGGACCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGCGGCGCGGAGGAGCTCTGGGTGAGGACCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCTTGGCGGAGGCTTGGGAGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGACCATGGCTTGGCGGAGGCTTGGGAGACCGCTTCGGCTGAAGCA 180
```

QY 181 TTTGACTCGGTCTTGGGTGATACGGGTCTTGCCACGGGCTGTGAGTTGACCTACCCC 240  
Db |||||  
QY 181 TTTGACTCGGTCTTGGGTGATACGGGTCTTGCCACGGGCTGTGAGTTGACCTACCCC 240  
Db |||||  
QY 241 TTGCACACCTACCTAAGGAAGGAGGTGTACGCATGTACAGAGAGTTTGCAGGCTGTTT 300  
Db |||||  
QY 241 TTGCACACCTACCTAAGGAAGGAGGTGTACGCATGTACAGAGAGTTTGCAGGCTGTTT 300  
Db |||||  
QY 301 TCAATTTGTCTAGTTTGGGATGATGAATGACTTAAATCGAAGTAAATGGAATGTGAA 360  
Db |||||  
QY 301 TCAATTTGTCTAGTTTGGGATGATGAATGACTTAAATCGAAGTAAATGGAATGTGAA 360  
Db |||||  
QY 361 TCTGCATGTACAGAAGCATATCCCAATCTGTAGTACCAATATGCTTGCCATCTTGGTTGC 420  
Db |||||  
QY 361 TCTGCATGTACAGAAGCATATCCCAATCTGTAGTACCAATATGCTTGCCATCTTGGTTGC 420  
Db |||||  
QY 421 CAGNATCAGCTGCCATTCGCTGAATCTGAGACAGACAACTTATGTCTCCTGATGCCAAA 480  
Db |||||  
QY 421 CAGNATCAGCTGCCATTCGCTGAATCTGAGACAGACAACTTATGTCTCCTGATGCCAAA 480  
Db |||||  
QY 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
Db |||||  
QY 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
Db |||||  
QY 541 GCACAGAGCTTCATACTCTTCAAGCACTTTTATCTTCAAGCCGATGACGGAATAA 600  
Db |||||  
QY 541 GCACAGAGCTTCATACTCTTCAAGCACTTTTATCTTCAAGCCGATGACGGAATAA 600  
Db |||||  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGAGCAGGAGCTTACA 660  
Db |||||  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGAGCAGGAGCTTACA 660  
Db |||||  
QY 661 AATTGAGAGAACTCATCTTAAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
Db |||||  
QY 661 AATTGAGAGAACTCATCTTAAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
Db |||||  
QY 721 CACAGGAAATTTCTGAGATGAGAAAGTGAAGGCTTTTAAAGTGCCTCTCTCTTAAC 780  
Db |||||  
QY 721 CACAGGAAATTTCTGAGATGAGAAAGTGAAGGCTTTTAAAGTGCCTCTCTCTTAAC 780  
Db |||||  
QY 781 TCTGGGTGGAATTTAACTACAACCTTGTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
Db |||||  
QY 781 TCTGGGTGGAATTTAACTACAACCTTGTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
Db |||||  
QY 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db |||||  
QY 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db |||||  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGT 960  
Db |||||  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGT 960  
Db |||||  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGAGGGCTCTACCTACAAAAGTGAAT 1020  
Db |||||  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGAGGGCTCTACCTACAAAAGTGAAT 1020  
Db |||||  
QY 1021 CTTGCTCATCTGAAATTTAAAGCAATTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
Db |||||  
QY 1021 CTTGCTCATCTGAAATTTAAAGCAATTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
Db |||||  
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
Db |||||  
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
Db |||||  
QY 1141 CTATATAATCAATAAAGTTACTCAAACTGTG 1174  
Db |||||  
QY 1141 CTATATAATCAATAAAGTTACTCAAACTGTG 1174  
Db |||||

RESULT 37  
ADA24868  
ID ADA24868 standard; cDNA; 1174 BP.

XX  
AC ADA24868;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; ss; tissue typing;  
KW chromosome identification; vaccine; cancer; retinal disorder;  
KW sports-related joint disorder; osteoarthritis; rheumatoid arthritis;  
KW wound healing; obesity; diabetes; kidney loss;  
KW cardiac insufficiency disorder; kidney disorder; nervous system disorder;  
KW haemoglobin associated disorder.  
XX  
OS Homo sapiens.  
XX  
PN US2003050241-A1.  
XX  
PD 13-MAR-2003.  
XX  
PF 16-OCT-2001; 2001US-00978564.  
XX  
PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081819P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082796P.  
PR 27-APR-1998; 98US-008336P.  
PR 28-APR-1998; 98US-0083322P.



Qy 241 TTGCACACCTACCCCTAAGAGAGAGAGTTGTAGCATGTCTCAGAGAGTTGCAGGCTGTTT 300  
Db |||||  
Qy 241 TTGCACACCTACCCCTAAGAGAGAGAGTTGTAGCATGTCTCAGAGAGTTGCAGGCTGTTT 300  
Db |||||  
Qy 301 TCAATTTGTCAAGTTTGTGATGATGAAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
Db |||||  
Qy 301 TCAATTTGTCAAGTTTGTGATGATGAAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
Db |||||  
Qy 361 TCTGCATGTACAGAACATATCCCAATCTGATGACATATGCTTGCATCTTGGTTGC 420  
Db |||||  
Qy 361 TCTGCATGTACAGAACATATCCCAATCTGATGACATATGCTTGCATCTTGGTTGC 420  
Db |||||  
Qy 421 CAGAATCAGCTGCATTCGCTCAATCGCTGAGACAGAACTTATGCTCCCTGATGCCAAA 480  
Db |||||  
Qy 421 CAGAATCAGCTGCATTCGCTCAATCGCTGAGACAGAACTTATGCTCCCTGATGCCAAA 480  
Db |||||  
Qy 481 ATGCACCTACTCTTCTCTAATCTCTGCTGAGTCAATCTGAGTGACATGATGACTCC 540  
Db |||||  
Qy 481 ATGCACCTACTCTTCTCTAATCTCTGCTGAGTCAATCTGAGTGACATGATGACTCC 540  
Db |||||  
Qy 541 GCACAGAGCTTCTAATACCTCTTCAATGCACTTTTATCTTCAAGCCGATGACGGAATA 600  
Db |||||  
Qy 541 GCACAGAGCTTCTAATACCTCTTCAATGCACTTTTATCTTCAAGCCGATGACGGAATA 600  
Db |||||  
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGAGCCTACA 660  
Db |||||  
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGAGCCTACA 660  
Db |||||  
Qy 661 AATTGAGCAATCACTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
Db |||||  
Qy 661 AATTGAGCAATCACTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
Db |||||  
Qy 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGTGCCTCTCTTAAAC 780  
Db |||||  
Qy 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGTGCCTCTCTTAAAC 780  
Db |||||  
Qy 781 TCTGGGTGAGTTTAACTCACTCTGCTCTGCTGATGATGCTTTGGATTTGT 840  
Db |||||  
Qy 781 TCTGGGTGAGTTTAACTCACTCTGCTCTGCTGATGATGCTTTGGATTTGT 840  
Db |||||  
Qy 841 TGTGCAACTCTTCTCAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
Db |||||  
Qy 841 TGTGCAACTCTTCTCAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
Db |||||  
Qy 901 GGTGACTTGAAGTTATGATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
Db |||||  
Qy 901 GGTGACTTGAAGTTATGATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
Db |||||  
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGCAGAGGCTCTACCTACAAAAGTGAAT 1020  
Db |||||  
Qy 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db |||||  
Qy 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db |||||  
Qy 1081 AATTCCACTCTCATAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140  
Db |||||  
Qy 1081 AATTCCACTCTCATAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140  
Db |||||  
Qy 1141 CTATPAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
Db |||||  
Qy 1141 CTATPAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
Db |||||

## RESULT 38

ADB18720

ID ADB18720 standard; cDNA; 1174 BP.

XX

AC

ADB18720;

XX

DT 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO195 cDNA.  
DE Human; secreted and transmembrane protein; PRO; gene; ss;  
XX Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; PFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokin.  
XX  
OS Homo sapiens.  
XX US2003073211-A1.  
XX  
XX 17-APR-2003.  
XX  
XX 15-APR-2002; 2002US-00123292.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021030.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 200WO-US007532.  
PR 30-MAR-2000; 200WO-US008439.  
PR 17-MAY-2000; 200WO-US013705.  
PR 22-MAY-2000; 200WO-US014042.  
PR 30-MAY-2000; 200WO-US014941.  
PR 02-JUN-2000; 200WO-US015264.  
PR 28-JUL-2000; 200WO-US020710.  
PR 11-AUG-2000; 200WO-US022031.  
PR 23-AUG-2000; 200WO-US023522.  
PR 24-AUG-2000; 200WO-US023328.  
PR 08-NOV-2000; 200WO-US030952.  
PR 10-NOV-2000; 200WO-US030873.  
PR 01-DEC-2000; 200WO-US032678.  
PR 20-DEC-2000; 200WO-US0347259.  
PR 20-DEC-2000; 200WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001US-00796498.  
PR 01-MAR-2001; 2001US-00806520.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001US-0089692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001US-00920116.  
PR 29-JUN-2001; 2001US-00921066.  
PR 09-JUL-2001; 2001US-00921735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff R, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI: 2003-695954/66.  
DR P-PDB; ADB18721.

XX New isolated nucleic acid and encoded PRO polypeptide, are useful in the  
PT diagnosis and treatment of cancer.

XX Claim 2; Fig 271; 638pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (1). (i) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGAGCGTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGAGCGTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGACCACTGGCCCTTGGCCGAGAGTTCGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGACCACTGGCCCTTGGCCGAGAGTTCGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGTCTTGGGTGATAGCGGCTTTCGCCACCGGCTGTCAGTTCACCTACCC 240  
DB 181 TTTGACTCGGTCTTGGGTGATAGCGGCTTTCGCCACCGGCTGTCAGTTCACCTACCC 240  
QY 241 TTGCACACCTTACCCCTAAGCAAGAGAGTGTAGCATGTTCAGAGAGTTCAGAGCTGTTT 300  
DB 241 TTGCACACCTTACCCCTAAGCAAGAGAGTGTAGCATGTTCAGAGAGTTCAGAGCTGTTT 300  
QY 301 TCAATTTGTGAGTGTGAGATGGAATTAATCGAATTAATCGAATTAATCGAATTAATCGA 360  
DB 301 TCAATTTGTGAGTGTGAGATGGAATTAATCGAATTAATCGAATTAATCGAATTAATCGA 360  
QY 361 TCTGCATGTACAGACATATTCCTCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGACATATTCCTCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480  
DB 421 CAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480  
QY 481 ATGCACCTACTCTTCTCTTAACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 540  
DB 481 ATGCACCTACTCTTCTCTTAACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 540  
QY 541 GCACAGAGCTTCAACCTCTTCAAGCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 600  
DB 541 GCACAGAGCTTCAACCTCTTCAAGCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 600  
QY 601 GTTATATTCAGTCTAAGCCAGCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 660  
DB 601 GTTATATTCAGTCTAAGCCAGCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 660  
QY 661 AATTGAGAGATCATCTCTAAGCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
DB 661 AATTGAGAGATCATCTCTAAGCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
QY 721 CACAGAGATTTCTTGAAGATGAGAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 780  
DB 721 CACAGAGATTTCTTGAAGATGAGAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 780  
QY 781 TCTGGGTGATTTAACTACAACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 840  
DB 781 TCTGGGTGATTTAACTACAACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGAGAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGAGAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTCTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTCTG 960  
QY 961 GTTGTAGTCTTAACTGAAGTATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020  
DB 961 GTTGTAGTCTTAACTGAAGTATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTAAATGCTTAAATGCTTAAATGCTTAAATGCT 1140  
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTAAATGCTTAAATGCTTAAATGCTTAAATGCT 1140  
QY 1141 CTATATAAATGCAATAAAGTTACTCAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 39

ADA93935

ADA93935 standard; cDNA; 1174 BP.

XX ADA93935;

XX ADA93935;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #136.

XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; FFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.

XX Homo sapiens.

XX US2003077722-A1.

XX 24-APR-2003.

XX 03-MAY-2002; 2002US-00137872.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032878.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart FA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755077/71.

XX P-PSDB; ADA93936.

XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the  
XX diagnosis, prevention and/or treatment of tumors, such as lung, colon,  
XX breast, prostate, rectal, cervical and/or liver tumors.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
DB 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCGGAGAGCGCTCTGGGTGAGGACCAACTGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCGGAGAGCGCTCTGGGTGAGGACCAACTGGGCTCCCG 120  
QY 121 CGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTCGGGAGCCGCTTCGGCTGAAGCA 180  
DB 121 CGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTCGGGAGCCGCTTCGGCTGAAGCA 180  
QY 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTTCAGTGAACCTACCC 240  
DB 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTTCAGTGAACCTACCC 240  
QY 241 TTGCACACCTACCCCTAAGGAGAGGTTGTACGATGTGAGAGGTTGAGGCTGTTT 300  
DB 241 TTGCACACCTACCCCTAAGGAGAGGTTGTACGATGTGAGAGGTTGAGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTGTGGATGATGAAATGTACTTAAATCGAACTAAATTTGGAATGGA 360  
DB 301 TCAATTTGTGAGTTGTGGATGATGAAATGTACTTAAATCGAACTAAATTTGGAATGGA 360  
QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420  
DB 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420  
QY 421 CAGAATCAGCTGCGCATTCGCTGAACTGAGACAAGAACCAACTTATGTCCTGATGCCAAA 480  
DB 421 CAGAATCAGCTGCGCATTCGCTGAACTGAGACAAGAACCAACTTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 540  
DB 481 ATGCACCTACTCTTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 540  
QY 541 GCACAGAGCTTCTATAACCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 600  
DB 541 GCACAGAGCTTCTATAACCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTGGAGCAGAGGCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTGGAGCAGAGGCTTACA 660  
QY 661 AATTGTGAGAAATCATCTCTTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTTACAAGCG 720  
DB 661 AATTGTGAGAAATCATCTCTTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTTACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAATGATGGCTTTTGAAGTGGCTCTCTCTTAC 780  
DB 721 CACAGGAATTTCTTGAAGATGAGAAATGATGGCTTTTGAAGTGGCTCTCTCTTAC 780  
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCTGATGATGATTTGTTGGATTTCT 840

Db 781 TCTGGTGGATTTTAACTACACACTTTGTCTCTCGGTGATGGTATTTGCTTTGGATTTGT 840  
Qy 841 TGTGCAACTGTTGCTACAGCTGTGGACGATGTTTCCCTCTCAGAAAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTTGCTACAGCTGTGGACGATGTTTCCCTCTCAGAAAGCTGAGTATCTAT 900  
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGACGAGGGCTCTACTCAAAAGTGAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGACGAGGGCTCTACTCAAAAGTGAT 1020  
Qy 1021 CTTCGCTATCTGAAATTAAGCAATTTTCTTTTAAAGACAGAGTGTATAGACATCTAA 1080  
Db 1021 CTTCGCTATCTGAAATTAAGCAATTTTCTTTTAAAGACAGAGTGTATAGACATCTAA 1080  
Qy 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGCTTAAAGAAATCA 1140  
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGCTTAAAGAAATCA 1140  
Qy 1141 CTATAAATGCATAAAGTTTACTCAAAATCTGTG 1174  
Db 1141 CTATAAATGCATAAAGTTTACTCAAAATCTGTG 1174

RESULT 40  
ADBI9831  
ID ADBI9831 standard; cDNA; 1174 BP.  
AC ADBI9831;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; as;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; PFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
EN US2003082691-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 22-APR-2002; 2002US-00127838.  
XX  
PR 17-NOV-1998; 98US-0108802P.  
PR 01-SEP-1999; 99US-0202011.  
PR 18-OCT-1999; 99US-00403297.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI: 2003-755108/71.  
DR P-PSDB; ADBI9832.  
XX  
XX PRO nucleic acid, useful for preparing a composition for treating e.g.,

PT tumor or for tissue typing.  
XX Claim 2; Fig 271; 637pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from BMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60  
Db 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60  
Qy 61 GGGAAACAAGATGGGGGCGCGAGAGGGGCTTGGGTGAGGAGCCCACTGGGGTCCCG 120  
Db 61 GGGAAACAAGATGGGGGCGCGAGAGGGGCTTGGGTGAGGAGCCCACTGGGGTCCCG 120  
Qy 121 CCGCTGCTGCTGACCATGGCTTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CCGCTGCTGCTGACCATGGCTTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Qy 181 TTGACTCGGTCTTGGGTGATACGGGCTCTTGCCACCGGGCTGTGAGTTGACCTACCCC 240  
Db 181 TTGACTCGGTCTTGGGTGATACGGGCTCTTGCCACCGGGCTGTGAGTTGACCTACCCC 240  
Qy 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTCCAGAGGTTGCAGGCTGTTT 300  
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTCCAGAGGTTGCAGGCTGTTT 300  
Qy 301 TCAATTTGTGAGTTTGGGATGATGGAATTCGATTTAAATCGAACTAAATGGAATGTGAA 360  
Db 301 TCAATTTGTGAGTTTGGGATGATGGAATTCGATTTAAATCGAACTAAATGGAATGTGAA 360  
Qy 361 TCTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATCTTGCCATCTTGTTGC 420  
Db 361 TCTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATCTTGCCATCTTGTTGC 420  
Qy 421 CAGAAATCAGCTGCCATTCGCTGAACTAGAGCAAGAAACAATATGTCCTGTATGCCAAA 480  
Db 421 CAGAAATCAGCTGCCATTCGCTGAACTAGAGCAAGAAACAATATGTCCTGTATGCCAAA 480  
Qy 481 ATGCACTACTCTTTCTCTTAACCTCTGCTGAGTCTATCTTGGAGTGACATGATGACTCC 540

Dbb 481 ATGCACCTACTCTTCTCTTAACCTCTGGTGAAGTCAATCTTGGAGTGACATGATGGAGCTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAATAA 600  
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTTAAGCCGAAATCCAGTACGACACCATTTGGAGGAGGCTTACA 660  
Db 601 GTTATATTCAGTCTTAAGCCGAAATCCAGTACGACACCATTTGGAGGAGGCTTACA 660  
QY 661 AATTGTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
Db 661 AATTGTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTGAAGATGGAAGAGTATGCTCTTTTATAGATGCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTGAAGATGGAAGAGTATGCTCTTTTATAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGTTATGCTTTCGATTTGT 840  
Db 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGTTATGCTTTCGATTTGT 840  
QY 841 TGTGCACTGTGCTACAGCTGTGAGCAGPATCTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCACTGTGCTACAGCTGTGAGCAGPATCTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGCTTCTCTCTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGCTTCTCTCTGTG 960  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGACAGCGCTCTTACCTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGACAGCGCTCTTACCTACAAAGTGAAT 1020  
QY 1021 CTGCTCACTTCTGAATTTAGCACTTTTCTTTTAAAGCAAGCTGTAATAGACATCTAA 1080  
Db 1021 CTGCTCACTTCTGAATTTAGCACTTTTCTTTTAAAGCAAGCTGTAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCTAGAGCTTTTAAATGTTTTCATTTGGATATAGCCCTTAAGAAATCA 1140  
Db 1081 AATTCACCTCTCTAGAGCTTTTAAATGTTTTCATTTGGATATAGCCCTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174  
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

## RESULT 41

ADB13143

ID ADB13143 standard; cDNA; 1174 BP.

AC ADB13143;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #136.

XX DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; PFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX US2003082710-A1.

XX XX 01-MAY-2003.

PD

XX 16-MAY-2002; 2002US-00147484.  
PF 09-DEC-1999; 99US-0170262P.  
XX 01-DEC-2000; 2000MO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786913/74.  
DR P-PSDB; ADB13144.  
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
PT preparing a composition for treating e.g., tumor, or for tissue typing.  
PS Claim 2; Fig 271; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGGAACCTTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
Db 1 CGGACGGCTGGGGGAACCTTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCGAGAGGGAGCCTTGGGTGAGGACCAACATGGGGTCCCG 120  
Db 61 GGGAAACAAGATGGCGCGCGAGAGGGAGCCTTGGGTGAGGACCAACATGGGGTCCCG 120  
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGCTGAGCA 180  
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGCTGAGCA 180



QY 181 TTTGACTCGGTCTTGGGTGATACGGGCTTTGCCACCGGCTGTGCTGACCTACCCC 240  
Db 181 TTTGACTCGGTCTTGGGTGATACGGGCTTTGCCACCGGCTGTGCTGACCTACCCC 240  
QY 241 TTCACACCTTACCTAAGGAAGAGGATTTGTACGATGTTCAGAGAGGTTGACGGCTGTTT 300  
Db 241 TTCACACCTTACCTAAGGAAGAGGATTTGTACGATGTTCAGAGAGGTTGACGGCTGTTT 300  
QY 301 TCAATTTGTCAGTTTGTGATGATGGAATTTGATTTAAATCGAATCTAAATTTGGAATGTGAA 360  
Db 301 TCAATTTGTCAGTTTGTGATGATGGAATTTGATTTAAATCGAATCTAAATTTGGAATGTGAA 360  
QY 361 TCTGCATGTACAGAATCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTGTC 420  
Db 361 TCTGCATGTACAGAATCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTGTC 420  
QY 421 CAGAAATCAGTGCCTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 480  
Db 421 CAGAAATCAGTGCCTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 540  
Db 481 ATGCACCTACTCTTCTCTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 540  
QY 541 GCACAGAGCTTCATACCTCTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 600  
Db 541 GCACAGAGCTTCATACCTCTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 600  
QY 601 GTTATATTCAGTCTAAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 660  
Db 601 GTTATATTCAGTCTAAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 660  
QY 661 AATTGAGAGATTCATCTTCTGATGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 720  
Db 661 AATTGAGAGATTCATCTTCTGATGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 720  
QY 721 CACAGAAATTTCTGATGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 780  
Db 721 CACAGAAATTTCTGATGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 780  
QY 781 TCTGGTGGATTTAACTACAACTCTTCTGATGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 840  
Db 781 TCTGGTGGATTTAACTACAACTCTTCTGATGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 840  
QY 841 TGTGCAACTGTTGCTACAGCTGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 900  
Db 841 TGTGCAACTGTTGCTACAGCTGAGCAAGAACTTCTGATGAGCAAGAACTTATGTCCTGATGCCAAA 900  
QY 901 GGTGACTTGGAGTTTATGAATCAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTC 960  
Db 901 GGTGACTTGGAGTTTATGAATCAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTC 960  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCTCTACCTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATTCTGAAATTTATGCAATTTCTTAAAGAGCAAGTGAATAGACATCTAA 1080  
Db 1021 CTTGCTCATTCTGAAATTTATGCAATTTCTTAAAGAGCAAGTGAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCTTATGATATAGGCTTAAAGATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCTTATGATATAGGCTTAAAGATCA 1140  
QY 1141 CTATAAATGCAATTAAGTACTCAATCTGTC 1174  
Db 1141 CTATAAATGCAATTAAGTACTCAATCTGTC 1174

RESULT 42  
ACD98559  
ID ACD98559 standard; cdna; 1174 BP.  
XX

AC ACD98559;  
XX 26-SEP-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
XX Human; secreted and transmembrane protein; PRO; gene therapy;  
KW chromosome identification; tissue typing; gene; ss.  
XX Homo sapiens.  
XX US2003044945-A1.  
XX 06-MAR-2003.  
XX 10-MAY-2002; 2002US-00142419.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US020111.  
PR 01-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 22-DEC-1999; 99WO-US030999.  
PR 30-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 05-JAN-2000; 99WO-US031274.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.





PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99US-0134287P.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 16-JUN-1999; 99US-0139557P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0142680P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 16-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001WO-US009552.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 30-JUL-2001; 2001US-00918585.  
XX (GETH ) GENENTECH INC.  
PA  
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;  
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NP, Roy MA, Shelton DL;  
PI Stewart TA, Tumas D, Williams PM, Wood WL;  
XX WPI; 2003-503575/47.  
DR P-PSDB; ABO19690.  
DR  
XX Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, identifying agonists or  
PT antagonists of polypeptide, and as molecular weight markers.  
XX Claim 2; Fig 131; 459pp; English.  
XX  
CC The invention describes an isolated, secreted and transmembrane  
CC polypeptide, termed PRO polypeptide (I). (I) is useful for detecting  
CC PRO493, PRO159, PRO1559, PRO725, PRO700 or PRO739 polypeptide, and for  
CC linking a bioactive molecule to a cell expressing the above polypeptides.  
CC The bioactive molecule is a toxin, radiolabel or an antibody and causes  
CC cell death. (I) is useful as therapeutic agent, in medical and industrial  
CC applications e.g. for treating neuropathy, especially peripheral  
CC neuropathy, diabetic peripheral neuropathy, AIDS-associated neuropathy,  
CC Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinaemia,  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;

QY 1081 AATTCACCTCCATAGAGCTTTTAAATGCTTTTCATTTGGATAGGCTTAAGAAATCA 1140  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1081 AATTCACCTCCATAGAGCTTTTAAATGCTTTTCATTTGGATAGGCTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAAAATAAAGTTACTCAATCTGTG 1174  
Db |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1141 CTATAAATGCAAAATAAAGTTACTCAATCTGTG 1174

RESULT 44  
ADAI2529  
ID ADAI2529 standard; cDNA; 1174 BP.  
XX  
AC ADAI2529;  
XX  
DT 06-NOV-2003 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane polypeptide PRO195.  
XX  
KW ss; gene; inflammatory disease; organ failure; atherosclerosis;  
KW cardiac injury; infertility; birth defect; premature aging; AIDS; cancer;  
KW diabetic complication; tissue typing; human.  
XX  
OS Homo sapiens.  
XX  
PN US2003055216-A1.  
XX  
PD 20-MAR-2003.  
XX  
PF 17-OCT-2001; 2001US-00978824.  
XX  
PR 21-MAY-1996; 96US-0018049P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 17-MAR-1998; 98US-00040220.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 23-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079820P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081617P.  
PR 15-APR-1998; 98US-0081619P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082796P.  
PR 27-APR-1998; 98US-0083336P.  
PR 28-APR-1998; 98US-0083332P.  
PR 29-APR-1998; 98US-0083352P.  
PR 29-APR-1998; 98US-0083435P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 30-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087088P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 11-SEP-1998; 98US-0094651P.  
PR 07-OCT-1998; 98US-00186978.  
PR 07-OCT-1998; 98WO-US021141.  
PR 02-NOV-1998; 98US-00187368.  
PR 02-NOV-1998; 98US-00187368.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98WO-US024855.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 98WO-US000106.  
PR 05-MAR-1999; 99US-00254465.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98US-00265686.  
PR 10-MAR-1999; 98WO-US005190.  
PR 12-MAR-1999; 98US-00267213.  
PR 12-MAR-1999; 99US-0123957P.



QY 1141 CTATAAATGCAATATAGTTACTCAATCTGTG 1174  
 Db 1141 CTATAAATGCAATATAGTTACTCAATCTGTG 1174

RESULT 45  
 ADA74397  
 ID ADA74397 standard; cDNA; 1174 BP.  
 XX  
 AC ADA74397;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polynucleotide #136.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; PFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003068798-A1.  
 XX  
 PD 10-APR-2003.  
 XX  
 PF 07-MAY-2002; 2002US-00140928.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022921.  
 PR 29-OCT-1998; 98WO-US022922.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 13-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028651.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 01-MAR-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-625490/59.  
 DR P-PSDB; ADA74398.  
 XX  
 PT Novel secreted and transmembrane PRO polypeptides and polynucleotides  
 encoding them, useful for treating bone disorders, arthritis, heart

PT attack, injuries, tumors, and stimulating release of Tumor Necrosis  
PT Factor-alpha from human blood.

PS Claim 2; Fig 271; 659pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis.  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OY 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACGACACAGCTGAGCTGCTGTGACAG 60
DB 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACGACACAGCTGAGCTGCTGTGACAG 60
OY 61 GGGAAACAGATGGCGGCGCGGAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAGATGGCGGCGCGGAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
OY 121 CCGCTGCTGCTGTCGACATGCGCCCTTGGCGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 180
DB 121 CCGCTGCTGCTGTCGACATGCGCCCTTGGCGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 180
OY 181 TTTGACTCGGCTTGGGTGATACGGCGCTTGGCACCGGGCCCTGTGAGTTGACCTACCC 240
DB 181 TTTGACTCGGCTTGGGTGATACGGCGCTTGGCACCGGGCCCTGTGAGTTGACCTACCC 240
OY 241 TTGCACACCTTACCTTAGGAGAGAGGTTGTACGATGTGACAGAGGTTGCGAGGCTGTTT 300
DB 241 TTGCACACCTTACCTTAGGAGAGAGGTTGTACGATGTGACAGAGGTTGCGAGGCTGTTT 300
OY 301 TCAATTTGTGCTGTTGGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGAAATGAA 360
DB 301 TCAATTTGTGCTGTTGGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGAAATGAA 360
OY 361 TCTGATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCTTGTGCTGC 420
DB 361 TCTGATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCTTGTGCTGC 420
```

```
OY 421 CAGAATCAGCTGCCATTTCGCTGAATCTGAGACAGAACCACTTATGTCCCTGATGCAAAA 480
DB 421 CAGAATCAGCTGCCATTTCGCTGAATCTGAGACAGAACCACTTATGTCCCTGATGCAAAA 480
OY 481 ATGCACCTACTTTTCTTAACTCTGTGAGGTCAATCTGAGTGACATGAGTACTCC 540
DB 481 ATGCACCTACTTTTCTTAACTCTGTGAGGTCAATCTGAGTGACATGAGTACTCC 540
OY 541 GCACAGAGCTTCATACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600
DB 541 GCACAGAGCTTCATACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600
OY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660
OY 661 AATTGAGAGAAATCATCTCTAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGG 720
DB 661 AATTGAGAGAAATCATCTCTAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGG 720
OY 721 CACAGGAATTTTCTGAAGATGAGAGAAAGTGAGTGGCTTTTAAAGATGCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTGAAGATGAGAGAAAGTGAGTGGCTTTTAAAGATGCTCTCTTAAC 780
OY 781 TCTGGGTGGATTTTAACTACACTCTTGTCTCTCTGATGATGATGATGATGATGAT 840
DB 781 TCTGGGTGGATTTTAACTACACTCTTGTCTCTCTGATGATGATGATGATGATGAT 840
OY 841 TGTGCAACTCTTCTCAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTCTTCTCAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
OY 901 GGTGACTGTGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTCTTGTG 960
DB 901 GGTGACTGTGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTCTTGTG 960
OY 961 GTTGTAGATCTAAAATCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAAATCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020
OY 1021 CTGCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
DB 1021 CTGCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
OY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
OY 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174
```

RESULT 46

ADB24630

ID ADB24630 standard; cDNA; 1174 BP.

XX AC ADB24630;

XX XX

DT 20-NOV-2003 (first entry)

DE Human PRO polynucleotide SEQ ID NO 271.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.



XX	Homo sapiens.	
OS	US200307713-A1.	
XX		
FN	24-APR-2003.	
XX		
PD	22-APR-2002; 2002US-00127839.	
XX		
PF	05-JUN-2000; 2000US-029882P.	
XX		
PR	11-DEC-2000; 2000WO-US032678.	
PR	19-DEC-2001; 2001US-00028072.	
XX	(GETH ) GENENTECH INC.	
XX		
PA	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TR, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX		
XX	WPI; 2003-755068/71.	
DR	P-PSDB; ADB24631.	
DR		
XX		
PT	New isolated, secreted and transmembrane PRO polypeptides and nucleic	
PT	acids, useful for the diagnosis, prevention and/or treatment of tumors,	
PT	such as lung, colon, breast, prostate, rectal, cervical and/or liver	
PT	tumors.	
XX		
XX	Claim 2; Fig 271; 637pp; English.	
XX		
XX	The invention relates to isolated human PRO polypeptides (secreted and	
CC	transmembrane polypeptides) and the polynucleotides encoding them. The	
CC	invention also relates to an antibody which specifically binds to a PRO	
CC	polypeptide, a method for stimulating the release of tumour necrosis	
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the	
CC	proliferation or differentiation of chondrocyte cells and a method for	
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,	
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The	
CC	polynucleotides are useful in molecular biology, including uses as	
CC	hybridisation probes, in chromosome and gene mapping, in generating	
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	
CC	be used in preparing PRO polypeptides by recombinant techniques and in	
CC	generating either transgenic animals or knock-out animals which are	
CC	useful in the development and screening of therapeutically useful	
CC	reagents. The PRO polypeptides or antibodies are used in preparing a	
CC	medicament for treating a condition responsive to the polypeptides or	
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation	
CC	of human microvascular endothelial cells, for modulating the uptake of	
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
CC	stimulating differentiation of adipocyte cells, for stimulating	
CC	proliferation of or gene expression in pericyte cells, for stimulating	
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte	
CC	cells, for inducing endothelial cell tube formation and for treating	
CC	various bone and/or cartilage disorders such as sports injuries and	
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans	
CC	from cartilage are useful for treating sports-related joint problems,	
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO	
CC	polypeptides are also useful for treating various mammalian haemoglobin-	
CC	associated disorders such as various thalassaemias and conditions which	
CC	may benefit from enhanced local immune system cell infiltration. This	
CC	sequence represents a human PRO polynucleotide of the invention. Note:	
CC	The sequence data for this patent is also available in electronic format	
CC	from USPTO at <a href="http://seqdata.uspto.gov/sequence.html">seqdata.uspto.gov/sequence.html</a> .	
XX		
XX	Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;	
XX		
XX	Query Match 100.0%; Score 1174; DB 8; Length 1174;	
XX	Best Local Similarity 100.0%; Pred. No. 0;	
XX	Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Oy	1 CGGAGCGCTGGGGAAACCCCTTCGAGAAAACGACAACTGACCTGCTGTGACAG 60	
db	1 CGGAGCGCTGGGGAAACCCCTTCGAGAAAACGACAACTGACCTGCTGTGACAG 60	

1141 CTAATAAATGCAATAAAGTTACTCAAATCTGTG 1174

RESULT 47  
ADA82154  
ID ADA82154 standard; cDNA; 1174 BP.

AC ADA82154;

DT 20-NOV-2003 (first entry)

DE Human PRO polynucleotide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

OS Homo sapiens.

PN US2003082701-A1.

PD 01-MAY-2003.

PF 23-APR-2002; 2002US-00128686.

PR 31-AUG-1998; 98US-0098525P.

PR 16-SEP-1998; 98US-0100634P.

PR 02-JUN-1999; 99WO-0012252P.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 02-JUN-2000; 2000WO-US015264.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

PS (GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755110/71.

P-PSDB; ADA82155.

PRO nucleic acid, useful for preparing a composition for treating e.g.,  
tumor or for tissue typing.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation

of human microvascular endothelial cells, for modulating the uptake of  
glucose or PFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating  
proliferation of or gene expression in pericyte cells, for stimulating  
the proliferation of inner ear utricular supporting cells or T-lymphocyte  
cells, for inducing endothelial cell tube formation and for treating  
various bone and/or cartilage disorders such as sports injuries and  
arthritis. PRO polypeptides which stimulate the release of proteoglycans  
from cartilage are useful for treating sports-related joint problems, PRO  
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
polypeptides are also useful for treating various mammalian haemoglobin-  
associated disorders such as various thalassaemias and conditions which  
may benefit from enhanced local immune system cell infiltration. This  
sequence represents a human PRO polynucleotide of the invention. Note:  
The sequence data for this patent is also available in electronic format  
from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

	Query Match	100.0%;	Score 1174;	DB 8;	Length 1174;
	Best Local Similarity	100.0%;	Pred. No. 0;		
	Matches 1174;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	CGGACGCGTGGGGGAAACCCCTTCCGAGAAAAACAGCAAAAGCTGAGCTGTGACAGAG	60		
Db	1	CGGACGCGTGGGGGAAACCCCTTCCGAGAAAAACAGCAAAAGCTGAGCTGTGACAGAG	60		
Qy	61	GGGAAACAGATGGGGGGCGGAGGAGCGCTGGGTGAGGACCCCACTGGGGCTCCCG	120		
Db	61	GGGAAACAGATGGGGGGCGGAGGAGCGCTGGGTGAGGACCCCACTGGGGCTCCCG	120		
Qy	121	CCGCTGCTGCTGACCATGGCCCTTGGCGGGAGGTTCCGGGACCGCTTCCGCTGAAGCA	180		
Db	121	CCGCTGCTGCTGACCATGGCCCTTGGCGGGAGGTTCCGGGACCGCTTCCGCTGAAGCA	180		
Qy	181	TTTGACTCGGCTTTGGGTGATACGGCGCTCTTGGCCACCGGGCTGTGAGTGAACCTT	240		
Db	181	TTTGACTCGGCTTTGGGTGATACGGCGCTCTTGGCCACCGGGCTGTGAGTGAACCTT	240		
Qy	241	TTGCACACCTTACCCTTAAGGAAGAGGAGTTGTAGCGCATGTCCAGAGAGTTGACGGCTGTTT	300		
Db	241	TTGCACACCTTACCCTTAAGGAAGAGGAGTTGTAGCGCATGTCCAGAGAGTTGACGGCTGTTT	300		
Qy	301	TCAATTTGTCAGTTGTGGATGATGAATGACTTAATCGAACTAAATGGAATGTGA	360		
Db	301	TCAATTTGTCAGTTGTGGATGATGAATGACTTAATCGAACTAAATGGAATGTGA	360		
Qy	361	TCTGCATGTACAGAGCATATTCCTCAATCTGATGACCAATATGCTTGCATCTTGGTTGC	420		
Db	361	TCTGCATGTACAGAGCATATTCCTCAATCTGATGACCAATATGCTTGCATCTTGGTTGC	420		
Qy	421	CAGAAATCAGCTGCGCTGAACCTGAGACAGAAACAACTTATGTCCCTGATGCCAAA	480		
Db	421	CAGAAATCAGCTGCGCTGAACCTGAGACAGAAACAACTTATGTCCCTGATGCCAAA	480		
Qy	481	ATGCACCTACTCTTCTCTAACTCTGTGAGTCTTCTGAGTGACATGATGACTCC	540		
Db	481	ATGCACCTACTCTTCTCTAACTCTGTGAGTCTTCTGAGTGACATGATGACTCC	540		
Qy	541	GCACAGAGCTTCATAACCTCTTCATCGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600		
Db	541	GCACAGAGCTTCATAACCTCTTCATCGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600		
Qy	601	GTTATATTCAGTCTAAGCCAGAAAAATCCAGTAGCGCACCACTTTGGAGCAGAGGCTACA	660		
Db	601	GTTATATTCAGTCTAAGCCAGAAAAATCCAGTAGCGCACCACTTTGGAGCAGAGGCTACA	660		
Qy	661	AAATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTCAAAATGAGAAATTCACAGGG	720		
Db	661	AAATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAGGG	720		
Qy	721	CACAGGAATTTCTTGAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTTCTTAC	780		

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780  
QY 781 TCTGGTGGAATTTAACTACAACCTTTGTCTCTCGTGATGATGATTTGGATTTCT 840  
Db 781 TCTGGTGGAATTTAACTACAACCTTTGTCTCTCGTGATGATGATTTGGATTTCT 840  
QY 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTACTAT 900  
Db 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTACTAT 900  
QY 901 GGTGACCTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTCTCTCTGTG 960  
Db 901 GGTGACCTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTCTCTCTGTG 960  
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGACAGGCGCTCTCTCAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGACAGGCGCTCTCTCAAAAGTGAAT 1020  
QY 1021 CTGTCTCTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db 1021 CTGTCTCTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCATGATAGAGCTTAAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCATGATAGAGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATATAAGTTTACTCAAACTCTGTG 1174  
Db 1141 CTATAAATGCAATATAAGTTTACTCAAACTCTGTG 1174

RESULT 48  
ID ADA75117 standard; cDNA; 1174 BP.  
XX  
AC ADA75117;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polynucleotide #136.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW Cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003073216-A1.  
XX  
PD 17-APR-2003.  
XX  
PF 30-MAY-2002; 2002US-00160498.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030311.  
PR 22-DEC-1999; 99WO-US030999.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 21-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.

05-JUN-2001; 2001US-00874503.  
 14-JUN-2001; 2001US-00892636.  
 19-JUN-2001; 2001US-00886342.  
 20-JUN-2001; 2001WO-US019692.  
 21-JUN-2001; 2001US-00887879.  
 22-JUN-2001; 2001WO-US020116.  
 23-JUN-2001; 2001WO-US021066.  
 09-JUL-2001; 2001WO-US021735.  
 18-JUL-2001; 2001US-00908827.  
 06-AUG-2001; 2001US-00924419.  
 09-AUG-2001; 2001US-00927796.  
 16-AUG-2001; 2001US-00931836.  
 19-DEC-2001; 2001US-00028072.  
 (GETH ) GENENTECH INC.  
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen MF, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI: 2003-765392/72.  
 P-PSDB; ADA75118.  
 New secreted and transmembrane PRO polypeptides useful for stimulating  
 the release of tumor necrosis factor alpha in human blood and detecting  
 the presence of tumor in a mammal.  
 Claim 2; Fig 271; 638pp; English.  
 The invention relates to isolated human PRO polypeptides (secreted and  
 transmembrane polypeptides) and the polynucleotides encoding them. The  
 invention also relates to an antibody which specifically binds to a PRO  
 polypeptide, a method for stimulating the release of tumor necrosis  
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 proliferation or differentiation of chondrocyte cells and a method for  
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 polynucleotides are useful in molecular biology, including uses as  
 hybridisation probes, in chromosome and gene mapping, in generating  
 antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 be used in preparing PRO polypeptides by recombinant techniques and in  
 generating either transgenic animals or knock-out animals which are  
 useful in the development and screening of therapeutically useful  
 reagents. The PRO polypeptides or antibodies are used in preparing a  
 medicament for treating a condition responsive to the polypeptides or  
 antibodies, such as tumours, for stimulating and inhibiting proliferation  
 of human microvascular endothelial cells, for modulating the uptake of  
 glucose or PFA by skeletal muscle cells or adipocyte cells, for  
 stimulating differentiation of adipocyte cells, for stimulating  
 proliferation of or gene expression in pericyte cells, for stimulating  
 the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 cells, for inducing endothelial cell tube formation and for treating  
 various bone and/or cartilage disorders such as sports injuries and  
 arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 from cartilage are useful for treating sports-related joint problems,  
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 polypeptides are also useful for treating various mammalian haemoglobin-  
 associated disorders such as various thalassaemias and conditions which  
 may benefit from enhanced local immune system cell infiltration. This  
 sequence represents a human PRO polynucleotide of the invention. Note:  
 The sequence data for this patent is also available in electronic format  
 from USPTO at seqdata.uspto.gov/sequence.html.  
 Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 1174; DB 8; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 1 CGGACGGGTGGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
 1 CGGACGGGTGGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60

61 GGGAAACAAGATGGCGGCGCCGAAAGGGGAGGCTCTGGGTGAGGAGCCCAACTGGGCTCCCG 120  
 61 GGGAAACAAGATGGCGGCGCCGAAAGGGGAGGCTCTGGGTGAGGAGCCCAACTGGGCTCCCG 120  
 121 CGGCTGCTGCTGCTGCTACCATCGCCCTTGCCCGGAGGTTTCGGGAGACCGCTTCGGCTGAAGCA 180  
 121 CGGCTGCTGCTGCTGCTACCATCGCCCTTGCCCGGAGGTTTCGGGAGACCGCTTCGGCTGAAGCA 180  
 181 TTTGACTCGGCTTGGGTGATACCGCGCTTTGCCACCGGCGCTCTGAGTTGACCTACCC 240  
 181 TTTGACTCGGCTTGGGTGATACCGCGCTTTGCCACCGGCGCTCTGAGTTGACCTACCC 240  
 241 TTTGCACACCTACCTTAAGGAAAGAGAGGTTGTACGCACTGTACAGAGAGGTTGACGAGCTGTTT 300  
 241 TTTGCACACCTACCTTAAGGAAAGAGAGGTTGTACGCACTGTACAGAGAGGTTGACGAGCTGTTT 300  
 301 TCAATTTGTGAGTTGTGATGAGTAATGCACTTAATTAATTAATTAATTAATTAATTAATTAATTAAT 360  
 301 TCAATTTGTGAGTTGTGATGAGTAATGCACTTAATTAATTAATTAATTAATTAATTAATTAATTAAT 360  
 361 TCTGCAATGTACAGAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCATCTTTGGTTGC 420  
 361 TCTGCAATGTACAGAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCATCTTTGGTTGC 420  
 421 CAGAAATCAGCTGCCATTTGCTGAACTGAGACAGAACTTATGCTCCCTGATGCCAAA 480  
 421 CAGAAATCAGCTGCCATTTGCTGAACTGAGACAGAACTTATGCTCCCTGATGCCAAA 480  
 481 ATGCACTACTCTTTCTCTACTCTGCTGAGGTCATTTCTGAGTGACATGATGAGACTCC 540  
 481 ATGCACTACTCTTTCTCTACTCTGCTGAGGTCATTTCTGAGTGACATGATGAGACTCC 540  
 541 GCACAGAGCTTCATAACCTCTTTCAAGGAGCTTTTATCTTCAAGCGGATGACGCGAAAATA 600  
 541 GCACAGAGCTTCATAACCTCTTTCAAGGAGCTTTTATCTTCAAGCGGATGACGCGAAAATA 600  
 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACACACACATTTGGAGCAGAGCTTACA 660  
 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACACACATTTGGAGCAGAGCTTACA 660  
 661 AATTTGAGAGAAATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCG 720  
 661 AATTTGAGAGAAATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCG 720  
 721 CACAGAAATTTCTTGAAGATGGAAGAGTATGCTCTTCTGCTGATGTTTCTTGGATTTGT 840  
 721 CACAGAAATTTCTTGAAGATGGAAGAGTATGCTCTTCTGCTGATGTTTCTTGGATTTGT 840  
 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCTCGTGATGTTTCTTGGATTTGT 840  
 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCTCGTGATGTTTCTTGGATTTGT 840  
 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGATCTAT 900  
 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGATCTAT 900  
 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTCTG 960  
 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTCTG 960  
 961 GTTGTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
 961 GTTGTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
 1021 CTGTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
 1021 CTGTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
 1081 AATTTCCACTCTCATAGAGCTTTTAAATGTTTCAATTGGATATAGGCTTTAGGAATCA 1140  
 1081 AATTTCCACTCTCATAGAGCTTTTAAATGTTTCAATTGGATATAGGCTTTAGGAATCA 1140  
 1141 CTATATAATGCAATAAAGTTACTCAAAATCTGTG 1174

|||||CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

Db

## RESULT 49

ADA85195  
ID ADA85195 standard; cDNA; 1174 BP.

XX

AC ADA85195;

XX

DT 20-NOV-2003 (first entry)

XX

XX Novel human secreted and transmembrane protein PRO195 cDNA.

DE

XX Human; secreted and transmembrane protein; PRO; gene; ss;

KW

XX Tumour necrosis factor alpha release; TNF-alpha release;

KW

XX Glucose uptake modulator; FFA uptake modulator;

KW

XX Cell proliferation stimulator; cell differentiation stimulator;

KW

XX Cell differentiation inhibitor; cytokine release stimulator; tumour;

KW

XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW

XX cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW

XX gene therapy; chromosome identification; chromosome marker.

XX

OS Homo sapiens.

XX

XX US2003082695-A1.

PN

XX 01-MAY-2003.

XX

XX 22-APR-2002; 2002US-00127846.

XX

XX 03-MAR-2000; 2000US-0187202P.

PR

XX 01-DEC-2000; 2000WO-US032678.

PR

XX 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

PA

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI

XX Gritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

PI

XX WPI; 2003-786909/74.

XX

XX P-PSDB; ADA85196.

DR

XX New nucleic acid encoding a PRO polypeptide, useful for preparing a

PT

XX composition for treating e.g. tumor by gene therapy, or for tissue

PT

XX typing.

PT

XX Claim 2; Fig 271; 637pp; English.

XX

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match

Best Local Similarity 100.0%; Score 1174; DB 8; Length 1174;

Mismatches 0; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Qy

1 CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Db

61 GGGAAACAAGATGCGCGCGCGAAGGGGAGCCCTCGGTGAGACCCAACTGGGGTCCGG 120

Qy

61 GGGAAACAAGATGCGCGCGCGAAGGGGAGCCCTCGGTGAGACCCAACTGGGGTCCGG 120

Db

121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGACCGCTTCGGCTCAAGCA 180

Qy

121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGACCGCTTCGGCTCAAGCA 180

Db

181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGCACCGGGCCTGTCACTGACCTACCCC 240

Qy

181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGCACCGGGCCTGTCACTGACCTACCCC 240

Db

241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAAGCTTT 300

Qy

241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAAGCTTT 300

Db

301 TCAATTTGTCAAGTTTGTGATGATGCAATTTGAATTAATCGAACTAAATGTGAA 360

Qy

301 TCAATTTGTCAAGTTTGTGATGATGCAATTTGAATTAATCGAACTAAATGTGAA 360

Db

361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATTTGGTTC 420

Qy

361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATTTGGTTC 420

Db

421 CAGAAATCAGCTGCCATTGCGTGAATCGAGCAAGAAACAACTTATGTCCCTGATGCCAAA 480

Qy

421 CAGAAATCAGCTGCCATTGCGTGAATCGAGCAAGAAACAACTTATGTCCCTGATGCCAAA 480

Db

481 ATGCACCTACTTTTCTTAACTCTGTGAGTCAATCTGAGTGACATGATGAGCTCC 540

Qy

481 ATGCACCTACTTTTCTTAACTCTGTGAGTCAATCTGAGTGACATGATGAGCTCC 540

Db

541 GCACAGAGCTTCATACCTCTTCAAGCCGATGATGAGCAAGAAATA 600

Qy

541 GCACAGAGCTTCATACCTCTTCAAGCCGATGATGAGCAAGAAATA 600

Db

601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCAACCAATTTGGAGCAGGCTTACA 660

Qy

601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCAACCAATTTGGAGCAGGCTTACA 660

Db

661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTCAATATGAGAAATTCACAAGCG 720

Qy

661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTCAATATGAGAAATTCACAAGCG 720

Db

721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCGTTTTTAAGATGCTCTCTCTAAC 780

Qy

721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCGTTTTTAAGATGCTCTCTCTAAC 780

Db

781 TCTGGGTGGATTTTAACTACATCTTGTCTCTCGGTGATGATTTGTTGGATTTCT 840

Qy

781 TCTGGGTGGATTTTAACTACATCTTGTCTCTCGGTGATGATTTGTTGGATTTCT 840

Db

841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

Qy

841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

Db

901 GGTGACTTGGAGTTTATGAATGAACAAACAACTAAACAGATATCCAGCTTCTTCTTGTG 960

Qy

Db 901 GGTGACTGGAGTTATGAATGAACAAAGCTAAACAGATATCCAGTCTCTCTTCTTG 960  
Qy 961 GTTGTAGATCTAAATCTGAAGATCATGAGAACGAGCGCTCTACTACAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAATCTGAAGATCATGAGAACGAGCGCTCTACTACAAAAGTGAAT 1020  
Qy 1021 CTTGCTCATCTGAAATTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db 1021 CTTGCTCATCTGAAATTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Qy 1081 AATTCCACTCTCATAGACTTTTAAATGGTTTCATTGGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCCACTCTCATAGACTTTTAAATGGTTTCATTGGATATAGGCTTAAAGAAATCA 1140  
Qy 1141 CTATAAATGCAATAAAGTTACTCAAACTCTGTG 1174  
Db 1141 CTATAAATGCAATAAAGTTACTCAAACTCTGTG 1174

## RESULT 50

ID ADA84643 standard; cDNA; 1174 BP.

XX ADA84643;

AC 20-NOV-2003 (first entry)

DT Novel human secreted and transmembrane protein PRO195 cDNA.

DE Human; secreted and transmembrane protein; PRO; gene; ss;  
XX Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003082708-Al.

PN 01-MAY-2003.

XX 15-MAY-2002; 2002US-00146729.

XX 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032878.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786911/74.

DR P-PSDB; ADA84644.

XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g. tumor or for tissue typing.

XX Claim 2; Fig 271; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Qy Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. NO. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Qy 61 GGGAAACAAGATGCGCGCGCGAGAGGGAGCCCTCTGGTGAGAGCCCACTGGGGTCCCG 120

Db 61 GGGAAACAAGATGCGCGCGCGAGAGGGAGCCCTCTGGTGAGAGCCCACTGGGGTCCCG 120

Qy 121 CGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTCGGCTCAAGCA 180

Db 121 CGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTCGGCTCAAGCA 180

Qy 181 TTTGACTCGGCTTTGGGTGATACGGGCTCTTCCACACCGGGCCCTGTGAGTTCACCTACCCC 240

Db 181 TTTGACTCGGCTTTGGGTGATACGGGCTCTTCCACACCGGGCCCTGTGAGTTCACCTACCCC 240

Qy 241 TTGCACACCTACCTAAGGAGAGGAGTTGTACGATGTTCAGAGAGTTGCGAGGTGTTT 300

Db 241 TTGCACACCTACCTAAGGAGAGGAGTTGTACGATGTTCAGAGAGTTGCGAGGTGTTT 300

Qy 301 TCAATTTGTGAGTTTGTGGATGATGAAATGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db 301 TCAATTTGTGAGTTTGTGGATGATGAAATGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Qy 361 TCTGCATGTACAGAGCATATTCCTAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAGCATATTCCTAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy 421 CAGAACTAGCTGCTGCTGAGCTGAGCAAGAACCACTTATGTCCTGTATGCCAAA 480

Db 421 CAGAACTAGCTGCTGCTGAGCTGAGCAAGAACCACTTATGTCCTGTATGCCAAA 480

Qy 481 ATGCACCTACTCTTTTCTTAACTCTGTTGAGGTCAATCTGGAGTGACATGATGACTCC 540

Db 481 ATGCACCTACTCTTTTCTTAACTCTGTTGAGGTCAATCTGGAGTGACATGATGACTCC 540

Qy 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600

Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600

Qy 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGACCACTTATGGAGCAGGAGCTTACA 660

Db 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGACCACTTATGGAGCAGGAGCTTACA 660

Qy 661 AATTGAGAGATCATCTTCAAGCAAAATGCTCTATCTGCAATATGAAATTCACAGGG 720

Db 661 AATTGAGAGATCATCTTCAAGCAAAATGCTCTATCTGCAATATGAAATTCACAGGG 720

Db 661 AATTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCAGAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGAATGCTTTTAAAGATGCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGAATGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGGTGATTTTAACCTACACTCTTCTCTCTCGGTGATGCTTTTGGATTTGT 840  
Db 781 TCTGGGTGATTTTAACCTACACTCTTCTCTCTCGGTGATGCTTTTGGATTTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900  
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900  
QY 901 GGTGACTTGGATTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960  
Db 901 GGTGACTTGGATTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960  
QY 961 GTTGTAGATCTAAACTGAAATCATGAAGAGCAGGCTCTACCTACAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAATCATGAAGAGCAGGCTCTACCTACAAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTAAAGACATCTAA 1080  
Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTAAAGACATCTAA 1080  
QY 1081 AATTCCACTCCTCATAGACTTTTAAATGGTTTCAATGGATATAGGCTTTAAGAAATCA 1140  
Db 1081 AATTCCACTCCTCATAGACTTTTAAATGGTTTCAATGGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATAAAATGCAAAATTAAGTTACTCAATCTGTG 1174  
Db 1141 CTATAAAATGCAAAATTAAGTTACTCAATCTGTG 1174

RESULT 51  
ADE29899 standard; cDNA; 1174 BP.  
XX AC ADE29899;  
XX XX  
DT 20-NOV-2003 (first entry)  
DE cDNA encoding human PRO polypeptide #136.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX OS Homo sapiens.  
XX PN US2003073214-A1.  
XX XX  
PD 17-APR-2003.  
XX PF 17-APR-2002; 2002US-00124822.  
XX PF 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 28-AUG-1998; 98WO-US014552.  
PR 10-SEP-1998; 98WO-US017888.  
PR 14-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 30-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 20-APR-1999; 98WO-US008615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 05-OCT-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 01-DEC-1999; 98WO-US028409.  
PR 01-DEC-1999; 98WO-US028634.  
PR 02-DEC-1999; 98WO-US028851.  
PR 02-DEC-1999; 98WO-US028856.  
PR 16-DEC-1999; 98WO-US028856.  
PR 20-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 22-DEC-1999; 98WO-US030720.  
PR 30-DEC-1999; 98WO-US031443.  
PR 30-DEC-1999; 98WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.



PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 XX WPI; 2003-720081/68.  
 DR P-PSDB; ADB29900.  
 XX  
 PR Novel secreted and transmembrane PRO polypeptides useful for stimulating  
 PT the release of tumor necrosis factor alpha and detecting the presence of  
 PT a tumor in a mammal.  
 XX  
 XX Claim 2; Fig 271; 638pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumor necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence encodes a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
 XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGAAACCCCTTCGGAGAAAACAGCAACAGCTGAGCTGCTGTCAGAG 60  
 DB 1 CGGACGGCTGGGGAAACCCCTTCGGAGAAAACAGCAACAGCTGAGCTGCTGTCAGAG 60  
 QY 61 GGGAAACAAGATGGCGCGCGGAGAGGAGCCTCTGGGTGAGGACCAACTGGGGCTCCG 120  
 DB 61 GGGAAACAAGATGGCGCGCGGAGAGGAGCCTCTGGGTGAGGAGCCTCTGGGGCTCCG 120  
 QY 121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGAGCCGCTTCGGCTGAAGCA 180  
 DB 121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGGAGCCGCTTCGGCTGAAGCA 180  
 QY 181 TTTGACTCGGTCTTGGGTGATAGGGGTCTTGGCCACCGGCTGTGTCAGTTGACCTACCCC 240  
 DB 181 TTTGACTCGGTCTTGGGTGATAGGGGTCTTGGCCACCGGCTGTGTCAGTTGACCTACCCC 240  
 QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGCGGCTGTTT 300  
 DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGCGGCTGTTT 300  
 QY 301 TCAATTTGTGATTTGGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360  
 DB 301 TCAATTTGTGATTTGGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360  
 QY 361 TCTGCAATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
 DB 361 TCTGCAATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
 QY 421 CAGATCAGCTGCCATTCGCTGAACTGAGACAAGAACCACTTATGTCCTCGATGCCCCAAA 480  
 DB 421 CAGATCAGCTGCCATTCGCTGAACTGAGACAAGAACCACTTATGTCCTCGATGCCCCAAA 480  
 QY 481 ATGCACCTACTCTTTCTCTAACTCTCGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540  
 DB 481 ATGCACCTACTCTTTCTCTAACTCTCGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540  
 QY 541 GCACAGAGCTTCAAACTCTTTCATGACCTTTTATCTTCAAGCCGATGACGAAATA 600  
 DB 541 GCACAGAGCTTCAAACTCTTTCATGACCTTTTATCTTCAAGCCGATGACGAAATA 600  
 QY 601 GTTATATTCCAGTCTAAAGCCAGAAATCCAGTACGACCAATTTGGAGAGGAGCTTACA 660  
 DB 601 GTTATATTCCAGTCTAAAGCCAGAAATCCAGTACGACCAATTTGGAGAGGAGCTTACA 660  
 QY 661 AATTTGAGAGATCATCTCTTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAGCG 720  
 DB 661 AATTTGAGAGATCATCTCTTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAGCG 720  
 QY 721 CACAGGAAATTTCTTGAAGATGGAAGAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780  
 DB 721 CACAGGAAATTTCTTGAAGATGGAAGAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780  
 QY 781 TCTGGGTGATTTTAACTTACAACTCTTCTCTCTCTCGGTGATGGTATTGCTTGGATTGT 840  
 DB 781 TCTGGGTGATTTTAACTTACAACTCTTCTCTCTCTCGGTGATGGTATTGCTTGGATTGT 840  
 QY 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTCCTCTCTGAGAGCTGAGTATCTAT 900  
 DB 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTCCTCTCTGAGAGCTGAGTATCTAT 900  
 QY 901 GTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTCTTCTCTTGTG 960  
 DB 901 GTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTCTTCTCTTGTG 960  
 QY 961 GTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGCTCTTACCTACAAAGTGAAT 1020  
 DB 961 GTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGCTCTTACCTACAAAGTGAAT 1020  
 QY 1021 CTTGCTCATCTTGAATAATTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
 DB 1021 CTTGCTCATCTTGAATAATTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
 QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGTTTCTTCTTGGATATAGGCTTAAAGAAATCA 1140



Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCATTGGATATAGGCTTAAGAAATCA 1140  
QY 1141 CTATATAAGTCAATAAAGTACTCAATCTGTG 1174  
Db 1141 CTATATAAGTCAATAAAGTACTCAATCTGTG 1174  
RESULT 52  
ADA80427  
ID ADA80427 standard; cDNA; 1174 BP.  
XX  
AC ADA80427;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
XX Human PRO polynucleotide #136.  
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
OS  
XX  
XX US2003082761-A1.  
PN  
XX  
XX 01-MAY-2003.  
PD  
XX  
XX 12-APR-2002; 2002US-00121061.  
PF  
XX  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019053.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022591.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 13-SEP-1999; 99WO-US020594.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 05-JAN-2000; 99WO-US031374.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005046.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022011.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00806889.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Gurney AL, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755115/71.  
DR P-PSDB; ADA80428.  
XX

PT New PRO polypeptides useful for treating diabetes, hyper- or hypo-  
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,  
PT various coagulation disorders and tumors.

PS Claim 2; Fig 271; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACCGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACCGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAAACAGATGGCGGCGCGGAGGAGGCTTGGGTGAGGACCCACCTGGGGCTCCCG	120
DB	61	GGGAAACAGATGGCGGCGCGGAGGAGGCTTGGGTGAGGACCCACCTGGGGCTCCCG	120
QY	121	CGGCTGCTGCTGACCCATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
DB	121	CGGCTGCTGCTGACCCATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGCTTGGGGTGATACGGGCTTTGACCCCGGCGCTGTGATGACCTACCCC	240
DB	181	TTTGACTCGGCTTGGGGTGATACGGGCTTTGACCCCGGCGCTGTGATGACCTACCCC	240
QY	241	TTTGACACCTACCTTAAGGAGAGAGTTGACGATGTGACAGAGGTTGACGCTGTTT	300
DB	241	TTTGACACCTACCTTAAGGAGAGAGTTGACGATGTGACAGAGGTTGACGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGGATGATGGAATTCGATTAATCGAACTAAATGGAAATGAA	360
DB	301	TCAATTTGTCAGTTTGGATGATGGAATTCGATTAATCGAACTAAATGGAAATGAA	360
QY	361	TTTGATCTACAGAGCATATCCCATCTCATGAGCAATATGCTGCAATCTTGTTC	420
DB	361	TTTGATCTACAGAGCATATCCCATCTCATGAGCAATATGCTGCAATCTTGTTC	420

QY	421	CAGAACTCAGCTGCCATTCCCTGAACTGAGCAAGAACAACTTATGTCCTGATGCCAAA	480
DB	421	CAGAACTCAGCTGCCATTCCCTGAACTGAGCAAGAACAACTTATGTCCTGATGCCAAA	480
QY	481	ATGCACTACTCTTTCTCTTAACTCTGGTGAGTCACTTCTGAGTGACATGATGACTCC	540
DB	481	ATGCACTACTCTTTCTCTTAACTCTGGTGAGTCACTTCTGAGTGACATGATGACTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCTATGGAATTTTATCTTCAAGCCGATGACGGAATA	600
DB	541	GCACAGAGCTTCATAACCTCTTCTATGGAATTTTATCTTCAAGCCGATGACGGAATA	600
QY	601	GTATATTCAGCTTAAGCAGCAATCCAGTACGACCAATTTGGAGCAGGAGCTACA	660
DB	601	GTATATTCAGCTTAAGCAGCAATCCAGTACGACCAATTTGGAGCAGGAGCTACA	660
QY	661	AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAG	720
DB	661	AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAG	720
QY	721	CACAGGAATTTCTCAAGATGAGAGAGTATGCTTTTAAGATGCTCTCTTAAAC	780
DB	721	CACAGGAATTTCTCAAGATGAGAGAGTATGCTTTTAAGATGCTCTCTTAAAC	780
QY	781	TCGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTCTTGGATTTGT	840
DB	781	TCGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTCTTGGATTTGT	840
QY	841	TGTGCAACTCTTCTCAAGCTGTGAGAGAGTATGCTTCCCTCTGAGAGCTGATCTAT	900
DB	841	TGTGCAACTCTTCTCAAGCTGTGAGAGAGTATGCTTCCCTCTGAGAGCTGATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGAGCTTAAACAGATATCCAGCTTCTCTTGTG	960
DB	901	GGTGACTTGGAGTTTATGAATGAACAAAGAGCTTAAACAGATATCCAGCTTCTCTTGTG	960
QY	961	GTGTTTATGATCTTAAACTGAAGATCATGAAGAGAGAGGCTCTACCTACAAAGATGA	1020
DB	961	GTGTTTATGATCTTAAACTGAAGATCATGAAGAGAGAGGCTCTACCTACAAAGATGA	1020
QY	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA	1080
DB	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA	1080
QY	1081	AATTTCACTCTCATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTTAAGAAATCA	1140
DB	1081	AATTTCACTCTCATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTTAAGAAATCA	1140
QY	1141	CTATATAATGCAATTAAGTTACTCAAACTCTG	1174
DB	1141	CTATATAATGCAATTAAGTTACTCAAACTCTG	1174

RESULT 53  
ADA75669 standard; cDNA; 1174 BP.  
XX ADA75669;  
XX 20-NOV-2003 (first entry)  
XX Human PRO polynucleotide #136.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

immune system cell infiltration.

Homo sapiens.

US2003082703-A1.

XX 01-MAY-2003.

XX 23-APR-2002; 2002US-00128691.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-765414/72.

XX P-PSDB; ADA75670.

XX New PRO nucleic acid, useful for preparing a composition for treating

XX e.g., tumor or for tissue typing.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear uricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGAGCGTGGGGAAACCTTCGAGAAAACAGCAACAGCTGAGTGTGTGACAGAG 60  
DB 1 CGGAGCGTGGGGAAACCTTCGAGAAAACAGCAACAGCTGAGTGTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCGGAGAGAGCGCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120

DB 61 GGGAAACAAGATGGCGCGCGGAGAGAGCGCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120  
QY 121 CCGCTGTGTGTGTGACCATATGCGCGAGGTTTCGGGAGACCCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGTGTGTGTGACCATATGCGCGAGGTTTCGGGAGACCCGCTTCGGCTGAAGCA 180  
QY 181 TTGACTCGGTCTGGGTGATACGGGTCTTGGCCACCGGGCTGTGAGTTGACCTACCC 240  
DB 181 TTGACTCGGTCTGGGTGATACGGGTCTTGGCCACCGGGCTGTGAGTTGACCTACCC 240  
QY 241 TTGACACACCTTACCTTAAGGAAGAGGAGTTGTACGATGTGACAGAGTTGCGAGGCTGTTT 300  
DB 241 TTGACACACCTTACCTTAAGGAAGAGGAGTTGTACGATGTGACAGAGTTGCGAGGCTGTTT 300  
QY 301 TCAATTTGTGATGTTGGGTGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360  
DB 301 TCAATTTGTGATGTTGGGTGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360  
QY 361 TCTGCATGTACAGAGCATATCCCAATCTGTAGAGCAATATGCTTGCCATCTTGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATCCCAATCTGTAGAGCAATATGCTTGCCATCTTGTTGC 420  
QY 421 CAGAAATCAGCTGCCATTTCGCTGAACCTGAGCAAGAACTATATGTCCTGTATGCAAAA 480  
DB 421 CAGAAATCAGCTGCCATTTCGCTGAACCTGAGCAAGAACTATATGTCCTGTATGCAAAA 480  
QY 481 ATGCACCTTACTCTTCTTAACTCTGCTGAGGTCAATCTGGAGTGACATGATGACTCC 540  
DB 481 ATGCACCTTACTCTTCTTAACTCTGCTGAGGTCAATCTGGAGTGACATGATGACTCC 540  
QY 541 GCACAGAGCTTTCATAAACCCTCTTCATGAGCTTTTATCTTCAAGCCGATGCGGAAAATA 600  
DB 541 GCACAGAGCTTTCATAAACCCTCTTCATGAGCTTTTATCTTCAAGCCGATGCGGAAAATA 600  
QY 601 GTTATATCCAGCTTAAGCCAGAAATCCAGTAGCCACCAATTTGGAGCAGAGGCTTACA 660  
DB 601 GTTATATCCAGCTTAAGCCAGAAATCCAGTAGCCACCAATTTGGAGCAGAGGCTTACA 660  
QY 661 AATTGTGAGAGATCATCTCTPAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGG 720  
DB 661 AATTGTGAGAGATCATCTCTPAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGG 720  
QY 721 CACAGGAATTTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATGCCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATGCCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGTGTGATGATTTGCTTTGGATTCT 840  
DB 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGTGTGATGATTTGCTTTGGATTCT 840  
QY 841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGATATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGATATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
QY 901 GGTGACCTGGAGTTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTCTCTTGG 960  
DB 901 GGTGACCTGGAGTTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTCTCTTGG 960  
QY 961 GTTCTTATGATCTTAAACTGAAATCATGAAAGCAGAGGCGCTCTACCTTACAAAGTGAAT 1020  
DB 961 GTTCTTATGATCTTAAACTGAAATCATGAAAGCAGAGGCGCTCTACCTTACAAAGTGAAT 1020  
QY 1021 CTTCCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGCAGAGTGTATATGACATCTAA 1080  
DB 1021 CTTCCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGCAGAGTGTATATGACATCTAA 1080  
QY 1081 AATTCCACTCTCTCATAGAGCTTTTAAAGTGTTCATTTGATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCCACTCTCTCATAGAGCTTTTAAAGTGTTCATTTGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATATAATGCAATTAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTACTCAAAATGTGTG 1174

RESULT 54

ADA46894

ID ADA46894 standard; cDNA; 1174 BP.

XX AC ADA46894;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #136.

XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; PFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003073210-A1.

XX PD 17-APR-2003.

XX PF 11-APR-2002; 2002US-00121045.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 98WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US021547.

PR 29-NOV-1999; 99WO-US023089.

PR 30-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028501.

PR 02-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028651.

PR 02-DEC-1999; 99WO-US028654.

PR 16-DEC-1999; 99WO-US028655.

PR 20-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030811.

PR 22-DEC-1999; 99WO-US030939.

PR 30-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00818744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart FA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-644800/61.

P-PSDB; ADA46895.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PR04978, useful in molecular biology, chromosome and gene mapping, in  
generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 271; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGCTGGGGAAACCCCTTCCGAGAAACAGCAACGAGCTGAGCTGCTGCACAGAG 60  
DB 1 CGGACCGCTGGGGAAACCCCTTCCGAGAAACAGCAACGAGCTGAGCTGCTGCACAGAG 60

QY 61 GGGAAACAAGATGCGCGCGCGGAGAGGAGCTCTGGGTGAGACCCAACTGGGCTCCCG 120  
DB 61 GGGAAACAAGATGCGCGCGCGGAGAGGAGCTCTGGGTGAGACCCAACTGGGCTCCCG 120

QY 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGAGCGGCTTCGGCTGAGCA 180  
DB 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGAGCGGCTTCGGCTGAGCA 180

QY 181 TTGATTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCTGTGCTGACCTACCCC 240  
DB 181 TTGATTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCTGTGCTGACCTACCCC 240

QY 241 TTGCACACCTACCTAAGAGAGGAGTGTACGATGTCAGAGGTTGAGGCTGTTT 300  
DB 241 TTGCACACCTACCTAAGAGAGGAGTGTACGATGTCAGAGGTTGAGGCTGTTT 300

QY 301 TCAATTGTGCTGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360  
DB 301 TCAATTGTGCTGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCAATGACAGACATATCCCACTGATGAGCAATATGCTTGGCACTTGGTTC 420  
DB 361 TCTGCAATGACAGACATATCCCACTGATGAGCAATATGCTTGGCACTTGGTTC 420

QY 421 CAGAATCAGCTGCCATTCCGCTGAACCTGAGACAGAACTTATGCTCCCTGATGCCAAA 480  
DB 421 CAGAATCAGCTGCCATTCCGCTGAACCTGAGACAGAACTTATGCTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTCCCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540  
DB 481 ATGCACCTACTCTTTCCCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATAAAGCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCATAAAGCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCTTACA 660

QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780

QY 781 TCTGGGTGGATTTAACTTACAACTCTTGTCTCTCGGTGATGCTTATGCTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTAACTTACAACTCTTGTCTCTCGGTGATGCTTATGCTTGGATTTGT 840

QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAAATGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAAATGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960

QY 961 GTTGTAGATCTAAACCTGAAGATCATCAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACCTGAAGATCATCAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020

QY 1021 CTGTCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080  
DB 1021 CTGTCTCATCTGAAATTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080

QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140

QY 1141 CTATATAATGCAATTAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATATAATGCAATTAAGTTACTCAAAATCTGTG 1174

RESULT 55  
ADB25190  
ID ADB25190 standard; cDNA; 1174 BP.

XX AC ADB25190;  
XX XX  
DT 20-NOV-2003 (first entry)  
XX Human PRO polynucleotide SEQ ID NO 271.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

OS Homo sapiens.  
XX OS  
XX PN US200307715-A1.

XX 24-APR-2003.

XX 23-APR-2002; 2002US-00128693.

XX 31-AUG-1998; 98US-0098525P.

XX 16-SEP-1998; 98US-0100634P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 02-JUN-2000; 2000WO-US015264.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-755070/71.

XX P-PSDB; ADB25191.

XX New isolated, secreted and transmembrane PRO nucleic acids, useful for

XX the diagnosis, prevention and/or treatment of tumors, such as lung,

XX colon, breast, prostate, rectal, cervical and/or liver tumors.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating differentiation of adipocyte cells, for stimulating

XX proliferation of or gene expression in pericyte cells, for stimulating

XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

XX cells, for inducing endothelial cell tube formation and for treating

XX various bone and/or cartilage disorders such as sports injuries and

XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

XX from cartilage are useful for treating sports-related joint problems,

XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

XX polypeptides are also useful for treating various mammalian haemoglobin-

XX associated disorders such as various thalassemias and conditions which

XX may benefit from enhanced local immune system cell infiltration. This

XX sequence represents a human PRO polynucleotide of the invention. Note:

XX The sequence data for this patent is also available in electronic format

XX from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1174; DB 8; Length 1174;

XX Best Local Similarity 100.0%; Pred. No. 0;

XX Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60

XX 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCGCGGAGAGCCCTCTGGGTGAGGAGCCCACTGGGGCTCCCG 120

DB 61 GGGAAACAAGATGGCGCGCGCGGAGAGCCCTCTGGGTGAGGAGCCCACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCCGGGAGACCCGCTTCGGCTGAAGCA 180

DB 121 CCGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCCGGGAGACCCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGGTCTTGGCAAGGGGCTGTGCTGAGTACCTTACCCC 240

DB 181 TTTGACTCGGTCTTGGGTGATACGGGTCTTGGCAAGGGGCTGTGCTGAGTACCTTACCCC 240

QY 241 TTGCACACCTTACCTTAAGGAAGAGGAGTTGTCAGCATGTCCAGAGGTTGCGAGGCTGTTT 300

DB 241 TTGCACACCTTACCTTAAGGAAGAGGAGTTGTCAGCATGTCCAGAGGTTGCGAGGCTGTTT 300

QY 301 TCAATTTGTGAGTTTGGAGTATGGAATGACTTAAATCGAACTAAATTTGGAATGTAA 360

DB 301 TCAATTTGTGAGTTTGGAGTATGGAATGACTTAAATCGAACTAAATTTGGAATGTAA 360

QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGGCTCCATCTTGGTTGC 420

DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGGCTCCATCTTGGTTGC 420

QY 421 CAGAACTCAGCTGCCATTCGCTGAACTGAGCAAGAAACAACTTATGTCCTGATGCAAAA 480

DB 421 CAGAACTCAGCTGCCATTCGCTGAACTGAGCAAGAAACAACTTATGTCCTGATGCAAAA 480

QY 481 ATGCACTACTCTTTCTCTTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGACTCC 540

DB 481 ATGCACTACTCTTTCTCTTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCTTAACTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600

DB 541 GCACAGAGCTTCTTAACTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600

QY 601 GTTATATTCAGTCTTAACTGAGCAAGAACTCAGTACGACCACTTGGAGGAGGCTTAC 660

DB 601 GTTATATTCAGTCTTAACTGAGCAAGAACTCAGTACGACCACTTGGAGGAGGCTTAC 660

QY 661 AATTTGAGAGAACTCATCTCTAAGCAAAATCTCTTCTGCAATGAGAAATTCACAAGCG 720

DB 661 AATTTGAGAGAACTCATCTCTAAGCAAAATCTCTTCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGAAATTTCTTGAAGTGGAGAAAGTGGCTTTTAAAGTCCCTCTCTCTTAAC 780

DB 721 CACAGAAATTTCTTGAAGTGGAGAAAGTGGCTTTTAAAGTCCCTCTCTCTTAAC 780

QY 781 TCTGGGTGATTTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTT 840

DB 781 TCTGGGTGATTTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTT 840

QY 841 TGTGCAACTGTTGCTTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900

DB 841 TGTGCAACTGTTGCTTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTG 960

DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTG 960

QY 961 GTTGTAGATCTAAACTGAAAGTATGAGAGAGAGGCGCTCTACCTACAAAGTGAAT 1020

DB 961 GTTGTAGATCTAAACTGAAAGTATGAGAGAGAGGCGCTCTACCTACAAAGTGAAT 1020

QY 1021 CTTGCTCACTTCGAAATTTTAAAGCAATTTTCTTTTAAAGCAAGTGTAAATGACATCTAA 1080

DB 1021 CTTGCTCACTTCGAAATTTTAAAGCAATTTTCTTTTAAAGCAAGTGTAAATGACATCTAA 1080

QY 1081 AATTCCTCACTTCGAGCTTTTAAATAGTTTCTTCAATGAGATAGGCTTTAAGAAATCA 1140

DB 1081 AATTCCTCACTTCGAGCTTTTAAATAGTTTCTTCAATGAGATAGGCTTTAAGAAATCA 1140

QY 1141 CTAATAAATGCAATAAAGTTACTCAATCTGTG 1174

1141 CTTAAATGCAATTAAGTACTCAATCTGTG 1174

## RESULT 56

ADA93366  
ID ADA93366 standard; cDNA; 1174 BP.

XX AC ADA93366;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.

XX US2003077721-A1.

XX PD 24-APR-2003.

XX XX 24-APR-2002; 2002US-00131837.

XX XX 09-DEC-1999; 99US-0170262P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX XX (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX DR WPI; 2003-755076/71.

XX DR P-PSDB; ADA93367.

XX PT New PRO nucleic acid, useful for recombinantly producing a PRO

XX PT polypeptide and for manufacturing a medicament for diagnosing or treating

XX PT tumor.

XX PS Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating  
proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems. PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGGGGGCCCGAAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGGGGGCCCGAAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTTCGGGGACCCGCTTCGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTTCGGGGACCCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTCTAGTTGACTATCCCC 240  
DB 181 TTTGACTCGGCTTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTCTAGTTGACTATCCCC 240  
QY 241 TTGCAACCTACCTTAAGGAAGAGGAGTTGTACCATGTGACAGAGTTTCAGGCTGTGT 300  
DB 241 TTGCAACCTACCTTAAGGAAGAGGAGTTGTACCATGTGACAGAGTTTCAGGCTGTGT 300  
QY 301 TCAATTTGTAGTTTGTGGATGATGGAATGACTTAAATCGAACTAATTTGGAATGTGA 360  
DB 301 TCAATTTGTAGTTTGTGGATGATGGAATGACTTAAATCGAACTAATTTGGAATGTGA 360  
QY 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420  
QY 421 CAGATCAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCCTGATGTCGCAAAA 480  
DB 421 CAGATCAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCCTGATGTCGCAAAA 480  
QY 481 ATGCACCTACTCTTTCTCTAACTCTCTGGTGAAGTCAATTCCTGAGTGAATGTGACTCC 540  
DB 481 ATGCACCTACTCTTTCTCTAACTCTCTGGTGAAGTCAATTCCTGAGTGAATGTGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGACCTTTTATCTTCAAGCCGATGACGAAAATA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCATGACCTTTTATCTTCAAGCCGATGACGAAAATA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAACCATTTGGAGAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAACCATTTGGAGAGGAGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAAATTCACAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAAATTCACAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780  
QY 781 TCTGGGTGATTTTAACTACAACTCTTGCTCTCTCGGTGATGTTTGGCTTGGATTTGT 840





PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
PA (GETH ) GENENTECH INC.  
XX Baker KP, Bresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-777249/73.  
DR P-PSDB; ADB26717.  
XX  
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or  
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
PT attack, various coagulation disorders, tumors.  
XX  
PS Claim 2; Fig 271; 660pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGTGGTGGACAGAG 60  
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGTGGTGGACAGAG 60  
QY 61 GGGACACAGATGGCGCGCGCGGAGGGAGCCTCTGGGTGAGGCCCACTGGGGCTCCCG 120  
Db 61 GGGACACAGATGGCGCGCGCGGAGGGAGCCTCTGGGTGAGGCCCACTGGGGCTCCCG 120

QY 121 CGCTGCTGCTGTGACCAATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CGCTGCTGCTGTGCTGACCAATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTCTGGGTGATACGGCGCTTCCGCCCGGGCTGTCACTGACCTACCCCC 240  
Db 181 TTTGACTCGGCTCTGGGTGATACGGCGCTTCCGCCCGGGCTGTCACTGACCTACCCCC 240  
QY 241 TTGCACACCTTACCCCTAAGGAAGAGAGTTGTATCGCATGTTCAGAGAGTTGCGAGGTGTT 300  
Db 241 TTGCACACCTTACCCCTAAGGAAGAGAGTTGTATCGCATGTTCAGAGAGTTGCGAGGTGTT 300  
QY 301 TCAATTTGTCAGTTTCTGGATGATGGAATGACTTAAATCGAATTAATTCGAATGTCAA 360  
Db 301 TCAATTTGTCAGTTTCTGGATGATGGAATGACTTAAATCGAATTAATTCGAATGTCAA 360  
QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCAATCTTGGTTGC 420  
Db 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCAATCTTGGTTGC 420  
QY 421 CAGATCAGCTGCCATTCGCTGACTGAGCAAGACACTTATGCTCCCTGATGCCAAA 480  
Db 421 CAGATCAGCTGCCATTCGCTGACTGAGCAAGACACTTATGCTCCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGGTCACTCTGGAGTGACATGATGGACTCC 540  
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGGTCACTCTGGAGTGACATGATGGACTCC 540  
QY 541 GCACAGAGCTTCAATACCTCTTCATGAGCTTTTATCTCAAGCCGATGACGGAAAAATA 600  
Db 541 GCACAGAGCTTCAATACCTCTTCATGAGCTTTTATCTTCACAGCCGATGACGGAAAAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAAAATCCAGTAGCGACACCATTTGGAGCAGAGGCTACA 660  
Db 601 GTTATATTCAGTCTAAGCCAGAAAAATCCAGTAGCGACACCATTTGGAGCAGAGGCTACA 660  
QY 661 AATTGAGAGAAATCACTCTAAGCAAAATGTCTATCTGCCAAATGAGAAATTCACAGCG 720  
Db 661 AATTGAGAGAAATCACTCTAAGCAAAATGTCTATCTGCCAAATGAGAAATTCACAGCG 720  
QY 721 CACAGGAAATTTCTTGAAGATGAGAAAGTAGTGGCTTTTAAAGATGCCCTCTCTTTAAC 780  
Db 721 CACAGGAAATTTCTTGAAGATGAGAAAGTAGTGGCTTTTAAAGATGCCCTCTCTTTAAC 780  
QY 781 TCTCGGTGGATTTTAACTACAACTCTTCTCGGTGATGGTATTTGGATTTGT 840  
Db 781 TCTCGGTGGATTTTAACTACAACTCTTCTCGGTGATGGTATTTGGATTTGT 840  
QY 841 TGTCAACTGTGCTACAGCTGTGGAGCAGTAGTTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTCAACTGTGCTACAGCTGTGGAGCAGTAGTTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960  
QY 961 GTTCTAGATCTTAAACTGAAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
Db 961 GTTCTAGATCTTAAACTGAAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATAGCATCTAA 1080  
Db 1021 CTTGCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATAGCATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGCCCTTAAAGTAATCA 1140  
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGCCCTTAAAGTAATCA 1140  
QY 1141 CTATAAAATGCAAAATAAGTTTACTTCAAAATCTGTG 1174  
Db 1141 CTATAAAATGCAAAATAAGTTTACTTCAAAATCTGTG 1174

## RESULT 58

ADB31003  
ID ADB31003 standard; cDNA; 1174 BP.  
XX  
XX AC ADB31003;  
XX  
XX DT 20-NOV-2003 (first entry)  
XX  
XX DE cDNA encoding human PRO polypeptide #136.  
XX  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
XX OS Homo sapiens.  
XX  
XX PN US2003096386-A1.  
XX  
XX PD 22-MAY-2003.  
XX  
XX PF 11-APR-2002; 2002US-00121042.  
XX  
XX PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 28-AUG-1998; 98WO-US014552.  
PR 10-SEP-1998; 98WO-US017888.  
PR 14-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028631.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUN-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-786990/74.  
DR P-PSDB; ADB31004.  
XX  
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or  
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
PT attack, various coagulation disorders, tumors.  
XX  
XX Claim 2; Fig 271; 638pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The

invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGTGGTGCACGAG	60
DB	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGTGGTGCACGAG	60
QY	61	GGGAAACAGATGGCGCGCGGAGGGGAGCCCTCGGTGGAGACCCCACTGGGCTCCCG	120
DB	61	GGGAAACAGATGGCGCGCGGAGGGGAGCCCTCGGTGGAGACCCCACTGGGCTCCCG	120
QY	121	CCGCTGCTGCTGTGACCATGGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGTGACCATGGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATAGCGGCTTTCGCCCGGCGCTGTCAGTTCACCTACCC	240
DB	181	TTTGACTCGGTCTTGGGTGATAGCGGCTTTCGCCCGGCGCTGTCAGTTCACCTACCC	240
QY	241	TTGCACACCTTACCCTAAGGAAGAGGAGTTGTACGATGTTCAGAGGTTGCAGGCTGTTT	300
DB	241	TTGCACACCTTACCCTAAGGAAGAGGAGTTGTACGATGTTCAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGTAATGTAATGTAATGTAATGTAATGTAATGTAATGTA	360
DB	301	TCAATTTGTCAGTTTGTGGATGTAATGTAATGTAATGTAATGTAATGTAATGTAATGTA	360
QY	361	TCTGCATGTACAGAACATATCCCAATCTGTATGAGCAATATGCTTGCCATCTTGTTGC	420
DB	361	TCTGCATGTACAGAACATATCCCAATCTGTATGAGCAATATGCTTGCCATCTTGTTGC	420
QY	421	CAGATCAGCTGCCATTCGCTGATGAGCAACAACTATGTCCTGATGCAAA	480
DB	421	CAGATCAGCTGCCATTCGCTGATGAGCAACAACTATGTCCTGATGCAAA	480
QY	481	ATGCACCTACTCTTCTCTTAACTCTGGTGAGTCAATCTGGAGTGCATGATGGACTCC	540
DB	481	ATGCACCTACTCTTCTCTTAACTCTGGTGAGTCAATCTGGAGTGCATGATGGACTCC	540

QY	541	GCACAGAGCTTCATAACCTCTTCATCGACTTTTATCTTCAAGCCGATCAGCGAAATA	600
DB	541	GCACAGAGCTTCATAACCTCTTCATCGACTTTTATCTTCAAGCCGATCAGCGAAATA	600
QY	601	GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGACCTACA	660
DB	601	GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGACCTACA	660
QY	661	AATTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGG	720
DB	661	AATTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGG	720
QY	721	CACAGGATTTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAC	780
DB	721	CACAGGATTTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAC	780
QY	781	TCTGGTGGATTTTAACTACACTCTTCTGCTCGGTGATGCTTTGGATTCT	840
DB	781	TCTGGTGGATTTTAACTACACTCTTCTGCTCGGTGATGCTTTGGATTCT	840
QY	841	TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
DB	841	TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
QY	901	GCTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGTCTTCTCTTG	960
DB	901	GCTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGTCTTCTCTTG	960
QY	961	GTTGTTAGATCTAAACTGAAGATCATGAAGACGAGGCTCTACCTACAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAACTGAAGATCATGAAGACGAGGCTCTACCTACAAAGTGAAT	1020
QY	1021	CTTGCTCACTTGAATAATTAAGCAATTTCTTTTAAAGCAAGTGTATAGCATCTAA	1080
DB	1021	CTTGCTCACTTGAATAATTAAGCAATTTCTTTTAAAGCAAGTGTATAGCATCTAA	1080
QY	1081	AAATCCACTCTCTATAGAGCTTTTAAATGCTTTTCTTGGATATAGCCCTTAAAGAAATCA	1140
DB	1081	AAATCCACTCTCTATAGAGCTTTTAAATGCTTTTCTTGGATATAGCCCTTAAAGAAATCA	1140
QY	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
DB	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174

RESULT 59

ADA60931

ID ADA60931 standard; cDNA; 1174 BP.

XX

AC ADA60931;

XX

DT 20-NOV-2003 (first entry)

XX

DE Homo sapiens.

XX

KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; FFA uptake modulator;

KW Cell proliferation stimulator; cell differentiation stimulator;

KW Cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX

OS Novel.

OS human.

OS secreted.

OS and.

OS transmembrane.

OS protein.

OS PRO195.

OS cDNA.

XX US2003049817-A1.  
 XX 13-MAR-2003.  
 XX 10-MAY-2002; 2002US-00142423.  
 XX 31-MAR-1997; 97WO-US005230.  
 XX 12-JUN-1998; 98WO-US012456.  
 XX 14-JUL-1998; 98WO-US014552.  
 XX 28-AUG-1998; 98WO-US017888.  
 XX 10-SEP-1998; 98WO-US018824.  
 XX 14-SEP-1998; 98WO-US019093.  
 XX 14-SEP-1998; 98WO-US019094.  
 XX 14-SEP-1998; 98WO-US019177.  
 XX 16-SEP-1998; 98WO-US019330.  
 XX 17-SEP-1998; 98WO-US019437.  
 XX 07-OCT-1998; 98WO-US021141.  
 XX 29-OCT-1998; 98WO-US022991.  
 XX 29-OCT-1998; 98WO-US022992.  
 XX 20-NOV-1998; 98WO-US024855.  
 XX 01-DEC-1998; 98WO-US025108.  
 XX 05-JAN-1999; 99WO-US000106.  
 XX 08-MAR-1999; 99WO-US005028.  
 XX 10-MAR-1999; 99WO-US005190.  
 XX 20-APR-1999; 99WO-US008615.  
 XX 14-MAY-1999; 99WO-US010733.  
 XX 02-JUN-1999; 99WO-US012252.  
 XX 01-SEP-1999; 99WO-US020111.  
 XX 08-SEP-1999; 99WO-US020594.  
 XX 13-SEP-1999; 99WO-US020944.  
 XX 15-SEP-1999; 99WO-US021090.  
 XX 15-SEP-1999; 99WO-US021547.  
 XX 05-OCT-1999; 99WO-US023089.  
 XX 29-NOV-1999; 99WO-US028214.  
 XX 30-NOV-1999; 99WO-US028313.  
 XX 30-NOV-1999; 99WO-US028409.  
 XX 01-DEC-1999; 99WO-US028301.  
 XX 01-DEC-1999; 99WO-US028634.  
 XX 02-DEC-1999; 99WO-US028651.  
 XX 02-DEC-1999; 99WO-US028654.  
 XX 02-DEC-1999; 99WO-US028655.  
 XX 16-DEC-1999; 99WO-US030095.  
 XX 20-DEC-1999; 99WO-US030911.  
 XX 20-DEC-1999; 99WO-US030999.  
 XX 22-DEC-1999; 99WO-US030720.  
 XX 30-DEC-1999; 99WO-US031243.  
 XX 30-DEC-1999; 99WO-US031274.  
 XX 05-JAN-2000; 2000WO-US000219.  
 XX 06-JAN-2000; 2000WO-US000277.  
 XX 06-JAN-2000; 2000WO-US000376.  
 XX 11-FEB-2000; 2000WO-US003565.  
 XX 18-FEB-2000; 2000WO-US004341.  
 XX 18-FEB-2000; 2000WO-US004342.  
 XX 22-FEB-2000; 2000WO-US004414.  
 XX 24-FEB-2000; 2000WO-US004914.  
 XX 24-FEB-2000; 2000WO-US005004.  
 XX 01-MAR-2000; 2000WO-US005601.  
 XX 02-MAR-2000; 2000WO-US005746.  
 XX 05-MAR-2000; 2000WO-US005841.  
 XX 15-MAR-2000; 2000WO-US006884.  
 XX 20-MAR-2000; 2000WO-US007377.  
 XX 21-MAR-2000; 2000WO-US007533.  
 XX 30-MAR-2000; 2000WO-US008439.  
 XX 17-MAY-2000; 2000WO-US013705.  
 XX 22-MAY-2000; 2000WO-US014042.  
 XX 30-MAY-2000; 2000WO-US014941.  
 XX 02-JUN-2000; 2000WO-US015264.  
 XX 28-JUL-2000; 2000WO-US020710.  
 XX 11-AUG-2000; 2000WO-US020731.  
 XX 23-AUG-2000; 2000WO-US023522.  
 XX 24-AUG-2000; 2000WO-US023328.  
 XX 08-NOV-2000; 2000WO-US030952.

XX 10-NOV-2000; 2000WO-US030873.  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX 20-DEC-2000; 2000US-00747259.  
 XX 20-DEC-2000; 2000WO-US034956.  
 XX 28-FEB-2001; 2001US-00796498.  
 XX 28-FEB-2001; 2001WO-US006520.  
 XX 01-MAR-2001; 2001WO-US006666.  
 XX 09-MAR-2001; 2001US-00802706.  
 XX 14-MAR-2001; 2001US-00808699.  
 XX 22-MAR-2001; 2001US-00816744.  
 XX 05-APR-2001; 2001US-00828366.  
 XX 10-MAY-2001; 2001US-00854208.  
 XX 18-MAY-2001; 2001US-00854280.  
 XX 25-MAY-2001; 2001US-00860216.  
 XX 25-MAY-2001; 2001US-00866028.  
 XX 25-MAY-2001; 2001US-00866034.  
 XX 01-JUN-2001; 2001WO-US017092.  
 XX 01-JUN-2001; 2001US-00872035.  
 XX 01-JUN-2001; 2001WO-US017800.  
 XX 05-JUN-2001; 2001US-00874503.  
 XX 14-JUN-2001; 2001US-00882636.  
 XX 19-JUN-2001; 2001US-00886342.  
 XX 20-JUN-2001; 2001WO-US019692.  
 XX 21-JUN-2001; 2001US-00887879.  
 XX 22-JUN-2001; 2001WO-US020116.  
 XX 29-JUN-2001; 2001WO-US021066.  
 XX 09-JUL-2001; 2001WO-US021735.  
 XX 18-JUL-2001; 2001US-00908827.  
 XX 06-AUG-2001; 2001US-00924419.  
 XX 09-AUG-2001; 2001US-00927796.  
 XX 16-AUG-2001; 2001US-00931836.  
 XX 19-DEC-2001; 2001US-00028072.  
 XX 10-MAR-2009; 2000WO-US006319.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Deanoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI; 2003-695893/66.  
 P-PSDB; ADA60932.

New secreted and transmembrane PRO polypeptide and nucleic acid, useful for manufacturing a medicament for diagnosing or treating tumor.

Claim 2; Fig 271; 658pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for inhibiting the binding of the release of a cytokine from PMC cells, for inhibiting the binding of alpha-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (i) and (ii) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCTGGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
QY 61 GGGAAACAGATGGCGGCGCCGAAAGGGGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGCGGCGCCGAAAGGGGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGACCATGCGCTTCGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGACCATGCGCTTCGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTGTAGTCGGTCTTGGGTGATACGGGCTTCGACCGGGCTGTGAGTTGACCTACCCC 240  
DB 181 TTGTAGTCGGTCTTGGGTGATACGGGCTTCGACCGGGCTGTGAGTTGACCTACCCC 240  
QY 241 TTGCACACTACCTTAAGGAAGAGGAGTTGATCGCATGTGAGAGGTTGACGAGCTGTTT 300  
DB 241 TTGCACACTACCTTAAGGAAGAGGAGTTGATCGCATGTGAGAGGTTGACGAGCTGTTT 300  
QY 301 TCAATTTGTCAGTTTGGTGGATGATGGAATGACATTAATCGAATTAATTTGGATGTGAA 360  
DB 301 TCAATTTGTCAGTTTGGTGGATGATGGAATGACATTAATCGAATTAATTTGGATGTGAA 360  
QY 361 TCTGATGTCAGAGAGCATATTCACAACTGATGAGCAATATGCTGCGCATCTTTGTTGC 420  
DB 361 TCTGATGTCAGAGAGCATATTCACAACTGATGAGCAATATGCTGCGCATCTTTGTTGC 420  
QY 421 CAGAATCAGCTCCATTCGCTGAACTGAGCAAGAAACAATTTATGTCCTGATGCGCAAAA 480  
DB 421 CAGAATCAGCTCCATTCGCTGAACTGAGCAAGAAACAATTTATGTCCTGATGCGCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTACTCTGCTGAGGTCATTCGAGTGACATGATGAGCTCC 540  
DB 481 ATGCACCTACTCTTCTCTACTCTGCTGAGGTCATTCGAGTGACATGATGAGCTCC 540  
QY 541 GCACAGAGCTTCATACCTCTTTTCAGGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCATACCTCTTTTCAGGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAACATTTGGAGCAGGACCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAACATTTGGAGCAGGACCTTACA 660  
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGAAATTTCTGAGATGAGAAAGTATGCTTTTAAAGTATGCTCTCTCTTAAAC 780  
DB 721 CACAGAAATTTCTGAGATGAGAAAGTATGCTTTTAAAGTATGCTCTCTCTTAAAC 780  
QY 781 TCTGGGTGGATTTTAACTACAACTCTTGTCCCTCGGTGATGATGTTGTTGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTACAACTCTTGTCCCTCGGTGATGATGTTGTTGATTTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGATATGTTCCCTCTGAGAACTGATATCAT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGATATGTTCCCTCTGAGAACTGATATCAT 900  
QY 901 GGTGACTTGAGTTTATGATGAAACAAAAGCTTAAACAGATATCCAGCTTCTCTCTG 960  
DB 901 GGTGACTTGAGTTTATGATGAAACAAAAGCTTAAACAGATATCCAGCTTCTCTCTG 960

QY 961 GTTGTAGATCTAAACTGAAGATCATGAAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACACTCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCACACTCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTTACTCAAACTCTGTG 1174  
DB 1141 CTATAAATGCAATTAAGTTACTCAAACTCTGTG 1174  
RESULT 60  
ADB24078  
ID ADB24078 standard; cDNA; 1174 BP.  
XX  
AC ADB24078;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polynucleotide SEQ ID NO 271.  
XX  
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; PFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US200307714-A1.  
XX  
PD 24-APR-2003.  
XX  
PF 22-APR-2002; 2003US-00127901.  
XX  
PR 17-JUN-1998; 98US-0089599P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-755069/71.  
DR P-PSDB; ADB24079.  
XX  
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
PT tumors.  
XX  
PS Claim 2; Fig 271; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC

CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.08; Score 1174; DB 8; Length 1174;  
 Best Local Similarity 100.08; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
 DB 1 CGGACGCTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60

QY 51 GGGACACAGATGGCGCGCCGAGGGAGCCTCGGCTGAGGACCCCACTGGGGCTCCCG 120  
 DB 61 GGGACACAGATGGCGCGCCGAGGGAGCCTCGGCTGAGGACCCCACTGGGGCTCCCG 120

QY 121 CGGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
 DB 121 CGGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTGTAGCTGGCTTGGGTGATACGGCGTCTTGCACCGGGCGTGTGAGTTGACCTACCCC 240  
 DB 181 TTGTAGCTGGCTTGGGTGATACGGCGTCTTGCACCGGGCGTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCTTAAGAGAGAGAGTTGACGATGTTCAGAGAGGTTTCAGGCTGTTT 300  
 DB 241 TTGCACACCTACCTTAAGAGAGAGAGTTGACGATGTTCAGAGAGGTTTCAGGCTGTTT 300

QY 301 TCAATTGTGCTGTTGTGATGATGGAATGACCTTAATCGAATTAATTTGGAATGTGAA 360  
 DB 301 TCAATTGTGCTGTTGTGATGATGGAATGACCTTAATCGAATTAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAGACATATTCACAACTGATGAGCAATATGCTCCCATCTTGGTTGC 420  
 DB 361 TCTGCATGTACAGAGACATATTCACAACTGATGAGCAATATGCTCCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480  
 DB 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTTCTTAACTCTGCTGAGTCACTTCTGAGTGACATGAGTCTCC 540  
 DB 481 ATGCACCTACTCTTTTCTTAACTCTGCTGAGTCACTTCTGAGTGACATGAGTCTCC 540

QY 541 GCACAGAGCTTCATAAACCTCTTCATGAGACTTTTATCTTCAAGCCGATGACCGGAAATA 600  
 DB 541 GCACAGAGCTTCATAAACCTCTTCATGAGACTTTTATCTTCAAGCCGATGACCGGAAATA 600

QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGTACGCCACCACTTTGGAGCAGGAGCTACA 660  
 DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGTACGCCACCACTTTGGAGCAGGAGCTACA 660

QY 661 AATTGAGAGATCATCTCTPAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGGG 720  
 DB 661 AATTGAGAGATCATCTCTPAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGGG 720

QY 721 CACAGGAATTTTCTGAAGATGAGAAAGTGTGGTCTTTTAAAGATGCCCTCTCTCTTAAC 780  
 DB 721 CACAGGAATTTTCTGAAGATGAGAAAGTGTGGTCTTTTAAAGATGCCCTCTCTCTTAAC 780

QY 781 TCTGGGTGGAATTTTAACTACAACTCTTGCTCTCGGTGATGGTATTTGGATTTGT 840  
 DB 781 TCTGGGTGGAATTTTAACTACAACTCTTGCTCTCGGTGATGGTATTTGGATTTGT 840

QY 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900  
 DB 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900

QY 901 GGTGCACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960  
 DB 901 GGTGCACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960

QY 961 GTTCTTAGATCTAAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
 DB 961 GTTCTTAGATCTAAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020

QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080  
 DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080

QY 1081 AATTCCACTCTCTATAGAGCTTTTAAAGTGTTCATTGATATAGCCTTAAAGAAATCA 1140  
 DB 1081 AATTCCACTCTCTATAGAGCTTTTAAAGTGTTCATTGATATAGCCTTAAAGAAATCA 1140

QY 1141 CTATAAATGCAATAAAGTTACTCAAACTCTG 1174  
 DB 1141 CTATAAATGCAATAAAGTTACTCAAACTCTG 1174

RESULT 61  
 ADA96407  
 ID ADA96407 standard; cDNA; 1174 BP.  
 XX ADA96407;  
 AC ADA96407;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polynucleotide #136.  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
 KW immune system cell infiltration.  
 XX Homo sapiens.  
 OS  
 XX  
 PN US2003082690-A1.  
 XX  
 PD 01-MAY-2003.  
 XX

PF 22-APR-2002; 2002US-00127837.  
XX 01-SEP-1998; 98US-0098750P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755107/71.  
DR P-PSDB; ADA96408.  
XX  
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,  
PT tumor or for tissue typing.  
XX  
PS Claim 2; Fig 271; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
SQ

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTACAGAG 60  
DB 1 CGGACCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGCTGACCAATGCGCTTGGCGGAGGCTTGGCGGACCGCTTGGCTGAAGCA 180

RESULT 62



ADA80979  
ID ADA80979 standard; cDNA; 1174 BP.  
XX  
AC ADA80979;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.

XX Homo sapiens.

OS US2003082702-A1.

XX 01-MAY-2003.

XX 23-APR-2002; 2002US-00128690.

XX 02-MAR-2000; 2000WO-US005841.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755111/71.

DR P-PSDB; ADA80980.

PT New PRO nucleic acid, useful for preparing a composition for treating

XX e.g., tumor or for tissue typing.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAAACGACAAAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAAACGACAAAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGGCGGCGGAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGGTCCCG 120  
DB 61 GGGAAACAAGATGGCGGCGGCGGAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGGTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
DB 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
QY 181 TTGACTCGGCTTTGGGTGATACGGGCTTTCCACCGGGCCCTGTCACTGACCTACCC 240  
DB 181 TTGACTCGGCTTTGGGTGATACGGGCTTTCCACCGGGCCCTGTCACTGACCTACCC 240  
QY 241 TTGCACACCTTACCTTAAGGAGGAGGTTGACGATGTGACGAGGTTGACGAGGTTGTT 300  
DB 241 TTGCACACCTTACCTTAAGGAGGAGGTTGACGATGTGACGAGGTTGACGAGGTTGTT 300  
QY 301 TCAATTTGTCAGTTTCTGGATGATGGAATGAACTTAAATCGAACTAAATGGAATGTGAA 360  
DB 301 TCAATTTGTCAGTTTCTGGATGATGGAATGAACTTAAATCGAACTAAATGGAATGTGAA 360  
QY 361 TCTGATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTGCATCTTGGTTGC 420  
DB 361 TCTGATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTGCATCTTGGTTGC 420  
QY 421 CAGAACTCAGCTGCGCATTCGCTGAATGAGACAAAGAACTTATGTCCTGATGCAAAA 480  
DB 421 CAGAACTCAGCTGCGCATTCGCTGAATGAGACAAAGAACTTATGTCCTGATGCAAAA 480  
QY 481 ATGCACCTACTTTTCTTAACTCTGGTGAAGTCAATCTGAGTGACATGATGAGCTCC 540  
DB 481 ATGCACCTACTTTTCTTAACTCTGGTGAAGTCAATCTGAGTGACATGATGAGCTCC 540  
QY 541 GCACAGAGCTTCATAACCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
DB 541 GCACAGAGCTTCATAACCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCACTTTGGAGCAGGACTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCACTTTGGAGCAGGACTACA 660  
QY 661 AATTGAGAGATCACTCTTAACCAAAATGTCATCTGCAATGAGAAATTCACAGCG 720  
DB 661 AATTGAGAGATCACTCTTAACCAAAATGTCATCTGCAATGAGAAATTCACAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACATACTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
DB 781 TCTGGTGGATTTTAACATACTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900



QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTG 960  
DB 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTG 960  
QY 961 GTTGTAGATCTAAACCTGAAGTATGATGAAGACAGCGGCTCTACTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACCTGAAGTATGATGAAGACAGCGGCTCTACTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTCTGAATTTAAAGCACTTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTCTGAATTTAAAGCACTTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATGATATAGCGCTTAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATGATATAGCGCTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAATATAAGTTACTCAATCTGTG 1174  
DB 1141 CTATAAATGCAATATAAGTTACTCAATCTGTG 1174  
RESULT 63  
ADA95855  
ID ADA95855 standard, cDNA; 1174 BP.  
XX  
AC ADA95855;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polynucleotide #136.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; hemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003082759-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 11-APR-2002; 2002US-00121040.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 20-APR-1999; 98WO-US008615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US021547.  
PR 29-NOV-1999; 99WO-US023089.  
PR 30-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 22-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007177.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-0074259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 23-JUN-2001; 2001WO-US021666.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755114/71.  
DR P-PSDB; ADA95856.

PT New isolated PRO polypeptides, useful for treating diabetes, hyper- or  
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
PT attack, various coagulation disorders and tumors.

XX Claim 2; Fig 271; 638pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems.  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGAGCGTGGGGGAAACCTTCCGAGAAACAGCAACAGCTGAGTGTGTGACAGAG 60  
DB 1 CGGAGCGTGGGGGAAACCTTCCGAGAAACAGCAACAGCTGAGTGTGTGACAGAG 60  
QY 61 GGGAAACAGATCGCGCGCCGAGGGGAGCTTGGGTGAGGACCCAACTGGGCTCCCG 120  
DB 61 GGGAAACAGATCGCGCGCCGAGGGGAGCTTGGGTGAGGACCCAACTGGGCTCCCG 120  
QY 121 CGGCTCTCTGCTGACCATGATCGCGGAGCTTGGCGGAGCGCTTGGCTGGAAGCA 180  
DB 121 CGGCTCTCTGCTGACCATGATCGCGGAGCTTGGCGGAGCGCTTGGCTGGAAGCA 180  
QY 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGGCTGTGACCTACCCC 240

DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCTGTGAGTTGACCTTACCCC 240  
QY 241 TTGCACACCTTACCTTAAGGAAGAGAGTGTGTGCGATGTGCAGAGGTTTGACGGCTGTTT 300  
DB 241 TTGCACACCTTACCTTAAGGAAGAGAGTGTGTGCGATGTGCAGAGGTTTGACGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAA 360  
DB 301 TCAATTTGTGAGTTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAA 360  
QY 361 TCTGATGTACAGAACATATCCCAATCTGTGATGAGCAATATGCTTGCCTATCTTGGTTCG 420  
DB 361 TCTGATGTACAGAACATATCCCAATCTGTGATGAGCAATATGCTTGCCTATCTTGGTTCG 420  
QY 421 CAGAAATCAGCTGCGATTCGCTGAACTGAGCAAGAAACAACCTTATGTCTCCGTGATGCNAAA 480  
DB 421 CAGAAATCAGCTGCGATTCGCTGAACTGAGCAAGAAACAACCTTATGTCTCCGTGATGCNAAA 480  
QY 481 ATGCACCTACTCTTCTCTCTAACTCTGTGTGAGTCACTTCTGGAGTGACATGATGACTCC 540  
DB 481 ATGCACCTACTCTTCTCTCTAACTCTGTGTGAGTCACTTCTGGAGTGACATGATGACTCC 540  
QY 541 GCACAGAGCTTCTATAACCTCTTCAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 541 GCACAGAGCTTCTATAACCTCTTCAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGAGCCCTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGAGCCCTACA 660  
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGTGGAGAGTGGTCTTTTAAAGTGCCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGTGGAGAGTGGTCTTTTAAAGTGCCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACTACAACCTTTGTCTCTCGGTGATGATGCTTTGCTTTGATTTGT 840  
DB 781 TCTGGTGGATTTTAACTACAACCTTTGTCTCTCGGTGATGATGCTTTGCTTTGATTTGT 840  
QY 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
QY 961 GTTGTAGATCTAAATCTGAAGTATGAAGAGAGAGCGGCTCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAATCTGAAGTATGAAGAGAGAGCGGCTCTTACCTACAAAGTGAAT 1020  
QY 1021 CTGTCTCTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
DB 1021 CTGTCTCTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCTATAGAGCTTTTAAATGTTTCTTGTGATATGAGCCCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCTATAGAGCTTTTAAATGTTTCTTGTGATATGAGCCCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAATGCAATTAAGTTTACTCAAAATCTGTG 1174

RESULT 64  
ADB26164  
ID ADB26164 standard; cDNA; 1174 BP.  
XX AC ADB26164;

XX DT 20-NOV-2003 (first entry)  
 XX DE CDNA encoding human PRO polypeptide #136.  
 XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX OS Homo sapiens.  
 XX PN US2003082760-A1.  
 XX PD 01-MAY-2003.  
 XX PF 12-APR-2002; 2002US-00121056.  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 14-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010733.  
 PR 02-JUN-1999; 98WO-US012252.  
 PR 01-SEP-1999; 98WO-US020111.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 23-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.  
 PR 30-DEC-1999; 98WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US000365.  
 PR 18-FEB-2000; 2000WO-US000341.  
 PR 18-FEB-2000; 2000WO-US000432.  
 PR 22-FEB-2000; 2000WO-US000414.  
 PR 24-FEB-2000; 2000WO-US000491.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 22-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001WO-US066034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-777204/73.  
 DR F-PSDB; ADH26165.  
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 PT in gene therapy, detecting the presence of tumor in a mammal, or  
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle  
 PT cells or adipocyte cells.  
 XX Claim 2; Fig 271; 659pp; English.  
 PS The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The CC polynucleotides are useful in molecular biology, including uses as CC hybridisation probes, in chromosome and gene mapping, in generating CC antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in CC generating either transgenic animals or knock-out animals which are CC useful in the development and screening of therapeutically useful CC reagents. The PRO polypeptides or antibodies are used in preparing a CC medicament for treating a condition responsive to the polypeptides or CC antibodies, such as tumours, for stimulating and inhibiting proliferation CC of human microvascular endothelial cells, for modulating the uptake of CC glucose or FFA by skeletal muscle cells or adipocyte cells, for CC stimulating differentiation of adipocyte cells, for stimulating CC proliferation of or gene expression in pericyte cells, for stimulating CC the proliferation of inner ear utricular supporting cells or T-lymphocyte CC cells, for inducing endothelial cell tube formation and for treating CC various bone and/or cartilage disorders such as sports injuries and CC arthritis. PRO polypeptides which stimulate the release of proteoglycans CC from cartilage are useful for treating sports-related joint problems, CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO CC polypeptides are also useful for treating various mammalian haemoglobin- CC associated disorders such as various thalassaemias and conditions which CC may benefit from enhanced local immune system cell infiltration. This CC sequence encodes a human PRO polypeptide of the invention. Note: The CC sequence data for this patent is also available in electronic format from CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGAAAACCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACGAG 60  
DB 1 CGGACGCTGGGGAAAACCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACGAG 60

QY 61 GGGACACAGATGGCGCGCCGAGGGAGCTCTGGGTGAGGACCCAACTCGGGGCTCCCG 120  
DB 61 GGGACACAGATGGCGCGCCGAGGGAGCTCTGGGTGAGGACCCAACTCGGGGCTCCCG 120

QY 121 CGCGTGTGCTGCTGACCATGAGCTTCGCGGAGGTTGCGGGACCGCTTCGGCTGAGCA 180  
DB 121 CGCGTGTGCTGCTGACCATGAGCTTCGCGGAGGTTGCGGGACCGCTTCGGCTGAGCA 180

QY 181 TTGTGACTGGTCTGGGTGATACGGCTTCGCGGAGGTTGCGGGACCGCTTCGGCTGAGCA 240  
DB 181 TTGTGACTGGTCTGGGTGATACGGCTTCGCGGAGGTTGCGGGACCGCTTCGGCTGAGCA 240

QY 241 TTGCACACTACCTAAGAGAGAGAGTTGTACGATGTACAGAGGTTGCGGCTGTTT 300  
DB 241 TTGCACACTACCTAAGAGAGAGAGTTGTACGATGTACAGAGGTTGCGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGTGATGATGGAATTCGACTTAATCGAATTAATGGAATGGA 360  
DB 301 TCAATTTGTCAGTTTGTGATGATGGAATTCGACTTAATCGAATTAATGGAATGGA 360

QY 361 TGTGATGTACAGAGACATATTCCTCAATCTGATGAGCAATATGCTTGGCTTGTGTC 420  
DB 361 TGTGATGTACAGAGACATATTCCTCAATCTGATGAGCAATATGCTTGGCTTGTGTC 420

QY 421 CAGAAATCAGCTGCGATTCGCTGAACTGAGACAGAACTATGCTCCCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTGCGATTCGCTGAACTGAGACAGAACTATGCTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTCTCTTAATCTGCTGAGGTCAATCTGAGGTGACATGATGACTCC 540  
DB 481 ATGCACCTACTCTTCTCTTAATCTGCTGAGGTCAATCTGAGGTGACATGATGACTCC 540

QY 541 GCACAGAGCTTCATACCTCTTTCATGAGCTTTTATCTTCAAGCGGATGACGGAAAATA 600  
DB 541 GCACAGAGCTTCATACCTCTTTCATGAGCTTTTATCTTCAAGCGGATGACGGAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGAGCCTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGAGCCTACA 660

QY 661 AATTGGAGAAATCACTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGGAGAAATCACTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCCTCTCTTAAC 780  
DB 721 CACAGGAAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCCTCTCTTAAC 780

QY 781 TCTGGTGGATTTTAACTACACTCTTCTGCTCCCTCGTATGCTATGCTTTGGATTCT 840  
DB 781 TCTGGTGGATTTTAACTACACTCTTCTGCTCCCTCGTATGCTATGCTTTGGATTCT 840

QY 841 TGTCAAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
DB 841 TGTCAAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

QY 901 GGTGACTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGG 960  
DB 901 GGTGACTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGG 960

QY 961 GTTCTTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTTACTCTACAAAGTGAAT 1020  
DB 961 GTTCTTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTTACTCTACAAAGTGAAT 1020

QY 1021 CTTGCTCATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGCTGATTAATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGCTGATTAATAGACATCTAA 1080

QY 1081 AATTCCACTCTCTACAGCTTTTAAATGCTTTTCAATGGATATAGCCCTTAAAGAAATCA 1140  
DB 1081 AATTCCACTCTCTACAGCTTTTAAATGCTTTTCAATGGATATAGCCCTTAAAGAAATCA 1140

QY 1141 CTATAAAATGCAAAATTAAGTTACTCAAACTGTG 1174  
DB 1141 CTATAAAATGCAAAATTAAGTTACTCAAACTGTG 1174

RESULT 65  
ADB21649  
ID ADB21649 standard; cDNA; 1174 BP.  
XX  
AC ADB21649;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
OS Homo sapiens.  
XX  
XX US2003082765-A1.  
PN  
XX  
PD 01-MAY-2003.  
XX  
XX 17-MAY-2002; 2002US-00147492.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR

PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019130.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005150.  
PR 20-APR-1999; 98WO-US008615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 05-OCT-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 01-DEC-1999; 98WO-US028301.  
PR 01-DEC-1999; 98WO-US028634.  
PR 02-DEC-1999; 98WO-US028551.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 22-DEC-1999; 98WO-US030720.  
PR 30-DEC-1999; 98WO-US031243.  
PR 30-DEC-1999; 98WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US0003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US0050914.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005716.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 28-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US0747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.

05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001US-00866034.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00883636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00933836.  
19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.  
Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI; 2003-786920/74.  
P-PSDB; ADB21650.

New secreted and transmembrane PRO polypeptide useful for detecting the presence of tumor in a mammal, or modulating the uptake of glucose or free fatty acid by skeletal muscle cells or adipocyte cells.

Claim 2; Fig 271; 638pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from BMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (i) and (ii) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
Db 1 CGGACGCTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGGCGCGGAGAGCCCTCTGGGTGAGAACCCAACTGGGCTCCCG 120  
Db 61 GGGAAACAAGATGGCGGCGCGGAGAGCCCTCTGGGTGAGAACCCAACTGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGCTGACCACTAGCGCTTGGCGGAGGCTTCGGGACCGCTTCGGCTGGAAGCA 180  
Db 121 CGGCTGCTGCTGCTGACCACTAGCGCTTGGCGGAGGCTTCGGGACCGCTTCGGCTGGAAGCA 180  
QY 181 TTGACTCGGCTGGGTGATACGGCTCTTGGCCACCGGCTCTGTCAAGTGAACCTACCCC 240  
Db 181 TTGACTCGGCTGGGTGATACGGCTCTTGGCCACCGGCTCTGTCAAGTGAACCTACCCC 240  
QY 241 TTGCACACCTACCTTAAGGAAGAGAGTTGACGATGTCAGAGGTTGAGAGGTTGAGGCTGTTT 300  
Db 241 TTGCACACCTACCTTAAGGAAGAGAGTTGACGATGTCAGAGGTTGAGAGGTTGAGGCTGTTT 300  
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360  
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360  
QY 361 TCTGATGTCAGAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
Db 361 TCTGATGTCAGAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
QY 421 CAGAACTAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAAA 480  
Db 421 CAGAACTAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAAA 480  
QY 481 ATGCACTACTCTTCTCTTAACTCTGCTGAGGTCATCTCGAGTGACATGATGAGCTCC 540  
Db 481 ATGCACTACTCTTCTCTTAACTCTGCTGAGGTCATCTCGAGTGACATGATGAGCTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
Db 541 GCACAGAGCTTCATAACCTCTTATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCAGTACGACCAACATTTGGAGCGAGGCTTACA 660  
Db 601 GTTATATTCAGTCTAAGCCAGAAATCAGTACGACCAACATTTGGAGCGAGGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAGCG 720  
Db 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAGCG 720  
QY 721 CACAGAAATTTCTTGAAGATGGAAGAAAGTATGGCTTTTAAAGATCCCTCTCTTAAAC 780  
Db 721 CACAGAAATTTCTTGAAGATGGAAGAAAGTATGGCTTTTAAAGATCCCTCTCTTAAAC 780  
QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 840  
Db 781 TCTGGTGGATTTTAACTACAACTCTTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 840  
QY 841 TGTGCAACTGTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GTGACTTGGAGTTTATGAATGAACAAAGCTAAGCAATATCCAGTCTTCTCTGCTGCTG 960  
Db 901 GTGACTTGGAGTTTATGAATGAACAAAGCTAAGCAATATCCAGTCTTCTCTGCTGCTG 960  
QY 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGAGCGGCTCTACCTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGAGCGGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAGCAATTTTCTTTTAAAGCAAGTGTATAGCATCTTAA 1080  
Db 1021 CTTGCTCATCTGAAATTTAGCAATTTTCTTTTAAAGCAAGTGTATAGCATCTTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCTTATGGATATAGGCTTTAAGAAATCA 1140

Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCTTATGGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAATAAAGTTTACTCAAATCTGTG 1174  
Db 1141 CTATAAATGCAATAAAGTTTACTCAAATCTGTG 1174  
RESULT 66  
ACD29300  
ID ACD29300 standard; cDNA; 1174 BP.  
XX  
AC ACD29300;  
DT 27-AUG-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane polypeptide cDNA #83.  
XX Human; secreted and transmembrane protein; PRO; viral infection;  
KW tumour growth; retinal disorder; injury; sight loss;  
KW retinitis pigmentosum; age-related macular degeneration;  
KW sport-related joint problem; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; wound healing; obesity; diabetes; insulinemia;  
KW kidney disorder; mesangial cell function; Berger disease; nephropathy;  
KW celiac disease; dermatitis; Crohn disease; neuropathy;  
KW diabetic peripheral neuropathy; peripheral neuropathy;  
KW reduced motility of the gastrointestinal tract;  
KW atony of the urinary bladder; post polio syndrome; Krabbe's disease;  
KW Charcot-Marie-Tooth disease; Fabry's disease; Tangier disease;  
KW Refsum's disease; gene; ss.  
XX Homo sapiens.  
OS  
PN US2003049633-A1.  
XX  
PD 13-MAR-2003.  
XX  
PF 16-OCT-2001; 2001US-00978585.  
XX  
PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0065364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 17-MAR-1998; 98US-0080402P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081617P.  
PR 15-APR-1998; 98US-0081819P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0083569P.  
PR 22-APR-1998; 98US-0083569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 27-APR-1998; 98US-0082796P.  
PR 28-APR-1998; 98US-0083336P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083392P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 29-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 13-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0085704P.  
PR 22-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 28-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 26-JUN-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98US-0018897P.  
PR 07-OCT-1998; 98US-00211141.  
PR 02-NOV-1998; 98US-00184216.  
PR 06-NOV-1998; 98US-00187368.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98US-0024855.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-01113296P.

PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 05-MAR-1999; 99WO-US0054465.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005686.  
PR 10-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 99US-00267213.  
PR 12-MAR-1999; 99US-0123957P.  
PR 29-MAR-1999; 99US-0126773P.  
PR 12-APR-1999; 99US-0084431.  
PR 12-APR-1999; 99US-0130232P.  
PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99US-0134287P.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 16-JUN-1999; 99US-0139557P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0142680P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146232P.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380142.  
PR 25-AUG-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 16-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US006319.  
PR 30-MAR-2000; 2000WO-US007532.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000US-00709238.  
PR 27-NOV-2000; 2000US-00723749.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 22-MAR-2001; 2001US-00816920.  
PR 10-MAY-2001; 2001WO-US009552.  
PR 10-MAY-2001; 2001US-00854208.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGGCTGGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGAGCTGTCGTGACAGAG 60

Db 1 CGGACGGCTGGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGAGCTGTCGTGACAGAG 60

QY 61 GGAACAAAGATGGGGCGCCGAGCGAGCTCTGGGTGAGGACCCAACTCGGGCTCCCG 120  
Db 61 GGAACAAAGATGGGGCGCCGAGCGAGCTCTGGGTGAGGACCCAACTCGGGCTCCCG 120  
QY 121 CGCTGCTGCTGTGACCAATGCGCTTGGCGGAGAGTTTCGGGACCGCTTCGGTGAAGCA 180  
Db 121 CGCTGCTGCTGTGACCAATGCGCTTGGCGGAGAGTTTCGGGACCGCTTCGGTGAAGCA 180  
QY 181 TTGTACTCGGCTTGGGTGATACCGGCTTCTGGCCACCGGCGCTGTGAGTTGACCTACCCC 240  
Db 181 TTGTACTCGGCTTGGGTGATACCGGCTTCTGGCCACCGGCGCTGTGAGTTGACCTACCCC 240  
QY 241 TTGCACACCTACCTAAGGAAGAGAGTTGACCATGTGACAGAGGTTGACAGGCTGTTT 300  
Db 241 TTGCACACCTACCTAAGGAAGAGAGTTGACCATGTGACAGAGGTTGACAGGCTGTTT 300  
QY 301 TCAATTTCTCAGTTTGGATGAGGAATGACTTAAATCGAATTAATTTGAATGTGA 360  
Db 301 TCAATTTCTCAGTTTGGATGAGGAATGACTTAAATCGAATTAATTTGAATGTGA 360  
QY 361 TCTGATGTACAGAGCATATTTCCAAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
Db 361 TCTGATGTACAGAGCATATTTCCAAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
QY 421 CAGATGAGTGCATTCGCTGATGAGCAAGAACAACTTATGCTCCCTGATGCCAAA 480  
Db 421 CAGATGAGTGCATTCGCTGATGAGCAAGAACAACTTATGCTCCCTGATGCCAAA 480  
QY 481 ATGCACCTTACTCTTCTCTAATCTCTGGTGAGGTGATCTGGAGTGACATGAGTCTCC 540  
Db 481 ATGCACCTTACTCTTCTCTAATCTCTGGTGAGGTGATCTGGAGTGACATGAGTCTCC 540  
QY 541 GCACAGAGCTTCAAACTCTTCTGATGAGTCTTCTTCAAGCGGATGACGGAATAA 600  
Db 541 GCACAGAGCTTCAAACTCTTCTGATGAGTCTTCTTCAAGCGGATGACGGAATAA 600  
QY 601 GTTATTTCCAGTCTTAAGCAGAAATCAGTACGACCAACATTTGGAGCAGGAGCTTCA 660  
Db 601 GTTATTTCCAGTCTTAAGCAGAAATCAGTACGACCAACATTTGGAGCAGGAGCTTCA 660  
QY 661 AATTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
Db 661 AATTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGATTTCTTGAAGATGGAAGATGAGTCTTCTTCAAGCGGATGACGCTCTCTTAC 780  
Db 721 CACAGGATTTCTTGAAGATGGAAGATGAGTCTTCTTCAAGCGGATGACGCTCTCTTAC 780  
QY 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATTTGGATTTGT 840  
Db 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATTTGGATTTGT 840  
QY 841 TGTGCACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
Db 841 TGTGCACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAAGATATCCAGTCTTCTCTTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAAGATATCCAGTCTTCTCTTGTG 960  
QY 961 GTTGTAGATCTAAATCTGAAGATCATGAAGAGCAGGCTCTACTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAATCTGAAGATCATGAAGAGCAGGCTCTACTACAAAGTGAAT 1020  
QY 1021 CTGTCTATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db 1021 CTGTCTATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCTAGAGCTTTTAAATGGTTTCATTTGATATAGCCCTTAAAGATCA 1140  
Db 1081 AATTCACCTCTCTAGAGCTTTTAAATGGTTTCATTTGATATAGCCCTTAAAGATCA 1140  
QY 1141 CTATAAATGCAAAATTAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAATGCAAAATTAAGTTACTCAAAATCTGTG 1174

## RESULT 67

ADA77428

ID ADA77428 standard; cDNA; 1174 BP.

XX ADA77428;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
immune system cell infiltration.

XX Homo sapiens.

OS US2003068797-A1.

XX 10-APR-2003.

XX 07-MAY-2002; 2002US-00140921.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 08-SEP-1999; 99WO-US020111.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US021547.

PR 29-NOV-1999; 99WO-US023089.

PR 30-NOV-1999; 99WO-US028214.

PR 01-DEC-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 02-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030095.

PR 22-DEC-1999; 99WO-US030911.

PR 22-DEC-1999; 99WO-US030999.

PR 30-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.



PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 13-MAR-2000; 2000WO-US006684.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US033678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 01-MAR-2001; 2001WO-US006520.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

PR Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-625489/59.

DR P-PSDB; ADA77429.  
 XX

XX Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801  
 PT and PRO1114, useful in the preparation of a medicament for treating a  
 PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.  
 PT vaccines.

XX  
PS  
XX

Claim 2; Fig 271; 659pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC the proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
 DB 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
 QY 61 GGGAAACAAGATGGCGCGCCCGAAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
 DB 61 GGGAAACAAGATGGCGCGCCCGAAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
 QY 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
 DB 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
 QY 181 TTGACTCGGTCTTTGGGFGATA CGGCGCTCTTGCCACCGGGCCCTGTCACTTGAACCTACCC 240  
 DB 181 TTGACTCGGTCTTTGGGFGATA CGGCGCTCTTGCCACCGGGCCCTGTCACTTGAACCTACCC 240  
 QY 241 TTGCACACTACCTTAAGGAAGAGGCTTGTAGCATGTCAGAGAGGTTGCGAGCTGTTT 300  
 DB 241 TTGCACACTACCTTAAGGAAGAGGCTTGTAGCATGTCAGAGAGGTTGCGAGCTGTTT 300  
 QY 301 TCAATTGTGCTAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTAA 360  
 DB 301 TCAATTGTGCTAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTAA 360  
 QY 361 TCTCATGTACAGAAGCATATTCCTCATCTGATGAGCAATATGCTTGGCATCTTGGTTCG 420  
 DB 361 TCTCATGTACAGAAGCATATTCCTCATCTGATGAGCAATATGCTTGGCATCTTGGTTCG 420  
 QY 421 CAGAACTCAGCTGCCATTTCGCTGAACCTGAGACAAGAACCACTTATGTCCCTGTATGCCAAA 480



QY 61 GGGAAAGATGGGGGCGGCGGAGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
Db 61 GGGAAAGATGGGGGCGGCGGAGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
QY 121 CGGTGCTGCTGCTGACCATGCTGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CGGTGCTGCTGCTGACCATGCTGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGTTGGGTGATACGGCTCTTGGCCACCGGCTCTGTCAGTTGACCTACCC 240  
Db 181 TTTGACTCGGTTGGGTGATACGGCTCTTGGCCACCGGCTCTGTCAGTTGACCTACCC 240  
QY 241 TTGCACACCTACCTACCTAGGAGAGGTTGTCAGCATGTCAGAGAGTTGTCAGGCTGTT 300  
Db 241 TTGCACACCTACCTACCTAGGAGAGGTTGTCAGCATGTCAGAGAGTTGTCAGGCTGTT 300  
QY 301 TCAATTTGTCAGTTGGTGTGATGAGTAATGACTTAATCGAACTAAATGGAATGTGAA 360  
Db 301 TCAATTTGTCAGTTGGTGTGATGAGTAATGACTTAATCGAACTAAATGGAATGTGAA 360  
QY 361 TCTGCATGTACAGAGCATATCCCATCTGATGAGCATATGCTTGGCATCTTGGTTGC 420  
Db 361 TCTGCATGTACAGAGCATATCCCATCTGATGAGCATATGCTTGGCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAACTATATGCTGATGCCAAA 480  
Db 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAACTATATGCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGTCAATCTGAGTGACATGATGACTCC 540  
Db 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGTCAATCTGAGTGACATGATGACTCC 540  
QY 541 GCACAGACTCTCAATCTCTCATGACCTTTTATCTTCAAGCCCATGACGAAATA 600  
Db 541 GCACAGACTCTCAATCTCTCATGACCTTTTATCTTCAAGCCCATGACGAAATA 600  
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAATTTGAGCAGAGCTACA 660  
Db 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGACCAATTTGAGCAGAGCTACA 660  
QY 661 AATTGTAGAGATCATCTTAAGCAAAATCTCTATCTGCAATGAGAAATTCAGAGG 720  
Db 661 AATTGTAGAGATCATCTTAAGCAAAATCTCTATCTGCAATGAGAAATTCAGAGG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACTCAACTCTGCTCGGTGATGATGATGATGATGATGATGAT 840  
Db 781 TCTGGTGGATTTTAACTCAACTCTGCTCGGTGATGATGATGATGATGATGATGAT 840  
QY 841 TGTCAAATGTTGTACAGCTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900  
Db 841 TGTCAAATGTTGTACAGCTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900  
QY 901 GGTGACTGGGTTTATGATGACAAAGCTTAAACAGATATCCAGCTTCTCTTGTG 960  
Db 901 GGTGACTGGGTTTATGATGACAAAGCTTAAACAGATATCCAGCTTCTCTTGTG 960  
QY 961 GTTGTAGATCTAAATCTGAAGATCATGAGAGAGGAGGCTCTACTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAATCTGAAGATCATGAGAGAGGAGGCTCTACTACAAAGTGAAT 1020  
QY 1021 CTTCCTCATCTGAAATTTAAGATTTTCTTTTAAAGAGAGTGTATAGATCTAA 1080  
Db 1021 CTTCCTCATCTGAAATTTAAGATTTTCTTTTAAAGAGAGTGTATAGATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140

QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
RESULT 69  
ADA86851  
ID ADA86851 standard; cDNA; 1174 BP.  
XX AC ADA86851;  
XX DT 20-NOV-2003 (first entry)  
XX XX  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
XX Human; secreted and transmembrane protein; PRO; gene; ss;  
XX Tumor necrosis factor alpha release; TNF-alpha release;  
XX Glucose uptake modulator; FFA uptake modulator;  
XX cell proliferation stimulator; cell differentiation stimulator;  
XX cell differentiation inhibitor; cytokine release stimulator;  
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX gene therapy; chromosome identification; chromosome marker.  
OS Homo sapiens.  
XX US2003082709-A1.  
XX PD 01-MAY-2003.  
XX 15-MAY-2002; 2002US-00146791.  
XX 17-AUG-1998; 98US-0096895P.  
XX 02-JUN-1999; 99WO-US012252.  
XX 25-AUG-1999; 99US-00380137.  
XX 30-MAR-2000; 2000WO-US008439.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GENTH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen MB, Goddard A, Godowski FJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786912/74.  
XX DR P-PSDB; ADA86852.  
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
XX for preparing a composition for treating e.g., tumor, or for tissue  
XX typing.  
XX Claim 2; Fig 271; 637pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
XX transmembrane) polypeptides (I). (I) is useful for stimulating the  
XX release of TNF-alpha from human blood, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating the proliferation or differentiation of chondrocyte cells,  
XX for stimulating the proliferation of or gene expression in pericyte  
XX cells, for stimulating the release of proteoglycans from cartilage, for  
XX stimulating the proliferation of inner ear utricular supporting cells,  
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating  
XX the release of a cytokine from FPMC cells, for inhibiting the binding of  
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
XX cells, for stimulating proliferation of endothelial cells, for detecting  
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,  
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
XX are useful for isolating genomic and cDNA nucleotide sequences or  
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
XX in assays to identify other proteins or molecules involved in binding  
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
XX and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.

XX  
 SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
 DB 1 CGGACGGCTGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
 QY 61 GGGACAGATGGGGCGCGCGAGGGAGGCTCTGGTGAGGACCACTGGGGCTCCGG 120  
 DB 61 GGGACAGATGGGGCGCGCGAGGGAGGCTCTGGTGAGGACCACTGGGGCTCCGG 120  
 QY 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
 DB 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
 QY 181 TTGACCTGGCTTGGGTGATAGGGGCTTGGCACCGGGCCCTGTGAGTTGACCTACCCC 240  
 DB 181 TTGACCTGGCTTGGGTGATAGGGGCTTGGCACCGGGCCCTGTGAGTTGACCTACCCC 240  
 QY 241 TTGCACACCTACCTACCTAGGAGGAGTGTAGCATGTGACAGAGGTTGACGGCTGTT 300  
 DB 241 TTGCACACCTACCTAGGAGGAGTGTAGCATGTGACAGAGGTTGACGGCTGTT 300  
 QY 301 TCAATTTGTCAGTTTGGGATGAGTAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
 DB 301 TCAATTTGTCAGTTTGGGATGAGTAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
 QY 361 TCTCATGTACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
 DB 361 TCTCATGTACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
 QY 421 CAGAACTAGCTGCTTACCTGCTGAGTGTGAGCAAGAACTATGCTTCCCTGATGCCAAA 480  
 DB 421 CAGAACTAGCTGCTTACCTGCTGAGTGTGAGCAAGAACTATGCTTCCCTGATGCCAAA 480  
 QY 481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGT 540  
 DB 481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGT 540  
 QY 541 GCACAGAGCTTCATACCTCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
 DB 541 GCACAGAGCTTCATACCTCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
 QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAACCACTTGGAGCAGAGCTTACA 660  
 DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAACCACTTGGAGCAGAGCTTACA 660  
 QY 661 AATTGAGAGAACTCATCTCTPAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAGCG 720  
 DB 661 AATTGAGAGAACTCATCTCTPAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAGCG 720  
 QY 721 CACAGGAATTTTCTGAGATGAGAAATGATGCTTTTAAAGTGCCTCTCTCTTAAC 780  
 DB 721 CACAGGAATTTTCTGAGATGAGAAATGATGCTTTTAAAGTGCCTCTCTCTTAAC 780  
 QY 781 TCTGGGTGGATTTTAACTCAACTCTTCTCTGCTGATGATGATGCTTGGATTTGT 840  
 DB 781 TCTGGGTGGATTTTAACTCAACTCTTCTCTGCTGATGATGATGCTTGGATTTGT 840  
 QY 841 TGTGCAACTGTTGCTACAGCTGGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
 QY 901 GGTGACTTGGAGTTTATGATGAACAACAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
 DB 901 GGTGACTTGGAGTTTATGATGAACAACAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
 QY 961 GTTGTAGATCTTAAACTGAAATCATGAAAGCAGGCGCTTCTACCTACAAAAGTGAAT 1020  
 DB 961 GTTGTAGATCTTAAACTGAAATCATGAAAGCAGGCGCTTCTACCTACAAAAGTGAAT 1020  
 QY 1021 CTTGCTCATCTGAAATTTAAAGCATTTTCTTTTAAAGCAGGCTTCTTAAAGCATCTAA 1080  
 DB 1021 CTTGCTCATCTGAAATTTAAAGCATTTTCTTTTAAAGCAGGCTTCTTAAAGCATCTAA 1080  
 QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
 DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
 QY 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174  
 DB 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174

## RESULT 70

ADA87954  
 ID ADA87954 standard; cDNA; 1174 BP.

XX ADA87954;

XX 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO195 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

XX Tumour necrosis factor alpha release; TNF-alpha release;

XX glucose uptake modulator; FFA uptake modulator;

XX cell proliferation stimulator; cell differentiation stimulator;

XX cell differentiation inhibitor; cytokine release stimulator; tumour;

XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX US2003082700-A1.

XX 01-MAY-2003.

XX 23-APR-2002; 2002US-00128684.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786910/74.

XX P-PSDB; ADA87955.

XX New PRO nucleic acid, useful for preparing a composition for treating

XX e.g., tumor or for tissue typing.

XX Claim 2; Fig 271; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

stimulating the proliferation or differentiation of chondrocyte cells,  
for stimulating the proliferation of or gene expression in pericyte  
cells, for stimulating the release of proteoglycans from cartilage, for  
stimulating the proliferation of inner ear utricular supporting cells,  
for stimulating the proliferation of T-lymphocyte cells, for stimulating  
the release of a cytokine from BMC cells, for inhibiting the binding of  
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
cells, for stimulating proliferation of endothelial cells, for detecting  
the presence of tumour in a mammal. The tumour is lung, colon, breast,  
prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
are useful for isolating genomic and cDNA nucleotide sequences or  
antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
in assays to identify other proteins or molecules involved in binding  
interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
and gene mapping, in generation of antisense RNA and DNA, in the  
preparation of PRO polypeptide, for generating transgenic animals or  
knockout animals which in turn are useful in the development and  
screening of therapeutically useful reagents, in gene therapy, for  
chromosome identification, as chromosome marker, and for generating  
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
detecting its expression in specific cells, tissues or serum, and for  
affinity purification of PRO from recombinant cell culture or natural  
sources. (I) and (II) are useful for tissue typing. This sequence encodes  
a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
1 CGGAGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
1 CGGAGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
61 GGGACACAGATGGGGCCCGAGAGGGAGCTCTGGGTGAGGACCCCACTGGGGTCCCG 120  
61 GGGACACAGATGGGGCCCGAGAGGGAGCTCTGGGTGAGGACCCCACTGGGGTCCCG 120  
121 CGCGTGTGCTGTGACCATGCGCTTGGCGGAGGTTGGGGACCGCTTGGCTGGAAGCA 180  
121 CGCGTGTGCTGTGACCATGCGCTTGGCGGAGGTTGGGGACCGCTTGGCTGGAAGCA 180  
181 TTGTGCTCGTCTGGGTGATAGCGGCTTGGCCACCGGCGCTGTGAGTTGACCTACCC 240  
181 TTGTGCTCGTCTGGGTGATAGCGGCTTGGCCACCGGCGCTGTGAGTTGACCTACCC 240  
241 TTGCACACTACCTAAGAGAGAGGTTGACCATGTGACAGAGGTTGACGCTGTTT 300  
241 TTGCACACTACCTAAGAGAGAGGTTGACCATGTGACAGAGGTTGACGCTGTTT 300  
301 TCAATTTGCTAGTTGTGGATGATGGAATGCACTTAATCGAACTAAATGGAATGGA 360  
301 TCAATTTGCTAGTTGTGGATGATGGAATGCACTTAATCGAACTAAATGGAATGGA 360  
361 TCTGATGTACAGAGCATATCCCATCTGATGAGCAATATGCTGCCATCTGCTTGC 420  
361 TCTGATGTACAGAGCATATCCCATCTGATGAGCAATATGCTGCCATCTGCTTGC 420  
421 CAGAATCAGCTGCCATTCGCTGAATGAGCAAGAACAACTATGTCCTGTGACCAAAA 480  
421 CAGAATCAGCTGCCATTCGCTGAATGAGCAAGAACAACTATGTCCTGTGACCAAAA 480  
481 ATGGACCTACTCTTCTCTCACTCTGGTGGAGTCATCTGGAGTGACATGAGTCTCC 540  
481 ATGGACCTACTCTTCTCTCACTCTGGTGGAGTCATCTGGAGTGACATGAGTCTCC 540  
541 GCACAGAGCTTCATAACCTCTTTCATGACTTTTATCTTCAAGCCGATGACGGAATA 600  
541 GCACAGAGCTTCATAACCTCTTTCATGACTTTTATCTTCAAGCCGATGACGGAATA 600  
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACCCACCACTTTGGAGGAGGACCTACA 660

Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGAGCTTACA 660  
Qy 661 AATTTGAGAGATCATCTCTTAAGCAAAATGTCTATCTCAAAATGAGAAATTCACAAGCG 720  
Db 661 AATTTGAGAGATCATCTCTTAAGCAAAATGTCTATCTCAAAATGAGAAATTCACAAGCG 720  
Qy 721 CACAGGAATTTCTTGAGATGAGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTTGAGATGAGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780  
Qy 781 TCTGGGTGGGATTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGTTGGGATTTGT 840  
Db 781 TCTGGGTGGGATTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGTTGGGATTTGT 840  
Qy 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGATATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGATATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
Qy 961 GTTCTTAGATCTAAACTGAAGATCATGAAGAGCAGAGCGCTCTACCTACAAAAGTGAAT 1020  
Db 961 GTTCTTAGATCTAAACTGAAGATCATGAAGAGCAGAGCGCTCTACCTACAAAAGTGAAT 1020  
Qy 1021 CTTCCTCATTTCTGAATTTAAAGCATTTTCTTTTAAAGACAAAGTGTATACATCTAA 1080  
Db 1021 CTTCCTCATTTCTGAATTTAAAGCATTTTCTTTTAAAGACAAAGTGTATACATCTAA 1080  
Qy 1081 AATTTCCACTCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCTTTAAGAAATCA 1140  
Db 1081 AATTTCCACTCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCTTTAAGAAATCA 1140  
Qy 1141 CTATAAATGCAATTAAGTACTCAATCTGTG 1174  
Db 1141 CTATAAATGCAATTAAGTACTCAATCTGTG 1174  
RESULT 71  
ADA46342  
ID ADA46342 standard; cDNA; 1174 BP.  
XX ADA46342;  
AC ADA46342;  
XX 20-NOV-2003 (first entry)  
DT 20-NOV-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
DE Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX gene therapy; chromosome identification; chromosome marker.  
OS Homo sapiens.  
XX  
XX US2003054516-A1.  
XX  
XX 20-MAR-2003.  
PD  
XX 12-APR-2002; 2002US-00121050.  
PF  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.



QY 61 GGGAAACAAGATGGCGGCGCCGAGAGGGAGAGCTCTGGGTGAGGACCAACTGGGGCTCCCG 120  
Db 61 GGGAAACAAGATGGCGGCGCCGAGAGGGAGAGCTCTGGGTGAGGACCAACTGGGGCTCCCG 120  
QY 121 CGCTGCTGCTGCTGACCACTGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CGCTGCTGCTGCTGACCACTGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTGAGCTCGGTCTTGGGTGATACGGCGCTCTTGGCAACCGGGCCCTGTCAAGTTGACCTACCC 240  
Db 181 TTGAGCTCGGTCTTGGGTGATACGGCGCTCTTGGCAACCGGGCCCTGTCAAGTTGACCTACCC 240  
QY 241 TTGACACCTACCTACCTAGGAGAGGAGTTGAGCATGTGAGAGAGTTGAGAGGTTGAGAGGTTT 300  
Db 241 TTGACACCTACCTACCTAGGAGAGGAGTTGAGCATGTGAGAGAGTTGAGAGGTTGAGAGGTTT 300  
QY 301 TCAATTTGTCTAGTTTGGATGATGGAATGACTTAATCAACTAAATGGAATGGA 360  
Db 301 TCAATTTGTCTAGTTTGGATGATGGAATGACTTAATCAACTAAATGGAATGGA 360  
QY 361 TCTCATGTCAGAGCATATCCCATCTGATGAGCATATGCTTGCATCTTGGTTGC 420  
Db 361 TCTCATGTCAGAGCATATCCCATCTGATGAGCATATGCTTGCATCTTGGTTGC 420  
QY 421 CAGAACTGAGTGCATTCGCTGACTGAGCAAGCAAACTTATGCTCCCTGATGCCAAA 480  
Db 421 CAGAACTGAGTGCATTCGCTGACTGAGCAAGCAAACTTATGCTCCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTCACTCTGCTGAGGTCACTCTGGAGTGACATGATGATCC 540  
Db 481 ATGCACCTACTCTTCTCTCACTCTGCTGAGGTCACTCTGGAGTGACATGATGATCC 540  
QY 541 GCACAGAGCTTCATAAAGCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
Db 541 GCACAGAGCTTCATAAAGCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
QY 601 GTTATATTCAGTCTAGCCAGCAATCCAGTACGCACCACTTTGAGCAGAGCCTTCA 660  
Db 601 GTTATATTCAGTCTAGCCAGCAATCCAGTACGCACCACTTTGAGCAGAGCCTTCA 660  
QY 661 AATTGAGAGATCATCTTCAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGGG 720  
Db 661 AATTGAGAGATCATCTTCAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGGG 720  
QY 721 CACAGGAATTTCTGAGATGAGAAAGTGTGGCTTTTAAAGTGCCTCTCTTAAAC 780  
Db 721 CACAGGAATTTCTGAGATGAGAAAGTGTGGCTTTTAAAGTGCCTCTCTTAAAC 780  
QY 781 TCTGGGTGATTTTAACTACAACTCTTCTCTCTCGGTGATGATGTTGTTGGATTCT 840  
Db 781 TCTGGGTGATTTTAACTACAACTCTTCTCTCTCGGTGATGATGTTGTTGGATTCT 840  
QY 841 TGTGCAACTGTGTACAGCTGTGAGCAGATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTGTACAGCTGTGAGCAGATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GTGAGCTGAGGTTTATGATGACAAAGCTAACAAGATATCCAGCTCTCTCTTGTG 960  
Db 901 GTGAGCTGAGGTTTATGATGACAAAGCTAACAAGATATCCAGCTCTCTCTTGTG 960  
QY 961 GTTGTAGATCTAAACTAGATCATGAAGAGAGGCGCTCTACTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTAGATCATGAAGAGAGGCGCTCTACTACAAAGTGAAT 1020  
QY 1021 CTTCCTATCTGAAATTTAGCAATTTCTTTTAAAGCAAGTGTATGACATCTTAA 1080  
Db 1021 CTTCCTATCTGAAATTTAGCAATTTCTTTTAAAGCAAGTGTATGACATCTTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 72  
ADB28372

ID ADB28372 standard; cDNA; 1174 BP.

XX AC ADB28372;

XX DT 20-NOV-2003 (first entry)

XX DE cDNA encoding human PRO polypeptide #136.

XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear uricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082699-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127851.

XX PR 17-JUN-1998; 98US-008599P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 30-MAR-2000; 2000WO-US008439.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH ) GENENTECH INC.

XX PI Baker KP, Bersesini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-777202/73.

XX P-PSDB; ADB28373.

XX PT New PRO nucleic acid, useful for preparing a composition for treating

PT e.g., tumor or for tissue typing.

XX PS Claim 2; Fig 271; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of



CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. Note: The  
 CC sequence encodes a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGGCTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGAGCTGCTGACAG 60  
 Db 1 CGGACGGCTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGAGCTGCTGACAG 60  
 Qy 61 GGGAAACAGATGCGGGCGCCGAAAGGGAGGCTCTGGGTGAGACCCCACTGGGGTCCCG 120  
 Db 61 GGGAAACAGATGCGGGCGCCGAAAGGGAGGCTCTGGGTGAGACCCCACTGGGGTCCCG 120  
 Qy 121 CCGCTGCTGCTGCTGACATGCGCTTGGCGGAGGTTGGGGACCGCTTCGGCTCAAGCA 180  
 Db 121 CCGCTGCTGCTGCTGACATGCGCTTGGCGGAGGTTGGGGACCGCTTCGGCTCAAGCA 180  
 Qy 181 TTGAGCTCGCTCTGGGTGATACGGCGCTCTGACACCGGGCGCTGACGTGACCTACCCC 240  
 Db 181 TTGAGCTCGCTCTGGGTGATACGGCGCTCTGACACCGGGCGCTGACGTGACCTACCCC 240  
 Qy 241 TTGCACACCTACCTACGAGGAGGAGTGTGACGATGTCAGAGGTTGACAGGCGTGT 300  
 Db 241 TTGCACACCTACCTACGAGGAGGAGTGTGACGATGTCAGAGGTTGACAGGCGTGT 300  
 Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
 Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
 Qy 361 TCTGCATGTACAGACATATCCCAATCTGATGACATATGCTGCCATCTTGTTGC 420  
 Db 361 TCTGCATGTACAGACATATCCCAATCTGATGACATATGCTGCCATCTTGTTGC 420  
 Qy 421 CAGAACTCAGCTGCCATTGCTGAACTGAGACAGAAACAATTTATGTCCCTGATGCCAAA 480  
 Db 421 CAGAACTCAGCTGCCATTGCTGAACTGAGACAGAAACAATTTATGTCCCTGATGCCAAA 480  
 Qy 481 ATGCACCTACTCTTCTCTTAATCTGTTGAGTGTGATCTGAGAGTGAATGAGTACTCC 540  
 Db 481 ATGCACCTACTCTTCTCTTAATCTGTTGAGTGTGATCTGAGAGTGAATGAGTACTCC 540  
 Qy 541 GCACAGAGCTTCATACTCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
 Db 541 GCACAGAGCTTCATACTCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
 Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGAGGCTTACA 660  
 Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGAGGCTTACA 660  
 Qy 661 AATTGTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
 Db 661 AATTGTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
 Qy 721 CACAGGAATTTCTTGAAGATGAGAAAGTGAATGGCTTTTAAAGTGCCTCTCTTAAAC 780  
 Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTGAATGGCTTTTAAAGTGCCTCTCTTAAAC 780

Qy 781 TCTGGGTGGAATTTAACTACAACTCTTCTCTCGGTGATGGTATTCTCTTTGGATTGT 840  
 Db 781 TCTGGGTGGAATTTAACTACAACTCTTCTCTCGGTGATGGTATTCTCTTTGGATTGT 840  
 Qy 841 TGTGCAACTGTGTTCTACAGCTGTGAGCAGATGTTCCCTCTGAGAACTGAGTATCTAT 900  
 Db 841 TGTGCAACTGTGTTCTACAGCTGTGAGCAGATGTTCCCTCTGAGAACTGAGTATCTAT 900  
 Qy 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960  
 Db 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960  
 Qy 961 GTTGTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
 Db 961 GTTGTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
 Qy 1021 CTGTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
 Db 1021 CTGTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
 Qy 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTTAAGAAATCA 1140  
 Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTTAAGAAATCA 1140  
 Qy 1141 CTATAAATGCAAAATAAGTACTCAATCTGTG 1174  
 Db 1141 CTATAAATGCAAAATAAGTACTCAATCTGTG 1174

## RESULT 73

ADB28924  
 ID ADB28924 standard; cDNA; 1174 BP.

XX AC ADB28924;

XX XX 20-NOV-2003 (first entry)

XX DE cDNA encoding human PRO polypeptide #136.

XX KW Human; gene; 88; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082706-A1.

XX PD 01-MAY-2003.

XX PF 24-APR-2002; 2002US-00131836.

XX PR 09-DEC-1999; 99US-0170262P.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforgre L, Desnoyers L, Filvaroff E;

XX PI Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-777203/73.

XX DR P-PSDB; ADB28925.



PT New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCTGGGGGAAACCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACGCTGGGGGAAACCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAAACAGAGTGGCGGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
DB	61	GGGAAACAGAGTGGCGGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CGGCTGCTGCTGCTACCATGCGCTTGGCCGAGGCTTGGGGACCGCTTCGGCTGAAGCA	180
DB	121	CGGCTGCTGCTGCTACCATGCGCTTGGCCGAGGCTTGGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGCTTGGGTGATACGGCGCTTTGCCACCGGGCGCTGTACAGTTGACCTACCC	240
DB	181	TTTGACTCGGCTTGGGTGATACGGCGCTTTGCCACCGGGCGCTGTACAGTTGACCTACCC	240
QY	241	TTTGACACCTACCTTAAGGAGAGGAGTTGACCATGTTCAGAGGTTGCAGGCTGTTT	300
DB	241	TTTGACACCTACCTTAAGGAGAGGAGTTGACCATGTTCAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTTGTGCTAGTTTGGATGATGGAATTCAGCTTAATCGAATTAATTTGGAATGTGA	360
DB	301	TCAATTTGTGCTAGTTTGGATGATGGAATTCAGCTTAATCGAATTAATTTGGAATGTGA	360
QY	361	TCTGATGTACAGAGCATATCCCAATCTCATGAGCAATATGCTTCCATCTTGGTTGC	420
DB	361	TCTGATGTACAGAGCATATCCCAATCTCATGAGCAATATGCTTCCATCTTGGTTGC	420

QY	421	CAGAACTCAGCTGCCATTCGCTGAACCTGAGACAGCAAGCAACTTATGTCCTGATGCCAAA	480
DB	421	CAGAACTCAGCTGCCATTCGCTGAACCTGAGACAGCAAGCAACTTATGTCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTCTCTTAACCTCTGGTGGAGTCAATTCGAGTGAATGATGAGCTCC	540
DB	481	ATGCACCTACTCTTTCTCTTAACCTCTGGTGGAGTCAATTCGAGTGAATGATGAGCTCC	540
QY	541	GCACAGAGCTTTCATAACCTCTCTCATGAGCTTTTATCTTTCAAGCCGATGACGAAAATA	600
DB	541	GCACAGAGCTTTCATAACCTCTCTCATGAGCTTTTATCTTTCAAGCCGATGACGAAAATA	600
QY	601	GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTCGAGCAGGAGCTTACA	660
DB	601	GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTCGAGCAGGAGCTTACA	660
QY	661	AATTTGAGAGAAATCATCTCTTAAGCAAAATGTCTATCTCTGCAATGAGAAATTCACAAGG	720
DB	661	AATTTGAGAGAAATCATCTCTTAAGCAAAATGTCTATCTCTGCAATGAGAAATTCACAAGG	720
QY	721	CACAGGAATTTCTGAGAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTTAAAC	780
DB	721	CACAGGAATTTCTGAGAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTTAAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACCTCTTCTCTCGTCTGATGCTATTTGCTTTGGATTTGT	840
DB	781	TCTGGGTGGATTTTAACTACAACCTCTTCTCTCGTCTGATGCTATTTGCTTTGGATTTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
DB	841	TGTGCAACTGTTGCTACAGCTGTGGAGAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
QY	901	GGTGACTGGAGTTTATGATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
DB	901	GGTGACTGGAGTTTATGATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
QY	961	GTTCTTAGATCTAAAACCTGAAGATCATGAAGAGCAGAGGCGCTTACCTACAAAAGTGAAT	1020
DB	961	GTTCTTAGATCTAAAACCTGAAGATCATGAAGAGCAGAGGCGCTTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGAAATTTAAGCATTTCTTTTAAAGCAAGTGTATAGACATCTAA	1080
DB	1021	CTTGCTCATCTGAAATTTAAGCATTTCTTTTAAAGCAAGTGTATAGACATCTAA	1080
QY	1081	AATTCCTACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
DB	1081	AATTCCTACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
QY	1141	CTATAAATGCAATTAAGTTACTCAAACTGTG	1174
DB	1141	CTATAAATGCAATTAAGTTACTCAAACTGTG	1174

RESULT 74

ADA76876

ID ADA76876 standard; cDNA; 1174 BP.

XX ADA76876;

XX AC ADA76876;

XX DT 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #136.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.  
XX OS US2003059909-A1.  
XX PN 27-MAR-2003.  
XX PD 10-MAY-2002; 2002US-00143032.  
XX PF 31-MAR-1997; 97WO-US005230.  
XX PF 12-JUN-1998; 98WO-US012456.  
XX PF 14-JUL-1998; 98WO-US014552.  
XX PF 28-AUG-1998; 98WO-US017888.  
XX PF 10-SEP-1998; 98WO-US018824.  
XX PF 14-SEP-1998; 98WO-US019093.  
XX PF 14-SEP-1998; 98WO-US019094.  
XX PF 14-SEP-1998; 98WO-US019177.  
XX PF 16-SEP-1998; 98WO-US019330.  
XX PF 17-SEP-1998; 98WO-US019437.  
XX PF 07-OCT-1998; 98WO-US021141.  
XX PF 29-OCT-1998; 98WO-US022991.  
XX PF 29-OCT-1998; 98WO-US022992.  
XX PF 20-NOV-1998; 98WO-US024855.  
XX PF 01-DEC-1998; 98WO-US025108.  
XX PF 05-JAN-1999; 99WO-US000106.  
XX PF 08-MAR-1999; 99WO-US005028.  
XX PF 10-MAR-1999; 99WO-US005190.  
XX PF 20-APR-1999; 99WO-US008615.  
XX PF 14-MAY-1999; 99WO-US010733.  
XX PF 02-JUN-1999; 99WO-US012252.  
XX PF 01-SEP-1999; 99WO-US020111.  
XX PF 08-SEP-1999; 99WO-US020594.  
XX PF 13-SEP-1999; 99WO-US020944.  
XX PF 15-SEP-1999; 99WO-US021090.  
XX PF 05-OCT-1999; 99WO-US021547.  
XX PF 15-OCT-1999; 99WO-US023089.  
XX PF 29-NOV-1999; 99WO-US028214.  
XX PF 30-NOV-1999; 99WO-US028313.  
XX PF 30-NOV-1999; 99WO-US028409.  
XX PF 01-DEC-1999; 99WO-US028501.  
XX PF 01-DEC-1999; 99WO-US028634.  
XX PF 02-DEC-1999; 99WO-US028851.  
XX PF 02-DEC-1999; 99WO-US028854.  
XX PF 02-DEC-1999; 99WO-US028856.  
XX PF 16-DEC-1999; 99WO-US030095.  
XX PF 20-DEC-1999; 99WO-US030911.  
XX PF 20-DEC-1999; 99WO-US030999.  
XX PF 22-DEC-1999; 99WO-US030720.  
XX PF 30-DEC-1999; 99WO-US031243.  
XX PF 30-DEC-1999; 99WO-US031274.  
XX PF 05-JAN-2000; 2000WO-US000219.  
XX PF 06-JAN-2000; 2000WO-US000277.  
XX PF 11-FEB-2000; 2000WO-US000376.  
XX PF 18-FEB-2000; 2000WO-US003565.  
XX PF 18-FEB-2000; 2000WO-US004341.  
XX PF 22-FEB-2000; 2000WO-US004342.  
XX PF 24-FEB-2000; 2000WO-US004414.  
XX PF 24-FEB-2000; 2000WO-US004914.  
XX PF 01-MAR-2000; 2000WO-US005004.  
XX PF 02-MAR-2000; 2000WO-US005601.  
XX PF 02-MAR-2000; 2000WO-US005746.  
XX PF 10-MAR-2000; 2000WO-US005841.  
XX PF 15-MAR-2000; 2000WO-US006319.  
XX PF 20-MAR-2000; 2000WO-US006884.  
XX PF 21-MAR-2000; 2000WO-US007377.  
XX PF 30-MAR-2000; 2000WO-US007532.  
XX PF 17-MAY-2000; 2000WO-US008439.  
XX PF 22-MAY-2000; 2000WO-US013705.  
XX PF 30-MAY-2000; 2000WO-US014042.  
XX PF 02-JUN-2000; 2000WO-US014941.  
XX PF 28-JUL-2000; 2000WO-US015264.  
XX PF 11-AUG-2000; 2000WO-US020710.  
XX PF 23-AUG-2000; 2000WO-US023522.  
XX PF 24-AUG-2000; 2000WO-US023328.  
XX PF 08-NOV-2000; 2000WO-US030952.  
XX PF 10-NOV-2000; 2000WO-US030873.  
XX PF 01-DEC-2000; 2000WO-US032678.  
XX PF 20-DEC-2000; 2000US-00747259.  
XX PF 20-DEC-2000; 2000WO-US034956.  
XX PF 28-FEB-2001; 2001US-00796498.  
XX PF 28-FEB-2001; 2001WO-US006520.  
XX PF 01-MAR-2001; 2001WO-US006666.  
XX PF 09-MAR-2001; 2001US-00802706.  
XX PF 14-MAR-2001; 2001US-00805689.  
XX PF 22-MAR-2001; 2001US-00816744.  
XX PF 05-APR-2001; 2001US-00828366.  
XX PF 10-MAY-2001; 2001US-00854208.  
XX PF 18-MAY-2001; 2001US-00854280.  
XX PF 25-MAY-2001; 2001US-00860216.  
XX PF 25-MAY-2001; 2001US-00866028.  
XX PF 25-MAY-2001; 2001US-00866034.  
XX PF 01-JUN-2001; 2001WO-US017092.  
XX PF 01-JUN-2001; 2001US-00872035.  
XX PF 05-JUN-2001; 2001WO-US017800.  
XX PF 14-JUN-2001; 2001US-00874503.  
XX PF 19-JUN-2001; 2001US-00882636.  
XX PF 20-JUN-2001; 2001US-00886342.  
XX PF 21-JUN-2001; 2001WO-US019692.  
XX PF 22-JUN-2001; 2001US-00887879.  
XX PF 22-JUN-2001; 2001WO-US020116.  
XX PF 29-JUN-2001; 2001WO-US021066.  
XX PF 09-JUL-2001; 2001WO-US021735.  
XX PF 18-JUL-2001; 2001US-00908827.  
XX PF 06-AUG-2001; 2001US-00924419.  
XX PF 09-AUG-2001; 2001US-00927796.  
XX PF 16-AUG-2001; 2001US-00931836.  
XX PF 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerisken ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-540684/51.  
XX P-PSDB; ADA76877.  
XX New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
PT cancer.  
PS Claim 2; Fig 271; 660pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
DB 1 CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
QY 61 GGGAAACAGATGCGCGCGCGGAGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
DB 61 GGGAAACAGATGCGCGCGCGGAGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
QY 121 CGCTCTGCTGTGACCAATGCGCTTGGCGGAGGCTTGGCGGAGCGCTTGGCGGAGCA 180  
DB 121 CGCTCTGCTGTGACCAATGCGCTTGGCGGAGGCTTGGCGGAGCGCTTGGCGGAGCA 180  
QY 181 TTGAGCTCGGTCTGGGTGATACGGGCTTGGCGGAGGCTTGGCGGAGCGCTTGGCGGAG 240  
DB 181 TTGAGCTCGGTCTGGGTGATACGGGCTTGGCGGAGGCTTGGCGGAGCGCTTGGCGGAG 240  
QY 241 TTGCACACCTACCTAAGGAAGGAGTTGTACGATGTTCAGAGGTTGAGGCTGTGTT 300  
DB 241 TTGCACACCTACCTAAGGAAGGAGTTGTACGATGTTCAGAGGTTGAGGCTGTGTT 300  
QY 301 TCAATTTGTCAGTTTGTGATGATGGAATTGATTTAAATCGAATTAATCGAATGGAATGAA 360  
DB 301 TCAATTTGTCAGTTTGTGATGATGGAATTGATTTAAATCGAATTAATCGAATGGAATGAA 360  
QY 361 TCTGCATGTACAGAGCATATCCCAATCTGATGAGCAATGCTTGCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATCCCAATCTGATGAGCAATGCTTGCATCTTGGTTGC 420  
QY 421 CAGAACTAGCTGCTTCCCTGATGAGCAAGCAAGCAACTTATGTCCTGATGCAAAA 480  
DB 421 CAGAACTAGCTGCTTCCCTGATGAGCAAGCAAGCAACTTATGTCCTGATGCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTTAACTCTGAGTCAATCTGAGTGACATGATGAGCTCC 540  
DB 481 ATGCACCTACTCTTCTCTTAACTCTGAGTCAATCTGAGTGACATGATGAGCTCC 540  
QY 541 GCACAGAGCTTCAATACCTTCTGATGAGCAATTTTATCTTCAAGCGATGACGAAAATA 600  
DB 541 GCACAGAGCTTCAATACCTTCTGATGAGCAATTTTATCTTCAAGCGATGACGAAAATA 600  
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAACCAATTTGGAGCAGGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAACCAATTTGGAGCAGGCTTACA 660  
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAGCG 720  
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAGCG 720  
QY 721 CACAGGATTTTCTGAGATGAGAAATGAGTGGCTTTTAAAGATGCTCTCTTAAAC 780  
DB 721 CACAGGATTTTCTGAGATGAGAAATGAGTGGCTTTTAAAGATGCTCTCTTAAAC 780  
QY 781 TCTGGGTGGATTTAACTCAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT 840

DB 781 TCTGGGTGGATTTAACTCAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTGCTTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGCTTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGCAGGCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACCTGAAGATCATGAAGCAGGCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTGTCTCTTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
DB 1021 CTTGTCTCTTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGCTTTCATGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGCTTTCATGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATATAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174  
DB 1141 CTATATAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174

RESULT 75

ADA88506

ID ADA88506 standard; cDNA; 1174 BP.

AC ADA88506;

XX AC

XX DT 20-NOV-2003 (first entry)

XX DE

Novel human secreted and transmembrane protein PRO195 cDNA.  
Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; PFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX XX

XX US2003073213-A1.

XX PD 17-APR-2003.

XX PF 17-APR-2002; 2002US-00124819.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028584.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005094.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034259.  
PR 28-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001WO-US0082706.  
PR 14-MAR-2001; 2001US-00806869.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00860228.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019652.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GEPH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-743816/70.  
XX P-PSDB; ADA88507.  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
XX in gene therapy, detecting the presence of tumor in a mammal, or  
XX modulating the uptake of glucose or free fatty acid by skeletal muscle  
XX cells or adipocyte cells.  
XX Claim 2; Fig 271; 659pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
XX transmembrane) polypeptides (I). (I) is useful for stimulating the  
XX release of TNF-alpha from human blood, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating the proliferation or differentiation of chondrocyte cells,  
XX for stimulating the proliferation of or gene expression in pericyte  
XX cells, for stimulating the release of proteoglycans from cartilage, for  
XX stimulating the proliferation of inner ear utricular supporting cells,  
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating  
XX the release of a cytokine from BMC cells, for inhibiting the binding of  
XX A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
XX cells, for stimulating proliferation of endothelial cells, for detecting  
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,  
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
XX are useful for isolating genomic and cDNA nucleotide sequences or  
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
XX in assays to identify other proteins or molecules involved in binding  
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
XX and gene mapping, in generation of antisense RNA and DNA, in the  
XX preparation of PRO polypeptide, for generating transgenic animals or  
XX knockout animals which in turn are useful in the development and  
XX screening of therapeutically useful reagents, in gene therapy, for  
XX chromosome identification, as chromosome marker, and for generating  
XX probes. An anti-(II)-antibody is useful in diagnostic assays for PRO, e.g.  
XX detecting its expression in specific cells, tissues or serum, and for  
XX affinity purification of PRO from recombinant cell culture or natural  
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes  
XX a novel human secreted and transmembrane PRO polypeptide.  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACACAGCAACAGCTGCTGTGACAGAG 60  
Db 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACACAGCAACAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAGATGGCGGCGCCGAGGGAGGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
Db 61 GGGAAACAGATGGCGGCGCCGAGGGAGGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTGACTCGGCTTGGGTGATACGGCGCTTTGCGCACCGGGCCCTGTCAGTTGACTACCCC 240  
Db 181 TTGACTCGGCTTGGGTGATACGGCGCTTTGCGCACCGGGCCCTGTCAGTTGACTACCCC 240

Db 181 TTTGACTCGGTCCTGGTGATACGGCGCTCTTGCCACCGGGCCCTGTGCTGACCTACCCCC 240  
Qy 241 TTGCACACCTTACCTTAAGGAAGAGGAGTTGTACGCAATGTACAGAGGTTGACGGCTGTTT 300  
Db 241 TTGCACACCTTACCTTAAGGAAGAGGAGTTGTACGCAATGTACAGAGGTTGACGGCTGTTT 300  
Qy 301 TCAATTTGTCAGTTTGGATGATGAATGACTTAATCGAATTAATGGAATGGAATGGA 360  
Db 301 TCAATTTGTCAGTTTGGATGATGAATGACTTAATCGAATTAATGGAATGGAATGGA 360  
Qy 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420  
Db 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420  
Qy 421 CAGATCAGCTGCATTCGCTGAACTGAGACAGAAACAACTATGTCCTGATGCAAAA 480  
Db 421 CAGATCAGCTGCATTCGCTGAACTGAGACAGAAACAACTATGTCCTGATGCAAAA 480  
Qy 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
Db 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
Qy 541 GCACAGAGCTTCAATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600  
Db 541 GCACAGAGCTTCAATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600  
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTTGGAGCGAGCTTACA 660  
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTTGGAGCGAGCTTACA 660  
Qy 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
Qy 721 CACAGGAAATTTCTTGAGATGAGAAAGTATGCTTTTAAAGTCCCTCTCTCTCTCTCT 780  
Db 721 CACAGGAAATTTCTTGAGATGAGAAAGTATGCTTTTAAAGTCCCTCTCTCTCTCTCT 780  
Qy 781 TCTGGTGGATTTTAACTACAACCTCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
Db 781 TCTGGTGGATTTTAACTACAACCTCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
Qy 841 TGTCACACTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
Db 841 TGTCACACTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTCTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTCTG 960  
Qy 961 GTTCTTAGATCTAAACTGAAGATCATGAAGAGAGCGGCTCTACCTACAAAAGTGAAT 1020  
Db 961 GTTCTTAGATCTAAACTGAAGATCATGAAGAGAGCGGCTCTACCTACAAAAGTGAAT 1020  
Qy 1021 CTTCTCATCTGAAATTTAAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db 1021 CTTCTCATCTGAAATTTAAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Qy 1081 AATTCCACTCTCATAGAGCTTTTAAAGTGTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1140  
Db 1081 AATTCCACTCTCATAGAGCTTTTAAAGTGTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1140  
Qy 1141 CTATAAATCAATTAAGTCTCTCAATCTGTG 1174  
Db 1141 CTATAAATCAATTAAGTCTCTCAATCTGTG 1174

RESULT 76  
ADA97511  
ID ADA97511 standard; cDNA; 1174 BP.  
XX  
AC ADA97511;  
XX

DT 20-NOV-2003 (first entry)  
XX Human PRO polynucleotide #136.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; PFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;  
XX immune system cell infiltration.  
XX Homo sapiens.  
XX US2003082686-A1.  
XX 01-MAY-2003.  
XX 19-APR-2002; 2002US-00125926.  
XX 05-JUN-2000; 2000US-0209832P.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen WB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755106/71.  
XX P-PSDB; ADA97512.  
XX Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in  
XX generating antisense RNA and DNA, and in gene therapy.  
XX Claim 2; Fig 271; 666pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or PFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX the proliferation of or gene expression in pericyte cells, for stimulating  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems,  
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX polypeptides are also useful for treating various mammalian haemoglobin-  
XX associated disorders such as various thalasassaemias and conditions which  
XX may benefit from enhanced local immune system cell infiltration. This  
XX sequence represents a human PRO polynucleotide of the invention. Note:





Query Match Best Local Similarity 100.0%; Score 1174; DB 8; Length 1174; Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY	1	CGGACGGTGGGGAACCCCTTCGAGAAACGACAAAGCTGCTGTGACAGAG	60						
DB	1	CGGACGGTGGGGAACCCCTTCGAGAAACGACAAAGCTGCTGTGACAGAG	60						
QY	61	GGGAAACAGATGGCGCGCGGAGGGGAGCTCTGGGTGAGGACCAACTGGGGCTCCCG	120						
DB	61	GGGAAACAGATGGCGCGCGGAGGGGAGCTCTGGGTGAGGACCAACTGGGGCTCCCG	120						
QY	121	CCGCTGCTGTCTGACCATGGCCCTTGGCGGAGGTTTGGGACCCCTTTCGGCTGAAGCA	180						
DB	121	CCGCTGCTGTCTGACCATGGCCCTTGGCGGAGGTTTGGGACCCCTTTCGGCTGAAGCA	180						
QY	181	TTTGACTCGGTCTTGGGTGATACGGCTCTTGGCACCGGGCCCTGTCAGTTGACCTACCC	240						
DB	181	TTTGACTCGGTCTTGGGTGATACGGCTCTTGGCACCGGGCCCTGTCAGTTGACCTACCC	240						
QY	241	TTGCACACCTACCTAAAGGAGAGGTTGTACGATGTTCAGAGAGGTTTCAGGCTGTTT	300						
DB	241	TTGCACACCTACCTAAAGGAGAGGTTGTACGATGTTCAGAGAGGTTTCAGGCTGTTT	300						
QY	301	TCAATTTGTGATTTGGATGATGAAATGACTTAATCGAACTAAATTTGGAATGTGAA	360						
DB	301	TCAATTTGTGATTTGGATGATGAAATGACTTAATCGAACTAAATTTGGAATGTGAA	360						
QY	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTC	420						
DB	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTC	420						
QY	421	CAGAACTAGCTGCGATTCGCTGAATGAGACAGAACTATGTCCTGATGCCAAA	480						
DB	421	CAGAACTAGCTGCGATTCGCTGAATGAGACAGAACTATGTCCTGATGCCAAA	480						
QY	481	ATGCACCTACTCTTCTCTAACTCTGGTGAAGTCAATCTGGAGTGACATGAGACTCC	540						
DB	481	ATGCACCTACTCTTCTCTAACTCTGGTGAAGTCAATCTGGAGTGACATGAGACTCC	540						
QY	541	GCACAGAGCTTCAACCTCTTCAAGGACTTTTATCTTCAAGCCGATGACGGAATAA	600						
DB	541	GCACAGAGCTTCAACCTCTTCAAGGACTTTTATCTTCAAGCCGATGACGGAATAA	600						
QY	601	GTTATTTCCAGTCTTACGCAAGATCCAGTACGACCAATTTGGAGAGGAGCCCTACA	660						
DB	601	GTTATTTCCAGTCTTACGCAAGATCCAGTACGACCAATTTGGAGAGGAGCCCTACA	660						
QY	661	AATTTGAGAGATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720						
DB	661	AATTTGAGAGATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720						
QY	721	CACAGGATTTCTGAGATGGAGAGTGGCTTTTAAAGTGCCTCTCTCTTAC	780						
DB	721	CACAGGATTTCTGAGATGGAGAGTGGCTTTTAAAGTGCCTCTCTCTTAC	780						
QY	781	TCTGGTGGATTTTAACTTACAACTCTTCTCTCTCGGTGATGTTTCTTTGGATTTGT	840						
DB	781	TCTGGTGGATTTTAACTTACAACTCTTCTCTCTCGGTGATGTTTCTTTGGATTTGT	840						
QY	841	TGTGCACTGTGCTACAGCTGTGGAGTATGTTTCCCTCTGAGAGCTGAGTATCTAT	900						
DB	841	TGTGCACTGTGCTACAGCTGTGGAGTATGTTTCCCTCTGAGAGCTGAGTATCTAT	900						
QY	901	GGTGATTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960						
DB	901	GGTGATTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960						
QY	961	GTGTTAGATCTAAACTGAAGATCATGAAGAGAGGCTCTTACCTACAAAGTGAAT	1020						
DB	961	GTGTTAGATCTAAACTGAAGATCATGAAGAGAGGCTCTTACCTACAAAGTGAAT	1020						

RESULT 78  
ADB22201  
ID ADB22201 standard; cDNA; 1174 BP.  
XX  
AC ADB22201;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
Novel human secreted and transmembrane protein PRO195 cDNA.  
XX  
Human; secreted and transmembrane protein; PRO; gene; ss;  
XX  
Tumour necrosis factor alpha release; TNF-alpha release;  
XX  
glucose uptake modulator; FFA uptake modulator;  
XX  
cell proliferation stimulator; cell differentiation stimulator;  
XX  
cell differentiation inhibitor; cytokine release stimulator; tumour;  
XX  
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX  
cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX  
gene therapy; chromosome identification; chromosome marker.  
OS Homo sapiens.  
XX  
XX US2003087344-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 16-APR-2002; 2002US-00123905.  
XX  
PR 18-JUN-1997; 97US-0049911P.  
PR 26-AUG-1997; 97US-0056974P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059463P.  
PR 19-SEP-1997; 97US-0059352P.  
PR 19-SEP-1997; 97US-0059588P.  
PR 24-SEP-1997; 97US-0059816P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062387P.  
PR 17-OCT-1997; 97US-0063755P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063082P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063350P.  
PR 28-OCT-1997; 97US-0063356P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063733P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 21-NOV-1997; 97US-0066364P.



PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 11-DEC-1997; 97US-0069212P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 16-DEC-1997; 97US-0069594P.  
PR 23-JAN-1998; 98US-0072320P.  
PR 04-FEB-1998; 98US-0073122P.  
PR 08-FEB-1998; 98US-0074086P.  
PR 08-FEB-1998; 98US-0074092P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 27-MAR-1998; 98US-0079653P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 03-APR-1998; 98US-0081229P.  
PR 14-APR-1998; 98US-0081695P.  
PR 15-APR-1998; 98US-0081817P.  
PR 24-APR-1998; 98US-0082999P.  
PR 24-APR-1998; 98US-0083222P.  
PR 28-APR-1998; 98US-0083345P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 12-MAY-1998; 98US-0085149P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-JUN-1998; 98US-0088730P.  
PR 10-JUN-1998; 98US-0088741P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 12-JUN-1998; 98US-0089124P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089947P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 26-JUN-1998; 98US-0090538P.  
PR 01-JUL-1998; 98US-0090863P.  
PR 02-JUL-1998; 98US-0091360P.  
PR 07-JUL-1998; 98US-0091519P.  
PR 14-JUL-1998; 98US-0091982P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 18-AUG-1998; 98US-0096895P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.

PR 26-AUG-1998; 98US-0097951P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 28-AUG-1998; 98US-0097988P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 01-SEP-1998; 98US-0098750P.  
PR 03-SEP-1998; 98US-0098536P.  
PR 03-SEP-1998; 98US-0098598P.  
PR 09-SEP-1998; 98US-0099601P.  
PR 10-SEP-1998; 98US-0099792P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98US-0099816P.  
PR 14-SEP-1998; 98US-0099824P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98US-0100263P.  
PR 14-SEP-1998; 98US-0100263P.  
PR 14-SEP-1998; 98US-0100263P.  
PR 14-SEP-1998; 98US-0100263P.  
PR 15-SEP-1998; 98US-0100390P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 17-SEP-1998; 98US-0100710P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 23-SEP-1998; 98US-0101474P.  
PR 23-SEP-1998; 98US-0101474P.  
PR 24-SEP-1998; 98US-0101474P.  
PR 07-OCT-1998; 98US-0103315P.  
PR 07-OCT-1998; 98US-0103328P.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-OCT-1998; 98US-0104987P.  
PR 22-OCT-1998; 98US-0105169P.  
PR 28-OCT-1998; 98US-0106030P.  
PR 29-OCT-1998; 98US-0106030P.  
PR 29-OCT-1998; 98US-0106030P.  
PR 30-OCT-1998; 98US-0106464P.  
PR 03-NOV-1998; 98US-0106856P.  
PR 10-NOV-1998; 98US-0106934P.  
PR 17-NOV-1998; 98US-0107783P.  
PR 17-NOV-1998; 98US-0108775P.  
PR 17-NOV-1998; 98US-0108801P.  
PR 17-NOV-1998; 98US-0108802P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-0112455P.  
PR 15-DEC-1998; 98US-0112743P.  
PR 16-DEC-1998; 98US-0112850P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 22-DEC-1998; 98US-0113300P.  
PR 22-DEC-1998; 98US-0113313P.  
PR 22-DEC-1998; 98US-0113314P.  
PR 22-DEC-1998; 98US-0113315P.  
PR 22-DEC-1998; 98US-0113510P.  
PR 23-DEC-1998; 98US-0113511P.  
PR 23-DEC-1998; 98US-0113605P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99US-00000106.  
PR 12-JAN-1999; 99US-0115549P.  
PR 12-JAN-1999; 99US-0115557P.  
PR 12-JAN-1999; 99US-0115562P.  
PR 12-JAN-1999; 99US-0115562P.  
PR 12-JAN-1999; 99US-0115564P.  
PR 12-JAN-1999; 99US-0115650P.  
PR 12-JAN-1999; 99US-0115705P.  
PR 12-JAN-1999; 99US-0115733P.  
PR 20-JAN-1999; 99US-0116533P.  
PR 01-FEB-1999; 99US-0118210P.

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGTGTGTGACAGAG 60  
Db |||||  
QY 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGTGTGTGACAGAG 60  
Db |||||  
QY 61 GGGAAACAGATGGGGGCGCGGAGGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
Db |||||  
QY 61 GGGAAACAGATGGGGGCGCGGAGGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
Db |||||  
QY 121 CGGCTGCTGCTGCTGACCATCGCTTGGCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180  
Db |||||  
QY 121 CGGCTGCTGCTGCTGACCATCGCTTGGCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180  
Db |||||  
QY 181 TTGAGTCGGTCTTGGGTGATACCGGCTTCTGCAACCGGCTCTGTCAGTTGAGCTACCCC 240  
Db |||||  
QY 181 TTGAGTCGGTCTTGGGTGATACCGGCTTCTGCAACCGGCTCTGTCAGTTGAGCTACCCC 240  
Db |||||  
QY 241 TTGCACACCTACCTTAAGGAAGAGAGTTGACCATGTGACAGAGGTTGACGGCTGTTT 300  
Db |||||  
QY 241 TTGCACACCTACCTTAAGGAAGAGAGTTGACCATGTGACAGAGGTTGACGGCTGTTT 300  
Db |||||  
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACCTTAATCGAACTAAATGGAATGAA 360  
Db |||||  
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACCTTAATCGAACTAAATGGAATGAA 360  
Db |||||  
QY 361 TCTGCTGTCAGAGCATATCCCAATCTGATGAGCAATATGTTGCCATCTTGTTC 420  
Db |||||  
QY 361 TCTGCTGTCAGAGCATATCCCAATCTGATGAGCAATATGTTGCCATCTTGTTC 420  
Db |||||  
QY 421 CAGAACTCAGCTGCGCATTCGCTGAATGAGCAAGCAACACTTATGTCCTGATGCCAAA 480  
Db |||||  
QY 421 CAGAACTCAGCTGCGCATTCGCTGAATGAGCAAGCAACACTTATGTCCTGATGCCAAA 480  
Db |||||  
QY 481 ATGCACTACTCTTCTCTCACTCTGCTGAGTGCATCTGAGTGCATGATGAGTCC 540  
Db |||||  
QY 481 ATGCACTACTCTTCTCTCACTCTGCTGAGTGCATCTGAGTGCATGATGAGTCC 540  
Db |||||  
QY 541 GCACAGAGCTTCAATACCTCTTCTGAGTCTTCTTATCTTCAAGCGGATGACGGAATA 600  
Db |||||  
QY 541 GCACAGAGCTTCAATACCTCTTCTGAGTCTTCTTATCTTCAAGCGGATGACGGAATA 600  
Db |||||  
QY 601 GTTATATTCAGTCTAAGCAGAAATCAGTACGACCAACATTTGGAGAGGAGCTTACA 660  
Db |||||  
QY 601 GTTATATTCAGTCTAAGCAGAAATCAGTACGACCAACATTTGGAGAGGAGCTTACA 660  
Db |||||  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
Db |||||  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
Db |||||  
QY 721 CACAGAAATTTCTTGAAGATGGAAGAGTGTATGCTTTTAAAGATGCTCTCTTAAAC 780  
Db |||||  
QY 721 CACAGAAATTTCTTGAAGATGGAAGAGTGTATGCTTTTAAAGATGCTCTCTTAAAC 780  
Db |||||  
QY 781 TCTGGGTGATTTAACTACACTCTTCTCTCGGTGATGTTGCTTTGATTTGT 840  
Db |||||  
QY 781 TCTGGGTGATTTAACTACACTCTTCTCTCGGTGATGTTGCTTTGATTTGT 840  
Db |||||  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGGAAGCTGAGTATCTAT 900  
Db |||||  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGGAAGCTGAGTATCTAT 900  
Db |||||  
QY 901 GGTGACTTGGAGTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTTGTG 960  
Db |||||  
QY 901 GGTGACTTGGAGTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTTGTG 960  
Db |||||  
QY 961 GTTGTGTAGTCTAAACTGAAAGATCATGAAGAGCAGGGCTCTACCTTACAAAAGTGAAT 1020  
Db |||||  
QY 961 GTTGTGTAGTCTAAACTGAAAGATCATGAAGAGCAGGGCTCTACCTTACAAAAGTGAAT 1020  
Db |||||  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAGTGTATAGACATCTAA 1080  
Db |||||  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAGTGTATAGACATCTAA 1080  
Db |||||

1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTATTCGATATAGCCTTAAGAAATCA 1140  
Db |||||  
1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTATTCGATATAGCCTTAAGAAATCA 1140  
Db |||||  
1141 CTATATAATCAATAAAGTTACTCAAACTGTG 1174  
Db |||||  
1141 CTATATAATCAATAAAGTTACTCAAACTGTG 1174  
Db |||||

RESULT 79  
ADA66892  
ID ADA66892 standard; cDNA; 1174 BP.  
XX  
AC ADA66892;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human PRO polynucleotide #136.  
XX  
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003068793-A1.  
XX  
PD 10-APR-2003.  
XX  
PF 15-APR-2002; 2002US-00123108.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US021547.  
PR 29-NOV-1999; 99WO-US023089.  
PR 30-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US000356.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 20-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001WO-US017800.  
PR 14-JUN-2001; 2001US-00874503.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887979.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 18-JUL-2001; 2001WO-US021735.  
PR 06-AUG-2001; 2001US-00908827.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
PR (GETH ) GENENTECH INC.  
PR Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PR Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PR Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
PR WPI; 2003-695925/66.  
PR P-PSDB; ADA66893.

XX Novel secreted and transmembrane PRO polypeptides useful for stimulating  
PT release of tumor necrosis factor-alpha from human blood and detecting the  
PT presence of a tumor in a mammal.  
XX Claim 2; Fig 271; 660pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGACACAGATGGCGCGCCGAGAGGGAGCCTCTGGGTGAGGACCACTGGGGCTCCCG 120  
DB 61 GGGACACAGATGGCGCGCCGAGAGGGAGCCTCTGGGTGAGGACCACTGGGGCTCCCG 120  
QY 121 CGGTGCTGCTGTGACCATGGGCTTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CGGTGCTGCTGTGACCATGGGCTTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTGTACTCGGTCTTGGGTGATAGGGGCTTTGGCCACCGGGCTGTGAGTGAACCTACCCC 240  
DB 181 TTGTACTCGGTCTTGGGTGATAGGGGCTTTGGCCACCGGGCTGTGAGTGAACCTACCCC 240  
QY 241 TTGCACACCTACCTTAAGGAGAGGAGTTGTACGATGTTCAGAGAGGTTGCAAGCTGTTT 300  
DB 241 TTGCACACCTACCTTAAGGAGAGGAGTTGTACGATGTTCAGAGAGGTTGCAAGCTGTTT 300  
QY 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTTGATTTAAATCGAACTAAATTTGGAATGTGA 360  
DB 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTTGATTTAAATCGAACTAAATTTGGAATGTGA 360  
QY 361 TCTGCATGTACAGAGCATATTCCTATCTGATGACATATGCTTGCATCTTGGTTC 420

Db 361 TCTGATGTACAGACATATCCAACTGATGACCAATATGCTTGCATCTTGGTTGC 420  
QY 421 CAGAACTGATGCGTATGCGTGAACATGACAGCAAGAACTTATATCTCCCTGATCCAAAA 480  
Db 421 CAGAACTGATGCGTATGCGTGAACATGACAGCAAGAACTTATATCTCCCTGATCCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGTCAATCTGAGTGAATGATGATGATCC 540  
Db 481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGTCAATCTGAGTGAATGATGATGATCC 540  
QY 541 GCACAGCTTCAATACCTCTTCAATGAGCTTTTATTTTATTTTCAAGCGATGACGAAAAATA 600  
Db 541 GCACAGCTTCAATACCTCTTCAATGAGCTTTTATTTTATTTTCAAGCGATGACGAAAAATA 600  
QY 601 GTTATATTCAGTCTTAAGCAGCAAAATCCAGTACGACACCACTTTTTCAGCAGGAGCTTACA 660  
Db 601 GTTATATTCAGTCTTAAGCAGCAAAATCCAGTACGACACCACTTTTTCAGCAGGAGCTTACA 660  
QY 661 AATTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAGCG 720  
Db 661 AATTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAGCG 720  
QY 721 CACAGGAAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780  
Db 721 CACAGGAAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780  
QY 781 TCTGGTGGATTTTAACTACACTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 840  
Db 781 TCTGGTGGATTTTAACTACACTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 840  
QY 841 TGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTTCCCTCTGCAAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTTCCCTCTGCAAGCTGAGTATCTAT 900  
QY 901 GGTGACTGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTG 960  
Db 901 GGTGACTGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTG 960  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCTCTACCTACACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCTCTACCTACACAAAGTGAAT 1020  
QY 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAAGTGTATGATGATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCCACTCTCATAGAGCTTTTAAAGTGTATGATGATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTATCTCAAACTGTG 1174  
Db 1141 CTATAAATGCAATTAAGTATCTCAAACTGTG 1174

RESULT 80  
ADB22753  
ID ADB22753 standard; cDNA; 1174 BP.  
XX ADB22753;  
AC ADB22753;  
DT 20-NOV-2003 (first entry)  
DE Human PRO polynucleotide #136.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.  
Homo sapiens.  
US200307711-A1.  
24-APR-2003.  
22-APR-2002; 2002US-00127829.  
22-OCT-1998; 98US-0105169P.  
01-SEP-1999; 99WO-US020111.  
18-OCT-1999; 99US-00403297.  
30-NOV-1999; 99WO-US028313.  
18-FEB-2000; 2000WO-US004342.  
01-DEC-2000; 2000WO-US032678.  
19-DEC-2001; 2001US-00028072.  
(GETH ) GENENTECH INC.  
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;  
WPI; 2003-755066/71.  
P-PSDB; ADB22754.  
New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
in gene therapy, as diagnostic markers for the presence of a disease  
condition, or as therapeutic targets for treating tumors, diabetes,  
obesity or arthritis.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating  
proliferation of or gene expression in pericyte cells, for stimulating  
the proliferation of inner ear utricular supporting cells or T-lymphocyte  
cells, for inducing endothelial cell tube formation and for treating  
various bone and/or cartilage disorders such as sports injuries and  
arthritis. PRO polypeptides which stimulate the release of proteoglycans  
from cartilage are useful for treating sports-related joint problems,  
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
polypeptides are also useful for treating various mammalian haemoglobin-  
associated disorders such as various thalassaemias and conditions which  
may benefit from enhanced local immune system cell infiltration. This  
sequence represents a human PRO polynucleotide of the invention. Note:  
The sequence data for this patent is also available in electronic format  
from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	1	CGGACGCTGGGGAAACCCCTCCGAGAAACACACAAACAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGCTGGGGAAACCCCTCCGAGAAACACACAAACAGCTGAGCTGCTGTGACAGAG	60
Qy	61	GGGACAAAGATGGCGCGCCGAGGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
Db	61	GGGACAAAGATGGCGCGCCGAGGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
Qy	121	CGGCTGCTGCTGCTGACCATGCTTGGCCGAGGTTGGGACCGCTTCGGGTGAAGCA	180
Db	121	CGGCTGCTGCTGCTGACCATGCTTGGCCGAGGTTGGGACCGCTTCGGGTGAAGCA	180
Qy	181	TTTGACTGGTCTTGGGTGATACGGCTCTTGGCACCGGGCTCTGAGTTGACCTACCC	240
Db	181	TTTGACTGGTCTTGGGTGATACGGCTCTTGGCACCGGGCTCTGAGTTGACCTACCC	240
Qy	241	TTTGACACCTACCTAAGGAGAGGAGTTGTACGATGTACAGAGGTTGAGGCTGTTT	300
Db	241	TTTGACACCTACCTAAGGAGAGGAGTTGTACGATGTACAGAGGTTGAGGCTGTTT	300
Qy	301	TCATTTGTGAGTTGTGATGGAATTTGACTTAAATCGAATTAATTTGGAATGTAA	360
Db	301	TCATTTGTGAGTTGTGATGGAATTTGACTTAAATCGAATTAATTTGGAATGTAA	360
Qy	361	TCTGCATGTACAGACATATTTCCCAATCTGATGACATATGCTTGCATCTTTGGTTGC	420
Db	361	TCTGCATGTACAGACATATTTCCCAATCTGATGACATATGCTTGCATCTTTGGTTGC	420
Qy	421	CAGAAATCAGCTGCTGCTGAGCTGAGACAGAACTATGTCCTGATGCCAAA	480
Db	421	CAGAAATCAGCTGCTGCTGAGCTGAGACAGAACTATGTCCTGATGCCAAA	480
Qy	481	ATGCACCTACTCTTCTCTAATCTGCTGAGTCAATCTGAGTGACATGATGACTCC	540
Db	481	ATGCACCTACTCTTCTCTAATCTGCTGAGTCAATCTGAGTGACATGATGACTCC	540
Qy	541	GCAACAGCTTCATACCTCTTCAATGGAATTTTATCTTCAAGCGATGACGGAATA	600
Db	541	GCAACAGCTTCATACCTCTTCAATGGAATTTTATCTTCAAGCGATGACGGAATA	600
Qy	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGCTACA	660
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGCTACA	660
Qy	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG	720
Db	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG	720
Qy	721	CACAGGAATTTCTTGAGATGGAGGAGTGATGGCTTTTAAAGTGCCTCTCTTAAAC	780
Db	721	CACAGGAATTTCTTGAGATGGAGGAGTGATGGCTTTTAAAGTGCCTCTCTTAAAC	780
Qy	781	TCTGGGTGGATTTTAACTACAACCTTTGCTCTCTCGGTGATGATGTTGGAATTTGT	840
Db	781	TCTGGGTGGATTTTAACTACAACCTTTGCTCTCTCGGTGATGATGTTGGAATTTGT	840
Qy	841	TGTCGAATTTGCTACAGCTGTGGAGCTATGTTTCCCTCTGAGAAGCTGATCTAT	900
Db	841	TGTCGAATTTGCTACAGCTGTGGAGCTATGTTTCCCTCTGAGAAGCTGATCTAT	900
Qy	901	GCTGACTTGGATTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTGTG	960
Db	901	GCTGACTTGGATTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTGTG	960
Qy	961	GTTGTTAGATCTAAATCTGAAGATCATGAGAGCAGGCGCTTACTCTCAAAAGTAA	1020
Db	961	GTTGTTAGATCTAAATCTGAAGATCATGAGAGCAGGCGCTTACTCTCAAAAGTAA	1020
Qy	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA	1080

Qy	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGCCCTTAAGAATCA	1140
Db	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGCCCTTAAGAATCA	1140
Qy	1141	CTATAAAATGCAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAAATGCAATAAAGTTACTCAAAATCTGTG	1174

RESULT 81  
ADB23526 standard; cDNA; 1174 BP.

XX ADB23526;  
XX 20-NOV-2003 (first entry)  
XX Human PRO polynucleotide SEQ ID NO 271.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; PFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
immune system cell infiltration.

Homo sapiens.

US2003077712-A1.

24-APR-2003.  
22-APR-2002; 2002US-00127835.  
20-OCT-1998; 9AUS-0104987P.  
01-SEP-1999; 9RWO-US020111.  
18-OCT-1999; 95US-00403297.  
01-FEB-2000; 2000WO-US004342.  
01-DEC-2000; 2000WO-US032678.  
19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen WB, Goddard A, Godowski FJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

WPI: 2003-755067/71.  
P-PSDB; ADB23527.

New isolated, secreted and transmembrane PRO nucleic acid, useful for the  
diagnosis, prevention and/or treatment of tumors, such as lung, colon,  
breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in

generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGGTGGGGAACCCCTCCGAGAAACGACAAAGCTGAGCTGTGACAGAG 60  
DB 1 CGGACGGGTGGGGAACCCCTCCGAGAAACGACAAAGCTGAGCTGTGACAGAG 60  
QY 61 GGGACAGAGTGGCGGCGCGAGGGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
DB 61 GGGACAGAGTGGCGGCGCGAGGGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCATGCCCTTGGCCGGAGGTTCCGGGACCGCTTGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGTGACCATGCCCTTGGCCGGAGGTTCCGGGACCGCTTGGCTGAAGCA 180  
QY 181 TTGACTCGGTCTGGGTGATACGGCTCTGGCCAGCGGCTGTGAGTGACCTACCCC 240  
DB 181 TTGACTCGGTCTGGGTGATACGGCTCTGGCCAGCGGCTGTGAGTGACCTACCCC 240  
QY 241 TTGCACACTACCTTAAAGGAGAGGTTGTACGCATGTGACAGAGGTTGACGGCTGTTT 300  
DB 241 TTGCACACTACCTTAAAGGAGAGGTTGTACGCATGTGACAGAGGTTGACGGCTGTTT 300  
QY 301 TCAATTTGCTGTTGGATGATGGAAATGACTTAAATCGAACTAAATGGAAATGGA 360  
DB 301 TCAATTTGCTGTTGGATGATGGAAATGACTTAAATCGAACTAAATGGAAATGGA 360  
QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420  
QY 421 CAGAAATAGCTGCCATTCGCTGAATGAGACAGAAACAACTTATGTCCTGATGCCAAA 480  
DB 421 CAGAAATAGCTGCCATTCGCTGAATGAGACAGAAACAACTTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTTCCCTTAACCTGCTGAGGTCACTTCTGGAGTGACATGAGACTCC 540  
DB 481 ATGCACCTACTCTTTCCCTTAACCTGCTGAGGTCACTTCTGGAGTGACATGAGACTCC 540  
QY 541 GCACAGAGCTTCATTAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATA 600  
DB 541 GCACAGAGCTTCATTAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATA 600  
QY 601 GTTATATTCAGTCTTAAGCCGAAATTCAGTACGACCAATTTGGAGGAGGCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCGAAATTCAGTACGACCAATTTGGAGGAGGCTTACA 660  
QY 661 AATTTGAGAGATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAGCG 720

661 AATTTGAGAGATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAGCG 720  
721 CACAGAAATTTCTTGAAGATCGAGAAAGTGAATGCTTTTAAAGATGCTCTCTCTTAAC 780  
721 CACAGAAATTTCTTGAAGATCGAGAAAGTGAATGCTTTTAAAGATGCTCTCTCTTAAC 780  
781 TCTGGGTGATTTAACTACAACTCTTGTCTCTCGGTGATGATGATGATGATGATGAT 840  
781 TCTGGGTGATTTAACTACAACTCTTGTCTCTCGGTGATGATGATGATGATGATGAT 840  
841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGATGATGTTCCCTCTGAGAAGCTGATCTAT 900  
841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGATGATGTTCCCTCTGAGAAGCTGATCTAT 900  
901 GGTGACTGTGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTG 960  
901 GGTGACTGTGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTG 960  
961 GTTGTGTAGTCTTAAACTCAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
961 GTTGTGTAGTCTTAAACTCAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
1021 CTTGCTCATCTCAAAATTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080  
1021 CTTGCTCATCTCAAAATTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080  
1081 AATCCACTCTCATAGAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140  
1081 AATCCACTCTCATAGAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140  
1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 82  
ADA92248  
ID ADA92248 standard; cdna; 1174 BP.  
XX  
AC ADA92248;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO195 cdna.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
XX US2003082712-A1.  
PN  
XX  
PD 01-MAY-2003.  
XX  
XX 16-MAY-2002; 2002US-00147512.  
PF  
XX  
XX 15-MAY-1998; 98US-0055697P.  
PR  
XX 08-MAR-1999; 99WO-US005028.  
PR  
XX 25-AUG-1999; 99US-00380138.  
PR  
XX 01-DEC-2000; 2000WO-US032678.  
PR  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, DeForge L, Deanoyers L, Filvaroff E, Gao W;  
PI Gerritsen MS, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786915/74.  
DR P-PSDB; ADA92249.  
XX  
XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.  
XX  
XX Claim 2; Fig 271; 637pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60  
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60  
QY 61 GGGACACAGATCGCGCGCCGAGGGAGCCCTCGGGTGAGGACCCCAACTGGGGCTCCCG 120  
Db 61 GGGACACAGATCGCGCGCCGAGGGAGCCCTCGGGTGAGGACCCCAACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTCCGGGACCGCTTGGCTGGAAGCA 180  
Db 121 CGGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTCCGGGACCGCTTGGCTGGAAGCA 180  
QY 181 TTGACTCGGCTTGGGTGATACGGCGCTTCCACCGGGCTGTGACCTACCTACCCC 240  
Db 181 TTGACTCGGCTTGGGTGATACGGCGCTTCCACCGGGCTGTGACCTACCTACCCC 240  
QY 241 TTGCACACCTTACCCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGGTTGAGCTGTTT 300  
Db 241 TTGCACACCTTACCCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGGTTGAGCTGTTT 300  
QY 301 TCAATTGTGAGTTTGTGATGATGGAATGCTTAATTCGAACTAAATTCGAATGGAATGAA 360  
Db 301 TCAATTGTGAGTTTGTGATGATGGAATGCTTAATTCGAACTAAATTCGAATGGAATGAA 360  
QY 361 TCTGCATGTACAGACGATATTCCTCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420  
Db 361 TCTGCATGTACAGACGATATTCCTCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAGAACCACTTATGTCCTGATGCGCAAAA 480  
Db 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAGAACCACTTATGTCCTGATGCGCAAAA 480  
QY 481 ATGCACCTACTCTTTTCCCTCTAACTCTGTGTGAGGTCAATCTGTGAGTGACATGAGACTCC 540  
Db 481 ATGCACCTACTCTTTTCCCTCTAACTCTGTGTGAGGTCAATCTGTGAGTGACATGAGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAGCCGATGACGCGAAATA 600  
Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAGCCGATGACGCGAAATA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCGACCACTTGTGAGCAGAGCTTACA 660  
Db 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCGACCACTTGTGAGCAGAGCTTACA 660  
QY 661 AATTGAGAGATCATCTCTTAAGCAAAATGCTCTCTGCAATGAGAAATTCACAGGG 720  
Db 661 AATTGAGAGATCATCTCTTAAGCAAAATGCTCTCTGCAATGAGAAATTCACAGGG 720  
QY 721 CACAGGAATTTTCTGAAGATGAGAAAGTAGTGGCTTTTAAAGATGCCCTCTCTTAAC 780  
Db 721 CACAGGAATTTTCTGAAGATGAGAAAGTAGTGGCTTTTAAAGATGCCCTCTCTTAAC 780  
QY 781 TCTGGGTGGATTTTAACTACACTCTTGTCTCTCGTGTGATGTTGCTTTGGATTGCT 840  
Db 781 TCTGGGTGGATTTTAACTACACTCTTGTCTCTCGTGTGATGTTGCTTTGGATTGCT 840  
QY 841 TGTCAACTGTGTGCTACAGCTGTGGAGCAGTAGTGTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTCAACTGTGTGCTACAGCTGTGGAGCAGTAGTGTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
Db 901 GGTGACTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTCGAAATTTAAGCAATTTCTTTTAAAGCAAGAGTGTATAGACATCTAA 1080  
Db 1021 CTTGCTCATCTCGAAATTTAAGCAATTTCTTTTAAAGCAAGAGTGTATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCTACAGCTTTTAAATGTTTCAATGGATATAGCCCTTAAAGAAATCA 1140  
Db 1081 AATTCCACTCTCTACAGCTTTTAAATGTTTCAATGGATATAGCCCTTAAAGAAATCA 1140  
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

## RESULT 83

ADBI5311

ID ADBI5311 standard; cDNA; 1174 BP.

XX

AC ADBI5311;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human PRO polynucleotide #136.

XX

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;  
KW immune system cell infiltration.



XX OS Homo sapiens.  
XX PN US2003087352-A1.  
XX PD 08-MAY-2003.  
XX PF 22-APR-2002; 2002US-00127824.  
XX PR 17-AUG-1998; 98US-0096891P.  
XX PR 02-JUN-1999; 99WO-US012252.  
XX PR 25-AUG-1999; 99US-00380137.  
XX PR 30-MAR-2000; 2000WO-US008439.  
XX PR 30-MAY-2000; 2000WO-US014941.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX FA (GETH ) GENENTECH INC.  
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX DR WPI; 2003-786943/74.  
XX DR P-PSDB; ADB15312.  
XX PT New PRO nucleic acid, useful for producing a recombinant PRO polypeptide  
XX PT and for manufacturing a medicament for diagnosing or treating tumor.  
XX PS Claim 2; Fig 271; 637pp; English.  
XX CC The invention relates to isolated human PRO polypeptides (secreted and  
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The  
XX CC invention also relates to an antibody which specifically binds to a PRO  
XX CC polypeptide, a method for stimulating the release of tumor necrosis  
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX CC proliferation or differentiation of chondrocyte cells and a method for  
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX CC polynucleotides are useful in molecular biology, including uses as  
XX CC hybridisation probes, in chromosome and gene mapping, in generating  
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX CC be used in preparing PRO polypeptides by recombinant techniques and in  
XX CC generating either transgenic animals or knock-out animals which are  
XX CC useful in the development and screening of therapeutically useful  
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a  
XX CC medicament for treating a condition responsive to the polypeptides or  
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX CC of human microvascular endothelial cells, for modulating the uptake of  
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX CC stimulating differentiation of adipocyte cells, for stimulating  
XX CC proliferation of or gene expression in pericyte cells, for stimulating  
XX CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX CC cells, for inducing endothelial cell tube formation and for treating  
XX CC various bone and/or cartilage disorders such as sports injuries and  
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX CC from cartilage are useful for treating sports-related joint problems,  
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX CC polypeptides are also useful for treating various mammalian haemoglobin-  
XX CC associated disorders such as various thalassemias and conditions which  
XX CC may benefit from enhanced local immune system cell infiltration. This  
XX CC sequence represents a human PRO polynucleotide of the invention. Note:  
XX CC The sequence data for this patent is also available in electronic format  
XX CC from USPTO at seqdata.uspto.gov/sequence.html.  
XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
1 CGGACGCTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
61 GGGAAACAAGATGGCGCGCGGAGGGAGCCTCTGGGTGAGGACCAACTGGGGCTCCCG 120  
61 GGGAAACAAGATGGCGCGCGGAGGGAGCCTCTGGGTGAGGACCAACTGGGGCTCCCG 120  
121 CCGCTGCTGCTGCTGACCACTATGCCCTTGGCGGAGGTTGGGGACCGCTTCGGCTCAAGCA 180  
121 CCGCTGCTGCTGCTGACCACTATGCCCTTGGCGGAGGTTGGGGACCGCTTCGGCTCAAGCA 180  
181 TTTGACTCGGTCTTGGGTGATAGCGGCTCTTGGCCACCGGCGCTGTCAGTTGACCTACCC 240  
181 TTTGACTCGGTCTTGGGTGATAGCGGCTCTTGGCCACCGGCGCTGTCAGTTGACCTACCC 240  
241 TTGCACACCTTACCCCTAAGGAAGAGAGTGTGTACGATGTGCAGAGGTTGCAAGGTGTTT 300  
241 TTGCACACCTTACCCCTAAGGAAGAGAGTGTGTACGATGTGCAGAGGTTGCAAGGTGTTT 300  
301 TCAATTTGTGAGTGTGGATGATGGAATTTGATTAATCGAACTAAATTTGGAATGTGAA 360  
301 TCAATTTGTGAGTGTGGATGATGGAATTTGATTAATCGAACTAAATTTGGAATGTGAA 360  
361 TCTGCATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGCTTGC 420  
361 TCTGCATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGCTTGC 420  
421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480  
421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480  
481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGGTCACTCTGAGTGACATGATGCACTCC 540  
481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGGTCACTCTGAGTGACATGATGCACTCC 540  
541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGAAATAA 600  
541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGAAATAA 600  
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGAGAGGCTTAC 660  
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGAGAGGCTTAC 660  
661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATAGAAATTCACAAGCG 720  
661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATAGAAATTCACAAGCG 720  
721 CACAGGAATTTCTTGAAGTGAAGAGTGGCTTTTAAAGTGCCTCTCTCTTAAC 780  
721 CACAGGAATTTCTTGAAGTGAAGAGTGGCTTTTAAAGTGCCTCTCTCTTAAC 780  
781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGCTATTGCTTTGGATTGT 840  
781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGCTATTGCTTTGGATTGT 840  
841 TGTGCACTGTGTGACAGCTGTGGAGCATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
841 TGTGCACTGTGTGACAGCTGTGGAGCATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960  
961 GTTGTAGATCTAAACATGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
961 GTTGTAGATCTAAACATGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
1021 CTTGCTCAATCTGAAATTTAAGCAATTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
1021 CTTGCTCAATCTGAAATTTAAGCAATTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
1081 AATTCACCTCTCATAGAGCTTTTAAATAGTGTTCATGTGATATAGCCCTTAAAGAAATCA 1140  
1081 AATTCACCTCTCATAGAGCTTTTAAATAGTGTTCATGTGATATAGCCCTTAAAGAAATCA 1140



Qy 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174  
 Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 84  
 ADB38563  
 ID ADB38563 standard; cDNA; 1174 BP.  
 AC ADB38563;  
 XX  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX  
 XX Novel human secreted and transmembrane protein PRO195 cDNA.  
 DE  
 XX Human; secreted and transmembrane protein; PRO; gene; ss;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; PFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003082766-A1.  
 PN  
 XX  
 XX  
 PD 01-MAY-2003.  
 XX  
 XX  
 PF 30-MAY-2002; 2002US-00158782.  
 XX  
 PR 31-MAR-1997; 97WO-US0052230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US023992.  
 PR 20-NOV-1998; 98WO-US024853.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010723.  
 PR 02-JUN-1999; 98WO-US020111.  
 PR 01-SEP-1999; 98WO-US020594.  
 PR 08-SEP-1999; 98WO-US020944.  
 PR 13-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 23-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028303.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.

PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023528.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-0074259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001US-00805520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854308.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882836.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00308827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786921/74.  
 XX P-PSDB; ADB38564.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 PT in gene therapy, detecting the presence of tumor in a mammal, or  
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle  
 PT cells or adipocyte cells.

XX Claim 2; Fig 271; 660pp; English.

PS The invention describes 305 nucleic acids encoding PRO (secreted and  
XX transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from BMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
1 CGGACGGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTCGACAGAG 60  
1 CGGACGGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTCGACAGAG 60  
61 GGGACAGATGGCGGCGCGGAGGAGGCTCGGCTGAGGAGCCCACTGGGGCTCCCG 120  
61 GGGACAGATGGCGGCGCGGAGGAGGCTCGGCTGAGGAGCCCACTGGGGCTCCCG 120  
121 CGGCTGCTGCTGACCATGCGCTTCGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180  
121 CGGCTGCTGCTGACCATGCGCTTCGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180  
181 TTGACTCGGCTTGGGTGATACGGGCTTCGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 240  
181 TTGACTCGGCTTGGGTGATACGGGCTTCGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 240  
241 TTGACACTACCTCCCTAAGGAGAGAGGTTGACGCTGTCAGAGAGGTTTCAGGCTGTTT 300  
241 TTGACACTACCTCCCTAAGGAGAGGTTGACGCTGTCAGAGAGGTTTCAGGCTGTTT 300  
301 TCAATTTGTCAGTTTGGATGATGGAATTCGATTAATCGAATTAATGGAATGGA 360  
301 TCAATTTGTCAGTTTGGATGATGGAATTCGATTAATCGAATTAATGGAATGGA 360  
361 TCTGCATGTACAGAGCATATTCCTCAATCTCATGAGCAATATGCTTCGCACTTGGTTGC 420  
361 TCTGCATGTACAGAGCATATTCCTCAATCTCATGAGCAATATGCTTCGCACTTGGTTGC 420  
421 CAGAAATCAGTCCCATTCGCTGAATCAGAGCAAGAAACAACTTATGTCCTGATGCCAATA 480  
421 CAGAAATCAGTCCCATTCGCTGAATCAGAGCAAGAAACAACTTATGTCCTGATGCCAATA 480  
481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540

QY 541 GCACAGAGCTTCATACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600  
DB 541 GCACAGAGCTTCATACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTAGCGACACACATTTTGGAGCAGGACTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTAGCGACACACATTTTGGAGCAGGACTTACA 660  
QY 661 AATTGAGAGATCATCTTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGGG 720  
DB 661 AATTGAGAGATCATCTTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGGG 720  
QY 721 CACAGAAATTTCTTCAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGAAATTTCTTCAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACTCAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT 840  
DB 781 TCTGGTGGATTTTAACTCAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT 840  
QY 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900  
DB 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGATGAACAAAAAGCTTAAACAGATATCCAGCTTCTCTTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGATGAACAAAAAGCTTAAACAGATATCCAGCTTCTCTTTGTG 960  
QY 961 GTTGTAGATCTTAAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTTAAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATGACATCTAA 1080  
DB 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATGACATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAAGTGTTCATTTGGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCCACTCTCATAGAGCTTTTAAAGTGTTCATTTGGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATATAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAATGCAATATAAGTTACTCAAAATCTGTG 1174  
RESULT 85  
ADB38011  
ID ADB38011 standard; cDNA; 1174 BP.  
XX AC ADB38011;  
XX DT 04-DEC-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX OS Homo sapiens.  
XX FN US2003087347-A1.  
XX PD 08-MAY-2003.  
XX PF 19-APR-2002; 2002US-00125921.  
XX

PR 17-AUG-1998; 98US-0096791P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 25-AUG-1999; 99US-00380137.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI: 2003-786938/74.  
 DR P-PSDB; ADB6483.  
 XX  
 PR New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
 PT and for manufacturing a medicament for diagnosing or treating tumor.  
 XX  
 PS Claim 2; Fig 271; 637pp; English.  
 XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (II) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX  
 SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAAACCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60  
 DB 1 CGGACGCTGGGGGAAACCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60  
 QY 61 GGGACACAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120  
 DB 61 GGGACACAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120  
 QY 121 CGGCTGCTGCTGACCATGCGCTTGGCGGAGGCTCGGGGACCGCTTCGGCTGAGGCA 180  
 DB 121 CGGCTGCTGCTGACCATGCGCTTGGCGGAGGCTTCGGGACCGCTTCGGCTGAGGCA 180  
 QY 181 TTGACTCGGCTTGGGTGATACGGCGTCTTGGCAACCGGGCTGTGCACTGACCTACCCC 240  
 DB 181 TTGACTCGGCTTGGGTGATACGGCGTCTTGGCAACCGGGCTGTGCACTGACCTACCCC 240  
 QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTGTGACGATGTCAGAGAGGTTGCAGGCTGTTT 300

## RESULT 86

ADB66483  
 ID ADB66483 standard; cDNA; 1174 BP;

XX AC ADB66483;

XX XX

DT 04-DEC-2003 (first entry)

XX XX

DE Novel human secreted and transmembrane protein PRO195 cDNA.

DB 241 TTGCACACCTTACCTTAAGGAAGAGGAGTTGTAGCAATGTCAGAGGTTGAGGCTGTTT 300  
 QY 301 TCAATTTGTGTCAGTTTGTGGATGATGAAATGCACTTAAATCGAATTAATGGAATGTA 360  
 DB 301 TCAATTTGTGTCAGTTTGTGGATGATGAAATGCACTTAAATCGAATTAATGGAATGTA 360  
 QY 361 TCTGCATGTACAGACGATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGTC 420  
 DB 361 TCTGCATGTACAGACGATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGTC 420  
 QY 421 CAGAATCAGCTGCTCATTCGCTGAACTGAGACCAAGAACAACTTATGTCCCTGATGCCAAA 480  
 DB 421 CAGAATCAGCTGCTCATTCGCTGAACTGAGACCAAGAACAACTTATGTCCCTGATGCCAAA 480  
 QY 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGTCACTCTGGAGTGACATGATGACTCC 540  
 DB 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGTCACTCTGGAGTGACATGATGACTCC 540  
 QY 541 GCACAGAGCTTTCATACCTCTTCATGAGCTTTTATATCTTCAAGCCGATGACGAAAAATA 600  
 DB 541 GCACAGAGCTTTCATACCTCTTCATGAGCTTTTATATCTTCAAGCCGATGACGAAAAATA 600  
 QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCGACCACTTTGGAGCAGGAGCTACA 660  
 DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCGACCACTTTGGAGCAGGAGCTACA 660  
 QY 661 AATTGTGAGCAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
 DB 661 AATTGTGAGCAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
 QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGGTCTTTTAAAGATGCTCTCTCTTAAC 780  
 DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGGTCTTTTAAAGATGCTCTCTCTCTTAAC 780  
 QY 781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGTTTGGATTTGT 840  
 DB 781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGTTTGGATTTGT 840  
 QY 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900  
 DB 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900  
 QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAAAGATATCCAGTCTTCTCTTTGG 960  
 DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAAAGATATCCAGTCTTCTCTTTGG 960  
 QY 961 GTTGTGATCTAAAAGCTGAAGATCATGAAGAGCGGGGCTCTACTACAAAAGTGAAT 1020  
 DB 961 GTTGTGATCTAAAAGCTGAAGATCATGAAGAGCGGGGCTCTACTACAAAAGTGAAT 1020  
 QY 1021 CTTGCTCATCTCGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
 DB 1021 CTTGCTCATCTCGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
 QY 1081 AATTCCACTCTCTATAGAGCTTTTAAATGTTTCAATGATATAGCCCTTAAAGAAATCA 1140  
 DB 1081 AATTCCACTCTCTATAGAGCTTTTAAATGTTTCAATGATATAGCCCTTAAAGAAATCA 1140  
 QY 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174  
 DB 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174

XX Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX Homo sapiens.  
XX US2003082689-A1.  
XX 01-MAY-2003.  
XX 22-APR-2002; 2002US-00127831.  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019093.  
XX 14-SEP-1998; 98WO-US019094.  
XX 16-SEP-1998; 98WO-US019177.  
XX 17-SEP-1998; 98WO-US019330.  
XX 07-OCT-1998; 98WO-US019437.  
XX 29-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022991.  
XX 20-NOV-1998; 98WO-US024855.  
XX 01-DEC-1998; 98WO-US025108.  
XX 05-JAN-1999; 98WO-US000106.  
XX 08-MAR-1999; 98WO-US005028.  
XX 10-MAR-1999; 98WO-US005190.  
XX 20-APR-1999; 98WO-US008615.  
XX 14-MAY-1999; 98WO-US010733.  
XX 02-JUN-1999; 98WO-US012252.  
XX 01-SEP-1999; 98WO-US020111.  
XX 08-SEP-1999; 98WO-US020594.  
XX 13-SEP-1999; 98WO-US020944.  
XX 15-SEP-1999; 98WO-US021090.  
XX 15-SEP-1999; 98WO-US021547.  
XX 05-OCT-1999; 98WO-US023089.  
XX 29-NOV-1999; 98WO-US028214.  
XX 30-NOV-1999; 98WO-US028313.  
XX 30-NOV-1999; 98WO-US028409.  
XX 01-DEC-1999; 98WO-US028301.  
XX 01-DEC-1999; 98WO-US028634.  
XX 02-DEC-1999; 98WO-US028551.  
XX 02-DEC-1999; 98WO-US028564.  
XX 16-DEC-1999; 98WO-US030095.  
XX 20-DEC-1999; 98WO-US030911.  
XX 20-DEC-1999; 98WO-US030999.  
XX 22-DEC-1999; 98WO-US030720.  
XX 30-DEC-1999; 98WO-US031243.  
XX 30-DEC-1999; 98WO-US031274.  
XX 05-JAN-2000; 2000WO-US000219.  
XX 06-JAN-2000; 2000WO-US000277.  
XX 06-JAN-2000; 2000WO-US000376.  
XX 11-FEB-2000; 2000WO-US003565.  
XX 18-FEB-2000; 2000WO-US004341.  
XX 18-FEB-2000; 2000WO-US004342.  
XX 22-FEB-2000; 2000WO-US004414.  
XX 24-FEB-2000; 2000WO-US004914.  
XX 24-FEB-2000; 2000WO-US005004.  
XX 01-MAR-2000; 2000WO-US005601.  
XX 02-MAR-2000; 2000WO-US005746.  
XX 02-MAR-2000; 2000WO-US005841.  
XX 10-MAR-2000; 2000WO-US006319.  
XX 15-MAR-2000; 2000WO-US006684.  
XX 20-MAR-2000; 2000WO-US007377.  
XX 21-MAR-2000; 2000WO-US007532.  
XX 30-MAR-2000; 2000WO-US008439.  
XX 17-MAY-2000; 2000WO-US013705.  
XX 22-MAY-2000; 2000WO-US014042.  
XX 30-MAY-2000; 2000WO-US014941.  
XX 02-JUN-2000; 2000WO-US015264.  
XX 28-JUN-2000; 2000WO-US020710.  
XX 11-AUG-2000; 2000WO-US022031.  
XX 23-AUG-2000; 2000WO-US023522.  
XX 24-AUG-2000; 2000WO-US023328.  
XX 08-NOV-2000; 2000WO-US030952.  
XX 10-NOV-2000; 2000WO-US030873.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 20-DEC-2000; 2000US-00747259.  
XX 20-DEC-2000; 2000WO-US034356.  
XX 28-FEB-2001; 2001US-00756498.  
XX 28-FEB-2001; 2001WO-US006520.  
XX 01-MAR-2001; 2001WO-US006666.  
XX 09-MAR-2001; 2001US-00802706.  
XX 14-MAR-2001; 2001US-00808689.  
XX 22-MAR-2001; 2001US-00816744.  
XX 05-APR-2001; 2001US-00828366.  
XX 10-MAY-2001; 2001US-00854208.  
XX 10-MAY-2001; 2001US-00854280.  
XX 18-MAY-2001; 2001US-00860216.  
XX 25-MAY-2001; 2001US-00866028.  
XX 25-MAY-2001; 2001US-00866034.  
XX 01-JUN-2001; 2001US-00872035.  
XX 01-JUN-2001; 2001WO-US017800.  
XX 05-JUN-2001; 2001US-00874503.  
XX 14-JUN-2001; 2001US-00882636.  
XX 19-JUN-2001; 2001US-00886342.  
XX 20-JUN-2001; 2001US-00919692.  
XX 21-JUN-2001; 2001US-00887879.  
XX 22-JUN-2001; 2001WO-US020116.  
XX 29-JUN-2001; 2001WO-US021066.  
XX 09-JUL-2001; 2001WO-US021735.  
XX 18-JUL-2001; 2001US-00908827.  
XX 06-AUG-2001; 2001US-00924419.  
XX 09-AUG-2001; 2001US-00927796.  
XX 16-AUG-2001; 2001US-00931836.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786905/74.  
XX P-PSDB; ADB6484.  
XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g. tumor or for tissue typing.  
XX Claim 2; Fig 271; 637pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from FMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGTGTGTCACAGAG 60  
Db 1 CGGACCGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGTGTGTCACAGAG 60

QY 61 GGGACACAGATGGCGCGCGCGAGGGGAGCTCTGGGTGAGACCCCACTGGGGCTCCCG 120  
Db 61 GGGACACAGATGGCGCGCGCGAGGGGAGCTCTGGGTGAGACCCCACTGGGGCTCCCG 120

QY 121 CGCGTCTGCTGCTGACCATGCGCTTGGCGGAGGCTTCGGGACCGCTTCGGCTGGAAGCA 180  
Db 121 CGCGTCTGCTGCTGACCATGCGCTTGGCGGAGGCTTCGGGACCGCTTCGGCTGGAAGCA 180

QY 181 TTGACTCGGTGTGGGTGATACGGGCTTTCGCCACCGGGCTGTGAGTGTGACCTACCCC 240  
Db 181 TTGACTCGGTGTGGGTGATACGGGCTTTCGCCACCGGGCTGTGAGTGTGACCTACCCC 240

QY 241 TTGCACACCTACCTAAGGAAGAGAGTGTGACGATGTGACAGAGGTTCAGAGCTGTTT 300  
Db 241 TTGCACACCTACCTAAGGAAGAGAGTGTGACGATGTGACAGAGGTTCAGAGCTGTTT 300

QY 301 TCAATTTGTCAGTTGTGGATGATGGAATGATCTTAATTCGACCTAATTCGATGTGAA 360  
Db 301 TCAATTTGTCAGTTGTGGATGATGGAATGATCTTAATTCGACCTAATTCGATGTGAA 360

QY 361 TCTGCATGTACAGAACATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
Db 361 TCTGCATGTACAGAACATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAAATCAGTGCCTGATGCACTGAGACAGAACCACTTATGTCCTCTGATGCCAAA 480  
Db 421 CAGAAATCAGTGCCTGATGCACTGAGACAGAACCACTTATGTCCTCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTCTCTTAACCTGCTGAGTGCATCTGAGTGCATGATGACTCC 540  
Db 481 ATGCACCTACTCTTCTCTTAACCTGCTGAGTGCATCTGAGTGCATGATGACTCC 540

QY 541 GCACAGAGCTTCAACCTTTCATGCACTTTTATCTTCAAGCCGATGACGGAAAATA 600  
Db 541 GCACAGAGCTTCAACCTTTCATGCACTTTTATCTTCAAGCCGATGACGGAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACATTTGAGCAGAGGCTTACA 660  
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACATTTGAGCAGAGGCTTACA 660

QY 661 AATTGTGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAGCG 720  
Db 661 AATTGTGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAGCG 720

QY 721 CACAGGAATTTCTTGAGATGAGAAAGTATGGCTTTTAAAGTGGCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTTGAGATGAGAAAGTATGGCTTTTAAAGTGGCTCTCTCTTAAC 780

QY 781 TCTGGTGGATTTTAACTACAACTCTTGCTCTCGGTGATGATGCTTTGGATTTCT 840  
Db 781 TCTGGTGGATTTTAACTACAACTCTTGCTCTCGGTGATGATGCTTTGGATTTCT 840

QY 841 TGTGCAATGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCAATGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960

QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGACAGCGGCTCTACTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGACAGCGGCTCTACTACAAAGTGAAT 1020

QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080

QY 1081 AATTCACCTCTCATAGAGCTTTTAAATAGTTCATGATATAGCCCTTAAGAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATAGTTCATGATATAGCCCTTAAGAATCA 1140

QY 1141 CTATATAATGCAATATAAGTTTACTCAAAATCTGTG 1174  
Db 1141 CTATATAATGCAATATAAGTTTACTCAAAATCTGTG 1174

RESULT 87  
ADB89563  
ID ADB89563 standard; cDNA; 1174 BP.  
XX  
AC ADB89563;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Human PRO polynucleotide #136.  
XX  
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US2003082698-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 22-APR-2002; 2002US-00127850.  
XX  
PR 20-AUG-1998; 98US-0097218P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-743896/70.  
DR

DR P-PSDB; ADB89564.

XX New PRO nucleic acids and encoded polypeptides, useful in the treatment

PT of cancer.

PS Claim 2; Fig 271; 637bp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCTTCCGAGAAAACAGCAACAGCTGAGTCTGTGACAGAG 60

DB 1 CGGACGCGTGGGGAAACCTTCCGAGAAAACAGCAACAGCTGAGTCTGTGACAGAG 60

QY 61 GGGACACAGATGCGCGCGCGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

DB 61 GGGACACAGATGCGCGCGCGGAGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

QY 121 CGGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGGGAGCGGCTTGGCTGGAAGCA 180

DB 121 CGGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGGGAGCGGCTTGGCTGGAAGCA 180

QY 181 TTGTACTCGGCTTGGGTGATACGGCGCTTGGCCACCGGGCTGTGAGTGAACCTACCC 240

DB 181 TTGTACTCGGCTTGGGTGATACGGCGCTTGGCCACCGGGCTGTGAGTGAACCTACCC 240

QY 241 TTGCACACCTACCTAAGGAAGAGAGTGTGACGATCTCAGAGAGGTTGAGGCTGTTT 300

DB 241 TTGCACACCTACCTAAGGAAGAGAGTGTGACGATCTCAGAGAGGTTGAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGTGATGATGGAATGCAATTAATCGAATTAATTTGGAATGGA 360

DB 301 TCAATTTGTCAGTTTGTGATGATGGAATGCAATTAATCGAATTAATTTGGAATGGA 360

QY 361 TCTGCATGTACAGACATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420

DB 361 TCTGCATGTACAGACATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420

QY 421 CAGAACTCAGCTGCCATTCCTGCTGAACTGAGACAAAGCAAACTTATCTCCTGATGCCAAA 480

DB 421 CAGAACTCAGCTGCCATTCCTGCTGAACTGAGACAAAGCAAACTTATCTCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTTCTTAACTCTGCTGAGGTGATCTTCTGAGTGAATGAGTACTCC 540

DB 481 ATGCACCTACTCTTTTCTTAACTCTGCTGAGGTGATCTTCTGAGTGAATGAGTACTCC 540

QY 541 GCACAGGCTTCATAACCTCTTTCATGAGCTTTTATCTTCAAGCGGATGACCGGAAAATA 600

DB 541 GCACAGGCTTCATAACCTCTTTCATGAGCTTTTATCTTCAAGCGGATGACCGGAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGAGCCTACA 660

DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGAGCCTACA 660

QY 661 AATTGAGAGATCACTCTTACGAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720

DB 661 AATTGAGAGATCACTCTTACGAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGAGAAAGTGGTCTTTTAAAGTGCCTCTCTCTTAAC 780

DB 721 CACAGGAATTTTCTTGAAGATGAGAAAGTGGTCTTTTAAAGTGCCTCTCTCTTAAC 780

QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGTCTGATGATGCTTCTTGGATTCT 840

DB 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGTCTGATGATGCTTCTTGGATTCT 840

QY 841 TGTCCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900

DB 841 TGTCCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900

QY 901 GGTGACTGGATTATGATGAAACAAAGCTTAAACAGATNCCAGCTTCTCTCTTGG 960

DB 901 GGTGACTGGATTATGATGAAACAAAGCTTAAACAGATNCCAGCTTCTCTCTTGG 960

QY 961 GTTCTTAGATCTAAACTGAAAGATCATGAAAGACAGGCGCTCTACTCAAAAGTGAAT 1020

DB 961 GTTCTTAGATCTAAACTGAAAGATCATGAAAGACAGGCGCTCTACTCAAAAGTGAAT 1020

QY 1021 CTTGCTCATCTTGAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080

DB 1021 CTTGCTCATCTTGAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080

QY 1081 AATTCCACTCTCTATAGAGCTTTTAAATGTTTCAATTTGGATATAGGCTTTAAGAAATCA 1140

DB 1081 AATTCCACTCTCTATAGAGCTTTTAAATGTTTCAATTTGGATATAGGCTTTAAGAAATCA 1140

QY 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174

DB 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174

RESULT 88

ADB90295

ID ADB90295 standard; cDNA; 1174 BP.

XX

AC ADB90295;

XX

DT 04-DEC-2003 (first entry)

XX

DE Human PRO polynucleotide #136.

XX

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGAAACCCCTCCGAGAAACACCAAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGCTGGGGAAACCCCTCCGAGAAACACCAAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGGCCGAGAGGAGCTCTGGGTGAGAGCCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGGCCGAGAGGAGCTCTGGGTGAGAGCCCAACTGGGGCTCCCG 120  
QY 121 CGCGTCTGCTGCTGACCATGAGCTTGGCGGAGCTTGGCGGACCGCTCGGCTGAAGCA 180  
DB 121 CGCGTCTGCTGCTGACCATGAGCTTGGCGGAGCTTGGCGGACCGCTCGGCTGAAGCA 180  
QY 181 TTGACTCGGCTTGGGTGATACGGCGCTTTGCCACCGGGCTCTGAGTTGACTACCCC 240  
DB 181 TTGACTCGGCTTGGGTGATACGGCGCTTTGCCACCGGGCTCTGAGTTGACTACCCC 240  
QY 241 TTGCACTACCTTGGGTGATACGGCGCTTTGCCACCGGGCTCTGAGTTGACTACCCC 300  
DB 241 TTGCACTACCTTGGGTGATACGGCGCTTTGCCACCGGGCTCTGAGTTGACTACCCC 300  
QY 301 TCAATTTGTGCTGGTGGATGAGATGAAATGAACTTAAATCGAATTAATGGAATGAA 360  
DB 301 TCAATTTGTGCTGGTGGATGAGATGAAATGAACTTAAATCGAATTAATGGAATGAA 360  
QY 361 TGTGATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTCCATCTTGGTGC 420  
DB 361 TGTGATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTCCATCTTGGTGC 420  
QY 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACCAAGAACTTATGCTCCCTGATGCCAAA 480  
DB 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACCAAGAACTTATGCTCCCTGATGCCAAA 480  
QY 481 ATGACCTACTCTTCTCTAATCTGCTGAGTCAATCTGAGTGCATGATGATGATCC 540  
DB 481 ATGACCTACTCTTCTCTAATCTGCTGAGTCAATCTGAGTGCATGATGATGATCC 540  
QY 541 GCACAGAGCTTCAATACCTCTTATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCAATACCTCTTATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCAAGCAAGATTCAGTACGCAATTTGGAGAGGAGCCCTACA 660  
DB 601 GTTATATTCAGTCAAGCAAGATTCAGTACGCAATTTGGAGAGGAGCCCTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGAAATTTCTTGAAGATCGAAGATGATGCTTTTAAAGATGCTCTCTTAAAC 780  
DB 721 CACAGAAATTTCTTGAAGATCGAAGATGATGCTTTTAAAGATGCTCTCTTAAAC 780  
QY 781 TCTGGGTGATTTAACTACACTCTCTCTCTCGGTGATGATGATGCTTTGATTTGT 840

DB 781 TCTGGGTGATTTTAACTACACTCTTCTCTCGGTGATGATGATGCTTTGATTTGT 840  
QY 841 TGTGCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCAT 900  
DB 841 TGTGCAACTCTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCAT 900  
QY 901 GGTGACCTGGAGTTTATGAATGAACAAAGAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
DB 901 GGTGACCTGGAGTTTATGAATGAACAAAGAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
QY 961 GTTCTTATGATCTTAAACTGAAATGATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020  
DB 961 GTTCTTATGATCTTAAACTGAAATGATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020  
QY 1021 CTTCTCATCTTGAATTTAAAGCATTTTCTTTTAAAGAGAGAGAGAGAGAGAGAGAGAG 1080  
DB 1021 CTTCTCATCTTGAATTTAAAGCATTTTCTTTTAAAGAGAGAGAGAGAGAGAGAGAGAG 1080  
QY 1081 AATTCCTCTCTCATAGAGCTTTTAAAGTGTTCATTTGATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCCTCTCTCATAGAGCTTTTAAAGTGTTCATTTGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATATAATGCAATTAAGTACTCAATCTGTG 1174  
DB 1141 CTATATAATGCAATTAAGTACTCAATCTGTG 1174

RESULT 89  
ADB39396  
ID ADB39396 standard; cdna; 1174 BP.  
XX  
AC ADB39396;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO195 cdna.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW Gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
PN US2003082764-A1.  
XX  
PD 01-MAY-2003.  
XX  
PF 03-MAY-2002; 2002US-00137868.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 16-SEP-1998; 98WO-US019177.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.



```
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 08-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908627.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX MPI; 2003-786919/74.
DR P-PSDB; ADB33397.
XX
XX New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
XX Claim 2; Fig 271; 659pp; English.
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGGGGCGCCCGAAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGGGGCGCCCGAAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CGGCTGCTGCTGTGACCATGGCTTGGCCGAGGTTGGGGAGCCGCTTCGGCTGAAGCA 180
DB 121 CGGCTGCTGCTGTGACCATGGCTTGGCCGAGGTTGGGGAGCCGCTTCGGCTGAAGCA 180
QY 181 TTGTGCTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCGCTGTGAGTGACCTACCCC 240
DB 181 TTGTGCTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCGCTGTGAGTGACCTACCCC 240
```

QY 241 TTGCACACCTACCTAAGGAGGAGTGTGTACGATGTACAGAGGTTGACAGGCTGTTT 300  
 Db 241 TTGCACACCTACCTAAGGAGGAGTGTGTACGATGTACAGAGGTTGACAGGCTGTTT 300  
 QY 301 TCAATTTGTGAGTTTGGATGATGAAATGATTAATGAACTGAAATGAAATGAA 360  
 Db 301 TCAATTTGTGAGTTTGGATGATGAAATGATTAATGAACTGAAATGAAATGAA 360  
 QY 361 TCTGCATGTACAGAGCATATTCCTATCTGATGAGCAATATGCTTGCCATCTTGGTGC 420  
 Db 361 TCTGCATGTACAGAGCATATTCCTATCTGATGAGCAATATGCTTGCCATCTTGGTGC 420  
 QY 421 CAGAAATCAGCTGCTTCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480  
 Db 421 CAGAAATCAGCTGCTTCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480  
 QY 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
 Db 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
 QY 541 GCACAGAGCTTCAATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
 Db 541 GCACAGAGCTTCAATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
 QY 601 GTTATATTCAGTCTAAGCAGCAATTCAGTACGACCAATTTGGAGCAGGACCTTAC 660  
 Db 601 GTTATATTCAGTCTAAGCAGCAATTCAGTACGACCAATTTGGAGCAGGACCTTAC 660  
 QY 661 AATTGAGAGATCATCTTCAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
 Db 661 AATTGAGAGATCATCTTCAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
 QY 721 CACAGAAATTTCTGAGATGGAAGATGATGCTTTTAAAGTGCCTCTCTCTTAAAC 780  
 Db 721 CACAGAAATTTCTGAGATGGAAGATGATGCTTTTAAAGTGCCTCTCTCTTAAAC 780  
 QY 781 TCTGGTGTGATTTTAACTACAACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
 Db 781 TCTGGTGTGATTTTAACTACAACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
 QY 841 TGTGCAACTGTGTGTACAGCTGTGAGCAGATATGTTCCCTCTGAGAACTGATCTAT 900  
 Db 841 TGTGCAACTGTGTGTACAGCTGTGAGCAGATATGTTCCCTCTGAGAACTGATCTAT 900  
 QY 901 GTGACTTGGATTTATGAATGAACAAAGCTAATCAAGATATCCAGCTTCTCTCTGTG 960  
 Db 901 GTGACTTGGATTTATGAATGAACAAAGCTAATCAAGATATCCAGCTTCTCTCTGTG 960  
 QY 961 GTTGTAGATCTAAACTGAAGATCATCAAGAGCAGGCTCTTACCTACAAAGTGAAT 1020  
 Db 961 GTTGTAGATCTAAACTGAAGATCATCAAGAGCAGGCTCTTACCTACAAAGTGAAT 1020  
 QY 1021 CTTGCTCATCTGAAATTTAGCATTTTCTTTTAAAGACAGTGAATAGACATCTAA 1080  
 Db 1021 CTTGCTCATCTGAAATTTAGCATTTTCTTTTAAAGACAGTGAATAGACATCTAA 1080  
 QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
 Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
 QY 1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174  
 Db 1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174

RESULT 90

ID ADB73835 standard; cDNA; 1174 bp.

XX AC ADB73835;

XX AC ADB73835;

DT 04-DEC-2003 (first entry)

XX DB Human PRO polynucleotide sequence #83.  
 XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;  
 KW cell death; neuropathy; neuropathy related disease;  
 KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;  
 KW chromosome mapping; gene mapping; genetic disorder; septic shock;  
 KW antibacterial; immunosuppressive; neuroprotective; gene; ss.  
 XX OS Homo sapiens.  
 XX PN US2003045462-A1.  
 XX PD 06-MAR-2003.  
 XX PF 16-OCT-2001; 2001US-00978608.  
 XX PR 17-OCT-1997; 97US-0062250P.  
 PR 03-NOV-1997; 97US-0064249P.  
 PR 13-NOV-1997; 97US-0065311P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 10-MAR-1998; 98US-0077450P.  
 PR 11-MAR-1998; 98US-0077632P.  
 PR 11-MAR-1998; 98US-0077641P.  
 PR 11-MAR-1998; 98US-0077649P.  
 PR 12-MAR-1998; 98US-0077791P.  
 PR 13-MAR-1998; 98US-0078004P.  
 PR 17-MAR-1998; 98US-0084822P.  
 PR 20-MAR-1998; 98US-0078866P.  
 PR 20-MAR-1998; 98US-0078910P.  
 PR 20-MAR-1998; 98US-0078936P.  
 PR 25-MAR-1998; 98US-0078939P.  
 PR 25-MAR-1998; 98US-0079294P.  
 PR 26-MAR-1998; 98US-0079656P.  
 PR 27-MAR-1998; 98US-0079663P.  
 PR 27-MAR-1998; 98US-0079664P.  
 PR 27-MAR-1998; 98US-0079689P.  
 PR 27-MAR-1998; 98US-0079728P.  
 PR 30-MAR-1998; 98US-0079786P.  
 PR 30-MAR-1998; 98US-0079920P.  
 PR 30-MAR-1998; 98US-0079923P.  
 PR 31-MAR-1998; 98US-0080105P.  
 PR 31-MAR-1998; 98US-0080107P.  
 PR 31-MAR-1998; 98US-0080165P.  
 PR 31-MAR-1998; 98US-0080194P.  
 PR 01-APR-1998; 98US-0080327P.  
 PR 01-APR-1998; 98US-0080328P.  
 PR 01-APR-1998; 98US-0080333P.  
 PR 01-APR-1998; 98US-0080334P.  
 PR 08-APR-1998; 98US-0081049P.  
 PR 08-APR-1998; 98US-0081070P.  
 PR 08-APR-1998; 98US-0081071P.  
 PR 09-APR-1998; 98US-0081195P.  
 PR 09-APR-1998; 98US-0081203P.  
 PR 09-APR-1998; 98US-0081229P.  
 PR 15-APR-1998; 98US-0081817P.  
 PR 15-APR-1998; 98US-0081819P.  
 PR 15-APR-1998; 98US-0081838P.  
 PR 15-APR-1998; 98US-0081952P.  
 PR 15-APR-1998; 98US-0081955P.  
 PR 21-APR-1998; 98US-0082568P.  
 PR 21-APR-1998; 98US-0082569P.  
 PR 22-APR-1998; 98US-0082700P.  
 PR 22-APR-1998; 98US-0082704P.  
 PR 22-APR-1998; 98US-0082797P.  
 PR 22-APR-1998; 98US-0082804P.  
 PR 23-APR-1998; 98US-0082966P.  
 PR 27-APR-1998; 98US-0083336P.  
 PR 28-APR-1998; 98US-0083322P.  
 PR 29-APR-1998; 98US-0083392P.  
 PR 29-APR-1998; 98US-0083495P.  
 PR 29-APR-1998; 98US-0083496P.  
 PR 29-APR-1998; 98US-0083499P.

PR	98US-00380138.
PR	98US-00380142.
PR	98US-00380146P.
PR	98US-00380150P.
PR	98US-00380154P.
PR	98US-00380158P.
PR	98US-00380162P.
PR	98US-00380166P.
PR	98US-00380170P.
PR	98US-00380174P.
PR	98US-00380178P.
PR	98US-00380182P.
PR	98US-00380186P.
PR	98US-00380190P.
PR	98US-00380194P.
PR	98US-00380198P.
PR	98US-00380202P.
PR	98US-00380206P.
PR	98US-00380210P.
PR	98US-00380214P.
PR	98US-00380218P.
PR	98US-00380222P.
PR	98US-00380226P.
PR	98US-00380230P.
PR	98US-00380234P.
PR	98US-00380238P.
PR	98US-00380242P.
PR	98US-00380246P.
PR	98US-00380250P.
PR	98US-00380254P.
PR	98US-00380258P.
PR	98US-00380262P.
PR	98US-00380266P.
PR	98US-00380270P.
PR	98US-00380274P.
PR	98US-00380278P.
PR	98US-00380282P.
PR	98US-00380286P.
PR	98US-00380290P.
PR	98US-00380294P.
PR	98US-00380298P.
PR	98US-00380302P.
PR	98US-00380306P.
PR	98US-00380310P.
PR	98US-00380314P.
PR	98US-00380318P.
PR	98US-00380322P.
PR	98US-00380326P.
PR	98US-00380330P.
PR	98US-00380334P.
PR	98US-00380338P.
PR	98US-00380342P.
PR	98US-00380346P.
PR	98US-00380350P.
PR	98US-00380354P.
PR	98US-00380358P.
PR	98US-00380362P.
PR	98US-00380366P.
PR	98US-00380370P.
PR	98US-00380374P.
PR	98US-00380378P.
PR	98US-00380382P.
PR	98US-00380386P.
PR	98US-00380390P.
PR	98US-00380394P.
PR	98US-00380398P.
PR	98US-00380402P.
PR	98US-00380406P.
PR	98US-00380410P.
PR	98US-00380414P.
PR	98US-00380418P.
PR	98US-00380422P.
PR	98US-00380426P.
PR	98US-00380430P.
PR	98US-00380434P.
PR	98US-00380438P.
PR	98US-00380442P.
PR	98US-00380446P.
PR	98US-00380450P.
PR	98US-00380454P.
PR	98US-00380458P.
PR	98US-00380462P.
PR	98US-00380466P.
PR	98US-00380470P.
PR	98US-00380474P.
PR	98US-00380478P.
PR	98US-00380482P.
PR	98US-00380486P.
PR	98US-00380490P.
PR	98US-00380494P.
PR	98US-00380498P.
PR	98US-00380502P.
PR	98US-00380506P.
PR	98US-00380510P.
PR	98US-00380514P.
PR	98US-00380518P.
PR	98US-00380522P.
PR	98US-00380526P.
PR	98US-00380530P.
PR	98US-00380534P.
PR	98US-00380538P.
PR	98US-00380542P.
PR	98US-00380546P.
PR	98US-00380550P.
PR	98US-00380554P.
PR	98US-00380558P.
PR	98US-00380562P.
PR	98US-00380566P.
PR	98US-00380570P.
PR	98US-00380574P.
PR	98US-00380578P.
PR	98US-00380582P.
PR	98US-00380586P.
PR	98US-00380590P.
PR	98US-00380594P.
PR	98US-00380598P.
PR	98US-00380602P.
PR	98US-00380606P.
PR	98US-00380610P.
PR	98US-00380614P.
PR	98US-00380618P.
PR	98US-00380622P.
PR	98US-00380626P.
PR	98US-00380630P.
PR	98US-00380634P.
PR	98US-00380638P.
PR	98US-00380642P.
PR	98US-00380646P.
PR	98US-00380650P.
PR	98US-00380654P.
PR	98US-00380658P.
PR	98US-00380662P.
PR	98US-00380666P.
PR	98US-00380670P.
PR	98US-00380674P.
PR	98US-00380678P.
PR	98US-00380682P.
PR	98US-00380686P.
PR	98US-00380690P.
PR	98US-00380694P.
PR	98US-00380698P.
PR	98US-00380702P.
PR	98US-00380706P.
PR	98US-00380710P.
PR	98US-00380714P.
PR	98US-00380718P.
PR	



QY 61 GGGACACAGATGGCGCGCGGAGGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
DB 61 GGGACACAGATGGCGCGCGGAGGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
QY 121 CGCTGCTGCTGCTGACCATGCTTGGCCGGAGGTTCCGGGACCGCTTGGCTGAAGCA 180  
DB 121 CGCTGCTGCTGCTGACCATGCTTGGCCGGAGGTTCCGGGACCGCTTGGCTGAAGCA 180  
QY 181 TTGACTCGGTCTTGGGTGATACGGGCTCTGTCACCGGCGCTGTGAGTTGACCTACCC 240  
DB 181 TTGACTCGGTCTTGGGTGATACGGGCTCTGTCACCGGCGCTGTGAGTTGACCTACCC 240  
QY 241 TTGCACACTACCTTAAAGGAGAGAGGTTGACGATGTGACAGAGGTTGACGCTGTTT 300  
DB 241 TTGCACACTACCTTAAAGGAGAGGTTGACGATGTGACAGAGGTTGACGCTGTTT 300  
QY 301 TCAATTTCTGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 360  
DB 301 TCAATTTCTGATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 360  
QY 361 TCTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTTGTTGC 420  
DB 361 TCTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTTGTTGC 420  
QY 421 CAGATACAGTGCCTATTCGCTGAACTGAGACAGAGCAACTATGCTGCTGATGCCAAA 480  
DB 421 CAGATACAGTGCCTATTCGCTGAACTGAGACAGAGCAACTATGCTGCTGATGCCAAA 480  
QY 481 ATGCACTACTCTTTCTCTTAACTCTGCTGAGGTCATCTGAGTGACATGAGCTCC 540  
DB 481 ATGCACTACTCTTTCTCTTAACTCTGCTGAGGTCATCTGAGTGACATGAGCTCC 540  
QY 541 GCACAGAGTTCATAACCTCTTCATGGAATTTTATCTTCAAGCGGATGACGGAATAA 600  
DB 541 GCACAGAGTTCATAACCTCTTCATGGAATTTTATCTTCAAGCGGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCAGTACGACCAACATTTGGAGAGGACCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCAGTACGACCAACATTTGGAGAGGACCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCAGAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCAGAGCG 720  
QY 721 CACAGGAATTTCTGAGATGAGGAAATGATGAGGCTTTTAAAGATGCTCTCTCTTAAAC 780  
DB 721 CACAGGAATTTCTGAGATGAGGAAATGATGAGGCTTTTAAAGATGCTCTCTCTTAAAC 780  
QY 781 TCTGGTGGATTTTAACTACAATCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840  
DB 781 TCTGGTGGATTTTAACTACAATCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840  
QY 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
DB 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTTG 960  
DB 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTTG 960  
QY 961 GTTGTAGATCTTAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
DB 961 GTTGTAGATCTTAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGGTGTAATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGGTGTAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCTATGGATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCTATGGATATAGGCTTTAAGAAATCA 1140

QY 1141 CTATAAATGCAATAAAGTTACTCTCAATCTCTG 1174  
DB 1141 CTATAAATGCAATAAAGTTACTCTCAATCTCTG 1174  
RESULT 92  
ADB86626  
ID ADB86626 standard; cDNA; 1174 BP.  
XX ADB86626;  
XX  
XX 04-DEC-2003 (first entry)  
XX Human PRO polynucleotide #136.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
OS  
PN US2003082697-A1.  
XX  
XX 01-MAY-2003.  
XX  
XX 22-APR-2002; 2002US-00127849.  
XX  
XX 20-OCT-1998; 98US-0104987P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI: 2003-743895/70.  
DR P-PSDB; ADB86627.  
XX  
XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis  
PT and treatment of cancer.  
XX  
XX Claim 2; Fig 271; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAGATGGCGGCGCCGAGCGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGCGGCGCCGAGCGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
QY 121 CGCTGCTGCTGTGACGATGCGCTTGGCGGAGGTTGCGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CGCTGCTGCTGTGACGATGCGCTTGGCGGAGGTTGCGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTTGGGGTGAACCGGCTTTCGCCCGGCGCTGTGAGTTGACTACCC 240  
DB 181 TTTGACTCGGCTTGGGGTGAACCGGCTTTCGCCCGGCGCTGTGAGTTGACTACCC 240  
QY 241 TTGCACACTACCCCTAAGGAAGAGAGTTGACGATGTGACAGAGGTTGACGGCTGTTT 300  
DB 241 TTGCACACTACCCCTAAGGAAGAGAGTTGACGATGTGACAGAGGTTGACGGCTGTTT 300  
QY 301 TCAATTTGCTGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 360  
DB 301 TCAATTTGCTGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 360  
QY 361 TCTGATGTGACAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
DB 361 TCTGATGTGACAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCGCTTGCCTGATGAGCAAGCAACTTATGCTGCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTGCGCTTGCCTGATGAGCAAGCAACTTATGCTGCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGGTCATCTTGGAGTGACATGATGAGCTCC 540  
DB 481 ATGCACCTACTCTTCTCTTAACTCTGCTGAGGTCATCTTGGAGTGACATGATGAGCTCC 540  
QY 541 GCACAGAGCTTCATACCTCTTTCATGAGCTTTTATCTTCAAGCGGATGACGGAAAATA 600  
DB 541 GCACAGAGCTTCATACCTCTTTCATGAGCTTTTATCTTCAAGCGGATGACGGAAAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGGAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGGAGGAGCTTACA 660  
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCAGAGCG 720  
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAAAATGAGAAATTCAGAGCG 720  
QY 721 CACAGGAATTTCTTGAGAGTGGAGAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780  
DB 721 CACAGGAATTTCTTGAGAGTGGAGAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780

QY 781 TCTGGGTGGATTTTAACTACAACTCTTGCTCTCGGTGATCGTATTCGTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTACAACTCTTGCTCTCGGTGATCGTATTCGTTGGATTTGT 840  
QY 841 TGTGCAACTCTTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTCTTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
QY 901 GGTGACTGTGAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960  
DB 901 GGTGACTGTGAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960  
QY 961 GTTGTAGATCTAAACTGAGATCATGAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAGATCATGAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
QY 1021 CTGCTCATTCTGAAATTTAAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
DB 1021 CTGCTCATTCTGAAATTTAAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
QY 1081 AATCCACTCTCATAGAGCTTTTAAAGTGTATGATGATGATGATGATGATGATGATGAT 1140  
DB 1081 AATCCACTCTCATAGAGCTTTTAAAGTGTATGATGATGATGATGATGATGATGATGAT 1140  
QY 1141 CTATAAATGCAAAATTAAGTACTCAAACTGTG 1174  
DB 1141 CTATAAATGCAAAATTAAGTACTCAAACTGTG 1174

## RESULT 93

ADB76551  
ID ADB76551 standard; cDNA; 1174 BP.

XX AC ADB76551;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide sequence #83.

XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;  
cell death; neuropathy; neuropathy related disease;  
Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;  
chromosome mapping; gene mapping; genetic disorder; septic shock;  
antibacterial; immunosuppressive; neuroprotective; gene; ss

XX OS Homo sapiens.

XX PN US2003083248-A1.

XX PD 01-MAY-2003.

XX PF 16-OCT-2001; 2001US-00978757.

XX PR 17-OCT-1997; 97US-0062250P.

PR 03-NOV-1997; 97US-0064249P.

PR 21-NOV-1997; 97US-0065311P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077641P.

PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078910P.

PR 20-MAR-1998; 98US-0078936P.

PR 25-MAR-1998; 98US-0078939P.

PR 26-MAR-1998; 98US-0079294P.

PR 27-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079689P.



XX The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides are useful for detecting other PRO polypeptides, for linking  
CC bioactive molecules to cells expressing PRO polypeptides, for modulating  
CC biological activities of cells expressing PRO polypeptides, and for  
CC identifying agonists or antagonists. The bioactive molecule maybe a  
CC toxin, radiolabel or antibody, and cause cell death. The PRO polypeptides  
CC are useful for treating neuropathy and neuropathy related diseases such  
CC as Charcot-Marie-Tooth disorder, Refsum's disease, and Krabbe's disease.  
CC The polynucleotide sequences encoding PRO polypeptides are useful as  
CC hybridisation probes, in chromosome and gene mapping, in the generation

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAAACCCCTCCGAGAAACACGAAACAGCTGAGCTGTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCCCTCCGAGAAACACGAAACAGCTGAGCTGTGTGACAGAG 60  
QY 61 GGGACAGATGGGGCCCGAGGGAGCCTCTGGGTGAGACCCGACTGGGGCTCCCG 120  
DB 61 GGGACAGATGGGGCCCGAGGGAGCCTCTGGGTGAGACCCGACTGGGGCTCCCG 120  
QY 121 CGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTGTGACTGGTCTGGGTGATGACGGCTTTCGACCGGGCTGTGAGTTGACCTACCC 240  
DB 181 TTGTGACTGGTCTGGGTGATGACGGCTTTCGACCGGGCTGTGAGTTGACCTACCC 240  
QY 241 TTGCACACTCCCTAAGGAGAGAGTTGACGATGTGACGAGGTGTCAGGCTGTTT 300  
DB 241 TTGCACACTCCCTAAGGAGAGAGTTGACGATGTGACGAGGTGTCAGGCTGTTT 300  
QY 301 TCAATTGTGCTGGATGATGGAATGACTTAATGAACTAAATGGAATGTGAA 360  
DB 301 TCAATTGTGCTGGATGATGGAATGACTTAATGAACTAAATGGAATGTGAA 360  
QY 361 TCTGATGTACAGAGCATATTCGCAATCTGATGAGCAATGCTGCCATCTGTGTGC 420  
DB 361 TCTGATGTACAGAGCATATTCGCAATCTGATGAGCAATGCTGCCATCTGTGTGC 420  
QY 421 CAGAATCAGCTGCCATTCGCTGAATGAGCAAGCAAACTATGTCCCTGATGCCAAA 480  
DB 421 CAGAATCAGCTGCCATTCGCTGAATGAGCAAGCAAACTATGTCCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCCCTTAACCTGCTGAGGTGATCTCGAGTGACATGAGCTCC 540  
DB 481 ATGCACCTACTCTTCCCTTAACCTGCTGAGGTGATCTCGAGTGACATGAGCTCC 540  
QY 541 GCACAGAGCTTCAATACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAANAATA 600  
DB 541 GCACAGAGCTTCAATACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAANAATA 600  
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAATTTGGAGAGAGCCCTACA 660  
DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCAATTTGGAGAGAGCCCTACA 660  
QY 661 AATTTCAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB 661 AATTTCAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720  
QY 721 CACAGAAATTTCTGAGAGATGAGAAATGATGCTTTTAAAGTGCCTCTCTTTAAC 780  
DB 721 CACAGAAATTTCTGAGAGATGAGAAATGATGCTTTTAAAGTGCCTCTCTTTAAC 780  
QY 781 TCTGGGTGATTTTAACTACAACCTCTGTCTCGGTGATGCTATGCTTTGATTTGT 840  
DB 781 TCTGGGTGATTTTAACTACAACCTCTGTCTCGGTGATGCTATGCTTTGATTTGT 840

QY 841 TGTGCAACTTGTCTACAGCTGTGGAGCAGTATGTTCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTTGTCTACAGCTGTGGAGCAGTATGTTCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
QY 961 GTTCTTGAATCTAAACTGAAGTATCATGAAAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
DB 961 GTTCTTGAATCTAAACTGAAGTATCATGAAAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTCCTCATTTCTGAATTTAAAGCATTTTCTTTTAAAGACAGTGTATATAGACATCTAA 1080  
DB 1021 CTTCCTCATTTCTGAATTTAAAGCATTTTCTTTTAAAGACAGTGTATATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCTCATAGAGCTTTTAAATGTTTCTTCAATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCCACTCTCTCATAGAGCTTTTAAATGTTTCTTCAATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 94  
ADB77231  
ID ADB77231 standard; cDNA; 1174 BP.  
XX ADB77231;  
XX 04-DEC-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
XX Human; secreted and transmembrane protein; PRO; gene: ss;  
XX Tumour necrosis factor alpha release; TNF-alpha release;  
XX Glucose uptake modulator; FFA uptake modulator;  
XX cell proliferation stimulator; cell differentiation stimulator;  
XX cell differentiation inhibitor; cytokine release stimulator; tumour;  
XX lung tumours; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX gene therapy; chromosome identification; chromosome marker.  
XX Homo sapiens.  
XX US2003082696-A1.  
XX 01-MAY-2003.  
XX 22-APR-2002; 2002US-00127848.  
XX 03-NOV-1998; 98US-0106934P.  
XX 26-JUL-1999; 99US-0145698P.  
XX 01-SEP-1999; 99WO-US020111.  
XX 18-OCT-1999; 99US-00403297.  
XX 05-JAN-2000; 2000WO-US000219.  
XX 18-FEB-2000; 2000WO-US004342.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755109/71.  
XX P-PSDB; ADB77232.  
XX PRO nucleic acid, useful for preparing a composition for treating e.g.,  
XX tumor or for tissue typing.



XX Claim 2; Fig 271; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMBC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGAGCCGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGCTGTCACAGAG 60  
DB 1 CGAGCCGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGCTGTCACAGAG 60

QY 61 GGGAAACAGATGCGCGCGCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGCGCGCGCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CGCGCTGCTGCTGACCATGCGCTTGGCCGAGGTTTCGGGAGCCGCTTCGGCTGAAGCA 180  
DB 121 CGCGCTGCTGCTGACCATGCGCTTGGCCGAGGTTTCGGGAGCCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGCTTTGGGTGATACGGCGCTTCCACCGCGGCTGTCAGTTCACCTACCCC 240  
DB 181 TTTGACTCGGCTTTGGGTGATACGGCGCTTCCACCGCGGCTGTCAGTTCACCTACCCC 240

QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTAAGCATGTCAGAGAGTTGAGGCTGTTT 300  
DB 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTAAGCATGTCAGAGAGTTGAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTCTGGATGATGGAATTGACTTAATTCGAACATAATTGGAATGTGAA 360  
DB 301 TCAATTTGTCAGTTTCTGGATGATGGAATTGACTTAATTCGAACATAATTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTGTATGAGCAATATGCTTGGCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATTTCCCAATCTGTATGAGCAATATGCTTGGCATCTTGGTTGC 420

QY 421 CAGATCAGTTCGCTGCTGACTGAGACAGACACTATCTCCCTGATGCCAAA 480  
DB 421 CAGATCAGTTCGCTGCTGACTGAGACAGACACTATCTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTCTGGAGTGACATGATGGACTCC 540  
DB 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATACCTCTTTCATGGACCTTTTATCTTTCAGGCCGATGACGGAAAAATA 600  
DB 541 GCACAGAGCTTCATACCTCTTTCATGGACCTTTTATCTTTCAGGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCAGAGCTTAAGCCAGAAATCCAGTACGACCACTATTGGAGCAGGACCTACA 660  
DB 601 GTTATATTCAGAGCTTAAGCCAGAAATCCAGTACGACCACTATTGGAGCAGGACCTACA 660

QY 661 AATTGGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGAAGGCTTTTAAAGATGCCCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGAAGGCTTTTAAAGATGCCCTCTCTCTTAAC 780

QY 781 TCTGGTGGATTTTAACTACACTCTTCTCTCGGTGATGCTTCTTGGATTCTT 840  
DB 781 TCTGGTGGATTTTAACTACACTCTTCTCTCGGTGATGCTTCTTGGATTCTT 840

QY 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTCAGAAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTCAGAAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960

QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGGCTCTACTCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGGCTCTACTCTACAAAGTGAAT 1020

QY 1021 CTTGCTCACTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTGTAATAGACATCTAA 1080  
DB 1021 CTTGCTCACTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTGTAATAGACATCTAA 1080

QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTCATTGGATATAGCCCTTAAAGAAATCA 1140  
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTCATTGGATATAGCCCTTAAAGAAATCA 1140

QY 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174

RESULT 95  
ADB34388  
ID ADB34388 standard; cDNA; 1174 BP.  
XX  
AC ADB34388;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Human PRO polynucleotide SEQ ID NO 271.  
XX  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
XX liver; microvascular endothelial cell; glucose; FFA;  
XX skeletal muscle cell; adipocyte cell; pericyte cell;  
XX inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;  
XX immune system cell infiltration.  
XX Homo sapiens.  
XX  
XX US200307717-A1.  
XX  
XX 24-APR-2003.



## RESULT 96

ADB35492  
ID ADB35492 standard; cDNA; 1174 BP.  
XX  
AC ADB35492;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Human PRO polynucleotide SEQ ID NO 271.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
PN US200307719-A1.  
XX  
PD 24-APR-2003.  
XX  
PF 24-APR-2002; 2002US-00131824.  
XX  
PR 09-FEB-1999; 99US-0119341P.  
PR 01-DEC-1999; 99WO-US028634.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-755074/71.  
XX  
PT P-PSDB; ADB35493.  
XX  
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
PT tumors.  
XX  
PS Claim 2; Fig 271; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACCGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
DB 1 CGGACCGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
QY 61 GGGAAACAGATGGCGCGCCGACGAGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGCGCGCCGACGAGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCATGCGCTTGGCCGAGAGTTTGGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGTGACCATGCGCTTGGCCGAGAGTTTGGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGCTCTGGGTGTATACCGCGCTTGGCCACCGGGCCTGTCACTTGTGACCTACCCCC 240  
DB 181 TTTGACTCGCTCTGGGTGTATACCGCGCTTGGCCACCGGGCCTGTCACTTGTGACCTACCCCC 240  
QY 241 TTGCAACCTACCTTAAGAGAGAGAGTTGTACCATGTGACAGAGTTTGCAGGCTGTGTTT 300  
DB 241 TTGCAACCTACCTTAAGAGAGAGAGTTGTACCATGTGACAGAGTTTGCAGGCTGTGTTT 300  
QY 301 TCAATTTGTAGTTTGTGGATGATGGAATTCGACTTAAATCGAATAAATGGAATGTGAA 360  
DB 301 TCAATTTGTAGTTTGTGGATGATGGAATTCGACTTAAATCGAATAAATGGAATGTGAA 360  
QY 361 TCTGATGTACAGAGCATATTTCCCAATTTGATGAGCAATATGCTTCCCATTTGGTTGC 420  
DB 361 TCTGATGTACAGAGCATATTTCCCAATTTGATGAGCAATATGCTTCCCATTTGGTTGC 420  
QY 421 CAGAAATGAGTGGCAATTCGCTGAACTGAGCAAGCAACTTATGTCCTCGATGTCACAAA 480  
DB 421 CAGAAATGAGTGGCAATTCGCTGAACTGAGCAAGCAACTTATGTCCTCGATGTCACAAA 480  
QY 481 ATGCACCTACTCTTTTCCTTAACCTCTGGTGAAGTTCATTTGGAGTGACATGAGGACTCC 540  
DB 481 ATGCACCTACTCTTTTCCTTAACCTCTGGTGAAGTTCATTTGGAGTGACATGAGGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACCGCACCATTTGGAGAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACCGCACCATTTGGAGAGGAGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCGAAATGCAAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCGAAATGCAAAATTCACAAGCG 720  
QY 721 CACAGAAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTTTAAGATGCCCTCTCTTTAAC 780  
DB 721 CACAGAAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTTTAAGATGCCCTCTCTTTAAC 780  
QY 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTATGCTTGGATTTGT 840  
DB 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTATGCTTGGATTTGT 840

QY 841 TGTGCAACTGTTCTACAGCTGTGGACGATATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTCTACAGCTGTGGACGATATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
QY 901 GGTGACCTGGAGTTATGATGACAAAGCTAAACAGATATCCAGCTTCTCTCTG 960  
DB 901 GGTGACCTGGAGTTATGATGACAAAGCTAAACAGATATCCAGCTTCTCTCTG 960  
QY 961 GTTCTTAGATCTAAACTGAGATCATGAGAAAGCGGGCTCTACTACAAAAGTGAAT 1020  
DB 961 GTTCTTAGATCTAAACTGAGATCATGAGAAAGCGGGCTCTACTACAAAAGTGAAT 1020  
QY 1021 CTGCTCATCTGAAATTAAGCATTTTCTTTAAAGCAAGTATATAGACATCTAA 1080  
DB 1021 CTGCTCATCTGAAATTAAGCATTTTCTTTAAAGCAAGTATATAGACATCTAA 1080  
QY 1081 AATTCCTACTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCCTACTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATATAATGCAATAAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATATAATGCAATAAAGTTACTCAAAATCTGTG 1174  
RESULT 97  
ADB33836  
ID ADB33836 standard; cDNA; 1174 BP.  
XX AC ADB33836;  
XX DT  
XX 04-DEC-2003 (first entry)  
XX Human PRO polynucleotide SEQ ID NO 271.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
XX OS  
XX PN US200307716-A1.  
XX PD 24-APR-2003.  
XX PF 24-APR-2002; 2002US-00131813.  
XX PR 07-OCT-1998; 98US-0103315P.  
XX PR 01-SEP-1999; 99WO-US020111.  
XX PR 18-OCT-1999; 99US-00403297.  
XX PR 18-FEB-2000; 2000WO-US004342.  
XX PR 10-NOV-2000; 2000WO-US030873.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX PA  
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI: 2003-755071/71.  
XX P-PSDB; ADB33837.  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful

in gene therapy, in chromosome and gene mapping, as chromosome markers,  
in tissue typing, and in identifying chromosomes.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCGGAGGAGGCTCTGCTGAGGACCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCGGAGGAGGCTCTGCTGAGGACCCCACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGACCATGGCTTGGCGGAGGTTGCGGGACCCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGACCATGGCTTGGCGGAGGTTGCGGGACCCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTTGGGTGATAGGGCTTTGGCCACCGGCGCTGTCAGTTGACCTACCCC 240  
DB 181 TTTGACTCGGCTTGGGTGATAGGGCTTTGGCCACCGGCGCTGTCAGTTGACCTACCCC 240  
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTTGTACGCATGTGACAGAGGTTCCAGGCTGTTT 300  
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTTGTACGCATGTGACAGAGGTTCCAGGCTGTTT 300  
QY 301 TCAATTTGTCAGTTTGGGTGATGGAATGATCTTAATCGAACTAAATGGAATCTGAA 360  
DB 301 TCAATTTGTCAGTTTGGGTGATGGAATGATCTTAATCGAACTAAATGGAATCTGAA 360  
QY 361 TCTGCATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGGCATCTTGTTC 420  
DB 361 TCTGCATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGGCATCTTGTTC 420

421	QY		CAGAAATCAGCTGCACATTCGCTGAACTGAGACAAGAAACAACATTATGTCTCCGTGATGCCAAA	480
421	DB		CAGAAATCAGCTGCACATTCGCTGAACTGAGACAAGAAACAACATTATGTCCCTGATGCCAAA	480
481	QY		ATGCACCTACTCTTTTCTCTAACTCTGGGTGAGGTCAATCTGGAGTGACATCATGGAGCTCC	540
481	DB		ATGCACCTACTCTTTTCTCTAACTCTGGGTGAGGTCAATCTGGAGTGACATCATGGAGCTCC	540
541	QY		GCACGAGCTTCTAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
541	DB		GCACGAGCTTCTAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
601	QY		GTTTATATCCAGTCTTAAGCCAGAGAAATCCAGTACGCACACATTTTGGAGCAGGAGCCTTACA	660
601	DB		GTTTATATCCAGTCTTAAGCCAGAGAAATCCAGTACGCACACATTTTGGAGCAGGAGCCTTACA	660
661	QY		AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAGAAATGAGAGAAATTCACAAGCG	720
661	DB		AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAGAAATGAGAGAAATTCACAAGCG	720
721	QY		CACAGGAATTTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAAC	780
721	DB		CACAGGAATTTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAAC	780
781	QY		TCCTGGTGGATTTTAACTACAACCTCTTGTCCTCTCGGTGATGGTATTTGCTTTGATTTGT	840
781	DB		TCCTGGTGGATTTTAACTACAACCTCTTGTCCTCTCGGTGATGGTATTTGCTTTGATTTGT	840
841	QY		TCGTCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
841	DB		TCGTCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
901	QY		GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAAAGATATCCAGCTTCTCTCTTGTG	960
901	DB		GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAAAGATATCCAGCTTCTCTCTTGTG	960
961	QY		GTTGTTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAAGTGAAT	1020
961	DB		GTTGTTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAAGTGAAT	1020
1021	QY		CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAAACAAGTGTAAATAGACATCTAA	1080
1021	DB		CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAAACAAGTGTAAATAGACATCTAA	1080
1081	QY		AATTCACCTCTCATAGAGCTTTTAAAATGTTTTCATTCGGATATAGGCTTAAAGAAATCA	1140
1081	DB		AATTCACCTCTCATAGAGCTTTTAAAATGTTTTCATTCGGATATAGGCTTAAAGAAATCA	1140
1141	QY		CTATAAATGCAAAATAAAGTTTACTCAAACTCTGTG	1174
1141	DB		CTATAAATGCAAAATAAAGTTTACTCAAACTCTGTG	1174

RESULT 98	
ADB34940	
ID	ADB34940 standard; cDNA; 1174 BP.
XX	
XX	
AC	ADB34940;
XX	
XX	
XX	04-DEC-2003 (first entry)
DT	
XX	
XX	
DE	Human PRO polynucleotide SEQ ID NO 271.
XX	
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW	immune system cell infiltration.

XX	Homo sapiens.
OS	US2003077718-A1.
PN	XX
XX	XX
PD	24-APR-2003.
XX	XX
XX	XX
PF	24-APR-2002; 2002US-00131823.
XX	XX
PR	31-MAR-1997; 97WO-US0005230.
FR	12-JUN-1998; 98WO-US0012456.
FR	12-JUL-1998; 98WO-US0014552.
FR	20-SEP-1998; 98WO-US0017888.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019094.
PR	14-SEP-1998; 98WO-US019177.
PR	16-SEP-1998; 98WO-US019330.
FR	17-SEP-1998; 98WO-US019437.
PR	07-OCT-1998; 98WO-US021141.
PR	27-OCT-1998; 98WO-US022991.
PR	29-OCT-1998; 98WO-US022992.
PR	20-NOV-1998; 98WO-US024855.
PR	01-DEC-1998; 98WO-US025108.
PR	05-JAN-1999; 98WO-US000106.
PR	08-MAR-1999; 98WO-US005028.
FR	10-MAR-1999; 98WO-US005190.
FR	20-APR-1999; 98WO-US008615.
PR	14-MAY-1999; 98WO-US010733.
PR	02-JUN-1999; 98WO-US012252.
PR	01-SEP-1999; 98WO-US020111.
PR	08-SEP-1999; 98WO-US020594.
PR	13-SEP-1999; 98WO-US020944.
PR	13-SEP-1999; 98WO-US021090.
PR	13-SEP-1998; 98WO-US021547.
PR	29-OCT-1999; 98WO-US023089.
PR	28-NOV-1999; 98WO-US028214.
PR	30-NOV-1999; 98WO-US028313.
PR	30-NOV-1999; 98WO-US028409.
PR	01-DSC-1999; 98WO-US028301.
PR	02-DSC-1999; 98WO-US028634.
PR	02-DSC-1999; 98WO-US028551.
PR	02-DSC-1999; 98WO-US028564.
PR	02-DSC-1999; 98WO-US028565.
PR	16-DEC-1999; 98WO-US030095.
PR	20-DEC-1999; 98WO-US030911.
PR	22-DEC-1999; 98WO-US030720.
PR	30-DEC-1999; 98WO-US030999.
PR	30-DEC-1999; 98WO-US031243.
PR	05-JAN-2000; 98WO-US031274.
PR	06-JAN-2000; 2000WO-US000219.
FR	06-JAN-2000; 2000WO-US000376.
PR	11-FEB-2000; 2000WO-US0003565.
PR	18-FEB-2000; 2000WO-US004341.
PR	18-FEB-2000; 2000WO-US004342.
PR	24-FEB-2000; 2000WO-US004414.
PR	24-FEB-2000; 2000WO-US004914.
PR	24-FEB-2000; 2000WO-US005004.
PR	01-MAR-2000; 2000WO-US005601.
FR	02-MAR-2000; 2000WO-US005746.
PR	02-MAR-2000; 2000WO-US005841.
PR	10-MAR-2000; 2000WO-US006319.
PR	15-MAR-2000; 2000WO-US006884.
PR	20-MAR-2000; 2000WO-US007377.
PR	21-MAR-2000; 2000WO-US007532.
PR	30-MAR-2000; 2000WO-US008439.
PR	17-MAY-2000; 2000WO-US013705.
FR	22-MAY-2000; 2000WO-US014042.
PR	30-JUN-2000; 2000WO-US014941.
PR	02-JUN-2000; 2000WO-US015264.
PR	28-JUL-2000; 2000WO-US020701.
PR	11-AUG-2000; 2000WO-US022031.

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. Note:  
CC sequence represents a human PRO polynucleotide of the invention. The:  
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAAAGCAACAAAGCTGAGTCTCTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAAAGCAACAAAGCTGAGTCTCTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGTGAGGACCCAACTGGGGCTCCG 120  
DB 61 GGGAAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGTGAGGACCCAACTGGGGCTCCG 120  
QY 121 CCGCTGCTGCTGCTGACCAATGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGCTGACCAATGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGCTCTTGGTGATACGGGCTCTTCCACCGGGCCCTGTCAGTGCCTACCC 240  
DB 181 TTTGACTCGCTCTTGGTGATACGGGCTCTTCCACCGGGCCCTGTCAGTGCCTACCC 240  
QY 241 TTGCACACCTACCTAAGGAAGGAGGTTGTACGATGTCAGAGAGGTTGACGGCTGTTT 300  
DB 241 TTGCACACCTACCTAAGGAAGGAGGTTGTACGATGTCAGAGAGGTTGACGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTTGTGGATGATGAATGACTTAAATCGAATTAATGGAATGAA 360  
DB 301 TCAATTTGTGAGTTTGTGGATGATGAATGACTTAAATCGAATTAATGGAATGAA 360  
QY 361 TCTGATGTACAGAGCATATTCCTATCTGATGAGCATATGCTTCCATCTTGGCTCC 420  
DB 361 TCTGATGTACAGAGCATATTCCTATCTGATGAGCATATGCTTCCATCTTGGCTCC 420  
QY 421 CAGATCAGCTGCCATTTCGCTGAACTGAGACAAAGAACACTTATGTCCTGATGCCAAA 480  
DB 421 CAGATCAGCTGCCATTTCGCTGAACTGAGACAAAGAACACTTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTAACTCTGAGTCAATCTGAGTGCATGATGAGTCC 540  
DB 481 ATGCACCTACTCTTCTCTAACTCTGAGTCAATCTGAGTGCATGATGAGTCC 540  
QY 541 GCACAGAGCTTCATAAATCTTTCATGACCTTTTATCTTCAAGCCGATGACGAAAAATA 600  
DB 541 GCACAGAGCTTCATAAATCTTTCATGACCTTTTATCTTCAAGCCGATGACGAAAAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660  
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGGCTTTTTTAAGATGCCCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGGCTTTTTTAAGATGCCCTCTCTTAAC 780  
QY 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGTTGCTTTCGATTTGT 840  
DB 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGTTGCTTTCGATTTGT 840

PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032578.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001US-00802706.  
PR 09-MAR-2001; 2001US-00808689.  
PR 14-MAR-2001; 2001US-00816744.  
PR 22-MAR-2001; 2001US-00828366.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00874503.  
PR 25-MAY-2001; 2001US-00866038.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 20-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755073/71.  
DR P-PSDB; ADB34941.  
XX  
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
PT tumors.  
XX  
PS Claim 2; Fig 271; 639pp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and  
PS transmembrane polypeptides) and the polynucleotides encoding them. The  
PS invention also relates to an antibody which specifically binds to a PRO  
PS polypeptide, a method for stimulating the release of tumour necrosis  
PS factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
PS proliferation or differentiation of chondrocyte cells and a method for  
PS detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
PS colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
PS polynucleotides are useful in molecular biology, including uses as  
PS hybridisation probes in chromosome and gene mapping, in generating  
PS antisense RNA and DNA and in gene therapy. The polynucleotides may also  
PS be used in preparing PRO polypeptides by recombinant techniques and in  
PS generating either transgenic animals or knock-out animals which are  
PS useful in the development and screening of therapeutically useful  
PS reagents. The PRO polypeptides or antibodies are used in preparing a  
PS medicament for treating a condition responsive to the polypeptides or  
PS antibodies, such as tumours, for stimulating and inhibiting proliferation  
PS of human microvascular endothelial cells, for modulating the uptake of  
PS glucose or FFA by skeletal muscle cells or adipocyte cells, for  
PS stimulating differentiation of adipocyte cells, for stimulating  
PS proliferation of or gene expression in pericyte cells, for stimulating

Dd		781	TCTGGGTGGATTTTAACTCAACTCTTGTCCTCGGTGATGGATTGCTTGGATTTGT	840
Qy		841	TGTCAAAC TG TGTCTACAGCTGTGGACGAGTAGTTCCTCTGAGAAGCTGAGTACTAT	900
Dd		841	TGTCAAAC TG TGTCTACAGCTGTGGACGAGTAGTTCCTCTGAGAAGCTGAGTACTAT	900
Qy		901	GGTCACTTGGAGTTTATGAATGAACAAAAGCTAAAAAGATATCCAGCTTCTTCTCTTG	960
Dd		901	GGTCACTTGGAGTTTATGAATGAACAAAAGCTAAAAAGATATCCAGCTTCTTCTCTTG	960
Qy		961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAGTGAAT	1020
Dd		961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAGTGAAT	1020
Qy		1021	CTTGCTCATCTGAAATTTAAGCATTTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
Dd		1021	CTTGCTCATCTGAAATTTAAGCATTTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
Qy		1081	AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
Dd		1081	AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
Qy		1141	CTATAAAATGC AAAATAAAGTTACTCTAAATCTGTG	1174
Dd		1141	CTATAAAATGC AAAATAAAGTTACTCTAAATCTGTG	1174

RESULT 99

RESULTS 33  
ADB36044  
ID ADB36044 standard: cDNA: 1174 bp.

XX  
AC ADB36044:XX  
DT 04-DEC-2003 (first entry)

Human PRO polynucleotide SEQ ID NO 271.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; PFA; skeletal muscle cell; adipocyte cell; paricycle cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

XX Homo sapiens.

XX  
PN  
US2003077720-A1.XX  
PD  
24-APR-2003XX  
DE  
24-APR-2002.

XX  
09-DEC-1999.  
99TTS-0170262P.

PR 01-DEC-2000; 2000WO-US032678.  
 19 DEC 2001. 2001US-00038072  
 20 DEC 2001. 2001US-00038073

XXXXXX

XX

PI Gerritsen ME, Goddard A, Go

[illegible]

DR P-PSDB; ADB36045.

XX  
PT  
New isolated, secreted and tr

PT acids; useful for the diagnosis of such as lung. colon: breast; PT

PT  
tumors.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match	100.0%;	Score 1174;	DB 9;	Length 1174;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1174;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACCAAGCTGAGCTCTCTGTGACGAG	60	
Db	1	CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACCAAGCTGAGCTCTCTGTGACGAG	60	
QY	61	GGGACACAGATGGCGGCGCGACGAGGGGAGAGCCTCTGGGTGAGGACCCAACTGGGGGCTCCCG	120	
Db	61	GGGACACAGATGGCGGCGCGAGAGGGAGGCGCTCTGGGTGAGGACCCAACTGGGGGCTCCCG	120	
QY	121	CGCGTCTGCTCTCTGTGACCAATGGCCCTTGGCCGGAAGGTTGGGGACCCGCTTCGCGCTGAAGCA	180	
Db	121	CGCGTCTGCTCTCTGACCATGGCCCTTGGCCGGAAGGTTGGGGACCCGCTTCGCGCTGAAGCA	180	
QY	181	TTTGTACTCGGTCTTTGGGTGATACGGCGCTCTTTGCCACCGGGCCCTGTGAGTTGACCTTACCCC	240	
Db	181	TTTGTACTCGGTCTTTGGGTGATACGGCGCTCTTTGCCACCGGGCCCTGTGAGTTGACCTTACCCC	240	
QY	241	TTTGCAACCTACCTTAAGAAAGAGAGGTTGTATGCATATCAGAGAGGTTGCAGGCGTGTT	300	
Db	241	TTTGCAACCTACCTTAAGAAAGAGAGGTTGTATGCATATCAGAGAGGTTGCAGGCGTGTT	300	
QY	301	TCAAATTTGTCACTTTGTGGAATGGAATTGACCTTAAATCGAACTGAAATTTGGAATGTGAA	360	
Db	301	TCAAATTTGTCACTTTGTGGAATGGAATTGACCTTAAATCGAACTGAAATTTGGAATGTGAA	360	
QY	361	CTGTGCATGTACAGAGCATATATCCCAATCTGATGAGCAATATGCTTGGCATCTTTGGTTGC	420	
Db	361	CTGTGCATGTACAGAGCATATATCCCAATCTGATGAGCAATATGCTTGGCATCTTTGGTTGC	420	
QY	421	CAGAATTCAGCTGCCATTGCTGAACTGAGACAAGAAACAACTTATGTGCTTCGTGATGCCAAA	480	



Dbb 421 CAGATACAGCTGCCATTCGCTGAACCTGAGACCAAGCACTATGTCTCCCTGATGCCAAA 480  
Qy 481 ATGACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
Db 481 ATGACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
Qy 541 GCACAGAGCTTCATACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600  
Db 541 GCACAGAGCTTCATACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600  
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660  
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660  
Qy 661 AATTGGAGAGATCATCTTAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
Db 661 AATTGGAGAGATCATCTTAAGCAAAATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
Qy 721 CACAGGAATTTCTTGAAGATGGAAGAGTATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 780  
Db 721 CACAGGAATTTCTTGAAGATGGAAGAGTATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 780  
Qy 781 TCTGGGTGGATTTAACTACAACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
Db 781 TCTGGGTGGATTTAACTACAACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840  
Qy 841 TGTGCAACTGTGTCTACAGCTGTGAGCAGTATGCTCTCTCTCTCTCTCTCTCTCTCTCTCT 900  
Db 841 TGTGCAACTGTGTCTACAGCTGTGAGCAGTATGCTCTCTCTCTCTCTCTCTCTCTCTCTCT 900  
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGTCTCTCTCTCTCTCT 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGTCTCTCTCTCTCTCT 960  
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGCAGGCGCTCTTACCTACAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGCAGGCGCTCTTACCTACAAAGTGAAT 1020  
Qy 1021 CTCTGCTCATCTGAATTTAAGATTTCTTTCTTTAAAGCAGAGTGAATGAGCATCTAA 1080  
Db 1021 CTCTGCTCATCTGAATTTAAGATTTCTTTCTTTAAAGCAGAGTGAATGAGCATCTAA 1080  
Qy 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTCTTAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTCTTAAGAAATCA 1140  
Qy 1141 CTATAAATGCAATTAAGTTACTCAAACTCTGTG 1174  
Db 1141 CTATAAATGCAATTAAGTTACTCAAACTCTGTG 1174

RESULT 100  
ADB46439  
ID ADB46439 standard; cDNA; 1174 BP.

XX AC ADB46439;  
XX DT 04-DEC-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;  
XX KW Tumour necrosis factor alpha release; TNF-alpha release;  
XX KW glucose uptake modulator; FFA uptake modulator;  
XX KW cell proliferation stimulator; cell differentiation stimulator;  
XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX KW gene therapy; chromosome identification; chromosome marker.  
OS Homo sapiens.  
XX US2003082692-A1.  
PN

XX PD 01-MAY-2003.  
XX PF 22-APR-2002; 2002US-00127842.  
XX PR 03-MAR-2000; 2000US-0187202P.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786906/74.  
XX P-FSDB; ADB46440.  
XX New PRO nucleic acid, useful for preparing a composition for treating  
XX e.g., tumor or for tissue typing.  
XX Claim 2; Fig 271; 637pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
XX transmembrane) polypeptides (I). (I) is useful for stimulating the  
XX release of TNF-alpha from human blood, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating the proliferation or differentiation of chondrocyte cells,  
XX for stimulating the proliferation of or gene expression in pericyte  
XX cells, for stimulating the release of proteoglycans from cartilage, for  
XX stimulating the proliferation of inner ear utricular supporting cells,  
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating  
XX the release of a cytokine from PBMC cells, for inhibiting the binding of  
XX A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
XX cells, for stimulating proliferation of endothelial cells, for detecting  
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,  
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
XX are useful for isolating genomic and cDNA nucleotide sequences or  
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
XX in assays to identify other proteins or molecules involved in binding  
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
XX and gene mapping, in generation of antisense RNA and DNA, in the  
XX preparation of PRO polypeptide, for generating transgenic animals or  
XX knockout animals which in turn are useful in the development and  
XX screening of therapeutically useful reagents, in gene therapy, for  
XX chromosome identification, as chromosome marker, and for generating  
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
XX detecting its expression in specific cells, tissues or serum, and for  
XX affinity purification of PRO from recombinant cell culture or natural  
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes  
XX a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 CGGACGGCTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
Db 1 CGGACGGCTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
Qy 61 GGGAAACAAGATGGCGGCGCCGAGAGGGAGCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120  
Db 61 GGGAAACAAGATGGCGGCGCCGAGAGGGAGCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120  
Qy 121 CCGCTGCTGCTGACCATGGCTTGGCGGAGGTTTCGGGAGCCGCTTCGGCTGAGCA 180  
Db 121 CCGCTGCTGCTGACCATGGCTTGGCGGAGGTTTCGGGAGCCGCTTCGGCTGAGCA 180  
Qy 181 TTGACTCGGTCTTGGGTGATACGGCTCTTGGCACCGGGCCCTGTGAGTACCTACCCC 240  
Db 181 TTGACTCGGTCTTGGGTGATACGGCTCTTGGCACCGGGCCCTGTGAGTACCTACCCC 240



QY	241	TTGCACACCTACCTTAAGGAAGAGGAGTTGTATCGCATGTCTCAGAGAGGTTGACGCTGTTT	300
Db	241	TTGCACACCTACCTTAAGGAAGAGGAGTTGTATCGCATGTCTCAGAGAGGTTGACGCTGTTT	300
QY	301	TCGAATTTGTCTCAGTTTGTGGATGATGCAATTGACTTTAAATCGAATCTAAATTCGAATGTGAA	360
Db	301	TCGAATTTGTCTCAGTTTGTGGATGATGCAATTGACTTTAAATCGAATCTAAATTCGAATGTGAA	360
QY	361	TCTGCATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC	420
Db	361	TCTGCATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC	420
QY	421	CAGAAATCAGCTGCCATTCGCTGAATCTGAGACAAGACAACATTTATGTCCCTGATGCCAAA	480
Db	421	CAGAAATCAGCTGCCATTCGCTGAATCTGAGACAAGACAACATTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTCTCTCTAACTCTCTGGTGAAGTCATTTCTGGAGTGACATGATGGACTCC	540
Db	481	ATGCACCTACTCTTTCTCTCTAACTCTCTGGTGAAGTCATTTCTGGAGTGACATGATGGACTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACCTTTTTATCTTCAAGCGGATGACGGAATAAATA	600
Db	541	GCACAGAGCTTCATAACCTCTTCATGGACCTTTTTATCTTCAAGCGGATGACGGAATAAATA	600
QY	601	GTTATATTCAGCTCTAAGCCAGAAATCCAGTAGCGACACACATTTTGGAGCAGGAGCCTACA	660
Db	601	GTTATATTCAGCTCTAAGCCAGAAATCCAGTAGCGACACACATTTTGGAGCAGGAGCCTACA	660
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGAGAAAGTATGCTTTTAAAGTAGCCTCTCTCTTAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGAGAAAGTATGCTTTTAAAGTAGCCTCTCTCTTAAC	780
QY	781	TCCTGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGATATGCTTTTGGATTTGT	840
Db	781	TCCTGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGATATGCTTTTGGATTTGT	840
QY	841	TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
QY	901	GGTGACTTTGGAGTTTATGAATGAACAAAGCTAAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901	GGTGACTTTGGAGTTTATGAATGAACAAAGCTAAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTTGTTAGATCTAAAACCTAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACCTAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
Db	1021	CTTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
QY	1081	AATTCACCTCTCATAGAGCTTTTAAAAATGGTTTCAATTCGATATAGGCTTTAAGAAATCA	1140
Db	1081	AATTCACCTCTCATAGAGCTTTTAAAAATGGTTTCAATTCGATATAGGCTTTAAGAAATCA	1140
QY	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174

RESULT 101

RESULT IN  
ADC43977

ID ADC43977 standard; cDNA; 1174 BP.

XX

AC ADC43977;



Human cdna encoding secreted/transmembrane protein, PRO195.  
Human; ss; gene; secreted protein; transmembrane protein; PRO;  
cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;  
vulnary; auditory; tumor growth; retinal disorder;  
sports-related joint problem; articular cartilage defects;  
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
Homo sapiens.

PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 30-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 13-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0030863P.  
PR 26-JUN-1998; 98US-0031010P.  
PR 01-JUL-1998; 98US-0031359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98US-00168978.  
PR 07-OCT-1998; 98US-00211141.  
PR 02-NOV-1998; 98US-00184216.  
PR 06-NOV-1998; 98US-00187368.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98US-0024855.  
PR 20-NOV-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 98US-0000106.  
PR 05-MAR-1999; 98US-00254465.  
PR 08-MAR-1999; 98US-0005028.  
PR 10-MAR-1999; 98US-00265686.  
PR 10-MAR-1999; 98US-0005190.  
PR 12-MAR-1999; 98US-00267213.  
PR 12-MAR-1999; 98US-0123957P.  
PR 29-MAR-1999; 98US-0126773P.  
PR 12-APR-1999; 98US-00284291.  
PR 21-APR-1999; 98US-0130232P.  
PR 26-APR-1999; 98US-0130102P.  
PR 28-APR-1999; 98US-0131445P.  
PR 14-MAY-1999; 98US-00311832.  
PR 14-MAY-1999; 98US-0134287P.  
PR 14-MAY-1999; 98US-01010733.  
PR 02-JUN-1999; 98US-0012252.  
PR 16-JUN-1999; 98US-0139557P.  
PR 23-JUN-1999; 98US-0141037P.  
PR 07-JUL-1999; 98US-0142680P.  
PR 26-JUL-1999; 98US-0145698P.  
PR 28-JUL-1999; 98US-0146222P.  
PR 25-AUG-1999; 98US-00380137.

PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380142.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99US-0028313.  
PR 02-DEC-1999; 99US-0028551.  
PR 02-DEC-1999; 99US-0028565.  
PR 16-DEC-1999; 99US-0030095.  
PR 30-DEC-1999; 99US-0031243.  
PR 30-DEC-1999; 99US-0031274.  
PR 05-JAN-2000; 2000US-0000219.  
PR 06-JAN-2000; 2000US-0000277.  
PR 06-JAN-2000; 2000US-0000376.  
PR 11-FEB-2000; 2000US-0003565.  
PR 18-FEB-2000; 2000US-0004341.  
PR 24-FEB-2000; 2000US-0005004.  
PR 02-MAR-2000; 2000US-0005841.  
PR 10-MAR-2000; 2000US-0006319.  
PR 21-MAR-2000; 2000US-0007532.  
PR 30-MAR-2000; 2000US-0008439.  
PR 17-MAY-2000; 2000US-0013705.  
PR 22-MAY-2000; 2000US-0014042.  
PR 30-MAY-2000; 2000US-0014941.  
PR 02-JUN-2000; 2000US-0015264.  
PR 28-JUL-2000; 2000US-0020710.  
PR 24-AUG-2000; 2000US-0023328.  
PR 08-NOV-2000; 2000US-00709238.  
PR 27-NOV-2000; 2000US-00723749.  
PR 01-DEC-2000; 2000US-0074259.  
PR 20-DEC-2000; 2000US-0074259.  
PR 20-DEC-2000; 2000US-0074259.  
PR 28-FEB-2001; 2000US-0006520.  
PR 22-MAR-2001; 2000US-00816744.  
PR 22-MAR-2001; 2000US-00816920.  
PR 22-MAR-2001; 2000US-00816920.  
PR 10-MAY-2001; 2000US-00854208.  
PR 10-MAY-2001; 2000US-00854208.  
PR 25-MAY-2001; 2000US-00854208.  
PR 01-JUN-2001; 2000US-00872035.  
PR 01-JUN-2001; 2000US-00872035.  
PR 05-JUN-2001; 2000US-00874503.  
PR 14-JUN-2001; 2000US-00882636.  
PR 19-JUN-2001; 2000US-00886342.  
PR 20-JUN-2001; 2000US-00886342.  
PR 29-JUN-2001; 2000US-0021066.  
PR 09-JUL-2001; 2000US-0021735.  
PR 30-JUL-2001; 2000US-00915585.  
XX (GETH ) GENENTECH INC.  
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAAAGCAAAAGCTGAGCTGCTGTGACAG 60  
Db 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAAAGCAAAAGCTGAGCTGCTGTGACAG 60  
Qy 61 GGGAAACAAGATGCGGCGCGGAGGAGCTCTGGTGAGGACCAACTGGGGCTCCCG 120  
Db 61 GGGAAACAAGATGCGGCGCGGAGGAGCTCTGGTGAGGACCAACTGGGGCTCCCG 120  
Qy 121 CCGCTGCTGCTGTGACCAATGCGCGGAGGTTGGGAGCCGCTTCGGCTGAAGCA 180  
Db 121 CCGCTGCTGCTGTGACCAATGCGCGGAGGTTGGGAGCCGCTTCGGCTGAAGCA 180  
Qy 181 TTTGACTCGGCTCTGGGTGATACGGGCTCTTCCACCGGCGCTGTCAGTTACCTACCCC 240  
Db 181 TTTGACTCGGCTCTGGGTGATACGGGCTCTTCCACCGGCGCTGTCAGTTACCTACCCC 240  
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGACAGGCTGTTT 300  
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGACAGGCTGTTT 300

Qy	301	TC	AATTTGTCAGTTGTGGATGTGGAATGACTTAAATCGAACTAAATTCGAATGTGAA	360
Db	301	TC	AATTTGTCAGTTGTGGATGTGGAATGACTTAAATCGAACTAAATTCGAATGTGAA	360
Qy	361	TC	TGCATCTGACAGAGCATATCCCAATCTGATGAGCAATATGCTTGCATCTTGTTGC	420
Db	361	TC	TGCATCTGACAGAGCAATATCCCAATCTGATGAGCAATATGCTTGCATCTTGTTGC	420
Qy	421	CAGA	ATCAGCTGCATTCGCTGAACCTGAGACAAGACAACTTATCTCCCTGATGCCAAA	480
Db	421	CAGA	ATCAGCTGCATTCGCTGAACCTGAGACAAGACAACTTATCTCCCTGATGCCAAA	480
Qy	481	ATGC	ACCTACTCTTTCTCTAACTCTGGTGAGTCAATCTGGAGTGAATGATGAGTCTCC	540
Db	481	ATGC	ACCTACTCTTTCTCTAACTCTGGTGAGTCAATCTGGAGTGAATGATGAGTCTCC	540
Qy	541	GCAC	GAGCTTCATAAACCTCTTCAATGAGCTTTTATCTTCAAGCGGATGACGGAATAA	600
Db	541	GCAC	GAGCTTCATAAACCTCTTCAATGAGCTTTTATCTTCAAGCGGATGACGGAATAA	600
Qy	601	GTTAT	ATCCAGTCTTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGAGCCTACA	660
Db	601	GTTAT	ATCCAGTCTTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGAGCCTACA	660
Qy	661	AATT	GAGAGATCATCTCTAAGCAAAATGTCTATCTGCAATGAGAAATCTACAAGCG	720
Db	661	AATT	GAGAGATCATCTCTAAGCAAAATGTCTATCTGCAATGAGAAATCTACAAGCG	720
Qy	721	CACAG	AAATTTCTGAGATGGAAGAGTGGCTTTTAAAGATGCTCTCTCTTAAC	780
Db	721	CACAG	AAATTTCTGAGATGGAAGAGTGGCTTTTAAAGATGCTCTCTCTTAAC	780
Qy	781	TC	TGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGGTATGCTTTGAGATTGT	840
Db	781	TC	TGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGGTATGCTTTGAGATTGT	840
Qy	841	TGTG	CAACTGTGCTACAGCTGTGGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
Db	841	TGTG	CAACTGTGCTACAGCTGTGGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
Qy	901	GGTG	ACTGAGTTTATCAATGAJCAAAAGCTAAACAGATATCCAGCTCTCTCTTGTG	960
Db	901	GGTG	ACTGAGTTTATCAATGAJCAAAAGCTAAACAGATATCCAGCTCTCTCTTGTG	960
Qy	961	GT	TGTAGATCTAAACCTGAAGATCATGAGAGCAGGGCTCTACCTACAAAGTGAAT	1020
Db	961	GT	TGTAGATCTAAACCTGAAGATCATGAGAGCAGGGCTCTACCTACAAAGTGAAT	1020
Qy	1021	CTTG	CTCATTTCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTG	CTCATTTCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Qy	1081	AATT	TCCACTCTCATAGAGCTTTTAAATGTTTTCATTTGGATATAGGCTTAAAGAAATCA	1140
Db	1081	AATT	TCCACTCTCATAGAGCTTTTAAATGTTTTCATTTGGATATAGGCTTAAAGAAATCA	1140
Qy	1141	CTATA	AAAAATGCAAAATAAAGTTTACTCAAATCTGTG	1174
Db	1141	CTATA	AAAAATGCAAAATAAAGTTTACTCAAATCTGTG	1174

RESIT.T 102

RESULT IN  
ADC61737

ADC61737  
ID ADC61737 standard: cDNA: 1174 BP.

XX  
TD  
ADULT 131

ADC61737:

AC  
XX  
ADUC61737;

XX  
DT 18-DEC-2003 (first entry)

DI 18-DEC-2003 (first entry)  
XX

XX Human cDNA encoding secreted/transmembrane protein, PRO195.

DE  
XX  
XX  
Human CDNA encoding secreted/cytoplasmic protein, ER0133.

Human: ss: gene: secreted protein: transmembrane protein; PRO:

AM  
human; ss; gene; secreted protein; transmembrane protein; FMO

```
PR 30-APR-1998; 98US-0083742P.
PR 03-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086466P.
PR 22-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091353P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0010038P.
PR 07-OCT-1998; 98US-0016897P.
PR 07-OCT-1998; 98US-0021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0019330P.
PR 20-NOV-1998; 98US-0024885P.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98US-00200106.
PR 05-JAN-1999; 98US-00254465.
PR 08-MAR-1999; 98US-00256028.
PR 10-MAR-1999; 98US-00256686.
PR 10-MAR-1999; 98US-00256686.
PR 12-MAR-1999; 98US-00267213.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 12-APR-1999; 98US-00284291.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-00311832.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98US-00107233.
PR 02-JUN-1999; 98US-0012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146228P.
PR 23-AUG-1999; 98US-00380137.
PR 25-AUG-1999; 98US-00380138.
PR 25-AUG-1999; 98US-00380142.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98US-0028313.
PR 02-DEC-1999; 98US-0028551.
PR 02-DEC-1999; 98US-0028551.
PR 02-DEC-1999; 98US-0028551.
PR 16-DEC-1999; 98US-0030095.
PR 30-DEC-1999; 98US-0031243.
PR 30-DEC-1999; 98US-0031274.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000277.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-0003565.
PR 18-FEB-2000; 2000US-0004341.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 10-MAR-2000; 2000US-0006319.
PR 21-MAR-2000; 2000US-0007532.
PR 30-MAR-2000; 2000US-0008439.
PR 17-MAY-2000; 2000US-0013705.
PR 22-MAY-2000; 2000US-0014042.
PR 30-MAY-2000; 2000US-0014941.
PR 02-JUN-2000; 2000US-0015264.
PR 28-JUL-2000; 2000US-0020710.
PR 04-AUG-2000; 2000US-0023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000US-0032678.
PR 20-DEC-2000; 2000US-00747252.
PR 20-DEC-2000; 2000US-0034956.
PR 28-FEB-2001; 2001US-0006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00817092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00871800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 29-JUN-2001; 2001US-0019692.
PR 09-JUL-2001; 2001US-0021066.
PR 30-JUL-2001; 2001US-0021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH ) GENENTECH INC.
PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGAQCGGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGCGGCGCGGAGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
DB 61 GGGAAACAAGATGCGGCGCGGAGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGTGTGACCAATGCGCGGAGGTTCCGGGACCGCTTCGGCTGAAAGCA 180
DB 121 CCGCTGCTGTGTGACCAATGCGCGGAGGTTCCGGGACCGCTTCGGCTGAAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGGCTCTTCCACCGGCTGTGCTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGGCTCTTCCACCGGCTGTGCTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGTTGACGATGTGAGAGGTTGAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGTTGACGATGTGAGAGGTTGAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAATCGAACTAAATCGAATGTGAA 360
DB 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAATCGAATGTGAAATGTGAA 360
```

[illegible]

PR	06-MAY-1998;	98US-0084441P.	PR	30-DEC-1999;	99WO-US031274.
PR	07-MAY-1998;	98US-0084598P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-MAY-1998;	98US-0084600P.	PR	06-JAN-2000;	2000WO-US000277.
PR	07-MAY-1998;	98US-0084627P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-MAY-1998;	98US-0084637P.	PR	11-FEB-2000;	2000WO-US003565.
PR	07-MAY-1998;	98US-0084639P.	PR	18-FEB-2000;	2000WO-US004341.
PR	07-MAY-1998;	98US-0084640P.	PR	24-FEB-2000;	2000WO-US005004.
PR	07-MAY-1998;	98US-0084643P.	PR	02-MAR-2000;	2000WO-US005841.
PR	13-MAY-1998;	98US-0085323P.	PR	10-MAR-2000;	2000WO-US006319.
PR	13-MAY-1998;	98US-0085338P.	PR	21-MAR-2000;	2000WO-US007532.
PR	13-MAY-1998;	98US-0085339P.	PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-1998;	98US-0085573P.	PR	17-MAY-2000;	2000WO-US013705.
PR	15-MAY-1998;	98US-0085579P.	PR	22-MAY-2000;	2000WO-US014042.
PR	15-MAY-1998;	98US-0085580P.	PR	30-MAY-2000;	2000WO-US014941.
PR	15-MAY-1998;	98US-0085582P.	PR	02-JUN-2000;	2000WO-US015264.
PR	15-MAY-1998;	98US-0085689P.	PR	28-JUL-2000;	2000WO-US020710.
PR	15-MAY-1998;	98US-0085697P.	PR	24-AUG-2000;	2000WO-US023328.
PR	15-MAY-1998;	98US-0085700P.	PR	08-NOV-2000;	2000US-00709238.
PR	15-MAY-1998;	98US-0085704P.	PR	27-NOV-2000;	2000US-00723749.
PR	18-MAY-1998;	98US-0086023P.	PR	01-DEC-2000;	2000WO-US034678.
PR	22-MAY-1998;	98US-0086392P.	PR	20-DEC-2000;	2000US-00747259.
PR	22-MAY-1998;	98US-0086414P.	PR	20-DEC-2000;	2000WO-US034956.
PR	22-MAY-1998;	98US-0086430P.	PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAY-1998;	98US-0086486P.	PR	22-MAR-2001;	2001US-00816744.
PR	28-MAY-1998;	98US-0087098P.	PR	22-MAR-2001;	2001US-00816920.
PR	28-MAY-1998;	98US-0087106P.	PR	10-MAY-2001;	2001US-00809552.
PR	28-MAY-1998;	98US-0087208P.	PR	10-MAY-2001;	2001US-00854208.
PR	26-JUN-1998;	98US-00105413.	PR	10-MAY-2001;	2001US-00854280.
PR	26-JUN-1998;	98US-0090863P.	PR	01-JUN-2001;	2001US-00872035.
PR	26-JUN-1998;	98US-0091010P.	PR	01-JUN-2001;	2001WO-US017800.
PR	01-JUL-1998;	98US-0091359P.	PR	05-JUN-2001;	2001US-00874503.
PR	30-JUL-1998;	98US-0094651P.	PR	14-JUN-2001;	2001US-00882536.
PR	11-SEP-1998;	98US-0100038P.	PR	19-JUN-2001;	2001US-00886342.
PR	07-OCT-1998;	98US-00168978.	PR	20-JUN-2001;	2001US-00919692.
PR	07-OCT-1998;	98WO-US021141.	PR	29-JUN-2001;	2001WO-US021066.
PR	02-NOV-1998;	98US-00184216.	PR	09-JUL-2001;	2001WO-US021735.
PR	06-NOV-1998;	98US-00187368.	PR	30-JUL-2001;	2001US-00918585.
PR	20-NOV-1998;	98US-0109304P.	XX		
PR	20-NOV-1998;	98WO-US024855.	PA	(GETH ) GENENTECH INC.	
PR	07-DEC-1998;	98US-00202054.	XX		
PR	22-DEC-1998;	98US-00218517.			
PR	22-DEC-1998;	98US-0113296P.			
PR	23-DEC-1998;	98US-0113621P.			
PR	05-JAN-1999;	99WO-US000106.			
PR	05-MAR-1999;	98US-00254465.			
PR	08-MAR-1999;	99WO-US005028.			
PR	10-MAR-1999;	99US-00285686.			
PR	10-MAR-1999;	99WO-US005190.			
PR	12-MAR-1999;	98US-00267213.			
PR	12-MAR-1999;	99US-0123957P.			
PR	29-MAR-1999;	99US-0126773P.			
PR	12-APR-1999;	99US-00284291.			
PR	21-APR-1999;	98US-0130232P.			
PR	26-APR-1999;	99US-0131022P.			
PR	28-APR-1999;	99US-0131445P.			
PR	14-MAY-1999;	98US-00311832.			
PR	14-MAY-1999;	99US-0134287P.			
PR	14-MAY-1999;	99WO-US010733.			
PR	02-JUN-1999;	99WO-US012252.			
PR	16-JUN-1999;	98US-0139557P.			
PR	23-JUN-1999;	99US-0144037P.			
PR	07-JUL-1999;	99US-0142680P.			
PR	26-JUL-1999;	99US-0145698P.			
PR	28-JUL-1999;	99US-0146222P.			
PR	25-AUG-1999;	99US-00380137.			
PR	25-AUG-1999;	99US-00380138.			
PR	25-AUG-1999;	99US-00380142.			
PR	29-OCT-1999;	99US-0162506P.			
PR	30-NOV-1999;	99WO-US028313.			
PR	02-DEC-1999;	99WO-US028551.			
PR	02-DEC-1999;	99WO-US028565.			
PR	16-DEC-1999;	99WO-US030095.			
PR	30-DEC-1999;	99WO-US031243.			
			Query Match 100.0%; Score 1174; DB 9; Length 1174;		
			Best Local Similarity 100.0%; Pred. No. 0;		
			Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1	CGGACGGGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60			
DB	1	CGGACGGGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60			
QY	61	GGGAACAAGATGGCGGCGCCGAAAGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120			
DB	61	GGGAACAAGATGGCGGCGCCGAAAGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120			
QY	121	CGGTGCTGCTGCTGACCATGGCTTCGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180			
DB	121	CGGTGCTGCTGCTGACCATGGCTTCGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180			
QY	181	TTTGACTCGGTCTTTGGGTGATACGGCGCTTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240			
DB	181	TTTGACTCGGTCTTTGGGTGATACGGCGCTTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240			
QY	241	TTGCACACTACCTTAAGGAAGAGGTTGTCATGCGATGTTCAGAGAGTTGCAGGCTGTTT 300			
DB	241	TTGCACACTACCTTAAGGAAGAGGTTGTCATGCGATGTTCAGAGAGTTGCAGGCTGTTT 300			
QY	301	TCAATTTCTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360			
DB	301	TCAATTTCTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360			
QY	361	TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTCCCATCTTGGTTC 420			
DB	361	TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTCCCATCTTGGTTC 420			

QY 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTATGTCCTGATGCCAAA 480  
Db 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGCTGAGTCACTCTGAGTGACATGAGTCTCC 540  
Db 481 ATGCACCTACTCTTTCCTCTAACTCTGCTGAGTCACTCTGAGTGACATGAGTCTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTTAAGCAGAAATCAGTACGACCAACATTTGGAGAGGAGCTTACA 660  
Db 601 GTTATATTCAGTCTTAAGCAGAAATCAGTACGACCAACATTTGGAGAGGAGCTTACA 660  
QY 661 AATTTGAGAGAAATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720  
Db 661 AATTTGAGAGAAATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAGATGGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC 780  
Db 721 CACAGGAATTTCTTGAGATGGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC 780  
QY 781 TCTGGTGGATTTAACTACAATCTTCTCTCTCGGTGATGATGCTTTGGATTGT 840  
Db 781 TCTGGTGGATTTAACTACAATCTTCTCTCTCGGTGATGATGCTTTGGATTGT 840  
QY 841 TGTGCACTGTGCTACAGCTGTGAGCAGATGATGCTTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCACTGTGCTACAGCTGTGAGCAGATGATGCTTCTGAGAGCTGAGTATCTAT 900  
QY 901 GTTGACTTGGATTTATGATGAACAAAGCTTAAACAGATATCCAGTCTTCTCTTGTG 960  
Db 901 GTTGACTTGGATTTATGATGAACAAAGCTTAAACAGATATCCAGTCTTCTCTTGTG 960  
QY 961 GTTGTAGATCTPAAACTGAAGATCATGAAGAGCAGGCTCTACCTACCAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTPAAACTGAAGATCATGAAGAGCAGGCTCTACCTACCAAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAATTTAAAGCTTTTCTTTTAAAGACAGTGAATAGACATCTAA 1080  
Db 1021 CTTGCTCATCTGAATTTAAAGCTTTTCTTTTAAAGACAGTGAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTCTCAATCTGTG 1174  
Db 1141 CTATAAATGCAATTAAGTCTCAATCTGTG 1174  
RESULT 104  
ADC66801  
ID ADC66801 standard; cDNA; 1174 BP.  
XX AC ADC66801;  
XX AC ADC66801;  
DT 18-DEC-2003 (first entry)  
XX Human cDNA encoding secreted/transmembrane protein, PRO195.  
DE DE  
XX vulnary; virucide; neuroprotective; cytostatic; gene therapy;  
KW tumour cell proliferation inhibitor;  
KW secreted and transmembrane protein; PRO; viral infection; wound healing;  
KW tissue growth; muscle generation; muscle regeneration;  
KW anyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;  
KW diabetic peripheral neuropathy; chromosome identification; antagonist;  
KW tissue typing; immunohistochemical staining; gene; ss.  
XX Homo sapiens.  
OS

XX PN US2003060406-A1.  
XX PD 27-MAR-2003.  
XX PF 30-JUL-2001; 2001US-00918585.  
XX PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 17-MAR-1998; 98US-00040220.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079234P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 26-JUN-1998; 98US-00105413.  
PR 07-OCT-1998; 98US-00168978.  
PR 07-OCT-1998; 98WO-US021141.  
PR 02-NOV-1998; 98US-00184216.  
PR 06-NOV-1998; 98US-00187368.  
PR 20-NOV-1998; 98WO-US024855.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 05-JAN-1999; 99WO-US000106.  
PR 05-MAR-1999; 99US-00254465.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99US-00265686.  
PR 12-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 99US-00267213.  
PR 12-APR-1999; 99US-00284291.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380142.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 16-DEC-1999; 99WO-US028565.  
PR 02-DEC-1999; 99WO-US030095.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.  
 24-AUG-2000; 2000WO-US023328.  
 08-NOV-2000; 2000US-00709238.  
 27-NOV-2000; 2000US-00723749.  
 01-DEC-2000; 2000WO-US032678.  
 20-DEC-2000; 2000US-00747259.  
 20-DEC-2000; 2000WO-US034956.  
 28-FEB-2001; 2001WO-US006520.  
 22-MAR-2001; 2001US-00816744.  
 22-MAR-2001; 2001US-00816920.  
 22-MAR-2001; 2001WO-US009552.  
 10-MAY-2001; 2001US-00854208.  
 10-MAY-2001; 2001US-00854280.  
 25-MAY-2001; 2001WO-US017092.  
 01-JUN-2001; 2001US-00872035.  
 01-JUN-2001; 2001WO-US017800.  
 05-JUN-2001; 2001US-00874503.  
 14-JUN-2001; 2001US-00882636.  
 19-JUN-2001; 2001US-00886342.  
 20-JUN-2001; 2001WO-US019692.  
 29-JUN-2001; 2001WO-US021066.  
 09-JUL-2001; 2001WO-US021735.  
 (GETH ) GENENTECH INC.  
 Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
 Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;  
 Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
 Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;  
 Stewart TA, Tumas D, Williams PM, Wood WI;  
 WPI; 2003-596568/56.  
 P-PSDB; ADC66802.  
 Novel secreted and transmembrane polypeptides and polynucleotides  
 encoding them, useful for treating wound healing, tissue growth and  
 muscle generation and regeneration, amyotrophic lateral sclerosis or  
 neuropathy.  
 Claim 2; SEQ ID NO 329; 472pp; English.  
 The invention describes an isolated and transmembrane PRO  
 polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615  
 is useful in biotechnological and medical research, as well as in various  
 industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,  
 PRO708, PRO320, PRO352, PRO381, PRO615, PRO618, PRO772, PRO853,  
 PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful  
 therapeutically in vivo for lessening the effects of viral infection.  
 PRO200 is useful for the treatment of wound healing, tissue growth and  
 muscle generation and regeneration. PRO337 is useful for treating  
 amyotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or  
 diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is  
 useful for generating transgenic animals or knockout animals which are  
 useful in the development and screening of therapeutically useful  
 reagents, as probes for generating a pool of sequences for identifying  
 related PRO coding sequences, and to construct hybridisation probes for  
 mapping the gene which encodes the PRO and for the genetic analysis of  
 individuals with genetic disorders, for recombinantly expressing (I) and  
 for chromosome identification. (I) is useful as molecular marker for  
 protein electrophoresis purposes, and as therapeutic agents. (I) is also  
 useful for screening compounds to identify those that mimic the PRO  
 polypeptide (agonists) or prevent the effect of the PRO polypeptide  
 (antagonists). (I) and (II) are useful for tissue typing. PRO antibodies  
 are useful for immunohistochemical staining and/or assay of sample  
 fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.  
 detecting its expression in specific cells, tissues or serum, and for  
 affinity purification of PRO from recombinant cell culture or natural  
 sources. This sequence encodes a human secreted and transmembrane PRO  
 protein.  
 Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity	100.0%;	Pred. No. 0;	Mismatches	0;	Indels	0;	Gaps	0;
Matches 1174;	Conservative	0;						
QY	1	CGGACGCGTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60					
Db	1	CGGACGCGTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60					
QY	61	GGGAAACAAGATGGCGCGCGGAGGAGGAGCTCTGGGTGAGGACCACTGGGGTCCCG	120					
Db	61	GGGAAACAAGATGGCGCGCGGAGGAGGAGCTCTGGGTGAGGACCACTGGGGTCCCG	120					
QY	121	CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGAGGTTTGGGGACCGCTTCGGCTGAAGCA	180					
Db	121	CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGAGGTTTGGGGACCGCTTCGGCTGAAGCA	180					
QY	181	TTTGACTCCGCTCTTGGGTGATACGGGCTTCCGACCGGCTCTGAGTTGACCTACCC	240					
Db	181	TTTGACTCCGCTCTTGGGTGATACGGGCTTCCGACCGGCTCTGAGTTGACCTACCC	240					
QY	241	TTGCACACCTTACCCCTAAGGAAGAGGAGTTGTACGATGTTCAGAGGTTGCAAGGCTGTT	300					
Db	241	TTGCACACCTTACCCCTAAGGAAGAGGAGTTGTACGATGTTCAGAGGTTGCAAGGCTGTT	300					
QY	301	TCAATTTGTGAGTTGTGATGATGAATGACTTAATCGAATTAATGGAATGGA	360					
Db	301	TCAATTTGTGAGTTGTGATGATGAATGACTTAATCGAATTAATGGAATGGA	360					
QY	361	TCGCAATGACAGACATATCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420					
Db	361	TCGCAATGACAGACATATCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420					
QY	421	CAGAAATCAGCTGCGCTGCACTGAGCAAGAAACAACTTATGTCCTGATGCCAAA	480					
Db	421	CAGAAATCAGCTGCGCTGCACTGAGCAAGAAACAACTTATGTCCTGATGCCAAA	480					
QY	481	ATGCACCTACTCTTCTCTTAACTCTGCTGAGGTCACTCTGAGGTGACATGATGGA	540					
Db	481	ATGCACCTACTCTTCTCTTAACTCTGCTGAGGTCACTCTGAGGTGACATGATGGA	540					
QY	541	GCACAGAGCTTCAATAAACCCTTTCATGAGCTTTTATCTTCAAGCCGATGACGAA	600					
Db	541	GCACAGAGCTTCAATAAACCCTTTCATGAGCTTTTATCTTCAAGCCGATGACGAA	600					
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGAGGAGGCTACA	660					
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGAGGAGGCTACA	660					
QY	661	AATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAG	720					
Db	661	AATTTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAG	720					
QY	721	CACAGGATTTTCTGAGATGGAAGTGGCTTTTAAAGATGCTCTCTCTTAAC	780					
Db	721	CACAGGATTTTCTGAGATGGAAGTGGCTTTTAAAGATGCTCTCTCTTAAC	780					
QY	781	TCTGGGTGATTTTAACTACAACCTTTGCTCTCGGTGATGATGCTTTGGATTTGT	840					
Db	781	TCTGGGTGATTTTAACTACAACCTTTGCTCTCGGTGATGATGCTTTGGATTTGT	840					
QY	841	TGTGCACTGTTGCTACAGCTGTGGAGCATGTTCCCTCTGAGAGCTGAGTACTAT	900					
Db	841	TGTGCACTGTTGCTACAGCTGTGGAGCATGTTCCCTCTGAGAGCTGAGTACTAT	900					
QY	901	GCTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960					
Db	901	GCTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960					
QY	961	GTGTTAGATCTAAACATGAAGATCAGAGAGCAGGCTCTACCTACAAAGTGAAT	1020					
Db	961	GTGTTAGATCTAAACATGAAGATCAGAGAGCAGGCTCTACCTACAAAGTGAAT	1020					
QY	1021	CTTGCTCTTCTGAAATTTAAGCAATTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA	1080					



Db 1021 CTGCTCATCTGAAATTAAGCATTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081819P.  
Qy 1081 AATTCCTACTCTCATAGAGCTTTTAAATCGTTTCATTCGATATAGGCTTAAGAAATCA 1140  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081852P.  
Db 1081 AATTCCTACTCTCATAGAGCTTTTAAATCGTTTCATTCGATATAGGCTTAAGAAATCA 1140  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
Qy 1141 CTATAAATGCAAAATGAAGTACTCAATCTGTG 1174  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
Db 1141 CTATAAATGCAAAATGAAGTACTCAATCTGTG 1174  
PR 22-APR-1998; 98US-0082804P.  
PR 22-APR-1998; 98US-0082796P.  
PR 23-APR-1998; 98US-0083336P.  
PR 23-APR-1998; 98US-0083332P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083392P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 30-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086450P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98US-00168978.  
PR 02-OCT-1998; 98WO-US021141.  
PR 02-NOV-1998; 98US-00184216.  
PR 06-NOV-1998; 98US-00187368.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98WO-US024855.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 22-DEC-1998; 98US-0113621P.  
PR 03-JAN-1999; 98WO-US000106.  
PR 05-MAR-1999; 99US-00254465.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99US-00265686.  
PR 10-MAR-1999; 99US-00265686.  
RESULT 105  
ID ADC68925 standard; cDNA; 1174 BP.  
XX  
AC ADC68925;  
XX  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane protein, PRO195.  
XX  
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;  
KW cytosolic; ophthalmological; aniarthritic; osteopathic; antirheumatic;  
KW vulnerability; tumour growth; retinal disorder;  
KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
XX  
OS Homo sapiens.  
XX  
XX US2003064407-A1.  
XX  
XX 03-APR-2003.  
XX  
XX 24-OCT-2001; 2001US-00999834.  
XX  
PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064243P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 17-MAR-1998; 98US-008040220.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 26-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.



Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAGAATCA 1140  
QY 1141 CTAATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
|||||  
Db 1141 CTAATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
RESULT 106  
ADC62985  
ID ADC62985 standard; cDNA; 1174 BP.  
XX  
AC ADC62985;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane protein, PRO195.  
XX  
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;  
KW cytosolic; ophthalmological; antirheumatic; osteopathic; antirheumatic;  
KW vulvaric; auditory; tumour growth; retinal disorder;  
KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
XX  
OS Homo sapiens.  
XX  
XX US2003068648-A1.  
XX  
PD 10-APR-2003.  
XX  
XX 25-OCT-2001; 2001US-00013921.  
XX  
PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077832P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079666P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 27-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081819P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 15-APR-1998; 98US-0082568P.  
PR 15-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082796P.  
PR 23-APR-1998; 98US-0083336P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083352P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 29-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087108P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98WO-US021141.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98WO-US024855.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 99US-0123957P.  
PR 29-MAR-1999; 99US-0126773P.  
PR 26-APR-1999; 99US-0130232P.  
PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99US-0134287P.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 16-JUN-1999; 99US-0135557P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.

30-DEC-1999; 99WO-US031243.  
PR 05-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001WO-US009852.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019892.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 30-JUL-2001; 2001US-00918585.  
XX (GETH) GENENTECH INC.  
XX Ashtkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;  
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;  
PI Stewart JA, Tumas D, Williams PW, Wood WI;  
XX WPI: 2003-695924/56.  
DR P-PSDB; AUC62386.  
XX  
XX New isolated secreted and transmembrane PRO polypeptides, useful in the  
PT preparation of a medicament for treating a condition responsive to the  
PT polypeptide, and as therapeutic agents e.g. vaccines.  
XX  
XX Claim 2; SEQ ID NO 329; 467pp; English.  
XX  
XX The invention relates to an isolated PRO polypeptide (secreted or  
CC transmembrane protein) having at least 80% amino acid sequence identity  
CC to an amino acid sequence chosen from 94 fully defined sequences as given  
CC in the specification (including PRO lacking its associated signal  
CC peptide, a PRO extracellular domain with or without its associated signal  
CC peptide). Also included are nucleic acids encoding the PRO proteins  
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell  
CC comprising the vector and producing PRO, a chimeric molecule comprising  
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO  
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993  
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.  
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337  
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting  
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting  
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a  
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive  
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGCTGTCGACAGAG 60  
DB 1 CGGACCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGCTGTCGACAGAG 60  
QY 61 GGGAAACAGATGGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

61 GGGAAACAGATGGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTCGAGCA 180  
DB 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTCGAGCA 180  
QY 181 TTTGACTCGGCTTTGGGTGATACGGGCTTTGCGACCGGGCCCTGTCACTGACCTACCCC 240  
DB 181 TTTGACTCGGCTTTGGGTGATACGGGCTTTGCGACCGGGCCCTGTCACTGACCTACCCC 240  
QY 241 TTGCACACCTTACCTTAAGGAAGGAGTTGTAGCATGTTCAGAGGTTGCAAGCTGTTT 300  
DB 241 TTGCACACCTTACCTTAAGGAAGGAGTTGTAGCATGTTCAGAGGTTGCAAGCTGTTT 300  
QY 301 TCAATTTGTCTGTTGAGATGAAATGAACTTAAATCGAACTAAATTTGAAATGTGAA 360  
DB 301 TCAATTTGTCTGTTGAGATGAAATGAACTTAAATCGAACTAAATTTGAAATGTGAA 360  
QY 361 TCTGATGTACAGACGATATCCCAATCTGTATGAGCAATATGCTTCCCATCTTGGTGC 420  
DB 361 TCTGATGTACAGACGATATCCCAATCTGTATGAGCAATATGCTTCCCATCTTGGTGC 420  
QY 421 CAGAAATCAGCTGCCATTTCGCTGAACCTGAGACAGAAACAACTTATGTCTGTATGCAAAA 480  
DB 421 CAGAAATCAGCTGCCATTTCGCTGAACCTGAGACAGAAACAACTTATGTCTGTATGCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTTAACTCTGGTGAGTCACTCTGGAGTGACATGTGACTCC 540  
DB 481 ATGCACCTACTCTTCTCTTAACTCTGGTGAGTCACTCTGGAGTGACATGTGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGAAATA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGAAATA 600  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660  
QY 661 AATTGGAGAGATCATCTCTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGGAGAGATCATCTCTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTTCTGGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC 780  
DB 721 CACAGGAATTTTCTGGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC 780  
QY 781 TCTGGTGAGATTTTAACTTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGATTTGT 840  
DB 781 TCTGGTGAGATTTTAACTTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGATTTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCATATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCATATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTTGGAGTTTAACTGAAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960  
DB 901 GGTGACTTTGGAGTTTAACTGAAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960  
QY 961 GTTGTAGATCTAAACCTGAAAGATCATGAAAGACGAGGCTCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACCTGAAAGATCATGAAAGACGAGGCTCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTAAGCAATTTCTTTTAAAGCAAGTGTAATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTAAGCAATTTCTTTTAAAGCAAGTGTAATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATTTGGATATAGCCCTTAAGAAATCA 1140  
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATTTGGATATAGCCCTTAAGAAATCA 1140  
QY 1141 CTATATAATGCAATTAAGTTACTCAATCTGTG 1174

Db 1141 CTTAATAAATGCAATAAAGTACTCAAAATCTGTG 1174

RESULT 107  
ADC68050  
ID ADC68050 standard; cDNA; 1174 BP.  
XX  
AC ADC68050;  
DT  
XX 18-DEC-2003 (first entry)  
XX Human cDNA encoding secreted/transmembrane protein, PRO195.  
XX Human; ss; gene; secreted protein; transmembrane protein; PRO;  
KW cytoskeletal; ophthalmological; antiarthritic; osteopathic; antirheumatic;  
KW vulnery; auditory; tumor growth; retinal disorder;  
KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
XX  
OS Homo sapiens.  
XX  
XX US2003069178-A1.  
XX  
XX 10-APR-2003.  
XX  
XX 16-OCT-2001; 2001US-00978423.  
XX  
PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 01-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081819P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082796P.  
PR 27-APR-1998; 98US-0083366P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083392P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 30-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 15-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98WO-US021141.  
PR 20-NOV-1998; 98WO-US019304P.  
PR 22-DEC-1998; 98WO-US024855.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 99US-0123957P.  
PR 29-MAR-1999; 99US-0126773P.  
PR 21-APR-1999; 99US-0130232P.  
PR 26-APR-1999; 99US-0131023P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99WO-US014287P.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 16-JUN-1999; 99US-0139557P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0142680P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.

PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US0003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006519.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUN-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001WO-US009552.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 30-JUL-2001; 2001US-00918585.  
XX (GETH ) GENENTECH INC.  
PA  
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Herritsen ME;  
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;  
PI Stewart TA, Tumas D, Williams PM, Wood WI;  
XX WPI; 2003-657582/62.  
DR P-PSDB; ADC68051.  
XX  
XX Novel secreted and transmembrane polypeptides, designated PRO  
PT polypeptides, and polynucleotides encoding them useful for treating  
PT kidney diseases, bone, cartilage and retinal disorders.  
XX  
XX Claim 2; SEQ ID NO 329; 468pp; English.  
PS  
CC The invention relates to an isolated PRO polypeptide (secreted or  
CC transmembrane protein) having at least 80% amino acid sequence identity  
CC to an amino acid sequence chosen from 94 fully defined sequences as given  
CC in the specification (including PRO lacking its associated signal  
CC peptide, a PRO extracellular domain with or without its associated signal  
CC peptide). Also included are nucleic acids encoding the PRO proteins  
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell  
CC comprising the vector and producing PRO, a chimeric molecule comprising  
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO  
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993  
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.  
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337  
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCTGGGGAAACCTTCGAGAAACAGCAACAGCTGAGTGTGTGACAGAG 60  
DB 1 CGGACGCTGGGGAAACCTTCGAGAAACAGCAACAGCTGAGTGTGTGACAGAG 60  
QY 61 GGGAAACAAGATCGCGCGCCGAGGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
DB 61 GGGAAACAAGATCGCGCGCCGAGGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
QY 121 CGGCTGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTGGGCGGACCGCTTCGGCTGAAGCA 180

DB 121 CGGCTGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTGGGCGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTCTTGGGTGATACGCGCTCTTGGCCACGCGGCTGTGCTGAGTTCACCTACCCC 240  
DB 181 TTTGACTCGGCTCTTGGGTGATACGCGCTCTTGGCCACGCGGCTGTGCTGAGTTCACCTACCCC 240  
QY 241 TTTGCACACCTACCTAAAGAGAGAGGTTGTACGCAATGTCTGAGAGAGTTGAGGCTGTTT 300  
DB 241 TTTGCACACCTACCTAAAGAGAGAGGTTGTACGCAATGTCTGAGAGAGTTGAGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTGTGGATGATGGAATTTGAAATCGAATTAATTTGAAATTTGAAATTTGAA 360  
DB 301 TCAATTTGTGAGTTGTGGATGATGGAATTTGAAATCGAATTAATTTGAAATTTGAAATTTGAA 360  
QY 361 TCTGCAATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCACTTGGTTGC 420  
DB 361 TCTGCAATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCACTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480  
DB 421 CAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480  
QY 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
DB 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540  
QY 541 GCACAGAGCTTCATAAACCCTCTTCAAGCAATTTTATCTTCAAGCGGATGACGGAATAATA 600  
DB 541 GCACAGAGCTTCATAAACCCTCTTCAAGCAATTTTATCTTCAAGCGGATGACGGAATAATA 600  
QY 601 GTTATATTCAGCTTAAGCCAGAAATCCAGTAGCGACCACTTTGGAGCAGAGCTTACAT 660  
DB 601 GTTATATTCAGCTTAAGCCAGAAATCCAGTAGCGACCACTTTGGAGCAGAGCTTACAT 660  
QY 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTTCAAGCG 720  
DB 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTTCAAGCG 720  
QY 721 CACAGGAAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAAC 780  
DB 721 CACAGGAAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAAC 780  
QY 781 TCTGGTGGGATTTTAACTACAACTCTTGTCTCTCGTGTGATGATGATGATGATGATGATGAT 840  
DB 781 TCTGGTGGGATTTTAACTACAACTCTTGTCTCTCGTGTGATGATGATGATGATGATGATGAT 840  
QY 841 TGTGCAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900  
DB 841 TGTGCAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960  
QY 961 GTTGTGATGCTTAAATCTGAAGATCATGAAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTGATGCTTAAATCTGAAGATCATGAAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAAGCAATTTTCTTTTAAAGCAAGTGTATATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAAGCAATTTTCTTTTAAAGCAAGTGTATATAGACATCTAA 1080  
QY 1081 AATTTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGGCTTAAAGTAAATCA 1140  
DB 1081 AATTTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGGCTTAAAGTAAATCA 1140  
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 108

ADC41370  
ID ADC41370 standard; cDNA; 1174 BP.  
XX  
AC ADC41370;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane protein, PRO195.  
XX  
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;  
KW cytosolic; ophthalmological; anarthritic; osteopathic; antirheumatic;  
KW vulnary; auditory; tumour growth; retinal disorder;  
KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
XX  
OS Homo sapiens.  
XX  
PN US200307245-A1.  
XX  
PD 17-APR-2003.  
XX  
PF 25-OCT-2001; 2001US-00013929.  
XX  
PR 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 26-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081819P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082796P.  
PR 27-APR-1998; 98US-0083336P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083392P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 29-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086352P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 28-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98WO-US021141.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98WO-US024855.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 99US-0123957P.  
PR 29-MAR-1999; 98US-0136773P.  
PR 21-APR-1999; 99US-0130232P.  
PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99US-0134287P.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-JUN-1999; 98US-0139557P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0142680P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 30-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-FEB-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001WO-US009552.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUL-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 30-JUL-2001; 2001US-00918585.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;  
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
PI Klijavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;  
PI Stewart TA, Tumas D, Williams PW, Wood WI;  
XX  
DR WPI; 2003-743806/70.  
DR P-PSDB; ADC41371.  
XX  
PT Novel isolated secreted and transmembrane PRO polypeptides, useful in the  
PT preparation of a medicament for treating a condition responsive to the  
PT polypeptide, and as therapeutic agents e.g. vaccines.  
XX  
PS Claim 2; SEQ ID NO 329; 465pp; English.  
XX  
CC The invention relates to an isolated PRO polypeptide (secreted or  
CC transmembrane protein) having at least 80% amino acid sequence identity  
CC to an amino acid sequence chosen from 94 fully defined sequences as given  
CC in the specification (including PRO lacking its associated signal  
CC peptide, a PRO extracellular domain with or without its associated signal  
CC peptide). Also included are nucleic acids encoding the PRO proteins  
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell  
CC comprising the vector and producing PRO, a chimaeric molecule comprising  
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO  
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993  
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGACACAGATCGCGCGCGGAGGGAGCTTGGGTGAGACCCCACTGGGGCTCCCG 120  
DB 61 GGGACACAGATCGCGCGCGGAGGGAGCTTGGGTGAGACCCCACTGGGGCTCCCG 120  
QY 121 CGCTGCTGCTGCTGACCATGAGCTTGGCGGAGGTTCCGGCTGGAAGCA 180  
DB 121 CGCTGCTGCTGCTGACCATGAGCTTGGCGGAGGTTCCGGCTGGAAGCA 180  
QY 181 TTGACTCGGCTGTTGGTGATACGGCGTCTTGGCCACCGGGCGCTGTCAGTTGACCTACCCC 240

DB 181 TTGACTCGGCTGTTGGTGATACGGCGTCTTGGCCACCGGGCGCTGTCAGTTGACCTACCCC 240  
QY 241 TTGCACACCTTACCCTAAGGAAGAGAGGTTGTACGATGTGACAGAGGTTGACGGCTGTTT 300  
DB 241 TTGCACACCTTACCCTAAGGAAGAGAGGTTGTACGATGTGACAGAGGTTGACGGCTGTTT 300  
QY 301 TCAATTGTGTCAGTTTGTGATGATGGAATTTAAATCGAACTAAATTTGAAATGTGAA 360  
DB 301 TCAATTGTGTCAGTTTGTGATGATGGAATTTAAATCGAACTAAATTTGAAATGTGAA 360  
QY 361 TCTGCATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420  
QY 421 CAGAACTCAGCTGCCATTCGCTGACAGCAAGAACTTATGCTCCGTGATGCTCAAAA 480  
DB 421 CAGAACTCAGCTGCCATTCGCTGACAGCAAGAACTTATGCTCCGTGATGCTCAAAA 480  
QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGAGCTCC 540  
DB 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGAGCTCC 540  
QY 541 GCACAGAGCTTCAATACCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600  
DB 541 GCACAGAGCTTCAATACCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCAATTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCAATTTGGAGCAGGAGCTTACA 660  
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGGG 720  
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGGG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACTACAATCTTCTCTCGGTGATGATGCTTGGATTTGT 840  
DB 781 TCTGGTGGATTTTAACTACAATCTTCTCTCGGTGATGATGCTTGGATTTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960  
QY 961 GTTGTAGATCTAAACTGAGATCATGAGAGAGCGGGCTCTACTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAGATCATGAGAGAGCGGGCTCTACTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAAATGCAATTAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAAATGCAATTAAGTTACTCAAAATCTGTG 1174  
RESULT 109  
ADC67425  
ID ADC67425 standard; cDNA; 1174 BP.  
XX  
AC ADC67425;



XX 18-DEC-2003 (first entry)  
XX Human cDNA encoding secreted/transmembrane protein, PRO195.  
XX vulnary; virucide; neuroprotective; cytostatic; gene therapy;  
KW tumour cell proliferation inhibitor;  
KW secreted and transmembrane protein; PRO; viral infection; wound healing;  
KW tissue growth; muscle generation; muscle regeneration;  
KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;  
KW diabetic peripheral neuropathy; chromosome identification; antagonist;  
KW tissue typing; immunohistochemical staining; gene; ss.  
XX Homo sapiens.  
XX US2003073131-A1.  
XX 17-APR-2003.  
XX 25-OCT-2001; 2001US-00016177.  
XX 17-OCT-1997; 97US-0062250P.  
PR 03-NOV-1997; 97US-0064249P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077641P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 13-MAR-1998; 98US-0078004P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 20-MAR-1998; 98US-0078936P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 26-MAR-1998; 98US-0079656P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079689P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 30-MAR-1998; 98US-0079920P.  
PR 30-MAR-1998; 98US-0079923P.  
PR 31-MAR-1998; 98US-0080105P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 01-APR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080328P.  
PR 01-APR-1998; 98US-0080333P.  
PR 01-APR-1998; 98US-0080334P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081071P.  
PR 09-APR-1998; 98US-0081195P.  
PR 09-APR-1998; 98US-0081203P.  
PR 09-APR-1998; 98US-0081229P.  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081819P.  
PR 15-APR-1998; 98US-0081838P.  
PR 15-APR-1998; 98US-0081952P.  
PR 15-APR-1998; 98US-0081955P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082700P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082796P.  
PR 27-APR-1998; 98US-0083336P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083392P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 29-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086352P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 28-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98WO-US021141.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98WO-US024855.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 99US-0123957P.  
PR 29-MAR-1999; 99US-0146773P.  
PR 21-APR-1999; 99US-0130232P.  
PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99US-0134287P.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 16-JUN-1999; 99US-0139557P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0142680P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.



XX Human; ss; gene; secreted protein; transmembrane protein; PRO;  
KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;  
KW vulnery; auditory; tumour growth; retinal disorder;  
KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
OS  
XX Homo sapiens.  
XX US2003073624-A1.  
XX 17-APR-2003.  
XX  
XX 15-OCT-2001; 2001US-00978193.  
XX 17-OCT-1997; 97US-0062250P.  
XX 03-NOV-1997; 97US-0064249P.  
XX 13-NOV-1997; 97US-0065311P.  
XX 21-NOV-1997; 97US-0066364P.  
XX 10-MAR-1998; 98US-0077450P.  
XX 11-MAR-1998; 98US-0077632P.  
XX 11-MAR-1998; 98US-0077641P.  
XX 11-MAR-1998; 98US-0077649P.  
XX 12-MAR-1998; 98US-0077791P.  
XX 13-MAR-1998; 98US-0078004P.  
XX 17-MAR-1998; 98US-0080402P.  
XX 20-MAR-1998; 98US-0078888P.  
XX 20-MAR-1998; 98US-0078910P.  
XX 20-MAR-1998; 98US-0078936P.  
XX 20-MAR-1998; 98US-0078939P.  
XX 25-MAR-1998; 98US-0079294P.  
XX 26-MAR-1998; 98US-0079656P.  
XX 27-MAR-1998; 98US-0079663P.  
XX 27-MAR-1998; 98US-0079664P.  
XX 27-MAR-1998; 98US-0079689P.  
XX 27-MAR-1998; 98US-0079728P.  
XX 27-MAR-1998; 98US-0079786P.  
XX 30-MAR-1998; 98US-0079920P.  
XX 30-MAR-1998; 98US-0079923P.  
XX 31-MAR-1998; 98US-0080105P.  
XX 31-MAR-1998; 98US-0080107P.  
XX 31-MAR-1998; 98US-0080194P.  
XX 01-APR-1998; 98US-0080327P.  
XX 01-APR-1998; 98US-0080328P.  
XX 01-APR-1998; 98US-0080333P.  
XX 01-APR-1998; 98US-0080334P.  
XX 08-APR-1998; 98US-0081049P.  
XX 08-APR-1998; 98US-0081070P.  
XX 08-APR-1998; 98US-0081071P.  
XX 09-APR-1998; 98US-0081195P.  
XX 09-APR-1998; 98US-0081203P.  
XX 09-APR-1998; 98US-0081229P.  
XX 15-APR-1998; 98US-0081817P.  
XX 15-APR-1998; 98US-0081819P.  
XX 15-APR-1998; 98US-0081838P.  
XX 15-APR-1998; 98US-0081952P.  
XX 15-APR-1998; 98US-0081955P.  
XX 21-APR-1998; 98US-0082568P.  
XX 21-APR-1998; 98US-0082569P.  
XX 22-APR-1998; 98US-0082700P.  
XX 22-APR-1998; 98US-0082704P.  
XX 22-APR-1998; 98US-0082797P.  
XX 22-APR-1998; 98US-0082804P.  
XX 23-APR-1998; 98US-0082966P.  
XX 27-APR-1998; 98US-0083336P.  
XX 28-APR-1998; 98US-0083322P.  
XX 29-APR-1998; 98US-0083392P.  
XX 29-APR-1998; 98US-0083495P.  
XX 29-APR-1998; 98US-0083496P.  
XX 29-APR-1998; 98US-0083499P.  
XX 29-APR-1998; 98US-0083500P.  
XX 29-APR-1998; 98US-0083545P.  
XX 29-APR-1998; 98US-0083554P.  
XX 29-APR-1998; 98US-0083558P.  
XX 29-APR-1998; 98US-0083559P.  
XX 30-APR-1998; 98US-0083742P.  
XX 05-MAY-1998; 98US-0084366P.  
XX 06-MAY-1998; 98US-0084414P.  
XX 06-MAY-1998; 98US-0084441P.  
XX 07-MAY-1998; 98US-0084588P.  
XX 07-MAY-1998; 98US-0084600P.  
XX 07-MAY-1998; 98US-0084627P.  
XX 07-MAY-1998; 98US-0084637P.  
XX 07-MAY-1998; 98US-0084639P.  
XX 07-MAY-1998; 98US-0084640P.  
XX 07-MAY-1998; 98US-0084643P.  
XX 13-MAY-1998; 98US-0085338P.  
XX 13-MAY-1998; 98US-0085339P.  
XX 15-MAY-1998; 98US-0085573P.  
XX 15-MAY-1998; 98US-0085579P.  
XX 15-MAY-1998; 98US-0085580P.  
XX 15-MAY-1998; 98US-0085582P.  
XX 15-MAY-1998; 98US-0085689P.  
XX 15-MAY-1998; 98US-0085697P.  
XX 15-MAY-1998; 98US-0085700P.  
XX 15-MAY-1998; 98US-0085704P.  
XX 18-MAY-1998; 98US-0086023P.  
XX 22-MAY-1998; 98US-0086414P.  
XX 22-MAY-1998; 98US-0086430P.  
XX 22-MAY-1998; 98US-0086486P.  
XX 28-MAY-1998; 98US-0087038P.  
XX 28-MAY-1998; 98US-0087106P.  
XX 28-MAY-1998; 98US-0087208P.  
XX 26-JUN-1998; 98US-00105413.  
XX 26-JUN-1998; 98US-0090863P.  
XX 26-JUN-1998; 98US-0091010P.  
XX 01-JUL-1998; 98US-0091359P.  
XX 30-JUL-1998; 98US-0094651P.  
XX 11-SEP-1998; 98US-0100038P.  
XX 07-OCT-1998; 98US-00168978.  
XX 07-OCT-1998; 98WO-US021141.  
XX 06-NOV-1998; 98US-00184216.  
XX 06-NOV-1998; 98US-00187368.  
XX 20-NOV-1998; 98US-0109304P.  
XX 20-NOV-1998; 98WO-US024855.  
XX 07-DEC-1998; 98US-00202054.  
XX 22-DEC-1998; 98US-00218517.  
XX 23-DEC-1998; 98US-0113296P.  
XX 05-JAN-1999; 99WO-US000106.  
XX 08-MAR-1999; 99US-C0254465.  
XX 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1999; 99US-C0265686.  
XX 10-MAR-1999; 99WO-US005190.  
XX 12-MAR-1999; 99US-00267213.  
XX 12-MAR-1999; 99US-0123957P.  
XX 29-MAR-1999; 99US-0126773P.  
XX 29-MAR-1999; 99US-00284291.  
XX 21-APR-1999; 98US-0130232P.  
XX 26-APR-1999; 98US-0131022P.  
XX 26-APR-1999; 99US-0131445P.  
XX 14-MAY-1999; 99US-00311832.  
XX 14-MAY-1999; 99US-0134287P.  
XX 14-MAY-1999; 99WO-US010733.  
XX 02-JUN-1999; 99WO-US012252.  
XX 12-JUN-1999; 99US-0139557P.  
XX 23-JUN-1999; 99US-0141037P.  
XX 07-JUL-1999; 99US-0142680P.  
XX 26-JUL-1999; 99US-0145698P.  
XX 28-JUL-1999; 99US-0146222P.  
XX 25-AUG-1999; 99US-00380137.  
XX 25-AUG-1999; 99US-00380138.  
XX 25-AUG-1999; 99US-00380142.  
XX 29-OCT-1999; 99US-0162506P.

```

PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 04-FEB-2000; 2000US-0180165P.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001WO-US0816920.
PR 10-MAY-2001; 2001US-00809552.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918595.
( GETH ) GENENTECH INC.

Query Match      100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGACAAAGATGGCGGCCGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB 61 GGGACAAAGATGGCGGCCGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CGCGTCTGCTGCTGCTGACCATGCGCTTGGCCGAGGAGTTGCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CGCGTCTGCTGCTGCTGACCATGCGCTTGGCCGAGGAGTTGCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTGTACTCGGTCTGGGTGATACGGCGTCTTGGCCACCGGGCTGTCAAGTGACCTACCCC 240
DB 181 TTGTACTCGGTCTGGGTGATACGGCGTCTTGGCCACCGGGCTGTCAAGTGACCTACCCC 240

QY 241 TTGCAACCTACCCCTAAGGAAGAGAGTTGTACGATGTACAGAGAGTTGAGAGGCTGTTT 300
DB 241 TTGCAACCTACCCCTAAGGAAGAGAGTTGTACGATGTACAGAGAGTTGAGAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTTAAATCGAATTAATGGAATGTGAA 360

```

```

DB 301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTTAAATCGAATTAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTGTATGAGCAATATGCTTGGCATCTTGGTGC 420
DB 361 TCTGCATGTACAGAGCATATTTCCCAATCTGTATGAGCAATATGCTTGGCATCTTGGTGC 420
QY 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAACAACTTATCTCCTGATGCAAAA 480
DB 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAACAACTTATCTCCTGATGCAAAA 480
QY 481 ATGCACCTACTCTTCTCTCTAACTCTGTGTGAGGTCAATCTGTGAGTGACATGAGACTCC 540
DB 481 ATGCACCTACTCTTCTCTCTAACTCTGTGTGAGGTCAATCTGTGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCAATACCTCTTCATGCACTTTTATCTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCAATACCTCTTCATGCACTTTTATCTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGACACACATTTGGAGCAGGACTACA 660
DB 601 GTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGACACACATTTGGAGCAGGACTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGGG 720
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGGG 720
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTAACTCAACTCTTCTCTCGTCTCGGTGATGATTTGCTTTGGATTTGT 840
DB 781 TCTGGTGGATTTAACTCAACTCTTCTCTCGTCTCGGTGATGATTTGCTTTGGATTTGT 840
QY 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
DB 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAAAGATATCCAGCTTCTCTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAAAGATATCCAGCTTCTCTCTTGTG 960
QY 961 GTTCTTAGATCTAAACTGAAGATCATGAGAGCAGGCGCTCTACTCTACAAAGTGAAT 1020
DB 961 GTTCTTAGATCTAAACTGAAGATCATGAGAGCAGGCGCTCTACTCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGACAAGTCTAATAGACATCTAA 1080
DB 1021 CTTGCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGACAAGTCTAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCTACAGCTTTTAAATGGTTTCAATGGATATAGGCTTGAAGAAATCA 1140
DB 1081 AATTCCACTCTCTACAGCTTTTAAATGGTTTCAATGGATATAGGCTTGAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 111
ADC41994
ID ADC41994 standard; cDNA; 1174 BP.
XX
AC ADC41994;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnery; auditory; tumour growth; retinal disorder;

```

KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
XX Homo sapiens.  
XX US2003104998-A1.  
XX 05-JUN-2003.  
XX 16-OCT-2001; 2001US-00978643.  
XX 17-OCT-1997; 97US-0062250P.  
XX 03-NOV-1997; 97US-0064242P.  
XX 13-NOV-1997; 97US-0065311P.  
XX 21-NOV-1997; 97US-0066364P.  
XX 10-MAR-1998; 98US-0077450P.  
XX 11-MAR-1998; 98US-0077632P.  
XX 11-MAR-1998; 98US-0077641P.  
XX 11-MAR-1998; 98US-0077649P.  
XX 12-MAR-1998; 98US-0077791P.  
XX 13-MAR-1998; 98US-0078004P.  
XX 17-MAR-1998; 98US-0080402P.  
XX 20-MAR-1998; 98US-0078886P.  
XX 20-MAR-1998; 98US-0078910P.  
XX 20-MAR-1998; 98US-0078936P.  
XX 20-MAR-1998; 98US-0078939P.  
XX 25-MAR-1998; 98US-0079294P.  
XX 26-MAR-1998; 98US-0079658P.  
XX 27-MAR-1998; 98US-0079663P.  
XX 27-MAR-1998; 98US-0079664P.  
XX 27-MAR-1998; 98US-0079689P.  
XX 27-MAR-1998; 98US-0079728P.  
XX 27-MAR-1998; 98US-0079786P.  
XX 30-MAR-1998; 98US-0079920P.  
XX 20-MAR-1998; 98US-0079923P.  
XX 31-MAR-1998; 98US-0080105P.  
XX 31-MAR-1998; 98US-0080107P.  
XX 31-MAR-1998; 98US-0080165P.  
XX 31-MAR-1998; 98US-0080194P.  
XX 01-APR-1998; 98US-0080327P.  
XX 01-APR-1998; 98US-0080328P.  
XX 01-APR-1998; 98US-0080333P.  
XX 01-APR-1998; 98US-0080334P.  
XX 08-APR-1998; 98US-0080404P.  
XX 08-APR-1998; 98US-0081070P.  
XX 08-APR-1998; 98US-0081071P.  
XX 09-APR-1998; 98US-0081195P.  
XX 09-APR-1998; 98US-0081203P.  
XX 15-APR-1998; 98US-0081229P.  
XX 15-APR-1998; 98US-0081817P.  
XX 15-APR-1998; 98US-0081819P.  
XX 15-APR-1998; 98US-0081838P.  
XX 15-APR-1998; 98US-0081952P.  
XX 15-APR-1998; 98US-0081955P.  
XX 21-APR-1998; 98US-0082568P.  
XX 21-APR-1998; 98US-0082569P.  
XX 22-APR-1998; 98US-0082700P.  
XX 22-APR-1998; 98US-0082704P.  
XX 22-APR-1998; 98US-0082797P.  
XX 22-APR-1998; 98US-0082804P.  
XX 23-APR-1998; 98US-0082966P.  
XX 27-APR-1998; 98US-0083336P.  
XX 28-APR-1998; 98US-0083322P.  
XX 28-APR-1998; 98US-0083392P.  
XX 28-APR-1998; 98US-0083495P.  
XX 28-APR-1998; 98US-0083496P.  
XX 29-APR-1998; 98US-0083499P.  
XX 29-APR-1998; 98US-0083500P.  
XX 29-APR-1998; 98US-0083545P.  
XX 29-APR-1998; 98US-0083545P.  
XX 29-APR-1998; 98US-0083558P.  
XX 29-APR-1998; 98US-0083559P.  
XX 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084441P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085689P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 28-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98US-00168978.  
PR 07-OCT-1998; 98WO-US021141.  
PR 02-NOV-1998; 98US-00184216.  
PR 06-NOV-1998; 98US-00187368.  
PR 20-NOV-1998; 98US-0109304P.  
PR 20-NOV-1998; 98WO-US024855.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 05-MAR-1999; 99US-00254465.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99US-00265686.  
PR 12-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 98US-00267213.  
PR 12-MAR-1999; 99US-0123957P.  
PR 29-MAR-1999; 99US-0126773P.  
PR 12-APR-1999; 99US-00284291.  
PR 21-APR-1999; 99US-0130232P.  
PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 98US-00311832.  
PR 14-MAY-1999; 98US-0134287P.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 16-JUN-1999; 99US-0139557P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0142680P.  
PR 26-JUL-1999; 98US-0145698P.  
PR 25-AUG-1999; 98US-0146222P.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380142.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028565.

```
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918595.
XX
PA (GETH ) GENENTECH INC.

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACACGACAAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACACGACAAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CGCGTCTGCTGCTGACCAATGCGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGAGCA 180
DB 121 CGCGTCTGCTGCTGACCAATGCGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGAGCA 180
QY 181 TTGTGACTCGGTCTGGGTGATACGCGCTTTGCCACCGGGCTGTGAGTGAACCTACCCC 240
DB 181 TTGTGACTCGGTCTGGGTGATACGCGCTTTGCCACCGGGCTGTGAGTGAACCTACCCC 240
QY 241 TTGCAACCTACCTTAAGAGAGAGAGTTGACGATGTGACAGAGGTTCAGGCTGTTT 300
DB 241 TTGCAACCTACCTTAAGAGAGAGAGTTGACGATGTGACAGAGGTTCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGATGATGGAATTCGACTTAATCGAACTAAATTTGGAATGAA 360
DB 301 TCAATTTGTCAGTTTGTGATGATGGAATTCGACTTAATCGAACTAAATTTGGAATGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
```

```
DB 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCCTGAACTGAGACAAGAACAACTTATCTCCTGATGCAAAA 480
DB 421 CAGAATCAGCTGCCATTCCTGAACTGAGACAAGAACAACTTATCTCCTGATGCAAAA 480
QY 481 ATGACCTACTCTTCTCTTAATCTGCTGAGTGTGAGTCAATCTGAGTGACATGATGACTCC 540
DB 481 ATGACCTACTCTTCTCTTAATCTGCTGAGTGTGAGTCAATCTGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCAAGCCGATTTTATCTTCAAGCCGATGACGGAATAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCAAGCCGATTTTATCTTCAAGCCGATGACGGAATAAATA 600
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTGAAAGTGAAGAAAGTGAAGGCTTTTAAAGATGCCCTCTCTTTAC 780
DB 721 CACAGGAATTTCTGAAAGTGAAGAAAGTGAAGGCTTTTAAAGATGCCCTCTCTTTAC 780
QY 781 TCTGGGTGGATTTTAACTCAACTCTTCTCGTGTGATGCTATTGCTTTGGATTTGT 840
DB 781 TCTGGGTGGATTTTAACTCAACTCTTCTCGTGTGATGCTATTGCTTTGGATTTGT 840
QY 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGATGTTCCCTCTGAGAGCTGATATCTAT 900
DB 841 TGTGCAACTCTGCTACAGCTGTGGAGCAGATGTTCCCTCTGAGAGCTGATATCTAT 900
QY 901 GGTGACTTGGAGTTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTCTTAGATCTAAAACCTGAAGATCATGAAAGACGAGGCGCTTACCTACAAAGTGAAT 1020
DB 961 GTTCTTAGATCTAAAACCTGAAGATCATGAAAGACGAGGCGCTTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGGCTTTAAGAAATCA 1140
DB 1081 AATTCCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGATATAGGCTTTAAGAAATCA 1140
QY 1141 CTATAAATGCAATTAAGTTACTCAAACTGTG 1174
DB 1141 CTATAAATGCAATTAAGTTACTCAAACTGTG 1174

RESULT 112
ADCS0312
ID ADCS0312 standard; cDNA; 1174 BP.
XX
AC ADCS0312;
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
```

endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
immune system cell infiltration; chromosome mapping; gene mapping;  
gene therapy; chromosome identification; chromosome marker; gene; ss.  
Homo sapiens.  
US2003092106-A1.  
15-MAY-2003.  
24-APR-2002; 2002US-00131822.  
19-AUG-1998; 98US-0097141P.  
02-JUN-1999; 99WO-US012252.  
25-AUG-1999; 99US-00380137.  
30-MAR-2000; 2000WO-US008439.  
01-DEC-2000; 2000WO-US032678.  
19-DEC-2001; 2001US-00028072.  
(GETH ) GENENTECH INC.  
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI; 2003-801171/75.  
P-PSDB; ADC50313.  
New secreted and transmembrane nucleic acid useful for treating  
inflammation, organ failure, atherosclerosis, cardiac injury,  
infertility, birth defects, premature aging, acquired immunodeficiency  
syndrome or cancer.

Claim 2; Fig 271; 637pp; English.  
The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems. articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match	100.0%;	Score 1174;	DB 9;	Length 1174;
Best Local Similarity	100.0%;	Pred. No. 0;	Mismatches 0;	Gaps 0;
Matches 1174;	Conservative	0;		
QY	1	CGGACGGCTGGGGGAAACCCCTTCGGAGAAAAACAGCAACAGCTGCTGTGACAGAG	60	
DB	1	CGGACGGCTGGGGGAAACCCCTTCGGAGAAAAACAGCAACAGCTGCTGTGACAGAG	60	
QY	61	GGGAACAAGATGGGGGCGGCGGAAGGGAGCCTTGGGTGAGGACCAACCTGGGGCTCCCG	120	
DB	61	GGGAACAAGATGGGGGCGGCGGAAGGGAGCCTTGGGTGAGGACCAACCTGGGGCTCCCG	120	
QY	121	CCGCTGCTGCTGTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180	
DB	121	CCGCTGCTGCTGTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180	
QY	181	TTTGACTCGGCTTGGGTGATACGGGCTTGGCCACCGGCGCTTGTCAAGTTGGAATGTGA	240	
DB	181	TTTGACTCGGCTTGGGTGATACGGGCTTGGCCACCGGCGCTTGTCAAGTTGGAATGTGA	240	
QY	241	TTGCACACCTTACCCCTAAGGAAGAGGAGCTTGTACGATGTCCAGAGAGGTTGCAGGCTG	300	
DB	241	TTGCACACCTTACCCCTAAGGAAGAGGAGCTTGTACGATGTCCAGAGAGGTTGCAGGCTG	300	
QY	301	TCAATTTGTCAGTTTGGTGTGATGTAATGACTTAATCGAATTAATTTGGAATGTGA	360	
DB	301	TCAATTTGTCAGTTTGGTGTGATGTAATGACTTAATCGAATTAATTTGGAATGTGA	360	
QY	361	TCTGCATGTACAGAAGCATATTCGAATCTGTGAGCAATATCTTGCATCTTGGTTGC	420	
DB	361	TCTGCATGTACAGAAGCATATTCGAATCTGTGAGCAATATCTTGCATCTTGGTTGC	420	
QY	421	CAGAAATCAGTGGCAATTCGCTGAATCAGACAGACAACTTATGTCCCTGATGCCAAA	480	
DB	421	CAGAAATCAGTGGCAATTCGCTGAATCAGACAGACAACTTATGTCCCTGATGCCAAA	480	
QY	481	ATGCACCTTACTCTTCTCTAACTCTGTGAGGTCATCTTGGAGTGACATGATGGACTCC	540	
DB	481	ATGCACCTTACTCTTCTCTAACTCTGTGAGGTCATCTTGGAGTGACATGATGGACTCC	540	
QY	541	GCAACAGCTTCATAACCTCTTCATGAGCACTTTTATCTTCAAGCCGATGACGGAATA	600	
DB	541	GCAACAGCTTCATAACCTCTTCATGAGCACTTTTATCTTCAAGCCGATGACGGAATA	600	
QY	601	GTATATTCAGTCTTAAGCCAGAAATCCAGTACCCACCAATTTGGAGCAGGAGCCTTACA	660	
DB	601	GTATATTCAGTCTTAAGCCAGAAATCCAGTACCCACCAATTTGGAGCAGGAGCCTTACA	660	
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG	720	
DB	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG	720	
QY	721	CACAGAAATTTCTTGAAGATGGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC	780	
DB	721	CACAGAAATTTCTTGAAGATGGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC	780	
QY	781	TCTGGGTGAAATTTAACTACAACTCTTCTCTCGGTGATGCTTGGATTTGT	840	
DB	781	TCTGGGTGAAATTTAACTACAACTCTTCTCTCGGTGATGCTTGGATTTGT	840	
QY	841	TGTGCACTGTTGCTACAGCTGTGGAGCAGATGTTCCCTCTGAGAGAGCTGAGTATCTAT	900	
DB	841	TGTGCACTGTTGCTACAGCTGTGGAGCAGATGTTCCCTCTGAGAGAGCTGAGTATCTAT	900	
QY	901	GGTGACTTGGAGTTTAAATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960	
DB	901	GGTGACTTGGAGTTTAAATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960	
QY	961	GTGTTTGTAGTCTAAACCTGAGATCATGAGAGCAGGCGCTCTTACCTTACAAAAGTGAAT	1020	
DB	961	GTGTTTGTAGTCTAAACCTGAGATCATGAGAGCAGGCGCTCTTACCTTACAAAAGTGAAT	1020	
QY	1021	CTTGCTCATCTGAAATTTTAAAGCATTTTCTTTTAAAGACAGAGTGTAATAGACATCTAA	1080	

Db 1021 CTTCGCTCATCTGAATTTAAAGCATTTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
Qy 1081 AATTCGCTCTCTATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCGCTCTCTATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
Qy 1141 CTATAAATGCATAAAGTTACTCAATCTGTG 1174  
Db 1141 CTATAAATGCATAAAGTTACTCAATCTGTG 1174  
RESULT 113  
ADCT1859  
ID ADCT1859 standard; cDNA; 1174 BP.  
XX AC ADCT1859;  
XX DT 18-DEC-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
XX OS Homo sapiens.  
XX PN US2003092107-A1.  
XX PD 15-MAY-2003.  
XX PF 24-APR-2002; 2002US-00131828.  
XX PR 07-OCT-1998; 98US-0103315P.  
XX PR 01-SEP-1999; 99WO-US020111.  
XX PR 18-OCT-1999; 98US-00403297.  
XX PR 18-FEB-2000; 2000WO-US004342.  
XX PR 10-NOV-2000; 2000WO-US030873.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX PI  
DR WPI; 2003-801172/75.  
XX P-PSDB; ADCT1860.  
XX PT New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
PT cancer.  
XX PS Claim 2; Fig 271; 637pp; English.  
XX CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, or  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polynucleotide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAACAGCAAGCTGAGCTGCTGTGACAGAG 60  
Db 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAACAGCAAGCTGAGCTGCTGTGACAGAG 60  
Qy 61 GGGAAACAAGATGCGCGCGCGAGGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
Db 61 GGGAAACAAGATGCGCGCGCGAGGGAGGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
Qy 121 CCGCTGCTGCTGTGACCATGCGCTTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
Db 121 CCGCTGCTGCTGTGACCATGCGCTTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
Qy 181 TTTGACTCGCTTTGGGTGATACGGCTCTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240  
Db 181 TTTGACTCGCTTTGGGTGATACGGCTCTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240  
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300  
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300  
Qy 301 TCAATTTGTGAGTTTGGATGATGGAAATGACTTAAATCGAACTAAATGGAAATGAA 360  
Db 301 TCAATTTGTGAGTTTGGATGATGGAAATGACTTAAATCGAACTAAATGGAAATGAA 360  
Qy 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGCTTC 420  
Db 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGCTTC 420  
Qy 421 CAGATCAGTCCGCTTCGCTGAGTACGACAGACAGCACTTATGTCCTGATGCCAAA 480  
Db 421 CAGATCAGTCCGCTTCGCTGAGTACGACAGACAGCACTTATGTCCTGATGCCAAA 480  
Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540  
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540  
Qy 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCACGCCGATGACGGAAAAATA 600  
Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCACGCCGATGACGGAAAAATA 600





Db 181 TTTGACTCGGCTTTGGGTGATACGGGCTCTTGGCACCGGCGCTGTGAGTTGACCTACCC 240  
Qy 241 TTGCACACCTACCTACCTAAGGAAGAGGAGTGTAGCGCATGTGACAGAGGTTGACAGGCTGTT 300  
Db 241 TTGCACACCTACCTAAGGAAGAGGAGTGTAGCGCATGTGACAGAGGTTGACAGGCTGTT 300  
Qy 301 TCAATTTGTCAGTTTGGGATGATGGAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
Db 301 TCAATTTGTCAGTTTGGGATGATGGAATGACTTAAATCGAACTAAATGGAATGTGAA 360  
Qy 361 TCTGCATGTACAGAAAGCATATCCCAATCTGATGAGCAATATGCTTGGCCATCTTGGTTC 420  
Db 361 TCTGCATGTACAGAAAGCATATCCCAATCTGATGAGCAATATGCTTGGCCATCTTGGTTC 420  
Qy 421 CAGAATCAGCTGCCATTCGCTGAATCGAGCAAGAACAACTTATGCTCCCTGATGCCAAA 480  
Db 421 CAGAATCAGCTGCCATTCGCTGAATCGAGCAAGAACAACTTATGCTCCCTGATGCCAAA 480  
Qy 481 ATGCACCTACTCTTCTCTTAACCTCTGAGTGCATCTCGAGTGACATGATGAGTGC 540  
Db 481 ATGCACCTACTCTTCTCTTAACCTCTGAGTGCATCTCGAGTGACATGATGAGTGC 540  
Qy 541 GCACAGAGCTTCATAACCTCTTCAATGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
Db 541 GCACAGAGCTTCATAACCTCTTCAATGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
Qy 601 GTTATATCCAGTCTAGCAGCAATCCAGTACGCACACATTTGGAGCAGGACCTCA 660  
Db 601 GTTATATCCAGTCTAGCAGCAATCCAGTACGCACACATTTGGAGCAGGACCTCA 660  
Qy 661 AATTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
Db 661 AATTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
Qy 721 CACAGGAATTTCTGGAAGTGAAGATGAGTGGCTTTTAAAGTGCCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTGGAAGTGAAGATGAGTGGCTTTTAAAGTGCCTCTCTCTTAAC 780  
Qy 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGTTGCTTTGGATTTGT 840  
Db 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGTTGCTTTGGATTTGT 840  
Qy 841 TGTGCAACTGTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGTCTCTCTTTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAACAGATATCCAGTCTCTCTTTG 960  
Qy 961 GTTGTAGATCTAAACTGAAGTCAATGAAGACAGGCGCTCTACCTACAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGTCAATGAAGACAGGCGCTCTACCTACAAAAGTGAAT 1020  
Qy 1021 CTTGCTCATCTGAATTTAGCAATTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
Db 1021 CTTGCTCATCTGAATTTAGCAATTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
Qy 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAITGGATATAGCCCTTAAGAAATCA 1140  
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAITGGATATAGCCCTTAAGAAATCA 1140  
Qy 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174  
Db 1141 CTATTAATGCAATTAAGTTACTCAATCTGTG 1174

RESULT 115

ADC52845

ID ADC52845 standard; cDNA; 1174 BP.

XX

AC ADC52845;

XX 18-DEC-2003 (first entry)  
DT Novel human secreted and transmembrane protein cDNA Seq ID271.  
XX human; PRO; membrane bound protein; membrane bound receptor;  
XX cell proliferation; cell migration; cell differentiation;  
KW mitogenic factor; survival factor; cytotoxic factor; receptor;  
KW differentiation factor; neuropeptide; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.  
XX Homo sapiens.  
OS US2003087365-A1.  
XX PD 08-MAY-2003.  
XX 23-APR-2002; 2002US-00128689.  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US006319.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 05-JAN-2000; 99WO-US031274.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.

15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
21-MAR-2000; 2000WO-US007532.  
30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.  
24-AUG-2000; 2000WO-US023328.  
08-NOV-2000; 2000WO-US030952.  
10-NOV-2000; 2000WO-US030873.  
20-DEC-2000; 2000WO-US032678.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US006666.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00808689.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.  
(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godwoski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI; 2003-801150/75.  
F-PSDB; ADC52846.

New PRO nucleic acid, useful for manufacturing a medicament for  
diagnosing or treating tumor.

Claim 2; SEQ ID NO 271; 637pp; English.

This invention relates to novel nucleic acids encoding human PRO secreted  
and transmembrane proteins. Extracellular proteins play important roles  
in the formation, differentiation and maintenance of multicellular  
organisms. The fate of many individual cells (for example proliferation,  
migration or differentiation) is typically governed by information  
received from other cells and the immediate environment. The information  
is often transmitted by secreted polypeptides (for example mitogenic  
factors, survival factors, cytotoxic factors, differentiation factors,  
neuropeptides and hormones) which are received and interpreted by diverse  
cell receptors or membrane bound proteins. These membrane bound proteins  
and receptors may be of use as pharmaceutical and diagnostic agents, such  
as in the blocking of receptor-ligand interactions. The current invention  
provides the amino acid sequences of novel human membrane bound receptors

CC and proteins, along with the cDNA sequences encoding them. The novel  
CC proteins of the invention may have cytostatic activities through the  
CC stimulation of chondrocytes. The nucleic acids of the invention may be  
CC useful for the manufacture of a medicament for diagnosing or treating a  
CC tumour in a mammal. In addition, they may be useful for measuring or  
CC detecting the expression of a tumour associated gene. The present  
CC sequence is a cDNA sequence which encodes a human PRO protein of the  
CC invention.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 CGGACGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
  
QY 61 GGGAAACAAGATGGCGCGCGGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
DB 61 GGGAAACAAGATGGCGCGCGGAGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
  
QY 121 CCCTGCTGCTGCTGACCATGGCTTGGCCGAGGTTGGGGACCGCTTCGGCTCAAGCA 180  
DB 121 CCCTGCTGCTGCTGACCATGGCTTGGCCGAGGTTGGGGACCGCTTCGGCTCAAGCA 180  
  
QY 181 TTTGACTCGGCTCTTGGGTGATAGCGGCTCTTGGCCAGGCTTGGGAGCTTCACTACCC 240  
DB 181 TTTGACTCGGCTCTTGGGTGATAGCGGCTCTTGGCCAGGCTTGGGAGCTTCACTACCC 240  
  
QY 241 TTGCACACCTACCTTAAGGAAGGAGGTTGTAGCGATGTCAGAGAGTTGCGAGCTGTTT 300  
DB 241 TTGCACACCTACCTTAAGGAAGGAGGTTGTAGCGATGTCAGAGAGTTGCGAGCTGTTT 300  
  
QY 301 TCAATTTGTGAGTTGTGGATGAAATGAACTTAAATCGAACTAAATGGAATGTGAA 360  
DB 301 TCAATTTGTGAGTTGTGGATGAAATGAACTTAAATCGAACTAAATGGAATGTGAA 360  
  
QY 361 TCTGCATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420  
  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAAACAACTTATGTCCTGTATGCCAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAAACAACTTATGTCCTGTATGCCAAA 480  
  
QY 481 ATGCACCTACTCTTTCTCTTAACTCTGCTGAGCTATTCTGGAGTCACATGAGTCTCC 540  
DB 481 ATGCACCTACTCTTTCTCTTAACTCTGCTGAGCTATTCTGGAGTCACATGAGTCTCC 540  
  
QY 541 GCACAGAGCTTCATAACCTCTTCATGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCATGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
  
QY 601 GTTATATTCCAGTCTTAAGCCAGAAATCCAGTAGCACCACATTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCCAGTCTTAAGCCAGAAATCCAGTAGCACCACATTTGGAGCAGGAGCTTACA 660  
  
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720  
  
QY 721 CACAGGAATTTCTTGAAGATGGAAGATGAGCTGCTTTTAAGATGCCCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGGAAGATGAGCTGCTTTTAAGATGCCCTCTCTTAAC 780  
  
QY 781 TCTGGGTGAAATTTAACTACAACTCTTGTCTCTCGGTGATGCTATTGCTTTGGATTTGT 840  
DB 781 TCTGGGTGAAATTTAACTACAACTCTTGTCTCTCGGTGATGCTATTGCTTTGGATTTGT 840  
  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCATGTTCCCTCTCGAGAGCTGAGTACTAT 900

Db 841 TGTGCAACTGTTGCTACAGTCTGGAGCGAGTANGTTCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960  
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960  
QY 961 GTTGTAGATCTAAACTGAAGATGATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATGATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAT 1020  
QY 1021 CTGTGCTCAATCTGAATTTAAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080  
Db 1021 CTGTGCTCAATCTGAATTTAAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAAATGCAAAATGAATTAAGTACTCAAACTCTGTG 1174  
Db 1141 CTATAAAATGCAAAATGAATTAAGTACTCAAACTCTGTG 1174

## RESULT 116

ADCS7199  
ID ADCS7199 standard; cDNA; 1174 BP.

AC ADCS7199;

XX 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein cDNA Seq ID271.

XX human; PRO; membrane bound protein; membrane bound receptor;  
XX cell proliferation; cell migration; cell differentiation;  
XX mitogenic factor; survival factor; cytotoxic factor;  
XX differentiation factor; neurotrophic factor; hormone; cell  
XX receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; es; gene.

OS Homo sapiens.

XX US2003087366-A1.

XX 08-MAY-2003.

XX 23-APR-2002; 2002US-00128694.

XX 02-MAR-2000; 2000WO-US005841.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801151/75.

XX P-PSDB; ADCS7200.

XX New PRO nucleic acid, useful for manufacturing a medicament for  
XX diagnosing or treating tumor.

XX Claim 2; SEQ ID NO 271; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted  
XX and transmembrane proteins. Extracellular proteins play important roles  
XX in the formation, differentiation and maintenance of multicellular  
XX organisms. The fate of many individual cells (for example proliferation,  
XX migration or differentiation) is typically governed by information  
XX received from other cells and the immediate environment. The information  
XX is often transmitted by secreted polypeptides (for example mitogenic

CC factors, survival factors, cytotoxic factors, differentiation factors,  
CC neuropeptides and hormones) which are received and interpreted by diverse  
CC cell receptors or membrane bound proteins. These membrane bound proteins  
CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
CC as in the blocking of receptor-ligand interactions. The current invention  
CC provides the amino acid sequences of novel human membrane bound receptors  
CC and proteins, along with the cDNA sequences encoding them. The novel  
CC proteins of the invention may have cytostatic activities through the  
CC stimulation of chondrocytes. The nucleic acids of the invention may be  
CC useful for the manufacture of a medicament for diagnosing or treating a  
CC tumour in a mammal. In addition, they may be useful for measuring or  
CC detecting the expression of a tumour associated gene. The present  
CC sequence is a cDNA sequence which encodes a human PRO protein of the  
CC invention.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

QY Query Match 100.0%; Score 1174; DB 9; Length 1174;

Db Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACACACACACAGCTGAGCTGCTGACAGAG 60

Db 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACACACACAGCTGAGCTGCTGACAGAG 60

QY 61 GGGACACAGATGCGCGCGCGCGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120

Db 61 GGGACACAGATGCGCGCGCGCGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120

QY 121 CGGCTGCTGCTGACCATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG 180

Db 121 CGGCTGCTGCTGACCATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG 180

QY 181 TTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240

Db 181 TTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240

QY 241 TTGACACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCT 300

Db 241 TTGACACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCTACCT 300

QY 301 TCAATTTGTCAGTTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATG 360

Db 301 TCAATTTGTCAGTTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATG 360

QY 361 TGTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTTC 420

Db 361 TGTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTTC 420

QY 421 CAGATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480

Db 421 CAGATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480

QY 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540

Db 481 ATGCACCTACTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 540

QY 541 GCACAGAGCTTCAATACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600

Db 541 GCACAGAGCTTCAATACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600

QY 601 GTTATATTCAGTCTTAAGCCAGAGAAATCCAGTACGACCAATTTGGACAGAGAGCTTACA 660

Db 601 GTTATATTCAGTCTTAAGCCAGAGAAATCCAGTACGACCAATTTGGACAGAGAGCTTACA 660

QY 661 AATTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720

Db 661 AATTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720

QY 721 CACAGGAATTTCTTCAAGATGAGAGAGTGTGCTTTTAAAGATGCTCTCTCTCTTAAAC 780

Db 721 CACAGGAATTTCTTCAAGATGAGAGAGTGTGCTTTTAAAGATGCTCTCTCTCTTAAAC 780

```
QY 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGTAATGCTTTGGATTTGT 840
|
|
|
Db 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGTAATGCTTTGGATTTGT 840
|
|
|
QY 841 TCTGCACTGTGTCTACAGCTGTGGACAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
|
|
|
Db 841 TGTGCACTGTGTCTACAGCTGTGGACAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
|
|
|
QY 901 CGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
|
|
|
Db 901 CGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
|
|
|
QY 961 GTTGTAGATCTAAATCTGAGATCATGAAGACGGGCTCTACTACAAAGTGAAT 1020
|
|
|
Db 961 GTTGTAGATCTAAATCTGAGATCATGAAGACGGGCTCTACTACAAAGTGAAT 1020
|
|
|
QY 1021 CTTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
|
|
|
Db 1021 CTTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
|
|
|
QY 1081 AATTCACCTCTCTAGAGCTTTTAAATGGTTTCATTTGATATAGCCCTTAAGAATCA 1140
|
|
|
Db 1081 AATTCACCTCTCTAGAGCTTTTAAATGGTTTCATTTGATATAGCCCTTAAGAATCA 1140
|
|
|
QY 1141 CTATATAATGCAATATAAGTTACTCAATCTGTG 1174
|
|
|
Db 1141 CTATATAATGCAATATAAGTTACTCAATCTGTG 1174
|
|
|
RESULT 117
ADC60390
ID ADC60390 standard; cDNA; 1174 BP.
XX
AC ADC60390;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumor necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumor; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte disorder;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003087367-A1.
XX
PN 08-MAY-2003.
XX
PD 24-APR-2002; 2002US-00131825.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 28-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000356.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 15-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006866.
PR 14-MAR-2001; 2001US-00802706.
PR 09-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
```

```

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US0211735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801152/75.
DR P-FSDB; ADC60391.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
PT
XX
XX Claim 2; Fig 271; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC F-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGAGCGGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGACACAGATGGCGGCGCGAGGGGAGCCTCTGGGTGAGGACCCACACTGGGGCTCCCG 120

```

```

DB 61 GGGACACAGATGGCGGCGCGAGGGGAGCCTCTGGGTGAGGACCCACACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGCGCTTTGGCCGAGGTTTGGGACCCGCTTCGCTCGAACA 180
DB 121 CCGCTGCTGCTGCTGACCATGCGCTTTGGCCGAGGTTTGGGACCCGCTTCGCTCGAACA 180
QY 181 TTTGACTCGGTCTTTGGGTGATAGCGGCTTTGGCCACCGGCTGTCAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTTGGGTGATAGCGGCTTTGGCCACCGGCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTTACCCTTAAGGAAGAGGAGTTGTACGCAATGTTCAGAGGTTTGCAGGCTGTTT 300
DB 241 TTGCACACCTTACCCTTAAGGAAGAGGAGTTGTACGCAATGTTCAGAGGTTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGAGTATGAAATGAAATCGAATCGAATCGAATCGAATCGAAT 360
DB 301 TCAATTTGTGAGTTTGTGAGTATGAAATGAAATCGAATCGAATCGAATCGAATCGAAT 360
QY 361 TCTGATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGCTTGC 420
DB 361 TCTGATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGCTTGC 420
QY 421 CAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480
DB 421 CAGAAATCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480
QY 481 ATGCACCTTACTCTTTCTCTTAACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 540
DB 481 ATGCACCTTACTCTTTCTCTTAACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCCTCAAGCCGATGACGGAATAA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCCTCAAGCCGATGACGGAATAA 600
QY 601 GTTATATTCAGTCTAAGCCAGAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGATTTCTTGAAGTGGAGAGGAGGCTTTTGAAGTGGCTCTCTCTCTCTCTCTTAAC 780
DB 721 CACAGGATTTCTTGAAGTGGAGAGGAGGCTTTTGAAGTGGCTCTCTCTCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840
DB 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 840
QY 841 TGTGCACTGTTGCTACAGCTGTTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
DB 841 TGTGCACTGTTGCTACAGCTGTTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTCTCTCT 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTCTCTCT 960
QY 961 GTTGTAGATCTAAACTGAAGTATGAGATCATGAGAGCAGGCGCTTACCTACCAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGTATGAGATCATGAGAGCAGGCGCTTACCTACCAAGTGAAT 1020
QY 1021 CTGTCTCATCTGAAATTTAAAGCATTTTCTTTTAAAGCATTTTCTTTTAAAGCATTTTCTTT 1080
DB 1021 CTGTCTCATCTGAAATTTAAAGCATTTTCTTTTAAAGCATTTTCTTTTAAAGCATTTTCTTT 1080
QY 1081 AATTCCACTCTCTAGAGCTTTTAAATGCTTTTCAATGATATAGCCCTTAAAGAAATCA 1140
DB 1081 AATTCCACTCTCTAGAGCTTTTAAATGCTTTTCAATGATATAGCCCTTAAAGAAATCA 1140
QY 1141 CTATATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

```

Db 1141 CTTATTAATGCAATATAAGTTTACTCAATCTGTG 1174

# RESULT 118

ADC50865

ID ADC50865 standard; cDNA; 1174 BP.

XX AC ADC50865;

XX AC ADC50865;

DT 18-DEC-2003 (first entry)

XX AC

XX AC

DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; tumour; cancer; adrenal; lung; breast; prostate;  
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
 KW cell differentiation; skeletal muscle cell; adipocyte cell;  
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
 KW immune system cell infiltration; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX OS Homo sapiens.

XX XX

PN US2003087361-A1.

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-801146/75.  
 DR P-PSDB; ADC50866.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
 PT and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
 CC cells, for stimulating differentiation of adipocyte cells, for  
 CC stimulating proliferation of or gene expression in pericyte cells, for  
 CC stimulating the proliferation of inner ear utricular supporting cells or  
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
 CC treating various bone and/or cartilage disorders such as sports injuries  
 CC and arthritis. PRO polypeptides which stimulate the release of  
 CC proteoglycans from cartilage are useful for treating sports-related joint  
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
 CC arthritis. PRO polypeptides are also useful for treating various  
 CC mammalian haemoglobin-associated disorders such as various thalassemias  
 CC and conditions which may benefit from enhanced local immune system cell  
 CC infiltration. This sequence represents a human PRO polynucleotide of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPIO at seqdata.uspto.gov/sequence.html.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60

Db 1 CGGACGGGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60

QY 61 GGGACCAAGATGGCGCGCCGAGGGGAGGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

Db 61 GGGACCAAGATGGCGCGCCGAGGGGAGGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

QY 121 CCGTGTGCTGTGACCATGGGCTTGGCCGAGGTTGGGGACCCGCTTCGGCTGAAGCA 180

Db 121 CCGTGTGCTGTGACCATGGGCTTGGCCGAGGTTGGGGACCCGCTTCGGCTGAAGCA 180

QY 181 TTGACTCGGTCCTGGGTGATAGGGCTCTTGGCCACCGGGCCCTGTCAGTTGACTACCCC 240

Db 181 TTGACTCGGTCCTGGGTGATAGGGCTCTTGGCCACCGGGCCCTGTCAGTTGACTACCCC 240

QY 241 TTGCACACTACCTTAAGGAAGAGGAGTTGTACGCAATGTGAGAGGTTGAGGCTGTTT 300

Db 241 TTGCACACTACCTTAAGGAAGAGGAGTTGTACGCAATGTGAGAGGTTGAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGGATGATGGAATTCATTAATCGAATTAATTTGGAATGTGAA 360

Db 301 TCAATTTGTCAGTTTGGATGATGGAATTCATTAATCGAATTAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420

Db 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420

QY 421 CAGATCAGCTGCCATTCGCTGAATCGAGACAGACAACTTATGTCCTGATGCCAABA 480

Db 421 CAGATCAGCTGCCATTCGCTGAATCGAGACAGACAACTTATGTCCTGATGCCAABA 480

QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600

Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600

QY 601 GTTATATTCCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCCTACA 660

Db 601 GTTATATTCCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCCTACA 660

QY 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAGCG 720

Db 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780



QY 781 TCTGGGTGGATTTTAACTACAACTCTTGCTCCTCGGTGATGGTATTGCTTTGGATTTGT 840  
 DB 781 TCTGGGTGGATTTTAACTACAACTCTTGCTCCTCGGTGATGGTATTGCTTTGGATTTGT 840  
 QY 841 TTGCGAACTCTTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTCGAAGCTGAGTATCTAT 900  
 DB 841 TTGCGAACTCTTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTCGAAGCTGAGTATCTAT 900  
 QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTCTGTG 960  
 DB 501 GGTGACTTGGAGTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTCTGTG 960  
 QY 961 GTTGTGTAGATCTAAATCTGAAGATCATGAAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
 DB 961 GTTGTGTAGATCTAAATCTGAAGATCATGAAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
 QY 1021 CTGCTCATCTCAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
 DB 1021 CTGCTCATCTCAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
 QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
 DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
 QY 1141 CTATAAATGCAATTAAGTTACTCAAAATCTGTG 1174  
 DB 1141 CTATAAATGCAATTAAGTTACTCAAAATCTGTG 1174

RESULT 119  
 AD65392  
 ID ADC65392 standard; cDNA; 1174 BP.  
 AC AD65392;  
 DT 18-DEC-2003 (first entry)  
 XX Human PRO polynucleotide #136.  
 DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 OS Homo sapiens.  
 XX US2003087362-A1.  
 XX 08-MAY-2003.  
 XX 22-APR-2002; 2002US-00127844.  
 XX 05-JUN-2000; 2000US-0209832P.  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-801147/75.  
 DR P-PSDB; ADC65393.  
 XX New PRO nucleic acid, useful for manufacturing a medicament for

PT diagnosing or treating tumor.  
 PS Claim 2; Fig 271; 637pp; English.  
 XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting the proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 1174; DB 9; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
 DB 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
 QY 61 GGGAAACAAGATGCGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
 DB 61 GGGAAACAAGATGCGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120  
 QY 121 CCGCTGCTGCTGTGACCATGCGCTTGGCCGAGAGTTGGGGACCGCTTCGGCTGAAGCA 180  
 DB 121 CCGCTGCTGCTGTGACCATGCGCTTGGCCGAGAGTTGGGGACCGCTTCGGCTGAAGCA 180  
 QY 181 TTTGACTCGGCTTTGGGTGATACGGGCTCTTCCACCGGGCTGTGACCTGACCTACCCC 240  
 DB 181 TTTGACTCGGCTTTGGGTGATACGGGCTCTTCCACCGGGCTGTGACCTGACCTACCCC 240  
 QY 241 TTGCACACCTTACCTTAAGGAGGAGTGTGACGATGTTCAGAGAGTTGAGGCTGTTT 300  
 DB 241 TTGCACACCTTACCTTAAGGAGGAGTGTGACGATGTTCAGAGAGTTGAGGCTGTTT 300  
 QY 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGGA 360  
 DB 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGGA 360  
 QY 361 TCTGATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
 DB 361 TCTGATGTACAGAGCATATCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
 QY 421 CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAAGAACAACTTATGTCCTCCCTGATGCCAAA 480





Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAAATCGAATCTAAATGGAAATGTGAA 360  
Qy 361 TCTGATGTCAGAGCATATTCCTATCTGATGAGCAATATCTTGGCCATCTTGTGTC 420  
Db 361 TCTGATGTCAGAGCATATTCCTATCTGATGAGCAATATCTTGGCCATCTTGTGTC 420  
Qy 421 CAGAAATCAGCTGCAATGCTGTAATCTGAGCAAGAACAACTTATGTCCTGATGCCAAA 480  
Db 421 CAGAAATCAGCTGCAATGCTGTAATCTGAGCAAGAACAACTTATGTCCTGATGCCAAA 480  
Qy 481 ATGACCTACTCTTCTTAACTCTGCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTG 540  
Db 481 ATGACCTACTCTTCTTAACTCTGCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTG 540  
Qy 541 GCACAGAGCTTCAATGCTTCTGAGTCTTCTTCAAGCCGATGAGCGGAAATA 600  
Db 541 GCACAGAGCTTCAATGCTTCTGAGTCTTCTTCAAGCCGATGAGCGGAAATA 600  
Qy 601 GTTATATTCAGTCTTAACTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTG 660  
Db 601 GTTATATTCAGTCTTAACTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTG 660  
Qy 661 AATTGAGAGATCATCTTAAAGCAAAATGCTTCTTCTGCAATGAGAAATTCACAAGCG 720  
Db 661 AATTGAGAGATCATCTTAAAGCAAAATGCTTCTTCTGCAATGAGAAATTCACAAGCG 720  
Qy 721 CACAGGAATTTCTGAGATGGAAGTATGATGCTTTTAAAGTCCCTCTCTTAAAC 780  
Db 721 CACAGGAATTTCTGAGATGGAAGTATGATGCTTTTAAAGTCCCTCTCTTAAAC 780  
Qy 781 TCTGGGTGGATTTTAACTPACAACTCTTCTCTGCTGATGATGATGATGATGATGATG 840  
Db 781 TCTGGGTGGATTTTAACTPACAACTCTTCTCTGCTGATGATGATGATGATGATGATG 840  
Qy 841 TGTGCAACTGTTGTACAGCTGTGAGCAGTATGTTTCTCTGAGAGAGCTGATCTAT 900  
Db 841 TGTGCAACTGTTGTACAGCTGTGAGCAGTATGTTTCTCTGAGAGAGCTGATCTAT 900  
Qy 901 GTTGACTTGGATTTTAACTGAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAA 960  
Db 901 GTTGACTTGGATTTTAACTGAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAA 960  
Qy 961 GTTGACTTGGATTTTAACTGAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAA 1020  
Db 961 GTTGACTTGGATTTTAACTGAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAA 1020  
Qy 1021 CTTGCTCATCTGAAATTTAAGTATTTTCTTAAAGTAAAGTAAAGTAAAGTAAAGTAA 1080  
Db 1021 CTTGCTCATCTGAAATTTAAGTATTTTCTTAAAGTAAAGTAAAGTAAAGTAAAGTAA 1080  
Qy 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
Qy 1141 CTATAAATGCAATTAAGTACTCAATCTGTG 1174  
Db 1141 CTATAAATGCAATTAAGTACTCAATCTGTG 1174

## RESULT 121

ID ADC53451

XX ADC53451 standard; cDNA; 1174 BP.

XX AC

XX ADC53451;

XX 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein cDNA Seq ID271.

XX human; PRO; membrane bound protein; membrane bound receptor;

XX cell proliferation; cell migration; cell differentiation;

XX mitogenic factor; survival factor; cytotoxic factor;

KW

KW

KW differentiation factor; neuropeptide; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.  
XX Homo sapiens.  
XX US2003087364-A1.  
XX 08-MAY-2003.  
XX 23-APR-2002; 2002US-00128688.  
XX 09-FEB-1999; 99US-0119341P.  
XX 01-DEC-1999; 99WO-US028634.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerisken ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-801149/75.  
XX P-PSDB; ADC53452.  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
XX diagnosing or treating tumor.  
XX Claim 2; SEQ ID NO 271; 637pp; English.  
XX This invention relates to novel nucleic acids encoding human PRO secreted  
XX and transmembrane proteins. Extracellular proteins play important roles  
XX in the formation, differentiation and maintenance of multicellular  
XX organisms. The fate of many individual cells (for example proliferation,  
XX migration or differentiation) is typically governed by information  
XX received from other cells and the immediate environment. The information  
XX is often transmitted by secreted polypeptides (for example mitogenic  
XX factors, survival factors, cytotoxic factors, differentiation factors,  
XX neuropeptides and hormones) which are received and interpreted by diverse  
XX cell receptors or membrane bound proteins. These membrane bound proteins  
XX and receptors may be of use as pharmaceutical and diagnostic agents, such  
XX as in the blocking of receptor-ligand interactions. The current invention  
XX provides the amino acid sequences of novel human membrane bound receptors  
XX and proteins, along with the cDNA sequences encoding them. The novel  
XX proteins of the invention may have cytostatic activities through the  
XX stimulation of chondrocytes. The nucleic acids of the invention may be  
XX useful for the manufacture of a medicament for diagnosing or treating a  
XX tumour in a mammal. In addition, they may be useful for measuring or  
XX detecting the expression of a tumour associated gene. The present  
XX sequence is a cDNA sequence which encodes a human PRO protein of the  
XX invention.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

Qy 61 GGGAAACAGATGGCGCGCCCGAGGGAGCTCTGGGTGAGGAGCCCAACCTGGGGCTCCCG 120

Db 61 GGGAAACAGATGGCGCGCCCGAGGGAGCTCTGGGTGAGGAGCCCAACCTGGGGCTCCCG 120

Qy 121 CGCTGTGCTGTGACCATGCGCTTGGCCGAGGTTGGGGACCGCTTGGCTGAGCA 180

Db 121 CGCTGTGCTGTGACCATGCGCTTGGCCGAGGTTGGGGACCGCTTGGCTGAGCA 180

Qy 181 TTGTACTCGTCTTGGGTGATACCGGCTCTTGCCACCGGGCTGTCACTTACCTACCCC 240

Db 181 TTGTACTCGTCTTGGGTGATACCGGCTCTTGCCACCGGGCTGTCACTTACCTACCCC 240

QY 241 TTGCACACCTACCTTAAGAGAGAGAGTTGATCCATGTCAGAGAGTTGCAGGCTGTTT 300  
DB 241 TTGCACACCTACCTTAAGAGAGAGAGTTGATCCATGTCAGAGAGTTGCAGGCTGTTT 300  
QY 301 TCAATTTGTCAGTTTGGGATGATGGAATGACTTAATCGAACTAAATGGAAATGTGAA 360  
DB 301 TCAATTTGTCAGTTTGGGATGATGGAATGACTTAATCGAACTAAATGGAAATGTGAA 360  
QY 361 TCTGATGTCAGAGAGCATATCCCATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
DB 361 TCTGATGTCAGAGAGCATATCCCATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420  
QY 421 CAGAACTAGCTGCCATTCGCTGAATGAGCAAGAACTATGCTTCCCTGATGCCAAAA 480  
DB 421 CAGAACTAGCTGCCATTCGCTGAATGAGCAAGAACTATGCTTCCCTGATGCCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGATCATCTGAGTGAATGAGTGCCTC 540  
DB 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGATCATCTGAGTGAATGAGTGCCTC 540  
QY 541 GCACAGAGCTTCAATAACCTCTTCTGAGTCTTTTATCTTCAAGCCGATGACGAAAAATA 600  
DB 541 GCACAGAGCTTCAATAACCTCTTCTGAGTCTTTTATCTTCAAGCCGATGACGAAAAATA 600  
QY 601 GTTATATCCAGTCTAAGCAAAATCCAGTACGACCAATTTGGAGAGGAGCTTACA 660  
DB 601 GTTATATCCAGTCTAAGCAAAATCCAGTACGACCAATTTGGAGAGGAGCTTACA 660  
QY 661 AATTTGAGAGATCATCTTGAAGCAAAATGCTTATCTTCAAGCCGATGACGAAAAATA 720  
DB 661 AATTTGAGAGATCATCTTGAAGCAAAATGCTTATCTTCAAGCCGATGACGAAAAATA 720  
QY 721 CACAGAAATTTCTTGAAGTGGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGAAATTTCTTGAAGTGGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTAACTACAACTCTTCTCTCTGCTGATGATGCTTGGATTTGT 840  
DB 781 TCTGGTGGATTTAACTACAACTCTTCTCTCTGCTGATGATGCTTGGATTTGT 840  
QY 841 TGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900  
QY 901 GTGAGCTGGATTTATGATGAACAAAGCTTAACAGATATCCAGCTTCTCTCTTTGTG 960  
DB 901 GTGAGCTGGATTTATGATGAACAAAGCTTAACAGATATCCAGCTTCTCTCTTTGTG 960  
QY 961 GTTGTAGATCTAAACTGAGATCATGAGAGCAGGCTCTACCTTACAAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAGATCATGAGAGCAGGCTCTACCTTACAAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATTTGGATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATTTGGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTTACTCAAACTGTG 1174  
DB 1141 CTATAAATGCAATTAAGTTACTCAAACTGTG 1174

RESULT 122

ADC58974

ID ADC58974 standard; cDNA; 1174 BP.

XX

AC ADC58974;

XX

DT 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein cDNA Seq ID271.  
XX human; PRO; membrane bound protein; membrane bound receptor;  
XX cell proliferation; cell migration; cell differentiation;  
XX mitogenic factor; survival factor; cytotoxic factor;  
XX differentiation factor; neuropeptide; hormone; cell receptor;  
XX receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.  
XX Homo sapiens.  
XX US2003087359-A1.  
XX 08-MAY-2003.  
XX 22-APR-2002; 2002US-00127834.  
XX 17-SEP-1998; 98US-0100710P.  
XX 01-SEP-1999; 99WO-US020111.  
XX 18-OCT-1999; 99US-08403297.  
XX 30-NOV-1999; 99WO-US028313.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-801144/75.  
XX P-PSDB; ADC58975.  
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide  
XX and for manufacturing a medicament for diagnosing or treating tumor.  
XX Claim 2; SEQ ID NO 271; 637pp; English.  
XX This invention relates to novel nucleic acids encoding human PRO secreted  
XX and transmembrane proteins. Extracellular proteins play important roles  
XX in the formation, differentiation and maintenance of multicellular  
XX organisms. The fate of many individual cells (for example proliferation,  
XX migration or differentiation) is typically governed by information  
XX received from other cells and the immediate environment. The information  
XX is often transmitted by secreted polypeptides (for example mitogenic  
XX factors, survival factors, cytotoxic factors, differentiation factors,  
XX neuropeptides and hormones) which are received and interpreted by diverse  
XX cell receptors or membrane bound proteins. These membrane bound proteins  
XX and receptors may be of use as pharmaceutical and diagnostic agents, such  
XX as in the blocking of receptor-ligand interactions. The current invention  
XX provides the amino acid sequences of novel human membrane bound receptors  
XX and proteins, along with the cDNA sequences encoding them. The novel  
XX proteins of the invention may have cytostatic activities through the  
XX stimulation of chondrocytes. The nucleic acids of the invention may be  
XX useful for the manufacture of a medicament for diagnosing or treating a  
XX tumour in a mammal. In addition, they may be useful for measuring or  
XX detecting the expression of a tumour associated gene. The present  
XX invention is a cDNA sequence which encodes a human PRO protein of the  
XX sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGAGCGGTGGGGGAAACCTTCCGAGAAAAACAGCAACAGCTGCTGTGACAGAG 60

DB 1 CGGAGCGGTGGGGGAAACCTTCCGAGAAAAACAGCAACAGCTGCTGTGACAGAG 60

QY 61 GGGACACAGATGCGCGCGCCGAGGGGAGCTCTGGGTGAGAGCCCAACTGGGGCTCCCG 120

DB 61 GGGACACAGATGCGCGCGCCGAGGGGAGCTCTGGGTGAGAGCCCAACTGGGGCTCCCG 120

121 CCGTCTGCTGCTGACCAATGGCCCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
121 CCGTCTGCTGCTGACCAATGGCCCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180  
181 TTTGACTCGGCTTGGGTGATCGGCGTCTTGCCACCGGSCCTGTGACGTTGACCTACCCC 240  
181 TTTGACTCGGCTTGGGTGATCGGCGTCTTGCCACCGGSCCTGTGACGTTGACCTACCCC 240  
241 TTGCACACCTACCCCTAAGGAGGAGTGTGTACGCATGTGACAGAGGTTGACGCTGTTT 300  
241 TTGCACACCTACCCCTAAGGAGGAGTGTGTACGCATGTGACAGAGGTTGACGCTGTTT 300  
301 TCAATTTGTCAGTTTGGGTGATGAGTAAATGACCTAAATCGACTAAATGGAATGGA 360  
301 TCAATTTGTCAGTTTGGGTGATGAGTAAATGACCTAAATCGACTAAATGGAATGGA 360  
361 TCTGCATGTGACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCCTATCTTGGTTGC 420  
361 TCTGCATGTGACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCCTATCTTGGTTGC 420  
421 CAGAACTGAGTGCATTCGCTGAACTGACAGACAGACAACTTATGTCCTGATGCCAAA 480  
421 CAGAACTGAGTGCATTCGCTGAACTGACAGACAGACAACTTATGTCCTGATGCCAAA 480  
481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGAGTGCATGATGACTCC 540  
481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGAGTGCATGATGACTCC 540  
541 GCACAGAGCTTCATAACTCTTCTGATGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
541 GCACAGAGCTTCATAACTCTTCTGATGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGAGGAGCTTACA 660  
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGAGGAGCTTACA 660  
661 AATTGAGAGAAATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
661 AATTGAGAGAAATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
721 CACAGGAATTTCTGAGAGTGGAGAAAGTATGCTGCTTTTAAAGTCCCTCTCTTAAAC 780  
721 CACAGGAATTTCTGAGAGTGGAGAAAGTATGCTGCTTTTAAAGTCCCTCTCTTAAAC 780  
781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTGGATTGT 840  
781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTGGATTGT 840  
841 TGTGCACTGTTGCTACAGCTGTGAGCAGTATGCTTCCCTGAGAGCTGAGTATCTAT 900  
841 TGTGCACTGTTGCTACAGCTGTGAGCAGTATGCTTCCCTGAGAGCTGAGTATCTAT 900  
901 GGTGACTTTGGAGTTTATGAATCAACAAAGCTAAACAGATATCCAGCTTCTTCTGTG 960  
901 GGTGACTTTGGAGTTTATGAATCAACAAAGCTAAACAGATATCCAGCTTCTTCTGTG 960  
961 GTTGTAGATCTAAACTGAGATCAAGAGCAGGCTCTACCTACCAAGAGTGAAT 1020  
961 GTTGTAGATCTAAACTGAGATCAAGAGCAGGCTCTACCTACCAAGAGTGAAT 1020  
1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTAAATAGCATCTAA 1080  
1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTAAATAGCATCTAA 1080  
1081 AATTCCACTCCCTATAGAGCTTTTAAATGTTTCAATGATAGGCTTAAAGATCA 1140  
1081 AATTCCACTCCCTATAGAGCTTTTAAATGTTTCAATGATAGGCTTAAAGATCA 1140  
1141 CTATAAATGCAAAATAGTACTCAAAATCTGTG 1174  
1141 CTATAAATGCAAAATAGTACTCAAAATCTGTG 1174

RESULT 123  
ADC55852  
ID ADC55852 standard; cDNA; 1174 BP.  
XX  
AC ADC55852;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein cDNA Seq ID271.  
XX  
KW human; PRO; membrane bound protein; membrane bound receptor;  
KW cell proliferation; cell migration; cell differentiation;  
KW mitogenic factor; survival factor; cytotoxic factor;  
KW differentiation factor; neurotrophic factor; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.  
XX  
OS Homo sapiens.  
XX  
FN US2003087360-A1.  
XX  
PD 08-MAY-2003.  
XX  
PF 22-APR-2002; 2002US-00127836.  
XX  
PR 17-NOV-1998; 98US-0108802P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
(GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
WI WPI; 2003-801145/75.  
DR P-PSDB; ADC55853.  
XX  
PT New PRO nucleic acid, useful for manufacturing a medicament for  
diagnosing or treating tumor.  
XX  
PS Claim 2; SEQ ID NO 271; 637pp; English.  
XX  
CC This invention relates to novel nucleic acids encoding human PRO secreted  
and transmembrane proteins. Extracellular proteins play important roles  
in the formation, differentiation and maintenance of multicellular  
organisms. The fate of many individual cells (for example proliferation,  
migration or differentiation) is typically governed by information  
received from other cells and the immediate environment. The information  
is often transmitted by secreted polypeptides (for example mitogenic  
factors, survival factors, cytotoxic factors, differentiation factors,  
neurotrophic factors and hormones) which are received and interpreted by diverse  
cell receptors or membrane bound proteins. These membrane bound proteins,  
as in the blocking of receptor-ligand interactions. The current invention  
provides the amino acid sequences of novel human membrane bound receptors  
and proteins, along with the cDNA sequences encoding them. The novel  
proteins of the invention may have cytostatic activities through the  
stimulation of chondrocytes. The nucleic acids of the invention may be  
useful for the manufacture of a medicament for diagnosing or treating a  
tumour in a mammal. In addition, they may be useful for measuring or  
detecting the expression of a tumour associated gene. The present  
sequence is a cDNA sequence which encodes a human PRO protein of the  
invention.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;			
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	CGGAGCGTGGGGGAAACCCCTTCGAGAAACACGACACAGCTGAGCTGTGACAGAG	60
Db	1	CGGAGCGTGGGGGAAACCCCTTCGAGAAACACGACACAGCTGAGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGGGGGCGGCGGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
Db	61	GGGAACAAGATGGGGGGCGGCGGAGGAGCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CGGTGCTGCTGTGACCATGCGCTTCGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
Db	121	CGGTGCTGCTGTGACCATGCGCTTCGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTGGGTGATACGCGCTTCGACCCGGGCGCTGTGAGTTGACCTACCC	240
Db	181	TTTGACTCGGTCTGGGTGATACGCGCTTCGACCCGGGCGCTGTGAGTTGACCTACCC	240
QY	241	TTGCACTACCTACCTAAGGAGGAGTTGACGATGTCAGAGGTTGACGAGTTCAGGCTGTT	300
Db	241	TTGCACTACCTACCTAAGGAGGAGTTGACGATGTCAGAGGTTGACGAGTTCAGGCTGTT	300
QY	301	TCAATTTGCTGAGTTGTTGGATGATGGAATTCGACTTAATCGAATAAATGGAATGAA	360
Db	301	TCAATTTGCTGAGTTGTTGGATGATGGAATTCGACTTAATCGAATAAATGGAATGAA	360
QY	361	TCTGATGTAAGAAGCATATTCGCAATCTGATGAGCAATATGCTTCCGATCTGTTTC	420
Db	361	TCTGATGTAAGAAGCATATTCGCAATCTGATGAGCAATATGCTTCCGATCTGTTTC	420
QY	421	CAGAACTCAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCTCGATGCCAA	480
Db	421	CAGAACTCAGCTGCCATTCGCTGAACTGAGACAGAAACAACTTATGTCCTCGATGCCAA	480
QY	481	ATGCACTACTCTTTCCTTAACTCTGTTGAGGTCATCTCTGAGTGCATGATGAGCTCC	540
Db	481	ATGCACTACTCTTTCCTTAACTCTGTTGAGGTCATCTCTGAGTGCATGATGAGCTCC	540
QY	541	GCACAGAGCTTCAATACCTCTTCAGGACTTTTATCTTCAAGCGGATGACGGAATAA	600
Db	541	GCACAGAGCTTCAATACCTCTTCAGGACTTTTATCTTCAAGCGGATGACGGAATAA	600
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCGAGGACCTACA	660
Db	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCGAGGACCTACA	660
QY	661	AAATTTGAGAGATCTCTTCAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAGCG	720
Db	661	AAATTTGAGAGATCTCTTCAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGGAAGATGATGGCTTTTAAAGATGCTCTCTCTTAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGGAAGATGATGGCTTTTAAAGATGCTCTCTCTTAAC	780
QY	781	TCTGGGTGATTTTAACTTAACTCTTCTCGGTGATGATGATGATGATGATGATGATGAT	840
Db	781	TCTGGGTGATTTTAACTTAACTCTTCTCGGTGATGATGATGATGATGATGATGATGAT	840
QY	841	TGTGCACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGGAAGCTGAGTATCTAT	900
Db	841	TGTGCACTCTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGATTTATGATGAACAAAGCTTAAACAGATATCCAGTCTTCTCTTGTG	960
Db	901	GGTGACTTGGATTTATGATGAACAAAGCTTAAACAGATATCCAGTCTTCTCTTGTG	960
QY	961	GTTGTTAGATCTTAAACTGAGATCATGGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTTAAACTGAGATCATGGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGAAATTTAAGATTTTCTTTTAAAGACAGTGTATAGACATCTAA	1080

Db	1021	CTTGCTCATCTGAAATTTAAGATTTTCTTTTAAAGACAGTGTATAGACATCTAA	1080
QY	1081	AAATCCACTCTCATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTAAAGAAATCA	1140
Db	1081	AAATCCACTCTCATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTAAAGAAATCA	1140
QY	1141	CTATATAATGCAATATAAGTTACTCAAACTCTGTG	1174
Db	1141	CTATATAATGCAATATAAGTTACTCAAACTCTGTG	1174
RESULT 124			
ADC58422			
ID	ADC58422 standard; cDNA; 1174 BP.		
XX	AC ADC58422;		
XX	18-DEC-2003 (first entry)		
XX	Novel human secreted and transmembrane protein cDNA Seq ID271.		
XX	human; PRO: membrane bound protein; membrane bound receptor;		
KW	cell proliferation; cell migration; cell differentiation; cell		
KW	mitogenic factor; survival factor; cytotoxic factor; receptor;		
KW	differentiation factor; neuroepithelial; hormone; cell		
KW	receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.		
XX	Homo sapiens.		
OS	US2003087346-A1.		
XX	08-MAY-2003.		
PD	17-APR-2002; 2002US-00124815.		
XX	09-DEC-1999; 99US-0170262P.		
PR	01-DEC-2000; 2000WO-US032878.		
PR	19-DEC-2001; 2001US-00028072.		
XX	(GETH ) GENENTECH INC.		
XX	Baker K, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;		
PI	Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;		
XX	WPI; 2003-801137/75.		
DR	P-PSDB; ADC58423.		
XX	Isolated nucleic acid for use in industrial applications has at least 80		
PT	percent nucleic acid sequence identity to nucleotide sequence that		
PT	encodes amino acid sequence selected from amino acid sequence group.		
XX	Claim 2; SEQ ID NO 271; 637pp; English.		
XX	This invention relates to novel nucleic acids encoding human PRO secreted		
CC	and transmembrane proteins. Extracellular proteins play important roles		
CC	in the formation, differentiation and maintenance of multicellular		
CC	organisms. The fate of many individual cells (for example proliferation,		
CC	migration or differentiation) is typically governed by information		
CC	received from other cells and the immediate environment. The information		
CC	is often transmitted by secreted polypeptides (for example mitogenic		
CC	factors, survival factors, cytotoxic factors, differentiation factors,		
CC	neuropeptides or hormones) which are received and interpreted by diverse		
CC	cell receptors or membrane bound proteins. These membrane bound proteins		
CC	as in the blocking of receptor-ligand interactions. The current invention		
CC	provides the amino acid sequences of novel human membrane bound receptors		
CC	and proteins, along with the cDNA sequences encoding them. The novel		
CC	proteins of the invention may have cytostatic activities through the		
CC	stimulation of chondrocytes. The nucleic acids of the invention may be		
CC	useful for the manufacture of a medicament for diagnosing or treating a		
CC	tumour in a mammal. In addition, they may be useful for measuring or		
CC	detecting the expression of a tumour associated gene. The present		

CC sequence is a cDNA sequence which encodes a human PRO protein of the  
CC invention.  
XX  
SQ

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG	60
DB	1	CGGACGGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG	60
QY	61	GGAAACAAGATGCGCGCGCGGAGGAGGCTCTGGGTGAGAGCCCACTGGGGTCCCG	120
DB	61	GGAAACAAGATGCGCGCGCGGAGGAGGCTCTGGGTGAGAGCCCACTGGGGTCCCG	120
QY	121	CCGCTGCTGCTGTGACCACTGGCGGAGGTTGGGGAGCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGTGACCACTGGCGGAGGTTGGGGAGCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGGCTCTTGCCACCGGGCTGTGACCTACCCC	240
DB	181	TTTGACTCGGTCTTGGGTGATACGGGCTCTTGCCACCGGGCTGTGACCTACCCC	240
QY	241	TTGACACCTACCTAAGGAGGAGTGTACGCATGTCAGAGAGTTGCAGGCTGTTT	300
DB	241	TTGACACCTACCTAAGGAGGAGTGTGTAGCATGTCAGAGAGTTGCAGGCTGTTT	300
QY	301	TCRAATTTGTGAGTGTGGATGATGAATGACCTAAATCGAACTAAATTTGAAATGAA	360
DB	301	TCRAATTTGTGAGTGTGGATGATGAATGACCTAAATCGAACTAAATTTGAAATGAA	360
QY	361	TCGTCATGTACAGAGCATATCCCACTGATGAGCAATATGCTTGCCTCTGTTGTC	420
DB	361	TCGTCATGTACAGAGCATATCCCACTGATGAGCAATATGCTTGCCTCTGTTGTC	420
QY	421	CAGAACTGAGTGCCTTTCGCTGAGCAAGCAACCTATGATGCTGATGCAAAA	480
DB	421	CAGAACTGAGTGCCTTTCGCTGAGCAAGCAACCTATGATGCTGATGCAAAA	480
QY	481	ATGCACCTACTCTTCTCTTCACTCTGCTGAGTGCATCTGAGTGCATGATGCTCC	540
DB	481	ATGCACCTACTCTTCTCTTCACTCTGCTGAGTGCATCTGAGTGCATGATGCTCC	540
QY	541	GCACAGAGCTTCAACCTCTTCACTGAGCTTTTATCTTCAAGCCCATGACGGAATAA	600
DB	541	GCACAGAGCTTCAACCTCTTCACTGAGCTTTTATCTTCAAGCCCATGACGGAATAA	600
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGGAGGCTTACA	660
DB	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGGAGGCTTACA	660
QY	661	AATTTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG	720
DB	661	AATTTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG	720
QY	721	CACAGGAAATTTCTTGAAGATGGAAGATGAGTGGCTTTTAAAGATGCTCTCTTAAC	780
DB	721	CACAGGAAATTTCTTGAAGATGGAAGATGAGTGGCTTTTAAAGATGCTCTCTTAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACTTGTCTCTCGGTGATGTTATGCTTCTGATTTGT	840
DB	781	TCTGGGTGGATTTTAACTACAACTTGTCTCTCGGTGATGTTATGCTTCTGATTTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAACTGATCTAT	900
DB	841	TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAACTGATCTAT	900
QY	901	GCTGACTTGGAGTTTATGAATGACAAAGCTAAACAGATATCCAGCTTCTCTCTTG	960
DB	901	GCTGACTTGGAGTTTATGAATGACAAAGCTAAACAGATATCCAGCTTCTCTCTTG	960

QY	961	GTTGTTAGATCTAAACTGAAGATCATGAAGACGAGGCTCTTACCTACAAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAACTGAAGATCATGAAGACGAGGCTCTTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
DB	1021	CTTGCTCATCTTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCACCTCTCATAGAGCTTTTAAATGTTTCATTTGGATATAGGCTTTAAGAAATCA	1140
DB	1081	AATTCACCTCTCATAGAGCTTTTAAATGTTTCATTTGGATATAGGCTTTAAGAAATCA	1140
QY	1141	CTATATAATGCAATAAAGTTTACTCAAAATCTGTG	1174
DB	1141	CTATATAATGCAATAAAGTTTACTCAAAATCTGTG	1174
RESULT 125			
ADD03096			
ID	ADD03096 standard; cDNA; 1174 BP.		
XX	ADD03096;		
AC	ADD03096;		
XX	01-JAN-2004 (first entry)		
DT	Novel human secreted and transmembrane protein PRO195 cDNA.		
XX	Human; secreted and transmembrane protein; PRO; secreted polypeptide;		
DE	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;		
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;		
KW	glucose uptake modulator; PFA uptake modulator; cell proliferation;		
KW	cell differentiation; skeletal muscle cell; adipocyte cell;		
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;		
KW	immune system cell infiltration; chromosome mapping; gene mapping;		
XX	gene therapy; chromosome identification; chromosome marker; gene; ss.		
OS	Homo sapiens.		
XX	US2003092104-A1.		
PN	15-MAY-2003.		
XX	24-APR-2002; 2002US-00131817.		
PD	31-MAR-1997; 97WO-US005230.		
PF	12-JUN-1998; 98WO-US012456.		
XX	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		
PR	17-SEP-1998; 98WO-US019437.		
PR	07-OCT-1998; 98WO-US021141.		
PR	29-OCT-1998; 98WO-US022992.		
PR	20-NOV-1998; 98WO-US024855.		
PR	01-DEC-1998; 98WO-US025108.		
PR	05-JAN-1999; 98WO-US000106.		
PR	08-MAR-1999; 98WO-US005028.		
PR	10-MAR-1999; 98WO-US005190.		
PR	20-APR-1999; 98WO-US008615.		
PR	14-MAY-1999; 98WO-US010733.		
PR	02-JUN-1999; 98WO-US012252.		
PR	01-SEP-1999; 98WO-US020111.		
PR	08-SEP-1999; 98WO-US020594.		
PR	13-SEP-1999; 98WO-US020944.		
PR	15-SEP-1999; 98WO-US021090.		

PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUN-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US020731.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030973.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00806589.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-801169/75.  
DR P-PSDB; ADD03097.  
XX  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
PS Claim 2; Fig 271; 638pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon,  
CC breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polynucleotide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAACAGCAACGCTGAGCTGCTGTGACAG 60  
Db 1 CGGACGGCTGGGGGAAACCTTCCGAGAAAACAGCAACGCTGAGCTGCTGTGACAG 60  
QY 61 GGGAAACAAGATGCGCGCGCGGAGAGCGCTTGGGTGAGACCCCACTGGGGTCCCG 120  
Db 61 GGGAAACAAGATGCGCGCGCGGAGAGCGCTTGGGTGAGACCCCACTGGGGTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCATGGCTTGGCGGAGGTTGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CCGCTGCTGCTGTGACCATGGCTTGGCGGAGGTTGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTCAGCTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCGCTGTGAGTGACCTACCCC 240  
Db 181 TTTCAGCTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCGCTGTGAGTGACCTACCCC 240



QY 241 TTGCACACCTACCTAAGGAAGAGAGATTGTACGCATGTTCAGAGAGGTTTCAGGCTGTTT 300  
DB |||||  
QY 241 TTGCACACCTAACCCTAAGGAAGAGAGATTGTACGCATGTTCAGAGAGGTTTCAGGCTGTTT 300  
DB |||||  
QY 301 TCAATTTGTCAGTTTGTGATGATGGAATTCACCTTAATCGAATCAATTTGGAATGTGA 360  
DB |||||  
QY 301 TCAATTTGTCAGTTTGTGATGATGGAATTCACCTTAATCGAATCAATTTGGAATGTGA 360  
DB |||||  
QY 361 TCTGCATGTACAGAAAGCATATTCCTAATCTGATGAGCAATATGCTTTGCCATCTTGTGTC 420  
DB |||||  
QY 421 CAGATCAGCTGCCATTCGCTGCACTGAGACAGACAACTTATGCTCCCTGATGCCAAA 480  
DB |||||  
QY 421 CAGATCAGCTGCCATTCGCTGCACTGAGACAGACAACTTATGCTCCCTGATGCCAAA 480  
DB |||||  
QY 481 ATGCACCTACTCTTCTCTTAACCTCTGCTGAGTCAATTCGAGTGCATGATGCACTCC 540  
DB |||||  
QY 481 ATGCACCTACTCTTCTCTTAACCTCTGCTGAGTCAATTCGAGTGCATGATGCACTCC 540  
DB |||||  
QY 541 GCACAGAGCTTCATACCTCTTCTGACCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB |||||  
QY 541 GCACAGAGCTTCATACCTCTTCTGACCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB |||||  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGAGCAGAGCTTACA 660  
DB |||||  
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACCAATTTGAGCAGAGCTTACA 660  
DB |||||  
QY 661 AATTGAGAGAAATCATCTCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB |||||  
QY 661 AATTGAGAGAAATCATCTCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB |||||  
QY 721 CACAGGAATTTCTTGAAGATGGAAGAGTGAAGCTTTTAAAGATGCTCTCTCTTAC 780  
DB |||||  
QY 721 CACAGGAATTTCTTGAAGATGGAAGAGTGAAGCTTTTAAAGATGCTCTCTCTTAC 780  
DB |||||  
QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGATGCTTTGGATTTCT 840  
DB |||||  
QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGATGCTTTGGATTTCT 840  
DB |||||  
QY 841 TGTCACACTGTGTCACAGCTGTGAGCAGTATGTTCCCTCTCAGAGCTGAGTATCTAT 900  
DB |||||  
QY 841 TGTCACACTGTGTCACAGCTGTGAGCAGTATGTTCCCTCTCAGAGCTGAGTATCTAT 900  
DB |||||  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960  
DB |||||  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960  
DB |||||  
QY 961 GTTGTAGATCTAAACTGAGATCATGAAGACGAGGCTCTACTACAAAAGTAA 1020  
DB |||||  
QY 961 GTTGTAGATCTAAACTGAGATCATGAAGACGAGGCTCTACTACAAAAGTAA 1020  
DB |||||  
QY 1021 CTTCCTATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
DB |||||  
QY 1081 AATTCCACTCTCTATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
DB |||||  
QY 1081 AATTCCACTCTCTATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
DB |||||  
QY 1141 CTATAAATGCAAAATAAGTACTCAATCTGTG 1174  
DB |||||  
QY 1141 CTATAAATGCAAAATAAGTACTCAATCTGTG 1174  
DB |||||

RESULT 126

ADC90088

ID ADC90088 standard; cDNA; 1174 BP.

XX

AC ADC90088;

XX

DT 01-JAN-2004 (first entry)

XX

DE Human secreted and transmembrane protein PRO195 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; Gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW Cell proliferation stimulator; cell differentiation stimulator;  
KW Lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW Gene therapy; chromosome identification; chromosome marker.  
OS Homo sapiens.  
XX  
XX US2003087348-A1.  
XX  
XX 08-MAY-2003.  
XX  
XX 19-APR-2002; 2002US-00125923.  
XX  
XX 05-JUN-2000; 2000US-0209832P.  
XX  
XX 01-DEC-2000; 2000WO-US032678.  
XX  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gunney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-786939/74.  
XX  
XX P-PSDB; ADC90089.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
XX diagnosing or treating tumor.  
XX  
XX Claim 2; SEQ ID NO 271; 637pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
XX transmembrane) polypeptides (I). (I) is useful for stimulating the  
XX release of TNF-alpha from human blood, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating the proliferation or differentiation of chondrocyte cells,  
XX for stimulating the proliferation of or gene expression in pericyte  
XX cells, for stimulating the release of proteoglycans from cartilage, for  
XX stimulating the proliferation of inner ear utricular supporting cells,  
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating  
XX the release of a cytokine from PBMC cells, for inhibiting the binding of  
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
XX cells, for stimulating proliferation of endothelial cells, for detecting  
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,  
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
XX are useful for isolating genomic and cDNA nucleotide sequences or  
XX antisense probes. (II) is also useful as therapeutic agent. PRO is useful  
XX in assays to identify other proteins or molecules involved in binding  
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
XX and gene mapping, in generation of antisense RNA and DNA, in the  
XX preparation of PRO polypeptide, for generating transgenic animals or  
XX knockout animals which in turn are useful in the development and  
XX screening of therapeutically useful reagents, in gene therapy, for  
XX chromosome identification, as chromosome marker, and for generating  
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
XX detecting its expression in specific cells, tissues or serum, and for  
XX affinity purification of PRO from recombinant cell culture or natural  
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes  
XX a novel human secreted and transmembrane PRO polypeptide.  
XX  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAAACCTCTCCGAGAAACAGCAACAGCTGAGCTGCTGAGAGAG 60



Db 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
Qy 61 GGGAAACAGATGGCGGCGCCGAGGAGCCTCTGGGTGAGGACCCAACTGGGCGCTCCCG 120  
Db 61 GGGAAACAGATGGCGGCGCCGAGGAGCCTCTGGGTGAGGACCCAACTGGGCGCTCCCG 120  
Qy 121 CGGTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGCGGAGCCGCTTCGGCTGAAGCA 180  
Db 121 CGGTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTGCGGAGCCGCTTCGGCTGAAGCA 180  
Qy 181 TTTGACTCGGTCTGGGTGATACGGCTCTTGGCCACCGGCGCTGTGAGTTGACTACCCC 240  
Db 181 TTTGACTCGGTCTGGGTGATACGGCTCTTGGCCACCGGCGCTGTGAGTTGACTACCCC 240  
Qy 241 TTGCAACCTACCCCTAAGGAAGAGGTTGACGATGTACAGAGTTGCGAGCTGTTT 300  
Db 241 TTGCAACCTACCCCTAAGGAAGAGGTTGACGATGTACAGAGTTGCGAGCTGTTT 300  
Qy 301 TCAATTTGTCAGTTGTGATGATGGAATTCATTAATCGAATTAATGGAATGGA 360  
Db 301 TCAATTTGTCAGTTGTGATGATGGAATTCATTAATCGAATTAATGGAATGGA 360  
Qy 361 TCTGATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGTTGCCATCTTGTGTC 420  
Db 361 TCTGATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGTTGCCATCTTGTGTC 420  
Qy 421 CAGATCAGCTGCGATTCGCTGAATCTGAGACAGCAACTTATGTCCTGATGCCAAA 480  
Db 421 CAGATCAGCTGCGATTCGCTGAATCTGAGACAGCAACTTATGTCCTGATGCCAAA 480  
Qy 481 ATGCACTACTCTTCTCTTACTCTGCTGAGGTCAATCTGAGTGACATGAGACTCC 540  
Db 481 ATGCACTACTCTTCTCTTACTCTGCTGAGGTCAATCTGAGTGACATGAGACTCC 540  
Qy 541 GCACAGAGCTTCAATACCTCTTCATGAGCTTTTATCTCAAGCGATGACGGAATA 600  
Db 541 GCACAGAGCTTCAATACCTCTTCATGAGCTTTTATCTCAAGCGATGACGGAATA 600  
Qy 601 GTTATATTCAGTCTAAGCAGCAATTCAGTACGACCACTTTGGAGCAGGACCTTACA 660  
Db 601 GTTATATTCAGTCTAAGCAGCAATTCAGTACGACCACTTTGGAGCAGGACCTTACA 660  
Qy 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAANTGAGAAATTCAGAGCG 720  
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAANTGAGAAATTCAGAGCG 720  
Qy 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780  
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAAC 780  
Qy 781 TCTGGGTGATTTAACTCAACTCTTGTCTCTCGGTGATGATGATGATGATGATGAT 840  
Db 781 TCTGGGTGATTTAACTCAACTCTTGTCTCTCGGTGATGATGATGATGATGATGAT 840  
Qy 841 TGTGCACTGTGCTACAGCTGTGAGCAGATGTTTCTCTCTGAGAGCTGATATCTAT 900  
Db 841 TGTGCACTGTGCTACAGCTGTGAGCAGATGTTTCTCTCTGAGAGCTGATATCTAT 900  
Qy 901 GGTGACTGTGGATTTATGAATGAACAAAGCTTAAACAGATTCAGCTTCTCTCTG 960  
Db 901 GGTGACTGTGGATTTATGAATGAACAAAGCTTAAACAGATTCAGCTTCTCTCTG 960  
Qy 961 GTTGTGTAGATCTAAACTGAGATCATGAGAGCAGGCGCTCTACCTTACAAAGTGAAT 1020  
Db 961 GTTGTGTAGATCTAAACTGAGATCATGAGAGCAGGCGCTCTACCTTACAAAGTGAAT 1020  
Qy 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGGTTGATAGATCTTAA 1080  
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGGTTGATAGATCTTAA 1080  
Qy 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATTGGATATAGGCTTAAAGATCA 1140

Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATTGGATATAGGCTTAAAGATCA 1140  
Qy 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174  
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

## RESULT 127

ADC69507  
ID ADC69507 standard; cDNA; 1174 BP.

XX AC ADC69507;

DT 01-JAN-2004 (first entry)

XX cDNA encoding human PRO polypeptide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
immune system cell infiltration.

XX Homo sapiens.

OS US2003194770-A1.

XX 16-OCT-2003.

XX 21-MAY-2002; 2002US-00152375.

XX 03-MAR-2000; 2000US-0187202P.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-844453/78.

XX P-PSDB; ADC69508.  
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
acids, useful for the diagnosis, prevention and/or treatment of tumors,  
such as lung, colon, breast, prostate, rectal, cervical and/or liver  
tumors.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or



DR P-PSDB; ADC48397.  
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful  
PT for detecting a tumor, stimulating the release of tumor necrosis factor  
PT alpha and stimulating the proliferation of endothelial cells.  
XX Claim 2; Fig 271; 637pp; English.  
PS The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACCGGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGCACAGAG 60  
DB 1 CGGACCGGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGCACAGAG 60  
QY 61 GGGAAACAAGATGCGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGCGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
QY 121 CCCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGGAAGCA 180  
DB 121 CCCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGGAAGCA 180  
QY 181 TTTGACTCGGTCTTGGGTGATGACGGGCTCTTGGCCACCGGGCCCTGTCACTGACCTACCCC 240  
DB 181 TTTGACTCGGTCTTGGGTGATGACGGGCTCTTGGCCACCGGGCCCTGTCACTGACCTACCCC 240  
QY 241 TTGCACACCTTACCCTTAAGGAGAGGAGTTGTAGCATGTTCAGAGAGTTGACGGCTGTTT 300  
DB 241 TTGCACACCTTACCCTTAAGGAGAGGAGTTGTAGCATGTTCAGAGAGTTGACGGCTGTTT 300  
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAAATCGAACTTAAATGGAATGTGAA 360  
DB 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAAATCGAACTTAAATGGAATGTGAA 360  
QY 361 TCTGCAATGACAGACGATATCCCAATCTGATGACGATATGCTTGCCATCTTGGTTGC 420

DB 361 TCTGCAATGACAGACGATATCCCAATCTGATGACGATATGCTTGCCATCTTGGTTGC 420  
QY 421 CAGAATCAGCTGCCATTGCTGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAA 480  
DB 421 CAGAATCAGCTGCCATTGCTGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTTAACCTCTGGTGAGTCACTCTGGAGTGACATGATGGAATCC 540  
DB 481 ATGCACCTACTCTTCTCTTAACCTCTGGTGAGTCACTCTGGAGTGACATGATGGAATCC 540  
QY 541 GCACAGAGCTTCAACCTCTTCAAGCTTTTATCTTCAAGCCGATGACGGAATAATA 600  
DB 541 GCACAGAGCTTCAACCTCTTCAAGCTTTTATCTTCAAGCCGATGACGGAATAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCACTTTGGAGCAGGAGCTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCACTTTGGAGCAGGAGCTACA 660  
QY 661 AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGATTTCTTGAGATGAGAAAGTGAGGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGATTTCTTGAGATGAGAAAGTGAGGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGGTGGATTTTAACTACAACTCTTCTGCTCGGTGATGATGCTTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTACAACTCTTCTGCTCGGTGATGATGCTTTGGATTTGT 840  
QY 841 TGTGCACTGTTGTACAGCTGTGGAGCTGTTCCCTCTCAGAGCTGAGTATCTAT 900  
DB 841 TGTGCACTGTTGTACAGCTGTGGAGCTGTTCCCTCTCAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960  
QY 961 GTTGTAGATCTAAACCTGAGATCATGAGAGCAGGCGCTCTACTCAAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACCTGAGATCATGAGAGCAGGCGCTCTACTCAAAAGTGAAT 1020  
QY 1021 CTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
DB 1021 CTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCTATTGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCTATTGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
RESULT 129  
ADD09925  
ID ADD09925 standard; cDNA; 1174 BP.  
XX  
AC ADD09925;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
XX Human PRO polynucleotide #136.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
XX US2003194776-A1.  
XX 16-OCT-2003.  
XX 29-MAY-2002; 2002US-00157785.  
XX 05-JUN-2000; 2000US-0209832P.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-852596/79.  
XX P-PSDB; ADD09926.  
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful  
XX for detecting a tumor, stimulating the release of proteoglycans from  
XX cartilage and inhibiting the differentiation of adipocyte cells.  
XX Claim 2; Fig 271; 637pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems,  
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
XX polypeptides are also useful for treating various mammalian haemoglobin-  
XX associated disorders such as various thalassemias and conditions which  
XX may benefit from enhanced local immune system cell infiltration. This  
XX sequence represents a human PRO polynucleotide of the invention. Note:  
XX The sequence data for this patent is also available in electronic format  
XX from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
SQ Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
1 CGGACGCGTGGGGAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60  
61 GGGAAACAAGATGGCGCGCGGAGGGGAGCTCTGGGGTGAGGACCCCACTGGGCTCCCG 120  
61 GGGAAACAAGATGGCGCGCGGAGGGGAGCTCTGGGGTGAGGACCCCACTGGGCTCCCG 120  
121 CCGCTGCTGCTGCTGACCATGCGCTTGGCCGAGGTTCCGGGACCGCTTCCGCTGAAGCA 180  
121 CCGCTGCTGCTGCTGACCATGCGCTTGGCCGAGGTTCCGGGACCGCTTCCGCTGAAGCA 180  
181 TTTGACTCGGCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTCACTTGCCTTACCCC 240  
181 TTTGACTCGGCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTCACTTGCCTTACCCC 240  
241 TTGCACACCTTACCCCTAAGCAAGAGGAGTTGTACGCAATGTTCAGAGAGGTTGCGGCTGTTT 300  
241 TTGCACACCTTACCCCTAAGCAAGAGGAGTTGTACGCAATGTTCAGAGAGGTTGCGGCTGTTT 300  
301 TCAATTTGTCAGTTTGTGATGATGGAATTTAAATCGAACTAAATTTGGAATGTGAA 360  
301 TCAATTTGTCAGTTTGTGATGATGGAATTTAAATCGAACTAAATTTGGAATGTGAA 360  
361 TCTGCATGTACAGAACATATTCCTTCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420  
361 TCTGCATGTACAGAACATATTCCTTCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420  
421 CAGAATCAGCTGCCATTCGCTGAACTGAGCAAGAACAACTTATGCTCCTGATGCAAAA 480  
421 CAGAATCAGCTGCCATTCGCTGAACTGAGCAAGAACAACTTATGCTCCTGATGCAAAA 480  
481 ATGCACCTACTCTTCTTAACTCTGGTGAGTCAATCTGAGTGACATGATGAGTCC 540  
481 ATGCACCTACTCTTCTTAACTCTGGTGAGTCAATCTGAGTGACATGATGAGTCC 540  
541 GCACAGAGCTTCAATACCTCTTCAATGCACTTTTATCTTCAAGCCGATGACGGAATA 600  
541 GCACAGAGCTTCAATACCTCTTCAATGCACTTTTATCTTCAAGCCGATGACGGAATA 600  
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660  
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660  
661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGG 720  
661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGG 720  
721 CACAGGAAATTTCTTGAAGATGAGAAAGTATGAGGCTTTTGAAGTGCCTCTCTTAAC 780  
721 CACAGGAAATTTCTTGAAGATGAGAAAGTATGAGGCTTTTGAAGTGCCTCTCTTAAC 780  
781 TCTGGGTGGATTTTAACTACAACCTTCTGCTCGGTGATGATGATGATGATGATGAT 840  
781 TCTGGGTGGATTTTAACTACAACCTTCTGCTCGGTGATGATGATGATGATGATGAT 840  
841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
901 GGTGACTTGGAGTTTAAATGAAACAAAAGCTTAAACAGATATCCAGCTTCTTCTCTG 960  
901 GGTGACTTGGAGTTTAAATGAAACAAAAGCTTAAACAGATATCCAGCTTCTTCTCTG 960  
961 GTTGTGATGATCTAAACTGAAATGATGAGAGAGAGGCGCTTACCTACAAAGTGAAT 1020  
961 GTTGTGATGATCTAAACTGAAATGATGAGAGAGAGGCGCTTACCTACAAAGTGAAT 1020  
1021 CTTCCTCACTTCTGAAATTTAAGCAATTTCTTTTAAAGACAGAGTGAATAGACATCTAA 1080  
1021 CTTCCTCACTTCTGAAATTTAAGCAATTTCTTTTAAAGACAGAGTGAATAGACATCTAA 1080  
1081 AATTCCACTCTCTATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
1081 AATTCCACTCTCTATAGAGCTTTTAAATGGTTTCAATGATATAGGCTTTAAGAAATCA 1140

QY 1141 CTATAAATGCATAAATAGTTACTCAATCTGTG 1174  
Db |||||  
1141 CTATAAATGCATAAATAGTTACTCAATCTGTG 1174

RESULT 130  
ADD04500  
ID ADD04500 standard; cDNA; 1174 BP.  
XX  
AC ADD04500;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
XX Novel human secreted and transmembrane protein PRO195 cDNA.

Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
rectum; kidney; cervix; liver; microvascular endothelial cell;  
glucose uptake modulator; FFA uptake modulator; cell proliferation;  
cell differentiation; skeletal muscle cell; adipocyte cell;  
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
immune system cell infiltration; chromosome mapping; gene mapping;  
gene therapy; chromosome identification; chromosome marker; gene; ss.

OS Homo sapiens.  
XX  
XX US2003087354-A1.  
PN  
XX  
XX 08-MAY-2003.  
XX  
XX 22-APR-2002; 2002US-00127827.  
XX  
XX 17-AUG-1998; 98US-0096891P.  
PR  
XX 02-JUN-1999; 99WO-US012252.  
PR  
XX 25-AUG-1999; 99US-00380137.  
PR  
XX 30-MAR-2000; 2000WO-US008439.  
PR  
XX 30-MAY-2000; 2000WO-US014941.  
PR  
XX 01-DEC-2000; 2000WO-US032678.  
PR  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;  
XX  
XX WPI; 2003-801139/75.  
DR  
XX P-PSDB; ADD04501.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
PT diagnosing or treating tumor.  
PT  
XX  
XX Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polynucleotide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
SQ

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAACAGCACAGCTGAGCTGTGTGACAGAG 60  
Db 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAACAGCACAGCTGAGCTGTGTGACAGAG 60

QY 61 GGGACAAAGATGGGGGGCGCGGAGGAGGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
Db 61 GGGACAAAGATGGGGGGCGCGGAGGAGGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

QY 121 CGGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
Db 121 CGGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAGCA 180

QY 181 TTTGACTCGGCTTGGGTGATACCGGCTCTTGGCCACCGGCGCTGTGAGTTGACCTACCC 240  
Db 181 TTTGACTCGGCTTGGGTGATACCGGCTCTTGGCCACCGGCGCTGTGAGTTGACCTACCC 240

QY 241 TTGCACACTACCTTAAGAAAGAGAGTGTGACCATGTGACAGAGGTTGCAGGCTGTTT 300  
Db 241 TTGCACACTACCTTAAGAAAGAGAGTGTGACCATGTGACAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTGAGTTGTGGATGATGAAATGACTTAAATCGAACTAAATTTGGAATGTGA 360  
Db 301 TCAATTTGTGAGTTGTGGATGATGAAATGACTTAAATCGAACTAAATTTGGAATGTGA 360

QY 361 TCTGATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCTATCTGGTTC 420  
Db 361 TCTGATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCTATCTGGTTC 420

QY 421 CAGAACTAGCTGCCATTGCTGAACTGAGACAGAACTTATGCTCCCTGATGCCAATA 480  
Db 421 CAGAACTAGCTGCCATTGCTGAACTGAGACAGAACTTATGCTCCCTGATGCCAATA 480

QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAAGTTCATCTGGAGTGACATGAGGACTCC 540  
Db 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAAGTTCATCTGGAGTGACATGAGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600  
Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAATA 600

QY 601 GTTATATTCAGCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGAGGAGGCTTACA 660  
Db 601 GTTATATTCAGCTTAAGCCAGAAATCCAGTACGACCAATTTGGAGAGGAGGCTTACA 660

QY 661 AATTGAGAGATCTCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
Db 661 AATTGAGAGATCTCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAAATTTCTTGAAGATGGAAGAGTGGCTTTTAAAGATGCTCTCTTAAAC 780  
DB |||||  
QY 721 CACAGGAAATTTCTTGAAGATGGAAGAGTGGCTTTTAAAGATGCTCTCTTAAAC 780  
DB |||||  
QY 781 TCTGGGTGGATTTTAACTACAACCTTTGTCTCTCGGTGATGTAATGTTGGATTGT 840  
DB |||||  
QY 781 TCTGGGTGGATTTTAACTACAACCTTTGTCTCTCGGTGATGTAATGTTGGATTGT 840  
DB |||||  
QY 841 TGTGCAACTGTGTCAGCTGAGGACGATGTTCCCTCTCAGAGCTGAGTATCTAT 900  
DB |||||  
QY 841 TGTGCAACTGTGTCAGCTGAGGACGATGTTCCCTCTCAGAGCTGAGTATCTAT 900  
DB |||||  
QY 901 GGTGACCTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTG 960  
DB |||||  
QY 901 GGTGACCTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTG 960  
DB |||||  
QY 961 GTTGTGATGCTAAACTGAAGATCATGAAGACGAGGCGCTTACTCTACAAAGTGAAT 1020  
DB |||||  
QY 961 GTTGTGATGCTAAACTGAAGATCATGAAGACGAGGCGCTTACTCTACAAAGTGAAT 1020  
DB |||||  
QY 1021 CTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
DB |||||  
QY 1021 CTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
DB |||||  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCATGATAGAGCTTAAAGAAATCA 1140  
DB |||||  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCATGATAGAGCTTAAAGAAATCA 1140  
DB |||||  
QY 1141 CTATTAATGCAATTAAGTACTCAATCTGTG 1174  
DB |||||  
QY 1141 CTATTAATGCAATTAAGTACTCAATCTGTG 1174  
DB |||||

RESULT 131  
ID ADC80456  
ID ADC80456 standard; cDNA; 1174 BP.  
XX  
AC ADC80456;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;  
KW sports injury; proteoglycan; articular cartilage defect; thalassaemia;  
KW rheumatoid arthritis; haemoglobin-associated disorder; gene mapping;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2003092103-A1.  
XX  
XX 15-MAY-2003.  
XX  
XX 24-APR-2002; 2002US-00131815.  
XX  
XX 22-DEC-1998; 98US-0113511P.  
XX  
XX 01-DEC-1999; 99WO-US028634.  
XX  
XX 22-FEB-2000; 2000WO-US004414.  
XX  
XX 01-DEC-2000; 2000WO-US032678.  
XX  
XX 19-DEC-2001; 2001WO-00028072.  
XX  
XX (GETH ) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2003-801168/75.  
DR P-PSDB; ADC80457.  
XX  
XX  
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
XX  
XX Claim 2; Fig 271; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassaemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polynucleotide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
XX  
XX Query Match 100.0%; Score 1174; DB 9; Length 1174;  
XX Best Local Similarity 100.0%; Pred. No. 0;  
XX Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCTGGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGGCGCCGAGAGGGAGGCTCTGGGTGAGGACCCACCTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGGCGCCGAGAGGGAGGCTCTGGGTGAGGACCCACCTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCGCTGTCACTTACCCC 240  
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCGCTGTCACTTACCCC 240  
QY 241 TTGCAACCTACCTTAAGAGAGAGGTTGTACCATGTTCAGAGAGGTTTCAGAGCTTTT 300  
DB 241 TTGCAACCTACCTTAAGAGAGAGGTTGTACCATGTTCAGAGAGGTTTCAGAGCTTTT 300

QY 301 TCAATTGTGTCAGTTGGATGATGGAAATGACCTTAATAATCGAACTAAATGGAAATGGAA 360  
DB 301 TCAATTGTGTCAGTTGGATGATGGAAATGACCTTAATAATCGAACTAAATGGAAATGGAA 360  
QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTCATGAGCAATATGCTTCCCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTCATGAGCAATATGCTTCCCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAACCTTATGCTCCCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAACTGAGACAGAAACAACCTTATGCTCCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 540  
DB 481 ATGCACCTACTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 540  
QY 541 GCACAGAGCTTCATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATCCAGTCTAAGCCGAATTCAGTACGACCAACATTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATCCAGTCTAAGCCGAATTCAGTACGACCAACATTTGGAGCAGGAGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTGAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC 780  
DB 721 CACAGGAATTTCTGAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAAC 780  
QY 781 TCTGGGTGATTTTAACTACAACTCTTCTCTCTGCTGATGATGATGATGATGATGATGAT 840  
DB 781 TCTGGGTGATTTTAACTACAACTCTTCTCTCTGCTGATGATGATGATGATGATGATGAT 840  
QY 841 TGTGCACTGTGCTACAGCTGTGAGCAGATGATGCTTCTCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCACTGTGCTACAGCTGTGAGCAGATGATGCTTCTCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTTGTG 960  
QY 961 GTTGTAGATCTTAACTGAAGATCATGAGAGAGAGGAGGCTCTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTTAACTGAAGATCATGAGAGAGAGGAGGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTGTCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080  
DB 1021 CTGTCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTACTCAATCTCTG 1174  
DB 1141 CTATAAATGCAATTAAGTACTCAATCTCTG 1174

RESULT 132  
ADD10963  
ID ADD10963 standard; cDNA; 1174 BP.  
XX  
AC ADD10963;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
DE Human PRO polynucleotide #136.  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone cartilage defect; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
immune system cell infiltration.

Homo sapiens.

US2003194774-A1.

16-OCT-2003.

21-MAY-2002; 2002US-00152399.

03-MAR-2000; 2000US-0187202P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-852594/79.

P-PSDB; ADD10964.

New secreted and transmembrane PRO nucleic acids and polypeptides, useful

for detecting a tumor, stimulating the proliferation or differentiation

of chondrocyte cells and stimulating the release of tumor necrosis factor

alpha.

Claim 2; SEQ ID NO 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The

invention also relates to an antibody which specifically binds to a PRO

polypeptide, a method for stimulating the release of tumor necrosis

factor-alpha (TNF-alpha) from human blood, a method for stimulating the

proliferation or differentiation of chondrocyte cells and a method for

detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

polynucleotides are useful in molecular biology, including uses as

hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also

be used in preparing PRO polypeptides by recombinant techniques and in

generating either transgenic animals or knock-out animals which are

useful in the development and screening of therapeutically useful

reagents. The PRO polypeptides or antibodies are used in preparing a

medicament for treating a condition responsive to the polypeptides or

antibodies, such as tumours, for stimulating and inhibiting proliferation

of human microvascular endothelial cells, for modulating the uptake of

glucose or FFA by skeletal muscle cells or adipocyte cells, for

stimulating differentiation of adipocyte cells, for stimulating

proliferation of or gene expression in pericyte cells, for stimulating

the proliferation of inner ear utricular supporting cells or T-lymphocyte

cells, for inducing endothelial cell tube formation and for treating

various bone and/or cartilage disorders such as sports injuries and

arthritis. PRO polypeptides which stimulate the release of proteoglycans

from cartilage are useful for treating sports-related joint problems,

articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

polypeptides are also useful for treating various mammalian haemoglobin-

associated disorders such as various thalassemias and conditions which

may benefit from enhanced local immune system cell infiltration. This

sequence represents a human PRO polynucleotide of the invention. Note:

The sequence data for this patent is also available in electronic format

from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;







XX	Sequence	1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;	
SQ	Query Match	100.0%; Score 1174; DB 9; Length 1174;	
	Best Local Similarity	100.0%; Pred. No. 0;	
	Matches 1174; Conservative	0; Mismatches 0; Indels 0; Gaps 0;	
QY	1	CGGACGCGTGGGGAACCCCTCCGAGAAACACGAAACAGCTGAGCTGTGACAGAG 60	
DB	1	CGGACGCGTGGGGAACCCCTCCGAGAAACACGAAACAGCTGAGCTGTGACAGAG 60	
QY	61	GGGACACAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGCGTCCCG 120	
DB	61	GGGACACAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGCGTCCCG 120	
QY	121	CGCGTCTGCTGCTGACCATGCGCTTGGCCGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180	
DB	121	CGCGTCTGCTGCTGACCATGCGCTTGGCCGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180	
QY	181	TTTGACTCGGCTTGGGTGATACGGCGTCTTGGCCAGCGGCTGTGAGTTCAGCTACCCC 240	
DB	181	TTTGACTCGGCTTGGGTGATACGGCGTCTTGGCCAGCGGCTGTGAGTTCAGCTACCCC 240	
QY	241	TTGCACACCTACCTCCAAAGAGAGAGTTGACGATGTGACAGAGGTTGACGCGTGT 300	
DB	241	TTGCACACCTACCTCCAAAGAGAGAGTTGACGATGTGACAGAGGTTGACGCGTGT 300	
QY	301	TCGAATTTGCTGATGATGAGTGAATTCGACTTAATCGAATTAATTTGGAATGGA 360	
DB	301	TCGAATTTGCTGATGATGAGTGAATTCGACTTAATCGAATTAATTTGGAATGGA 360	
QY	361	TTGCTGATGACAGAGACATATCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTC 420	
DB	361	TTGCTGATGACAGAGACATATCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTC 420	
QY	421	CAGAACTGAGCTGCCATTCGCTGAACTGAGCAAGAACTATGCTGCTGATGCCAAA 480	
DB	421	CAGAACTGAGCTGCCATTCGCTGAACTGAGCAAGAACTATGCTGCTGATGCCAAA 480	
QY	481	ATGCACTACTCTTCTCTACTCTGCTGAGTCAATCTGAGTGAATGAGTGCCTCC 540	
DB	481	ATGCACTACTCTTCTCTACTCTGCTGAGTCAATCTGAGTGAATGAGTGCCTCC 540	
QY	541	GCAAGAGCTTCAATACCTCTTCTGAGCTTTTATCTTCAAGCGATGACGGAATA 600	
DB	541	GCAAGAGCTTCAATACCTCTTCTGAGCTTTTATCTTCAAGCGATGACGGAATA 600	
QY	601	GTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCGAGCTTACA 660	
DB	601	GTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCGAGCTTACA 660	
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTATCTGCAAAATGAGAAATTCACAGCG 720	
DB	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTATCTGCAAAATGAGAAATTCACAGCG 720	
QY	721	CACAGAAATTTCTGAGATGGAAGATGATGCTTTTAAAGATGCTCTCTTTAAC 780	
DB	721	CACAGAAATTTCTGAGATGGAAGATGATGCTTTTAAAGATGCTCTCTTTAAC 780	
QY	781	TTGCGTGGATTTTAACTACAACTCTTCTCTCGGTGATGATGCTTTGATTTGT 840	
DB	781	TTGCGTGGATTTTAACTACAACTCTTCTCTCGGTGATGATGCTTTGATTTGT 840	
QY	841	TTGCACTGTTGCTACAGCTGAGGAGTATGTTTCCCTGAGAGCTGAGTATCTAT 900	
DB	841	TTGCACTGTTGCTACAGCTGAGGAGTATGTTTCCCTGAGAGCTGAGTATCTAT 900	
QY	901	GCTGACTTGGATTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTCTTTGTG 960	
DB	901	GCTGACTTGGATTTATGATGAAACAAAGCTTAAACAGATATCCAGCTTCTCTTTGTG 960	
QY	961	GTGTTGATGATCTAAATCTGAGATCATGAGAGAGCGGCTCTACCTACAAAGTGAAT 1020	
DB	961	GTGTTGATGATCTAAATCTGAGATCATGAGAGAGCGGCTCTACCTACAAAGTGAAT 1020	

DB	961	GTGTTGATGATCTAAATCTGAGATCATGAGAGAGCGGCTCTACCTACAAAGTGAAT 1020	
QY	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080	
DB	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080	
QY	1081	AATTCGACTCTCATAGAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140	
DB	1081	AATTCGACTCTCATAGAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140	
QY	1141	CTATAAATGCAATTAAGTTTACTCAAACTCTGTG 1174	
DB	1141	CTATAAATGCAATTAAGTTTACTCAAACTCTGTG 1174	
RESULT 134			
ADC47844			
ID	ADC47844	standard; cDNA; 1174 BP.	
XX	AC	ADC47844;	
XX	AC	ADC47844;	
DT	01-JAN-2004	(first entry)	
XX	Human	PRO polynucleotide #136.	
DE	Human	Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
XX	Human	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
XX	Human	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW	Human	liver; microvascular endothelial cell; glucose; FFA;	
KW	Human	skeletal muscle cell; adipocyte cell; pericyte cell;	
KW	Human	inner ear utricular supporting cell; T-lymphocyte cell;	
KW	Human	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	Human	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW	Human	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;	
KW	Human	immune system cell infiltration.	
XX	Homo sapiens.		
OS	Homo sapiens.		
PN	US2003194771-A1.		
XX	16-OCT-2003.		
XX	21-MAY-2002; 2002US-00152377.		
XX	09-DEC-1999; 99US-0170262P.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	19-DEC-2001; 2001US-00028072.		
XX	(GETH ) GENENTECH INC.		
XX	Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;		
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Gurney SL, Smith V;		
PI	Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX	WPI; 2003-844454/78.		
DR	P-PSDB; ADC47845.		
XX	New secreted and transmembrane PRO polypeptides and nucleic acids useful		
PT	for detecting a tumor, stimulating the release of proteoglycans from		
PT	cartilage and stimulating the proliferation of endothelial cells.		
XX	Claim 2; Fig 271; 637pp; English.		
XX	The invention relates to isolated human PRO polypeptides (secreted and		
CC	transmembrane polypeptides) and the polynucleotides encoding them. The		
CC	invention also relates to an antibody which specifically binds to a PRO		
CC	polypeptide, a method for stimulating the release of tumour necrosis		
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the		
CC	proliferation or differentiation of chondrocyte cells and a method for		
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,		
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The		
CC	polynucleotides are useful in molecular biology, including uses as		
CC	hybridisation probes, in chromosome and gene mapping, in generating		

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX

QY	1	CGGACGCGTGGGGAAACCCCTCCGAGAAACACGACACACGACGCTGCTGACAGAG	60
DB	1	CGGACGCGTGGGGAAACCCCTCCGAGAAACACGACACACGACGCTGCTGACAGAG	60
QY	61	GGGACACAGATGGCGCGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGCGCTCCCG	120
DB	61	GGGACACAGATGGCGCGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGCGCTCCCG	120
QY	121	CGCGTGTCTGCTGACGATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAGCA	180
DB	121	CGCGTGTCTGCTGACGATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAGCA	180
QY	181	TTTGACTCGGCTTGGGTGATACGGCTCTTGGCACCGGGCGCTGACGTTGACCTACCCC	240
DB	181	TTTGACTCGGCTTGGGTGATACGGCTCTTGGCACCGGGCGCTGACGTTGACCTACCCC	240
QY	241	TTGCACACCTACCTAAGGAGGAGGTTGACGATGTCAGAGGTTGAGGCTGTTT	300
DB	241	TTGCACACCTACCTAAGGAGGAGGTTGACGATGTCAGAGGTTGAGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGATCATGGAATTGACTTAAATCGAATTAATTCGAATGTGAA	360
DB	301	TCAATTTGTCAGTTTGTGATCATGGAATTGACTTAAATCGAATTAATTCGAATGTGAA	360
QY	361	TCGCAATGTACAGACATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420
DB	361	TCGCAATGTACAGACATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420
QY	421	CAGAATCAGTGCATTCCTGACACTGACAGACACACTTATGCTCCCTGATGCCAAA	480
DB	421	CAGAATCAGTGCATTCCTGACACTGACAGACACACTTATGCTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTCTCTTAATCTGTTGAGGTCACTTCGGAGTGACATGAGTACTCC	540
DB	481	ATGCACCTACTCTTCTCTTAATCTGTTGAGGTCACTTCGGAGTGACATGAGTACTCC	540
QY	541	GCACAGGCTTCAATCTTTCATGAGCTTTTATCTTCAAGCGATGACGGAAATA	600
DB	541	GCACAGGCTTCAATCTTTCATGAGCTTTTATCTTCAAGCGATGACGGAAATA	600
QY	601	GTTATATTCAGTCTAAGCCAGAAATTCAGTACGACACATTTGGAGCAGGAGCTACA	660
DB	601	GTTATATTCAGTCTAAGCCAGAAATTCAGTACGACACATTTGGAGCAGGAGCTACA	660

QY	661	AATTTGAGAGAAATCATCTCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB	661	AATTTGAGAGAAATCATCTCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC	780
DB	721	CACAGGAATTTTCTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC	780
QY	781	TCGGGTGGGATTTTAACTACAACCTCTTGTCCCTCGGTGATGTTGCTTTGGATTTGT	840
DB	781	TCGGGTGGGATTTTAACTACAACCTCTTGTCCCTCGGTGATGTTGCTTTGGATTTGT	840
QY	841	TGTGCAAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
DB	841	TGTGCAAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACCTTGAGTTTATGAATGAACAAAAGCTAAAACAGATATCCAGCTTCTCTCTTGTG	960
DB	901	GGTGACCTTGAGTTTATGAATGAACAAAAGCTAAAACAGATATCCAGCTTCTCTCTTGTG	960
QY	961	GTTGTTAGATCTAAAACGTGAAGATCATGAGAAGCGGGCTTACCTACAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAAACGTGAAGATCATGAGAAGCGGGCTTACCTACAAAGTGAAT	1020
QY	1021	CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGCAAGTCTAATAGACATCTAA	1080
DB	1021	CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGCAAGTCTAATAGACATCTAA	1080
QY	1081	AATTTCCACTCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGCGCTTAAAGAAATCA	1140
DB	1081	AATTTCCACTCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGCGCTTAAAGAAATCA	1140
QY	1141	CTATAAATGCAATTAAGTTACTCAATCTGTG	1174
DB	1141	CTATAAATGCAATTAAGTTACTCAATCTGTG	1174

RESULT 135  
ADCT79904  
ID ADCT79904 standard; cDNA; 1174 BP.  
XX AC ADCT79904;  
XX AC ADCT79904;  
XX 01-JAN-2004 (first entry)  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
XX chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
XX rectum; kidney; cervix; liver; microvascular endothelial cell;  
XX glucose uptake modulator; PFA uptake modulator; cell proliferation;  
XX cell differentiation; skeletal muscle cell; adipocyte cell;  
XX pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
XX immune system cell infiltration; chromosome mapping; gene mapping;  
XX gene therapy; chromosome identification; chromosome marker; gene; ss.  
XX Homo sapiens.  
XX US2003087358-A1.  
XX 08-MAY-2003.  
XX 22-APR-2002; 2002US-00127833.  
XX 01-SEP-1998; 98US-0098750P.  
XX 01-SEP-1999; 99WO-US020111.  
XX 18-OCT-1999; 99US-00403297.  
XX 18-FEB-2000; 2000WO-US004342.

PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-801143/75.  
DR P-PSDB; ADC79905.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
PT diagnosing or treating tumor.  
XX  
XX Claim 2; Fig 271; 637pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polynucleotide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
QY 61 GGGAAACAGATGGCGGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120  
DB 61 GGGAAACAGATGGCGGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120  
QY 121 CCGTGTGCTGTGACATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
DB 121 CCGTGTGCTGTGACATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
QY 181 TTTCAGCTCGGCTTGGGTGATACGGCGCTTTGGCACCGGGCGCTGTGAGTTGACCTACCCC 240  
DB 181 TTTCAGCTCGGCTTGGGTGATACGGCGCTTTGGCACCGGGCGCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCTTAAGGAGGAGGTTGTACGCATGTCCAGAGGTTGCGGCTGTTT 300  
DB 241 TTGCACACCTACCTTAAGGAGGAGGTTGTACGCATGTCCAGAGGTTGCGGCTGTTT 300  
QY 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTCGAACTAAATCGAACTAAATGGAATGAA 360  
DB 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTCGAACTAAATCGAACTAAATGGAATGAA 360  
QY 361 TCTGCATGTACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATTCCTCATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACTCGAGCAAGAACTAAATTCGCTTCCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAACTCGAGCAAGAACTAAATTCGCTTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAGTCACTTCTGGAGTGCATGATGGACTCC 540  
DB 481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAGTCACTTCTGGAGTGCATGATGGACTCC 540  
QY 541 GCACAGAGCTTCATAAAGCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCATAAAGCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATCACAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATCACAGCG 720  
QY 721 CACAGAAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCCCTCTCTTTAAC 780  
DB 721 CACAGAAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCCCTCTCTTTAAC 780  
QY 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTATGCTTTGGATTGT 840  
DB 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGCTTATGCTTTGGATTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAACTGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAACTGAAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
QY 961 GTTGTAGATCTAAGCTGAAAGATCATGAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAGCTGAAAGATCATGAGAGCAGGCGCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080  
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAITTTGGATATAGGCTTAAGAAATCA 1140  
DB 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAITTTGGATATAGGCTTAAGAAATCA 1140  
QY 1141 CTATATAATGCAAAATAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATATAATGCAAAATAAGTTACTCAAAATCTGTG 1174

RESULT 136  
ADD11256  
ID ADD11256 standard; cDNA; 1174 BP.  
XX AC ADD11256;  
XX XX  
DT 01-JAN-2004 (first entry)

XX Human secreted/transmembrane PRO polypeptide cDNA #4.  
DE ss; gene; human; secreted protein; transmembrane protein;  
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;  
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;  
KW age-related macular degeneration; angiogenesis;  
KW endothelial cell apoptosis; smooth muscle cell growth;  
KW endothelial cell tube formation.  
XX Homo sapiens.  
OS  
XX US2003105013-A1.  
XX 05-JUN-2003.  
XX 16-AUG-2002; 2002US-00223090.  
XX 20-JUN-2001; 2001WO-US019692.  
XX 09-JUL-2001; 2001WO-US021735.  
XX 20-FEB-2002; 2002US-00081056.  
XX (GETH) GENENTECH INC.  
XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;  
XX Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;  
XX Watanabe CK, Williams PM, Wood WI, Ye W;  
XX  
XX WPI: 2003-801242/75.  
XX P-PSDB; ADD11257.  
XX New isolated nucleic acid encoding a secreted and transmembrane  
XX polypeptide, useful for treating a cardiovascular, endothelial, or  
XX angiogenic disorder in a mammal, such as cancer or age-related macular  
XX degeneration.  
XX  
XX Claim 2; SEQ ID NO 7; 493pp; English.  
XX  
XX The invention relates to an isolated nucleic acid encoding a secreted and  
XX transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded  
XX by the nucleic acid, or an agonist or antagonist, is used to treat a  
XX cardiovascular, endothelial, or angiogenic disorder in a mammal,  
XX preferably a human. The human may have suffered a myocardial infarction  
XX or has cardiac hypertrophy, trauma, a cancer, or age-related macular  
XX degeneration. The cardiac hypertrophy is characterized by the presence of  
XX an elevated level of FGF-2 alpha. A PRO polypeptide, given in the  
XX specification, or an agonist is used to inhibit or stimulate endothelial  
XX cell growth in a mammal. PRO21 or an agonist is used to induce cardiac  
XX hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.  
XX PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO  
XX polypeptide, given in the specification, or an agonist is used to  
XX stimulate or inhibit smooth muscle cell growth, or to induce endothelial  
XX cell tube formation. The present sequence represents a cDNA encoding a  
XX PRO polypeptide of the invention.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60  
QY 61 GGGAAACAGATGGCGCGCGGAGGAGCCCTCGGGTGGAGACCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGCGCGCGGAGGAGCCCTCGGGTGGAGACCCCACTGGGGCTCCCG 120  
QY 121 CCCTGCTGCTGCTGACCAATGCGCTTGGCCGAGGTTCCGGGACCGCTTGGCTGAGACA 180  
DB 121 CCCTGCTGCTGCTGACCAATGCGCTTGGCCGAGGTTCCGGGACCGCTTGGCTGAGACA 180

QY 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCTGTGAGTGACCTACCCC 240  
DB 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCTGTGAGTGACCTACCCC 240  
QY 241 TTGACACCTTACCTTAAAGAGAGAGTTGTACGATGTTCAGAGAGTTGAGGCTGTTT 300  
DB 241 TTGACACCTTACCTTAAAGAGAGAGTTGTACGATGTTCAGAGAGTTGAGGCTGTTT 300  
QY 301 TCAATTTGTCTAGTTTGTGGATGATGAAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360  
DB 301 TCAATTTGTCTAGTTTGTGGATGATGAAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360  
QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTCCATCTTGGTTC 420  
DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTCCATCTTGGTTC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480  
QY 481 ATGCACTTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGAGTGACATGATGAGTCC 540  
DB 481 ATGCACTTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGAGTGACATGATGAGTCC 540  
QY 541 GCACAGAGCTTCATACTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
DB 541 GCACAGAGCTTCATACTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGAGCCCTACA 660  
DB 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGAGCCCTACA 660  
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTCTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTTCTTGAAGATGAGAAAGTGTGGCTTTTAAAGATGCGCTCTCTTTAAC 780  
DB 721 CACAGGAATTTTCTTGAAGATGAGAAAGTGTGGCTTTTAAAGATGCGCTCTCTTTAAC 780  
QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGTGTGATGATGCTTTGCTTGGATTTGT 840  
DB 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGTGTGATGATGCTTTGCTTGGATTTGT 840  
QY 841 TGTGCAACTGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTG 960  
DB 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTG 960  
QY 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGCAGGGCCTCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGCAGGGCCTCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTGTCTATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGTGTAAATGACATCTAA 1080  
DB 1021 CTTGTCTATCTGAAATTAAGCAATTTTCTTTTAAAGCAAGTGTAAATGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGCTTTTAAATGCTTTTAAATGCTTTTAAATGCTTT 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGCTTTTAAATGCTTTTAAATGCTTTTAAATGCTTT 1140  
QY 1141 CTATATAATGCAATTAAGTTTACTCAAAATCTGTG 1174  
DB 1141 CTATATAATGCAATTAAGTTTACTCAAAATCTGTG 1174

RESULT 137  
ADD09373  
ID ADD09373 standard; cDNA; 1174 BP.  
XX

AC ADD09373;  
 XX  
 DT 01-JAN-2004 (first entry)  
 XX  
 DE Human PRO polynucleotide #136.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; PFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003194775-A1.  
 XX  
 PD 16-OCT-2003.  
 XX  
 PF 28-MAY-2002; 2002US-00156849.  
 XX  
 PR 03-MAR-2000; 2000US-0187202P.  
 PR 01-DEC-2000; 2000RO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Bersini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI: 2003-852595/79.  
 DR P-PSDB; ADD09374.  
 XX  
 PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful  
 PT for detecting a tumor, stimulating the release of tumor necrosis factor  
 PT alpha from blood and stimulating the release of proteoglycans from  
 PT cartilage.  
 XX  
 PS Claim 2; Fig 271; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC the sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 1174; DB 9; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
 DB 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
 QY 61 GGGAAACAGATGGCGGCGCGGAGGAGCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120  
 DB 61 GGGAAACAGATGGCGGCGCGGAGGAGGCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120  
 QY 121 CGGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTGGGGGACCCGCTTCGGCTGAAGCA 180  
 DB 121 CGGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTGGGGGACCCGCTTCGGCTGAAGCA 180  
 QY 181 TTGACTCGGTCTTGGGTGATACGGCGCTCTTGCACCGGGCCCTGTCAGTTGACCTACCCC 240  
 DB 181 TTGACTCGGTCTTGGGTGATACGGCGCTCTTGCACCGGGCCCTGTCAGTTGACCTACCCC 240  
 QY 241 TTGCACACTACCTTAAGGAAGAGGAGTTGTACGATGTGAGAGGTTGCAGGCTGCTTT 300  
 DB 241 TTGCACACTACCTTAAGGAAGAGGAGTTGTGTGATGTGAGAGGTTGCAGGCTGCTTT 300  
 QY 301 TCAATTTCTGAGTTTGGTGTGATGAGGAAATGACTTAAATCGAACTAAATGGAAATGAA 360  
 DB 301 TCAATTTCTGAGTTTGGTGTGATGAGGAAATGACTTAAATCGAACTAAATGGAAATGAA 360  
 QY 361 TCTGCATGTACAGAAGCATATTCCTCAATTCGATGAGCAATATGCTTGCCTATCTTGTTC 420  
 DB 361 TCTGCATGTACAGAAGCATATTCCTCAATTCGATGAGCAATATGCTTGCCTATCTTGTTC 420  
 QY 421 CAGATCAGCTGCCATTCGCTGAGCAAGCAACAACTTATGTCCTCCCTGATGCCAAAA 480  
 DB 421 CAGATCAGCTGCCATTCGCTGAGCAAGCAACAACTTATGTCCTCCCTGATGCCAAAA 480  
 QY 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAAGTCATCTGGAGTGACATGATGGACTCC 540  
 DB 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAAGTCATCTGGAGTGACATGATGGACTCC 540  
 QY 541 GCACAGAGCTTCATTAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
 DB 541 GCACAGAGCTTCATTAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
 QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660  
 DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660  
 QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720  
 DB 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720  
 QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAAC 780  
 DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAAC 780  
 QY 781 TCTGGGTGAGATTTTAACTACAACTCTTCTCTCTGCTGCTGATGCTTATGCTTTGATTTGT 840  
 DB 781 TCTGGGTGAGATTTTAACTACAACTCTTCTCTCTGCTGCTGATGCTTATGCTTTGATTTGT 840  
 QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
 DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900  
 QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Db 901 GTTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGTCTTCTCTGTG 960  
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
QY 1021 CTTGTCTATCTCGAATTAAAGCTTTTCTTTAAAGACAGATGTAATAGACATCTAA 1080  
Db 1021 CTTGTCTATCTCGAATTAAAGCTTTTCTTTAAAGACAGATGTAATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATTAATGCAAAATTAAGTCTACTCAATCTGTG 1174  
Db 1141 CTATTAATGCAAAATTAAGTCTACTCAATCTGTG 1174

RESULT 138  
ADD41086  
ID ADD41086 standard; cDNA; 1174 BP.  
AC ADD41086;  
XX  
XX 15-JAN-2004 (first entry)  
XX Novel human secreted and transmembrane protein PRO195 cDNA.  
XX Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
XX US2003203438-A1.  
XX  
XX 30-OCT-2003.  
XX  
XX 15-MAY-2002; 2002US-00146786.  
XX  
XX 24-NOV-1997; 97US-0066511P.  
XX 16-SEP-1998; 98WO-US019330.  
XX 25-AUG-1999; 99US-00380139.  
XX 22-FEB-2000; 2000WO-US004414.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX MPI; 2003-875645/81.  
XX P-PSDB; ADD41087.  
XX  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
XX Claim 2; SEQ ID NO 271; 637pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear lymphocyte supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PBMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60  
Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60  
QY 61 GGGACACAGATGGCGGCGCGAGGAGGAGCTCTGGGTGAGGAGCCCACTGGGGCTCCCG 120  
Db 61 GGGACACAGATGGCGGCGCGCGAGGAGGAGCTCTGGGTGAGGAGCCCACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CGGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTTGACTCGGCTTTGGGTGATACGGCCCTTTCGACCGGGCCTGTGAGTGGACTACCCC 240  
Db 181 TTTGACTCGGCTTTGGGTGATACGGCCCTTTCGACCGGGCCTGTGAGTGGACTACCCC 240  
QY 241 TTGCACACCTTACCTTAAGGAAGAGAGTTGTACGCATGTTCAGAGAGGTTTCAGGCTGTTT 300  
Db 241 TTGCACACCTTACCTTAAGGAAGAGAGTTGTACGCATGTTCAGAGAGGTTTCAGGCTGTTT 300  
QY 301 TCATTTGTGCTTTGGGTGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360  
Db 301 TCATTTGTGCTTTGGGTGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360  
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGCCATTTCCGTGAACTCAGACAGAGCAACTTATGTCCCTGATGCCAAA 480  
Db 421 CAGAAATCAGCTGCCATTTCCGTGAACTCAGACAGAGCAACTTATGTCCCTGATGCCAAA 480  
QY 481 ATGCACCTTACTCTTTCTCTAATCTCTGGTGGGTGATTTCTGGAGTGCATGATGGACTCC 540  
Db 481 ATGCACCTTACTCTTTCTCTAATCTCTGGTGGGTGATTTCTGGAGTGCATGATGGACTCC 540  
QY 541 GCACAGAGCTTCATTAACCTCTTTCATGAGCTTTTATTTTCAAGCCGATGACGGAAATA 600  
Db 541 GCACAGAGCTTCATTAACCTCTTTCATGAGCTTTTATTTTCAAGCCGATGACGGAAATA 600  
QY 601 GTTATATTCAGTCTTACGCCAGAAATCCAGTACCACACATTTTGGAGGAGGCTTACA 660  
Db 601 GTTATATTCAGTCTTACGCCAGAAATCCAGTACCACACATTTTGGAGGAGGCTTACA 660

601 GTTATATCCAGCTTAAGCCGAAATCCAGTACGCCACCAATTTGGAGCAGGACCTACA 660  
661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720  
721 CACAGGAATTTTCTGAAGATGAGAAAGTGAATGCTTTTAAAGATGCTCTCTCTTAAC 780  
721 CACAGGAATTTTCTGAAGATGAGAAAGTGAATGCTTTTAAAGATGCTCTCTCTTAAC 780  
781 TCTGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840  
781 TCTGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840  
841 TGTGCACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
841 TGTGCACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960  
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960  
961 GTTGTGATCTAAACTGAAGTATGAGAGAGCAGGCTCTACCTACGAAAGTGAAT 1020  
961 GTTGTGATCTAAACTGAAGTATGAGAGAGCAGGCTCTACCTACGAAAGTGAAT 1020  
1021 CTGTGCTCATCTCAATTTAAAGCAATTTTCTTTAAAGACAAGTGAATAGACATCTAA 1080  
1021 CTGTGCTCATCTCAATTTAAAGCAATTTTCTTTAAAGACAAGTGAATAGACATCTAA 1080  
1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGATCA 1140  
1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGATCA 1140  
1141 CTATAAATGCAAAATGAAGTACTCAATCTGTG 1174  
1141 CTATAAATGCAAAATGAAGTACTCAATCTGTG 1174

RESULT 139

ADP52225

ID ADD52225 standard; cDNA; 1174 BP.

AC ADD52225;

XX

DT 15-JAN-2004 (first entry)

XX

DE cDNA encoding human PRO polypeptide #136.

XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX

XX US2003194769-A1.

XX

XX 16-OCT-2003.

XX

XX 21-MAY-2002; 2002US-00152374.

XX

XX 09-DEC-1999; 99US-0170262P.

XX

XX 01-DEC-2000; 2000WO-US032678.

XX

XX 19-DEC-2001; 2001US-00028072.

XX

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Deenoysers L, Filvaroff R, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX MPI: 2003-852593/79.  
DR P-PSDB; ADD52226.  
XX

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
PT acids, useful for detection of tumors, modulating the uptake of glucose  
PT or free fatty acids and stimulating the release of proteoglycans from  
PT cartilage.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at segdata.uspto.gov.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. NO. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGAGCGCTGGGGGAAACCCCTTCGAGAAAACAGCAAGCTGAGCTGCTGACAGAG 60

Db 1 CGGAGCGCTGGGGGAAACCCCTTCGAGAAAACAGCAAGCTGAGCTGCTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCCGAGCGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGCGCCCGAGCGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

QY 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCCGCTTCGGGTGAAGCA 180

Db 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCCGCTTCGGGTGAAGCA 180

QY 181 TTGTACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCTGTCAAGTGTACATACCC 240

Db 181 TTGTACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCTGTCAAGTGTACATACCC 240

QY 241 TTGCACACTTACCCCTAAGGAGAGGAGTGTGACCATGTTCAGAGAGGTTGCAGGCTGTTT 300

XX







PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030352.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US047259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US079649.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017032.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX XX

(GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR P-PSDB; 2003-852599/79.  
DR P-PSDB; ADD52966.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4578, useful in chromosome and gene mapping, in generating antisense  
PT RNA and DNA, and in the treatment of cancer.

XX Claim 2; Fig 271; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. The  
CC sequence encodes a human PRO polypeptide of the invention. Note: This  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

	Query Match	100.0%;	Score 1174;	DB 9;	Length 1174;
	Best Local Similarity	100.0%;	Pred. No. 0;		
	Matches 1174;	Conservative	0;	Mismatches	0;
				Indels	Gaps
				0;	0;
QY	1	CGGACGGGTGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGAGCTGCTGACAGAG	60		
DB	1	CGGACGGGTGGGGAAACCCCTTCGGAGAAACAGCAACAGCTGAGCTGCTGACAGAG	60		
QY	61	GGGAACAAAGATGCGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120		
DB	61	GGGAACAAAGATGCGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120		
QY	121	CGGCTGCTGCTGACCATGGCTTGGCCGGAGGTTGGGGACCCGCTCGGCTGAAGCA	180		
DB	121	CGGCTGCTGCTGACCATGGCTTGGCCGGAGGTTGGGGACCCGCTCGGCTGAAGCA	180		
QY	181	TTTGACTCGGTCTTGGGTGATACGGCCCTCTTGCCACCGGGCCCTGTCAGTTGACTACCCC	240		
DB	181	TTTGACTCGGTCTTGGGTGATACGGCCCTCTTGCCACCGGGCCCTGTCAGTTGACTACCCC	240		
QY	241	TGCAACACCTACCTTAAGGAAGAGGAGTTGTACGATGTCAGAGAGTTGCAGGCTGTT	300		
DB	241	TGCAACACCTACCTTAAGGAAGAGGAGTTGTACGATGTCAGAGAGTTGCAGGCTGTT	300		
QY	301	TCAATTTCTCAGTTTGTGGATGATGGAATTCGACTTAAATCGAACTAAATTTGGAATGAA	360		
DB	301	TCAATTTCTCAGTTTGTGGATGATGGAATTCGACTTAAATCGAACTAAATTTGGAATGAA	360		
QY	361	TCTGCATGTA CAGAAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCATCTGTTGC	420		
DB	361	TCTGCATGTA CAGAAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCATCTGTTGC	420		
QY	421	CAGATACGCTGCCATTCGCTGAACTCAGACACAGAACCACTTATGTCCTCCATGACAAA	480		
DB	421	CAGATACGCTGCCATTCGCTGAACTCAGACACAGAACCACTTATGTCCTCCATGACAAA	480		
QY	481	ATGCACCTACTCTTTCCTCTAACTCTGCTGAGGTCAATCTGGAGTGACATGATGGACTCC	540		
DB	481	ATGCACCTACTCTTTCCTCTAACTCTGCTGAGGTCAATCTGGAGTGACATGATGGACTCC	540		
QY	541	GCACAGAGCTTCATACCTCTTCATGACTTTTATCTTCAAGCCGATACGGGAAATA	600		
DB	541	GCACAGAGCTTCATACCTCTTCATGACTTTTATCTTCAAGCCGATACGGGAAATA	600		
QY	601	GTTATATTCCAGTCTTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCTTACA	660		
DB	601	GTTATATTCCAGTCTTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCTTACA	660		
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAGCG	720		

Db 661 AATTGAGAGATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAATTCACAAGG 720  
Qy 721 CACAGGAATTTCTTGAAGATGGAAGATGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTTGAAGATGGAAGATGATGGCTTTTAAAGATGCTCTCTCTTAAC 780  
Qy 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
Qy 841 TGTCACTGTGCTACAGCTGTGAGCAGTATGCTCTCTGAGAGCTGATCTAT 900  
Db 841 TGTCACTGTGCTACAGCTGTGAGCAGTATGCTCTCTGAGAGCTGATCTAT 900  
Qy 901 GGTGACTGGAGTTTGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960  
Db 901 GGTGACTGGAGTTTGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960  
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAGAGCAGGCTCTCTCTCAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAGATCATGAGAGCAGGCTCTCTCTCAAAAGTGAAT 1020  
Qy 1021 CTGTCTCTCTGAAATTAAGCAATTTTCTTTAAAGCAAGTGTAAAGATCTAA 1080  
Db 1021 CTGTCTCTCTGAAATTAAGCAATTTTCTTTAAAGCAAGTGTAAAGATCTAA 1080  
Qy 1081 AATTCACCTCTCATAGAGCTTTTAAAGTTCATGATATAGGCTTAAAGATCA 1140  
Db 1081 AATTCACCTCTCATAGAGCTTTTAAAGTTCATGATATAGGCTTAAAGATCA 1140  
Qy 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174  
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 141  
ID ADD53517 standard; cDNA; 1174 BP.  
XX AC ADD53517;  
XX DT 15-JAN-2004 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;  
XX KW Tumour necrosis factor alpha release; TNF-alpha release;  
XX KW Glucose uptake modulator; FFA uptake modulator;  
XX KW Cell proliferation stimulator; cell differentiation stimulator;  
XX KW Cell differentiation inhibitor; cytokine release stimulator; tumour;  
XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
XX KW gene therapy; chromosome identification; chromosome marker.  
XX OS Homo sapiens.  
XX PN US2003203437-A1.  
XX PD 30-OCT-2003.  
XX PF 15-MAY-2002; 2002US-00146728.  
XX PR 01-JUL-1998; 98US-0091360P.  
XX PR 02-JUN-1999; 99WO-US012252.  
XX PR 01-DEC-2000; 2000US-00380137.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-875644/81.  
DR P-PSDB; ADD53518.  
XX  
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
PS Claim 2; SEQ ID NO 271; 659pp; English.  
XX  
CC The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation of or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from BMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
Db 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60  
Qy 61 GGGAAACAGATGGCGCGCGAGAGGAGCTCTGGTGAGGAGCCCACTGGGGCTCCCG 120  
Db 61 GGGAAACAGATGGCGCGCGAGAGGAGCTCTGGTGAGGAGCCCACTGGGGCTCCCG 120  
Qy 121 CGCTGTCTGTCTGACCATGGCTTCGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
Db 121 CGCTGTCTGTCTGACCATGGCTTCGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
Qy 181 TTGACTCGCTCTGGGTGATACGGCTCTTGCCACCGGGCTGTGAGTTGACTATCCCC 240  
Db 181 TTGACTCGCTCTGGGTGATACGGCTCTTGCCACCGGGCTGTGAGTTGACTATCCCC 240  
Qy 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGTTTCAGGCTGTTT 300  
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGTTTCAGGCTGTTT 300  
Qy 301 TCAATTTCTCAGTTTGTGGATGATGGAATTGAATTAAATCGAATTAATTTGGAATGTGA 360  
Db 301 TCAATTTCTCAGTTTGTGGATGATGGAATTGAATTAAATCGAATTAATTTGGAATGTGA 360  
Qy 361 TCTGCATCTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420  
Db 361 TCTGCATCTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420

QY 421 CAGAAATCAGCTCCATTGCTGAACTGAGACAGAACTTATGTCCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTCCATTGCTGAACTGAGACAGAACTTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTTTCTCTTAACTCTGCTGAGGTCATTCTGAGTGACATGAGGACTCC 540  
DB 481 ATGCACCTACTCTTTTCTCTTAACTCTGCTGAGGTCATTCTGAGTGACATGAGGACTCC 540  
QY 541 GCACAGAGCTTCAATACCTCTTCAAGCTTTTATCTTCAAGCGGATGAGCGGAATA 600  
DB 541 GCACAGAGCTTCAATACCTCTTCAAGCTTTTATCTTCAAGCGGATGAGCGGAATA 600  
QY 601 GTTATATTCAGCTTCAAGCCAAATCCAGTACGACACACATTTGGAGCGAGGCTTACA 660  
DB 601 GTTATATTCAGCTTCAAGCCAAATCCAGTACGACACACATTTGGAGCGAGGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTTAAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAGCG 720  
DB 661 AATTTGAGAGATCATCTCTTAAAGCAAAATGCTTATCTGCAAAATGAGAAATTCACAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGAGAAATGATGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGAATTTAACTACAACTCTTCTCTCGGTGATGATGCTTTGGATTTGT 840  
DB 781 TCTGGTGGAATTTAACTACAACTCTTCTCTCGGTGATGATGCTTTGGATTTGT 840  
QY 841 TGTGCACTGTTGCTACAGCTGAGGAGATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCACTGTTGCTACAGCTGAGGAGATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960  
QY 961 GTTGTGATCTTAACTGAAGATCATGAGAGAGAGGCTCTACCTTACAAAGTGAAT 1020  
DB 961 GTTGTGATCTTAACTGAAGATCATGAGAGAGAGGCTCTACCTTACAAAGTGAAT 1020  
QY 1021 CTGTCTCATCTTGAATTTAAGCTTTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
DB 1021 CTGTCTCATCTTGAATTTAAGCTTTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAAGTGTTCATTTGGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAAGTGTTCATTTGGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 142

ADD37049

ID ADD37049 standard; cDNA; 1174 BP.

XX AC ADD37049;

XX AC ADD37049;

DT 15-JAN-2004 (first entry)

XX DE Human secreted/transmembrane PRO polypeptide cDNA #4.

XX KW ss; gene; human; secreted protein; transmembrane protein;  
XX KW cardiovascular disorder; endothelial disorder; angiogenic disorder;  
XX KW myocardial infarction; cardiac hypertrophy; trauma; cancer;  
XX KW age-related macular degeneration; angiogenesis;  
XX KW endothelial cell apoptosis; smooth muscle cell growth;  
XX KW endothelial cell tube formation.

XX OS Homo sapiens.

XX

US2003105012-A1.  
05-JUN-2003.  
16-AUG-2002; 2002US-00223088.  
15-SEP-2000; 2000US-0232887P.  
20-JUN-2001; 2001WO-US019692.  
09-JUL-2001; 2001WO-US021735.  
20-FEB-2002; 2002US-00081056.  
(GETH ) GENENTECH INC.  
Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;  
Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;  
Watanabe CK, Williams PM, Wood WI, Ye W;  
WPI: 2003-829354/77.  
P-PSDB; ADD37050.  
New isolated nucleic acids encoding a secreted and transmembrane  
polypeptide for treating a cardiovascular, endothelial, or angiogenic  
disorder in a mammal, such as cancer or age-related macular degeneration.  
Claim 2; SEQ ID NO 7; 492pp; English.  
The invention relates to an isolated nucleic acid encoding a secreted and  
transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded  
by the nucleic acid, or an agonist or antagonist, is used to treat a  
cardiovascular, endothelial, or angiogenic disorder in a mammal,  
preferably a human. The human may have suffered a myocardial infarction  
or has cardiac hypertrophy, trauma, a cancer, or age-related macular  
degeneration. The cardiac hypertrophy is characterised by the presence of  
an elevated level of PGR-2 alpha. A PRO polypeptide, given in the  
specification, or an agonist is used to inhibit or stimulate endothelial  
cell growth in a mammal. PRO21 or an agonist is used to induce cardiac  
hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.  
PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO  
polypeptide, given in the specification, or an agonist is used to  
stimulate or inhibit smooth muscle cell growth, or to induce endothelial  
cell tube formation. The present sequence represents a cDNA encoding a  
PRO polypeptide of the invention.

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAACACGACCAAGCTGAGCTGTGACAGAG 60

DB 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAACACGACCAAGCTGAGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCCGAGAGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120

DB 61 GGGAAACAAGATGGCGGCGCCGAGAGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCCGAGAGTTCCGGGACCGCTTCGGCTGAGCA 180

DB 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCCGAGAGTTCCGGGACCGCTTCGGCTGAGCA 180

QY 181 TTTGACTCGTCTTGGGTGATACGCGCTTTGCCACCGGGCTCTGAGTTGACCTACCC 240

DB 181 TTTGACTCGTCTTGGGTGATACGCGCTTTGCCACCGGGCTCTGAGTTGACCTACCC 240

QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACCATGTACAGAGGTTGAGGCTTTT 300

DB 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACCATGTACAGAGGTTGAGGCTTTT 300

QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTCACCTAAATCGAACTAAATCGAATGTGAA 360

DB 301 TCAATTTGTCAGTTTGTGGATGATGGAATTCACCTAAATCGAATGTGAA 360



Db 1 CGGACGCGTGGGGAACCCCTCCGAGAAACAGCAACAGCTGAGTCTGTGACAGAG 60  
Qy 61 GGGAAACAGATGGCGGCGCGGAGGAGCCTCTGGGTGAGGAGCCCACTGGGCGCTCCCG 120  
Db 61 GGGAAACAGATGGCGGCGCGGAGGAGCCTCTGGGTGAGGAGCCCACTGGGCGCTCCCG 120  
Qy 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGAGCCGCTTGGCTGAGCA 180  
Db 121 CGGCTGCTGCTGCTGACCATGGCTTGGCGGAGGTTGGGAGCCGCTTGGCTGAGCA 180  
Qy 181 TTGTACTGGTCTTGGGTGATACGGCGTCTTGGCCACCGGCGCTCTCAGTTGACCTACCC 240  
Db 181 TTGTACTGGTCTTGGGTGATACGGCGTCTTGGCCACCGGCGCTCTCAGTTGACCTACCC 240  
Qy 241 TTGCAACCTACCTTAAGAGAGAGTGTACCATGTCTGAGAGGTTCAGGCTGTTT 300  
Db 241 TTGCAACCTACCTTAAGAGAGAGTGTACCATGTCTGAGAGGTTCAGGCTGTTT 300  
Qy 301 TCAATTTGTGCTGATGATGGAATTCAGCTTAATCAATCAATGGAATGGAATGGA 360  
Db 301 TCAATTTGTGCTGATGATGGAATTCAGCTTAATCAATGGAATGGAATGGA 360  
Qy 361 TCTGATGATGAGAGCATATTCCTGATGAGCAATATGCTTGGCATCTTGGTTC 420  
Db 361 TCTGATGATGAGAGCATATTCCTGATGAGCAATATGCTTGGCATCTTGGTTC 420  
Qy 421 CAGAATCAGCTGCATTCGCTGAACTGAGACAAAGCAAACTTATGTCCCTGATGCCAAA 480  
Db 421 CAGAATCAGCTGCATTCGCTGAACTGAGACAAAGCAAACTTATGTCCCTGATGCCAAA 480  
Qy 481 ATGACCTACTCTTCTCTAACTCTGGTGGAGTCAATCTGGAGTGACATGAGACTCC 540  
Db 481 ATGACCTACTCTTCTCTAACTCTGGTGGAGTCAATCTGGAGTGACATGAGACTCC 540  
Qy 541 GCACAGCTTCTATACCTCTTCAGGACTTTTATCTCAAGCGATGACGGAATAA 600  
Db 541 GCACAGCTTCTATACCTCTTCAGGACTTTTATCTCAAGCGATGACGGAATAA 600  
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660  
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660  
Qy 661 AATTTGAGAGATCATCTCTAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
Db 661 AATTTGAGAGATCATCTCTAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720  
Qy 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC 780  
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC 780  
Qy 781 TCTGGGTGGATTTTAACTACACTCTTGTCTCTGCTGATGATGATGCTTGGATTTGT 840  
Db 781 TCTGGGTGGATTTTAACTACACTCTTGTCTCTGCTGATGATGATGCTTGGATTTGT 840  
Qy 841 TGTGCAACTGTTGCTACAGCTGTGAGAGCATATGTTTCCCTCTGAGAAGCTGAGTATCTAT 900  
Db 841 TGTGCAACTGTTGCTACAGCTGTGAGAGCATATGTTTCCCTCTGAGAAGCTGAGTATCTAT 900  
Qy 901 GGTGACTTGGATTTTATGATGAGAAAGCTTAACAGATATCCAGCTTCTCTCTGTTG 960  
Db 901 GGTGACTTGGATTTTATGATGAGAAAGCTTAACAGATATCCAGCTTCTCTCTGTTG 960  
Qy 961 GTTGTAGATCTAAACTGAAATCATGAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
Db 961 GTTGTAGATCTAAACTGAAATCATGAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
Qy 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080  
Db 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080  
Qy 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATTCGATATAGGCTTTAAGAAATCA 1140

Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATTCGATATAGGCTTTAAGAAATCA 1140  
Qy 1141 CTATATAATGCAATTAAGTTACTCAAACTGTG 1174  
Db 1141 CTATATAATGCAATTAAGTTACTCAAACTGTG 1174  
RESULT 144  
ADD02472  
ID ADD02472 standard; cDNA; 1174 BP.  
XX  
AC ADD02472;  
DT 15-JAN-2004 (first entry)  
XX Human PRO polynucleotide #136.  
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
OS  
XX  
XX US2003203431-A1.  
XX 30-OCT-2003.  
XX  
XX 24-APR-2002; 2002US-00131820.  
XX 28-OCT-1998; 98US-0106030P.  
PR 01-SEP-1993; 99MO-US020111.  
PR 18-OCT-1993; 99US-00403297.  
PR 18-OCT-1993; 99US-00403297.  
PR 18-FEB-2000; 2000MO-US004342.  
PR 24-AUG-2000; 2000MO-US023328.  
PR 01-DEC-2000; 2000MO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-875638/81.  
DR P-PSDB; ADD02473.  
XX  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PRO4978, useful in molecular biology, chromosome and gene mapping, in  
generating antisense RNA and DNA, and in gene therapy.  
XX  
XX Claim 2; Fig 271; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTCTGTGACAG 60  
DB 1 CGGACGGGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTCTGTGACAG 60  
QY 61 GGGAAACAGATGGCGGCGCGGAGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
DB 61 GGGAAACAGATGGCGGCGCGGAGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCG 120  
QY 121 CCGTGCTGCTGTGACATGCGCTTCGGCGGAGGTTCCGGGACCGCTTCGCTGAAGCA 180  
DB 121 CCGTGCTGCTGTGACATGCGCTTCGGCGGAGGTTCCGGGACCGCTTCGCTGAAGCA 180  
QY 181 TTTGACTCGGTCTTGGGTGATACGGCTCTTGGCACCGGSCCTGTGAGTGACCTACCC 240  
DB 181 TTTGACTCGGTCTTGGGTGATACGGCTCTTGGCACCGGSCCTGTGAGTGACCTACCC 240  
QY 241 TTGCACACCTACCTTAGGAGAGGAGTTGATGCGATGTGAGAGAGTTGCGAGGCTGTT 300  
DB 241 TTGCACACCTACCTTAGGAGAGGAGTTGATGCGATGTGAGAGAGTTGCGAGGCTGTT 300  
QY 301 TCAATTTGTCAAGTTGTGGATGATGGAATTAAGCTTAATCGAACTAAATGGAATGTGA 360  
DB 301 TCAATTTGTCAAGTTGTGGATGATGGAATTAAGCTTAATCGAACTAAATGGAATGTGA 360  
QY 361 TCTGATGTACAGAGCATATTCGAATCTGATGAGCATATGCTTGCATCTTGGTTGC 420  
DB 361 TCTGATGTACAGAGCATATTCGAATCTGATGAGCATATGCTTGCATCTTGGTTGC 420  
QY 421 CAGAACTAGCTGCCATTCGCTGAATGAGACAGAACTTATGTCCTGTGATGCCAAA 480  
DB 421 CAGAACTAGCTGCCATTCGCTGAATGAGACAGAACTTATGTCCTGTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTTCTTAACTCTGCTGAGGTCATCTTGGAGTGACATGAGTCC 540  
DB 481 ATGCACCTACTCTTCTTCTTAACTCTGCTGAGGTCATCTTGGAGTGACATGAGTCC 540  
QY 541 GCACAGCTTTCATACCTCTTCTGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGCTTTCATACCTCTTCTGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATTTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCTACA 660  
DB 601 GTTATTTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCTACA 660  
QY 661 AATTTGAGAGATCATCTTGAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720  
DB 661 AATTTGAGAGATCATCTTGAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTAGTCTTTTAAAGATGCTCTCTTAAAC 780  
DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTAGTCTTTTAAAGATGCTCTCTTAAAC 780  
QY 781 TCTGGGTGGATTTTAACTACTCAACTCTTGTCTCGTGATGCTATTGCTTTGGATTGT 840  
DB 781 TCTGGGTGGATTTTAACTACTCAACTCTTGTCTCGTGATGCTATTGCTTTGGATTGT 840  
QY 841 TGTGCAACTTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAACAGATATCCAGCTTCTTCTTTG 960  
DB 901 GGTGACTTGGAGTTTATGATGAACAAAGCTTAACAGATATCCAGCTTCTTCTTTG 960  
QY 961 GTTGTAGATCTTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACACTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140  
DB 1081 AATTCACACTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174  
DB 1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174  
RESULT 145  
ADD01905  
ID ADD01906 standard; cDNA; 1174 BP.  
XX AC ADD01906;  
XX DT 15-JAN-2004 (first entry)  
XX DE Human PRO polynucleotide #136.  
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; PFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX OS Homo sapiens.  
XX PN US2003203430-A1.  
XX PD 30-OCT-2003.  
XX PF 23-APR-2002; 2002US-00128685.  
XX PR 11-AUG-1998; 98US-0096143P.  
XX PR 02-JUN-1999; 99WO-US012252.  
XX PR 30-MAR-2000; 2000US-00380137.  
XX PR 30-MAR-2000; 2000WO-US008439.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX BK Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;  
PI

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI; 2003-875637/81.

DR P-PSDB; ADD01907.

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
 PRO4978, useful in molecular biology, chromosome and gene mapping, in  
 generating antisense RNA and DNA, and in gene therapy.

XX Claim 2; Fig 271; 637pp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear uricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems.  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

DB 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

QY 61 GGGACACAGATGCGCGCGCGGAGGGAGCCTCGGGTGAGGCCCACTGGGGCTCCCG 120

DB 61 GGGACACAGATGCGCGCGCGGAGGGAGCCTCGGGTGAGGCCCACTGGGGCTCCCG 120

QY 121 CGCGTCTGCTGCTGACCATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA 180

DB 121 CGCGTCTGCTGCTGACCATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA 180

QY 181 TTGTGACTCGGCTTGGGTGATACGGGCTTTGGCCACCGGGCTGTCAGTTGACCTACCCC 240

DB 181 TTGTGACTCGGCTTGGGTGATACGGGCTTTGGCCACCGGGCTGTCAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCTAAGGAGAGGAGTTGTACGCATGTCHAGAGGTTGCGAGCTGTTT 300

DB 241 TTGCACACCTACCTAAGGAGAGGAGTTGTACGCATGTCHAGAGGTTGCGAGCTGTTT 300

QY 301 TCAATTGTGCTGTTGTGATGATGGAATTGACTTAATCGAACTAAATGGATGTGAA 360

DB 301 TCAATTGTGCTGTTGTGATGATGGAATTGACTTAATCGAACTAAATGGATGTGAA 360

QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCCATCTTGTTGC 420

DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCCATCTTGTTGC 420

QY 421 CAGAACTGAGCTGCCATTCGCTGAACTGAGACAGACAACTTATGTCCTGATGCCAAA 480

DB 421 CAGAACTGAGCTGCCATTCGCTGAACTGAGACAGACAACTTATGTCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTTCCTTAACTCTGCTGAGCTCATCTGGAGTGACATGATGGACTCC 540

DB 481 ATGCACCTACTCTTTTCCTTAACTCTGCTGAGCTCATCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATPAACCTCTTCATGCACTTTTATCTCAAGCCGATGACGGAAAAATA 600

DB 541 GCACAGAGCTTCATPAACCTCTTCATGCACTTTTATCTTCACAGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCCAGTCTAAGCCAGAAAATCCAGTACGACACCACTTTGGAGCAGGAGCTACA 660

DB 601 GTTATATTCCAGTCTAAGCCAGAAAATCCAGTACGACACCACTTTGGAGCAGGAGCTACA 660

QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720

DB 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATGCCCTCTCTTTAAC 780

DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATGCCCTCTCTTTAAC 780

QY 781 TCTGGGTGGATTTTAACTACAACCTTTGCTCTCGGTGATGTTGCTTTGGATTTGT 840

DB 781 TCTGGGTGGATTTTAACTACAACCTTTGCTCTCGGTGATGTTGCTTTGGATTTGT 840

QY 841 TGTCCACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

DB 841 TGTCCACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960

DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960

QY 961 GTTCTGATGCTTAAACTGAGATCATGAGAGAGCGGCTCTACTACAAAGTGAAT 1020

DB 961 GTTCTGATGCTTAAACTGAGATCATGAGAGAGCGGCTCTACTACAAAGTGAAT 1020

QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATAGCATCTAA 1080

DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATAGCATCTAA 1080

QY 1081 AATTCCTCTCTATAGAGCTTTTAAAGTGTTCATTGGATATAGCCCTTAAGAATCA 1140

DB 1081 AATTCCTCTCTATAGAGCTTTTAAAGTGTTCATTGGATATAGCCCTTAAGAATCA 1140

QY 1141 CTATAAATGCAATAAAGTTACTTCAAACTGTG 1174

DB 1141 CTATAAATGCAATAAAGTTACTTCAAACTGTG 1174

RESULT 146

ADD54088

ID ADD54088 standard; cDNA; 1174 BP.

XX AC ADD54088;

XX DT 15-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;



KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX Homo sapiens.  
FN US2003203432-A1.  
XX 30-OCT-2003.  
XX 10-MAY-2002; 2002US-00142886.  
XX 05-JUN-2000; 2000US-0209832P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-875639/81.  
DR P-PSDB; ADD54089.  
XX  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
XX Claim 2; SEQ ID NO 271; 637pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear utricular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting  
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (II) and (I) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGTGGGGAAACCCCTTCGAGAAACACGACAGCTGAGCTGTCGACAG 60  
DB 1 CGGACGGTGGGGAAACCCCTTCGAGAAACACGACAGCTGAGCTGTCGACAG 60  
QY 61 GGGAAACAAGATGGCGGCGCCGAGGGAGGCTCTGGGTGAGGACCAACTGGGGCTCCCG 120

DB GGGAAACAAGATGGCGGCGCCGAGGGAGGCTCTGGGTGAGGACCAACTGGGGCTCCCG 120  
QY CCCTCTCTCTGCTGACCATGCGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGAAGCA 180  
DB CCCTCTCTCTGCTGACCATGCGCTTGGCGGAGGTTCGGGACCGCTTCGGCTGAAGCA 180  
QY TTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCCTGTCACTTACCC 240  
DB TTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCCTGTCACTTACCC 240  
QY TTGCACACCTTACCCCTAAGGAGGAGTTGTACGATGTCAAGAGGTTCAGAGGTGTTT 300  
DB TTGCACACCTTACCCCTAAGGAGGAGTTGTACGATGTCAAGAGGTTCAGAGGTGTTT 300  
QY TCAATTTGTGAGTTTGTGATGATGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360  
DB TCAATTTGTGAGTTTGTGATGATGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360  
QY TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATTCCTGTTGC 420  
DB TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATTCCTGTTGC 420  
QY CAGAACTCAGCTGCCATTTCGTGAATGTGACACAGAACCACTTATGCTCCTGATGCAAAA 480  
DB CAGAACTCAGCTGCCATTTCGTGAATGTGACACAGAACCACTTATGCTCCTGATGCAAAA 480  
QY ATGCACCTACTCTTCTTAACTCTGAGGTGAGTCACTTCTGAGTGACATGATGAGCTCC 540  
DB ATGCACCTACTCTTCTTAACTCTGAGGTGAGTCACTTCTGAGTGACATGATGAGCTCC 540  
QY GCACAGAGCTTCATACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGCAAAAATA 600  
DB GCACAGAGCTTCATACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGCAAAAATA 600  
QY GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACCATTTGGAGCAGGACTACA 660  
DB GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACCATTTGGAGCAGGACTACA 660  
QY AATTGAGAGATCANTCTCTAGCAAAATGCTCTATCTGCAATAGAGAAATTCACAGGG 720  
DB AATTGAGAGATCANTCTCTAGCAAAATGCTCTATCTGCAATAGAGAAATTCACAGGG 720  
QY CACAGGAATTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB CACAGGAATTTCTTGAAGATGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY TCTGGGTGGATTTTAACTACACTCTTGTCTCTCTCGGTGATGCTTCTGTTGGATTTGT 840  
DB TCTGGGTGGATTTTAACTACACTCTTGTCTCTCTCGGTGATGCTTCTGTTGGATTTGT 840  
QY TGTGCAACTCTTCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
DB TGTGCAACTCTTCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
QY GGTGACTTGGAGTTTATGATGAACAAAGCTTAACAGATATCCAGCTTCTTCTTGTG 960  
DB GGTGACTTGGAGTTTATGATGAACAAAGCTTAACAGATATCCAGCTTCTTCTTGTG 960  
QY GTTGTAGATCTAAACTGAAAGTCAATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
DB GTTGTAGATCTAAACTGAAAGTCAATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
QY CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
DB CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
QY AATTTCACCTCTCATAGAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140  
DB AATTTCACCTCTCATAGAGCTTTTAAAGTGTTCATTCGATATAGGCTTAAAGAAATCA 1140  
QY CTATAAATCAAAATAAAGTTACTCAAAATCTGTG 1174



Db 1141 CTATTAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 147  
ADE49363  
ID ADE49363 standard; cDNA; 1174 BP.  
XX ADE49363;  
AC ADE49363;  
XX 29-JAN-2004 (first entry)  
XX Human cDNA encoding secreted/transmembrane protein, PRO195.  
XX Human; ss; gene; secreted protein; transmembrane protein; PRO;  
KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;  
KW vulnery; auditory; tumour growth; retinal disorder;  
KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
XX Homo sapiens.  
XX US2003096744-A1.  
XX 22-MAY-2003.  
XX 28-JAN-2002; 2002US-00978187.  
XX 17-OCT-1997; 97US-0062250P.  
XX 03-NOV-1997; 97US-0064249P.  
XX 13-NOV-1997; 97US-0065311P.  
XX 21-NOV-1997; 97US-0066364P.  
XX 10-MAR-1998; 98US-0077450P.  
XX 11-MAR-1998; 98US-0077632P.  
XX 11-MAR-1998; 98US-0077641P.  
XX 11-MAR-1998; 98US-0077649P.  
XX 12-MAR-1998; 98US-0077791P.  
XX 13-MAR-1998; 98US-0078004P.  
XX 17-MAR-1998; 98US-0080402P.  
XX 20-MAR-1998; 98US-0078886P.  
XX 20-MAR-1998; 98US-0078910P.  
XX 20-MAR-1998; 98US-0078936P.  
XX 20-MAR-1998; 98US-0078939P.  
XX 25-MAR-1998; 98US-0079294P.  
XX 26-MAR-1998; 98US-0079566P.  
XX 27-MAR-1998; 98US-0079663P.  
XX 27-MAR-1998; 98US-0079664P.  
XX 27-MAR-1998; 98US-0079689P.  
XX 27-MAR-1998; 98US-0079728P.  
XX 27-MAR-1998; 98US-0079786P.  
XX 30-MAR-1998; 98US-0079920P.  
XX 30-MAR-1998; 98US-0079923P.  
XX 31-MAR-1998; 98US-0080105P.  
XX 31-MAR-1998; 98US-0080165P.  
XX 31-MAR-1998; 98US-0080194P.  
XX 01-APR-1998; 98US-0080327P.  
XX 01-APR-1998; 98US-0080328P.  
XX 01-APR-1998; 98US-0080333P.  
XX 01-APR-1998; 98US-0080334P.  
XX 08-APR-1998; 98US-0081049P.  
XX 08-APR-1998; 98US-0081070P.  
XX 08-APR-1998; 98US-0081071P.  
XX 09-APR-1998; 98US-0081195P.  
XX 09-APR-1998; 98US-0081203P.  
XX 09-APR-1998; 98US-0081229P.  
XX 15-APR-1998; 98US-0081817P.  
XX 15-APR-1998; 98US-0081819P.  
XX 15-APR-1998; 98US-0081838P.  
XX 15-APR-1998; 98US-0081952P.  
XX 15-APR-1998; 98US-0081955P.  
XX 21-APR-1998; 98US-0082568P.  
XX 21-APR-1998; 98US-0082569P.  
XX 22-APR-1998; 98US-0082700P.  
XX 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 22-APR-1998; 98US-0082804P.  
PR 23-APR-1998; 98US-0082796P.  
PR 27-APR-1998; 98US-0083336P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083392P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083500P.  
PR 29-APR-1998; 98US-0083545P.  
PR 29-APR-1998; 98US-0083554P.  
PR 29-APR-1998; 98US-0083558P.  
PR 29-APR-1998; 98US-0083559P.  
PR 30-APR-1998; 98US-0083742P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 06-MAY-1998; 98US-0084416P.  
PR 07-MAY-1998; 98US-0084416P.  
PR 07-MAY-1998; 98US-0084598P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 13-MAY-1998; 98US-0085339P.  
PR 15-MAY-1998; 98US-0085573P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085589P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 11-SEP-1998; 98US-0100038P.  
PR 07-OCT-1998; 98US-00168978.  
PR 07-OCT-1998; 98WO-US021141.  
PR 02-NOV-1998; 98US-00184216.  
PR 06-NOV-1998; 98US-00187168.  
PR 20-NOV-1998; 98US-01093304P.  
PR 20-NOV-1998; 98WO-US024855.  
PR 07-DEC-1998; 98US-00202054.  
PR 22-DEC-1998; 98US-00218517.  
PR 23-DEC-1998; 98US-0113296P.  
PR 23-DEC-1998; 98US-0113621P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 05-MAR-1999; 99US-00254455.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99US-00265686.  
PR 10-MAR-1999; 99WO-US005190.  
PR 12-MAR-1999; 99US-00267213.  
PR 12-MAR-1999; 99US-0123957P.  
PR 12-MAR-1999; 99US-0126773P.  
PR 12-APR-1999; 99US-00284231.  
PR 21-APR-1999; 99US-0130234P.  
PR 26-APR-1999; 99US-0131022P.  
PR 28-APR-1999; 99US-0131445P.  
PR 14-MAY-1999; 99US-00311832.

```
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 16-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034356.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
XX
PI (GETH ) GENENTECH INC.
Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACCGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGTGACAGAG 60
DB 1 CGGACCGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCGAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCGAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CGGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
```

RESULT 148

ADD92405  
ID ADD92405 standard; cDNA; 1174 BP.

AC ADD92405;

DT 29-JAN-2004 (first entry)

DE Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003199030-A1.

XX 23-OCT-2003.

XX 28-MAY-2002; 2002US-00156841.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2000; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerzitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;  
XX MPI; 2003-900159/82.  
DR P-PSDB; ADD92406.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 271; 636pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
XX from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1174; DB 9; Length 1174;  
XX Best Local Similarity 100.0%; Pred. NO. 0;  
XX Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
DB 1 CGGACGGCTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60  
QY 61 GGGAAACAGATGGCGGCCCGAAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGCGGCCCGAAGGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGACCATGGCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAGCA 180  
DB 121 CGGCTGCTGCTGACCATGGCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAGCA 180  
QY 181 TTGCACTCGGCTTTGGGTGATACGGCGCTCTTGCCACCGGGCTGTGAGTTGACTACCCC 240  
DB 181 TTGCACTCGGCTTTGGGTGATACGGCGCTCTTGCCACCGGGCTGTGAGTTGACTACCCC 240  
QY 241 TTGCACTACCTTACGAAAGAGGAGTTGATGCGCATGTGAGAGGTTGAGGCTGTTT 300  
DB 241 TTGCACTACCTTACGAAAGAGGAGTTGATGCGCATGTGAGAGGTTGAGGCTGTTT 300  
QY 301 TCAATTTGCTAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGA 360  
DB 301 TCAATTTGCTAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGA 360  
QY 361 TGTGATGTACAGAGCAATATCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTC 420  
DB 361 TGTGATGTACAGAGCAATATCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTC 420  
QY 421 CAGAAATGAGTCCCATTCGCTGAACTGAGCAACAGAACTTATGTCCTGATGCCAAAA 480  
DB 421 CAGAAATGAGTCCCATTCGCTGAACTGAGCAACAGAACTTATGTCCTGATGCCAAAA 480  
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATCTTGGAGTGCATGATGGACTCC 540  
DB 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATCTTGGAGTGCATGATGGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGACATTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCATGACATTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGGAGGCTTACA 660  
DB 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGGAGGCTTACA 660  
QY 661 AATTTGAGAGATCATCTTAAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGATCATCTTAAAGCAAAATGCTTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGAAATTTCTTGAAGATGGAAGAGTATGCTTTTAAAGATGCTCTCTTTAAC 780  
DB 721 CACAGAAATTTCTTGAAGATGGAAGAGTATGCTTTTAAAGATGCTCTCTTTAAC 780  
QY 781 TCTGGGTGATTTTAACTACCACTTCTCTCTCGGTGATGTTGTTGATTTGT 840  
DB 781 TCTGGGTGATTTTAACTACCACTTCTCTCTCGGTGATGTTGTTGATTTGT 840  
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900



PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931936.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-900165/82.  
DR P-PSDB; ADD91302.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 2; SEQ ID NO 271; 636pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. NO. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGGCTGGGGGAAACCTCCCGAGAAAACAGCAAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGGCTGGGGGAAACCTCCCGAGAAAACAGCAAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGGGGCGCGGAGGGAGCTCTGGGTGAGACCCCACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGGGGCGCGGAGGGAGCTCTGGGTGAGACCCCACTGGGGCTCCCG 120  
QY 121 CCGCTGCTGCTGTGACCAATGGCTTGGCGGAGGTTGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CCGCTGCTGCTGTGACCAATGGCTTGGCGGAGGTTGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTGTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCGCTGTGACGTGACCTACCCC 240

DB 181 TTGTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCGCTGTGACGTGACCTACCCC 240  
QY 241 TTGCACACCTTACCTTAAGGAAGAGAGAGTTGTACGCGATGTGCAGAGAGGTTGCGAGGCTGTTT 300  
DB 241 TTGCACACCTTACCTTAAGGAAGAGAGAGTTGTACGCGATGTGCAGAGAGGTTGCGAGGCTGTTT 300  
QY 301 TCAATTTGTGAGTTGTGAGATGGAATGACTTAAATCGAACTAAATTTGGAATGTGA 360  
DB 301 TCAATTTGTGAGTTGTGAGATGGAATGACTTAAATCGAACTAAATTTGGAATGTGA 360  
QY 361 TCTGCAATGACAGAGCATAATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
DB 361 TCTGCAATGACAGAGCATAATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420  
QY 421 CAGAAATCAGCTGGCATTCGGTGAACTGAGCAAGAACTATGTCCTCGATGCCAAA 480  
DB 421 CAGAAATCAGCTGGCATTCGGTGAACTGAGCAAGAACTATGTCCTCGATGCCAAA 480  
QY 481 ATGCACCTTACTCTTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540  
DB 481 ATGCACCTTACTCTTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCCTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCCTACA 660  
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATCTCTATCTGCAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAAATTTCTTGAAGTGGGAAGGAGGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAAATTTCTTGAAGTGGGAAGGAGGCTTTTAAAGATGCTCTCTCTCTTAAC 780  
QY 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960  
QY 961 GTTGTAGATCTAAATCTGAAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAATCTGAAGATCATGAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020  
QY 1021 CTTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCAA 1080  
DB 1021 CTTGTCTATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAAATAGACATCAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTTCATTTGATAGGCTTACGCTTGAAGATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTTCATTTGATAGGCTTACGCTTGAAGATCA 1140  
QY 1141 CTATAAATGCAATATAAAGTTACTCAAACTCTGTG 1174  
DB 1141 CTATAAATGCAATATAAAGTTACTCAAACTCTGTG 1174

RESULT 150  
ADE03915  
ID ADE03915 standard; cDNA; 1174 BP.  
XX  
AC ADE03915;

XX DT 29-JAN-2004 (first entry)  
XX DE Human PRO polynucleotide #136.  
XX KW Human; Gene; ss; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX OS Homo sapiens.  
XX FN US2003199057-A1.  
XX PD 23-OCT-2003.  
XX PF 15-APR-2002; 2002US-00123213.  
XX PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 28-AUG-1998; 98WO-US014552.  
PR 10-SEP-1998; 98WO-US017888.  
PR 14-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUN-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US020201.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurley AL, Sherwood S;  
Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900167/82.

P-PSDB; ADE03916.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
useful for treating pericyte-associated tumors, diabetes and various bone  
and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAAACCCCTCCGAGAAACACCAACAGCTGAGCTGTGTGACAGAG 50  
DB 1 CGGACGCTGGGGGAAACCCCTCCGAGAAACACCAACAGCTGAGCTGTGTGACAGAG 50  
QY 61 GGGAAACAGATGGGGGCGGCGGAGGAGCTTGGGTGAGAGCCCACTGGGGGCTCCCG 120  
DB 61 GGGAAACAGATGGGGGCGGCGGAGGAGCTTGGGTGAGAGCCCACTGGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGTGACCATGCGCTTGGCGGAGGTTGCGGGACCGCTTGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGTGACCATGCGCTTGGCGGAGGTTGCGGGACCGCTTGGCTGAAGCA 180  
QY 181 TTGACTCGGCTTGGGTGATACGGGCTTGGCCACCGGCGCTGTGAGTTGACTACCC 240  
DB 181 TTGACTCGGCTTGGGTGATACGGGCTTGGCCACCGGCGCTGTGAGTTGACTACCC 240  
QY 241 TTGCACACCTACCTAAGGAGAGAGTTGATGATGTCAGAGAGTTGACGGCTGTTT 300  
DB 241 TTGCACACCTACCTAAGGAGAGAGTTGATGATGTCAGAGAGTTGACGGCTGTTT 300  
QY 301 TCAATTTGTGATTTGGTGGATGATGGAATGCACTTAATCGAACTAAATTTGGAATGTGA 360  
DB 301 TCAATTTGTGATTTGGTGGATGATGGAATGCACTTAATCGAACTAAATTTGGAATGTGA 360  
QY 361 TCTGATGTCAGAGAGCATATCCCATCTGATGAGCAATATGCTTCCATCTTGTGTC 420  
DB 361 TCTGATGTCAGAGAGCATATCCCATCTGATGAGCAATATGCTTCCATCTTGTGTC 420  
QY 421 CAGAAATCAGCTGCCATTCGCTGAATCAGAGCAAGAACTATATGTCCTGATGCCAAA 480  
DB 421 CAGAAATCAGCTGCCATTCGCTGAATCAGAGCAAGAACTATATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTCTCACTCTGGTGAAGGTCATCTGGAGTGACATGATGACTCC 540  
DB 481 ATGCACCTACTCTTCTCTCACTCTGGTGAAGGTCATCTGGAGTGACATGATGACTCC 540  
QY 541 GCACAGAGCTTCATACCTCTTTCATGACTTTTATCTTCAAGCCGATGACGAAAAATA 600  
DB 541 GCACAGAGCTTCATACCTCTTTCATGACTTTTATCTTCAAGCCGATGACGAAAAATA 600

QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCAGCACCATTTGGAGCAGGAGCTTACA 660  
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCAGCACCATTTGGAGCAGGAGCTTACA 660  
QY 661 AATTTGAGAGAAATCATCTCTTAAGCAAAATGTCTTCTGCAATAGAGAAATTCACAAGCG 720  
DB 661 AATTTGAGAGAAATCATCTCTTAAGCAAAATGTCTTCTGCAATAGAGAAATTCACAAGCG 720  
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTGAAGATGCTCTCTTAAAC 780  
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTGAAGATGCTCTCTTAAAC 780  
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTGCTCGGTGATGATTTGCTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTGCTCGGTGATGATTTGCTTGGATTTGT 840  
QY 841 TGTGCAACTCTTCTGACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATATCTAT 900  
DB 841 TGTGCAACTCTTCTGACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
QY 961 GTTGTATAGATCTTAAACTGAAGATCATGAAGAGCAGAGGCGCTCTACCTACAAAAGTGAAT 1020  
DB 961 GTTGTATAGATCTTAAACTGAAGATCATGAAGAGCAGAGGCGCTCTACCTACAAAAGTGAAT 1020  
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTAAAGACAAAGTGTATACACATCTAA 1080  
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTAAAGACAAAGTGTATACACATCTAA 1080  
QY 1081 AATTTCCACTCTCATAGAGCTTTTAAATAGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTTCCACTCTCATAGAGCTTTTAAATAGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAATTAAGTTACTCAAACTGTG 1174  
DB 1141 CTATAAATGCAATTAAGTTACTCAAACTGTG 1174  
RESULT 151  
ADE32212  
ID ADE32212 standard; cDNA; 1174 BP.  
XX AC ADE32212;  
XX DT 29-JAN-2004 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO195 cDNA.  
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW Cell proliferation stimulator; Cell differentiation stimulator;  
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
OS Homo sapiens.  
XX US2003194765-A1.  
PN 16-OCT-2003.  
PD 09-MAY-2002; 2002US-00142889.  
XX 03-MAR-2000; 2000US-0187202P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
PA (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 FI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI: 2003-899784/82.  
 DR P-PSDB; ADE32213.  
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
 PT useful for treating pericyte-associated tumors, diabetes and various bone  
 PT and/or cartilage disorders, e.g. arthritis.  
 XX Claim 2; SEQ ID NO 271; 636pp; English.  
 XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
 SQ  
 Query Match 100.0%; Score 1174; DB 9; Length 1174;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CGGACGGTGGGGAAACCCCTCCGAGAAACACGACACAGCTGAGCTGCTGTGACAGAG 60  
 DB 1 CGGACGGTGGGGAAACCCCTCCGAGAAACACGACACAGCTGAGCTGCTGTGACAGAG 60  
 QY 61 GGGAAACAGATGGCGGCGCGGAGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
 DB 61 GGGAAACAGATGGCGGCGCGGAGGGAGGCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120  
 QY 121 CGGCTGCTGCTGTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
 DB 121 CGGCTGCTGCTGTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180  
 QY 181 TTGACTCGGTCTGGGTGTATACCGGCTCTTGGCCACCGGCGCTGTGAGTTGACCTACCC 240  
 DB 181 TTGACTCGGTCTGGGTGTATACCGGCTCTTGGCCACCGGCGCTGTGAGTTGACCTACCC 240  
 QY 241 TTGCACCTACCTAAGGAAGAGAGTTGATGCATGTGACAGAGGTTGACAGGCTGTTT 300  
 DB 241 TTGCACCTACCTAAGGAAGAGAGTTGATGCATGTGACAGAGGTTGACAGGCTGTTT 300  
 QY 301 TCAATTTCTGAGTTTGGATGGATGAGTGAATGACTTAATCGAATAATTGGAAATGGA 360  
 DB 301 TCAATTTCTGAGTTTGGATGGATGAGTGAATGACTTAATCGAATAATTGGAAATGGA 360

QY 361 TCTGCAATGTACAGAGAGCATATTCCCAATCTGTATGAGCAATATGCTTGCATCTTGGTTGC 420  
 DB 361 TCTGCAATGTACAGAGAGCATATTCCCAATCTGTATGAGCAATATGCTTGCATCTTGGTTGC 420  
 QY 421 CAGAATCAGCTGCCATTGCTGCACTGAGACAGAAACAACTTATGTCCTGATGCAAAA 480  
 DB 421 CAGAATCAGCTGCCATTGCTGCACTGAGACAGAAACAACTTATGTCCTGATGCAAAA 480  
 QY 481 ATGCACTACTCTTTCTCTTAATCTCTGAGAGGTCAATCTGAGAGTGACATGATGACTCC 540  
 DB 481 ATGCACTACTCTTTCTCTTAATCTCTGAGAGGTCAATCTGAGAGTGACATGATGACTCC 540  
 QY 541 GCACAGAGCTTCATACACCTCTTCTGAGACTTTTATCTTCAAGCCGATGACCGAAATA 600  
 DB 541 GCACAGAGCTTCATACACCTCTTCTGAGACTTTTATCTTCAAGCCGATGACCGAAATA 600  
 QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCAGCACCACTTTGGAGAGGAGCTTACA 660  
 DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTAGCAGCACCACTTTGGAGAGGAGCTTACA 660  
 QY 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
 DB 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720  
 QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC 780  
 DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTTTAAAGATGCTCTCTCTTAAC 780  
 QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCTGCTGGTGTATGCTTTGGATTGT 840  
 DB 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCTGCTGGTGTATGCTTTGGATTGT 840  
 QY 841 TGTGCAACTCTTCTACAGCTGTGAGAGCAGTAGTGTTCCTCTGAGAGCTGAGTATCTAT 900  
 DB 841 TGTGCAACTCTTCTACAGCTGTGAGAGCAGTAGTGTTCCTCTGAGAGCTGAGTATCTAT 900  
 QY 901 GGTGACTTGAGTTTATGATGAACAAAGAGCTTAACAGATATCCAGCTTCTCTTGTG 960  
 DB 901 GGTGACTTGAGTTTATGATGAACAAAGAGCTTAACAGATATCCAGCTTCTCTTGTG 960  
 QY 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
 DB 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020  
 QY 1021 CTGCTCATTTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
 DB 1021 CTGCTCATTTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080  
 QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
 DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140  
 QY 1141 CTATAAATGCAATTAAGTTACTCAAAATCTGTG 1174  
 DB 1141 CTATAAATGCAATTAAGTTACTCAAAATCTGTG 1174  
 RESULT 152  
 ADE22144  
 ID ADE22144 standard; cDNA; 1174 BP.  
 XX AC ADE22144;  
 XX DT 29-JAN-2004 (first entry)  
 XX DE cDNA encoding human PRO polypeptide #136.  
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;



KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
XX immune system cell infiltration.  
XX Homo sapiens.  
OS US2003199056-A1.  
XX 23-OCT-2003.  
XX 15-APR-2002; 2002US-00123212.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 98WO-US008615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 05-OCT-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 30-NOV-1999; 98WO-US028409.  
PR 01-DEC-1999; 98WO-US028301.  
PR 01-DEC-1999; 98WO-US028634.  
PR 02-DEC-1999; 98WO-US028551.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 22-DEC-1999; 98WO-US030720.  
PR 30-DEC-1999; 98WO-US031243.  
PR 30-DEC-1999; 98WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004934.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005061.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US005884.  
PR 20-MAR-2000; 2000WO-US006887.  
PR 21-MAR-2000; 2000WO-US007372.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00815744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001US-00887879.  
PR 29-JUN-2001; 2001WO-US020116.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI, 2003-900166/82.  
XX P-FSDB; ADE22145.  
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
XX useful for treating pericyte-associated tumors, diabetes and various bone  
XX and/or cartilage disorders, e.g. arthritis.  
XX Claim 2; Fig 271; 638pp; English.  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumors, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAACCCCTCCGAGAAAACGACCAAGCTGAGCTCTGTGACAGAG 60  
DB 1 CGGACGCGTGGGGAACCCCTCCGAGAAAACGACCAAGCTGAGCTCTGTGACAGAG 60  
QY 61 GGGACACAGATGGCGGCGCGGACGAGGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCG 120  
DB 61 GGGACACAGATGGCGGCGCGGACGAGGAGCTCTGGGTGAGGACCCCAACTGGGGCTCCG 120  
QY 121 CCGTGTCTGCTGCTGACCATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGTGAAGCA 180  
DB 121 CCGTGTCTGCTGCTGACCATGCGCTTGGCGGAGGTTTCGGGACCGCTTCGGTGAAGCA 180  
QY 181 TTTGACTCGGTTGGGTGATACGGCTCTTGGCAACGGGCTGTGACGTTGACCTACCC 240  
DB 181 TTTGACTCGGTTGGGTGATACGGCTCTTGGCAACGGGCTGTGACGTTGACCTACCC 240  
QY 241 TTGCACACTACCTAAGGAGAGAGCTGTGACGATGTGACGAGAGTTGCGGCTGTT 300  
DB 241 TTGCACACTACCTAAGGAGAGAGCTGTGACGATGTGACGAGAGTTGCGGCTGTT 300  
QY 301 TCAATTTGTCAGTTTGGGATGATGGAATTGACTTTAAATCGAACTAAATGGAATGTGAA 360  
DB 301 TCAATTTGTCAGTTTGGGATGATGGAATTGACTTTAAATCGAACTAAATGGAATGTGAA 360  
QY 361 TCTCGATGTACAGAGCATATTCCTATCTGATGAGCAATATCTTGCATCTTGGTTGC 420  
DB 361 TCTCGATGTACAGAGCATATTCCTATCTGATGAGCAATATCTTGCATCTTGGTTGC 420  
QY 421 CAGAACTAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCTGATGCCAAA 480  
DB 421 CAGAACTAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCTGATGCCAAA 480  
QY 481 ATGCACCTACTCTTCTTCACTCTGCTGAGGTCATCTTGGAGTGACATGAGTCTCC 540  
DB 481 ATGCACCTACTCTTCTTCACTCTGCTGAGGTCATCTTGGAGTGACATGAGTCTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATA 600  
QY 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCACACATTTGAGCAGGAGCTTCA 660  
DB 601 GTTATATTCAGTCTAAGCAGAAATCCAGTACGCACACATTTGAGCAGGAGCTTCA 660  
QY 661 AATTTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720  
DB 661 AATTTGAGAGATCATCTTAAGCAAAATGCTTATCTGCAATGAGAAATTCACAGCG 720  
QY 721 CACAGAAATTTCTTGAAGATGGAAGTGAAGTGGCTTTTGAAGTGCCTCTCTCTAAC 780  
DB 721 CACAGAAATTTCTTGAAGATGGAAGTGAAGTGGCTTTTGAAGTGCCTCTCTCTAAC 780

QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840  
QY 841 TGTGCAACTGTTTCTACACCTGTGGAGCAGTATGTTCCCTCTGGAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTGTTTCTACACCTGTGGAGCAGTATGTTCCCTCTGGAAGCTGAGTATCTAT 900  
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG 960  
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGACAGGCGCTCTACCTACAAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGACAGGCGCTCTACCTACAAAAGTGAAT 1020  
QY 1021 CTGTCTCATCTCAAAATTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
DB 1021 CTGTCTCATCTCAAAATTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080  
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174

RESULT 153  
ADD79368

ID ADD79368 standard; cDNA; 1174 BP.

XX ADD79368;

XX 29-JAN-2004 (first entry)

XX cDNA encoding human PRO polypeptide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

Homo sapiens.

US2003203428-A1.

XX 30-OCT-2003.

XX 22-APR-2002; 2002US-00127852.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-875635/81.

XX P-PSDB; ADD79369.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
XX tumors.

PS Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.08; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.08; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CGGACGCTGGGGGAAACCCCTCCGAGAAACACGACAAAGCTGAGCTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCCCTCCGAGAAACACGACAAAGCTGAGCTGTGACAGAG 60  
QY 61 GGGACACAGATGGCGGCGCCGAGGGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
DB 61 GGGACACAGATGGCGGCGCCGAGGGGAGCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGACCATGGCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
DB 121 CGGCTGCTGCTGACCATGGCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180  
QY 181 TTGTAGCTGCTTGGGTGATACGGCTGTTCACCGGGCTGTGAGTTGACTACCC 240  
DB 181 TTGTAGCTGCTTGGGTGATACGGCTGTTCACCGGGCTGTGAGTTGACTACCC 240  
QY 241 TTGCACACTACCCCTAAGAGAGAGAGTTGATCATGTGTGAGAGGTTTCAGGCTGTTT 300  
DB 241 TTGCACACTACCCCTAAGAGAGAGAGTTGATCATGTGTGAGAGGTTTCAGGCTGTTT 300  
QY 301 TCAATTTGTGCTGTTGGTGTGATGGAATTCGCTTAATGCACTAAATGGAATGGA 360  
DB 301 TCAATTTGTGCTGTTGGTGTGATGGAATTCGCTTAATGCACTAAATGGAATGGA 360  
QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTCATGAGCAATATGCTGCCATCTTGGTTGC 420  
DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTCATGAGCAATATGCTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTCCCTGAACTGAGACAAAGAACAACTTATCTCCTGATGCAAAA 480  
DB 421 CAGAATCAGCTGCCATTCCCTGAACTGAGACAAAGAACAACTTATCTCCTGATGCAAAA 480  
QY 481 ATGCACCTACTCTTTCTCTTAATCTCTGGTGAGTCAATCTGGAGTGACATGATGACTCC 540  
DB 481 ATGCACCTACTCTTTCTCTTAATCTCTGGTGAGTCAATCTGGAGTGACATGATGACTCC 540  
QY 541 GCACAGAGCTTCATAACCTCTTCTATGAGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
DB 541 GCACAGAGCTTCATAACCTCTTCTATGAGACTTTTATCTTCAAGCCGATGACGGAATAA 600  
QY 601 GTTATATTCAGTCAAGCCGATGAGCAATCTTCAAGCCGATGAGCAATCTTCAAGCCGATGAGCA 660  
DB 601 GTTATATTCAGTCAAGCCGATGAGCAATCTTCAAGCCGATGAGCAATCTTCAAGCCGATGAGCA 660  
QY 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720  
DB 661 AATTGAGAGATCATCTCTTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720  
QY 721 CACAGGAAATTTCTTCAAGATGAGAGAGTGGTCTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAAATTTCTTCAAGATGAGAGAGTGGTCTTAAAGATGCTCTCTCTCTTAAC 780  
QY 781 TCTGGGTGGATTTAACTACAACCTCTTGTCTCTCGGTGATGCTATTGCTTTGGATTTGT 840  
DB 781 TCTGGGTGGATTTAACTACAACCTCTTGTCTCTCGGTGATGCTATTGCTTTGGATTTGT 840  
QY 841 TGTGCAACTTCTGCTACAGCTGTGGAGAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTTCTGCTACAGCTGTGGAGAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900  
QY 901 GGTGACITGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960  
DB 901 GGTGACITGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960  
QY 961 GTTGTAGATCTAAACTGAGATCATGAGAGAGAGGCGCTTACCTACAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAGATCATGAGAGAGAGGCGCTTACCTACAAAGTGAAT 1020  
QY 1021 CTTCCTCATTTCTGAAATTTAAAGCATTTTCTTTTAAAGACAAAGTGTATATAGACATCTAA 1080  
DB 1021 CTTCCTCATTTCTGAAATTTAAAGCATTTTCTTTTAAAGACAAAGTGTATATAGACATCTAA 1080  
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTCATTGATATAGGCTTAAAGAAATCA 1140  
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTCATTGATATAGGCTTAAAGAAATCA 1140  
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
DB 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174  
RESULT 154  
ADE35417  
ID ADE35417 standard; cDNA; 1174 BP.  
XX AC ADE35417;  
XX DT 29-JAN-2004 (first entry)  
DE Human cDNA encoding secreted/transmembrane protein, PRO195.  
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;  
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;  
KW vulnery; auditory; tumour growth; retinal disorder;  
KW sports-related joint problem; articular cartilage defects;  
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.  
XX Homo sapiens.  
OS  
XX  
PN US2003203434-A1.

XX PD 30-OCT-2003.  
XX PF 18-OCT-2001; 2001US-00145088.  
XX PR 15-MAY-1998; 98US-0085689P.  
XX PR 08-MAR-1999; 99WO-US005028.  
XX PR 28-APR-1999; 99US-0131445P.  
XX PR 25-AUG-1999; 99US-00380138.  
XX PR 18-FEB-2000; 2000WO-US004341.  
XX PR 30-JUL-2001; 2001US-00918585.  
XX PA (GETH ) GENENTECH INC.  
XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Filvarovski E, Fong S, Gao W, Gerber H, Gerritsen ME;  
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KM;  
PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;  
PI Stewart TA, Tumas D, Williams PM, Wood WI;  
XX DR WPI: 2003-975641/81.  
XX DR P-PSDB; ADE35418.  
XX PT New genes, and its encoded secreted and transmembrane polypeptides,  
PT useful for treating e.g. lung or breast tumors, osteoarthritis,  
PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,  
PT hypoinsulinemia or wounds.  
XX PS Claim 2; SEQ ID NO 329; 462pp; English.  
XX CC The invention relates to an isolated PRO polypeptide (secreted or  
CC transmembrane protein) having at least 80% amino acid sequence identity  
CC to an amino acid sequence chosen from 94 fully defined sequences as given  
CC in the specification (including PRO lacking its associated signal  
CC peptide, a PRO extracellular domain with or without its associated signal  
CC peptide). Also included are nucleic acids encoding the PRO proteins  
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell  
CC comprising the vector and producing PRO, a chimeric molecule comprising  
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO  
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993  
CC polypeptide in a sample suspected of containing PRO337.  
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337.  
CC PRO1559 polypeptide, and PRO700 or PRO739 polypeptide is useful for detecting  
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting a  
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive  
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule  
CC causes death of the cell. PRO337 polypeptide is useful for linking a  
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,  
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule  
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is  
CC useful for linking a bioactive molecule to a cell expressing PRO725,  
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337  
CC polypeptide is useful for modulating at least one biological activity of  
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337  
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the  
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,  
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for  
CC modulating the biological activity of the cell expressing PRO1559  
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-  
CC PRO739 polypeptide is useful for modulating the biological activity of  
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The  
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,  
CC sports-related joint problems, articular cartilage defects,  
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in  
CC mammals. The present sequence encodes a PRO protein.  
XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;  
Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAAACCCCTTCGAGAAACACAAACAGCTGAGCTGCTGTGACAGAG 60  
DB 1 CGGACGCTGGGGGAAACCCCTTCGAGAAACACAAACAGCTGAGCTGCTGTGACAGAG 60  
QY 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCTCTGGGFTGAGGACCAACTGGGGCTCCCG 120  
DB 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCTCTGGGFTGAGGACCAACTGGGGCTCCCG 120  
QY 121 CGGCTGCTGCTGACCATGGCCTTGGCGGAGGTTGGGGAGCCGCTTGGCTGGAAGCA 180  
DB 121 CGGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTGGGGAGCCGCTTGGCTGGAAGCA 180  
QY 181 TTGTGACTCGCTTGGGTCATACGGCGCTTTCGCCACCGGGCCCTCTCAGTTGACCTACCCC 240  
DB 181 TTGTGACTCGCTTGGGTCATACGGCGCTTTCGCCACCGGGCCCTCTCAGTTGACCTACCCC 240  
QY 241 TTGCACACCTACCTTAAGAGAGAGTTGACGATGTCAGAGAGTTGTCAGAGCTGTTT 300  
DB 241 TTGCACACCTACCTTAAGAGAGAGTTGACGATGTCAGAGAGTTGTCAGAGCTGTTT 300  
QY 301 TCAATTTGTGAGTTGTGATGATGGAATTCGACTTAATCGAACTTAATCGAAATGTGAA 360  
DB 301 TCAATTTGTGAGTTGTGATGATGGAATTCGACTTAATCGAACTTAATCGAAATGTGAA 360  
QY 361 TGTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
DB 361 TGTGATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420  
QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACTTATGTCCTGATGCAAAA 480  
DB 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACTTATGTCCTGATGCAAAA 480  
QY 481 ATGCACCTACTCTTCTCTTAACTCTGAGTGGTCAATCTGAGTGGATGATGAGACTCC 540  
DB 481 ATGCACCTACTCTTCTCTTAACTCTGAGTGGTCAATCTGAGTGGATGATGAGACTCC 540  
QY 541 GCACAGAGCTTCATACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
DB 541 GCACAGAGCTTCATACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600  
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCACTTTGGAGAGAGAGCTTACA 660  
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCACTTTGGAGAGAGAGCTTACA 660  
QY 661 AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCG 720  
DB 661 AATTTGAGAGATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAGCG 720  
QY 721 CACAGGAAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
DB 721 CACAGGAAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780  
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCGGTGATGATGCTTTTGGATTTGT 840  
DB 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCGGTGATGATGCTTTTGGATTTGT 840  
QY 841 TGTGCAACTCTTCTACAGCTGTGGAGAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
DB 841 TGTGCAACTCTTCTACAGCTGTGGAGAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900  
QY 901 GGTGACCTTGAGTTTATGAAATGAAACAAAGCTTAACAGATATCCAGCTTCTCTCTTGG 960  
DB 901 GGTGACCTTGAGTTTATGAAATGAAACAAAGCTTAACAGATATCCAGCTTCTCTCTTGG 960  
QY 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020  
DB 961 GTTGTAGATCTAAACTGAAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020  
QY 1021 CTTGCTCATTTCTGAAATTTAAGCAATTTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
DB 1021 CTTGCTCATTTCTGAAATTTAAGCAATTTTCTTTTAAAGACAGTGTATAGACATCTAA 1080  
QY 1081 AATTCCTCCTCATAGAGCTTTTAAATAGTGTTCATTTGGATATAGGCTTTAAGAAATCA 1140



661	DB	AATTGTGAGAGAACTCCTCTTAACCAAAATGTCTATCTGCAAAATGAGAAATTCACAGCG	720
721	QY	CACAGGAATTTTCTTGAAGATGAGAAAGTGATGCTTTTTAAAGATGCCTCTCTCTTAAC	780
721	DB	CACAGGAATTTTCTTGAAGATGAGAAAGTGATGCTTTTTAAAGATGCCTCTCTCTTAAC	780
781	QY	TCTGGTGGATTTTAACTCAACTCTTGTCCCTCTCGGTGATGGTATTGCTTTGGATTGTTG	840
781	DB	TCTGGTGGATTTTAACTCAACTCTTGTCCCTCTCGGTGATGGTATTGCTTTGGATTGTTG	840
841	QY	TGTGCAACTGTGTCTCAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTCAGTATCTAT	900
841	DB	TGTGCAACTGTGTCTCAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTCAGTATCTAT	900
901	QY	GGTCACCTGGAGTTTATGAATGAACAAAGCTATAACAGATATCCAGCTCTCTCTCTTGTG	960
901	DB	GGTCACCTGGAGTTTATGAATGAACAAAGCTATAACAGATATCCAGCTCTCTCTCTTGTG	960
961	QY	CTTGTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTTACCTACAAAAAGTGAAT	1020
961	DB	CTTGTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTTACCTACAAAAAGTGAAT	1020
1021	QY	CTTGCTCATTCCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
1021	DB	CTTGCTCATTCCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
1081	QY	TAATCCACTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA	1140
1081	DB	TAATCCACTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA	1140
1141	QY	CTATAAATGCAATAAAGTTACTCAAAATCTGTG	1174
1141	DB	CTATAAATGCAATAAAGTTACTCAAAATCTGTG	1174

RESIST, T 156

ADD73146					
ID	ADD73146	standard; cDNA; 1174 bp.			
XX	AC				
XX	AC	ADD73146;			
XX	DT	29-JAN-2004	(first entry)		
XX	DE	Human	cDNA encoding secreted/transmembrane protein, PRO195.		
XX	DE	Human; ss; gene;	secreted protein; transmembrane protein; PRO;		
XX	KW	cytostatic; ophthalmological;	antiarthritic; osteopathic; antirheumatic;		
XX	KW	vulnary; auditory;	tumour growth; retinal disorder;		
XX	KW	sports-related joint problem;	articular cartilage defects;		
XX	KW	osteoarthritis; rheumatoid arthritis;	wound healing; hearing loss.		

xx Homo sapiens.

XX  
XX  
XX

US2003203436-A1.

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525

PD 30-OCT-2003.

XXXXXX

18-OCT-2001: 2001US-00145129.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

PR 22-MAY-1998: 98US-0086414P.

PR 22-DEC-1998: 98US-0113296P.

PR 05-JAN-1999: 99WO-US000106:

PR 08-MAR-1999: 99WO-US005028:

12-APR-1999: 99JIS-00

25-AUG-1999: 99115-00

FR 23-AUG-1993; 3303-00  
PR 18-FEB-2000; 2000WQ-US

FR 18-FEB-2000; 2000NC-00  
PR 30-JUL-2001; 2001US-00

XX  
XX  
1007-700-06 YF  
00-00-007, 00-00-00 YF

AA (GETH ) GENENTECH INC

PPI Klavin LJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;  
PPI Stewart TA, Tumas D, Williams PM, Wood WI;  
XX WPI; 2003-875643/81.  
DR P-PSDB: ADD73147.  
DR

New PRO genes and encoded secreted and transmembrane polypeptides, useful for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or wounds.

Claim 2: SEO ID NO 329: 453pp: English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimaeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide.

XX  
sequence 1174 BP: 325 A: 250 C: 275 G: 324 T: 0 U: 0 Other:

Query Match 100.0%; Score 1174; DB 9; Length 1174;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1	CGGACGGTGGGGAAACCCCTTCGGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
1	CGGACGGTGGGGAAACCCCTTCGGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
61	GGGAACAAGATGCGCGCGCGCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGGCTCCCG	120
61	GGGAACAAGATGCGCGCGCGCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGGCTCCCG	120
121	CGCGTGTGCTGTGAACAATGGGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
121	CGCGTGTGCTGTGAACAATGGGCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
181	TTTGACTCGGCTTTGGGTGATACGGGCTTTGACCAACGGGCGCTGTTCAGTTGACCTACCCC	240
181	TTTGACTCGGCTTTGGGTGATACGGGCTTTGACCAACGGGCGCTGTTCAGTTGACCTACCCC	240
241	TTTGACACACTACCTCAAGGAAGAGGAGTTGTACGCATGTACAGAGAGGTTGCAGGCTGTTT	300

Db	241	TTGCRACCTTACCTTAAGGAGAGAGTTGTACGATGTCAGAGAGTTTCAGGCTGTTT	300
Qy	301	TCAATTTGTCAGTTTGTGATGATGGAATGACCTAAATCGAATGAAATGGAATGTGAA	360
Db	301	TCAATTTGTCAGTTTGTGATGATGGAATGACCTAAATCGAATGAAATGGAATGTGAA	360
Qy	361	TCGTGATGTACAGAGCATAATCCCAATCTGATGAGCAATATGCTTGCCCATCTTGGTTC	420
Db	361	TCGTGATGTACAGAGCATAATCCCAATCTGATGAGCAATATGCTTGCCCATCTTGGTTC	420
Qy	421	CAGAATCAGCTGCCATTCGCTGAATGAGACAGAAGAACAACTTATGTCCTGTGATGCCAAA	480
Db	421	CAGAATCAGCTGCCATTCGCTGAATGAGACAGAAGAACAACTTATGTCCTGTGATGCCAAA	480
Qy	481	ATGCACCTACTCTTCTCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCC	540
Db	481	ATGCACCTACTCTTCTCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCC	540
Qy	541	GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Db	541	GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Qy	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTAGTACGCCACCACTTTTGGAGCAGGAGCCTACA	660
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTAGTACGCCACCACTTTTGGAGCAGGAGCCTACA	660
Qy	661	AATTGGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATCACAAGCG	720
Db	661	AATTGGAGAGATCATCTCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATCACAAGCG	720
Qy	721	CACAGGAATTTCTTGGAGATGAGAAAGTGATGCTTTTAAAGTACGCTCTCTCTTTAAC	780
Db	721	CACAGGAATTTCTTGGAGATGAGAAAGTGATGCTTTTAAAGTACGCTCTCTCTTTAAC	780
Qy	781	TCTGGTGGATTTTAACTACAACCTCTTGCTCCCTCGGTGATGGTATGCTTTGATTTGT	840
Db	781	TCTGGTGGATTTTAACTACAACCTCTTGCTCCCTCGGTGATGGTATGCTTTGATTTGT	840
Qy	841	TGTCGCACTGTGCTACAGCTGTGGAGCAGTAGTTTCCCTCTGAGAGCTGAGTACTAT	900
Db	841	TGTCGCACTGTGCTACAGCTGTGGAGCAGTAGTTTCCCTCTGAGAGCTGAGTACTAT	900
Qy	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGGTTCTTCTCTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGGTTCTTCTCTGTG	960
Qy	961	GTTGTTAGATCTAAAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACTGAGATCATGAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
Qy	1021	CTTGCTCAATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCAATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Qy	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTTAAGAAATCA	1140
Db	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTTAAGAAATCA	1140
Qy	1141	CTATAAAATCGAAAATAAAGTTTACTCAAATCTGTG	1174
Db	1141	CTATAAAATCGAAAATAAAGTTTACTCAAATCTGTG	1174

RESULT 157

AD E41904

ID ADE41904 standard; cDNA; 1174 BP.



AC ADE41904;

XX  
DT 29-JAN-2004 (first entry)

Human PRO polynucleotide # XX DE

Human PRO polynucleotide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; EPA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

**Homo sapiens.**

US2003194772-A1.

16-OCT-2003.

21-MAY-2002: 2002US-00152386.

03-MAR-2000: 2000US-0187202P.

03-MAR-2000; 2000US-US032678  
01-DEC-2000: 2000WO-US032678

19-DEC-2001: 2001US-00028072:

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Baker KF, Beresini M, Bergeron D, Desnoyers Z, Gaudet L,  
Goddard A. Godowski PJ, Gurney AL, Sherwood S;  
Garritsen ME.

Smith V. Stewart TA. Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-899788/82.

P-PSDB: ADE41905.

Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

Claim 2: Fig 271: 637pp: English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [scidata.uspto.gov/sequence.html](http://scidata.uspto.gov/sequence.html).